ࡱ> $cdefghijklmnopqrstuvwxyz{|}~u R^bjbj]];b7f7fGm(p"p"p"p"p""""8" x0t"82($W(F1Ep"6{XX6{6{1p"p"~[?DPs>7?$p"P06{6{6{6{6{6{6{11x6{6{6{86{6{6{6{[?6{6{6{6{6{6{6{6{6{b 6!: SS'`Lvʋuĉ2019t^Hr -NNSNlqQTVV[kSueP^YXTO;S?e;S{@\ 1i SS'`Lv/fvMRbV,{4MO8^v`'`$vS,{2MO$v{kuV %N͑ZbVNlvu}TTeP^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_1" \o "Torre, 2015 #1347" 1  HYPERLINK \l "_ENREF_2" \o "Zhou, 2019 #2147" 2]0SS'`Lv;NSb~ހLvHepatocellular carcinoma HCC 0Qƀ{LvIntrahepatic cholangiocarcinoma ICC THCC-ICCmTW3y N Tutf[{|W 3(WSu:g6R0uirf[L:N0~~f[b_`0luelNSTI{eb]_'Y vQ-NHCC`S85%^90% Vdk,gĉ-Nv Lv cHCC0 :NۏNekĉbVLvʋuL:N 2017t^6gS-NNSNlqQTVkSuTRuYXTO;S?e;S{@\;Nc6R[T^N 0SS'`Lvʋuĉ2017t^Hr 00ĉv^S fNS_ebVLvʋeTYf[y~TluNSxvzvrQ [ĉLvʋuv4N^L:N09eULvuNT0O;Su(ϑT;Su[hQNSOS;SuDnS%cN͑\O(u02017t^N (WLvvʋe0RgSluebVQYeQsNY&{T_;Sf[SRvؚ~+Rnc $\vQ/f^-NVV`vxvzbg0:Ndk -NNSNlqQTVV[kSueP^YXTO;S?e;S{@\YXb-NNS;Sf[O$vf[RO~~hQVLvWvYf[yN[ ~TvMRLv4N^xvzv[E Ov^feb_b 0SS'`Lvʋuĉ2019t^Hr 0N N{yĉ 0,gĉSgqv_;Sf[ncI{~ cgq 0[r%m_;Sf[-N_2011Hr 0ۏLR~DU_1 0 2[{gTʋe 2.1LvؚqSNvvKm[{g [LvؚqSNv[{g gRNLvvegSs0egʋe0eglu /fcؚLvuHevsQ.0(WbV LvؚqSN;NSbwQ gYNWpukHepatitis B virus HBV Tb NWpukHepatitis C virus HCV ag0Ǐ^nR0^R|'`'`p0gߘ(uĞf k }algvߘir0TyvQNSV_wvlxS0NS gLv[eSI{N $\vQ/ft^>40\v7u'`Θif'Y0PRNXhgT@n2u΀ˆ}vAlpha-fetoprotein AFP ۏLLveg[{g ^ؚqSN\k6*NgۏL1!khg ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_3" \o "Zhang, 2004 #15" 3]0 2.2Lvvq_Pf[hg Tyq_Pf[hgKbkT gyrp ^:_~T^(u0ORNe0hQbċ0O0 2.2.1XhgUltrasonography US  XhgVd\O{O0[eeR0yROwcI{yrp /f4N^ Ng8^(uvq_Pf[hgel08^ĉpp6XSeg0Oea0WhQQ`SMO'`uS St+RvQ/fV'`b[('`0o'`bv`'` v^‰[QbyTQvsQlyvp0Q@{Sƀ{Or`QI{0i_rYnfR@AmbPS‰[uvpQ@O Tefnxuvp'`(SNQ͑@{vksQ|0X q_hgSc:y$vv@AmRRf[SS .^Rt+Rʋe N T'`($v (WċNLvv_@{LplT_[NeQluSNeQluTsS;Rċ0OuHeebwQ gOR0XTTq_P[*b/g:NLvv|Q[MOT[e_RmcON gHevKbk ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_4" \o "Dong, 2016 #6" 4]ncI{~3 0/g-NXS/g-NX q_hgfOea0W>f:yQv_~:N5 mmvLv f}Y0WOS TKb/glu ADDIN EN.CITE <EndNote><Cite><Author>da Silva</Author><Year>2019</Year><RecNum>5</RecNum><DisplayText><style face="superscript">[5]</style></DisplayText><record>5517da Silva, N. P. B.Hornung, M.Beyer, L. P.Hackl, C.Brunner, S.Schlitt, H. J.Wiggermann, P.Jung, E. M.Department of Radiology, University-Hospital Regensburg, Germany. Department of Surgery, University-Hospital Regensburg, Germany.Intraoperative Shear Wave Elastography vs. Contrast-Enhanced Ultrasound for the Characterization and Differentiation of Focal Liver Lesions to Optimize Liver Tumor SurgeryUltraschall MedUltraschall Med205-2114022018/10/202019AprIntraoperative Scherwellenelastografie vs. Kontrastmittelultraschall zur Charakterisierung und Differenzierung fokaler Leberlasionen und Optimierung von Lebertumoroperationen.1438-8782 (Electronic) 0172-4614 (Linking)30340245https://www.ncbi.nlm.nih.gov/pubmed/3034024510.1055/a-0649-1000</electronic-resource-num></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_5" \o "da Silva, 2019 #5" 5]ncI{~3~ 0X9_'`bPShKm[(TQ`SMO'`uvpv~~lx^ :NfnxLvKb/gvSL'`cOfYvROo` ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_6" \o "Hu, 2018 #8" 6  HYPERLINK \l "_ENREF_7" \o "Grgurevic, 2018 #7" 7]ncI{~3~ 0YyXb/gvTT^(u S:NLv|Qv/gMRʋe0/g-N[MO0/gTċ0Ow0R͑\O(u ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_8" \o "Berzigotti, 2018 #4" 8]0 2.2.2 X~{:geB\bPComputed tomography CT TxqQ/cbPMagnetic resonance imaging MRI  R`X:_CTTY!j`MRIkbc/fXT@nAFP[{g_8^fnxʋev q_Pf[hgel0 vMRR`X:_CTd8^^(uNLvv4N^ʋeSRgY _N^(uNLv@\萻luvuHeċN yr+R/f[~R Suh^XTransarterial chemoembolization TACE Txlly‰[ gOR0 Te PRCTTYtb/gSۏL N~@{͑^0SOyT$vSOyKmϑ0TI{vQNhVlyċN ^l^(uN4N^0 Y!j`MRIwQ ge\q_T0~~Rsؚ0SYeMOY^RSpebPvOR NwQ gb_`~TRSbibceRCgbPI{ ~TbPb/gR b:NLv4N^hQ0ʋe0RgTuHeċNvO q_Pb/g0Y!j`MRIhQTʋev_d"2.0cmLvvRONR`X:_CT ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_9" \o "Lee, 2015 #10" 9  HYPERLINK \l "_ENREF_10" \o "Liu, 2017 #11" 10]ncI{~1 0 O(u~ހyr_'`[kBR^XxNGd-EOB-DTPA Scؚv_d"1.0cmLvvhQsNS[LvʋeNt+RʋevQnx'` ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_11" \o "Zeng, 2013 #14" 11-15]ncI{~2 0Y!j`MRI(WċNLv/f&TOrY 0Y ;Nr^SvQR/e0NSyTbTym]~lyI{ebR`X:_CT_Nf>fOR0 Lvq_Pf[ʋe;N9hnc:N _ۏ_Q v:_Se_ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_16" \o "Marrero, 2018 #33" 16-18]ncI{~1 0R`X:_CTTMRIR g;N(WR Zfg $vHTGWSb NGWSf>f:_S Y gTb s^ag$v:_SNON[(0~ހyr_'`[kBRGd-EOB-DTPA^XxNl\m X:_MRIhg>f:y$vR gf>f:_S Y g:_SNON[( ƀyr_g8^HTf>fNOOS 5%^12%RS}Yv\Lv ƀyr_gSHT8T6e[kBRv zؚOS ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_19" \o "Cho, 2015 #23" 19]ncI{~3 0 LvMRIʋe \~TvQN_aYS7h:_S0T2RCgbP-NI{OS0ibceSPI{ ۏL~T$Re ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_20" \o "Hwang, 2015 #29" 20]ncI{~3 ~ހyr_'`[kBRGd-EOB-DTPAX:_MRIhgTT^(uƀyr_gNOOS0R g:_STibceSP_aSf>fcؚ\LvvʋeOea'` Te gRNt+Rؚ^_WXu~I{LvMRuS ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_21" \o "Renzulli, 2018 #38" 21]ncI{~3 0 WNLvCTTb MRIOo`v4N^penccc^zT!jW gRN9eU4N^QV{uNlueHh b0uHeċNSKmI{  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_22" \o "Xu, 2019 #2226" 22-24]ncI{~3 0 2.2.3peW[Qq_@{ q_Digital subtraction angiography DSA  DSA/fNyOeQ'`R$O'`hg Y;N _Ǒ(u~ b'`b b'`R ۏLDSAhg0勀b/gfY(uNLv@\萻lub%`'`Lv4xˆQ@luI{0DSAhgS>f:y$v@{S$vgr ؏Sfnx>f:y$vpev0'Y\SvQ@O`Q0DSAhgY:N@{VRS_0$vN͑@{VRsQ|0NSY xmmcOQnx[‰vOo` [N$ReKb/gRdvS'`0{_^'`NS6R[TtvlueHh g͑NfPvOR(WN`$[$vۏLRg ǏN!khgYhQbċN gem]~lyS܏YhV[vly ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_25" \o "Park, 2008 #37" 25  HYPERLINK \l "_ENREF_26" \o "Lin, 2012 #32" 26]ncI{~1 a$QRg VPET/CTRq_P NSVR~gvq_T SQnx>f:yVR~gSuSSTbVR~g YBgMOv YSlyvp ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_27" \o "Boellaard, 2015 #19" 27  HYPERLINK \l "_ENREF_28" \o "Boellaard, 2010 #20" 28]ncI{~2 b$uHeċN [Nb6R$v;m'`vvToir uHeċNfROea0Qnx ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_29" \o "Wahl, 2009 #42" 29  HYPERLINK \l "_ENREF_30" \o "Chalian, 2011 #21" 30]ncI{~2 c$c[>euuirv:SvR;u0nx[z:R;mhMO ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_27" \o "Boellaard, 2015 #19" 27  HYPERLINK \l "_ENREF_28" \o "Boellaard, 2010 #20" 28]ncI{~2 d$ċN$vvv`'` z^TT ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_31" \o "Ferda, 2015 #25" 31-34]ncI{~2 0x-11hvYNxv11C-acetate bƀx11C-choline PET>fPScؚ[ؚRSLvʋevupOe^ N18F-FDG PET/CT>fPwQ gNe\O(u ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_35" \o "Bertagna, 2014 #18" 35  HYPERLINK \l "_ENREF_36" \o "Cheung, 2013 #22" 36]0 2 USIQP[S\{:geB\bPSingle photon emission computed tomography/CT SPECT/CT SPECT/CT]nfNSPECTb:N8h;Sf[USIQP[>fPv;NAmY bhQs^b>fP@bSsvuvp QۏL@\SPECT/CTTq_Phg S Te_uvpMOvSPECTTʋeCTVP ʋeQnx'`_N>fWcؚ ADDIN EN.CITE <EndNote><Cite><Author>Zhang</Author><Year>2013</Year><RecNum>2148</RecNum><DisplayText><style face="superscript">[37]</style></DisplayText><record><rec-number>2148</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">214817Zhang, Y.Shi, H.Cheng, D.Jiang, L.Xiu, Y.Li, B.Gu, Y.Chen, S.Department of Nuclear Medicine, Zhongshan Hospital, Shanghai, China.Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignanciesNucl Med CommunNucl Med Commun451-83452013/02/28AdultAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedObserver VariationSensitivity and SpecificitySpinal Neoplasms/*diagnostic imaging*Tomography, Emission-Computed, Single-Photon*Tomography, Spiral Computed2013May1473-5628 (Electronic) 0143-3636 (Linking)23442544https://www.ncbi.nlm.nih.gov/pubmed/23442544</urls><electronic-resource-num>10.1097/MNM.0b013e32835fa552</electronic-resource-num></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_37" \o "Zhang, 2013 #2148" 37]ncI{~3 0 3 ck5uP[S\{:geB\xqQ/cbPPositron emission tomography/MRI PET/MRI 1!kPET/MRIhgS Te_uuVRNROo` cؚLvʋevupOe^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_38" \o "Hectors, 2018 #28" 38]0 2.2.5 z:R;mh wQ gxQWLvq_Pf[yr_v`SMO'`uS &{TLv4N^ʋehQvuN 8^ NNʋe:Nvvvuvpz:R;mh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_39" \o "Forner, 2008 #26" 39  HYPERLINK \l "_ENREF_40" \o "Roberts, 2018 #39" 40]ncI{~1 0[NKb/gRdbQYy ivLvuN N^/gMRLuvpz:R;mh NQ\$vdceΘi0[N:ONxQWLvq_Pf[yr_v`SMO'`uS uvpz:R;mhS_fnxvutʋe0uvpz:R;mhS[fnxuvp'`(0uuV0LvRP[RW ADDIN EN.CITE <EndNote><Cite><Author>Paradish</Author>20192312312315Paradish, V.Fukayama, M.Park, Y.N.Schirmacher, P.WHO Classification of Tumours Editorial BoardTumors of the liver and intrahepatic bile ductsWHO Classification of Tumours of the Digestive System85th Edition
8
2019World Health Organization Press[ HYPERLINK \l "_ENREF_41" \o "Paradish, 2019 #231" 41]0:Nc[luT$ReTcO gNPTvuN ^MQuvpz:R;mh0:NNMNO$v~4xˆTSy ilyvSu S b Tt_[z:R z:RTfwm~\핈S z:R_^=\S~Ǐck8^~~ MQvcz:Rhb~0^(Wq_P>f:y$v;mÍv$vQT$veSPg SPgTe(W~Gr NQ>eeQV[mV[ N2~~6e)b/_feˆ0 2 h,gSPgpLvhT:SW/f$vuirf[L:NvNh'`:SW ADDIN EN.CITE <EndNote><Cite><Author>Westra</Author><Year>2003</Year><RecNum>43</RecNum><DisplayText><style face="superscript">[43]</style></DisplayText><record><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="dww9d0de72psede9wsd5r02srt2vveafw5za" timestamp="1565785729">436William H. WestraRalph H. HrubanTimothy H. PhelpsChristina IsacsonSurgical Pathology Dissection: An Illustrated Guide258
404017Rodriguez-Peralvarez, M.Luong, T. V.Andreana, L.Meyer, T.Dhillon, A. P.Burroughs, A. K.The Royal Free Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital, London, UK.A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variabilityAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncology325-39201BiomarkersCarcinoma, Hepatocellular/*pathology/surgeryDisease-Free SurvivalHepatectomyHumansLiver Neoplasms/*pathology/surgeryLiver TransplantationMicrovessels/*pathologyNeoplasm InvasivenessPrognosis2013Jan1534-4681 (Electronic) 1068-9265 (Linking)23149850http://www.ncbi.nlm.nih.gov/pubmed/2314985010.1245/s10434-012-2513-1[ HYPERLINK \l "_ENREF_49" \o "Rodriguez-Peralvarez, 2013 #40" 49]ncI{~1 0utf[R~elM0:N*gSs MVIM1NOqS~ :N d"5 *N MVI NSuNяLve~~M2ؚqS~ :N 5 *NMVI bMVISuN܏Lve~~0S_Lve~~QvkSfvpNMVIN:SRe SNv^eQMVIR~ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 50]0MVI/fċ0OLv YSΘiT blueHhv͑SOnc ^\O:N8^ĉutf[hgch ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_51" \o "Eguchi, 2010 #24" 51-53]ncI{~2 0 kSf~Satellite nodule ;N/fc;N$vhT~~QQsvf_\ N\Lvvp N;N$vKN g~~v ݍy2cm ;NegnNMVIW@x NvQly0 3 MQu~~Sf[grhgTt~TO(uMQu~~Sf[grh_ir1[HCC0ICC0mTWHCC-ICCNSly'`LvۏLt+Rʋe ADDIN EN.CITE <EndNote><Cite><Author>Ne</Author><Year>2015</Year><RecNum>229</RecNum><DisplayText><style face="superscript">[45]</style></DisplayText><record><rec-number>229</rec-number><foreign-keys><key app="EN" db-id="dww9d0de72psede9wsd5r02srt2vveafw5za" timestamp="1565785730">229</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Ne</author></authors></contributors><titles><title>ƀ$vYyutf[</title><secondary-title>ƀ$vYyutf[</secondary-title></titles><pages>276-320</pages><dates><year>2015</year></dates><pub-location>SN</pub-location><publisher>NlkSuQHr>y</publisher><isbn>978-7-117-20280-0</isbn><urls></urls></record></Cite></EndNote>[ HYPERLINK 45]0cP8^(uv~ހ'`h_ir g|(lxv-1Arginase-1 Arg-1 0~ހw!1Hepatocyteparaffin1 Hep Par1 0xpˆ}vY|-3 Glypican-3 GPC-3 0AFP0YKQCEApCEA 0CD10(uNeg~ހLvv8^(uh_ir/fGPC-30HSP70T7(lpTbvGlutamine synthetase GS I{0[N~ހLv-N z^'`{kN-SSO1Programmed death-1 PD-1 T z^'`{kN-MSO1Programmed death ligand 1 PD-L1 vMQu~~Sf[grhKm_N g_U\ f:yY~'`LvT YS'`LveSN/fY-N_wnveu$v _NSN/fegMVI_vUS-N_wn FO_NSN$Nywn!j_ TeX[(W0>f6q Y~'`LvT/gT YS'`LvvKQwne_\Oq_T4N^RgTlu!j_v b ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_55" \o "Xie, 2019 #2149" 55  HYPERLINK \l "_ENREF_56" \o "Wen, 2018 #2150" 56]0FOُNLvvKQwnyr'`NǏ8^ĉ~~b_`f[‰[RNƋ+R0:Ndk SǑ(uWV~_kSfBgT'`:1YLoss of heterozygosity LOH I{elhKmNċ0OY~'`LvT/gT YS'`LvvKQwne_ :N4N^LvRgS6R*NSOSlueHhcOSOnc ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_57" \o "Wang, 2013 #2151" 57  HYPERLINK \l "_ENREF_58" \o "Cong, 2015 #2152" 58]0 2.4.3Lvutf[ʋebJT 1u'YSOh,gc0>f_\ Nc0MQu~~Sf[grhg~gSutf[ʋe TyI{R~b cPN~gSbJTf:yR guvpf>f:_S0Y gTb s^agQuvp:_SNON[(sS _ۏ_Q vLvxQWyr_ RSZPQLvv4N^ʋeSsQv_2cm~ R N4yq_Pf[hg-NS g1yxQWvLvyr_ sSS4N^ʋe:NLv0 2 gYNWuk'`pbNWuk'`p b gNUOSV_wlxS SsQv_d"2cm~ N4yq_Pf[hg-NebS g1yhg gxQWvLvyr_ SۏLuvpz:R;mhbk2^3*Ngvq_Pf[hgv^~T@nAFP4ls^NfnxʋeSsQv_2cmv~ N4yq_Pf[hgexQWvLvyr_ RۏLuvpz:R;mhNfnxʋe0 3 gYNWuk'`pbNWuk'`p b gNUOSV_wlxS Y@nAFPGSؚ yr+R/fc~GSؚ ^ۏLq_Pf[hgNfnxLvʋeY*gSsQ~ (WcdY Z0ba'`b;mR'`u0ukzڀ΀n'`$vNSmSS$vvMRc N ^[R@nAFP4ls^NSk2^3*NgۏL1!kq_Pf[ Yg0  l xQWhsX:_R g;NR Zfg uvpf>f:_S Y bs^ag:_S NM HT _ۏ_Q :_Se_0 NxQWhs:ONR guvp:_SbY Ts^ag:_Sl g NMb NM Nf>f u:_S z gXRI{0 MRIxqQ/cR`X:_kbc0 CTCTR`X:_kbc0 CEUSX q_Contrast enhanced-ultrasonography O(uX[kBR[e‰[ck8^~~TuS~~v@AmLpl`Q0 EOB-MRI~ހyr_'`[kBR^XxNGd-EOB-DTPA X:_xqQ/ckbc0 AFP+ Ǐ@nAFPhKmck8^e\lu0hQluI{YyKbk Ttluelv b gؚ~+R_;Sf[ncv/ec FO_N TeQ0W:S~Nm4ls^v]_0 4.1LvvYylu LvvYylu/fLvuN_guX[g͑vKbk ;NSbRd/gTy i/g0 4.1.1Rd/gvW,gSR 1 {_^'`[teRd$v RekYu$v2 [hQ'`OYuYSOyN gRv~~wQ go}Y@ONSo}Yv@mTƀAlVAm NO/gTRNP Q\Kb/gv^Su0MNOKb/g{kNs0 4.1.2 /gMRuNvhQ`QSPYRċ0O (W/gMR^[uNvhQ`QSPYRۏLhQbċN 8^Ǒ(uVN萿$vOS\O~cQvRr`ċRECOG PS ċ0OuNvhQ`QǑ(uRChild-PughċR02TT~ICG nd[bwe9_'`bPKm[lx^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_59" \o "Imamura, 2003 #54" 59-64]ċNPYR`Q0Sb-NVf[vYxvz~gc:y~Ǐ bvY ؚSuuN NScSRdKb/g vQ/gTguX[ONcSvQNlu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_65" \o "Zhong, 2014 #2153" 65  HYPERLINK \l "_ENREF_66" \o "Xiao, 2015 #2154" 66]0Vdk f:N|nx0WċNY ؚSv z^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_67" \o "Bosch, 2009 #2157" 67  HYPERLINK \l "_ENREF_68" \o "Chen, 2012 #2158" 68] gRN[{ TKb/gRdvuN0YgOYu~~SOy\ RǑ(uCTTb MRIKm[iRYOSOy v^{iRYOSOy`ShQSSOyv~vRk ADDIN EN.CITE <EndNote><Cite><Author>Kubota</Author><Year>1997</Year><RecNum>56</RecNum><DisplayText><style face="superscript">[60]</style></DisplayText><record>565617Kubota, K.Makuuchi, M.Kusaka, K.Kobayashi, T.Miki, K.Hasegawa, K.Harihara, Y.Takayama, T.Second Department of Surgery, Faculty of Medicine, University of Tokyo, Japan.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumorsHepatologyHepatologyHepatologyHepatology1176-81265AgedBilirubin/blood*Decision MakingEmbolization, TherapeuticHepatectomy/*methodsHumansLiver/*physiopathology/*radiographyLiver Neoplasms/*physiopathology/*radiography/surgeryMiddle AgedPortal VeinTomography, X-Ray Computed1997Nov0270-9139 (Print) 0270-9139 (Linking)9362359http://www.ncbi.nlm.nih.gov/pubmed/936235910.1053/jhep.1997.v26.pm0009362359[ HYPERLINK \l "_ENREF_60" \o "Kubota, 1997 #56" 60]08^:NRChild-Pugh A~0ICG-R1530%/f[eKb/gRdv_agNiRYOSOy{`ShQSOyv40%N NlxSuN b30%N NelxSuN _N/f[eKb/gRdv_agN0 4.1.3 LvRdv^ 1 PYRo}YvCNLC Iag0IbgTIIagLv/fKb/gRdv ^0=\{N_xvz~g>f:y[Nv_d"3cmLv RdT@\萈muHee]_ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_69" \o "Chen, 2006 #48" 69]ncI{~1 FOgexvz>f:yKb/gRdT@\ YSs>fWNON\m $NyluTguX[e]_vSVS(WN YSTuNcSNfYv=cQe'`lu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_70" \o "Mohkam, 2018 #61" 70]ncI{~2 0'Yϑ‰[penc~g>f:yKb/gRdv܏guHef}Y ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_71" \o "Liu, 2016 #59" 71-73]ncI{~1 0 2 [NCNLC IIbgLvuN (WYpe`Q NKb/gRduHev^ NONTACEI{^Kb/glu0FOYg$v@\P(W TNkb TOJS bS TeL/g-N\mYtRdVYvuvp sSO$vpev3*N Kb/gRd gS_kvQNlue_f}YvHeg ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_74" \o "Yin, 2014 #74" 74  HYPERLINK \l "_ENREF_75" \o "Torzilli, 2013 #66" 75] Vdk_NcPKb/gRdncI{~2 FOf:N(Nav/gMRċ0O0 3 [NCNLC IIIagLv Y gN N`Q_NSQKb/gRd`$Tv^Y ;Nr^bR/eLvh 傿$v@\PNJS Y R/eLvh zlRWI/IIW DU_5 /fKb/g^ SQKb/gRd$vv^~Y Sh /gTQ[eTACE0Y SubvQN|~luY ;Nr^LvhIIIW Kb/gRd gN vQKb/guHeSNTACEbY>euvS_ Vdk N/fKb/gRdv~[^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_76" \o "Wang, 2016 #2159" 76]ncI{~3 0Ny:g[gqxvzSs [NSRdv gY LvhvuN /gMRcS N~b_>eu S9eU/gTuX[ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_77" \o "Wei, 2019 #69" 77]ncI{~2 0a$Tv^ƀ{LvhN4O gh;'`Ğu QuvpNSRd0b$4O gm]~ly Rd$vv TeLm]~nkbb/gTY>e\lu0c$hTVhVSOr SNv^Rd0 dkY [N/g-NcgSs N[Kb/gRdvLv SQL/g-NR 0Y c{Sub/g-NvQNv@\萻luceI{0 4.1.4 Lv9hl'`RdhQ 1 /g-N$RehQ`$Y 0Y 0ƀ{NS NTY *g<Cite><Author>Li</Author><Year>2019</Year><RecNum>57575717Li, X. L.Zhu, X. D.Cai, H.Li, Y.Zhou, J.Fan, J.Tang, Z. Y.Sun, H. C.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Electronic address: sun.huichuan@zs-hospital.sh.cn.Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysisSurgerySurgerySurgerySurgerySurgerySurgery1161-116716562019/03/092019Jun0039-60603084619210.1016/j.surg.2019.01.009NLMeng[ HYPERLINK \l "_ENREF_78" \o "Li, 2019 #57" 78]0 4.1.5Kb/gRdb/g 8^(uvKb/gRdb/g;N/fSbeQTQ@Amc6Rb/g0yeb/gNSbk@b/g0/gMR N~SƉSb/g gRN(W_$vf[9hl'`vMRc N f:N|QvRdVT_NObiRYOv{S ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_79" \o "Yang, 2018 #72" 79  HYPERLINK \l "_ENREF_80" \o "Mise, 2018 #60" 80]ncI{~3 0yT\Rd/gwQ gR$O\T/gTb` Y_I{Op ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_81" \o "Jiang, 2015 #55" 81]ncI{~2 V~'`xvzSsyT\RdvguHeN_yKb/gvf:yyT\Rd/gTuNTON\m yr+R/f$vMONhTMO(W g~v-N_ yT\RdQ@f\ICGgIQ03DyT\0:ghVNR\b:NyT\Rdv͑]wQ v^\ gRNcؚLvuNKb/gRdHeg ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_83" \o "Cheung, 2018 #49" 83]0 VR'`RdN^VR'`RdGW:N8^(uvKb/gb/g0 gxvzSs[RRݍy$vLu'Y vRdHegONzRvRd ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_84" \o "Shi, 2007 #2160" 84]ncI{~2 yr+R/f[N/gMRS$RX[(W_@{LvhvuN ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_85" \o "Yang, 2019 #73" 85]0[N]'YLv SǑ(u N8nyhT&^vMR_Rdl ADDIN EN.CITE <EndNote><Cite><Author>Liu</Author><Year>2000</Year><RecNum>58</RecNum><DisplayText><style face="superscript">[86]</style></DisplayText><record><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="dww9d0de72psede9wsd5r02srt2vveafw5za" timestamp="1565785729">5817Liu, C. L.Fan, S. T.Lo, C. M.Tung-Ping Poon, R.Wong, J.Centre of Liver Diseases, and Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, China.Anterior approach for major right hepatic resection for large hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery25-312321AdolescentAdultAgedBlood Loss, SurgicalCarcinoma, Hepatocellular/mortality/pathology/*surgeryFemaleHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedRetrospective StudiesSurvival Analysis2000Jul0003-4932 (Print) 0003-4932 (Linking)10862191<related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/10862191</url></related-urls></urls><custom2>1421104</custom2></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_86" \o "Liu, 2000 #58" 86]0[NYS'`Lv SǑ(uKb/gRd~T/g-N@\萈mY\mI{ e_lu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_87" \o "Zhou, 2019 #76" 87]ncI{~3 0[NY Lvh LY Sh/ge^fe;eePOY @Am 2bkLvhdce ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_88" \o "Zhang, 2015 #75" 88]0[NY LvhbTY Lvh SLhQ@Am;e =\SteWWSdLvh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_89" \o "Fu, 2010 #82" 89]0Tv^S_?bLvh S~R_S_?bSQLvh TeRd$v0Tv^TY bS_?bLvheKb/gΘi'Y ^Na͑ b0[NLv4Oƀ{Lvh (WSdLvhv Te 傿$v]OrRƀ{X R^ TeRdS/}ƀ{v^͑^ƀS NMNO@\ YSs ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_90" \o "Satoh, 2000 #100" 90]0 VRdV'Y [iRYOSOyǏ\_wiRYOR NhQ /fq_T9hl'`Rdv;NSV0:NNcؚLvvSRd'` SǑ(uY Nel 1 /gMRTACESOR NIgKb/gRduNv$v)\TQRd ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_91" \o "Tang, 1995 #64" 91  HYPERLINK \l "_ENREF_92" \o "Tang, 1995 #65" 92]0 2 ~Y h^XPortal vein embolization PVE ;N$v@b(WJS OiRYONP'`XuTQRd$v ADDIN EN.CITE <EndNote><Cite><Author>Wakabayashi</Author><Year>1997</Year><RecNum>67</RecNum><DisplayText><style face="superscript">[93]</style></DisplayText>676717Wakabayashi, H.Okada, S.Maeba, T.Maeta, H.First Department of Surgery, Kagawa Medical University, Japan.Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: a preliminary reportSurg TodaySurgery todaySurg TodaySurgery todaySurg TodaySurgery today403-10275AgedCarcinoma, Hepatocellular/*surgeryEmbolization, Therapeutic/*methods*HepatectomyHumansLiver/physiologyLiver Neoplasms/*surgeryMaleMiddle AgedPortal Vein/physiologyPostoperative Complications/prevention & controlPreoperative Care19970941-1291 (Print) 0941-1291 (Linking)9130341</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/9130341</url></related-urls></urls></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_93" \o "Wakabayashi, 1997 #67" 93]04N^bSvQv^Su NY FO4^6hTeI{_[OSOyXu :NQ\I{_g$vۏU\vΘi SQNTACETT ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_94" \o "Ogata, 2006 #62" 94]0 3 TTRTY ~NbvNekRd/gAssociating liver partition and portal vein ligation for staged hepatectomy ALPPS  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_95" \o "Wang, 2018 #68" 95]ncI{~3 TNgiRYOSOy`ShQSOy\N30%^40%vuN0/gMRċ0O^8^͑ ~TQlxS z^0uNt^0wgbS$N!kKb/gvRI{ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_96" \o "D'Haese, 2016 #50" 96]dkYSPRyT\b/gbmb/gI{MNON!kKb/gvR$O ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 97  HYPERLINK \l "_ENREF_98" \o "Hong de, 2016 #53" 98]0ALPPSS(WwgQcؚLvvRds FO Te_NX[(Wؚv^SuSusS{kNs Rekv‰[~g>f:yALPPSlu]'YbYSLvvHegONTACE0lawgQ$N!kKb/gvR$ONSNgKb/g1Y%vS'` ^(Na0Tt0W bKb/g[a0 4 [N_yTcgSslxS z^͑0$vMOnm(W0Y~vLv /g-N@\萈mSMNOKb/gΘi0 4.1.6/gMRlu [N NSRdLv /gMRTACE0Y>e\I{luSOۏ$vMgN ORuN_Kb/gRdv:gO MgTRdvLvuNS_}YvguX[Heg ADDIN EN.CITE <EndNote><Cite><Author>Tang</Author><Year>1995</Year><RecNum>64</RecNum><DisplayText><style face="superscript">[91]</style></DisplayText>646417Tang, Z. Y.Uy, Y. Q.Zhou, X. D.Ma, Z. C.Lu, J. Z.Lin, Z. Y.Liu, K. D.Ye, S. L.Yang, B. H.Wang, H. W.et al.,Liver Cancer Institute, Shanghai Medical University, People's Republic of China.Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patientsWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgery784-9196AdolescentAdultAgedCarcinoma, Hepatocellular/surgery/*therapyCombined Modality TherapyFemaleHumansLiver Neoplasms/surgery/*therapyMaleMiddle AgedMultivariate AnalysisPrognosis1995Nov-Dec0364-2313 (Print) 0364-2313 (Linking)8553666http://www.ncbi.nlm.nih.gov/pubmed/8553666[ HYPERLINK \l "_ENREF_91" \o "Tang, 1995 #64" 91]0[NSRdLv /gMRTACEv^ N9eUuNuX[ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_99" \o "Shi, 2014 #102" 99  HYPERLINK \l "_ENREF_100" \o "Zhou, 2009 #112" 100]ncI{~2 0 [NHBVvsQLvuN/gMRYgHBV-DNA4ls^ؚ NALT4ls^>2 Pck8^

f_8^uNS=\_Kb/g Te~N gHevbuklu0bHBVlu NNYc6RW@xu ؏ gRNMNO/gT$v YSs ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_101" \o "Yin, 2013 #109" 101  HYPERLINK \l "_ENREF_102" \o "Huang, 2015 #85" 102]ncI{~1 0 4.1.7/gTlu/gTly YSv2l  LvRd/gT5t^$v YSlysؚ40%^70% ُN/gMRS]X[(W_\dcevpbY-N_Su gsQ Ee@b guN/gTcS[R0NeSs$v YS 9hnc YS$vvyr_ SN bQ!kKb/gRd0@\萈m0TACE0>e\lubhQluI{ ^uNuX[e0[NwQ gؚqS YSΘivuN $Ny:g[gqxvz[/gTTACEluwQ gQ\ YS0^uX[vHeg ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_103" \o "Wang, 2018 #107" 103  HYPERLINK \l "_ENREF_104" \o "Wei, 2018 #108" 104]ncI{~2 0SNy:g[gqxvz~g>f:yRd/gTcSi3|luSQ\ YSv^^uNuX[e ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_105" \o "Chen, 2018 #78" 105]ncI{~1 0[NHBVagvLvuN 8h{|f:y "}b^<\luv^*g9eUegLvuNv/gTuX[ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_113" \o "Bruix, 2015 #77" 113] g\W4N^xvzc:y[N YSؚqSuN/gTv"}b^<\luSQ\$v YSv^^uX[e ADDIN EN.CITE <EndNote><Cite><Author>Wang</Author><Year>2014</Year><RecNum>106</RecNum><DisplayText>10610617Wang, S. N.Chuang, S. C.Lee, K. T.Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University; Division of Hepato-biliary-pancreatic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot studyHepatol ResHepatology research : the official journal of the Japan Society of HepatologyHepatol ResHepatology research : the official journal of the Japan Society of HepatologyHepatol ResHepatology research : the official journal of the Japan Society of Hepatology523-314452014May1386-6346 (Print) 1386-6346 (Linking)23672310http://www.ncbi.nlm.nih.gov/pubmed/23672310</url></related-urls></urls><electronic-resource-num>10.1111/hepr.12159</electronic-resource-num></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_114" \o "Wang, 2014 #106" 114]0 p 1 Rd/g/fLvuN_guX[v͑Kbk0 2 Rd/gvSR/f[teRd$vv^OYuYSOyN gRv~~ Vdk[Uv/gMRPYRċ0ON$vf[ċ0O^8^͑0 3 N,:NRChild-Pugh A~0ICG-R1530%/f[eKb/gRdv_agNiRYOSOy{`ShQSOyv40%N NlxSuN 0b30%N NelxSuN _N/f[eKb/gRdv_agN0/gMRċ0Oel ؏Sblx^vKm[0Y ؚS z^I{0 4 PYRo}YvCNLC Iag0IbgTIIagLv/fKb/gRdv ^0(WRCNLC IIbgTIIIagLvuN-N Kb/gRd gS_o}YvHeg0dkY /g-N@\萈m0/gMRTACE0/gMRb_>euI{elScؚCNLC IIbgTIIIagLvvRds0 5 Rde~8^Ǒ(ueQR TY TQY @Amc6Rb/g/gMR N~SƉSb/g gRNcؚRdvQnx'`yT\b/g gRNQ\Kb/gR$O FOvQgvuHe\:g[gqxvz0 6 [N$v]'YNiRYOSOy\vuN SǑ(u/gMRTACEO$v)\ bY h^X/~NbTALPPSOiRYONP'`XuvelcؚRds0 7 [N NSRdvLv /gMRSO(uTACE0Y>euI{_MgTQLRdFO/f[NSRdLv /gMRTACEv^ NcؚuHe0 8 Lv/gTRluNQ\ YS:N;Nvh0[/gT YSؚqSuNvTACEluSQ\ YS0^uX[/gTS gi3|_N gRNQ\ YS0^uX[0dkY /gTO(u8hx {|<Cite><Author>Sapisochin</Author><Year>2017</Year><RecNum>99</RecNum><DisplayText><style face="superscript">[115]</style></DisplayText><record><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="dww9d0de72psede9wsd5r02srt2vveafw5za" timestamp="1565785729">9917Sapisochin, G.Bruix, J.University Health Network, Toronto General Hospital, Department of Surgery, University of Toronto, 585 University Avenue, 11-PMB-184, Toronto Ontario M5G2N2, Canada. Barcelona Clinic Liver Cancer group, Liver Unit, Hospital Clinic, University of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Villaroel 170, Barcelona 08036, Spain.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approachesNat Rev Gastroenterol HepatolNature reviews. Gastroenterology & hepatologyNat Rev Gastroenterol HepatolNat Rev Gastroenterol HepatolNature reviews. Gastroenterology & hepatology203-2171442017/01/06Carcinoma, Hepatocellular/*surgeryHumansLiver Neoplasms/*surgeryLiver Transplantation/*mortalityNeoplasm Recurrence, Local/*surgeryTreatment Outcome2017Apr1759-50452805334210.1038/nrgastro.2016.193NLMeng[ HYPERLINK \l "_ENREF_115" \o "Sapisochin, 2017 #99" 115]ncI{~ 3 0sQNLvy i^ VE N;NǑ(us|pQMilan hQ0VR]'Yf[eёq\R!hUCSF hQI{0VQ\e~NhQ ] gY[USMOTf[F~cQN N TvhQ Sbmg]hQ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_116" \o "Zheng, 2008 #110" 116]0 Nwm YehQ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_117" \o "Fan, 2009 #79" 117]0NShQ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_118" \o "Li, 2009 #89" 118]T NNqQƋ ADDIN EN.CITE <EndNote><Cite><Author>SS</Author><Year>2008</Year><RecNum>228</RecNum><DisplayText><style face="superscript">[119]22822817<authors><author>SS</author><author>hg^z</author><author>hg[</author><author> _wme</author><author>Sl</author><author>4T0u0u</author><author>NgV~</author></authors></contributors><auth-address>,{NQ;S'Yf[NeƀYy;Sb, Nwm,200438</auth-address><titles><title> NNqQƋ(WSS'`Lvy ilu-NvЏ(u</title><secondary-title>-NV[(uYyBg_</secondary-title></titles><periodical><full-title>-NV[(uYyBg_</full-title></periodical><pages>466-469</pages><volume>28</volume><number>6</number><keywords><keyword> NNqQƋSS'`Lvy i</keyword></keywords><dates><year>2008</year>1005-2208http://d.g.wanfangdata.com.cn/Periodical_zgsywkzz200806018.aspx10.3321/j.issn:1005-2208.2008.06.018SNNepencN gPlQS</remote-database-provider><language>chi</language></record></Cite></EndNote>[ HYPERLINK 119]I{ ُNhQ[Ne'Y@{Or0m]~lySYlyvBl/fNv FO[N$vv'Y\TpevvBl N=\v T0 NVQhQ(W*gf>fMNO/gT;`SOuX[sTe$vuX[svMRc N GW N T z^0Wib'YNLvy iv(uV OfYvLvuNVy iKb/gSv0FONY-N_OS\OxvzN/ecTf N _ؚ~+Rv_;Sf[nc0~N[~EQR s6k,gĉcPǑ(uUCSFhQ sSUS*N$vv_d"6.5cm$vpevd"3*N vQ-Ng'Y$vv_d"4.5cm N$vv_;`Td"8.0cme'Y@{Or0 Yyb/gvSU\ib'YNS(uvO0;mSOy iluLvv^S\ՋۏNekib'Y ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_120" \o "Llovet, 2018 #92" 120] FO;mSOy iluLv O~OSO/gT$v YSsSGSؚ0uX[sef>fORncI{~4  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_121" \o "Pinheiro, 2017 #97" 121]0 4.2.2 Lvy i/gT YSv2Tlu SS$vv YS/fLvy i/gTb4Nv;N ADDIN EN.CITE <EndNote><Cite><Author>Sposito</Author><Year>2019</Year><RecNum>10310310317Sposito, C.Cucchetti, A.Mazzaferro, V.Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy. Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Vincenzo.Mazzaferro@istitutotumori.mi.it. Department of Oncology, University of Milan, Milan, Italy. Vincenzo.Mazzaferro@istitutotumori.mi.it.Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular CarcinomaDig Dis SciDigestive diseases and sciencesDig Dis SciDigestive diseases and sciencesDig Dis SciDigestive diseases and sciences1001-10076442019/03/11Competing risksHepatocellular carcinomaLiver transplantRecurrence2019Apr0163-21163085277010.1007/s10620-019-05538-1NLMeng[ HYPERLINK \l "_ENREF_122" \o "Sposito, 2019 #103" 122]0vQqSiV }Sb$vRg0@{Or0@nAFP4ls^0MQub6RBR/}y(uoBRϑI{0egddb/gTeo }eHh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_123" \o "Segev, 2008 #101" 123]0Q\y iTegxxvb6RBRv(uϑSMNO$v YSs ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_124" \o "Rodriguez-Peralvarez, 2013 #98" 124]ncI{~3 0Lvy i/gTǑ(umTORb6RBRvMQub6ReHhY^ }0O~S NSQ\$v YS cؚuX[s ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_125" \o "Liang, 2012 #91" 125-128]ncI{~3 0 Lvy i/gTNe$v YSly75%Su(Wy i/gT2t^Q u`ۏU\ŏ YSlyTuN-NMOuX[e:N7^16*Ng ADDIN EN.CITE <EndNote><Cite><Author>Filgueira</Author><Year>2019</Year><RecNum>2171</RecNum><DisplayText><style face="superscript">[129]</style></DisplayText><record><rec-number>2171</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">217117Filgueira, N. A.Department of Internal Medicine, Universidade Federal de Pernambuco, Recife, Pernambuco 50670-901, Brazil. norma.arteiro@hotmail.com.Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentationWorld J HepatolWorld J Hepatol261-2721132019/04/11Alpha-fetoproteinHepatocellular carcinomaLiver transplantationPrognosisRecurrenceRisk factorsSurvivalsupport2019Mar 271948-5182 (Print)30967904https://www.ncbi.nlm.nih.gov/pubmed/30967904PMC644742210.4254/wjh.v11.i3.261eng[ HYPERLINK \l "_ENREF_129" \o "Filgueira, 2019 #2171" 129]0(WYf[yʋuvW@x N ǑSSbSfMQub6ReHh0Q!kKb/gRd0TACE0@\萈mlu0>e\lu0|~luI{~TluKbk S^uNuX[ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_130" \o "Au, 2018 #2170" 130]ncI{~4 0 p 1 y i/fLv9hl'`luKbkKNN $\vQ(uNR1YNP0 NTKb/gRdS@\萈mvegLvuN0 2 cPUCSFhQ\O:N-NVLvy i^hQ0 3 Lvy i/gTegdd/eo }eHh0Q\y iTegxxvb6RBRv(uϑ0Ǒ(umTORb6RBRvMQub6ReHhY^ }0O~S I{S gRNQ\$v YS cؚuX[s0 4 Lvy i/gTNe$v YSly u`ۏU\ŏ (WYf[yʋuW@x Nv~Tlu S^uNuX[e0 4.3@\萈mlu =\{YyKb/g/fLvv luel FOVLvuN'YYTv^ glxS b(Wnxʋe'YRuN]-NZfg _Kb/gRd:gOvuNN20%^30%0яt^eg^l^(uv@\萈mlu wQ g[Rq_T\0R$O\0uHenxRvyrp ONN NTKb/gRdvLvuNNS_9hl:gO0 @\萈mlu/fPR;Sf[q_Pb/gv_[[$vvT[MO @\Ǒ(uirtbSf[velvc@gmp$v~~vN{|luKbk0;NSb\mRadiofrequency ablation RFA 0_lmMicrowave ablation MWA 0e4lYNl\luPercutaneous ethanol injection PEI 0QQlu0ؚ:_^XZ&qmHigh intensity focused ultrasound ablation HIFU 0oIQm0 NS5uzT[Irreversible electroporation IRE I{0@\萈mg8^(uX_[ wQ geO0[e0ؚHevyrp0CT0MRISY!j`VPT|~S(uN‰[T_[8^ĉXelcSvuvp0CTSMRI_[b/g؏S^(uN0 Nz0I{lyvpvmI{0 mv_ g~v0yT\0b_y3ye_0'YYpev\LvS~vz:Rm wQ g~Nm0eO0_Rvyrp0MONS NvLv yr+R/fzQSYvLv0~vz:RmΘi'Y0q_Pf[_[VvLv0b~vmؚqSMOvLv4я_00ÀS0ƀVI{ NelǑ(uN]4lby4lI{pyObce SQ~yT\mT_ymvel0 @\萈mlu(uNCNLC IagSRIbgLvsSUS*N$v0v_d"5cmb2^3*N$v0g'Yv_d"3cm e@{0ƀ{TяhV[OrNS܏Yly RR~Child-Pugh A/B~ S_9hl'`vluHeg ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_69" \o "Chen, 2006 #48" 69  HYPERLINK \l "_ENREF_72" \o "Feng, 2012 #51" 72  HYPERLINK \l "_ENREF_131" \o "Hasegawa, 2014 #84" 131-134]HYPERLINK \l "_ENREF_78" \o "Hasegawa, 2014 #101"ncI{~1 0[N NKb/gRdvv_3^7cmvUSS$vbYS$v STTTACE ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_135" \o "Peng, 2013 #96" 135-137]ncI{~1 0 NcPm9hl'`luvuN ~N"}b^<\/gTRlu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_113" \o "Bruix, 2015 #77" 113]ncI{~1 0 4.3.18^mKbkSb 1 RFARFA/fLv_Rlu8^(ume_ vQOp/fd\OeO0OObew0uHenxR0mVSc'`}Y yr+R(uNؚ0Tv^vQNuu0%N͑lxS0$vMONmb-N.YWLvvuN0[NYKb/gvegLvuN RFAve$vuX[sT;`uX[s{|f:yRFAvuHe{|fWOR ADDIN EN.CITE Cho200911711711717Cho, Y. K.Kim, J. K.Kim, M. Y.Rhim, H.Han, J. K.Department of Radiology, Seoul Veterans Hospital, Seoul, Korea. yunkucho2004@yahoo.co.krSystematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapiesHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)453-94922008/12/10Carcinoma, Hepatocellular/epidemiology/mortality/*surgeryCatheter Ablation/*methodsEurope/epidemiologyHumansLiver Neoplasms/epidemiology/mortality/*surgeryMeta-Analysis as TopicPatient SelectionRandomized Controlled Trials as TopicSample SizeSurvival AnalysisUnited States/epidemiology2009Feb0270-91391906567610.1002/hep.22648NLMeng[ HYPERLINK \l "_ENREF_143" \o "Cho, 2009 #117" 143]ncI{~1 0RFAluv|Ӛ/f[$vteSOmp;mTYvm[hQLu v^=\ϑQ\ck8^~~_c$O vQMRc/f[$vxmmvQnxċ0OTkSfvpvƋ+R0Vdk ASR:_luMR|nxvq_Pf[hg0X q_b/g gRNnx$vv[E'Y\Tb_`0Lu[$vxmmV0hQ_\LvTkSfvp :N6R[meHhmp;m$vcONS`vSOnc0 2 MWA MWA/f8^(uvpmel (W@\萗uHe0v^SuSusNS܏guX[ebNRFAvke>fW]_0vQyrp/fmHesؚ0@bmew0MNORFA@bX[(Wv plHe^ [N@O0N[v'Y$vNS4Nя@{$v>f:yQOR luewN NSSOQё^\ir(q_T :NؚNSeNS/eg0wdhV ieQ/gTuNcON:gO яt^eg4N^^(unXY0^z)n^vc|~SNc gHep:WV OMWAǏ zfR[hQ0:g[gqxvz>f:y RFANMWA$NKNe/f(W@\萗uHeTv^Sueb ؏/fuX[sI{eb]_GWe~f[aIN ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_144" \o "Shibata, 2002 #128" 144]ncI{~ 2 0MWATRFAُ$Nyme_v b S9hnc$vv'Y\0MOn bf[vme_ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_145" \o "Di Vece, 2014 #118" 145]ncI{~2 0 3 PEIPEI(uNv_d"3cmLvvlu @\ YSsؚNRFA FOPEI[v_d"2cmvLvmHegnxR ܏guHe{|<Cite>Cho200911711711717Cho, Y. K.Kim, J. K.Kim, M. Y.Rhim, H.Han, J. K.Department of Radiology, Seoul Veterans Hospital, Seoul, Korea. yunkucho2004@yahoo.co.krSystematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapiesHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)453-94922008/12/10Carcinoma, Hepatocellular/epidemiology/mortality/*surgeryCatheter Ablation/*methodsEurope/epidemiologyHumansLiver Neoplasms/epidemiology/mortality/*surgeryMeta-Analysis as TopicPatient SelectionRandomized Controlled Trials as TopicSample SizeSurvival AnalysisUnited States/epidemiology2009Feb0270-91391906567610.1002/hep.22648NLMeng[ HYPERLINK \l "_ENREF_143" \o "Cho, 2009 #117" 143]ncI{~1 0PEIvOp/f[hQ yr+R(uNLvvp4я0ƀVSÀS~~I{ؚqSMO FOY!k0Ypz:RN[soir(W$vQ%_ce\O(u0 4.3.2 W,gb/gBllaN Neb 1 d\O;S^_{~Ǐ%Nf:y Kb/gRd[  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_71" \o "Liu, 2016 #59" 71-73  HYPERLINK \l "_ENREF_131" \o "Hasegawa, 2014 #84" 131  HYPERLINK \l "_ENREF_133" \o "Huang, 2010 #86" 133]ncI{~1 0(W4N^[-N ^9hncuNvN,rQTR $vv'Y\0pev0MOnQ[ v^~TNNmlu;S^vb/gT~ hQbQT bTvRYluKbk08^:N YguNYSRd/g NSLvMOnhEmbMONb NTmؚqSMOvLv ^ Kb/gRd0@\萈mS\O:NKb/gRdKNYvSNylu b0[N NKb/gRd02^3*NLvvpMON N T:SW0bMOE\mb-N.YWvLv @\萈mSN0RKb/gRduHe __R N9hl'`m0 4.3.4LvmluTvċ0OT @\萗uHeċ0OvcPeHh/f(WmT1*Ng]S YgR`X:_CTbMRI bX q_ NċNmHeg0[NluMR@nAFPGSؚvuN hKm@nAFPR`SS0mHegSR:N ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_146" \o "Ahmed, 2014 #2172" 146]1 [hQmComplete ablation ~R`X:_CTbMRIkbc bX q_ $vmuvpR g*g:_S c:y$v[hQOW{k2 N[hQmIn-complete ablation ~R`X:_CTbMRIkbc bX q_ $vmuvpQR g@\ g:_S c:y g$vkYu0[luT g$vkYu SNۏLQ!kmlu2!kmTN g$vkYu ^>e_mul 9e(uvQNul0[hQmT^[g Yg 8^`Q Nk2(3*Ng Yg@nf[$vh_ir0Xhg0MRIbCT NOSeSsSv@\ YSuvpTQeSuvp )R(um_R[hQT{OfNS YeLvOp gHe0Wc6R$vۏU\0 p 1 @\萈mlu(uNCNLC IagSRIbgLvsSUS*N$v0v_d"5cmb2^3*N$v0g'Yv_d"3cm e@{0ƀ{TяhV[OrNS܏Yly RR~Child-Pugh A~bB~ S_9hl'`vluHeg0[N NKb/gRdvv_3^7cmvUSS$vbYS$v STTTACE0 NcPm9hl'`luvuN ~N/gT"}b^<\Rlu0 2 [NYKb/gRdvegLvuN RFAve$vuX[sT;`uX[s{|fW]_0MWATRFAُ$Nyme_v bS9hnc$vv'Y\0MOnQ[0 4 PEI(uNv_d"3cmLvvlu @\ YSsؚNRFA FOPEI[v_d"2cmvLvmHegnxR ܏guHe{|euI{0 4.4.2 TACEv^ 1 CNLC IIb0IIIaTRIIIbgLvuN RChild-PughA~bB~ PSċR0^2R2 SNKb/gRd FO1uNvQNSVYؚ0%N͑lxSI{ Nb N?acSKb/gluvCNLC Ib0IIagLvuN3 Y ;Nr^*g[hQ;^X b}[hQ;^XFOY NP'`O/e@{0N[bǏY /eg ieQSN YY @AmvLvuN4 R - YRAm bY ؚSQ@vLvuN5 LvRd/gT DSASNegSskLvb YSvp v^~NTACElu0 4.4.3 TACEy_ 1 R%N͑xRChild-Pugh C~ SbĞu0'`u0l'`yTymb~T_I{2 el~ckvQ@Rx3 Y ;Nr^[hQLvhh^X NO/e@{b_b\4 Tv^;mR'`pb%N͑agN N Telu5 $v܏Y^lly 0OuX[e3*Ng6 v`m(bYhV[pz7 $v`ShQSOyvkOe"70%YgRW,gck8^ SQǑ(u\ϑxlsNBRT|'`h^XBRR!kh^X 8 YhT@}v~ހT@\g>fWQ\ }v~ހ3.0109/L @\g50109/L^~[y_ Y>RNۏ cdSu'`Ӛb6R 9 Rx@P2mg/dLb@Pnds30mL/min0 4.4.4 TACEd\O z^pTR{| ADDIN EN.CITE <EndNote><Cite><Author>-NNS;Sf[O>e\f[RONeQf[~OS\O~</Author><Year>2011</Year><RecNum>11411411417</ref-type><contributors><authors><author><style face="normal" font="default" charset="134" size="100%">-NNS;Sf[O>e\f[RONeQf[~OS\O~</style></author></authors></contributors><titles><title><style face="normal" font="default" charset="134" size="100%">SS'`~ހLv~[{R Su'`h^Xlub/gd\OĉN[qQƋ</style></title><secondary-title><style face="normal" font="default" charset="134" size="100%">-NNS>e\f[Bg_</style></secondary-title></titles><periodical><full-title>-NNS>e\f[Bg_</full-title></periodical><pages>908-912</pages><volume>45</volume><number>1020111005-1201http://d.g.wanfangdata.com.cn/Periodical_zhfsx201110003.aspx10.3760/cma.j.issn.1005-1201.2011.10.003<remote-database-provider><style face="normal" font="default" charset="134" size="100%">SNNepencN gPlQS</style></remote-database-provider><language>chi</language></record></Cite></EndNote>[ HYPERLINK 153]ncI{~3  1 R q_ 8^Ǒ(uSeldingerel ~vz:RR _c{b[ gagNvuNǑ(u~vz:RahR _c{ \[{nNyTr^b;`R LDSA q_ q_VPǑƖ^SbR g0[(gSY g^ZP| NR I{ q_0la[~bO/eO@0N~Rg q_hs fnx$vMO0'Y\0pevNSO@R 02 9hncR c{Su0h^Xd\Ov N T 8^R:N `$R LplSuTransarterial infusion TAI ~$vO@R LplSu 8^(uSuoir gs{|0”{|I{0a$R h^XTransarterial embolization TAE US~(uh^XBR5X^X$vvO@R 0b$TACEbSuoirNh^XBRmT(WNw ~$vvO@R /eleQ0TACElug8^(uvh^XBR/fxlsNBRQ+TSuoir 0hQSfwm~|0zz}v_t0ZYNp|Toirm1_t0HQLplNRSuoir N,Lple N^20 min06qT\SNRSuoirNxlmTbsNBRۏLh^X0xl(uϑN,:N5^20 mL NǏ30 mL0(WƉvƉ NOnc$v:Sxlly/f&TSm[0$vhT/f&T]QsY \R/eq_:NLuP0(WxlsNBRh^XTR(u|'`h^XBR0c!PO(umSYNxlNSuoirEQRmTbsNBR =\ϑMQh^XBRSAmh^Xck8^~~bۏeQ^vhV[0h^Xe^=\ϑh^X$vv@b gO{Q@{ N=\ϑO$vS@{S0 4.4.5 TACE/gT8^ NoS^Tv^Su TACEluvg8^ NoS^/fh^XT~T_ ;Nhs:NSp0uu0v`_TUTTI{0Sp0uuvSuSV/fR h^XT_w@\~~:@0OW{k v`_0UTT;NNSuoir gsQ0dkY ؏ gz:RMOQ@0}v~ހ NM0NǏ'`R_8^0R_c[NSc?\VI{vQN8^ NoS^0NeQlu/gTv NoS^Oc~5^7d ~[uluT'YYpeuNSN[hQb` Y0v^Su%`'`0R_c[mSSQ@ƀVpTƀVzT[TƀAl$vb_bh^XBR_MOh^XSbxSlTh^X0mSSzT[0 Ӛ_c$O0_c$OI{ 0 4.4.6 TACEluvuHeċN 9hnc[SO$vmRECISTċNhQNSEASLċNhQċ0OLv@\萗uHe guHech:NuN;`uX[eOverall survival OS wguHe:N[‰^T{sObjective response rate ORR 0TACEluuuۏU\eTime to progress TTP 0 4.4.7q_TTACE܏guHev;NV } ADDIN EN.CITE Lencioni201612012012017Lencioni, R.de Baere, T.Soulen, M. C.Rilling, W. S.Geschwind, J. F.Division of Vascular and Interventional Radiology, University of Miami Miller School of Medicine, Miami, FL. Department of Interventional Radiology, Institut Gustav-Roussy, Villejuif Cedex, France. Division of Interventional Radiology, University of Pennsylvania, Radnor, PA. Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety dataHepatologyHepatologyHepatologyHepatology106-166412016Jul1527-3350 (Electronic) 0270-9139 (Linking)26765068http://www.ncbi.nlm.nih.gov/pubmed/2676506810.1002/hep.28453[ HYPERLINK \l "_ENREF_147" \o "Lencioni, 2016 #120" 147] 1 lxS z^0Rr`2 @nAFP4ls^3 $vv[yTwϑ4 $vS/f&T[te5 Y geLvh6 $v@O`Q7 $vvutf[RW8 uNvSOr`9 gba'`YNWuk'`p̀ofuNv@nHBV-DNA4ls^0 4.4.8 STACEglu N,^,{1!kTACEluT4^6hTe YgCTTb MRI0$vvsQh_ir0RT@8^ĉhgI{q_Pf[hg>f:y$vvpQvxllySm[0$v~~OW{kNeX'YTeeuvp feSN NZPTACElu0NT~TACEluv!k^O~g [ ;NSbuN[ NN!kluvS^0RTSOrQvSS0eS1^3*Ngbfe OncCTTb MRIR`X:_kbcċN$vvX[;m`Q NQ[/f&TQ!kۏLTACElu0FO/f [N'YLv/]WWWLv8^2^4!kvTACElu0vMR;N _~TTACElu sSTACETTvQNluel vv/fc6R$v0cؚuNu;m(ϑTuN&^$vguX[0 4.4.9 TACElulap 1 c!P(u_[{ b'`c{0ceQ$vvO@R /e |Q0WleQxlsNBRT|'`h^XBR NcؚuHeTObR02 SO(uY Q/egneQ/gTx-125|P[agbx-125|P[Y /egneQ/g gHeYtY ;Nr^Lvh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_154" \o "Yang, 2014 #132" 154]ncI{~2 0Ǒ(ux-125|P[agbvcz:R ieQx-125|P[luY N~R/eLvh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 155]03 TACETT@\萈mluvMR g$NyTACETTpmlue_0`$^/mHQLTACElu /gT1^4hTQR(u@\萈mlu0a$ Tekm(WTACEluv Te~N@\萈mlu SNf>fcؚ4N^uHe v^Q{R_c$O ADDIN EN.CITE <EndNote><Cite><Author>Si</Author><Year>2016</Year><RecNum>129</RecNum><DisplayText><style face="superscript">[156]</style>12912917Si, Z. M.Wang, G. Z.Qian, S.Qu, X. D.Yan, Z. P.Liu, R.Wang, J. H.Shanghai Institute of Medical Imaging and Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Department of Intervention Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. Shanghai Institute of Medical Imaging and Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: jianhuawang2011@sina.com.Combination Therapies in the Management of Large (>/= 5 cm) Hepatocellular Carcinoma: Microwave Ablation Immediately Followed by Transarterial ChemoembolizationJ Vasc Interv RadiolJournal of vascular and interventional radiology : JVIRJ Vasc Interv RadiolJ Vasc Interv RadiolJournal of vascular and interventional radiology : JVIR2016Apr 181535-7732 (Electronic) 1051-0443 (Linking)27103146http://www.ncbi.nlm.nih.gov/pubmed/2710314610.1016/j.jvir.2016.02.014[ HYPERLINK \l "_ENREF_156" \o "Si, 2016 #129" 156]ncI{~2 0:NcؚTACEuHe ;N _(WTACEluW@x NL`TTmlu04 |'`h^XBRv^(uSbhQSfwm~|0ZYNp|0_tToirm1_tI{08^ĉTACENy:NC-TACE 8^O(u&^SuoirvxlsNBRNhQSfwm~_|0zz}v_t0ZYNp|I{TT0oir'`m1_tDrug-eluting beads DEB /fNyevh^XBR SNR}SuoirluLvNy:ND-TACE FONC-TACEvkluv;`SOuHee>fW]_05 ͑Ɖ@\萠R@\萻luT@\TThQlu ADDIN EN.CITE Lencioni201612012012017Lencioni, R.de Baere, T.Soulen, M. C.Rilling, W. S.Geschwind, J. F.Division of Vascular and Interventional Radiology, University of Miami Miller School of Medicine, Miami, FL. Department of Interventional Radiology, Institut Gustav-Roussy, Villejuif Cedex, France. Division of Interventional Radiology, University of Pennsylvania, Radnor, PA. Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety dataHepatologyHepatologyHepatologyHepatology106-166412016Jul1527-3350 (Electronic) 0270-9139 (Linking)26765068http://www.ncbi.nlm.nih.gov/pubmed/2676506810.1002/hep.28453[ HYPERLINK \l "_ENREF_147" \o "Lencioni, 2016 #120" 147]`$TACETT@\萈m SbRFA0MWA0QQI{lu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_154" \o "Yang, 2014 #132" 154]ncI{~2 0a$TACETTY>e\ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_154" \o "Yang, 2014 #132" 154]ncI{~2 ;NcY ;Nr^Lvh0 NTY LvhT@\P'`'YLvNeQluTvlu0b$TACETTNgYyKb/gRd'YLvb]WWWLv(WTACEluT)\v^_Kb/g:gOe cPYyKb/gRd ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_154" \o "Yang, 2014 #132" 154]ncI{~3 0c$TACETTvQNluSbTTRP[vToir0MQulu0|~Su0>e\MQuvToirYx-131hvYfUSKQbSO I{0d$TACETTbuklu[ gYNWuk'`p0NWuk'`p̀ofLvuNTACElu Te^ygbuklu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_157" \o "Jang, 2004 #2220" 157]ncI{~3 0 TACEяgvluۏU\DU_60 p 1 TACE/fLv^Kb/glug8^(uvelKNN0 2 ^%Ne\lu0RP[vToir0MQulu0bukluI{~TluNۏNekcؚTACEuHe0 9 [Lv4OY ;Nr^bN~R/eLvhSO(uY Q/egneQ/gTTx-125|P[lubvcz:R ieQx-125|P[ۏLlu0 4.5>e\lu >e\lu{y>eu R:NY>euTQ>eu0Y>eu/f)R(u>euYNuv\~IQP[b|P[ NSOY[$vgq\0Q>eu/f)R(u>e\'`8h } ~:gSO{SbǏS ieQ$vQ0 4.5.1Y>e\lu 1 Y>e\lu^`$CNLC Ia0RIbgLvuN YeKb/gRdb@\萈mlu^b N?acS gRlu _NSQǑ(uLvzSO[T>euStereotactic body radiation therapy SBRT \O:NfNluKbk ncbSvQuX[eNKb/gRdb@\萈mlu{|eu S9eU@\萧c6Rs0^uX[e US(uTACE0"}b^<\bTACETT"}b^<\luvuHe}Y ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_159" \o "Chino, 2018 #138" 159  HYPERLINK \l "_ENREF_166" \o "Ohri, 2016 #146" 166-172]ncI{~2 SS_Ǒ(u0b$CNLC IIIbgLvuNR[lyvp SLSBRT ^uX[eY>eu_NSQ{m]~000b Nzly@buu0h;bQ@I{ur ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 173-175]ncI{~3 0c$NRelKb/gRdvLvuN$v>euT)\bMg SlS:NKb/gRd ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 173  HYPERLINK \l "_ENREF_176" \o "Wang, 2015 #154" 176  HYPERLINK \l "_ENREF_177" \o "Sapisochin, 2017 #149" 177]ncI{~2  ADDIN NE.Ref.{64344E0A-7183-4750-BD6D-F9BCB0F69BE0}Y>eu_NS(uNI{_Lvy i/gMRvehcluLvKb/gRݍ$vd"1cmvzR/gTSNR>eu Q\uvp@\ YSb܏Yly ^uNeuuۏU\g ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_176" \o "Wang, 2015 #154" 176  HYPERLINK \l "_ENREF_177" \o "Sapisochin, 2017 #149" 177]ncI{~3 0 2 Y>e\luy_LvuNYQuvp%_ceR^ bCNLC IVg N^LY>e\lu0 3 Y>e\lu[eSRNpLvY>eu[eSR:N~TQ$vgq\BRϑ hTVck8^~~SBRϑ NS@bǑ(uv>eub/g0 LvY>eu[ep:N`$>euR6R[e Quvp(WX:_CT-N[IN _eSMRIq_PI{Yyq_PDe S)R(uck8^~~vQuR >eueOYuRck8^ NSgq\ SORck8^~~_Xu0a$Lvgq\BRϑ NuNuX[eS@\萧c6Rs[RvsQ W,gSQNhTck8^~~vSBRϑ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_162" \o "Bujold, 2013 #135" 162  HYPERLINK \l "_ENREF_178" \o "Byun, 2019 #136" 178]0Lvgq\BRϑzSO[T>euN,cPe"30^60Gy/3^6!k ADDIN EN.CITE <EndNote><Cite><Author>f-fQ</Author><Year>2015</Year><RecNum>133</RecNum><DisplayText><style face="superscript">[179]</style></DisplayText><record><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="dww9d0de72psede9wsd5r02srt2vveafw5za" timestamp="1565785729">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" charset="134" size="100%">f-fQ</style></author></authors></contributors><auth-address><style face="normal" font="default" charset="134" size="100%"> Ye'Yf[D^\-Nq\;Sb>euy</style><style face="normal" font="default" size="100%">, </style><style face="normal" font="default" charset="134" size="100%"> Nwm</style><style face="normal" font="default" size="100%">,200032</style></auth-address><titles><title><style face="normal" font="default" charset="134" size="100%">~ހLvvzSO[T>e\lu</style></title><secondary-title><style face="normal" font="default" size="100%"></style><style face="normal" font="default" charset="134" size="100%">-NNS$vBg_</style></secondary-title></titles><pages>650-652,653</pages><number>9</number><keywords><keyword>Lv</keyword><keyword>~ހ</keyword><keyword>>e\ul</keyword><keyword>zSO[Tb/g</keyword></keywords><dates><year>2015</year></dates><isbn>0253-3766http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhzl20150900410.3760/cma.j.issn.0253-3766.2015.09.0042300230017<author>-NNS;Sf[O>e\$vf[RO</author><author>-NVuir;Sf[] zf[O|nx>euROLvf[~NmS|~$vN[YXTO</author><author>-NVxvzW;Sbf[O>e\$vf[ROLvf[~</author></authors></contributors><titles><title>2016t^SS'`Lv>euqQƋ</title><secondary-title>-NNS>e\$vf[Bg_</secondary-title></titles><periodical><full-title>-NNS>e\$vf[Bg_</full-title></periodical><pages>1141-1150</pages><volume>25</volume><number>11</number><keywords><keyword>$v/>e\ul</keyword><keyword>$v</keyword><keyword>SS'`</keyword><keyword>qQƋ</keyword></keywords><dates><year>2016</year></dates><isbn>1004-4221</isbn>http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfszl20161100110.3760/cma.j.issn.1004-4221.2016.11.001SNNepencN gPlQS</remote-database-provider><language>chi</language></record></Cite></EndNote>[ HYPERLINK 173]0 4.5.2Q>e\lu >e\'`|P[ ieQ/f@\萻luLvvNyel Sb90Y_tul0131IUSKQbSO0>e\'`xSl0125I|P[ ieQI{ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_36" \o "Cheung, 2013 #22" 36  HYPERLINK \l "_ENREF_174" \o "Jihye, 2012 #2174" 174  HYPERLINK \l "_ENREF_175" \o "Soliman, 2013 #152" 175]0|P[ ieQb/gSb~~ ieQ0Y ieQ0 NTY ieQTƀSQ ieQ R+RluQuvp0Y Lvh0 NTY LvhTƀ{QLvbLvh0/lS689Sr S\Q\~ S(uNvTluLvlyuvp ADDIN EN.CITE <EndNote><Cite><Author>-NNS;Sf[O8h;Sf[ROly'`$vlu]\OYXTO</Author><Year>2018</Year><RecNum>2207</RecNum><DisplayText><style face="superscript">[181]</style></DisplayText><record><rec-number>2207</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">2207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>-NNS;Sf[O8h;Sf[ROly'`$vlu]\OYXTO</author></authors></contributors><titles><title>/lS6[89Sr]luly'`$vN[qQƋ(2017t^Hr)</title><secondary-title>-NNS8h;Sf[NRP[q_PBg_</secondary-title></titles><periodical><full-title>-NNS8h;Sf[NRP[q_PBg_</full-title></periodical><pages>412-415</pages><volume>6</volume><number>38</number><dates><year>2018</year></dates><urls></urls><remote-database-provider>SNNepencN gPlQS</remote-database-provider></record></Cite></EndNote>[ HYPERLINK 181]ncI{~3 0 p 1 CNLC Ia0RIbgLvuN YeKb/gRdb@\萈mlu^b N?acS gRlu _NSQǑ(uLvzSO[T>eu\O:NfNluKbk0 2 CNLC IIa IIb0IIIagLvuN TACETTY>eu S9eU@\萧c6Rs0^uX[ SS_Ǒ(u0 3 CNLC IIIbgLvuNR[lyvp SLSBRT>eu ^uX[Y>eu_NSQ{m]~000b Nzly@buu0h;bQ@I{ur0 4 R$v>euT)\bMgS_Kb/gRd:gOY>eu_NS(uNLvy i/gMRehclubzRRd/gTRlu0 5 $vgq\BRϑzSO[T>euN,cPe"30^60Gy/3^6!k 8^ĉRrR>euN,:N50^75Gy gq\BRϑNuNuX[[RvsQ0 6 ck8^~~vSBRϑ_{Q>euRrRe_0RChild-PughR~0ck8^-$v SOy0ÀSv@TQ@RrQI{0 7 VP_[>euON N~b_>eub:_>eub/g zSO[T>eu_{(WVP_[>eu NۏL0 8 >e\'`|P[ ieQ/f@\萻luLvvNyel /lS6S(uNvTluLvlyuvp0 4.6|~lu [NZfgLvuN gHev|~luSNQ{$vw 9eU$vvsQur cؚu;m(ϑ ^uX[e0vMR|~luHegN N=\YNa uNSNSRTv4N^xvz0 Yo`N~0N~|~luv^;N:N1 Tv^ g@{OrbYlyvCNLC IIIa0IIIbgLvuN2 }:N@\uS FO NTKb/gRdbTACEvCNLC IIbgLvuN3 Tv^Y ;Nr^b NTY $vh4 Y!kTACET@{;^XTb TACEluTۏU\vuN0v[y_;N:N1 ECOG PSċR2R RChild-PughċR7R2 -N͑^ӚRx3 0Rf>f_8^ Y(lWlyvASTbALT 5 Pck8^

fWGSؚ2 Pck8^

f ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_184" \o "Pressiani, 2013 #147" 184]0la[HBVTRvq_T c!PhQ z{tW@xu0g8^v NoS^:Nyl0SO(ϑ NM0Kb~T_0vu0_:@NSؚ@SI{ N,Su(Wlu_YTv2^6hTQ0 2 NOf<\ NOf<\Lenvatinib (uN NSRdvCNLC IIb0IIIa0IIIbg0RChild-Pugh A~vLvuN vQN~luHeg NRN"}b^<\ HBVvsQLvwQ g}YvuX[v ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_185" \o "Kudo, 2018 #169" 185]ncI{~1 0NOf<\]~_ybQ(uNRChild-Pugh A~vZfgLvuN0(ul:NSO(ϑe"60kg 12mg S g ke1!kSO(ϑ<60kg 8mg S g ke1!k08^ NoS^:Nؚ@S0yl0ߘ2k NM0uR0Kb~T_0ˆ}v?\0v`_NS2urzRQI{0 3 |~Su FOLFOX4eHh(WbVybQ(uNlu NTKb/gRdb@\萻luv@\ZfgTly'`Lv ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_186" \o "Qin, 2013 #172" 186  HYPERLINK \l "_ENREF_187" \o "Qin, 2014 #173" 187]ncI{~1 0YyIIgxvzbJT+TeYl)R”v|~SuTT"}b^<\SO[‰㉇s g@bcؚ eۏU\uX[eT;`uX[eGW g^ N[hQ'`o}Y ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_188" \o "Assenat, 2019 #164" 188]ncI{~3 0[NRTSORr`o}YvuN SQdkTTlu FO\4N^:g[gqxvzcOؚ~+R_;Sf[nc0SY N'lSN7x[-NZfgLvwQ gN[vYo`lu\O(u ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 189]ncI{~3 (W4N^^(ue^lavKmT2bkk'`0 4.6.2 N~lu 1 ^tb^<\ ^tb^<\Regorafenib ybQ(uNe_cSǏ"}b^<\luvCNLC IIb0IIIaTIIIbgLvuN ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_190" \o "Bruix, 2017 #166" 190]ncI{~1 0(ul:N160mg ke1!k ޏ(u3hT \P(u1hT0(WbV RYBRϑSǑ(uN!k80mgb120mg ke1!k 9hncuNvS`QnXϑ08^ NoNN/fؚ@S0KbvS^0ONRSylI{0 2 vQNN~lueHh VFDAybQ~fk)R$\USKQbSONivolumab T HYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" ^ZS)RsUSKQbSOPembrolizumab (uNe_ HYPERLINK "https://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" "}b^<\luTۏU\belS"}b^<\vLvuN ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_191" \o "El-Khoueiry, 2017 #167" 191  HYPERLINK \l "_ENREF_192" \o "Zhu, 2018 #175" 192]ncI{~2 0vMR -NVON;NxSvMQuhgpb6RBR YaS^t)RsUSKQbSO0yr^tnf)RUSKQbSO0O)RUSKQbSOI{ck(W_U\4N^xvz0MQuluNvToir0Suoir0@\萻luvTTeHh_N(W Ne0Wc"}-NDh8 0MQuvsQk'`S^Immune-related adverse events irAEs SSu(Wv0^y~QRl0ÀS000_0I{T*N|~0yr+Rf`MQu'`p0p0pT_pI{%N͑ NoS^0N, -N^b͑^irAEs-NeMQuhgpb6RBRv^/T(u|v({|VMQub6RBRlu Yt^9hnc NoS^SuvMOT%N͑ z^ _ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_193" \o "Brahmer, 2018 #165" 193-195]0ck(WۏLNMQuhgpb6RBR gsQvxvzDU_80 vQNMQuBRYr^pb }0z1I{  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_109" \o "Sun, 2006 #104" 109  HYPERLINK 196]0~ހMQuluYL]TbSSSOT~ހulsSCAR-T ADDIN EN.CITE <EndNote><Cite><Author>Wang</Author><Year>2018</Year><RecNum>2176</RecNum>2176217617Wang, Y.Chen, M.Wu, Z.Tong, C.Dai, H.Guo, Y.Liu, Y.Huang, J.Lv, H.Luo, C.Feng, K. C.Yang, Q. M.Li, X. L.Han, W.Department of Molecular & Immunology, Chinese PLA General Hospital, Beijing, China. Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing, China. Department of 3Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trialOncoimmunologyOncoimmunologye1440169772018/06/15Adoptive T cell therapiesCd133advanced metastasis malignanciesautologous T cellschimeric antigen receptor (CAR)phase I trialtherapeutic trials20182162-4011 (Print) 2162-4011 (Linking)29900044https://www.ncbi.nlm.nih.gov/pubmed/29900044PMC599348010.1080/2162402X.2018.1440169eng[ HYPERLINK \l "_ENREF_197" \o "Wang, 2018 #2176" 197]0~ހVP[[v@g$O~ހulsSCIK ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_198" \o "Lee, 2015 #170" 198] GW gN[b$v\O(u FO\_'Yĉ!jv4N^xvzRN0 dkY VFDAybQ HYPERLINK "https://www.uptodate.com/contents/zh-Hans/92811?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" aSZSf<\(uNN~|~luTۏU\vLvuN ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_199" \o "Abou-Alfa, 2018 #163" 199]ncI{~1 ybQ HYPERLINK "https://www.uptodate.com/contents/zh-Hans/100927?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" USKQbSO(uN@nAFP4ls^e"400ng/mLLvuNvN~lu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_200" \o "Zhu, 2015 #177" 200  HYPERLINK \l "_ENREF_201" \o "Zhu, 2019 #176" 201]ncI{~1 0FO/f ُ$Nyoir\*g(WVQ N^0VN\RP[b@{ubvToir?^f<\(uNLvuNN~luv4N^xvzck(WۏL-N0 4.6.3 vQNlu 1 -N;S-Nolu -N;S-NoluY9eU4N^ur cؚ:gSOvbbR Q{>eSu NoS^ cؚuNvu;m(ϑ0 `$ l ADDIN EN.CITE <EndNote><Cite><Author>-NNS-N;Sof[O</Author><Year>2008</Year><RecNum>2284</RecNum><DisplayText><style face="superscript">[202]</style></DisplayText><record><rec-number>2284</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1574499100">2284</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>-NNS-N;Sof[O</author></authors></contributors><titles><title>-NNS-N;Sof[OhQ(ZYYXH/T136-156-2008):$v-N;SʋucWS</title></titles><dates><year>2008</year></dates><pub-location>SN</pub-location><publisher>-NV-N;SoQHr>y</publisher><urls></urls></record></Cite></EndNote>[ HYPERLINK 202] A >Z ;Nu NyWW N m&vONR &P `wl y~\ ۏߘTu Sr^ NUn 'YOnpe \OĞw uRQsy4l0Ğu0 Nnm0  (ր0 Ԃ}v &_~0 lleP>vl uoZW0 cPeo eceTVTP[dlRQ0ZQS15g0}v/g15g0/ӂ15g0ChN9g0g10g0S_R_10g0}v15g0kQg-g15g0]4g10g0hP[10g0/g9g0uuI6gI{0 Bƀnp ;Nu4Y͑V vĞg _pf` SpS4n Sr^ u u|pp yn NuWW ~FTUTv` \Ow\Ğd 'YOy~b N=r0  (~0 ԂĞ{ &_peb&_n0 llnp)Rn Q@k0 cPeo5HdlRsT0~5H20g0hP[10g0'YĞ10g0ёI15g0*sӂ15g0g10g0}v15g0ё10g0]]iP[6g0gX10g0JSg15g0NSNg15g0fMRI10g0ll10gI{0 C p@v ;Nu NyWWwlx vuub c buub c bpu N pp Sr^Uq 'YOr^~ \OĞbwd uR2u0  (~bf~ Ԃ}vS &_peb&_n gR0 llnQ@ k[yv0 cPeoƀldlT Nv@dlRQ0ƀI10g0JSg15g0hP[10g0ll10g0(g6g0fMRP[10gSNq 0u0WĞ15g0g10g0ChN9g0/g9g0'YĞ10g09h15g09Nv15g0uuI6gI{0 D>ZnV ;Nuy'Yn ^yuONR ͑~FT ͑ ?\\0S| N2kn eɉv`_ 'YOnp0  m gu ԂS{ ~&_bnbo0 lleP>vl )Rnk0 eoVTP[dlTNvnRQ0Ğ20g0ZQS15g0}v/g15g0/ӂv15g0D10g0gX10g0Hv6g0'Yyv10g0Qtv10g0ll10g0N20g0u10g0ChN9g0/g9g0JSg15g0uI6gI{0 E4Z ;Nú نyRK{ Vg&v wlUO U~Sr^ ~FTOuߘ p N w nwOpe ub_cxd^ N N@n0  (~~0 IQeԂ ~peeR b YDU0 lRnp{Q4 oZWce~0 eoN/NqRsT0u0W15g0lS10g0Q10g0S_R_10g0g^gP[15g0Qh9iP[15g0]]iP[6g0d15g0֜2u15gHQNq 0sYP[15g0eI15g09Nv10gI{0 a$-No6RBR dNǑ(u O~vl0 g(udlBRKNY bVovN]ybQNr^ysN-No6RBRYi3|S(uNKb/gRdTvRluncI{~1  ADDIN EN.CITE <EndNote><Cite><Author>m</Author><Year>2012</Year><RecNum>2290</RecNum><DisplayText><style face="superscript">[203]</style></DisplayText><record><rec-number>2290</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1574857877">2290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>m</author><author>ke[</author><author>eN</author><author>hTePV</author><author>u^Q</author><author>Ğ/c</author><author>hTwmm</author><author>Ngj</author><author>NgS</author><author>us^</author><author>!^:_</author></authors><translated-authors><author>Y. A. N. Tao</author><author>B. I. Xin-yu</author><author>Fang Yi</author><author>Zhou Jian-guo</author>Zhao Jian-junHuang ZhenZhou Hai-taoL. I. CongL. I. YuanZhao PingC. A. I. Jian-qiang100021, SNOST;Sf[b-NV;Sf[yf[b$v;SbyYy</auth-address><titles><title>i3|[SS'`Lv`/gTguX[vq_T</title><secondary-title>-NNSƀYyBg_</secondary-title></titles><periodical><full-title>-NNSƀYyBg_</full-title></periodical><pages>99-102</pages><volume>18</volume><number>2</number><keywords><keyword>SS'`Lv</keyword><keyword>i3|</keyword><keyword>ly YS</keyword></keywords><dates><year>2012</year></dates><isbn>1007-8118</isbn><urls><related-urls><url>http://www.wanfangdata.com.cn/details/detail.do?_type=perio&amp;id=zhgdwk201202006</url></related-urls></urls><electronic-resource-num>10.3760/cma.j.issn.1007-8118.2012.02.006</electronic-resource-num><remote-database-provider>SNNepencN gPlQS</remote-database-provider><language>chi</language></record></Cite></EndNote>[ HYPERLINK 203]0SY ip0NS }0^yr0^~0 YPN0ёV0~0&ƀP[lNS YeeeVI{(uNluLv ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK 204-210]ncI{~4 wQ gN[vuHe uNvON'`0[hQ'`TS'`GW}Y FO/fۏNekĉS4N^xvzN_ؚ~+Rv_;Sf[nc/ec0 b$-N;Syrrul Axplu 9hncu`S4N^[ES b^(uSO04Y05u030U0<Cite><Author>-NNS;Sf[Oaguf[RO</Author><Year>2019</Year><RecNum>2285</RecNum><DisplayText><style face="superscript">[211]</style></DisplayText><record><rec-number>2285</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1574500277">2285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>-NNS;Sf[Oaguf[RO, -NNS;Sf[Ouf[RO</author></authors></contributors><titles><title>ba'`YNWp2lcWS(2019t^Hr)</title><secondary-title>-NNS4N^aguBg_</secondary-title></titles><periodical><full-title>-NNS4N^aguBg_</full-title></periodical><pages>1674-2397</pages><volume>12</volume><number>6</number><dates><year>2019</year></dates><urls></urls></record></Cite></EndNote>[ HYPERLINK 211]ncI{~1 0[NHCVvsQLv Yg gp;mR^^LvcbukoirDirect-acting antiviral agents DAA bZYNNr^pb }TT)R]旗gbuklu ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_212" \o ", 2015 #240" 212  HYPERLINK \l "_ENREF_213" \o "European Association for the Study of the Liver. Electronic address, 2018 #241" 213]ncI{~1 0 LvuN(W6qu z-NbluǏ z-NSO4OR_8^ ^SeS_0WO(uwQ gbp0Mv0b'lS0k0)RƀT~ހO YOb\O(uvOoir Y_uIxAl\m0uIxN0 YeuIx0Ss04lޘ߄ }0؏SW7u0zˆ(lx0qS'lƀx0Ypxpƀx0LNSNNI{0ُNoirSNObR0cؚlu[hQ'` MNOv^SuT9eUu;m(ϑ0 3 [u/eclu [NZfgLvuN ^~NgsO/eclu SbygGu0~ck+@0~ckNO}vˆ}v@u0R:_%{Q/ec c6RTv^|?\uuNv@|4ls^ Yty4l0Ğu0'`u0mSSQ@S~T_I{v^Su0[ gurvlyuN SO(uSxxv{|oir0SY ^v^ YЏRSNX:_uNvMQuR0 Te tuNS[^\v_` ǑSygvce Sboirlu tevQv^vr` bmg_tlS:Nyg_t ǏubvQN g[hQa0a Q\bN&qQ0 4 |~luvuHeċN [NǑ(u|~luvuN vMR'YYǑ(uRECIST 1.1hQۏLuHeċN0[NcSb@{RP[vTluvuN STTmRECISThQ0[NcSMQuhgpb6RBRluvuN _NSSiRECISThQ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_214" \o "Seymour, 2017 #2178" 214] p 1 [Nl gy_vZfgLvuN ^RuNygSR4N^[0 2 Yo`N~0N~|~luv^;N:N`$Tv^ g@{OrbYlyvCNLC IIIa0IIIbgLvuNa$}:N@\uS FO NTKb/gRdTTACEvCNLC IIbgLvuNb$Tv^Y ;Nr^b NTY $vhc$Y!kTACET@{;^XTb TACEluTۏU\vuN0 3 ZfgLvuNvYo`N~lueHhS b"}b^<\0NOf<\b+TeYl)R”v|~Su0 4 N~Yo`lueHhS b^tb^<\0 5 [N NSb N?acSN~TN~|~luvLvuN S^-N;S-NoSgsO/eclu0 6 (Wb$vluv Te ^ygc6RW@xu Sbbuk0O)Rƀlu ؏L`ۏL/ec[uluI{0 4.7Lv4xˆlu Lv4xˆ/fLv\o(Wv{k'`v^Su US~O[lu(Wbu{ksgؚ Vdk(WgRbQebRT ^EQRċ0OuN@AmRRf[0R0hQ`QNS$v/f&TSRd 6R*NSOSlueHh ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_215" \o "Yoshida, 2016 #205" 215-218]0 1 [N$vSRd0PYRo}Y0@AmRRf[3z[vuN Kb/gRd ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_219" \o "Aoki, 2014 #2181" 219  HYPERLINK \l "_ENREF_220" \o "Lai, 2006 #2179" 220]ncI{~2 0 2 [NPYR] @AmRRf[ N3z[0eKb/gagNvuN S bTAE ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_221" \o "Shin, 2011 #2180" 221]ncI{~4 0 3 S%`ʋagNP6R RS$v`QelEQRċ0O SHQLTAE ~TT~ċ0OQ bv^lueHh LNgKb/gRdS_>fWvuX[v ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_219" \o "Aoki, 2014 #2181" 219]ncI{~2 0 DU_ DU_1 ncI{~[r%m_;Sf[-N_2011Hr 4N^ ek1ek2ek3ek4ek5I{~1* I{~2* I{~3* I{~4* I{~5* ُ*Nuu gYnfM?`us S_0Wv S_MRv:g7h,ggbnfg NS_0W`Qv9SMgv|~~**S_0Wv ^:g7h,gg**uO|R**N/AʋebvKm[/f&TQnxʋe N0W^(uNShQTvlv*jebxvzv|~~N0W^(uNShQTvlv*jebxvz^ޏ~uOxvz bxvz*gN0W^(uShQ**uO[gqxvz b^(uN]vb^rzvShQ**WN:g6Rvct N~Nُ*NluOSuNHN?T wYRxvzv|~~wYRxvzRxvzb:gxvzv[gq~*uO|RbuO[gqxvz bNO(ϑTRxvz**N/Aُ*Nlu g(uT? luHev :g[bUSuO:g[gq[v|~~:g[bwQ g]'YHegv‰['`xvz^:g[gqR/xvz**uO|R uO[gqxvz bSS[gqxvz**WN:g6Rvctُ*Nlu8^v$O[/fNHNlu$O[ :g[v|~~ ]_uO[gqxvzv|~~ [`O@bc4N^uNvn-of-1[ wQ g]'YHegv‰['`xvzUS*N:g[byrk0W wQ g]'YHegv‰['`xvz^:g[gqR/xvz N^TvKm cO Ypeϑegcd8^v$O[[g$O[Yve **uO|R uO[gqxvz bSS[gqxvz**WN:g6Rvctُ*Nlu\v$O[/fNHN?lu$O[ :g[bn-of-1[v|~~:g[byrk0W wQ g]'YHegv‰['`xvzُ*N[egSs <Cite><Author>Zhou</Author><Year>2016</Year><RecNum>2190</RecNum><DisplayText><style face="superscript">[222]</style></DisplayText><record><rec-number>2190</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">219017Zhou, J.Huang, A.Yang, X. R.Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 20032, China. zhou.jian@zs-hospital.sh.cn. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 20032, China.Liquid Biopsy and its Potential for Management of Hepatocellular CarcinomaJ Gastrointest CancerJ Gastrointest Cancer157-674722016/03/13Biopsy/*methodsCarcinoma, Hepatocellular/*therapyDNA, Neoplasm/*geneticsFemaleHumansLiver Neoplasms/*therapyMaleNeoplastic Cells, Circulating/*pathologyGenetic aberrationsHepatocellular carcinomaLiquid biopsyNext-generation sequencing2016Jun1941-6636 (Electronic)26969471https://www.ncbi.nlm.nih.gov/pubmed/26969471</url></related-urls></urls><electronic-resource-num>10.1007/s12029-016-9801-0</electronic-resource-num><language>eng</language></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_222" \o "Zhou, 2016 #2190" 222]0 _s8nymiRNA~T[NRLvegʋewQ gؚNeuTLv YSTۏU\wQ gKm\O(u ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_226" \o "Guo, 2014 #2189" 226] N TMOvCTCKm N Tly{|W ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_227" \o "Sun, 2018 #2198" 227]0 ctDNA/f1u$vʑ>eYhT@vyr_'`zSDNAGrk YS^$vvWV~Oo` S(uNegʋe0vKm$vۏU\S[luS^I{0 gbS ctDNA(uNLvegʋevupOe^Tyr_^GWON@nAFP ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_228" \o "Qu, 2019 #2200" 228  HYPERLINK \l "_ENREF_229" \o "Huang, 2016 #2192" 229] ؏SS^Lv/gTR`SS ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_230" \o "Huang, 2017 #2195" 230  HYPERLINK \l "_ENREF_231" \o "Huang, 2016 #2194" 231]0_N gbS )R(uyr[WVh‰W OOpyr_ Y2uWS ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_232" \o "Cai, 2019 #2201" 232]05-hmc ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_233" \o "Li, 2017 #2197" 233]I{_NS(uNLvegʋe0 WV~0"$2:>DFJLNPRVXnpƻƻuhZhZhM<!jhheOJQJUaJhhpOJQJaJhhYoOJQJaJo(hhYoOJQJaJh;h*5CJh;hp5CJQJh;hW5CJOJQJo(hWQJaJo(h>hJo7QJaJh>hJo7QJaJo(hghWQJaJhghWQJaJo(hA,h*5CJOJQJo(hA,hp5CJOJQJhA,hp5CJOJQJo($PX8 4 "fT ! WD`gd^gdH WD`gdak@$-DM WD`a$gdak@gdak@YD2gd6 WD`gdak@$dYD2a$gd6$a$   d f h j l n p ⽩}b}P}5}5j)hhQ H*OJQJUaJmHnHu#hH*OJQJaJmHnHo(u5jhhQ H*OJQJUaJmHnHu&hhQ H*OJQJaJmHnHu/jhhQ H*OJQJUaJmHnHu&hhx-H*OJQJaJmHnHu!jhheOJQJUaJ'jhhx-OJQJUaJ!jhhx-OJQJUaJhhx-OJQJaJ   ( * 0 2 > @ ~    $ & * , . 4 6 8 V X d f ββΥΘthBInhpOJQJaJhBInhpOJQJaJo(hpQJaJo(hh*OJQJaJhh.OJQJaJhh.OJQJaJo(hhpOJQJaJo(hhpOJQJaJ!jhheOJQJUaJ&hhx-H*OJQJaJmHnHu-f t x   , .     N | 㙌~n^hBInhNZ5OJQJaJo(hBInhp5OJQJaJo(hBInh^rOJQJaJo(hBInhJo7OJQJaJhBInhJo7OJQJaJo(hBInh8=OJQJaJo(hBInhpOJQJaJhBInhp5OJQJ\aJ!hBInhp5OJQJ\aJo(hBInhpOJQJaJo(hBInh.OJQJaJo(!  .24PR`jóueueueueXJXJXJXhhpCJ^JaJo(hhpCJ^JaJhhp@CJ^JaJo(hhp@CJ^JaJ h*5aJhp5QJaJhp5KHQJaJhp5KHaJhp5KHaJo(hh^r5OJQJaJo(h;h*5CJKHh;hp5CJKHQJh;h^r5CJOJQJo( h*aJhBInh*OJQJaJ &(,.6>@LPTVdfjlt|~Ķ׶׶ħ׶׶׶ssssY2hh^rB*CJ^JaJfHph333q hhp@CJ^JaJo($hhpB*CJ^JaJo(ph!hhpB*CJ^JaJphhhp@CJ^JaJhhpCJ^JaJo(%hhp@B*CJ^JaJphhhpCJ^JaJhh^rCJ^JaJhh^rCJ^JaJo(" ,046<>@FHfhͺںںͬڛoo[oGo'j#hheCJU^JaJ'jhheCJU^JaJ!jhheCJU^JaJhh^rCJ^JaJo(hh^rCJ^JaJ!hh^rB*CJ^JaJphhhpCJ^JaJo($hhpB*CJ^JaJo(phhhpCJ^JaJ!hhpB*CJ^JaJph(hhp@B*CJ^JaJo(ph  ".0JNdfк񩜏vmgWEWEW7h*@B*KHaJph"hp@B*KHQJaJo(phhp@B*KHQJaJph h*aJhp5QJaJhhho5OJQJaJo(hOU5QJaJhh*CJ^JaJhhpCJ^JaJ!jhheCJU^JaJ*j,hhQ CJH*U^JaJhhQ CJH*^JaJ$jhhQ CJH*U^JaJhhpCJH*^JaJfprtxz| $&:Fdf:tvxǼǼDZǟ{m{{{{{{{{{{{hh$xOJQJaJo(hhhoOJQJaJo(hhhoOJQJaJh^5QJaJhho5QJaJo( hp5aJh5QJaJo(hp5QJaJo(hp5QJaJ,hhp5@B*KHOJQJaJph/hhho5@B*KHOJQJaJo(ph*PRTVXZ\^fhӫӝ|||f|VHhhho5OJQJaJhhho5OJQJaJo(*j?hhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhhoH*OJQJaJ'je6hhhoOJQJUaJ'jK-hhhoOJQJUaJ!jhhhoOJQJUaJhhhoOJQJaJhhhoOJQJaJo(ɸ个schhho5OJQJaJo(*j?hhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhhoH*OJQJaJ!jhhhoOJQJUaJhhhoOJQJaJo(hh$xOJQJaJhhhoOJQJaJhh$xOJQJaJo(!04FHJVX`dhjƵƵơl^^^H*jrhhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhhoH*OJQJaJ'jYhhhoOJQJUaJ'je@hhhoOJQJUaJ!jhhhoOJQJUaJhhhoOJQJaJhhhoOJQJaJo(hhho5OJQJaJo(hhho5OJQJaJ 68:߻~p~ccO'jshhhoOJQJUaJhhhoOJQJaJhhho5OJQJaJhhho5OJQJaJo(hhhoOJQJaJo(!jhhhoOJQJUaJhhhoH*OJQJaJ*j4shhQ H*OJQJUaJhhH*OJQJaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJ:<>@B̹ڇhPC8Chp5OJQJaJhp5OJQJaJo(/hhp5@B*KHOJQJaJo(ph/hh5@B*KHOJQJaJo(ph h*5aJhhhoOJQJaJo(*j?hhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhhoH*OJQJaJ!jhhhoOJQJUaJ'j}hhhoOJQJUaJ  $ & 8 : F H P R T !!!!!""""##:#<#>#ø~~~~m`m`Lm'jhheOJQJUaJhhpOJQJaJ!jhheOJQJUaJhhpOJQJaJo(h*OJQJaJhpOJQJaJhpOJQJaJo(hgh*OJQJaJhOJQJaJo(h^5OJQJaJh5OJQJaJo(hp5OJQJaJhp5OJQJaJo(h5OJQJaJo(>#@#B#D#F#########$$$$ $$$$$$ $"$̹q_O_DhOJQJaJo(hhp5OJQJaJo(#hhp@CJKHOJQJo(*jhhQ H*OJQJUaJhhH*OJQJaJ*jhhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ!jhheOJQJUaJ'jhheOJQJUaJ"$$$$$$$$$$$$$$R%T%V%`%b%d%f%h%űҝҏ|nX|n|F#hhp@CJKHOJQJo(*jjhhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ'jhheOJQJUaJ'jrhheOJQJUaJhhpOJQJaJ!jhheOJQJUaJhhpOJQJaJo(hhJOJQJaJo(!$$%)+-~-./8pCDE*LnOpOOS S,SS$WD`a$gd> WD`gd^ WD`gd> WD`gd^gdak@ WD`gdak@h%p%r%t%%%%%%%%&&&&&:&<&d&f&h&j&l&n&p&´§š´‰uaS@$jhhQ H*OJQJUaJhhpH*OJQJaJ'j39hheOJQJUaJ'jhheOJQJUaJ!jhheOJQJUaJhh*OJQJaJhhpOJQJaJhhfeOJQJaJo(hhpOJQJaJo(#hhp@CJKHOJQJo(hhp5OJQJaJhhp5OJQJaJo(p&&&&&&&&&&&B'D'J'P'x'|'~'''''''''Ⱥykyky^y^yPyByPyhh$xOJQJaJo(hhGhOJQJaJo(hhpOJQJaJhhfeOJQJaJo(hhpOJQJaJo(hhp5OJQJaJo(#hhp@CJKHOJQJo(!jhheOJQJUaJhhpH*OJQJaJ$jhhQ H*OJQJUaJ*jYhhQ H*OJQJUaJhhQ H*OJQJaJ'(((( (D(F(d(f((((((((((((())) )ӫӝ|f|TDhhp5OJQJaJo(#hhp@CJKHOJQJo(*jkhhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ'jbhheOJQJUaJ'jYhheOJQJUaJ!jhheOJQJUaJhhpOJQJaJhhpOJQJaJo( )))))D)P)r)t)))))))))))**&*ѶѥpbOAAAAhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ'juhheOJQJUaJ'jilhheOJQJUaJhhpOJQJaJ!jhheOJQJUaJhhGhOJQJaJo(hh*OJQJaJhhpOJQJaJo(#hhp@CJKHOJQJo(hhp5OJQJaJ&*(***.*0*2*4*6*>*@*B*P*T*v*z****++<+>+@+׻zl_lQl___='j6hheOJQJUaJhhGhOJQJaJo(hhpOJQJaJhhpOJQJaJo(hhp5OJQJaJhhp5OJQJaJo(#hhp@CJKHOJQJo(!jhheOJQJUaJhhpH*OJQJaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJ*j~hhQ H*OJQJUaJ@+B+D+F+H+++++++++++++++++̹ڃseWJW=WhhpOJQJaJhhOUOJQJaJhhpOJQJaJo(hhp5OJQJaJhhp5OJQJaJo(#hhp@CJKHOJQJo(*jΖhhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ!jhheOJQJUaJ'jhheOJQJUaJ+++++,,, ,>,@,^,`,,,,,,,,,,,,---ŴӴӠ~k]Gk]k~*jshhQ H*OJQJUaJhhQ H*OJQJaJ$jhhQ H*OJQJUaJhhpH*OJQJaJ'j۵hheOJQJUaJ'jChheOJQJUaJ!jhheOJQJUaJhhpOJQJaJo(hhpOJQJaJ!hhGhhGhOJQJaJo(hhGhOJQJaJo(------- -B-D-Z-\-p-r-x-z-|-ss^I4)hb"5@B*KHOJQJaJo(ph)h15@B*KHOJQJaJo(ph)h5@B*KHOJQJaJo(ph&hp5@B*KHOJQJaJph)hp5@B*KHOJQJaJo(ph/hhGh5@B*KHOJQJaJo(phhh*OJQJaJhhpOJQJaJo(hhp5OJQJaJhhp5OJQJaJo(#hhp@CJKHOJQJo(|-~----.... ...Z.^.b.p.t.........../ڲڲڲڲڲڲڊr[,hhp5@B*KHOJQJaJph/hh j5@B*KHOJQJaJo(ph&hJ@B*KHOJQJaJo(ph&h j@B*KHOJQJaJo(ph&hb"@B*KHOJQJaJo(ph&hu@B*KHOJQJaJo(ph#hb"@B*KHOJQJaJph&h^5@B*KHOJQJaJph// ////B/D/T/V/n/p/~//////00иvavavJvJv3vvv,hhp@B*H*KHOJQJaJph,hh@B*KHOJQJaJo(ph)hhp@B*KHOJQJaJph,hhp@B*KHOJQJaJo(ph,hh j@B*KHOJQJaJo(ph&h^5@B*KHOJQJaJph/hh j5@B*KHOJQJaJo(ph,hhp5@B*KHOJQJaJph/hh!5@B*KHOJQJaJo(ph0 00,0.0V0X0Z0\0^0`00ϺgF*7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphu7hhx-@B*H*KHOJQJaJmHnHphu8jhhx-@B*KHOJQJUaJph2jhhx-@B*KHOJQJUaJph)hhx-@B*KHOJQJaJph2jhhe@B*KHOJQJUaJph,hhp@B*KHOJQJaJo(ph 0000000$1&1(1,1.10121ܻ_C)2jhhe@B*KHOJQJUaJph7hhx-@B*H*KHOJQJaJmHnHphuFjwhhQ @B*H*KHOJQJUaJmHnHphu7hh@B*H*KHOJQJaJmHnHphu7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphuFjhhQ @B*H*KHOJQJUaJmHnHphu 2141>1B1D1T1Z111111122v\v?\8jhhx-@B*KHOJQJUaJph2jhhx-@B*KHOJQJUaJph)hhx-@B*KHOJQJaJph2jhhe@B*KHOJQJUaJph)hhp@B*KHOJQJaJph,hh j@B*KHOJQJaJo(ph/hhp5@B*KHOJQJaJo(ph,hhp@B*KHOJQJaJo(ph2222l2n2p2t2v2x2z2222222¦¦f¦B¦FjhhQ @B*H*KHOJQJUaJmHnHphu7hh@B*H*KHOJQJaJmHnHphuFjhhQ @B*H*KHOJQJUaJmHnHphu7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphu7hhx-@B*H*KHOJQJaJmHnHphu222223<3>3\3^333333ϷϠqTq87hhx-@B*H*KHOJQJaJmHnHphu8jhhx-@B*KHOJQJUaJph2jhhx-@B*KHOJQJUaJph)hhx-@B*KHOJQJaJph,hh j@B*KHOJQJaJo(ph/hhp5@B*KHOJQJaJo(ph,hhp@B*KHOJQJaJo(ph2jhhe@B*KHOJQJUaJph33333333344\4^4`4d4f4h4ß߃_C7hhx-@B*H*KHOJQJaJmHnHphuFjhhQ @B*H*KHOJQJUaJmHnHphu7hh@B*H*KHOJQJaJmHnHphuFj*hhQ @B*H*KHOJQJUaJmHnHphu7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphuh4j4l4t4v4z4|444444444ϷωtZt=Z8jhhx-@B*KHOJQJUaJph2jhhx-@B*KHOJQJUaJph)hhx-@B*KHOJQJaJph,hh j@B*KHOJQJaJo(ph,hhp5@B*KHOJQJaJph/hhp5@B*KHOJQJaJo(ph,hhp@B*KHOJQJaJo(ph2jhhe@B*KHOJQJUaJph444^5`5b5f5h5j5l5555555¦¦f¦B¦Fj(hhQ @B*H*KHOJQJUaJmHnHphu7hh@B*H*KHOJQJaJmHnHphuFjD(hhQ @B*H*KHOJQJUaJmHnHphu7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphu7hhx-@B*H*KHOJQJaJmHnHphu55555566 6 6*6,6T6V6X6Z6\6^6ϷϠnQ:,hhp@B*H*KHOJQJaJph8j\chhe@B*KHOJQJUaJph8j.)hhe@B*KHOJQJUaJph)hhp@B*KHOJQJaJph,hh j@B*KHOJQJaJo(ph/hhp5@B*KHOJQJaJo(ph,hhp@B*KHOJQJaJo(ph2jhhe@B*KHOJQJUaJph^6`66666666666677\7`7777ͯ~gOgggg~:)hhx-@B*KHOJQJaJph/hhp5@B*KHOJQJaJo(ph,hhp@B*KHOJQJaJo(ph2jhhe@B*KHOJQJUaJph,hhp@B*H*KHOJQJaJph;jhhQ @B*H*KHOJQJUaJph,hhQ @B*H*KHOJQJaJph5jhhQ @B*H*KHOJQJUaJph7777777788@8Ѵ~]AAA7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphu7hhx-@B*H*KHOJQJaJmHnHphu2jhhe@B*KHOJQJUaJph8jhhx-@B*KHOJQJUaJph)hhx-@B*KHOJQJaJph2jhhx-@B*KHOJQJUaJph @8B8D8H8J8L8N88888888ܻ_C)2jhhe@B*KHOJQJUaJph7hhx-@B*H*KHOJQJaJmHnHphuFjbhhQ @B*H*KHOJQJUaJmHnHphu7hh@B*H*KHOJQJaJmHnHphu7hhQ @B*H*KHOJQJaJmHnHphu@jhhQ @B*H*KHOJQJUaJmHnHphuFjhhQ @B*H*KHOJQJUaJmHnHphu 8888888899 9"9:::: :<<==>>??@@AABBBBBBoW/jhQ @B*H*KHOJQJUaJph&hp@B*H*KHOJQJaJph,jhe@B*KHOJQJUaJph#hp@B*KHOJQJaJph&hp@B*KHOJQJaJo(ph&h j@B*KHOJQJaJo(ph)hh*@B*KHOJQJaJph,hhp@B*KHOJQJaJo(ph"BPCRCTCXCZC\C^C`ChCjCnCpCvCѹ칥zeQz?(,heb h j@B*KHOJQJaJo(ph#h*@B*KHOJQJaJph&hp5@B*KHOJQJaJph)hp5@B*KHOJQJaJo(ph&hp@B*KHOJQJaJo(ph,jhe@B*KHOJQJUaJph&hp@B*H*KHOJQJaJph/jhQ @B*H*KHOJQJUaJph5jױhQ @B*H*KHOJQJUaJph&hQ @B*H*KHOJQJaJph vCCCCCCCCDDDD&D(D4D6DTDVD~DDDDD馦ԌoR8jLheb he@B*KHOJQJUaJph8jLheb he@B*KHOJQJUaJph2jheb he@B*KHOJQJUaJph,heb haU@B*KHOJQJaJo(ph,heb h@B*KHOJQJaJo(ph)heb hp@B*KHOJQJaJph,heb hp@B*KHOJQJaJo(phDDDDDDDDDDDDE EEEEηηoaQCCQ8h^5OJQJaJheb haU5OJQJaJheb haU5OJQJaJo(heb h*5OJQJaJheb h"75OJQJaJo(2jheb he@B*KHOJQJUaJph;jLheb hQ @B*H*KHOJQJUaJph,heb hQ @B*H*KHOJQJaJph5jheb hQ @B*H*KHOJQJUaJph,heb hp@B*H*KHOJQJaJphE.E0EXE\EbEpErEvE~EEEEEEEEEEFFιι󨛊vbJ66&heb hQ H*OJQJaJmHnHu/jheb hQ H*OJQJUaJmHnHu&heb hx-H*OJQJaJmHnHu'jheb hx-OJQJUaJ!jheb hx-OJQJUaJheb hx-OJQJaJ!jheb heOJQJUaJ)heb hp@B*KHOJQJaJph,heb hp@B*KHOJQJaJo(phheb hpOJQJaJo(heb hpOJQJaJF F2F4F6F:FF@FFFFFFFFFFFFѹ칥승veWG9Wheb hp5OJQJaJheb hp5OJQJaJo(heb hpOJQJaJo(!jheb heOJQJUaJ&heb hx-H*OJQJaJmHnHu5jnheb hQ H*OJQJUaJmHnHu&heb hH*OJQJaJmHnHu/jheb hQ H*OJQJUaJmHnHu5jheb hQ H*OJQJUaJmHnHu&heb hQ H*OJQJaJmHnHuFFG G(G2G6GDGHGVGZGdGfGhGlGtGvGxGGGGGGHHHIIIJJJKKKKKKKй~k$jheb hQ H*OJQJUaJheb hpH*OJQJaJ!jheb heOJQJUaJheb hWcOJQJaJo(heb haUOJQJaJo(,heb hp@B*KHOJQJaJo(ph)heb hp@B*KHOJQJaJphheb hpOJQJaJo(heb hpOJQJaJ&KKKKKKKKLL(L*L4L6L:LBLZL^LhLtLvLxL|LLLLLLLLLLLLM MM4MN NȺssesssssssssssssheb h_o[OJQJaJo(heb hpOJQJaJheb h*OJQJaJheb h8=OJQJaJo(heb hpOJQJaJo(!jheb heOJQJUaJheb hpH*OJQJaJ$jheb hQ H*OJQJUaJ*jheb hQ H*OJQJUaJheb hQ H*OJQJaJ' NNNNNNNNlOnOpOvOOOOOOOOOOOOPPP,P QQQQRRR:R㺱vhhWW!jheb heOJQJUaJheb hq OJQJaJo(heb h8=OJQJaJheb hp5OJQJaJheb hp5OJQJaJo(heb haU5OJQJaJo(hOU5QJaJheb h*5OJQJaJheb hpOJQJaJheb h8=OJQJaJo(heb hpOJQJaJo(heb hOKOJQJaJo(":RR@RBRDRFRRRRRRRRRRRRRRRRRRSS SSڸsfsfsfsXKXKXKXheb h~OJQJaJheb h~OJQJaJo(heb hpOJQJaJheb hpOJQJaJo(*jxheb hQ H*OJQJUaJheb hQ H*OJQJaJ$jheb hQ H*OJQJUaJheb hpH*OJQJaJ'jheb heOJQJUaJ!jheb heOJQJUaJ'jXheb heOJQJUaJSSSSS S,SSSSSST&T(T*TxTzTTTU UUUUUUU˻{k]F,heb hp5@B*KHOJQJaJphheb hp5OJQJaJheb hq 5OJQJaJo(hOU5QJaJheb hOKOJQJaJo(heb hOUOJQJaJheb hJOJQJaJo(heb h"7OJQJaJo(heb h"75OJQJaJo(hOUQJaJheb hOUOJQJaJo(heb h~5OJQJaJo(heb h~5OJQJaJSS*TzTT UUUU\VVVX``daaa$a$gd\ $a$gdak@$a$gdg WD`gd> WD`gd^ WD`gdak@gdak@$WD`a$gd>UUUUUUUUUVVV$V0V6VPVTVZV\V`VbVfVhVVVVVVVVVVVVVVVܲܲܥܲܗwiw^h^5OJQJaJheb hp5OJQJaJheb hp5OJQJaJo(heb hl5OJQJaJo(heb h*OJQJaJo(heb h*OJQJaJheb hpOJQJaJo(heb hlOJQJaJo(heb hq OJQJaJo(heb hpOJQJaJ,heb h*5@B*KHOJQJaJph$VVVVVJWLWbWnWWWWWWWWWWWWWWWXXX X@XBXZZ[[\\b]d]f]ԷԷԩԟԩԩԒsseheb hpH*OJQJaJ!jheb heOJQJUaJheb hlOJQJaJo(heb h*OJQJaJhl\OJQJaJheb hpOJQJaJo(heb hpOJQJ^JaJo(heb h_o[OJQJaJheb hpOJQJaJheb hlOJQJ^JaJo(heb hOUOJQJaJo(%f]h]]]]]]]]]]]]]]]]^^^^^^^^^ ^&^(^<^@^B^H^\^b^r^t^z^^^^^^^^vh1OJQJaJo(heb hp5OJQJaJheb hpOJQJaJo(heb hpOJQJaJ!jheb heOJQJUaJheb hpH*OJQJaJ*jheb hQ H*OJQJUaJheb hQ H*OJQJaJ$jheb hQ H*OJQJUaJ,^^^_$_&_,_._0_2_6_x_|____________``2`4`6`:`ععإpbbbLpb*jrheb hQ H*OJQJUaJheb hQ H*OJQJaJ$jheb hQ H*OJQJUaJheb hpH*OJQJaJ'jheb heOJQJUaJ'jbheb heOJQJUaJ!jheb heOJQJUaJheb hpOJQJaJo(heb hpOJQJaJheb hi1OJQJaJo(heb hi1OJQJaJ:`<`>`@`B`J`L`N`P``````````ι}obTbboFo9heb h*OJQJaJheb hi1OJQJaJo(heb hOKOJQJaJo(heb hOKOJQJaJheb hpOJQJaJo(heb hpOJQJaJ/heb hp5@B*KHOJQJaJo(ph,heb hp5@B*KHOJQJaJph)heb hp@B*KHOJQJaJph!jheb heOJQJUaJheb hpH*OJQJaJ$jheb hQ H*OJQJUaJ`````badafahavaaaaaaaaaaaaabbd׹{k^Q@QQQ!jhvBheOJQJUaJhvBhpOJQJaJhvBh*OJQJaJhvBhp5OJQJaJo(hvBhW5OJQJaJo(hvBhp5OJQJaJhvBhA5OJQJaJo(heb h\5OJQJaJo(heb hp5OJQJaJheb hOK5OJQJaJo(heb h~:5OJQJaJo( h8yaJ$jhjh WD`gd> WD`gd^gdak@$1$7$8$H$WD`a$gd}. WD`gd}. WD`gd>@hBhDhFhhhhhhZi^i`ibifiiiiiiiijjzj|jjjjjjjjjõõӨӉuaShvBhpH*OJQJaJ'jhvBheOJQJUaJ'jAnhvBheOJQJUaJ!jhvBheOJQJUaJhvBh%<OJQJaJo(hvBhpOJQJaJhvBh~5OJQJaJhvBh~:5OJQJaJo(hvBhpOJQJaJo(hvBhp5OJQJaJo(hvBhp5OJQJaJ jj2k4k6k@kBkDkFkHkJkPknkrkkkkkllmmnnooppqqrrsssssstt4t6t8tl*jhvBhQ H*OJQJUaJhvBhpOJQJaJhvBh*OJQJaJhvBhpOJQJaJo(!jhvBheOJQJUaJhvBhpH*OJQJaJ*jhvBhQ H*OJQJUaJhvBhQ H*OJQJaJ$jhvBhQ H*OJQJUaJ*8tt@tBtDtLtNtPtRtVtXtbtfthtntvtxt|tttttttttttttttttttttt.u0uNuпxxxmxmhvBOJQJaJo(hvBhAOJQJaJo(hvBhpOJQJaJo(hvBhp5OJQJaJo(hvBhp5OJQJaJhvBhpOJQJaJ!jhvBheOJQJUaJhvBhpH*OJQJaJ$jhvBhQ H*OJQJUaJhvBhQ H*OJQJaJ*NuPuxuzu|u~uuuuuuuuuuuuuuuuvvvvvBvDvFvHvJvLvNv|hT'jqhvBheOJQJUaJ'jרhvBheOJQJUaJhvBhAOJQJaJo(hvBhQ H*OJQJaJ$jhvBhQ H*OJQJUaJhvBhpH*OJQJaJ'jhvBheOJQJUaJ'jshvBheOJQJUaJhvBhpOJQJaJ!jhvBheOJQJUaJ NvvvvvvvvvvvvvLwRwXw^wdwrw|w~wwwȺ~qcccqSFhvBhOUOJQJaJhvBhA5OJQJaJo(hvBhpOJQJaJo(hvBh*OJQJaJhvBhp5OJQJaJo(hvBhp5OJQJaJhvBhpOJQJaJ!jhvBheOJQJUaJhvBhpH*OJQJaJ$jhvBhQ H*OJQJUaJ*j hvBhQ H*OJQJUaJhvBhQ H*OJQJaJwwwwwwwwwwwwwwwwwwwxxxzzz|||R}T}V}X}p}r}v}x}z}|}~}}ɼɝ䝏|n|n|hvBhQ H*OJQJaJ$jhvBhQ H*OJQJUaJhvBhpH*OJQJaJ!jhvBheOJQJUaJhvBh>%OJQJaJo(hvBh>%OJQJaJhvBhpOJQJaJo(hvBhOUOJQJaJhvBhpOJQJaJhvBhOUOJQJaJo('}}}}}}}}~~~,~.~N~P~R~X~b~f~j~p~~~~~~~~~~~~^ݷݪМݎݎ݁sshvBh>%OJQJaJo(hvBh>%OJQJaJhvBhi1OJQJaJo(hvBhp0J,OJQJo(hvBhp0J,OJQJhvBh KOJQJaJo(h1OJQJaJo(hvBhpOJQJaJhvBhpOJQJaJo(h1OJQJaJhvBhpOJQJ*xz|tfYIfhvBh K5OJQJaJo(hvBh*OJQJaJhvBhpOJQJaJo(*jhvBhQ H*OJQJUaJhvBhQ H*OJQJaJ$jhvBhQ H*OJQJUaJhvBhpH*OJQJaJ'jNhvBheOJQJUaJ'jhvBheOJQJUaJhvBhpOJQJaJ!jhvBheOJQJUaJZ\z| ŴŠҌt`Et`t5jhvBhQ H*OJQJUaJmHnHu&hvBhQ H*OJQJaJmHnHu/jhvBhQ H*OJQJUaJmHnHu&hvBhx-H*OJQJaJmHnHu'jhvBhx-OJQJUaJ!jhvBhx-OJQJUaJhvBhx-OJQJaJ!jhvBheOJQJUaJhvBhpOJQJaJo(hvBhh#QOJQJaJo(xz|ZtxԑrdWWWWWIdr;rhvBh%<OJQJaJo(hvBh8yOJQJaJo(hvBh8yOJQJaJhvBhpOJQJaJo(hvBhh#QOJQJaJo(!jhvBheOJQJUaJ&hvBhx-H*OJQJaJmHnHu5jxhvBhQ H*OJQJUaJmHnHu&hvBhQ H*OJQJaJmHnHu/jhvBhQ H*OJQJUaJmHnHu&hvBhH*OJQJaJmHnHu҄Ԅք؄ڄ܄ބ>@BFHJL⬙ugQChvBhpOJQJaJo(*j8hvBhQ H*OJQJUaJhvBhH*OJQJaJ*j7hvBhQ H*OJQJUaJhvBhQ H*OJQJaJ$jhvBhQ H*OJQJUaJhvBhpH*OJQJaJ'j?$hvBheOJQJUaJ'jhvBheOJQJUaJ!jhvBheOJQJUaJhvBhpOJQJaJƅȅЅ҅څ܅ޅ .JNPĆƆȆŵttfXJAhOU5QJaJhvBh8yOJQJaJo(hvBh~5OJQJaJhvBh~:5OJQJaJhvBh~:OJQJaJo(hvBh%<OJQJaJhvBh%<OJQJaJo(hvBh~:OJQJaJh^5OJQJaJhvBh~:5OJQJaJo(hvBhp5OJQJaJhvBhJ5OJQJaJo(hvBhh#Q5OJQJaJo(hvBhJOJQJaJȆ҆Ԇچ"npv~‡Ƈȇ·Ї҇؇އȸȡԓxj]UE7hvBhp5OJQJaJhvBhw5OJQJaJo(h*QJaJhvBh*OJQJaJhvBhi1OJQJaJo(hvBhpOJQJaJhvBhwOJQJaJo(hvBhpOJQJaJo(hvBh*OJQJhvBh8yOJQJo(hvBh8y5OJQJaJo(hvBhpOJQJo(hvBh8yOJQJaJo(hvBhOU5OJQJaJhvBhp5OJQJaJo(އ&(NPRVXZ`flv|؈܈ 2<@NPðÅãxhZZZZZhvBhwOJQJaJo(hvBhw5OJQJaJo(hvBh*OJQJaJhvBhp5OJQJaJo(hvBhpOJQJaJo(hvBhpOJQJaJ$hvBh*5B*OJQJaJphhvBhp5OJQJaJ/hvBhp5@B*KHOJQJaJo(ph,hvBhp5@B*KHOJQJaJph#PVlntvxz.06<BLR.2>@vz$*hvBhJOJQJaJo(hvBhw5OJQJaJo(hvBh*OJQJaJhvBhpOJQJaJhvBhHOJQJaJo(hvBhwOJQJaJo(hvBhpOJQJaJo(; 24jlnv68:JL\ƲƲƞƲƲwƲ'h2yhhO5@KHOJQJ^JaJ$h2yhhO@KHOJQJ^JaJ'h2yhIg*@KHOJQJ^JaJo('h2yhhO@KHOJQJ^JaJo(*h2yhhO5@KHOJQJ^JaJo(/j{8hjhf5CJKHQJUmHnHuh*5CJKHQJ(n:ЎҎڎ`,  VD^gdak@ WD`gdak@ WD`gdak@YD2gd6gd$a$gdf $a$gdfgdfΎЎҎ֎؎ڎ&.068>@ïÙwlZJw9999999 h2yhp@KHOJQJaJh2yhp5CJKHOJQJ"h2yhY5CJKHOJQJo(hD35CJKHQJh2yh*5CJKHOJQJ#h2yhp5@KHOJQJaJ*h2yhp5@KHOJQJ^JaJo('h2yhIg*@KHOJQJ^JaJo('h2yhhO@KHOJQJ^JaJo(*h2yhhO5@KHOJQJ^JaJo($h15@KHOJQJ^JaJo(@JLR| "&.2:>BDFX\^`nprݺݔo h2yh*@KHOJQJaJ&h2yhIg*5@KHOJQJaJo(#h2yhIg*@KHOJQJaJo(&h2yhp5@KHOJQJaJo(#h2yhp5@KHOJQJaJ h2yh@KHOJQJaJ#h2yhp@KHOJQJaJo( h2yhp@KHOJQJaJ*r~ސ ",.튻ygSB h!hp@KHOJQJaJ&h!hp5@KHOJQJaJo(#h!hp5@KHOJQJaJ h2yh*@KHOJQJaJ#h2yhp@KHOJQJaJo( h2yh9N@KHOJQJaJhl\@KHOJQJaJ h2yhp@KHOJQJaJ#h2yh@KHOJQJaJo(h1@KHOJQJaJo(#h2yhvu@KHOJQJaJo(.024V^hlptvxƑȑʑ̑Α *,<>HJLNPrv˺˺˺˺˺˺˺˺˨˺˺˺˺˺˺x˺hak@@KHOJQJaJhl\@KHOJQJaJ&h!hp5@KHOJQJaJo(#h!hp5@KHOJQJaJ h!hp@KHOJQJaJ#h!hp@KHOJQJaJo(#h!hvu@KHOJQJaJo( h!h9N@KHOJQJaJ/vz~ʒ̒ΒВҒ 24>@BDFht˺˺xgU˺˺˺˺xgU˺˺#h!hvu@KHOJQJaJo( h!h5@KHOJQJaJhl\@KHOJQJaJ&h!hp5@KHOJQJaJo(#h!hp5@KHOJQJaJhak@@KHOJQJaJ h!hp@KHOJQJaJ#h!hp@KHOJQJaJo(#h!hi1@KHOJQJaJo( h!hi1@KHOJQJaJ!֓Ͻ{iX h!h*@KHOJQJaJ#h!hi1@KHOJQJaJo(h_\@KHOJQJaJo(hl\@KHOJQJaJ h!h5@KHOJQJaJ&h!hp5@KHOJQJaJo(#h!hp5@KHOJQJaJhak@@KHOJQJaJ#h!hp@KHOJQJaJo( h!hp@KHOJQJaJ *,.24ДҔ*кrbVKK?V4V4Vh5lhpOJQJh5lhvuOJQJo(h5lhvuOJQJh5lhpOJQJo(h5lh*5CJKHOJQJh5lhp5CJKHOJQJ"h5lh5CJKHOJQJo('h5lh*5@KHOJQJ^JaJ#h5lhp5@KHOJQJaJ*h5lhp5@KHOJQJ^JaJo(!h#B 5@KHOJQJ^JaJ;j hjhf5@KHOJQJU^JaJmHnHu ,4j@tΦl WD`gd>$WD`a$gd^$WD`a$gd^ $a$gdak@ WD`gdak@gdak@ WD`gdak@YD2gdXW $WD`a$ $WD`a$gdjΕؕ hjlt̸~l̸XIh^5@KHOJQJaJ&h5lhD35@KHOJQJaJo(#h5lh*5@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp5@KHOJQJaJ&h5lh5@KHOJQJaJo(&h5lhi15@KHOJQJaJo( h5lh*@KHOJQJaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ–",.>@BJLP`bdprt﷣ɑ}}iZI h5lhp>@KHOJQJaJh^5@KHOJQJaJ&h5lhNX75@KHOJQJaJo(&h5lhp5@KHOJQJaJo(#h5lhp5@KHOJQJaJ&h5lhi15@KHOJQJaJo(#h5lhvu@KHOJQJaJo(&h5lh5@KHOJQJaJo(#h5lh@KHOJQJaJo( h5lh@KHOJQJaJԗ "&,.26PRprܸܣܣ܋saJ,jh5lhQ @H*KHOJQJUaJ#h5lhp>@H*KHOJQJaJ/jTh5lhp>@KHOJQJUaJ/jh5lhp>@KHOJQJUaJ)jh5lhp>@KHOJQJUaJ#h5lhO@KHOJQJaJo(#h5lhi1@KHOJQJaJo( h5lhp>@KHOJQJaJ#h5lhp>@KHOJQJaJo( "$0PRfh™Ӽrr`r`rO:O)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ#h5lhO@KHOJQJaJo(#h5lhp>@KHOJQJaJo( h5lhp>@KHOJQJaJ)jh5lhp>@KHOJQJUaJ#h5lhp>@H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j0 h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJVXZ^`bdĚҽqqqqRq:q.h5lh@H*KHOJQJaJmHnHu=jiC h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu)jh5lhp>@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ/j%1 h5lhx-@KHOJQJUaJĚƚȚ̚ΚКҚBDFHJĬĔm\\D,/jT h5lhp>@KHOJQJUaJ/jSD h5lhp>@KHOJQJUaJ h5lhp>@KHOJQJaJ#h5lhp>@KHOJQJaJo()jh5lhp>@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu=jC h5lhQ @H*KHOJQJUaJmHnHuJLN "&(*,LXZnrtvxĪ֘~iWFWFFFWF h5lhp>@KHOJQJaJ#h5lhp>@KHOJQJaJo()jh5lhp>@KHOJQJUaJ2je h5lhQ @H*KHOJQJUaJ#h5lh@H*KHOJQJaJ2jWe h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp>@H*KHOJQJaJxz PQRTUVWǵr2jAf h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp>@H*KHOJQJaJ)jh5lhp>@KHOJQJUaJ h5lhp>@KHOJQJaJ#h5lhp>@KHOJQJaJo(, (,:<B\^bdrtzʦ̦ΦЦ֦ڦܦަܸ~llXl~&h5lhp5@KHOJQJaJo(#h5lhp5@KHOJQJaJ&h5lhNX75@KHOJQJaJo(&h5lhi15@KHOJQJaJo(#h5lh`5@KHOJQJaJ#h5lhQL7@KHOJQJaJo(#h5lhp>@KHOJQJaJo( h5lhp>@KHOJQJaJ#h5lhO@KHOJQJaJo( &(,BDPT\hlntx|~Чҧԧ֧اȶȶȶȶȶȤȶȶȶȶȏȏw_/jvo h5lhe@KHOJQJUaJ/jf h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ#h5lhO@KHOJQJaJo(#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ&h5lhNX75@KHOJQJaJo(#h5lh*5@KHOJQJaJ"اڧܧ8:<@BDFHPRTШҨĪ핈zjXGG h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(h5lhp5OJQJaJo(h5lhp5OJQJaJh5lhpOJQJaJ)jh5lhe@KHOJQJUaJ2j6x h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ "$&ҺҨeWG5#h5lhp@KHOJQJaJo(h5lhp5OJQJaJo(h5lhpOJQJaJo(2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/jG h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ/jx h5lhe@KHOJQJUaJΩЩ "$~ȘȆo]Co]o2j( h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j h5lhe@KHOJQJUaJ/jX h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJʪNT^`dثګܫijčččččxx`x/j h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo(&h5lhNX75@KHOJQJaJo( h5lh*@KHOJQJaJ h5lhp@KHOJQJaJh5lhp5OJQJaJo(h5lhp5OJQJaJh5lhpOJQJaJܫޫ>@BFHJLҬ}kQ?#h5lhp@KHOJQJaJo(2j h5lhQ @H*KHOJQJUaJ#h5lh@H*KHOJQJaJ2j1 h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/jg h5lhe@KHOJQJUaJҬԬܬެ "<>@n~пЙЙЙЙudЙR>&h5lha5@KHOJQJaJo(#h5lha@KHOJQJaJo( h5lh5@KHOJQJaJ#h5lh5@KHOJQJaJo(#h5lhNX7@KHOJQJaJo(#h5lhp@KHOJQJaJo(&h5lhNX75@KHOJQJaJo( h5lh*@KHOJQJaJ h5lhp@KHOJQJaJh5lhp5KHOJQJaJh5lhpKHOJQJaJҭ֭ 6>hjʹʹʹʹʹʤtbK,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j h5lhe@KHOJQJUaJ/j h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo( h5lha@KHOJQJaJ#h5lha5@KHOJQJaJ "&(*,.8Ӽo^^F./j h5lhe@KHOJQJUaJ/j h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j{ h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJFHJNPRTV^`dfܰo]K:K:K: h5lhp@KHOJQJaJ#h5lhNX7@KHOJQJaJo(#h5lhp5@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo(2j\! h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ  24jlnvұԱ\^d˷{gUCCCC܏#h5lhNX7@KHOJQJaJo(#h5lh&5@KHOJQJaJ&h5lh&5@KHOJQJaJo(&h5lhp5@KHOJQJaJo(&h5lhNX75@KHOJQJaJo(&h5lh::5@KHOJQJaJo(&h5lh*5@KHOJQJaJo( h5lhp@KHOJQJaJ h5lh*@KHOJQJaJ#h5lhp@KHOJQJaJo(l^\H@VpN `gd> WD`gd^ WD`gdak@ WD`gdak@ WD`gd> WD`gd>gdak@drtxz|~@BDpr^_`aʹʕlZ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJh5l@KHOJQJaJo( h5lhl\@KHOJQJaJ h5lhp@KHOJQJaJ#h5lhNX7@KHOJQJaJo(#h5lhp@KHOJQJaJo( Ͻϫs_K7%K#h5lhp5@KHOJQJaJ&h5lh55@KHOJQJaJo(&h5lh.,5@KHOJQJaJo(&h5lh::5@KHOJQJaJo( h5lh*@KHOJQJaJ#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j! h5lhQ @H*KHOJQJUaJ &*.2nҼԼ "$&ʵw_C7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu/jF" h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lh*5@KHOJQJaJ&ɭ譕v^I7#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu=jC3 h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu=j2 h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu46TV~ɴɴɜr[I/[I2jdE h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j< h5lhe@KHOJQJUaJ/j3 h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(&h5lhp5@KHOJQJaJo("*8:XZ³o^o^^F/jE h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(h5lhpKHOJQJaJo("h5lhp5KHOJQJaJo(h5lhp5KHOJQJaJh5lhpKHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ "&}kWEk4k4k4 h5lhp@KHOJQJaJ#h5lhp5@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo(2jZ h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/jO h5lhe@KHOJQJUaJ&*,HT HJLNPRTܯǗDžn\Bn\n2jp h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/je h5lhe@KHOJQJUaJ/jZ h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(8:XZ޺̥ޥލucL:#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j[y h5lhe@KHOJQJUaJ/jp h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ#h5lhY@KHOJQJaJo(#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ h5lh*@KHOJQJaJ24RT|~Ͻϫp^MM5/j0 h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ#h5lhp5@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j h5lhQ @H*KHOJQJUaJ&($&(*}kZkZZZZZZZZZ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(2j@ h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/j h5lhe@KHOJQJUaJ$&(*,.0Ͻϫsss[CϽ/jt h5lhe@KHOJQJUaJ/j* h5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j h5lhQ @H*KHOJQJUaJ<>@Ͻϫp____G/j3 h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j h5lhQ @H*KHOJQJUaJ@BDFHBDF}lZllllB/j h5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/jٻ h5lhe@KHOJQJUaJFHJLN$}lZlllB/je h5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/jr h5lhe@KHOJQJUaJJLNRTVXZ\^jlprvx~}l[IlIlIlIlIlIlIl#h5lhp@KHOJQJaJo( h5lh*@KHOJQJaJ h5lhp@KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ/j% h5lhe@KHOJQJUaJ<>fhjlnp޷yaE7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu/jZ h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ h5lh*@KHOJQJaJp68:>@BDFɭ譕v^I7#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu=ju h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu=j h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHuFHJL:<>@̷޷|b|2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ h5lh*@KHOJQJaJ&$(*HJrtvxz|~ȘȆo]Co]2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j h5lhe@KHOJQJUaJ/j_ h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ r±±±v^L#h5lhQ @H*KHOJQJaJ/j\ h5lhe@KHOJQJUaJ/jp h5lhe@KHOJQJUaJ#h5lhp@KHOJQJaJo( h5lh*@KHOJQJaJ h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJrtvz|~:Ͻϫp__M_;____#h5lh%<@KHOJQJaJo(#h5lhO@KHOJQJaJo( h5lhp@KHOJQJaJ&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo()jh5lhe@KHOJQJUaJ#h5lhp@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2jH! h5lhQ @H*KHOJQJUaJ:<dfhjlnpꗀnTnB#h5lhp@KHOJQJaJo(2j= h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j/ h5lhe@KHOJQJUaJ/j! h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ46^`bdfhڭyayayIya*=jK h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu)jh5lhe@KHOJQJUaJ/j> h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJlnr"&*>@㳞{i{{X{{{F#h5lhO@KHOJQJaJo( h5lh*@KHOJQJaJ#h5lh5@KHOJQJaJo(#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu@BJRTVhn|}~ƲkkY#h5lhN$@H*KHOJQJaJ)jh5lhN$@KHOJQJUaJ#h5lhN$@KHOJQJaJo( h5lhN$@KHOJQJaJh^5@KHOJQJaJ&h5lhN$5@KHOJQJaJo(#h5lhp5@KHOJQJaJ&h5lh55@KHOJQJaJo(&h5lh::5@KHOJQJaJo(~02PRz|~׽髖sbMb5M/jK h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ#h5lhN$@KHOJQJaJo( h5lhN$@KHOJQJaJ)jh5lhN$@KHOJQJUaJ#h5lhN$@H*KHOJQJaJ2jK h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJNPRXZ\^`̴̴}̴^̴I:h5lhN$KHOJQJaJ)jh5lhN$@KHOJQJUaJ=j_ h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu=j^ h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu`hjlnptz  &:>bdjνygyVD#h5lh::@KHOJQJaJo( h5lh::@KHOJQJaJ#h5lh%<@KHOJQJaJo(#h5lh_o[@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(h5lh*KHOJQJaJ h5lhN$@KHOJQJaJh5lhN$KHOJQJaJ"h5lhN$5KHOJQJaJo(h5lhN$5KHOJQJaJjn˺˺mUm=.h5lhx-@H*KHOJQJaJmHnHu/j~_ h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ)jh5lhe@KHOJQJUaJ#h5lhN$@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(#h5lh::@KHOJQJaJo( h5lh::@KHOJQJaJPRTZ\^`ˬu]H7 h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu=js h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu=js h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu 0>ʿtcQcccccQcQcQcQc#h5lhdBU@KHOJQJaJo( h5lhdBU@KHOJQJaJh^5@KHOJQJaJ&h5lhp5@KHOJQJaJo(&h5lhN$5@KHOJQJaJo(&h5lh::5@KHOJQJaJo(hB/<@KHaJo(#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhp5@KHOJQJaJ ".:<F^bdܵw_C7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu/jrt h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ)jh5lhdBU@KHOJQJUaJ#h5lhdBU@KHOJQJaJo( h5lhdBU@KHOJQJaJ#h5lhO@KHOJQJaJo( "$&ɭ譕v^I7#h5lhdBU@KHOJQJaJo()jh5lhdBU@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu=j h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu=jv h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu>@BDFHȷȥȓȥ~~f~N~<#h5lhdBU@H*KHOJQJaJ/jb h5lhdBU@KHOJQJUaJ/jd h5lhdBU@KHOJQJUaJ)jh5lhdBU@KHOJQJUaJ#h5lh_o[@KHOJQJaJo(#h5lhO@KHOJQJaJo( h5lhdBU@KHOJQJaJ#h5lhdBU@KHOJQJaJo(#h5lhdBU5@KHOJQJaJ&h5lhdBU5@KHOJQJaJo(HJ ׽髖p^M;#h5lhO@KHOJQJaJo( h5lhdBU@KHOJQJaJ#h5lhdBU5@KHOJQJaJ&h5lhdBU5@KHOJQJaJo(#h5lhdBU@KHOJQJaJo()jh5lhdBU@KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ2j` h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ.0XZ\^`b0ڭyaByay*ya.h5lh@H*KHOJQJaJmHnHu=jY h5lhQ @H*KHOJQJUaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu.h5lhx-@H*KHOJQJaJmHnHu)jh5lhdBU@KHOJQJUaJ/j׾ h5lhx-@KHOJQJUaJ)jh5lhx-@KHOJQJUaJ h5lhx-@KHOJQJaJ024:<>@ĬĔĬuĬ]H9h1@KHOJQJaJo()jh5lhdBU@KHOJQJUaJ.h5lhx-@H*KHOJQJaJmHnHu=jG h5lhQ @H*KHOJQJUaJmHnHu.h5lh@H*KHOJQJaJmHnHu.h5lhQ @H*KHOJQJaJmHnHu7jh5lhQ @H*KHOJQJUaJmHnHu=j h5lhQ @H*KHOJQJUaJmHnHu68`bdfhj˹iQ?#h5lhdBU@H*KHOJQJaJ/j h5lhdBU@KHOJQJUaJ/j h5lhdBU@KHOJQJUaJ)jh5lhdBU@KHOJQJUaJ#h5lhO@KHOJQJaJo( h5lhdBU@KHOJQJaJ#h5lhdBU@KHOJQJaJo(h1@KHOJQJaJo(#h5lhdBU5@KHOJQJaJ&h5lhdBU5@KHOJQJaJo(jl24\^`bdfh׽髖ss[C/jq h5lhdBU@KHOJQJUaJ/jA h5lhdBU@KHOJQJUaJ#h5lhO@KHOJQJaJo( h5lhdBU@KHOJQJaJ)jh5lhdBU@KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ>@BDϽϫwwfffffN6/j@5 h5lhdBU@KHOJQJUaJ/j* h5lhdBU@KHOJQJUaJ h5lhdBU@KHOJQJaJh5lhdBU5KHOJQJaJh5lhdBUKHOJQJaJ)jh5lhdBU@KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j) h5lhQ @H*KHOJQJUaJDFHJ "JLNPRrZB/jL h5lhdBU@KHOJQJUaJ/j@ h5lhdBU@KHOJQJUaJ#h5lhdBU@KHOJQJaJo( h5lhdBU@KHOJQJaJ2jh@ h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ)jh5lhdBU@KHOJQJUaJRTV &*,JLtvxĪ필rrrrrZ/jBY h5lhdBU@KHOJQJUaJ#h5lhdBU@KHOJQJaJo( h5lhdBU@KHOJQJaJ)jh5lhdBU@KHOJQJUaJ2jX h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhdBU@H*KHOJQJaJxz|~>BD "}lZlllllllllllllll#h5lhO@KHOJQJaJo( h5lhdBU@KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ)jh5lhdBU@KHOJQJUaJ/jm h5lhdBU@KHOJQJUaJ!ϽϫsfR@.s..#h5lhp@KHOJQJaJo(#h5lh*5@KHOJQJaJ&h5lhp5@KHOJQJaJo(hD3@KHQJaJo( h5lh*@KHOJQJaJ#h5lhdBU@KHOJQJaJo()jh5lhdBU@KHOJQJUaJ#h5lhdBU@H*KHOJQJaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ2j h5lhQ @H*KHOJQJUaJLNT\^bz~DFTV\nprxz|~ʹܧ#h5lh5@KHOJQJaJo(#h5lh@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhN$@KHOJQJaJo( h5lh*@KHOJQJaJ#h5lhp@KHOJQJaJo(:NVd  ,   & D $'0'3^=`=l== >>$? WD`gd>  WD` gdak@ WD`gdak@ WD`gd^gdak@ WD`gdak@ `gd>8@VXbdj  $ V X ^ v x               * , 2 n p v         ˹˹˹˹r&h5lhZq5@KHOJQJaJo(&h5lh::5@KHOJQJaJo(hD35@KHQJaJ#h5lhQL7@KHOJQJaJo(#h5lhZq@KHOJQJaJo( h5lh*@KHOJQJaJ h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(+ $ & ( 0 @ B D n p                        ®|||||||||m|m||T1jh5lhs;T@KHOJQJUaJmHsHh1@KHOJQJaJo(#h5lhs;T@KHOJQJaJo( h5lhs;T@KHOJQJaJh^5@KHOJQJaJ&h5lhZq5@KHOJQJaJo(&h5lh::5@KHOJQJaJo(,h5lh*5@B*KHOJQJaJph#h5lhp5@KHOJQJaJ  =>?BCDEҼmW+h5lhs;T@KHOJQJaJmHo(sH:jt h5lhQ @H*KHOJQJUaJmHsH+h5lhQ @H*KHOJQJaJmHsH4jh5lhQ @H*KHOJQJUaJmHsH+h5lhs;T@H*KHOJQJaJmHsH1jh5lhs;T@KHOJQJUaJmHsH(h5lhs;T@KHOJQJaJmHsH &(:<FHLNdfnpįvaKaKvKKaK+h5lhp@KHOJQJaJmHo(sH(h5lhp@KHOJQJaJmHsH#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ+h5lhQL7@KHOJQJaJmHo(sH(h5lhs;T@KHOJQJaJmHsH+h5lhs;T5@KHOJQJaJmHsH#h5lhs;T5@KHOJQJaJ&h5lhs;T5@KHOJQJaJo(  vxzꗀnTn</j h5lhe@KHOJQJUaJ2j? h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j h5lhe@KHOJQJUaJ/j h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJFHJPRTV`b}lllT</j h5lhe@KHOJQJUaJ/j h5lhe@KHOJQJUaJ h5lhp@KHOJQJaJ2jB h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ/j h5lhe@KHOJQJUaJ)jh5lhe@KHOJQJUaJ *,  !""""""""""""*#,#0#2#f#h####Ī필필rrrrr#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ)jh5lhe@KHOJQJUaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ+###$$F$N$R$l$n$t$x$$$$$$$$$$$$$$% %%%%4%6%^%`%b%ʹʤ܍{{a2j h5lhe@H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ,jh5lhe@H*KHOJQJUaJ(h5lh*@KHOJQJaJmHsH h5lhO@KHOJQJaJ#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhs;T@KHOJQJaJo("b%d%f%h%j%%%%%%%%%%%%&&$&&&*&ϽziWiWWWWWC&h5lhp5@KHOJQJaJo(#h5lhp@KHOJQJaJo( h5lhp@KHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhp@H*KHOJQJaJ,jh5lhe@H*KHOJQJUaJ2j h5lhe@H*KHOJQJUaJ*&0&2&4&R&T&|&~&&&&&&&&&&&&&ųųųhV0B0F0J0N0V0X0\0f0h00ցppppp^^Ip)jh5lhyQ@KHOJQJUaJ#h5lh%<@KHOJQJaJo( h5lhyQ@KHOJQJaJ#h5lhyQ@KHOJQJaJo(2j^ h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ,jh5lhyQ@H*KHOJQJUaJ#h5lhyQ@H*KHOJQJaJ0000000001 1"1(1*1,1.1014161f1h1111ꗀnTnBB#h5lhyQ@KHOJQJaJo(2j= h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhyQ@H*KHOJQJaJ/j h5lhyQ@KHOJQJUaJ/j h5lhyQ@KHOJQJUaJ h5lhyQ@KHOJQJaJ)jh5lhyQ@KHOJQJUaJ11111112:2<2>2D2F2H2J2L2T2V2X2d2ҺҨeVFFV5 h5lhyQ@KHOJQJaJh5lhyQ5KHOJQJaJh5lhyQKHOJQJaJ2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhyQ@H*KHOJQJaJ/j h5lhyQ@KHOJQJUaJ)jh5lhyQ@KHOJQJUaJ/j h5lhyQ@KHOJQJUaJd2h2l2t222222222223 3 33333t3v3x333ܯǗDžn\Bn\n2j h5lhQ @H*KHOJQJUaJ#h5lhQ @H*KHOJQJaJ,jh5lhQ @H*KHOJQJUaJ#h5lhyQ@H*KHOJQJaJ/jM h5lhyQ@KHOJQJUaJ/jW h5lhyQ@KHOJQJUaJ)jh5lhyQ@KHOJQJUaJ h5lhyQ@KHOJQJaJ#h5lhyQ@KHOJQJaJo(3333333333333333444 4 4446789:;h;i;ɹvhvv]NNjh5lhyQOJQJUh5lhl\OJQJh5lhyQ6OJQJo(h5lhtOJQJh5lhyQOJQJh5lhyQOJQJo( h5lhyQ@KHOJQJaJh5lhyQKHOJQJaJo(h5lhyQ5KHOJQJaJh5lhyQKHOJQJaJ)jh5lhyQ@KHOJQJUaJ#h5lhyQ@H*KHOJQJaJi;j;k;;;;;;;;<<<<<<$<(<,<2<B<H<\<`<f<j<<<<<<<<<<<<<=>=@=󳧜xd&j h5lhQ H*OJQJU#j+ h5lhyQOJQJU#j h5lhyQOJQJUh5lhyQOJQJh5lhyQOJQJo(jh5lhyQOJQJU&j6 h5lhQ H*OJQJUh5lhQ H*OJQJ jh5lhQ H*OJQJUh5lhyQH*OJQJ'@=F=H=J=L=N=V=X=Z=\=^=`=j=l=t==ǻkWE3#h5lhp@KHOJQJaJo(#h5lhD @KHOJQJaJo(&h5lh5@KHOJQJaJo(&h5lhp5@KHOJQJaJo(hD35@KHaJh5lh5"OJQJh5lhQL7OJQJo(h5lhyQ5OJQJh5lhyQ5OJQJo(h5lhyQOJQJo(jh5lhyQOJQJUh5lhyQH*OJQJ jh5lhQ H*OJQJUh5lhQ H*OJQJ========>>> >>&>(>`>h>>>>? ?"?$?&?(?,?ɸɸۘylXD&h5lho5@KHOJQJaJo(&h5lh5@KHOJQJaJo(hD35@KHQJaJ#h5lh5"@KHOJQJaJo(h5lhD KHOJQJh5lhD KHOJQJo(#h5lh :@KHOJQJaJo( h5lhp@KHOJQJaJ#h5lhp@KHOJQJaJo(#h5lhD @KHOJQJaJo(#h5lh@KHOJQJaJo($?&?:?B@(CpDII4YB]ffghhZii*mRm"q$q0q WD`gd^ WD`gd> WD`gdak@ WD`gd> `gdak@gdak@,?8?:????????@@@@@B@@@@@@@@@AA(A*A0A2ADAHAAAAAAAAAAABB B BB&B^B`BhBBBBBBBBBBBBCC&Cɻɭɭɠɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭɭh5lh*OJQJaJh5lhpOJQJaJo(h5lhfOJQJaJo(h5lhpOJQJaJ,h5lh*5@B*KHOJQJaJph#h5lhp5@KHOJQJaJ?&C(CHCJCCCCCCCCD,D8DHDnDpDDDDDDDDDDDDDE,E.E0E2ELENElEnEEEEEEEEǟǑ~$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'j> h5lheOJQJUaJ'j h5lheOJQJUaJ!jh5lheOJQJUaJh5lhpOJQJaJo(h5lhpOJQJaJh5lh*OJQJaJ,EEFFFF F FhFjFlFpFrFtFvFFFFFFFFFXGZG\G^GȺȺȀo`U``Hh5lhpOJQJaJh5lheOJQJjh5lheOJQJU!jh5lheOJQJUaJh5lhpH*OJQJaJ*jF h5lhQ H*OJQJUaJ*j h5lhQ H*OJQJUaJh5lhH*OJQJaJ$jh5lhQ H*OJQJUaJ*j\ h5lhQ H*OJQJUaJh5lhQ H*OJQJaJ^GfGhGGGGGGGGGGGGGHHHHdHfHhHvHxHzH|Hɸ䤸oaKoao*j4h5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'jh5lheOJQJUaJ'j h5lheOJQJUaJ!jh5lheOJQJUaJh5lhpOJQJaJo(h5lhl\OJQJaJh5lhpOJQJaJh5lhp5OJQJaJ|H~HHHHHHHHH I IIIIIIvIxIzII´£{mZL6ZL*j]h5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'jIh5lheOJQJUaJ'j|4h5lheOJQJUaJ!jh5lheOJQJUaJh5lhpOJQJaJo(h5lhpOJQJaJ"h5lhp5KHOJQJaJo(h5lhp5KHOJQJaJh5lhpKHOJQJaJIIIIIIIIIIIIIIIοrbTD6h5lh&5OJQJaJh5lh&5OJQJaJo(h5lhp5OJQJaJh5lho5OJQJaJo(h5lh5OJQJaJo(h5lh*OJQJaJh5lhpOJQJaJo("h5lhp5KHOJQJaJo(h5lhp5KHOJQJaJh5lhpKHOJQJaJ!jh5lheOJQJUaJh5lhpH*OJQJaJ$jh5lhQ H*OJQJUaJIIIIIIIIIJJJ JlJnJrJJJJJJJJJKKK K KǶt[0jUh5lhdBUB*OJQJUaJph0j7^h5lhdBUB*OJQJUaJph*jh5lhdBUB*OJQJUaJph$h5lhdBUB*OJQJaJo(ph!h5lhdBUB*OJQJaJphh5lhdBUOJQJaJh5lhdBUOJQJaJo(h5lhdBU5OJQJaJh5lhdBU5OJQJaJo( KKKlKnKpKtKvKxKzKKKKKKKKLJLLLNL\L^L`LbLé֖|֖bL*jh5lhdBUB*OJQJUaJph3j]h5lhQ B*H*OJQJUaJph3jh5lhQ B*H*OJQJUaJph$h5lhB*H*OJQJaJph3jsh5lhQ B*H*OJQJUaJph$h5lhQ B*H*OJQJaJph-jh5lhQ B*H*OJQJUaJph$h5lhdBUB*H*OJQJaJphbLLLLLLLLLLLLLLLLLMMM@MμެެjjQj0jh5lhdBUB*OJQJUaJph*jh5lhdBUB*OJQJUaJph!h5lhdBUB*OJQJaJphh5lhdBUOJQJaJh5lhdBUOJQJaJo(h5lhdBUKHOJQJaJo("h5lhdBU5KHOJQJaJo(h5lhdBU5KHOJQJaJh5lhdBUKHOJQJaJ$h5lhdBUB*OJQJaJo(ph@MBMDMFMHMMMMMMMMN N"N$N*N,N.N0N2NѾzgM:$h5lhdBUB*OJQJaJo(ph3j#h5lhQ B*H*OJQJUaJph$h5lhB*H*OJQJaJph3jh5lhQ B*H*OJQJUaJph$h5lhQ B*H*OJQJaJph-jh5lhQ B*H*OJQJUaJph$h5lhdBUB*H*OJQJaJph*jh5lhdBUB*OJQJUaJph0j@h5lhdBUB*OJQJUaJph2NN`NhNNNNNNNNNNOOOOOO OȷطؓzaN7-jh5lhQ B*H*OJQJUaJph$h5lhdBUB*H*OJQJaJph0jh5lhdBUB*OJQJUaJph0jh5lhdBUB*OJQJUaJph*jh5lhdBUB*OJQJUaJphh5lhdBUOJQJaJo(!h5lhdBUB*OJQJaJphh5lhdBUKHOJQJaJo($h5lhdBUB*OJQJaJo(ph'h5lhdBU5B*OJQJaJo(ph OOOOOOOOOOOOOOOOOOӼttdS@333h5lhdBUOJQJaJ$h5lhdBUB*OJQJaJo(ph!h5lhdBUB*OJQJaJphh5lhdBUKHOJQJaJo(h5lhdBU5KHOJQJaJh5lhdBUKHOJQJaJ*jh5lhdBUB*OJQJUaJph$h5lhdBUB*H*OJQJaJph-jh5lhQ B*H*OJQJUaJph3jzh5lhQ B*H*OJQJUaJph$h5lhQ B*H*OJQJaJphOOOOPQRSTUVWWWWWWWWWWWWX X XXXX0XFXrXXXXXXŲo]"h5lhdBU5KHOJQJaJo(h5lhdBU5KHOJQJaJh5lhdBUKHOJQJaJ*jh5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhdBUH*OJQJaJ!jh5lhdBUOJQJUaJh5lhdBUOJQJaJh5lhdBUOJQJaJo($X2Y4Y:Y@YBYDYFYYYYYYYYYYZZjZnZzZZZZZZZZZZZ6[8[V[X[[ȷoo!jh5lheOJQJUaJh5lh_o[OJQJaJo(h5lhpOJQJaJh5lhpOJQJaJo(h5lhp5OJQJaJ!h5lhh5OJQJaJh5lh5OJQJaJh5lho5OJQJaJo(h5lh*OJQJaJh5lhdBUOJQJaJ$[[[[[[[[[[[[\\\ \\\\"\6\8\d\f\\\\ڸscUsHsHsHHHh5lhpOJQJaJh5lhp5OJQJaJh5lhp5OJQJaJo(h5lhpOJQJaJo(*j0h5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'j'h5lheOJQJUaJ!jh5lheOJQJUaJ'jhh5lheOJQJUaJ\\\\\\\ ]"]$]*],].]0]2]:]<]>]@]B]F]H]ڸrbbrUH88h5lh=N5OJQJaJo(h5lh*OJQJaJh5lhpOJQJaJh5lhp5KHOJQJaJh5lhpKHOJQJaJ*jOCh5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'j1:h5lheOJQJUaJ!jh5lheOJQJUaJ'j1h5lheOJQJUaJH]N]P]R]`]b]h]]]]]]]]]]]]^^__``aabbccddeeeeeeeeeeeefŷ*jCh5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ!jh5lheOJQJUaJh5lhpOJQJaJh5lhpOJQJaJo(h5lhp5OJQJaJ,f f ffff$ffffffffff gggggggggggghhh hԷyk^k^k^PPh5lhQL7OJQJaJo(h5lhdBUOJQJaJh5lhdBUOJQJaJo(h5lh&5OJQJaJh5lhdBU5OJQJaJo(h5lh=N5OJQJaJo(h5lh5OJQJaJo(h5lh*5OJQJaJo(h5lhpOJQJaJh5lhpOJQJaJo(h5lhp5OJQJaJh5lhp5OJQJaJo( hhhhh,hVh\h`hdhfhlhrhhhhhhhhhhhhhhhhFiJiViXiZi\idilipitiiiiʺ|qh^5OJQJaJh5lhA5OJQJaJo(h5lhp5OJQJaJo(h5lhp5OJQJaJh5lh=N5OJQJaJo(h5lhIQ5OJQJaJo(h5lhSbmOJQJaJo(h5lh*OJQJaJh5lhpOJQJaJo(h5lhpOJQJaJ(iiiiiiiijjjjjjjjjtjvjxjjjjjjسǟǑ~pZ~p~L~ph5lhH*OJQJaJ*juh5lhQ H*OJQJUaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJh5lhpH*OJQJaJ'jYoh5lheOJQJUaJ'j=Dh5lheOJQJUaJ!jh5lheOJQJUaJh5lhpOJQJaJh5lhIQOJQJaJo(h5lhIQOJQJaJjjjjjjj^k`kbkhkjklknkpkxkzk|kk׻ɥחvfTE8h5lhpOJQJaJh5lhpKHOJQJaJ"h5lhp5KHOJQJaJo(h5lhp5KHOJQJaJh5lhpKHOJQJaJo(!jh5lheOJQJUaJh5lhpH*OJQJaJ*jah5lhQ H*OJQJUaJh5lhH*OJQJaJh5lhQ H*OJQJaJ$jh5lhQ H*OJQJUaJ*jh5lhQ H*OJQJUaJkkkkllPljlrlvllllll(m*m,m4mNmPmRm`mhmrmtmmmmmmmmm乩sessssssseseh=!ehdBUOJQJaJo(h=!ehdBUOJQJaJh^5OJQJaJh=!ehp5OJQJaJh=!ehA5OJQJaJo(h=!ehSbm5OJQJaJo(h5lh*5OJQJaJo(h5lhl\OJQJaJh5lhpOJQJaJo(h5lhpOJQJaJh5lhnOJQJaJo(!mmmmmmmnnnnDnFnHnJnLnNnPnnnnnnnnn±±{hZDhZh{*j(h=!ehQ H*OJQJUaJh=!ehQ H*OJQJaJ$jh=!ehQ H*OJQJUaJh=!ehdBUH*OJQJaJ'jh=!ehdBUOJQJUaJ'j؛h=!ehdBUOJQJUaJ!jh=!ehdBUOJQJUaJh=!ehdBUOJQJaJ1h=!ehdBUB*OJQJfHo(phq .h=!ehdBUB*OJQJfHphq nnnnnno o oo,o4oBoToVo\ofojoooooooooppp p|p~pppppppppppppppppq q"q$q.qƹ䫝h=!ehp5OJQJaJo(h&5QJaJh=!eh*5OJQJaJh=!ehQL7OJQJaJo(h=!eh_o[OJQJaJh=!eh_o[OJQJaJo( j~h=!ehdBUOJQJaJh=!ehdBUOJQJaJh=!ehdBUOJQJaJo(4.q0q6qHqJqVqZqbqvqzq|qqqqqqqqrrr,r.r0rrrrss s&s,s2sööööѪѪѐтtdödS!h=!ehpB*OJQJaJphh=!ehpKHOJQJaJo(h=!ehSnOJQJaJo(h=!ehD3OJQJ\aJh=!ehl\OJQJ\aJh=!ehnOJQJo(h=!ehpOJQJo(h=!ehpOJQJaJh=!ehpOJQJaJo(h=!ehpOJQJ\aJo(h=!ehSnOJQJ\aJo(h=!ehD35OJQJaJ 0qrsXtluuuuJwlwxxzz2}ʇj؏* WD`gd^ WD`gdak@gdak@ WD`gd>2sBsJsdssssttVtXt^t"u$ujuluruvuzu|u~uuuuuuuuuuΥΘviU&h=!ehK5@KHOJQJaJo(hD35@KHQJaJ&h=!eh*5@KHOJQJaJo(h=!ehnOJQJaJo(h=!ehpOJQJaJh=!ehkOJQJaJo(h=!ehSnOJQJaJo(h=!ehD3OJQJaJh=!ehpOJQJaJo(!h=!ehpB*OJQJaJph$h=!ehpB*OJQJaJo(phuuuuuuvv*v,vbvdvvvvvvvvvƴ||d|L|:#h=!ehp@H*KHOJQJaJ/jh=!ehe@KHOJQJUaJ/jh=!ehe@KHOJQJUaJ)jh=!ehe@KHOJQJUaJ#h=!eh@KHOJQJaJo( h=!ehp@KHOJQJaJ#h=!ehp@KHOJQJaJo(#h=!eh*5@KHOJQJaJ&h=!ehp5@KHOJQJaJo(&h=!ehSn5@KHOJQJaJo(vv w"w$w2w4w6w8w:wDwHwJwLwTw׽髖p_K7&h=!eh\lv5@KHOJQJaJo(&h=!ehK5@KHOJQJaJo( h=!eh*@KHOJQJaJ&h=!ehp5@KHOJQJaJo(#h=!ehp@KHOJQJaJo()jh=!ehe@KHOJQJUaJ#h=!ehp@H*KHOJQJaJ2jh=!ehQ @H*KHOJQJUaJ#h=!ehQ @H*KHOJQJaJ,jh=!ehQ @H*KHOJQJUaJTwVw^whwjwlwwwxxxx2x4xxxxxǶucO;&h=!eh\lv5@KHOJQJaJo(&h=!ehK5@KHOJQJaJo(#h=!ehn@KHOJQJaJo( h=!ehl\@KHOJQJaJh=!e@KHOJQJaJo(#h=!eh\lv@KHOJQJaJo(h^5@KHOJQJaJ h=!e5@KHOJQJaJo(&h=!ehp5@KHOJQJaJo(#h=!ehp5@KHOJQJaJ#h=!ehn5@KHOJQJaJxxxxxxxxxxxyy"y&y,y.y0y2yyyyyyyyzzz zzzz zJzPzTzVzz˹t h=!ehH,@KHOJQJaJ h=!ehl\@KHOJQJaJ#h=!ehn@KHOJQJaJo( h=!ehp@KHOJQJaJ#h=!ehp@KHOJQJaJo(h^5@KHOJQJaJ#h=!eh^)5@KHOJQJaJ&h=!eh^)5@KHOJQJaJo(&zzzzzzzzzzz{{{{{{| | |||ŶŶ~l~~ZI~7~~~~~#hEh>%@KHOJQJaJo( hEhf@KHOJQJaJ#hEhf@KHOJQJaJo(#hEhn@KHOJQJaJo(#hEhp@KHOJQJaJo(&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJh^5@KHOJQJaJ&hEh_5@KHOJQJaJo(&hEh5@KHOJQJaJo(#h=!eh*@KHOJQJaJo(||||} }}&}0}2}4}>}F}X}Z}~~~؁؃(ڶ|hS)jhEhe@KHOJQJUaJ&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEh_5@KHOJQJaJo(&hEh5@KHOJQJaJo(#hEh*@KHOJQJaJo(#hEh_@KHOJQJaJo(#hEhp@KHOJQJaJo(&hEhp@H*KHOJQJaJo((ćƇȇʇ̇Ї؇hj؉ȱڍygYG#hEh@KHOJQJaJo(h^@KHOJQJaJ#hEh_@KHOJQJaJo(&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ$LN^`؋hjlnt~č۸۸ۦlXlIh^5@KHOJQJaJ&hEhp5@KHOJQJaJo(&hEh_5@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEh5@KHOJQJaJo(#hEh*@KHOJQJaJo( hEhp@KHOJQJaJ#hEh_@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEh@KHOJQJaJo(čƍ؍46Tɵ}iUF4#hEh@KHOJQJaJo(h^5@KHOJQJaJ&hEhp75@KHOJQJaJo(&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ#hEh_5@KHOJQJaJ&hEh_5@KHOJQJaJo(&hEh5@KHOJQJaJo(#hEh_@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEhl\@KHOJQJaJo(T֏؏ڏ̺~l~~WFFFFFFFFFFFFFFF hEh*1@KHOJQJaJ)jhEh*1@KHOJQJUaJ#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(&hEh*15@KHOJQJaJo(&hEh5@KHOJQJaJo(#hEh_@KHOJQJaJo(#hEhp@KHOJQJaJo( hEh@KHOJQJaJ hEhp@KHOJQJaJ9:;<pqruvwxȱqbP#hEhp@KHOJQJaJo(h^5@KHOJQJaJ&hEh*15@KHOJQJaJo(2jhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEh*1@H*KHOJQJaJ)jhEh*1@KHOJQJUaJ hEh*1@KHOJQJaJҘؘ &(*8Z\^`ɵ{{{lZ#hEhl\@KHOJQJaJo(h^5@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEh_A5@KHOJQJaJo(&hEh5@KHOJQJaJo(#hEh*@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEh_A@KHOJQJaJo( h|~ƜȜʜǵǒkZkZBk/j}hEhe@KHOJQJUaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhp@KHOJQJaJo(h^5@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEh_A5@KHOJQJaJo(&hEh5@KHOJQJaJo( hEh@KHOJQJaJ6XZfȷ&h\,Zpz WD`gd> WD`gd> WD`gdak@ WD`gd^gdak@ʜ̜ΜМҜ246<>@BDN}kWkFF hEhp@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(2j=5hEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ/j]*hEhe@KHOJQJUaJtttttҺҨmm\\\\\\\\\\\\\\\\\\\\ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/jRBhEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ/j5hEhe@KHOJQJUaJ$ttt !"PQRUVWX 8dȱs_ssss&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(2jNhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ%/012fghklmn8:XZȱs[/jOhEhe@KHOJQJUaJ#hEhp@KHOJQJaJo(2jgOhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ "$BDl}kWkFF hEhp@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(2jehEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ/jZhEhe@KHOJQJUaJlnprtvxسڳܳҺҨeS?SS&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(2j{hEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/jphEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ/jfhEhe@KHOJQJUaJ´ĴXZ\bdfhjtڪژoUoC/&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo(2j hEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/j,hEhe@KHOJQJUaJ/jL|hEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJt̵εеص&,HL\^|~ʣʋsaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/jhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ#hEh_A@KHOJQJaJo( hEhp@KHOJQJaJ#hEhk@KHOJQJaJo(#hEhp@KHOJQJaJo( "$&.0468>BӼo]K9(9 hEha@KHOJQJaJ#hEha@KHOJQJaJo(#h^h*@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp@KHOJQJaJo()jhEhe@KHOJQJUaJ#hEhp@H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ2jӦhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJBDNTVXZ^bdfltݹsaP>-a>P hEhD3@KHOJQJaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ#hEh_A@KHOJQJaJo(#hEhD35@KHOJQJaJ#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(haha5@KHaJ#hEhD3@KHOJQJaJo(#hEha5@KHOJQJaJ#hEha@KHOJQJaJo( hEha@KHOJQJaJƷȷηַ$&,fhnZ\bjt¹$*,2pxʹʹ햌|hHh5OJQJaJo(h*@KHaJ hEh*@KHOJQJaJ#hEh_A@KHOJQJaJo( hEhp@KHOJQJaJ#hEh-8@KHOJQJaJo( hEhD3@KHOJQJaJ#hEhp@KHOJQJaJo(-XZ\dnpvTòxfRxR@/ hEhEh@KHOJQJaJ#hEhi@KHOJQJaJo(&hEhD35@KHOJQJaJo(#hEhD35@KHOJQJaJ#hEhp5@KHOJQJaJ&hEhi5@KHOJQJaJo(&hEh5@KHOJQJaJo( hEh*@KHOJQJaJ hEhp@KHOJQJaJhHh*5OJQJaJhHhp5OJQJaJhHh-85OJQJaJo(Tfjtڼܼ޼FHJXܵܝs\J0\J2j=hEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/jhEhe@KHOJQJUaJ/jJhEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ#hEh>%@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(XZ\^`jnpֽڽ68`bd±{i±±Q/j9>hEhe@KHOJQJUaJ#hEh_@KHOJQJaJo(#hEhi@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhp@H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJdfhjlξоҾؾھܾ޾>@BPRTVX}kQ@ hEhp@KHOJQJaJ2jhEhQ @H*KHOJQJUaJ#hEh@H*KHOJQJaJ2jIhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ)jhEhe@KHOJQJUaJ/jAhEhe@KHOJQJUaJXbdfprtƿؿڿܿ޿"$LNPʹܧܧܧn]n]En/j7hEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEh@KHOJQJaJo(#hEhi@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhEh@KHOJQJaJ#hEhEh@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp5@KHOJQJaJPRTVXprҺucOu=+#hEhi@KHOJQJaJo(#hEhp@KHOJQJaJo(&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu)jhEhe@KHOJQJUaJ/jehEhe@KHOJQJUaJ$&(*,.0HJPRǶǶdžnR:R:R.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jcChEhe@KHOJQJUaJ/j)hEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(RTV246<>@BD̴̴̴v̴^I8 hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=j]hEhQ @H*KHOJQJUaJmHnHu=j3]hEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHuDNPRNPnpǵܵܵܵܵܵǤǤt\.hEh]\<@H*KHOJQJaJmHnHu/jkrhEhe@KHOJQJUaJ/j!^hEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ#hEhp@KHOJQJaJo()jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ#hEhp5@KHOJQJaJˬu]H7 hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=j,hEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu "4ȷْȀȀȀo[Iْ#hEhD35@KHOJQJaJ&hEhD35@KHOJQJaJo( hEhD3@KHOJQJaJ#hEhp@KHOJQJaJo( h15@KHOJQJaJo(&hEhi5@KHOJQJaJo( hEh*@KHOJQJaJ hEhp@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ46BJPXxz(2468jtx۸ۦۑh/jhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhi@KHOJQJaJo(#hEhQL7@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(#hEh@KHOJQJaJo(#DFHNPRTҺgO0=j¬hEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHu=jKhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu)jhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ- PZ\ǶǞjj_ShEhpOJQJo(hEhpOJQJ.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(\^|~ &D^prx𵤘xfUCUCUC#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ#hEh[H1@KHOJQJaJo(hEhpOJQJo(&jhEhQ H*OJQJUhEhQ H*OJQJ jhEhQ H*OJQJUhEhpH*OJQJ#jhEheOJQJU#j9hEheOJQJUhEhpOJQJjhEheOJQJUx|~NRTrtɷݥݐx`N#hEhp@H*KHOJQJaJ/jRhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ#hEhi@KHOJQJaJo(#hEhf5@KHOJQJaJ&hEh5@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ @xz׽髖ssssss\JJJJJJ#hEh]\<@H*KHOJQJaJ,jhEhe@H*KHOJQJUaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo()jhEhe@KHOJQJUaJ#hEhp@H*KHOJQJaJ2jhEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJBF־kZHZ6Z6#hEhp@KHOJQJaJo(#hEhi@KHOJQJaJo( hEhp@KHOJQJaJ=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu,jhEhe@H*KHOJQJUaJ#hEh]\<@H*KHOJQJaJFHfh  ꗀnTn@&hEh*5@KHOJQJaJo(2j hEhQ @H*KHOJQJUaJ#hEhQ @H*KHOJQJaJ,jhEhQ @H*KHOJQJUaJ#hEhp@H*KHOJQJaJ/jBhEhe@KHOJQJUaJ/jxhEhe@KHOJQJUaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ",.68: 8<>DJȴrr`O hEhf@KHOJQJaJ#hEhf@KHOJQJaJo(h1@KHOJQJaJ hEh3v#@KHOJQJaJ#hEh3v#@KHOJQJaJo( h15@KHOJQJaJo(&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ#hEhD35@KHOJQJaJ&hEhD35@KHOJQJaJo(JLPV޺̔ޔ|`H`H`.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh3v#@H*KHOJQJaJmHnHu)jhEh3v#@KHOJQJUaJ hEhf@KHOJQJaJ#hEhf@KHOJQJaJo(#hEh3v#@KHOJQJaJo( hEh3v#@KHOJQJaJ hEh@KHOJQJaJ(,8>Z`lsbSB0B0B0B#hEhp@H*KHOJQJaJ hEhp@KHOJQJaJh^5@KHOJQJaJ h15@KHOJQJaJo(#hEhp5@KHOJQJaJ&hEh3v#5@KHOJQJaJo(&hEh5@KHOJQJaJo(&hEh*5@KHOJQJaJo(#hEh3v#@KHOJQJaJo()jhEh3v#@KHOJQJUaJ.hEh3v#@H*KHOJQJaJmHnHu0<4jl| WD`gdak@ qWD2`qgdak@ WD`gd>$7$8$H$a$gdak@ WD`gd^gdak@ WD`gd>ln"$&*,u]]]>u]u=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ,.0  ̴̴̴v̴^I8 hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHuVXZ\tv|~pXpXp.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhp@H*KHOJQJaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(.0246FHȶكtbtQtbt@ hEh@KHOJQJaJ hEhD3@KHOJQJaJ#hEh3v#@KHOJQJaJo(h1@KHOJQJaJo(#hEhD35@KHOJQJaJhD35@KHOJQJaJ#hEh*@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ&hEhp5@KHOJQJaJo(#hEhp5@KHOJQJaJ:<>@B2468: BZ^hj˺˺˺˺ˇˇˇu#hEh*@KHOJQJaJo(#hEhp@KHOJQJaJo(#hEh3v#@KHOJQJaJo(h1@KHOJQJaJo( hEh*@KHOJQJaJ hEhp@KHOJQJaJ hEhEh@KHOJQJaJ#hEhEh@KHOJQJaJo(.jlnrvz|`h~dz}l}Z}I}l}l}l}l}}}}} hEh*@KHOJQJaJ#hEh@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(#hEh*5@KHOJQJaJ#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(&hEh3S5@KHOJQJaJo(&hEh5@KHOJQJaJo( hEh&@KHOJQJaJ^bfhlpNP޺ީީ޺޺ީީޘp^pLp#hEh*5@KHOJQJaJ#hEhp5@KHOJQJaJ&hEh3S5@KHOJQJaJo(&hEh5@KHOJQJaJo( hEh*@KHOJQJaJ hEhp@KHOJQJaJ#hEh3S@KHOJQJaJo(#hEh@KHOJQJaJo(#hEhp@KHOJQJaJo(h1@KHOJQJaJo( 248\`tvɸɸɸzhQh7Qz2jvhEhx-@H*KHOJQJUaJ,jhEhx-@H*KHOJQJUaJ#hEhx-@H*KHOJQJaJ,jhEhe@H*KHOJQJUaJ'hEhp@CJKHOJQJaJo($hEhp@CJKHOJQJaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(#hEh*5@KHOJQJaJ#hEhp5@KHOJQJaJ,.068:<̴̴}̴^̴G6 hEhp@KHOJQJaJ,jhEhe@H*KHOJQJUaJ=j3hEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHu=j3hEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEhx-@H*KHOJQJaJmHnHu tvɷɷɷɥɎ||bH2j@hEhe@H*KHOJQJUaJ2j4hEhe@H*KHOJQJUaJ#hEh]\<@H*KHOJQJaJ,jhEhe@H*KHOJQJUaJ#hEh(g@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(468>@BDNVbx̴̴~m[m[mJ8Jm#hEh{@KHOJQJaJo( hEh{@KHOJQJaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ,jhEhe@H*KHOJQJUaJ=jMhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu4:<DFNRpvx~̻}i]hEhpOJQJo(&hEh*5@KHOJQJ\aJ&hEhp5@KHOJQJ\aJ)hEhp5@KHOJQJ\aJo()hEh{5@KHOJQJ\aJo( hEh*@KHOJQJaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ hEhl\@KHOJQJaJ    "2"F""''T(t((B)P)1$WD`gdak@dWD`gd>gdak@ WD`gd> WD`gdak@  rtv|~u]>u]u=jihEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/j[hEhe@KHOJQJUaJ/jMhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ"$*4l&hEhcM5@KHOJQJaJo( hEh*@KHOJQJaJ#hEhcM@KHOJQJaJo( hEhcM@KHOJQJaJhEhpOJQJo(hEhpOJQJ#hEhp@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ"FHJLNPȷgO7.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/jjhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ#hEh*5@KHOJQJaJ#hEhp5@KHOJQJaJ&hEhp5@KHOJQJaJo(PR "(*,.0ˬu]H7 hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=j}hEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu0:hpt~  ۷ۢyaI.hEh]\<@H*KHOJQJaJmHnHu/jVhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEh>%@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ&hEhp5@KHOJQJaJo( tvx~&(Fˬn\nJnJnnnnJn9 hEh]\<@KHOJQJaJ#hEhp@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHuFHprtvxz|u]u]uL:L#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/j/hEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ  H V X ȳvbP H ^ ` h l | ~       ĬĔn\nJnJnJnJnJn5)hEh(g5@KHOJQJ\aJo(#hEhp@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu=j hEhQ @H*KHOJQJUaJmHnHu      $ ( , 4 > V X    D F N X Z x   l n v ֭peeeepREpephEhpOJQJaJ%jhEheKHOJQJUaJhEhoOJQJjhEheOJQJUhEhcMKHOJQJaJhEhpKHOJQJaJhEhpKHOJQJaJo(&hEh*5@KHOJQJ\aJ)hEhp5@KHOJQJ\aJo(&hEhp5@KHOJQJ\aJ)hEhcM5@KHOJQJ\aJo(v x             `bdjl쾫eOO2eOe9j-hEhQ H*KHOJQJUaJmHnHu*hEhQ H*KHOJQJaJmHnHu3jhEhQ H*KHOJQJUaJmHnHu*hEhx-H*KHOJQJaJmHnHu+j. hEhx-KHOJQJUaJ%jhEhx-KHOJQJUaJhEhx-KHOJQJaJhEhpKHOJQJaJo(hEhpKHOJQJaJ%jhEheKHOJQJUaJlnp",6@HRккЇtdRdBdBdBdRhEhcMKHOJQJaJo("hEhp5KHOJQJaJo(hEhpKHOJQJaJo(%jhEheKHOJQJUaJ*hEhx-H*KHOJQJaJmHnHu9j.hEhQ H*KHOJQJUaJmHnHu*hEhQ H*KHOJQJaJmHnHu3jhEhQ H*KHOJQJUaJmHnHu*hEhH*KHOJQJaJmHnHu >B (*RTVXZ\^ޭr\B3jhEhQ H*KHOJQJUaJmHnHu*hEh]\<H*KHOJQJaJmHnHu+jPhEheKHOJQJUaJ+j.hEheKHOJQJUaJhEh]\<KHOJQJaJ%jhEheKHOJQJUaJhEhKHOJQJaJhEhpKHOJQJaJhEhpKHOJQJaJo("hEhf5KHOJQJaJo(^  ͳ곝zjjjjjZjJz9 hEhp@KHOJQJaJhEh*KHOJQJaJo(hEha5KHOJQJaJhEhaKHOJQJaJo(hEhpKHOJQJaJo(%jhEheKHOJQJUaJ*hEh]\<H*KHOJQJaJmHnHu3jhEhQ H*KHOJQJUaJmHnHu9jNshEhQ H*KHOJQJUaJmHnHu*hEhQ H*KHOJQJaJmHnHu 48:XZǶǶdžnR:.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/jshEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo( "246HJLĬĔĬĬ|gVDV/VD)hEhpB*CJOJQJ^JaJph333#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu.hEh@H*KHOJQJaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu=j-hEhQ @H*KHOJQJUaJmHnHuLRTVXȷȟk.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu hEh]\<@KHOJQJaJ)jhEhe@KHOJQJUaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ!$&DFnpĬĔm]N==%/jhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJhEhpKHOJQJaJhEhpKHOJQJaJo(#hEhp@KHOJQJaJo()jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHuprtvxz $꺞gUD5*hEhpOJQJhEh*KHOJQJaJ hEhp@KHOJQJaJ#hEhp@KHOJQJaJo(=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ)jhEhe@KHOJQJUaJ$,46 "*,DHLNlnٽmU=.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/jhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ#hEhp@KHOJQJaJo()jhEhe@KHOJQJUaJ hEhp@KHOJQJaJhEhoOJQJjhEheOJQJUhEhpOJQJhEhpOJQJo( (*02   & ˬn\nJ;00;nhEhoOJQJjhEheOJQJU#hEhp@KHOJQJaJo(#hEhp5@KHOJQJaJ hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu& 0 2 V h j          !ɷڦڦv^B*.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu.hEh]\<@H*KHOJQJaJmHnHu/jhEhe@KHOJQJUaJ/jAhEhe@KHOJQJUaJ hEh]\<@KHOJQJaJ#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ hEhcM@KHOJQJaJ!! !&!(!*!,!!!!!!!!!ĬĔĬuĬ]H7 hEhp@KHOJQJaJ)jhEhe@KHOJQJUaJ.hEh]\<@H*KHOJQJaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu.hEh@H*KHOJQJaJmHnHu.hEhQ @H*KHOJQJaJmHnHu7jhEhQ @H*KHOJQJUaJmHnHu=jhEhQ @H*KHOJQJUaJmHnHu!!!!!!!!!""""$"."0"2"8"<">"@"D"F"Z"ʶ|j|V|VE h3[<h{@KHOJQJaJ&h3[<hp5@KHOJQJaJo(#h3[<h*5@KHOJQJaJ#h3[<hp5@KHOJQJaJ&h3[<h{5@KHOJQJaJo(&h3[<hB/<5@KHOJQJaJo(&hEh*5@KHOJQJaJo(#hEhp@KHOJQJaJo( hEhp@KHOJQJaJ#hEhp5@KHOJQJaJZ"^"""""""""$&''''''''''ʶrT;T;Tr1h3[<hQ @H*KHOJQJ\aJmHnHu:jh3[<hQ @H*KHOJQJU\aJmHnHu1h3[<h]\<@H*KHOJQJ\aJmHnHu&h3[<h]\<@KHOJQJ\aJo(,jh3[<he@KHOJQJU\aJ&h3[<hp5@KHOJQJaJo(#h3[<hp5@KHOJQJaJ h3[<h{@KHOJQJaJ#h3[<h{@KHOJQJaJo('''''''((R(T(r(t(((@)B)D)N)P))))**** *"*****++|+~++++++,,:,<,@,B,,,,,,ǵٵٓٵh1@KHOJQJaJo( h3[<hp@KHOJQJaJ h3[<h*@KHOJQJaJ#h3[<hp@KHOJQJaJo(#h3[<hp5@KHOJQJaJ&h3[<h{5@KHOJQJaJo(#h3[<h*5@KHOJQJaJ4P))*"**+~+++,, -<-X-:.H...///h?x???@@ Agdak@ WD`gdak@,- -:-<-V-X--..8.:.<.F.H.....//////////00"0>0H0J0L0ܶȤ퓓~i)jh3[<he@KHOJQJUaJ)h3[<hp5@KHOJQJ\aJo( h3[<hp@KHOJQJaJ#h3[<h*5@KHOJQJaJ#h3[<h{@KHOJQJaJo(&h3[<h{5@KHOJQJaJo( h3[<h*@KHOJQJaJ#h3[<hp@KHOJQJaJo(#L0123456679:;<==========>>V>b>d>>>>zzziXX h3[<h]\<@KHOJQJaJ h3[<hp@KHOJQJaJ#h3[<hp@KHOJQJaJo(.h3[<hQ @H*KHOJQJaJmHnHu7jh3[<hQ @H*KHOJQJUaJmHnHu.h3[<h]\<@H*KHOJQJaJmHnHu)jh3[<he@KHOJQJUaJ#h3[<h]\<@KHOJQJaJo(>>>>>>>>>>>>>>>(?*?.?L?`?d?f?ҺҢnn]K]9]9]9]#h3[<hp@KHOJQJaJo(#h3[<hp5@KHOJQJaJ h3[<hp@KHOJQJaJ.h3[<hQ @H*KHOJQJaJmHnHu7jh3[<hQ @H*KHOJQJUaJmHnHu.h3[<h]\<@H*KHOJQJaJmHnHu/j9h3[<he@KHOJQJUaJ)jh3[<he@KHOJQJUaJ/jh3[<he@KHOJQJUaJf?h?j?v?x?z??????@@@@@@@A AAA(A*A0A6A:A@ARAɷɷɷ}kYHHH h3[<h{@KHOJQJaJ#h3[<hp5@KHOJQJaJ#h3[<hit5@KHOJQJaJ&h3[<hit5@KHOJQJaJo(#h3[<hp@KHOJQJaJo(&h3[<h{5@KHOJQJaJo(#h3[<h*5@KHOJQJaJ&h3[<hp5@KHOJQJaJo(#h3[<h{@KHOJQJaJo( h3[<h*@KHOJQJaJ A*A*J|KK@MZMNNN>OVPPP2QQQQ*STUFW WD`gd> `gd>gdak@ WD`gdak@ WD`gd>RA\AbArAAAAAAABCDEFGGGGGGGGGGGGGȶȞjjX#h3[<hp5@KHOJQJaJ.h3[<hQ @H*KHOJQJaJmHnHu7jh3[<hQ @H*KHOJQJUaJmHnHu.h3[<h]\<@H*KHOJQJaJmHnHu#h3[<h]\<@KHOJQJaJo()jh3[<he@KHOJQJUaJ#h3[<hp@KHOJQJaJo( h3[<hp@KHOJQJaJGGGGGGGGHFHlHnHHHHHHHHH̺̺̥|dL.h3[<h]\<@H*KHOJQJaJmHnHu/jbh3[<he@KHOJQJUaJ/jkYh3[<he@KHOJQJUaJ h3[<h]\<@KHOJQJaJ)jh3[<he@KHOJQJUaJ#h3[<hp@KHOJQJaJo( h3[<hp@KHOJQJaJ#h3[<h{@KHOJQJaJo( h3[<h{@KHOJQJaJHHIII$I&I(I*IIJJ J JJJJJJˬu]H7 h3[<hp@KHOJQJaJ)jh3[<he@KHOJQJUaJ.h3[<h]\<@H*KHOJQJaJmHnHu=jblh3[<hQ @H*KHOJQJUaJmHnHu.h3[<h@H*KHOJQJaJmHnHu=jkh3[<hQ @H*KHOJQJUaJmHnHu.h3[<hQ @H*KHOJQJaJmHnHu7jh3[<hQ @H*KHOJQJUaJmHnHuJ$J(J*J`JjJlJ0K4K8K^K`KjKlKzK|KKKKKLL>M@MFMJMXMZM~Mܹܹܹܹ˓qqqq]I큹&h3[<hp5@KHOJQJaJo(&h3[<h5@KHOJQJaJo(h3[<hp@OJQJaJo(#h3[<h*5@KHOJQJaJ&h3[<hBn5@KHOJQJaJo(#h3[<h{@KHOJQJaJo(#h3[<hp@KHOJQJaJo( h3[<h*@KHOJQJaJ h3[<hp@KHOJQJaJ#h3[<hp5@KHOJQJaJ~MMMMMNN NNN N>N@NhNjNlNnNpNrNtNڳrZ>7jh3[<hQ @H*KHOJQJUaJmHnHu.h3[<h]\<@H*KHOJQJaJmHnHu/j{h3[<he@KHOJQJUaJ/jlh3[<he@KHOJQJUaJ h3[<h]\<@KHOJQJaJ)jh3[<he@KHOJQJUaJ#h3[<hp5@KHOJQJaJ#h3[<hp@KHOJQJaJo(&h3[<hp5@KHOJQJaJo(tNNNNNNNNNNNNNɭ譕fU@,@&h3[<hp5@KHOJQJ\aJ)h3[<hp5@KHOJQJ\aJo( h3[<h*@KHOJQJaJ2h3[<h*B*OJQJaJfHphq )jh3[<he@KHOJQJUaJ.h3[<h]\<@H*KHOJQJaJmHnHu7jh3[<hQ @H*KHOJQJUaJmHnHu=jah3[<hQ @H*KHOJQJUaJmHnHu.h3[<hQ @H*KHOJQJaJmHnHu NNOODOOOOOOOOOOPP4P6P8P:PTPVP\PPPPPPP Q Q0Q2Q8QQQQQQȷȔȔȔȔȥȥȷȷȷȔȷȷvfhHh5OJQJaJo(hHh5OJQJaJo(h*@KHOJQJaJ h3[<hp@KHOJQJaJ#h3[<h@KHOJQJaJo( h3[<h*@KHOJQJaJ#h3[<hp@KHOJQJaJo(#h3[<h@KHOJQJaJo(&h3[<h*5@KHOJQJ\aJ'QQQQQQRRBRDRRRTRrRtRRRRRRRоЬЗnV>.hr'h]\<@H*KHOJQJaJmHnHu/jhr'he@KHOJQJUaJ/j؉hr'he@KHOJQJUaJ hr'h]\<@KHOJQJaJ)jhr'he@KHOJQJUaJ#hr'h(g@KHOJQJaJo(#hr'h*@KHOJQJaJo(#hr'hp@KHOJQJaJo(hHh*5OJQJaJhHhp5OJQJaJo(RRSSS S"S$S&S(S*S0SvSxSSˬm\Jm9 hr'hx-@KHOJQJaJ#hr'h*@KHOJQJaJo( hr'h*@KHOJQJaJ#hr'hp@KHOJQJaJo()jhr'he@KHOJQJUaJ.hr'h]\<@H*KHOJQJaJmHnHu=jhr'hQ @H*KHOJQJUaJmHnHu.hr'hQ @H*KHOJQJaJmHnHu7jhr'hQ @H*KHOJQJUaJmHnHuSSSSSSSSSST,T.T0T6T8Tꬔx````Ax`x=jhr'hQ @H*KHOJQJUaJmHnHu.hr'hQ @H*KHOJQJaJmHnHu7jhr'hQ @H*KHOJQJUaJmHnHu.hr'hx-@H*KHOJQJaJmHnHu)jhr'he@KHOJQJUaJ/jhr'hx-@KHOJQJUaJ hr'hx-@KHOJQJaJ)jhr'hx-@KHOJQJUaJ8T:TW@WBWDWFWĬĔmYGm6% hr'h*@KHOJQJaJ hr'hp@KHOJQJaJ#hr'hp5@KHOJQJaJ&hr'hp5@KHOJQJaJo(#hr'hp@KHOJQJaJo()jhr'he@KHOJQJUaJ.hr'h]\<@H*KHOJQJaJmHnHu.hr'hQ @H*KHOJQJaJmHnHu7jhr'hQ @H*KHOJQJUaJmHnHu=jRhr'hQ @H*KHOJQJUaJmHnHu FWHWLWNWRWTWVW|W~WWWWWWWWWWWWWWWWWWWλtataNaNaNaNaNaNCNthr'h*OJQJ%hr'h*B*OJQJ^JaJph$hr'hpB*OJQJaJo(phh1B*OJQJaJo(ph!h*5@KHOJQJ^JaJ$hat65@KHOJQJ^JaJo($h*5@KHOJQJ^JaJo($hp5@KHOJQJ^JaJo(!h*5@CJKHOJQJ^J$hp5@CJKHOJQJ^Jo(hp@KHOJQJaJFWNW~WWWWWWW$If $1$YD2a$gdXWWWWWWW82222$Ifkd$$Ifl4ֈ!/'16 B   \ t0|644 laytjWWWWWWWWWWWWWWWWWWWWXXX8X:X@XBXDXfXhXXXXXXXXXXXXXXXYYFYHYxYzYYYYYYYYYYYYYYYYYZ&Z(Z.Z0Z2ZFZHZPZRZʿʿʿʿhr'h*OJQJ%hr'h*B*OJQJ^JaJphh1B*OJQJaJo(ph$hr'hpB*OJQJaJo(phKWWWXXDX2kd $$Ifl4ֈ!/'16 B   \ t0|644 laytj$IfDXhXXXXX1kdU $$Iflֈ!/'16 B   \ t0|644 laytj$IfXXXYHYzYY$IfYYYYYY93333$Ifkd $$Iflֈ!/'16 B   \ t0|644 laytjY(Z0Z2ZTZ|Z3kd $$Iflֈ!/'16 B   \ t0|644 laytj$IfRZTZzZ|ZZZZZZZZZZ[[[ ["[[[[[[[\2\4\^\`\n\p\r\\\\\\\\\\\\\\\]] ]]]]]]0]2]:]<]V]X]]]]]]]]^^^ ^پپپپپپپپββhr'hpOJQJo(h1B*OJQJaJo(phhr'h*OJQJ$hr'hpB*OJQJaJo(ph%hr'h*B*OJQJ^JaJphF|ZZZZZZ3kd $$Iflֈ!/'16 B   \ t0|644 laytj$IfZ"[[[4\`\p\$Ifp\r\\\\\93333$IfkdQ $$Iflֈ!/'16 B   \ t0|644 laytj\\\\]2]3kd$$Iflֈ!/'16 B   \ t0|644 laytj$If2]<]X]]]]3kd$$Iflֈ!/'16 B   \ t0|644 laytj$If]^(^*^,^V^iJlputv""#####$d$Ifa$gdjd$d1$a$gdWj WD`gdak@ `gdak@ $1$a$gdak@ $d1$a$d ^"^&^(^*^,^.^2^4^T^V^l^n^^^^^^^__&_4_8_:_d_f_p________`` `˺~s~s~s~s~hs~s~shs~s~s~~~~~~hr'hOJQJhr'h~OJQJhr'h~OJQJo(hr'h~5OJQJaJhr'h~5KHOJQJaJ"hr'h~5KHOJQJaJo(!hp5@KHOJQJ^JaJ!h*5@KHOJQJ^JaJhr'h*OJQJhr'hpOJQJo(hr'h*OJQJo(% ` `aaabbbbccccddddeeeeffffggggh8i:iiiiiiiiiiiiiiiiiӽ{{{{{hr'h~OJQJhr'h~OJQJo(1jhr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu"hr'hx-H*OJQJmHnHuhr'hx-OJQJjhr'h~OJQJU0ijjjjjnjjjjjkkBkDkFkHkJkLkNkkkkkkkkkkkkkkkll(l,l6lHlJlplڶڪyf$hr'h~B*OJQJaJo(ph&j"!hr'hQ H*OJQJUhr'hQ H*OJQJ jhr'hQ H*OJQJUhr'h~H*OJQJ#jhr'h~OJQJU#jhr'h~OJQJUjhr'h~OJQJUhr'h~OJQJo(hr'h~OJQJ(pltlllllllllll4m6m8m>m@mBmDmmοέٛsZsHs"hr'hH*OJQJmHnHu1j=hr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu"hr'hx-H*OJQJmHnHu#j!hr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJjhr'h~OJQJUhr'h~OJQJhr'h~OJQJo(mmmmmmmmmmmmmmmmmnnnn0n2nZn\n^n`nbndnnоЬzo`oN`о#jw>hr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJhr'h~H*OJQJhr'h~OJQJhr'h~OJQJo(jhr'h~OJQJU"hr'hx-H*OJQJmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu1j>hr'hQ H*OJQJUmHnHunnnnnnnnnnoo o>o@ohojolonoporooooooоЬ{l{ZlоAо1jWhr'hQ H*OJQJUmHnHu#jIhr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJhr'h~OJQJhr'h~OJQJo(jhr'h~OJQJU"hr'hx-H*OJQJmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu1jAIhr'hQ H*OJQJUmHnHuoooooooopppp&p(pPpRpTpVpXpZpppppppppppppPqRqVq\q߽t[t1j}ehr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu#jXhr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJhr'h~OJQJhr'h~OJQJo(jhr'h~OJQJU"hr'hx-H*OJQJmHnHu#\qqqqqqqqqqqqqqqr>r@rBrHrJrLrNrrοέٛsssssZsHs"hr'hH*OJQJmHnHu1j6hr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu"hr'hx-H*OJQJmHnHu#jehr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJjhr'h~OJQJUhr'h~OJQJhr'h~OJQJo(rrrrrrrrrrr&s(s*s,s.s0sssssssоЬwewоLо:"hr'hH*OJQJmHnHu1j hr'hQ H*OJQJUmHnHu#j$hr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJhr'h~OJQJo(jhr'h~OJQJU"hr'hx-H*OJQJmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu1jhr'hQ H*OJQJUmHnHussssstt t tttttJtLtjtlttttttttuuu u uu׾鬝wewL鬝1jBhr'hQ H*OJQJUmHnHu#jhr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJhr'h~OJQJo(jhr'h~OJQJU"hr'hx-H*OJQJmHnHu1jhr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHuuuu:u<Cite><Author>Torbenson</Author><RecNum>2222</RecNum><DisplayText><style face="superscript">[237]</style></DisplayText><record><rec-number>2222</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">2222</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Torbenson, M.S.</author><author>Ng, I.O.L.</author><author>Park, Y.N.</author><author>Roncalli, M.</author><author>Sakamato, M.</author></authors></contributors><titles><secondary-title>WHO classification of digestive system tumor 5th edition</secondary-title></titles><pages>229-239</pages><volume>1</volume><dates></dates><pub-location>Geneva, Switzerland</pub-location><publisher>World Health Organization</publisher><urls></urls></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_237" \o "Torbenson, #2222" 237] h1 ~ހLvWHOR~|~2019 mS|~$vWHOR{|hQ R~teSOpSahQؚRS$v~ހ{^_W {|fW8h_W SS'`]~ހ0 h2 ~ހLvEdmondson-SteinerR~ `!~RSo}Y 8h/(kcяck8^ $v~ހSOy\ cRb~hr0 a!~~ހSOyT8h/(k`!~X'Y 8hgrRm g_W'`9eS ހFmHTUx'`|r S gGPz7h~g0 b!~RS] ~ހSOyT8h/(ka!~X'Y ~ހ_W'`f>f 8hgrm 8hRˆY0 c!~RSg] ހ(\ 8hmg ~ހb_rg NĉR ϞD'`] cR~gce ehr~g0 h3 SS'`~ހLvv{|W ~ހLvWHOR{|2019mS|~ ~ހLv ^yrc ~ހLv lxSW ~ހLv f~ހW ~ހLv '`p7hW ~ހLv |h[SOW ~ހLv ZrW ~ހLv [N-N'`|~ހW ~ހLv [Nm]~ހW DU_4 SS'`~ހLvʋebJT!jg Tch/g_R/hQUSS$v'Y\ cm cm cm YS$vpevn= 'Y\g'Y'Y\ cm cm cm g\'Y\ cm cm cm f_\ N@b e/ g/}S {peϑ/}r {g܏ݍymm `nmLv~ހd"50*N/50*NY R/eSb$vS Y R/eR R/em]{ MVIc:yΘiR~M0 *gSsMVIM1NOqS~ d"5*NMVI NSuNяLve~~d"1cm M2ؚqS~ >5*NMVI bSuN܏Lve~~>1cm  Rdb*g gLv ݍ$vgяݍy cm\ƀ{Lvh g/e*gOr/Orƀ{Or g/eLvhTV~~e/~ހ'Y0\~ހShTV^y~Or g/elxSe/ g \~/'Y~/'Y\~mTW܏Yly*gwpe/ g p z^G ~~SRgS m]~em]~ƀVOre/ g/*gwSeя~~Or*gw DU_5 Y LvhRW zlRW ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_238" \o "Shi, 2010 #2295" 238] IW Y LvhOrSbkvY R/e IIW Y LvhOrY ]/ebS/e IIIW Y LvhOrY ;Nr^ IVW Y LvhOr󁠀| NY  I0W /gTutf[ʋeY _@{Lvh0 e,gLvxvzf[OvVpRW ADDIN EN.CITE <EndNote><Cite><Author>Japan</Author><Year>2003</Year><RecNum>2296</RecNum><DisplayText><style face="superscript">[239]</style></DisplayText><record><rec-number>2296</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1575968495">2296</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Liver Cancer Study Group of Japan</author></authors></contributors><titles><title>General rules for the clinical and pathological study of primary liver cancer</title></titles><dates><year>2003</year></dates><pub-location>Tokyo: Kanehara</pub-location><urls></urls></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_239" \o "Japan, 2003 #2296" 239] Vp1 Y Lvh@\PNY N~R/eN܏ Vp2 Y LvhOrY N~R/e Vp3 Y LvhOrY N~R/e VP4 Y LvhOrY ;Nr^b[ON~R/e0 DU_6 ~[{R Suh^XluۏU\ 1 R n{c~SuLplHepatic Arterial Infusion Chemotherapy HAIC  gxvzhfǑ(uHAIClu[NY!kTACEluNubb0Lv4OY Lvh0Yy/gTX[(WؚqS YS0YlyvLvuN uHeONUS~"}b^<\luv4OY LvhuNǑ(uHAICTT"}b^<\luuHef>fONUS~"}b^<\lu0Vdk [NRLvuNTACEI{luTHeg N}Yv`Q N SNL`O(uHAICluel ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_240" \o "Lyu, 2018 #2202" 240-243]ncI{~2 0 2 TACETv/gMRKm!jW`$ Six-and-twelve !jWsS$v'Y\+peϑKNTd"6  6Nd"12 120!jW[cSTACEluvLvuNۏL*NSOSTċ0OTqSiRB\ uNvΘiRB\ N T vQ-NMOuX[e]_>fW0Vdk O(u Six-and-twelve !jW :NLvuNTACE/gMRcO/gTguX[vS

f9eU13.5 *Ngvs 25.2 *NgP=0.006  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_246" \o "Kudo, 2019 #2298" 246]ncI{~2 0 DU_7 LvY>e\luck8^~~wQSOSBRϑS zSO[T>eu1 RChild-Pugh A~ >euR!kpe3^5!k ck8^SOy[SOy-'YSO$vSOy Liver-Gross tumor volume GTV ]700 mLb800 mL Liver-GTVs^GWBRϑR+R15 Gyb18 Gy>euR!kpe6!k Liver-GTVSOy800 mL s^GWBRϑ20 Gyk!k$vRrRBRϑ4^8 Gy Liver-GTVs^GWBRϑ23 Gy:N[hQBRϑ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_247" \o "Marks, 2010 #2214" 247  HYPERLINK \l "_ENREF_248" \o "Pan, 2010 #2215" 248]ncI{~2 02 N2mLvuN8^4O glxST>RNۏ [ÀSv@TQ@R] ÀSv>e\SBRϑNONRTOGcPvBRϑ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_249" \o "Chon, 2011 #2216" 249]vMRe.sSN[qQƋ:N >euR!kpe3-5!k ÀT\g'YBRϑGW^d22.2^35Gy gsOd30Gy03 >euR!kpe3-5!k Ss^GWBRϑgsO10Gy Ӛg'YBRϑd21.9^30Gy gsOd18^23Gy ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_250" \o "Hanna, 2018 #2217" 250]0 8^ĉRrRBRϑ>eu1 RChild-Pugh A~ Liver-GTVs^GWBRϑ28^30 GyRChild-Pugh B~ [\~vSϑf>f NM gsO6 Gy MQRChild-Pugh C~uNL:S>eu ADDIN EN.CITE <EndNote><Cite><Author>Pan</Author><Year>2010</Year><RecNum>2215</RecNum><DisplayText><style face="superscript">[248]</style></DisplayText><record><rec-number>2215</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1570540962">2215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pan, C. C.</author><author>Kavanagh, B. D.</author><author>Dawson, L. A.</author><author>Li, X. A.</author><author>Das, S. K.</author><author>Miften, M.</author><author>Ten Haken, R. K.</author></authors></contributors><auth-address>Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109-5010, USA. cpan@umich.edu</auth-address><titles><title>Radiation-associated liver injury</title><secondary-title>Int J Radiat Oncol Biol Phys</secondary-title></titles><periodical><full-title>Int J Radiat Oncol Biol Phys</full-title><abbr-1>International journal of radiation oncology, biology, physics</abbr-1></periodical><pages>S94-100</pages><volume>76</volume><number>3 Suppl</number><edition>2010/03/05</edition><keywords><keyword>Humans</keyword><keyword>Liver/*radiation effects</keyword><keyword>Liver Neoplasms/*radiotherapy/secondary</keyword><keyword>Models, Biological</keyword><keyword>Radiation Dosage</keyword><keyword>Radiation Injuries/*complications/therapy</keyword><keyword>Radiation Tolerance</keyword><keyword>Risk</keyword></keywords><dates><year>2010</year><pub-dates><date>Mar 1</date></pub-dates></dates><isbn>1879-355X (Electronic)&#xD;0360-3016 (Linking)</isbn><accession-num>20171524</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/20171524</url></related-urls></urls><custom2>PMC4388033</custom2><electronic-resource-num>10.1016/j.ijrobp.2009.06.092</electronic-resource-num><language>eng</language></record></Cite></EndNote>[173  HYPERLINK \l "_ENREF_248" \o "Pan, 2010 #2215" 248]02 ÀT\g'YBRϑGW^d54Gy ÀV4545% \V50d"5%03 Ss^GWBRϑd"15Gy YNOs^GWBRϑ'YN19Gy RSNO=\ϑ_ Ӛg'YBRϑd45Gy ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_247" \o "Marks, 2010 #2214" 247]0 DU_8 ck(WۏLNMQuhgpb6RBR gsQvxvz 1 ]~[bvxvz I0IIgxvzCheckmate 040hf ~fk)R$\USKQbSO(uNe_O(u HYPERLINK "https://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" "}b^<\vLvuN mOS0R15.6*Ng vQ-NN2muNvmOS:N14.9*NgePD-L1h3'`b4'` GWS_4N^ ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_191" \o "El-Khoueiry, 2017 #167" 191]ncI{~2 0Vdk VFDA gagNybQN~fk)R$\USKQbSON~luLv0cPBRϑ:NN!k3mg/kgb240mg0k2hT1!kb1!k480mg0k4hT1!k0FO/f b!gxvzCheckmate 459 sSk~fk)R$\USKQbSO[k HYPERLINK "https://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" "}b^<\N~luLv 2019t^6glQ^v~gOSTPFS g^R FOv^l g0Rv~p0 IIgxvzKeynote224hf  HYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" ^ZS)RsUSKQbSO(uNe_ HYPERLINK "https://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" "}b^<\luTۏU\belS"}b^<\lu0RChild-Pugh A~LvuN [‰㉇s17%0uu3z[s44%0mPFS:N4.9*Ng0mOS:N12.9*Ng ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_192" \o "Zhu, 2018 #175" 192]ncI{~2 0Vdk VFDA gagNybQN^ZS)RsUSKQbSON~luLv0(ul:N1!k200 mg0k3hT1!k0FO/f 2019t^2gIIIgxvzKeynote240~gcSf  HYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" ^ZS)RsUSKQbSOTTgsO/eclu[k[paBRTTgsO/ecluN~luLv OSTPFSGW g@b^ FO*g0Rv~p0vMR [cSǏ|~lu0Ǒ(u HYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link" ^ZS)RsUSKQbSON~luN*Y:SLvuNvv4N^xvzKeynote394ck(WۏLKN-N0 IIIgxvzIMbrave150hf ?f)RsUSKQbSOTOsUSKQbSOTTluUS(u"}b^<\luSOOSΘiMNO42%[ΘikHR = 0.5895%CI0.42-0.79p=0.0006] OPFSΘiMNO41%HR=0.5995%CI0.47-0.76p<0.0001 0TTlu~v[‰㉇s0R27% vQ-N[hQ㉇s6% R㉇s22%0dkY TTul؏^uNbJTu;m(ϑSuv`Svev`SSuv-NMOe11.2*Ng vs 3.6*NgHR = 0.6395 CI0.46^0.85 ncI{~2  ADDIN EN.CITE <EndNote><Cite><Author>Cheng AL</Author><Year>2019</Year><RecNum>2299</RecNum><DisplayText><style face="superscript">[251]</style></DisplayText><record><rec-number>2299</rec-number><foreign-keys><key app="EN" db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v" timestamp="1575973494">2299</key></foreign-keys><ref-type name="Conference Paper">47</ref-type><contributors><authors><author>Cheng AL, Qin S, Ikeda M</author></authors></contributors><titles><title>IMbrave150: Efficacy and Safety Results From a Ph 3 Study Evaluating Atezolizumab (atezo) + Bevacizumab (bev) vs Sorafenib (Sor) as First Treatment (tx) for Patients (pts) With Unresectable Hepatocellular Carcinoma (HCC)</title><secondary-title>2019 ESMO Asia</secondary-title></titles><section>LBA3</section><dates><year>2019</year></dates><urls></urls></record></Cite></EndNote>[ HYPERLINK \l "_ENREF_251" \o "Cheng AL, 2019 #2299" 251]0 aS^t)RsUSKQbSOTT?^f<\luZfgLvvIgxvzhf?^f<\vg'YSBRϑ:N250 mg [‰㉇sTuuc6RsR+R:N50.0%T93.8% -NMOe:N3.4*NgluvsQ NoS^Sc uNS'`o}Y *g‰[0RHBVQ;mSncI{~3  ADDIN EN.CITE  ADDIN EN.CITE.DATA [ HYPERLINK \l "_ENREF_252" \o "Xu, 2019 #2297" 252]0 2 ck(WۏLvIIIg4N^xvz*b2019t^10g6e h4 MQuhgpb6RBRUSoSTTluvxvz(WLvW$\:N;mÍ0ُNxvzvg~b%N&TO[4N^[Nu_'Yvq_T0,gĉvTgHr,g_NO9hncv^vxvz~gS_~+RZPQv^vO9e0 h4 (WxvIIIg4N^Ջ (uo6kxvzeHhxvz{yNCT{vSRlu~fk)R$\USKQbSO vs. [paBRCheckmate 9DXNCT03383458 RluHYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link"^ZS)RsUSKQbSO vs. [paBRKeynote 937NCT03867084Rluyr^tnf)RUSKQbSO vs. [paBR/NCT03859128RluDurvalumab vs Durvalumab+OsUSKQbSO vs. [paBREMERALD-2NCT03847428Rlu?yrsUSKQbSO+OsUSKQbSOIMbrave 050NCT04102098N~luDurvalumab vs Durvalumab+Tremelimumab vs. "}b^<\HIMALAYANCT03298451N~luBGB-A317 vs. "}b^<\RATIONALE-301NCT03412773N~luO)RUSKQbSO+VEGFUSKQbSO vs. "}b^<\ORIENT-32NCT03794440N~lu?yrsUSKQbSO+OsUSKQbSO vs. "}b^<\IMbrave150NCT03434379N~lu?yrsUSKQbSO+aSZSf<\ vs. "}b^<\COSMIC-312NCT03755791N~luaS^t)RsUSKQbSO+?^f<\ vs. "}b^<\/NCT03764293N~luHYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link"^ZS)RsUSKQbSO+NOf<\ vs. NOf<\LEAP-002NCT03713593N~luaS^t)RsUSKQbSO+FOLFOX4 vs. FOLFOX4 b"}b^<\/NCT03605706N~luDurvalumab+OsUSKQbSO+TACE vs. Durvalumab +TACE vs. [paBR+TACEEMERALD-1NCT03778957N~lu~fk)R$\USKQbSO+ O9SUSKQbSO vs. "}b^<\bNOf<\Checkmate 9DWNCT04039607 N~lu~fk)R$\USKQbSO+NOf<\ vs. NOf<\/NCT04044651N~luyr^tnf)RUSKQbSOR Lpl vs. Y nl/NCT03949231N~luHYPERLINK "https://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link"^ZS)RsUSKQbSO vs. [paBRKeynote 394NCT03062358 DU_9 0SS'`Lvʋuĉ2019t^Hr 0QN[YXTO T;NNYXT4T_[ dl7s RAQ!` H][s^ sf[im Y[q ѐhh ;NNYXT j V oR;NNYXTc[? yS5 l Ng:_ hTO !yQ sOg !^:_ nvQ Yyf[~~hTO oR~hTOs^ +Rs^ Rޏe e)Y+Y NeQluf[~~s^NS oR~V[ s:_ R^t[ F] QyS@\萻lu~~yS5 oR~NckR HOeq\ f-fQ h q_Pf[~~fς oR~hy HOe %NyNS ses^ utf[~~Ne oR~~CQ N_s^ YXT cYlbc^  ![ HbQ befk zh N zf 4bgmQ 퐇el [ё ĞSffk ZkSN NgNf NgTfĖ h Q R X] R)Y TV` kN m_ m NOe w*mb eVf S_ Y[`] v_q\ sem sSf s _ s_f T_ 8l܀ [Mb _^f hg2uh hg^R hgNS hgNg S܀ 9\[ __ _ZSR` _ _4lQ _ P u8ly ѐ~R 1g~N 1g^z yfNY[`] s_ y fNRX] S_ 8l܀ Nzf Se.s  ADDIN EN.REFLIST [1] Torre LA Bray F Siegel RL Ferlay J Lortet-Tieulent J Jemal A. Global cancer statistics 2012[J]. CA Cancer J Clin 2015 652 87-108. [2] Zhou M Wang H Zeng X et al. Mortality morbidity and risk factors in China and its provinces 1990-2017a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet 2019 39410204 1145-58. [3] Zhang BH Yang BH Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol 2004 1307 417-22. [4] Dong Y Wang WP Mao F Ji ZB Huang BJ. Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasound[J]. J Gastroenterol Hepatol 2016 314 822-8. [5] Da Silva NPB Hornung M Beyer LP et al. Intraoperative Shear Wave Elastography vs. Contrast-Enhanced Ultrasound for the Characterization and Differentiation of Focal Liver Lesions to Optimize Liver Tumor Surgery[J]. Ultraschall Med 2019 402 205-11. [6] Hu H Han H Han XK Wang WP Ding H. Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinomathe evidence from ultrasound data[J]. Eur Radiol 2018 282 877-85. [7] Grgurevic I Bokun T Salkic NN et al. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions[J]. Liver Int 2018 386 1055-63. [8] Berzigotti A Ferraioli G Bota S Gilja OH Dietrich CF. Novel ultrasound-based methods to assess liver diseaseThe game has just begun[J]. Dig Liver Dis 2018 502 107-12. [9] Lee YJ Lee JM Lee JS et al. Hepatocellular carcinomadiagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology 2015 2751 97-109. [10] Liu X Jiang H Chen J Zhou Y Huang Z Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinomaA meta-analysis[J]. Liver Transpl 2017 2312 1505-18. [11] Zeng MS Ye HY Guo L et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patientsa multicenter open-label phase III study[J]. Hepatobiliary Pancreat Dis Int 2013 126 607-16. [12] Ichikawa T Saito K Yoshioka N et al. Detection and characterization of focal liver lesionsa Japanese phase III multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease[J]. Invest Radiol 2010 453 133-41. [13] N H"_ v#Wey I{. Gd+-EOB-DTPANGd+-DTPAX:_xqQ/chg~ހLvv[gqxvz[J]. -NNSnfYyBg_ 2013 289 682-85. [14] Yoo SH Choi JY Jang JW et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J]. Ann Surg Oncol 2013 209 2893-900. [15] Rao SX Wang J Wang J et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agentGadoxetic acid disodium[J]. J Dig Dis 2019 202 54-61. [16] Marrero JA Kulik LM Sirlin CB et al. Diagnosis Staging and Management of Hepatocellular Carcinoma2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology 2018 682 723-50. [17] EASL Clinical Practice GuidelinesManagement of hepatocellular carcinoma[J]. J Hepatol 2018 691 182-236. [18] Omata M Cheng AL Kokudo N et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinomaa 2017 update[J]. Hepatol Int 2017 114 317-70. [19] Cho ES Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior[J]. Korean J Radiol 2015 163 449-64. [20] Hwang J Kim YK Jeong WK Choi D Rhim H Lee WJ. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver DiseaseDiffusion-weighted Imaging for Characterization[J]. Radiology 2015 2761 137-46. [21] Renzulli M Biselli M Brocchi S et al. New hallmark of hepatocellular carcinoma early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosisa new diagnostic algorithm[J]. Gut 2018 679 1674-82. [22] Xu X Zhang HL Liu QP et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma[J]. J Hepatol 2019 706 1133-44. [23] Lei Z Li J Wu D et al. Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria[J]. JAMA Surg 2016 1514 356-63. [24] Peng J Zhang J Zhang Q Xu Y Zhou J Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma[J]. Diagn Interv Radiol 2018 243 121-27. [25] Park JW Kim JH Kim SK et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med 2008 4912 1912-21. [26] Lin CY Chen JH Liang JA Lin CC Jeng LB Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinomaa systematic review and meta-analysis[J]. Eur J Radiol 2012 819 2417-22. [27] Boellaard R Delgado-Bolton R Oyen WJ et al. FDG PET/CTEANM procedure guidelines for tumour imagingversion 2.0[J]. Eur J Nucl Med Mol Imaging 2015 422 328-54. [28] Boellaard R O'doherty MJ Weber WA et al. FDG PET and PET/CTEANM procedure guidelines for tumour PET imagingversion 1.0[J]. Eur J Nucl Med Mol Imaging 2010 371 181-200. [29] Wahl RL Jacene H Kasamon Y Lodge MA. From RECIST to PERCISTEvolving Considerations for PET response criteria in solid tumors[J]. J Nucl Med 2009 50 Suppl 1122S-50S. [30] Chalian H Tore HG Horowitz JM Salem R Miller FH Yaghmai V. Radiologic assessment of response to therapycomparison of RECIST Versions 1.1 and 1.0[J]. Radiographics 2011 317 2093-105. [31] Ferda J Ferdova E Baxa J et al. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography[J]. Anticancer Res 2015 354 2241-6. [32] Lee JW Oh JK Chung YA et al. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent ChemoradiotherapyA Multicenter Retrospective Cohort Study[J]. J Nucl Med 2016 574 509-16. [33] Hyun SH Eo JS Lee JW et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomasa multicenter retrospective cohort study[J]. Eur J Nucl Med Mol Imaging 2016 439 1638-45. [34] Na SJ Oh JK Hyun SH et al. 18 F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma PatientsA Multicenter Retrospective Cohort Study[J]. J Nucl Med 2017 585 730-36. [35] Bertagna F Bertoli M Bosio G et al. Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinomaa systematic review and meta-analysis[J]. Hepatol Int 2014 84 493-500. [36] Cheung TT Ho CL Lo CM et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteriasurgeon's perspective[J]. J Nucl Med 2013 542 192-200. [37] Zhang Y Shi H Cheng D et al. Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignancies[J]. Nucl Med Commun 2013 345 451-8. [38] Hectors SJ Wagner M Besa C Huang W Taouli B. Multiparametric FDG-PET/MRI of Hepatocellular CarcinomaInitial Experience[J]. Contrast Media Mol Imaging 2018 20185638283. [39] Forner A Vilana R Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosisProspective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology 2008 471 97-104. [40] Roberts LR Sirlin CB Zaiem F et al. Imaging for the diagnosis of hepatocellular carcinomaA systematic review and meta-analysis[J]. Hepatology 2018 671 401-21. [41] Paradish V Fukayama M Park YN Schirmacher PTumors of the liver and intrahepatic bile ducts Board W C O T E editor WHO Classification of Tumours of the Digestive SystemWorld Health Organization Press 2019. [42] Zhou J Yu L Gao X et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol 2011 2936 4781-8. [43] Westra WH Hruban RH Phelps TH Isacson C. Surgical Pathology DissectionAn Illustrated Guide[M]. New YorkSpringer 2003258. [44] Nara S Shimada K Sakamoto Y et al. Prognostic impact of marginal resection for patients with solitary hepatocellular carcinomaevidence from 570 hepatectomies[J]. Surgery 2012 1514 526-36. [45] Ne. ƀ$vYyutf[[M]. SNNlkSuQHr>y 2015276-320. [46] Scheuer PJ. Classification of chronic viral hepatitisa need for reassessment[J]. J Hepatol 1991 133 372-4. [47] uk'`p2leHh[J]. -NNS OguBg_ 2001 191 56-62. [48] Lasser C. Exosomes in diagnostic and therapeutic applicationsbiomarker vaccine and RNA interference delivery vehicle[J]. Expert Opin Biol Ther 2015 151 103-17. [49] Rodriguez-Peralvarez M Luong TV Andreana L Meyer T Dhillon AP Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinomadiagnostic and prognostic variability[J]. Ann Surg Oncol 2013 201 325-39. [50] -NVbLvOSOLvNNYXTO -NNS;Sf[Ouf[ROLvf[~ -NVbLvOSOutNNYXTO I{. SS'`LvĉSutʋecWS2015t^Hr [J]. -NNSƀYyBg_ 2015 213 145-51. [51] Eguchi S Takatsuki M Hidaka M et al. Predictor for histological microvascular invasion of hepatocellular carcinomaa lesson from 229 consecutive cases of curative liver resection[J]. World J Surg 2010 345 1034-8. [52] Fujita N Aishima S Iguchi T et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma[J]. Hum Pathol 2011 4210 1531-8. [53] Iguchi T Shirabe K Aishima S et al. New Pathologic Stratification of Microvascular Invasion in Hepatocellular CarcinomaPredicting Prognosis After Living-donor Liver Transplantation[J]. Transplantation 2015 996 1236-42. [54] Shi L Zhang SJ Chen J et al. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma[J]. Mod Pathol 2019. [55] Xie DY Fan HK Ren ZG Fan J Gao Q. Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications[J]. Clin Transl Gastroenterol 2019 102 e00006. [56] Wen T Jin C Facciorusso A et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resectionan international expert consensus[J]. Hepatobiliary Surg Nutr 2018 75 353-71. [57] Wang B Xia CY Lau WY et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluationa new strategy for hepatic surgery[J]. J Am Coll Surg 2013 2176 1054-62. [58] Cong WM Wu MC. New insights into molecular diagnostic pathology of primary liver cancerAdvances and challenges[J]. Cancer Lett 2015 3681 14-19. [59] Imamura H Seyama Y Kokudo N et al. One thousand fifty-six hepatectomies without mortality in 8 years[J]. Arch Surg 2003 13811 1198-206; discussion 206. [60] Kubota K Makuuchi M Kusaka K et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors[J]. Hepatology 1997 265 1176-81. [61] Bruix J Castells A Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patientsprognostic value of preoperative portal pressure[J]. Gastroenterology 1996 1114 1018-22. [62] Cescon M Colecchia A Cucchetti A et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma[J]. Ann Surg 2012 2565 706-12; discussion 12-3. [63] Shen Y Zhou C Zhu G et al. Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma[J]. J Gastrointest Surg 2017 219 1471-79. [64] Rajakannu M Cherqui D Ciacio O et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma[J]. Surgery 2017 1624 766-74. [65] Zhong JH Ke Y Gong WF et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg 2014 2602 329-40. [66] Xiao H Zhang B Mei B et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertensiona long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine Baltimore 2015 947 e495. [67] Bosch J Abraldes JG Berzigotti A Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol 2009 610 573-82. [68] Chen X Zhai J Cai X et al. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis[J]. Br J Surg 2012 9912 1701-10. [69] Chen MS Li JQ Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg 2006 2433 321-8. [70] Mohkam K Dumont PN Manichon AF et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cm[J]. J Hepatol 2018 686 1172-80. [71] Liu PH Hsu CY Hsia CY et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma </= 2 cm in a Propensity Score Model[J]. Ann Surg 2016 2633 538-45. [72] Feng K Yan J Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol 2012 574 794-802. [73] Xu Q Kobayashi S Ye X Meng X. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinomaa meta-analysis of 16 103 patients[J]. Sci Rep 2014 47252. [74] Yin L Li H Li AJ et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteriaa RCT[J]. J Hepatol 2014 611 82-8. [75] Torzilli G Belghiti J Kokudo N et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centersis it adherent to the EASL/AASLD recommendations?an observational study of the HCC East-West study group[J]. Ann Surg 2013 2575 929-37. [76] Wang K Guo WX Chen MS et al. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusA Large-Scale Multicenter Propensity Mathching Score Analysis[J]. Medicine Baltimore 2016 9511 e3015. [77] Wei X Jiang Y Zhang X et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombusA Randomized Open-Label Multicenter Controlled Study[J]. J Clin Oncol 2019Jco1802184. [78] Li XL Zhu XD Cai H et al. Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinomaA propensity score matching analysis[J]. Surgery 2019 1656 1161-67. [79] Yang J Tao HS Cai W et al. Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. J Surg Oncol 2018 1187 1081-87. [80] Mise Y Hasegawa K Satou S et al. How Has Virtual Hepatectomy Changed the Practice of Liver Surgery?Experience of 1194 Virtual Hepatectomy Before Liver Resection and Living Donor Liver Transplantation[J]. Ann Surg 2018 2681 127-33. [81] Jiang HT Cao JY. Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma[J]. Chin Med Sci J 2015 302 80-3. [82] Wu X Huang Z Lau WY et al. Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic backgrounda propensity score matching study[J]. Surg Endosc 2019 331 206-15. [83] Cheung TT Han HS She WH et al. The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular CarcinomaA Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong Kong[J]. Liver Cancer 2018 71 28-39. [84] Shi M Guo RP Lin XJ et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinomaa prospective randomized trial[J]. Ann Surg 2007 2451 36-43. [85] Yang P Si A Yang J et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery 2019 1654 721-30. [86] Liu CL Fan ST Lo CM Tung-Ping Poon R Wong J. Anterior approach for major right hepatic resection for large hepatocellular carcinoma[J]. Ann Surg 2000 2321 25-31. [87] Zhou C Peng Y Zhou K et al. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr 2019 81 19-28. [88] Zhang ZM Lai EC Zhang C et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg 2015 208-16. [89] Fu SY Lau WY Li AJ et al. Liver resection under total vascular exclusion with or without preceding Pringle manoeuvre[J]. Br J Surg 2010 971 50-5. [90] Satoh S Ikai I Honda G et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi[J]. Surgery 2000 1285 779-83. [91] Tang ZY Uy YQ Zhou XD et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinomaevaluation with analysis of 72 patients[J]. World J Surg 1995 196 784-9. [92] Tang ZY Yu YQ Zhou XD et al. Treatment of unresectable primary liver cancerwith reference to cytoreduction and sequential resection[J]. World J Surg 1995 191 47-52. [93] Wakabayashi H Okada S Maeba T Maeta H. Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured liversa preliminary report[J]. Surg Today 1997 275 403-10. [94] Ogata S Belghiti J Farges O Varma D Sibert A Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg 2006 939 1091-8. [95] Wang Z Peng Y Hu J et al. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular CarcinomaA Single Center Study of 45 Patients[J]. Ann Surg 2018. [96] D'haese JG Neumann J Weniger M et al. Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC?[J]. Ann Surg Oncol 2016 234 1335-43. [97] ѐhV Ng^O PN f)R O. hQyT\TTyeTY ~NbvNekRd/glulxSLv[J]. -NNSmSYyBg_ 2014 137 502-07. [98] Hong De F Zhang YB Peng SY Huang DS. Percutaneous Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver RegenerationA Minimally Invasive First Step of ALPPS for Hepatocellular Carcinoma[J]. Ann Surg 2016 2641 e1-2. [99] Shi HY Wang SN Wang SC Chuang SC Chen CM Lee KT. Preoperative transarterial chemoembolization and resection for hepatocellular carcinomaa nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol 2014 1095 487-93. [100] Zhou WP Lai EC Li AJ et al. A prospective randomized controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg 2009 2492 195-202. [101] Yin J Li N Han Y et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinomaa two-stage longitudinal clinical study[J]. J Clin Oncol 2013 3129 3647-55. [102] Huang G Lau WY Wang ZG et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinomaa randomized controlled trial[J]. Ann Surg 2015 2611 56-66. [103] Wang Z Ren Z Chen Y et al. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After ResectionA Randomized Controlled Study[J]. Clin Cancer Res 2018 249 2074-81. [104] Wei W Jian PE Li SH et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasiona randomized clinical trial of efficacy and safety[J]. Cancer Commun Lond 2018 381 61. [105] Chen Q Shu C Laurence AD et al. Effect of Huaier granule on recurrence after curative resection of HCCa multicentre randomised clinical trial[J]. Gut 2018 6711 2006-16. [106] Huang G Li PP Lau WY et al. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA LevelsA Randomized Controlled Trial[J]. Ann Surg 2018 2686 943-54. [107] Fan J Zhou J Wu ZQ et al. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis[J]. World J Gastroenterol 2005 118 1215-9. [108] Lo CM Liu CL Chan SC et al. A randomized controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J]. Ann Surg 2007 2456 831-42. [109] Sun HC Tang ZY Wang L et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinomaa randomized clinical trial[J]. J Cancer Res Clin Oncol 2006 1327 458-65. [110] Nishiguchi S Tamori A Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma[J]. Intervirology 2005 481 71-5. [111] Mazzaferro V Romito R Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis[J]. Hepatology 2006 446 1543-54. [112] Ji J Shi J Budhu A et al. MicroRNA expression survival and response to interferon in liver cancer[J]. N Engl J Med 2009 36115 1437-47. [113] Bruix J Takayama T Mazzaferro V et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation STORM a phase 3 randomised double-blind placebo-controlled trial[J]. Lancet Oncol 2015 1613 1344-54. [114] Wang SN Chuang SC Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgeryA pilot study[J]. Hepatol Res 2014 445 523-31. [115] Sapisochin G Bruix J. Liver transplantation for hepatocellular carcinomaoutcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol 2017 144 203-17. [116] Zheng SS Xu X Wu J et al. Liver transplantation for hepatocellular carcinomaHangzhou experiences[J]. Transplantation 2008 8512 1726-32. [117] Fan J Yang GS Fu ZR et al. Liver transplantation outcomes in 1 078 hepatocellular carcinoma patientsa multi-center experience in Shanghai China[J]. J Cancer Res Clin Oncol 2009 13510 1403-12. [118] Li J Yan LN Yang J et al. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients[J]. World J Gastroenterol 2009 1533 4170-6. [119] SS hg^z hg[ I{. NNqQƋ(WSS'`Lvy ilu-NvЏ(u[J]. -NV[(uYyBg_ 2008 286 466-69. [120] Llovet JM Pavel M Rimola J et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria Barcelona Clinic Liver Cancer extended criteria [J]. Liver Transpl 2018 243 369-79. [121] Pinheiro RS Waisberg DR Nacif LS et al. Living donor liver transplantation for hepatocellular canceran almost exclusive Eastern procedure?[J]. Transl Gastroenterol Hepatol 2017 268. [122] Sposito C Cucchetti A Mazzaferro V. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma[J]. Dig Dis Sci 2019 644 1001-07. [123] Segev DL Sozio SM Shin EJ et al. Steroid avoidance in liver transplantationmeta-analysis and meta-regression of randomized trials[J]. Liver Transpl 2008 144 512-25. [124] Rodriguez-Peralvarez M Tsochatzis E Naveas MC et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol 2013 596 1193-9. [125] Liang W Wang D Ling X et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinomaa meta-analysis[J]. Liver Transpl 2012 181 62-9. [126] Zhou J Wang Z Wu ZQ et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J]. Transplant Proc 2008 4010 3548-53. [127] Geissler EK Schnitzbauer AA Zulke C et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular CarcinomaA Randomized Multicenter Open-Label Phase 3 Trial[J]. Transplantation 2016 1001 116-25. [128] Thorat A Jeng LB Yang HR et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteriare-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg 2017 214 205-11. [129] Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantationRisk factors screening and clinical presentation[J]. World J Hepatol 2019 113 261-72. [130] Au KP Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinomaA proposed management algorithm[J]. World J Gastroenterol 2018 2445 5081-94. [131] Hasegawa K Aoki T Ishizawa T et al. Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma[J]. Ann Surg Oncol 2014 21 Suppl 3S348-55. [132] Li L Zhang J Liu X Li X Jiao B Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinomaa meta-analysis[J]. J Gastroenterol Hepatol 2012 271 51-8. [133] Huang J Yan L Cheng Z et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]. Ann Surg 2010 2526 903-12. [134] Feng Q Chi Y Liu Y Zhang L Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinomaa meta-analysis of 23 studies[J]. J Cancer Res Clin Oncol 2015 1411 1-9. [135] Peng ZW Zhang YJ Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinomaa prospective randomized trial[J]. J Clin Oncol 2013 314 426-32. [136] Morimoto M Numata K Kondou M Nozaki A Morita S Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinomaa randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer 2010 11623 5452-60. [137] Chen QW Ying HF Gao S et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinomaA systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol 2016 403 309-14. [138] Peng ZW Lin XJ Zhang YJ et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smallera retrospective comparative study[J]. Radiology 2012 2623 1022-33. [139] Livraghi T Meloni F Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosisIs resection still the treatment of choice?[J]. Hepatology 2008 471 82-9. [140] Weis S Franke A Mossner J Jakobsen JC Schoppmeyer K. Radiofrequency thermal ablation versus no intervention or other interventions for hepatocellular carcinoma[J]. Cochrane Database Syst Rev 2013 12 Cd003046. [141] Kim YS Lim HK Rhim H et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinomaanalysis of prognostic factors[J]. J Hepatol 2013 581 89-97. [142] Zhang L Ge NL Chen Y et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma10-year follow-up in Chinese patients[J]. Med Oncol 2015 323 77. [143] Cho YK Kim JK Kim MY Rhim H Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies[J]. Hepatology 2009 492 453-9. [144] Shibata T Iimuro Y Yamamoto Y et al. Small hepatocellular carcinomacomparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J]. Radiology 2002 2232 331-7. [145] Di Vece F Tombesi P Ermili F Maraldi C Sartori S. Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effectsa prospective pilot study[J]. Cardiovasc Intervent Radiol 2014 373 723-9. [146] Ahmed M Solbiati L Brace CL et al. Image-guided tumor ablationstandardization of terminology and reporting criteria--a 10-year update[J]. Radiology 2014 2731 241-60. [147] Lencioni R De Baere T Soulen MC Rilling WS Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinomaA systematic review of efficacy and safety data[J]. Hepatology 2016 641 106-16. [148] Pelletier G Ducreux M Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolizationa multicenter randomized trial. Groupe CHC[J]. J Hepatol 1998 291 129-34. [149] Lo CM Ngan H Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology 2002 355 1164-71. [150] Llovet JM Real MI Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinomaa randomised controlled trial[J]. Lancet 2002 3599319 1734-9. [151] Camma C Schepis F Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinomameta-analysis of randomized controlled trials[J]. Radiology 2002 2241 47-54. [152] Llovet JM Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinomaChemoembolization improves survival[J]. Hepatology 2003 372 429-42. [153] -NNS;Sf[O>e\f[RONeQf[~OS\O~. SS'`~ހLv~[{R Su'`h^Xlub/gd\OĉN[qQƋ[J]. -NNS>e\f[Bg_ 2011 4510 908-12. [154] Yang M Fang Z Yan Z et al. Transarterial chemoembolisation TACE combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alonea two-arm randomised clinical trial[J]. J Cancer Res Clin Oncol 2014 1402 211-9. [155] ?m ΞwmN hf3 I{. 125I|P[ ieQTTR Sf[h^XluSS'`LvTv^Y Lvh[J]. -NNS>e\f[Bg_ 2012 466 552-56. [156] Si ZM Wang GZ Qian S et al. Combination Therapies in the Management of Large >/= 5 cm Hepatocellular CarcinomaMicrowave Ablation Immediately Followed by Transarterial Chemoembolization[J]. J Vasc Interv Radiol 2016. [157] Jang JW Choi JY Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma[J]. J Hepatol 2004 413 427-35. [158] Wahl DR Stenmark MH Tao Y et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J]. J Clin Oncol 2016 345 452-9. [159] Chino F Stephens SJ Choi SS et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer[J]. Cancer 2018 12417 3476-89. [160] Shen PC Chang WC Lo CH et al. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys 2019. [161] Hara K Takeda A Tsurugai Y et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency AblationA Propensity Score Analysis[J]. Hepatology 2019 696 2533-45. [162] Bujold A Massey CA Kim JJ et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol 2013 3113 1631-9. [163] Su TS Liang P Liang J et al. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys 2017 983 639-46. [164] Kim N Kim HJ Won JY et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma[J]. Radiother Oncol 2019 13181-87. [165] Rim CH Kim HJ Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinomaA systematic review and meta-analysis of observational studies[J]. Radiother Oncol 2019 131135-44. [166] Ohri N Dawson LA Krishnan S et al. Radiotherapy for Hepatocellular CarcinomaNew Indications and Directions for Future Study[J]. J Natl Cancer Inst 2016 1089 . [167] Huo YR Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular CarcinomaA Systematic Review and Meta-analysis[J]. JAMA Oncol 2015 16 756-65. [168] Zeng ZC Tang ZY Fan J et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma[J]. Cancer J 2004 105 307-16. [169] Meng MB Cui YL Lu Y et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinomaa systematic review and meta-analysis[J]. Radiother Oncol 2009 922 184-94. [170] Yoon SM Ryoo BY Lee SJ et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular InvasionA Randomized Clinical Trial[J]. JAMA Oncol 2018 45 661-69. [171] Shen L Xi M Zhao L et al. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular InvasionStereotactic Body Radiotherapy versus Sorafenib[J]. Cancers Basel 2018 1012 . [172] Zeng ZC Fan J Tang ZY et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys 2005 612 432-43. [173] -NNS;Sf[O>e\$vf[RO -NVuir;Sf[] zf[O|nx>euROLvf[~NmS|~$vN[YXTO -NVxvzW;Sbf[O>e\$vf[ROLvf[~. 2016t^SS'`Lv>euqQƋ[J]. -NNS>e\$vf[Bg_ 2016 2511 1141-50. [174] Jihye C Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma[J]. Liver Cancer 2012 13-4 216-25. [175] Soliman H Ringash J Jiang H et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]. J Clin Oncol 2013 3131 3980-6. [176] Wang WH Wang Z Wu JX et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]. Liver Int 2015 3512 2603-10. [177] Sapisochin G Barry A Doherty M et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol 2017 671 92-99. [178] Byun HK Kim HJ Im YR Kim DY Han KH Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma[J]. Radiother Oncol 2019 1331-8. [179] f-fQ. ~ހLvvzSO[T>e\lu[J]. -NNS$vBg_ 2015 9 650-52 53. [180] Hu Y Zhou YK Chen YX Shi SM Zeng ZC. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys 2016 437 4335. [181] -NNS;Sf[O8h;Sf[ROly'`$vlu]\OYXTO. /lS6[89Sr]luly'`$vN[qQƋ2017t^Hr [J]. -NNS8h;Sf[NRP[q_PBg_ 2018 638 412-15. [182] Llovet JM Ricci S Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med 2008 3594 378-90. [183] Cheng AL Kang YK Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinomaa phase III randomised double-blind placebo-controlled trial[J]. Lancet Oncol 2009 101 25-34. [184] Pressiani T Boni C Rimassa L et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinomaa prospective feasibility analysis[J]. Ann Oncol 2013 242 406-11. [185] Kudo M Finn RS Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinomaa randomised phase 3 non-inferiority trial[J]. Lancet 2018 39110126 1163-73. [186] Qin S Bai Y Lim HY et al. Randomized multicenter open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol 2013 3128 3501-8. [187] Qin S Cheng Y Liang J et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinomaa subgroup analysis of the EACH study[J]. Oncologist 2014 1911 1169-78. [188] Assenat E Pageaux GP Thezenas S et al. Sorafenib alone vs. sorafenib plus GEMOX as 1st -line treatment for advanced HCCthe phase II randomised PRODIGE 10 trial[J]. Br J Cancer 2019 1209 896-902. [189] H\Q ݐf[_ yS5 I{. N7xxl\mluSS'`Lvva!gY-N_4N^xvz[J]. -NNS$vBg_ 2011 339 697-701. [190] Bruix J Qin S Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment RESORCE a randomised double-blind placebo-controlled phase 3 trial[J]. Lancet 2017 38910064 56-66. [191] El-Khoueiry AB Sangro B Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma CheckMate 040 an open-label non-comparative phase 1/2 dose escalation and expansion trial[J]. Lancet 2017 38910088 2492-502. [192] Zhu AX Finn RS Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib KEYNOTE-224 a non-randomised open-label phase 2 trial[J]. Lancet Oncol 2018 197 940-52. [193] Brahmer JR Lacchetti C Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor TherapyAmerican Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol 2018 3617 1714-68. [194] Haanen J Carbonnel F Robert C et al. Management of toxicities from immunotherapyESMO Clinical Practice Guidelines for diagnosis treatment and follow-up[J]. Ann Oncol 2018 29Supplement_4 iv264-iv66. [195] Puzanov I Diab A Abdallah K et al. Managing toxicities associated with immune checkpoint inhibitorsconsensus recommendations from the Society for Immunotherapy of Cancer SITC Toxicity Management Working Group[J]. J Immunother Cancer 2017 51 95. [196] zh 4T_[ HIl I{. z1[SS'`Lv/gT YSvq_T[J]. -NNSƀYyBg_ 2004 109 592-93. [197] Wang Y Chen M Wu Z et al. CD133-directed CAR T cells for advanced metastasis malignanciesA phase I trial[J]. Oncoimmunology 2018 77 e1440169. [198] Lee JH Lee JH Lim YS et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology 2015 1487 1383-91 e6. [199] Abou-Alfa GK Meyer T Cheng AL et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. N Engl J Med 2018 3791 54-63. [200] Zhu AX Park JO Ryoo BY et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib REACH a randomised double-blind multicentre phase 3 trial[J]. Lancet Oncol 2015 167 859-70. [201] Zhu AX Kang YK Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations REACH-2 a randomised double-blind placebo-controlled phase 3 trial[J]. Lancet Oncol 2019 202 282-96. [202] -NNS-N;Sof[O. $v-N;SʋucWS[M]. SN-NV-N;SoQHr>y 200834-37. [203] m ke[ eN I{. i3|[SS'`Lv`/gTguX[vq_T[J]. -NNSƀYyBg_ 2012 182 99-102. [204] b܏ NSwmn. ipluSS'`LvvxvzۏU\[J]. 4N^$vf[Bg_ 2017 2210 950-53. [205] 'YO ss:_ ukSg I{. ^yrTTR Suh^X/gluLvv4N^xvz[J]. NLu4N^;Sf[ 2017 115 70 72. [206] ؚ~o. YPNeBRluZfgSS'`LvvMRw'`0:g[gq4N^xvz[J]. -NV-NoBg_ 2014 3912 2367-69. [207]  Ng^n hT_m I{. TACETTёVluSS'`LvvHegxvz[J]. -NV[(u;So 2019 1421 42-44. [208] !e 9\%f=N ^y. ~TTR Suh^X/glu-NZfgSS'`Lvv4N^‰[[J]. -NV;S^Bg_ 2018 2011 1723-25. [209] hgeNS. TACETT&ƀP[lsNmY nl[Lv`v4N^uHeSVEGF4ls^vq_T[J]. wm\of[ 2017 2909 176-77. [210] m_e. YeeeVTTSulu-NZfgSS'`Lvv4N^uHe‰[[J]. $vof[ 2011 106 518-19+43. [211] -NNS;Sf[Oaguf[RO -NNS;Sf[Ouf[RO. ba'`YNWp2lcWS2019t^Hr [J]. -NNS4N^aguBg_ 2019 126 1674-2397. [212] -NNS;Sf[Ouf[RO -NNS;Sf[Oaguf[RO. NWp2lcWS2019t^Hr [J]. -NNS4N^aguBg_ 2019 131 1-18. [213] European Association for the Study of the Liver. Electronic Address EEE European Association for the Study of The L. EASL Recommendations on Treatment of Hepatitis C 2018[J]. J Hepatol 2018 692 461-511. [214] Seymour L Bogaerts J Perrone A et al. iRECISTguidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol 2017 183 e143-e52. [215] Yoshida H Mamada Y Taniai N Uchida E. Spontaneous ruptured hepatocellular carcinoma[J]. Hepatol. Res. 2016 461 13-21. [216] Zhong F Cheng XS He K Sun SB Zhou J Chen HM. Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shocka multicenter study[J]. Springerplus 2016 51 1101. [217] Moris D Chakedis J Sun SH et al. Management outcomes and prognostic factors of ruptured hepatocellular carcinomaA systematic review[J]. J Surg Oncol 2018 1173 341-53. [218] Sahu SK Chawla YK Dhiman RK et al. Rupture of Hepatocellular CarcinomaA Review of Literature[J]. J Clin Exp Hepatol 2019 92 245-56. [219] Aoki T Kokudo N Matsuyama Y et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinomaan analysis of 1160 cases from a nationwide survey[J]. Ann Surg 2014 2593 532-42. [220] Lai EC Lau WY. Spontaneous rupture of hepatocellular carcinomaa systematic review[J]. Arch Surg 2006 1412 191-8. [221] Shin BS Park MH Jeon GS. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization[J]. Acta Radiol 2011 523 331-5. [222] Zhou J Huang A Yang XR. Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma[J]. J Gastrointest Cancer 2016 472 157-67. [223] Guo W Sun YF Shen MN et al. Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis Prognosis and Therapeutic Response Evaluation in Hepatocellular Carcinoma[J]. Clin Cancer Res 2018 249 2203-13. [224] Zhou Y Wang B Wu J et al. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection[J]. BMC Cancer 2016 16506. [225] Sun YF Xu Y Yang XR et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology 2013 574 1458-68. [226] Guo W Yang XR Sun YF et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform[J]. Clin Cancer Res 2014 2018 4794-805. [227] Sun YF Guo W Xu Y et al. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma[J]. Clin Cancer Res 2018 243 547-59. [228] Qu C Wang Y Wang P et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A 2019 11613 6308-12. [229] Huang A Zhang X Zhou SL et al. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma[J]. J Cancer 2016 713 1798-803. [230] Huang A Zhao X Yang XR et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]. J Hepatol 2017 672 293-301. [231] Huang A Zhang X Zhou SL et al. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity[J]. J Cancer 2016 713 1907-14. [232] Cai J Chen L Zhang Z et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut 2019 6812 2195-205. [233] Li W Zhang X Lu X et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers[J]. Cell Res 2017 2710 1243-57. [234] Llovet JM Montal R Sia D Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol 2018 1510 599-616. [235] Gao Q Zhu H Dong L et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma[J]. Cell 2019 1792 561-77 e22. [236] Jiang Y Sun A Zhao Y et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature 2019 5677747 257-61. [237] Torbenson MS Ng IOL Park YN Roncalli M Sakamato M WHO classification of digestive system tumor 5th edition Geneva SwitzerlandWorld Health Organization229-39. [238] Shi J Lai EC Li N et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol 2010 178 2073-80. [239] Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer[M]. 2nd English ed. TokyoKanehara 2003. [240] Lyu N Lin Y Kong Y et al. FOXAIa phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut 2018 672 395-96. [241] Lyu N Kong Y Mu L et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol 2018 691 60-69. [242] He M Li Q Zou R et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin Fluorouracil and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein InvasionA Randomized Clinical Trial[J]. JAMA Oncol 2019 57 953-60. [243] Lyu N Kong Y Pan T et al. Hepatic Arterial Infusion of Oxaliplatin Fluorouracil and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread[J]. J Vasc Interv Radiol 2019 303 349-57 e2. [244] Wang Q Xia D Bai W et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinomaA multicentre observational study[J]. J Hepatol 2019 705 893-903. [245] Xu L Peng ZW Chen MS et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Hepatol 2015 631 122-30. [246] Kudo M Ueshima K Ikeda M et al. Randomised multicentre prospective trial of transarterial chemoembolisation TACE plus sorafenib as compared with TACE alone in patients with hepatocellular carcinomaTACTICS trial[J]. Gut 2019. [247] Marks LB Yorke ED Jackson A et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys 2010 763 Suppl S10-9. [248] Pan CC Kavanagh BD Dawson LA et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys 2010 763 Suppl S94-100. [249] Chon YE Seong J Kim BK et al. Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinomaendoscopic findings and risk factors[J]. Int J Radiat Oncol Biol Phys 2011 815 1343-51. [250] Hanna GG Murray L Patel R et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy[J]. Clin Oncol R Coll Radiol 2018 301 5-14. [251] Cheng AL Qin S Ikeda M. IMbrave150Efficacy and Safety Results From a Ph 3 Study Evaluating Atezolizumab atezo + Bevacizumab bev vs Sorafenib Sor as First Treatment tx for Patients pts With Unresectable Hepatocellular Carcinoma HCC [C]. 2019 ESMO AsiaLBA03. [252] Xu J Zhang Y Jia R et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma Gastric or Esophagogastric Junction CancerAn Open-label Dose Escalation and Expansion Study[J]. Clin Cancer Res 2019 252 515-23. ADDIN      PAGE1 / NUMPAGES78 RTV\^`brz~ٸ䦐~e~WJWJWJWJWJhr'h~OJQJaJhr'h~OJQJaJo(1j`hr'hQ H*OJQJUmHnHu"hr'hQ H*OJQJmHnHu+jhr'hQ H*OJQJUmHnHu"hr'hx-H*OJQJmHnHu#jhr'hx-OJQJUjhr'hx-OJQJUhr'hx-OJQJjhr'h~OJQJUhr'h~OJQJo(bdflnprӮnSn?'jhr'hx-OJQJUaJ5jhr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHu&hr'hx-H*OJQJaJmHnHu'jhr'hx-OJQJUaJ!jhr'hx-OJQJUaJhr'hx-OJQJaJ!jhr'h~OJQJUaJhr'h~OJQJaJo(`bdjlnprtvx|~®®xggTgAT$hat65@KHOJQJ^JaJo($hp5@KHOJQJ^JaJo(!h~5@KHOJQJ^JaJhr'h~OJQJaJhr'h~OJQJaJo(5jhr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHu&hr'hx-H*OJQJaJmHnHu!jhr'h~OJQJUaJ !!"B"D"F"H""""""""縛cH5hx-hQ @H*KHOJQJ\^JaJmHnHu>jYhQ @H*KHOJQJU\^JaJmHnHu/hQ @H*KHOJQJ\^JaJmHnHu8jhQ @H*KHOJQJU\^JaJmHnHu5hx-hx-@H*KHOJQJ\^JaJmHnHu'hx-hx-@KHOJQJ\^JaJ0jhx-he@KHOJQJU\^JaJ"""""""""### ###### #&#(#h#j##########ʹʹʹ|||x|dQdQdQx|dQ$hjh*@KHOJQJ^JaJ'hjhp@KHOJQJ^JaJo(h*'hjh*5@KHOJQJ^JaJ*hjhp5@KHOJQJ^JaJo($hat65@KHOJQJ^JaJo(!hp5@KHOJQJ^JaJ$hp5@KHOJQJ^JaJo(!hPs5@KHOJQJ^JaJ!h*5@KHOJQJ^JaJ# #(#j###n_SSS d$Ifgdj$d$Ifa$gdjkd$$IflF- 3 t06    44 laytg####$B$n_SSS d$Ifgdj$d$Ifa$gdjkdV$$IflF- 3 t06    44 laytg##$$$@$B$D$J$L$$$$$$$$$$$$$$%%%%%ԾԚvcvRRvv!h*5@KHOJQJ^JaJ$hat65@KHOJQJ^JaJo($hp5@KHOJQJ^JaJo(!hp5@KHOJQJ^JaJh*@KHOJQJ^JaJ'hjh*5@KHOJQJ^JaJ*hjhp5@KHOJQJ^JaJo(h*$hjh*@KHOJQJ^JaJ'hjhp@KHOJQJ^JaJo(B$D$L$$$$n_SSS d$Ifgdj$d$Ifa$gdjkd$$IflF- 3 t06    44 laytg$$$$%%T%%&nii^^WFFXWD^`Xgdak@gdak@ $1$a$gdak@dkdb$$IflF- 3 t06    44 laytg%R%T%Z%%%%%& &&&`&b&d&f&h&j&~&&&&&&޺zffXL@hr'hpOJQJo(hr'h*5OJQJhr'hp5OJQJo('hr'h*5@KHOJQJ^JaJ*hr'hat65@KHOJQJ^JaJo('hr'hp5@KHOJQJ^JaJ*hr'hp5@KHOJQJ^JaJo(!hp5@KHOJQJ^JaJ$hp5@KHOJQJ^JaJo(h*@KHOJQJ^JaJ!hp@KHOJQJ^JaJo(&b&&&&&&&&'&'B'\''''''''$d$1$9DIfa$$d$1$9DIfa$ d$Ifdgd;/+gdak@ $1$a$gdak@XWD^`Xgdak@&&&&&&&&'''$'&'@'B'Z'\'^'b'd'f'x'''''''Ŵ}lYHHH!hr'h*B*CJOJQJph$h;/+5@KHOJQJ^JaJo(!h*5@KHOJQJ^JaJ!hp5@KHOJQJ^JaJ$hp5@KHOJQJ^JaJo($hat65@KHOJQJ^JaJo(!h~5@KHOJQJ^JaJ$h*5@KHOJQJ^JaJo(!hak@5@KHOJQJ^JaJhr'hpOJQJo(hr'h*OJQJ'''''''''''''''''''''''''(:(<(>(@(H(ź|eN|-hr'hB*CJKHOJQJ^JaJph-hr'h*B*CJKHOJQJ^JaJph%hr'h*B*CJOJQJaJph'h1B*CJKHOJQJ^JaJph-hr'hpB*CJKHOJQJ^JaJphhr'h*OJQJ!hr'h*B*CJOJQJph$hr'h*5B*CJOJQJph,hr'hp5B*CJKHOJQJ^Jph'''''5kd$$Ifִ)a  Ay!88888888 t!    4a d$If'''>(@(t(((()SMkd$$If0! t!4aMkdl$$If0! t!4a$d$1$9DIfa$ H(J(r(t(|(~(((((((((((((((((((((((((((((((())) )))<)>)`)b)d)f)r)ԨԨԨԨԨԨԨԨ)hr'hpB*CJKHOJQJaJphhr'h*OJQJ0hr'hpB*CJKHOJQJ^JaJo(ph%hr'h*B*CJOJQJaJph-hr'hpB*CJKHOJQJ^JaJph'h1B*CJKHOJQJ^JaJph1) )>)b)d)f)SH d$IfMkdz$$If0! t!4a$d$1$9DIfa$Mkd $$If0! t!4ar)t))))))))))))))))))))))))))))))))))***** * * *ܨ񗿐z*hp5B*CJKHOJQJ^JaJph h*<CJ!hr'h*B*CJOJQJph,hr'hB*CJKHOJQJaJo(phhr'h*OJQJ#h1B*CJKHOJQJaJph)hr'hpB*CJKHOJQJaJphhr'h*CJKHOJQJ*f)t))))))))akd$$If\aA!pppp t!4ap($ddd$1$If[$\$a$))))))vaaaa$ddd$1$If[$\$a$kdY$$If\aA!pppp t!4ap())))))vaaaa$ddd$1$If[$\$a$kd$$If\aA!pppp t!4ap())****vaaaV d$If$ddd$1$If[$\$a$kdc$$If\aA!pppp t!4ap(* * **vo]$d$1$9DIfa$dkd$$If\aA!pppp t!4ap( *$*&*D*F******************* + ++++++ +,+.+D+ø|lVlälVlä*hpB*CJKHOJQJ^JaJo(phh*B*CJOJQJaJph'hB*CJKHOJQJ^JaJph'h1B*CJKHOJQJ^JaJph'hpB*CJKHOJQJ^JaJphh*<CJOJQJh*h*B*CJOJQJaJph'hB*CJKHOJQJ^JaJph'hpB*CJKHOJQJ^JaJph!****** ++_Mkd$$If0! t!4a$d$1$9DIfa$d:kdm$$IfJ!! t!4a+ +F+\+^+++SMkd{$$If0! t!4a$d$1$9DIfa$Mkd!$$If0! t!4aD+F+R+T+V+Z+\+^+d+f+l+n+++++++++++++++++++++++++,,,,,,,DZۙۙקּs&hpB*CJKHOJQJaJo(ph#hpB*CJKHOJQJaJph'hB*CJKHOJQJ^JaJphh**hpB*CJKHOJQJ^JaJo(ph'h1B*CJKHOJQJ^JaJph'hpB*CJKHOJQJ^JaJphh*B*CJOJQJaJph*++++++,SMkd/$$If0! t!4a$d$1$9DIfa$Mkd$$If0! t!4a,,,,,8,:, -8-d-hfXQQQQgdak@$d1$a$gdWj:kd$$If!! t!4a$d$1$Ifa$Mkd$$If0! t!4a ,,,, ,$,&,(,4,6,8,:,B,D,b,d,,κmVC,C-jhr'hx-B*OJQJU\aJph333$hr'hx-B*OJQJ\aJph333-jhr'heB*OJQJU\aJph333$hr'hPs5B*OJQJaJph333$hr'hq{5B*OJQJaJph333'hr'hat65B*OJQJaJo(ph333$hr'h~5B*OJQJaJph333'hr'hq{5B*OJQJaJo(ph333!hp5@KHOJQJ^JaJ!h*5@KHOJQJ^JaJh*h*CJKHOJQJ,,,,,,,,,-----ηeDe0'hr'hq{5B*OJQJaJo(ph333AjC hr'hQ B*H*OJQJU\aJmHnHph333u2hr'hQ B*H*OJQJ\aJmHnHph333u;jhr'hQ B*H*OJQJU\aJmHnHph333u2hr'hx-B*H*OJQJ\aJmHnHph333u-jhr'heB*OJQJU\aJph333-jhr'hx-B*OJQJU\aJph3333j=hr'hx-B*OJQJU\aJph333 - ----6-8-@-F-b-d-n-t------------------------.///ܶܢxeeeee$hr'hx-B*OJQJ\aJph333-jhr'heB*OJQJU\aJph333$hr'hq{5B*OJQJaJph333'hr'hq{5B*OJQJaJo(ph333$hr'hq{B*H*OJQJaJph333$hr'hq{B*OJQJaJo(ph333!hr'hq{B*OJQJaJph333$hr'ho5B*OJQJaJph333'd-----33 444f4h44478;<<<BrT$7$8$H$WD`a$gdU? WD`gdVC$d1$a$gdak@ $1$a$gdak@ $a$gdak@gdak@/01112383:3<3>3333333333ּcP?!hr'h B*OJQJaJph333$hr'hq{B*OJQJaJo(ph333Aj hr'hQ B*H*OJQJU\aJmHnHph333u2hr'hQ B*H*OJQJ\aJmHnHph333u;jhr'hQ B*H*OJQJU\aJmHnHph333u2hr'hx-B*H*OJQJ\aJmHnHph333u-jhr'heB*OJQJU\aJph333$hr'hx-B*OJQJ\aJph33333333333333344 4 44444042444:4B4F4J4T4V4b4d4f4h4j4r444444|nhr'hpOJQJaJo(hr'hat6OJQJaJo('hr'h*5@KHOJQJ^JaJhr'h*5KHOJQJaJ"hr'hp5KHOJQJaJo("hr'hat65KHOJQJaJo(hq{5KHaJ$hr'hq{B*OJQJaJo(ph333!hr'hq{B*OJQJaJph333'45555626:6<6Z6\666666666667777 7dzԟԋs_Ds_s5j)yhr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHu&hr'h]\<H*OJQJaJmHnHu'jChr'heOJQJUaJ'j1hr'heOJQJUaJhr'h]\<OJQJaJ!jhr'heOJQJUaJhr'hpOJQJaJo(hr'hpOJQJaJ 77777 7<7>77778J8~8888888888ƸԌkWC&hr'h]\<H*OJQJaJmHnHu'jhr'heOJQJUaJ'jyhr'heOJQJUaJhr'h]\<OJQJaJ!jhr'heOJQJUaJhr'h{vOJQJaJo(hr'hpOJQJaJhr'hat6OJQJaJo(hr'h*5OJQJaJhr'hpOJQJaJo(hr'hp5OJQJaJhr'hp5OJQJaJo(8896989:9@9B9D9F9H9J99999999:.:2:\:`:l:r:t:Ӹ礓wjj\jjjjjOjOjhr'h_o[OJQJaJhr'heOJQJaJo(hr'hpOJQJaJhr'h{vOJQJaJo(hr'hpOJQJaJo(!jhr'heOJQJUaJ&hr'h]\<H*OJQJaJmHnHu5jhr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHut::::::::::;$;&;(;.;0;2;4;6;8;>;⦎zz_zQD6hr'h@TOJQJaJo(hr'h*OJQJaJhr'hpOJQJaJo(5jhr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHu&hr'h]\<H*OJQJaJmHnHu'j[hr'heOJQJUaJ'jhr'heOJQJUaJ!jhr'heOJQJUaJhr'h]\<OJQJaJ>;;;;;;;;;;;;< <"<$<&<(<*<,<<<<<<<<dzԟԋs_Ds_s5j~hr'hQ H*OJQJUaJmHnHu&hr'hQ H*OJQJaJmHnHu/jhr'hQ H*OJQJUaJmHnHu&hr'h]\<H*OJQJaJmHnHu'jNhr'heOJQJUaJ'jhr'heOJQJUaJhr'h]\<OJQJaJ!jhr'heOJQJUaJhr'heOJQJaJo(hr'hpOJQJaJ<<<<<<<<<<<<<<<Ÿp_L;,h@T@KHOJQJaJo( hp5@KHOJQJaJo($hDc5@KHOJQJ^JaJo(!h*5@KHOJQJ^JaJ$hp5@KHOJQJ^JaJo(!hPs5@KHOJQJ^JaJ$hat65@KHOJQJ^JaJo(!hp5@CJKHOJQJ^Jhr'h*OJQJaJhr'hpOJQJaJo(hr'hq{5OJQJaJhr'hq{5OJQJaJo(hr'hq{OJQJaJo(<=&=(=8=:=============>>> >J>L>>>>>>>>>>ƷƷ򔆔q\)jhe@KHOJQJUaJ)jhe@KHOJQJUaJh]\<@KHOJQJaJ#jhe@KHOJQJUaJ h@Th@T@KHOJQJaJh@T@KHOJQJaJo(h@T@KHOJQJaJhp@KHOJQJaJo(hf@KHOJQJaJo(hp@KHOJQJaJ >>>?@?B?D?J?L?N?P?????????ϺφqϺUφC4hp@KHOJQJaJo(#jhe@KHOJQJUaJ7j'hQ @H*KHOJQJUaJmHnHu(h@H*KHOJQJaJmHnHu.h]\<hQ @H*KHOJQJaJmHnHu7j5'hQ @H*KHOJQJUaJmHnHu(hQ @H*KHOJQJaJmHnHu1jhQ @H*KHOJQJUaJmHnHu.h]\<h]\<@H*KHOJQJaJmHnHu???????@.@8@B@D@b@d@@@@@@@@ѱyaH1jhQ @H*KHOJQJUaJmHnHu.h]\<h]\<@H*KHOJQJaJmHnHu)ju3he@KHOJQJUaJ)j#(he@KHOJQJUaJh]\<@KHOJQJaJ#jhe@KHOJQJUaJhp@KHOJQJaJhp@KHOJQJaJo(h@T@KHOJQJaJo( hp5@KHOJQJaJo(@@@@AAA AA AVAXApArAtA϶teeWHW:+h1@KHOJQJaJo(h@T@KHOJQJaJhf@KHOJQJaJo(hp@KHOJQJaJhp@KHOJQJaJo(#jhe@KHOJQJUaJ.h]\<h]\<@H*KHOJQJaJmHnHu.h]\<hQ @H*KHOJQJaJmHnHu1jhQ @H*KHOJQJUaJmHnHu7j>hQ @H*KHOJQJUaJmHnHu(hQ @H*KHOJQJaJmHnHutAvAxAAAAAAAAAAAB(B*B,B.B0B2BӶӧr]E.h]\<h]\<@H*KHOJQJaJmHnHu)jJhe@KHOJQJUaJ)j>?he@KHOJQJUaJh]\<@KHOJQJaJ#jhe@KHOJQJUaJhp@KHOJQJaJo(hf@KHOJQJaJhf@KHOJQJaJo(hp@KHOJQJaJh1@KHOJQJaJo(h@T@KHOJQJaJo(2B4BBBBBBBBBBBBѵsdSB1 h@T5@KHOJQJaJo( hp5@KHOJQJaJo( h*5@KHOJQJaJo(hp@KHOJQJaJo(#jhe@KHOJQJUaJ.h]\<h]\<@H*KHOJQJaJmHnHu.h]\<hQ @H*KHOJQJaJmHnHu7jNVhQ @H*KHOJQJUaJmHnHu(hQ @H*KHOJQJaJmHnHu1jhQ @H*KHOJQJUaJmHnHu BBBBBCCC2C4CbCdCjCpCCCCCCCCDEEEFGGGHIIIJKKKLMMMNOOOPQQĵĦĘĦĦ҆xxxxxxxxxxxxxxxxxxxxxxxxxxxxxhQ @KHOJQJaJ#jhe@KHOJQJUaJh@KHOJQJaJhe@KHOJQJaJo(hf@KHOJQJaJo(hp@KHOJQJaJhp@KHOJQJaJo(h@T@KHOJQJaJo(h1@KHOJQJaJo(/QQRpRrRtRzR|R~RRRRRRRRRRRR SȳiȅZKZK<hp@KHOJQJaJo(h1@KHOJQJaJo(h @KHOJQJaJo(7jVhQ @H*KHOJQJUaJmHnHu1jhQ @H*KHOJQJUaJmHnHu(h@H*KHOJQJaJmHnHu(hQ @H*KHOJQJaJmHnHu.hQ hQ @H*KHOJQJaJmHnHu#jhe@KHOJQJUaJhQ @KHOJQJaJ SS8S:S@SSSSSSSSSSSSSSSST^T򸪸hO::::(hQ @H*KHOJQJaJmHnHu1jhQ @H*KHOJQJUaJmHnHu.h]\<h]\<@H*KHOJQJaJmHnHu)j_he@KHOJQJUaJ)jb@bHbJbbbbbbbbcccdeeefggghiFiܸܧܗrcccccccccccccchr'hx-KHOJQJaJ%jhr'hx-KHOJQJUaJ"hr'hj<*5KHOJQJaJo(hr'hj<*KHOJQJaJo(!hr'hl\B*OJQJaJph333$hr'hJ1B*OJQJaJo(ph333!hr'h_o[B*OJQJaJph333!hr'hj<*B*OJQJaJph333$hr'hj<*B*OJQJaJo(ph333&FiHiJiLiiiiiiiiiiiiiiiijjּxeR?RRxxxx$hr'hcMB*OJQJaJo(ph333$hr'hj<*B*OJQJaJo(ph333$hg|hj<*B*OJQJaJo(ph333!hr'hj<*B*OJQJaJph3339jɫhr'hQ H*KHOJQJUaJmHnHu*hr'hQ H*KHOJQJaJmHnHu3jhr'hQ H*KHOJQJUaJmHnHu*hr'hx-H*KHOJQJaJmHnHu%jhr'hx-KHOJQJUaJjjjj(j4j\j^jrjvjxjjjjjjjjjjjjjj k kkkkɹuu_I*hr'hx-H*KHOJQJaJmHnHu+j@hr'hx-KHOJQJUaJhr'hx-KHOJQJaJ%jhr'hx-KHOJQJUaJhr'hj<*5KHOJQJaJ"hr'hj<*5KHOJQJaJo(hr'hj<*KHOJQJaJo(!hr'hj<*B*OJQJaJph333$hr'hj<*B*OJQJaJo(ph333$hr'h:B*OJQJaJo(ph333kkrktkvk|k~kkkkkkkkkkkkkϲ圉xxdP>P>P>d#hr'hp5@KHOJQJaJ&hr'hp5@KHOJQJaJo(&hr'hh5@KHOJQJaJo(!hr'hj<*B*OJQJaJph333%jhr'hx-KHOJQJUaJ*hr'hx-H*KHOJQJaJmHnHu9j8hr'hQ H*KHOJQJUaJmHnHu*hr'hQ H*KHOJQJaJmHnHu3jhr'hQ H*KHOJQJUaJmHnHukkkkkkkltlvlxl|l~lllllȸ}iS?-?#hr'hh5@KHOJQJaJ&hr'hh5@KHOJQJaJo(*hr'h0m5@KHOJQJ^JaJo('hr'hPs5@KHOJQJ^JaJ*hr'hB/<5@KHOJQJ^JaJo(!hp5@KHOJQJ^JaJ'hr'h*5@KHOJQJ^JaJhr'hpKHOJQJaJo(hr'hhKHOJQJaJo(&hr'hB/<5@KHOJQJaJo(&hr'h25@KHOJQJaJo(llllllllllllllllllll mmm&m(m*m2m4mƶƶƶ{l{\M{lMlMMl{lhr'hpKHOJQJaJhr'hcMKHOJQJaJo(hr'h*KHOJQJaJhr'hpKHOJQJaJo(hr'h*OJQJhr'hp5KHOJQJaJhr'hp5OJQJaJo(hr'h*5KHOJQJaJ"hr'hp5KHOJQJaJo('hr'h*5@KHOJQJ^JaJ&hr'h0m5@KHOJQJaJo(llllm(mT8888$$&`#$/7$8$H$Ifa$gdjkd$$Ifl \&..B2 t 6`0~.44 laytj(m*m4mFn^nvnT8888$$&`#$/7$8$H$Ifa$gdjkdp$$Ifl\&..B2 t 6`0~.44 laytj4m6mmmmnn n(n2n4n>nDnFn\n^ntnvnxnnnnnnnnnnnnnnnooooo o"o4o6oLoNoPoXoZo\oٳyyhr'hcMKHOJQJaJo(hr'hpKHOJQJaJo(hr'h*OJQJhr'hpKHOJQJaJhr'h*KHOJQJaJhr'hpOJQJhr'hcMOJQJo(hr'hpOJQJo(hr'heOJQJjhr'heOJQJU/vnxnnnnnT8888$$&`#$/7$8$H$Ifa$gdjkd7$$Ifl\&..B2 t 6`0~.44 laytjnnn"o6oNoT8888$$&`#$/7$8$H$Ifa$gdjkd$$Ifl\&..B2 t 6`0~.44 laytjNoPoZo~oooT8888$$&`#$/7$8$H$Ifa$gdjkdŸ$$Ifl\&..B2 t 6`0~.44 laytj\o`ojoloro|o~oooooooooooooopppp(p*p@pBpDpHpLpNphppprppppppppppppppppppqqqqq q"q(q2q4q:qDqNqVqXq·ѧ·ѧ·ѧ·ѧhr'h0mKHOJQJaJo(hr'h*OJQJhr'h*KHOJQJaJhr'hpKHOJQJaJo(hr'hcMKHOJQJaJo(hr'hpKHOJQJaJBooop*pBpT8888$$&`#$/7$8$H$Ifa$gdjkd$$Ifl\&..B2 t 6`0~.44 laytjBpDpNprpppT8888$$&`#$/7$8$H$Ifa$gdr'kdG$$Ifl\&..B2 t 6`0~.44 laytjpppppqT8888$$&`#$/7$8$H$Ifa$gdjkd$$Ifl\&..B2 t 6`0~.44 laytr'qq"qXqnqqT8888$$&`#$/7$8$H$Ifa$gdjkdɻ$$Ifl\&..B2 t 6`0~.44 laytjXqlqnqqqqqqqqqqqqqqqqqqqqqqqqrr rrr r(r*r,r.rDrFrHrLrPrRrTrssFsǷǧǷǧǷ☍hr'hpOJQJo(hr'heOJQJjhr'heOJQJUhr'hcMKHOJQJaJo(hr'h0mKHOJQJaJo(hr'hpKHOJQJaJo(hr'h*OJQJhr'h*KHOJQJaJhr'hpKHOJQJaJ.qqqqqqT8888$$&`#$/7$8$H$Ifa$gdjkd$$Ifl\&..B2 t 6`0~.44 laytjqqq*r.rFrT8888$$&`#$/7$8$H$Ifa$gdjkdK$$Ifl\&..B2 t 6`0~.44 laytjFrHrRrpsssT8888$$&`#$/7$8$H$Ifa$gdjkd $$Ifl\&..B2 t 6`0~.44 laytjFsPsRsTs\sfsnspssssssssssssssssssstt t tttt,t2tw@wBwDwFwHwNw˿Ⱐ񕄄sbL*hT hat65@CJKHOJQJ^Jo(!hWj5@CJKHOJQJ^J!h*5@KHOJQJ^JaJ!h*5@CJKHOJQJ^Jhr'h*OJQJhr'hpKHOJQJaJo(hr'hpKHOJQJaJhr'hcMOJQJo(hr'hpOJQJo(hr'heOJQJjhr'heOJQJUhr'h*KHOJQJaJ8w:ww@wBwDwT=====$hdP1$WD^h`a$kde$$Ifl\&..B2 t 6`0~.44 laytjDwFwwww.xBxlxxxxxy@BDRTZ\hjxzԀLNVX\^`bdrxzȂFHPRVXZ\^ntv~#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR,~TrnJ 6ʐFʓbĘXܢN"$gdQ „"$,.2468:JPRhjxzΆІ  ,.:<z|V#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRVX`bhjlnp‰Љ҉ډ܉~TV^`dfjln֋؋pvx "$&6>@TVdfz|ҍԍ#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR ZЏҏ "&(.068:NʐҐԐ̑Α$&*,.02<FNP\^jlxzXZhmHnHo(tHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuLƓȓʓғԓ(02@BZ\dfjlnpr•ĕΕЕ8:BDHJLNPbjlz|\^ȗʗ֗ؗhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuRĘ̘Θܘޘ  lnvx~Țʚܚޚ<>`bjlprtvxʝ̝ԝ֝ڝܝޝ#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR npxzΟП؟ڟ02:<@BDFHX`bpr~¢ƢȢʢܢ"$24h1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuRtv~npĥƥΥХԥ֥إڥܥ &(8:lnΦЦ$&.0468:<NVXfhtxzΧЧprz|#hQ hQ CJOJQJmHnHuhOmHnHuh1mHnHuhQ hQ mHnHuR|¨ĨҨԨ^~  "*,:<NP\^24N68@BFHJLN^fhtvBƭȭ68@BFHJLN^fhOmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuR"^^>ȳȵTnd hlP$gdQ fhvx4Ȱʰ԰ְ& "&(*,.>FH\^pr46ȳгҳh1mHnHuhOmHnHuhQ hQ mHnHu#hQ hQ CJOJQJmHnHuR TV|~ȵеҵ.08:>@BDFT\^rtxz&(̸θ޸rtFHPRVXZ\#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR\^nvxҺ*,npĻƻڻܻ|~VXdhjlnz|jltvz|ľƾؾھ*,dhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuRdfpr¿Ŀؿڿ   (*TVZ\dfnpBDLNRTVXZhprFHPRZ\#hQ hQ CJOJQJmHnHuhOmHnHuh1mHnHuhQ hQ mHnHuRHJZ\nprFHLN"$>@BZbdnprHJhQ hQ mHnHo(uhmHnHo(tHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuGJDFJNPTVXZ\ltvDF&(4@B& "#hQ hQ CJOJQJmHnHuhOmHnHuh1mHnHuhQ hQ mHnHuR">@(*248:<>@PXZdfpr<>^` $&24,.68|~#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR"$02462:<LNbdtv.0*,24<>DFHJL^fhxz$#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR2^$^8:JjVHfh$gdQ $&(,.:<HJTV $&dfnpvxz|~"$  $&24BDNP h1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuR "8:RT68@BDFJLN^fhtv~ ",.<>ntv~#hQ hQ CJOJQJmHnHuhOmHnHuhQ hQ mHnHuh1mHnHuRb "$&8@BNP\^lnV "$&(:BDLNdfnp<>hjhmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuN 0&(0268:<>JRThj~ "~,.@BDLNRT#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRTXZ\jrt~24<>V^`jlxz  &(46BDNP(*8:hOmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuR:$&.0468:<HPRZ\jlxz>@HJNPRTVfnpprDFNPRTVX#hQ hQ CJOJQJmHnHuhOmHnHuh1mHnHuhQ hQ mHnHuRXZhpr|~ln Z\dflnprt |hOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuR "*,.0246DLN^`ln|~bdlnrtX #hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRD|  h 6b0 $"#%'$)B*,-$gdQ JVX`bfhjln|                      0   4 6 | ~                          @ B J L P R T #hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRT V X h p r ~       (*6>@TVhj|~8:BDHJLNPbjlrtz|*,<>LN46hOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuR &(68JLZ\ &(PRfh^`hjprtvxZ\dfjlprhOmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuRrt &(46jltvz|~hOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuR 0:<JLVXdfv 6 8                   h!!!""" """""$"."0":"<"H"J"X"Z"""""Z#n#p#x#z###hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR###############$$$.%0%L%%%%%%%%%%%%%%%%&&&B''''''''''''''''''''((((()) ) ))))$).)0)8):)D)F)T)V))))hOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuR)))**** *&*(*,*.*0*B*L*N*\*^*r*t*****+4+6+@+B+D+V+X+l+n+++++++++++++,,,, ,",4,6,,,-6-8-r-t-|-~------------.6.8.......#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR.......... //// /"///////////0000(0*080:0D0F000000002141v1x1111111111111111112~2222222222223 3hmHnHuhOmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuN-.0133z56X89f;<l>@BCpEGH.JLMJP*RSUW6YZ$gdQ  333333 3"3$3h3j3r3t3x3z3|3~3333333333334z4|4444,5.5R5T5\5^5b5d5f5h5j5z55555555556N6P6V6X6d6f6v6x666666666777707h1mHnHuhmHnHo(tHuhOmHnHuhQ hQ mHnHu#hQ hQ CJOJQJmHnHuL072778.80888:8>8@8B8D8F8X8b8d8r8t8v8888888999999999999999:::::n:p::>;@;H;J;N;P;R;T;V;f;p;r;;;;;;;;<Z<\<j<l<z<<<<<<<<<<<#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR<<<<<<<<<=>@>B>J>L>P>R>V>X>Z>f>h>l>v>x>>>>>>>b?d?|?~????????@@@@@@"@$@4@6@D@F@R@T@V@b@d@AAABNB`BbBnBpBxBzB~BBBBBBBBCVCXCCh1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuRCCCCCCCCCCCCCDDDG@GJGLGTGVGbGdGGHH@HBHRHTHHHHHHHHHHHHHH#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRHHHHHHIJJJJJJJJJJ.J8J:JFJHJNJPJRJTJ^J`JnJpJnKpKKKKKKKKKKKLLLL L"L2L4LBLDLJLLLLMNMMMMMMMMMMMMMMMMMNNNNN*N,NNFNHN#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRHNNNOOPPP&P(P.P0P4P6P8PBPDPJPTPVPdPfPtPvPPPpQrQQQRRR RRRRRRR*R4R6R>R@RDRFRRRTRdRfRRSTSSSSSSSSSSSSSSSTTT&T(T:Tab|degaHaJaLa^a`atavaaaaaabb bFbHbbbbbbbbbbbbbcc"c$c.c0c6ccccdddTdVd^d`dddfdhdjdld|ddddddddd(eeeeeeeeeeeeeef#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRffffff*f,fg6g8gggggggggggggggggggghhhhh iiii i&i(i*i,i.im@mmmmmmmmmmmmmmmmmmmmmnnn6n8nPnRnZn\n`nbndnfnhnxnnnnnnnnnno o0o2odofoop,p.p:phQ hQ mHnHo(uh78mHnHo(tHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuG:pDpFpTpVpdpfprptppqqqqqqqqqqqqqqqqqqqqrrrrrssss s ss$s&s4s6sLsNs\s^sssst"t$t,t.t4t6t:ttPtZt\tjtlt|t~ttttuuuuuv v vvvh1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuRv*v,v@vBvvwwlwnwvwxw|w~wwwwwwwwwwwwwwwwxxxxxxxxxxyyyy&y(y6y8yFyHyyyyzzzzzzzzzzzzzzzzzzzz{{{| |"|*|,|2|4|B|#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRB|L|N|Z|\|h|j|n|<}>}}}}}}}}~~~~~ ~2~4~H~J~`~~~8:BDJLNPT^`lnX~(*8:DFJXZbdhjlnph1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuR&(,.0246DNP^`np|~Ѕ҅܅ޅ&(,02468:<LVXdfnp|~HJ‡ć·Ї҇؇ڇ܇h1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuRL҉ʊ\ ΕΖ>ʟdʣfjĮ&$gdQ "$‰҉։؉܉މ8:ʊԊ֊ԋ֋ދ&(:<JL24<>BDHJL\fhvxЍҍ#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRĎƎʎ̎ЎҎԎ  .0ΏЏ~̐ΐؐڐ̑ΑБjltv|~ΒВؒڒܒޒ ,.hmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuN.:<ȓʓ tvĕƕΕؕڕΖؖږ —ė"$<>#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR˜ؘژ "&(*,.>HJVXfhrtVX|›ě̛Λԛ֛ &(JLbdlԝ֝ޝ $&h1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuR&4646^ʟԟ֟~ƠȠ8:BDJLNPRdnpvx~ҡԡܡޡ"$24ƹhmHnHo(tHuhmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuI (*6BDhjʣԣ֣Ԥ֤ fhprxzĥƥإڥƦȦʦ>@HJNPRTVf#hQ hQ CJOJQJmHnHuhOmHnHuh1mHnHuhQ hQ mHnHuRfpr>@HJNPTVXjtvvxªĪ̪ΪҪԪ&(46JLګܫjltvh1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuR"$(*,npxz~ƭȭTVĮήЮܮޮ  &02JLZ\ln<>FHNPRT#hQ hQ CJOJQJmHnHuh1mHnHuhmHnHo(tHuhOmHnHuhQ hQ mHnHuLTVdnp|~ҲԲ޲,.jltvz|~ȳʳԴִ@B~ĵh]\<hmHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuh1mHnHuM&d<θl<ػ~ξʿTzn R*$gdQ   &(,.0xz  &(.068>@B|~ʸʢʢʸʢʢʸʢʢh1mHnHuhmHnHo(tHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuhmHnHuh1mHnHo(uhOmHnHuh]\<hmHnHu< "&(*<FHLNTVX\^`θظڸ@BJLPRVXZltvxܹ޹@dfnϹhmHnHo(tHuh1mHnHuhOmHnHu#hQ hQ CJOJQJmHnHuhQ hQ mHnHuhmHnHuInprtxz|ʺ "$&<FHJ\^nptvxĻƻȻʻ̻Իֻػ*rtTøøøäähmHnHuhOmHnHo(uhmHnHo(uh]\<hmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHu@TV^`dfhjl~ƽȽξؾھfhʿԿֿ24<>@BDFHT^`bnp#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRp@BLNZ\PRVXZ\bdfhjzFHP#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRPRXZ\^`nxzPR  "$02@BLNJL#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuRprz|HJ(*248:<>@R\^hjxzFH| *46BDNPXZDFp  0:<DFRT#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR*0b~.d \ d$gdf$gdQ T`bBDd68@BDFJLNRbln|~<>@TV^`bdhjl~#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuR4:<  .8:BDRT\^(8:Z\dfjlprt46#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuhOmHnHuR  "$02<>JLZ\pr RTdnpz|,.dfnptvxz|÷hlkhG"NmHnHuhG"NhG"NmHnHuh1mHnHuhOmHnHuhQ hQ mHnHu#hQ hQ CJOJQJmHnHuC&(npxz~$&&(24°°°#hQ hQ CJOJQJmHnHuhQ hQ mHnHuhOmHnHuh1mHnHuhlkhG"NmHnHu hlkhG"Nh]\<hG"NmHnHuE"$|~(* VX`bfhjln  "02@B`bjl#hQ hQ CJOJQJmHnHuh1mHnHuhOmHnHuhQ hQ mHnHuRlprtvxlnvx"$NP\fhxztv~h~hOmHnHu#hQ hQ CJOJQJmHnHuh1mHnHuhQ hQ mHnHuRZdfnptvxz| &(B 8:>@\^dfh]\<hmHnHuh<hmHnHu#hQ hQ CJOJQJmHnHuhOmHnHuhQ hQ mHnHuh1mHnHuH "$.0:DF`b   󦦖hjhUh*hp@KHOJQJ^JaJ'jhe@KHOJQJU^JaJhOmHnHu#hQ hQ CJOJQJmHnHuhmHnHuh1mHnHuh]\<hmHnHuhQ hQ mHnHu4"$VXZ\^$gdf$a$d "$&,.024:<LNRTVXZ\^h*hh5CJaJhmHsHh5mHnHu h5jh5CJUaJh9182P0:p`A .!"#$%S DTorre201513471347134717Torre, L. A.Bray, F.Siegel, R. L.Ferlay, J.Lortet-Tieulent, J.Jemal, A.Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.Global cancer statistics, 2012CA Cancer J ClinCA Cancer J Clin87-1086522015/02/06Body Mass IndexBreast Neoplasms/epidemiologyColorectal Neoplasms/epidemiologyDeveloped Countries/*statistics & numerical dataDeveloping Countries/*statistics & numerical dataFemaleGlobal HealthHumansIncidenceLiver Neoplasms/epidemiologyLung Neoplasms/epidemiologyMaleNeoplasms/diagnosis/*epidemiology/etiology/mortality/prevention & control/therapyOverweight/epidemiologyPovertyPrevalenceProstatic Neoplasms/epidemiologyRisk FactorsSedentary LifestyleSmoking/adverse effectsStomach Neoplasms/epidemiologySurvival RateUterine Cervical Neoplasms/epidemiologycancerepidemiologyhealth disparitiessurvival2015Mar1542-4863 (Electronic) 0007-9235 (Linking)25651787https://www.ncbi.nlm.nih.gov/pubmed/25651787https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.2126210.3322/caac.21262Zhou201921472147214717Zhou, M.Wang, H.Zeng, X.Yin, P.Zhu, J.Chen, W.Li, X.Wang, L.Wang, L.Liu, Y.Liu, J.Zhang, M.Qi, J.Yu, S.Afshin, A.Gakidou, E.Glenn, S.Krish, V. S.Miller-Petrie, M. K.Mountjoy-Venning, W. C.Mullany, E. C.Redford, S. B.Liu, H.Naghavi, M.Hay, S. I.Wang, L.Murray, C. J. L.Liang, X.National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. National Office for Maternal and Child Health Surveillance, Chengdu, China. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Chinese Center for Disease Control and Prevention, Beijing, China. China Population and Development Research Center, Beijing, China. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: cjlm@uw.edu. Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: liangxf@chinacdc.cn.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017LancetLancet1145-1158394102042019/06/30AdolescentAdultAgedAged, 80 and overAir Pollution/statistics & numerical dataCause of DeathChildChild, PreschoolChina/epidemiologyDiet/statistics & numerical dataFemale*Global Burden of DiseaseHumansHypertension/epidemiologyInfantInfant, NewbornLiver Neoplasms/epidemiology/mortalityLung Neoplasms/epidemiology/mortalityMaleMental Disorders/epidemiologyMiddle Aged*Morbidity*MortalityMusculoskeletal Diseases/epidemiologyMyocardial Ischemia/epidemiology/mortalityParticulate MatterPulmonary Disease, Chronic Obstructive/epidemiology/mortalityQuality-Adjusted Life YearsRisk FactorsSmoking/epidemiologyStroke/epidemiology/mortalityYoung Adult2019Sep 281474-547X (Electronic) 0140-6736 (Linking)31248666https://www.ncbi.nlm.nih.gov/pubmed/3124866610.1016/S0140-6736(19)30427-1sDyK  _ENREF_1sDyK  _ENREF_2 DZhang200415151517Zhang, B. H.Yang, B. H.Tang, Z. Y.Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai 200032, China. bzhang@zshospital.netRandomized controlled trial of screening for hepatocellular carcinomaJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology417-221307AdultBiomarkers, Tumor/bloodCarcinoma, Hepatocellular/*mortality/pathology/*prevention &control/ultrasonographyChina/epidemiologyFemaleHumansIncidenceLiver Neoplasms/*mortality/pathology/*prevention & control/ultrasonographyMale*Mass Screening/methodsMiddle AgedNeoplasm StagingSurvival RateUrban Population/statistics & numerical dataalpha-Fetoproteins/metabolism2004Jul0171-5216 (Print) 0171-5216 (Linking)15042359http://www.ncbi.nlm.nih.gov/pubmed/1504235910.1007/s00432-004-0552-0@ DZhang200415151517Zhang, B. H.Yang, B. H.Tang, Z. Y.Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai 200032, China. bzhang@zshospital.netRandomized controlled trial of screening for hepatocellular carcinomaJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology417-221307AdultBiomarkers, Tumor/bloodCarcinoma, Hepatocellular/*mortality/pathology/*prevention &control/ultrasonographyChina/epidemiologyFemaleHumansIncidenceLiver Neoplasms/*mortality/pathology/*prevention & control/ultrasonographyMale*Mass Screening/methodsMiddle AgedNeoplasm StagingSurvival RateUrban Population/statistics & numerical dataalpha-Fetoproteins/metabolism2004Jul0171-5216 (Print) 0171-5216 (Linking)15042359http://www.ncbi.nlm.nih.gov/pubmed/1504235910.1007/s00432-004-0552-0@sDyK  _ENREF_3 DDong201666617Dong, Y.Wang, W. P.Mao, F.Ji, Z. B.Huang, B. J.Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. Institute of Medical Ultrasound and Engineering, Fudan University, Shanghai, China.Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasoundJ Gastroenterol HepatolJ Gastroenterol Hepatol822-83142015/10/20AdultCarcinoma, Hepatocellular/*diagnostic imaging/surgeryCatheter AblationContrast MediaFemaleHumansLiver Neoplasms/*diagnostic imaging/surgeryMagnetic Resonance Imaging/*methodsMaleMiddle AgedProspective StudiesSurgery, Computer-AssistedUltrasonography/*methodscontrast-enhanced ultrasound (CEUS)dynamic MR imaging (MRI)hepatic cellular carcinomas (HCC)undetectablevolume navigation image fusion2016Apr1440-1746 (Electronic) 0815-9319 (Linking)26480287https://www.ncbi.nlm.nih.gov/pubmed/2648028710.1111/jgh.13202 DDong201666617Dong, Y.Wang, W. P.Mao, F.Ji, Z. B.Huang, B. J.Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. Institute of Medical Ultrasound and Engineering, Fudan University, Shanghai, China.Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasoundJ Gastroenterol HepatolJ Gastroenterol Hepatol822-83142015/10/20AdultCarcinoma, Hepatocellular/*diagnostic imaging/surgeryCatheter AblationContrast MediaFemaleHumansLiver Neoplasms/*diagnostic imaging/surgeryMagnetic Resonance Imaging/*methodsMaleMiddle AgedProspective StudiesSurgery, Computer-AssistedUltrasonography/*methodscontrast-enhanced ultrasound (CEUS)dynamic MR imaging (MRI)hepatic cellular carcinomas (HCC)undetectablevolume navigation image fusion2016Apr1440-1746 (Electronic) 0815-9319 (Linking)26480287https://www.ncbi.nlm.nih.gov/pubmed/2648028710.1111/jgh.13202sDyK  _ENREF_4sDyK  _ENREF_5.DHu201888817Hu, H.Han, H.Han, X. K.Wang, W. P.Ding, H.Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. han.hong@zs-hospital.sh.cn. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. han.hong@zs-hospital.sh.cn. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. wang.wenping@zs-hospital.sh.cn. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. wang.wenping@zs-hospital.sh.cn.Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma: the evidence from ultrasound dataEur RadiolEur Radiol877-8852822017/08/06Carcinoma, Hepatocellular/*surgeryElasticity Imaging TechniquesFemaleHepatectomy/*adverse effectsHumansLiver Failure/*diagnosis/etiologyLiver Neoplasms/*surgeryMaleMiddle Aged*NomogramsPostoperative Complications/*diagnosisProspective StudiesROC CurveRisk FactorsHepatectomyHepatocellular carcinomaLiver failureLiver stiffnessNomogram2018Feb1432-1084 (Electronic) 0938-7994 (Linking)28779402https://www.ncbi.nlm.nih.gov/pubmed/2877940210.1007/s00330-017-4900-2Grgurevic201877717Grgurevic, I.Bokun, T.Salkic, N. N.Brkljacic, B.Vukelic-Markovic, M.Stoos-Veic, T.Aralica, G.Rakic, M.Filipec-Kanizaj, T.Berzigotti, A.Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia. Department of Gastroenterology and Hepatology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. Department of Diagnostic and Interventional Radiology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia. Department of Pathology and Cytology, University Hospital Dubrava, Zagreb, Croatia. Faculty of Medicine, University "J.J. Strossmayer", Osijek, Croatia. Department of Pathology and Cytology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia. Department of Abdominal Surgery, University Hospital Dubrava, Zagreb, Croatia. Department of Gastroenterology and Hepatology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia. Hepatology, Swiss Liver Center, University Clinic for Visceral Surgery and Medicine, Inselspital, University of Berne, Berne, Switzerland.Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesionsLiver IntLiver Int1055-10633862017/10/14AgedCarcinoma, Hepatocellular/*diagnostic imagingCholangiocarcinoma/*diagnostic imagingElasticity Imaging TechniquesFemaleFocal Nodular Hyperplasia/*diagnostic imagingHemangioma/*diagnostic imagingHumansLiver/diagnostic imaging/pathologyLiver Neoplasms/*diagnostic imagingLogistic ModelsMaleMiddle AgedReproducibility of ResultsSensitivity and SpecificitySeverity of Illness IndexTomography, X-Ray Computed*liver tumors*non-invasive diagnosis*shear wave elastography*ultrasound2018Jun1478-3231 (Electronic) 1478-3223 (Linking)29028279https://www.ncbi.nlm.nih.gov/pubmed/2902827910.1111/liv.13611p.DHu201888817Hu, H.Han, H.Han, X. K.Wang, W. P.Ding, H.Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. han.hong@zs-hospital.sh.cn. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. han.hong@zs-hospital.sh.cn. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. wang.wenping@zs-hospital.sh.cn. Shanghai Institute of Medical Imaging, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. wang.wenping@zs-hospital.sh.cn.Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma: the evidence from ultrasound dataEur RadiolEur Radiol877-8852822017/08/06Carcinoma, Hepatocellular/*surgeryElasticity Imaging TechniquesFemaleHepatectomy/*adverse effectsHumansLiver Failure/*diagnosis/etiologyLiver Neoplasms/*surgeryMaleMiddle Aged*NomogramsPostoperative Complications/*diagnosisProspective StudiesROC CurveRisk FactorsHepatectomyHepatocellular carcinomaLiver failureLiver stiffnessNomogram2018Feb1432-1084 (Electronic) 0938-7994 (Linking)28779402https://www.ncbi.nlm.nih.gov/pubmed/2877940210.1007/s00330-017-4900-2Grgurevic201877717Grgurevic, I.Bokun, T.Salkic, N. N.Brkljacic, B.Vukelic-Markovic, M.Stoos-Veic, T.Aralica, G.Rakic, M.Filipec-Kanizaj, T.Berzigotti, A.Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia. Department of Gastroenterology and Hepatology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina. Department of Diagnostic and Interventional Radiology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia. Department of Pathology and Cytology, University Hospital Dubrava, Zagreb, Croatia. Faculty of Medicine, University "J.J. Strossmayer", Osijek, Croatia. Department of Pathology and Cytology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia. Department of Abdominal Surgery, University Hospital Dubrava, Zagreb, Croatia. Department of Gastroenterology and Hepatology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia. Hepatology, Swiss Liver Center, University Clinic for Visceral Surgery and Medicine, Inselspital, University of Berne, Berne, Switzerland.Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesionsLiver IntLiver Int1055-10633862017/10/14AgedCarcinoma, Hepatocellular/*diagnostic imagingCholangiocarcinoma/*diagnostic imagingElasticity Imaging TechniquesFemaleFocal Nodular Hyperplasia/*diagnostic imagingHemangioma/*diagnostic imagingHumansLiver/diagnostic imaging/pathologyLiver Neoplasms/*diagnostic imagingLogistic ModelsMaleMiddle AgedReproducibility of ResultsSensitivity and SpecificitySeverity of Illness IndexTomography, X-Ray Computed*liver tumors*non-invasive diagnosis*shear wave elastography*ultrasound2018Jun1478-3231 (Electronic) 1478-3223 (Linking)29028279https://www.ncbi.nlm.nih.gov/pubmed/2902827910.1111/liv.13611psDyK  _ENREF_6sDyK  _ENREF_7L DBerzigotti201844417Berzigotti, A.Ferraioli, G.Bota, S.Gilja, O. H.Dietrich, C. F.Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Berne, Switzerland. Electronic address: Annalisa.Berzigotti@insel.ch. Clinical Sciences and Infectious Diseases Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. Electronic address: giovanna.ferraioli@unipv.it. Department of Gastroenterology, Hepatology, Nephrology and Endocrinology, Klinikum Klagenfurt, Klagenfurt am Worthersee, Austria. Electronic address: Simona.Bota@kabeg.at. National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen and Department of Clinical Medicine, University of Bergen, Norway. Electronic address: odd.helge.gilja@helse-bergen.no. Department of Internal Medicine 2, Caritas Krankenhaus, Bad Mergentheim, Germany. Electronic address: Christoph.dietrich@ckbm.de.Novel ultrasound-based methods to assess liver disease: The game has just begunDig Liver DisDig Liver Dis107-1125022017/12/21Elasticity Imaging Techniques/*trendsFatty Liver/diagnostic imagingHumansLiver/*diagnostic imagingLiver Cirrhosis/diagnostic imagingSpleen/*diagnostic imagingCirrhosisFibrosisFocal lesionsGuidelinesShear wave elastography2018Feb1878-3562 (Electronic) 1590-8658 (Linking)29258813https://www.ncbi.nlm.nih.gov/pubmed/2925881310.1016/j.dld.2017.11.019pL DBerzigotti201844417Berzigotti, A.Ferraioli, G.Bota, S.Gilja, O. H.Dietrich, C. F.Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Berne, Switzerland. Electronic address: Annalisa.Berzigotti@insel.ch. Clinical Sciences and Infectious Diseases Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. Electronic address: giovanna.ferraioli@unipv.it. Department of Gastroenterology, Hepatology, Nephrology and Endocrinology, Klinikum Klagenfurt, Klagenfurt am Worthersee, Austria. Electronic address: Simona.Bota@kabeg.at. National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen and Department of Clinical Medicine, University of Bergen, Norway. Electronic address: odd.helge.gilja@helse-bergen.no. Department of Internal Medicine 2, Caritas Krankenhaus, Bad Mergentheim, Germany. Electronic address: Christoph.dietrich@ckbm.de.Novel ultrasound-based methods to assess liver disease: The game has just begunDig Liver DisDig Liver Dis107-1125022017/12/21Elasticity Imaging Techniques/*trendsFatty Liver/diagnostic imagingHumansLiver/*diagnostic imagingLiver Cirrhosis/diagnostic imagingSpleen/*diagnostic imagingCirrhosisFibrosisFocal lesionsGuidelinesShear wave elastography2018Feb1878-3562 (Electronic) 1590-8658 (Linking)29258813https://www.ncbi.nlm.nih.gov/pubmed/2925881310.1016/j.dld.2017.11.019psDyK  _ENREF_8DLee201510101017Lee, Y. J.Lee, J. M.Lee, J. S.Lee, H. Y.Park, B. H.Kim, Y. H.Han, J. K.Choi, B. I.From the Department of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Korea (Y.J.L., Y.H.K.); Department of Radiology, Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul 110-744, Korea (J.M.L., J.K.H., B.I.C.); Biostatistical Consulting Unit, Soonchunhyang University Medical Center, Seoul, Korea (J.S.L.); and Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea (H.Y.L., B.H.P.).Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysisRadiologyRadiologyRadiologyRadiology97-1092751Carcinoma, Hepatocellular/*diagnosis/pathology/radiographyContrast MediaHumansLiver Neoplasms/*diagnosis/pathology/radiographyMagnetic Resonance Imaging/*methodsTomography, X-Ray Computed/*methods2015Apr1527-1315 (Electronic) 0033-8419 (Linking)25559230http://www.ncbi.nlm.nih.gov/pubmed/2555923010.1148/radiol.14140690Liu201711111117Liu, X.Jiang, H.Chen, J.Zhou, Y.Huang, Z.Song, B.Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Systems Immunity Research Institute, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom.Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysisLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society1505-151823122017/09/09Carcinoma, Hepatocellular/*diagnostic imagingContrast Media/administration & dosageEarly Detection of Cancer/*methodsGadolinium DTPA/administration & dosageHumansLiver Neoplasms/*diagnostic imagingMagnetic Resonance Imaging/*methods*Multidetector Computed TomographyROC Curve2017Dec1527-64652888623110.1002/lt.24867NLMeng@0DLee201510101017Lee, Y. J.Lee, J. M.Lee, J. S.Lee, H. Y.Park, B. H.Kim, Y. H.Han, J. K.Choi, B. I.From the Department of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Korea (Y.J.L., Y.H.K.); Department of Radiology, Institute of Radiation Medicine, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul 110-744, Korea (J.M.L., J.K.H., B.I.C.); Biostatistical Consulting Unit, Soonchunhyang University Medical Center, Seoul, Korea (J.S.L.); and Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea (H.Y.L., B.H.P.).Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysisRadiologyRadiologyRadiologyRadiology97-1092751Carcinoma, Hepatocellular/*diagnosis/pathology/radiographyContrast MediaHumansLiver Neoplasms/*diagnosis/pathology/radiographyMagnetic Resonance Imaging/*methodsTomography, X-Ray Computed/*methods2015Apr1527-1315 (Electronic) 0033-8419 (Linking)25559230http://www.ncbi.nlm.nih.gov/pubmed/2555923010.1148/radiol.14140690Liu201711111117Liu, X.Jiang, H.Chen, J.Zhou, Y.Huang, Z.Song, B.Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Systems Immunity Research Institute, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom.Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysisLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society1505-151823122017/09/09Carcinoma, Hepatocellular/*diagnostic imagingContrast Media/administration & dosageEarly Detection of Cancer/*methodsGadolinium DTPA/administration & dosageHumansLiver Neoplasms/*diagnostic imagingMagnetic Resonance Imaging/*methods*Multidetector Computed TomographyROC Curve2017Dec1527-64652888623110.1002/lt.24867NLMeng@0sDyK  _ENREF_9uDyK  _ENREF_10|4DZeng201314141417Zeng, M. S.Ye, H. Y.Guo, L.Peng, W. J.Lu, J. P.Teng, G. J.Huan, Y.Li, P.Xu, J. R.Liang, C. H.Breuer, J.Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. zeng.mengsu@zs-hospital.sh.cn.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase III studyHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INTHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INTHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INT607-16126AdultAged*Asian Continental Ancestry GroupChinaContrast Media/administration & dosageFemale*Gadolinium DTPA/administration & dosageHumansInjections, IntravenousLiver Neoplasms/*diagnosis/epidemiology/*pathologyMagnetic Resonance Imaging/*methodsMaleMiddle AgedPatient SafetySensitivity and SpecificityTreatment Outcome2013Dec1499-3872 (Print)24322746http://www.ncbi.nlm.nih.gov/pubmed/24322746Ichikawa201099917Ichikawa, T.Saito, K.Yoshioka, N.Tanimoto, A.Gokan, T.Takehara, Y.Kamura, T.Gabata, T.Murakami, T.Ito, K.Hirohashi, S.Nishie, A.Saito, Y.Onaya, H.Kuwatsuru, R.Morimoto, A.Ueda, K.Kurauchi, M.Breuer, J.Department of Radiology, University of Yamanashi, School of Medicine, Yamanashi, Japan. ichikawa@yamanashi.ac.jpDetection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver diseaseInvest RadiolInvestigative radiologyInvest RadiolInvestigative radiologyInvest RadiolInvestigative radiology133-41453AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*diagnosis/pathology/radiographyChronic DiseaseContrast MediaDextransFemale*Ferrosoferric Oxide*Gadolinium DTPAHumansImage Enhancement/*methodsJapanLiver Diseases/*complicationsLiver Neoplasms/*diagnosis/pathology/radiographyMagnetic Resonance Imaging/*methodsMagnetite NanoparticlesMaleMiddle AgedProspective StudiesTomography, Spiral Computed/*methods2010Mar1536-0210 (Electronic) 0020-9996 (Linking)20098330http://www.ncbi.nlm.nih.gov/pubmed/2009833010.1097/RLI.0b013e3181caea5b丁莺201333317Ding YingChen Cai-zhongR. A. O. Sheng-xiangZeng Meng-su<style face="normal" font="default" size="100%">Gd+-EOB-DTPA</style><style face="normal" font="default" charset="134" size="100%">与</style><style face="normal" font="default" size="100%">Gd+-DTPA</style><style face="normal" font="default" charset="134" size="100%">增强磁共振检查肝细胞癌的对照研究</style>中华普通外科杂志682-685289癌肝细胞磁共振成像对比噪声比20131007-631Xhttp://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhptwk20130901010.3760/cma.j.issn.1007-631X.2013.09.010chiYoo201313131317Yoo, S. H.Choi, J. Y.Jang, J. W.Bae, S. H.Yoon, S. K.Kim, D. G.Yoo, Y. K.Rha, S. E.Lee, Y. J.Jung, E. S.Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncology2893-900209Carcinoma, Hepatocellular/*pathology/radiography/therapy*Contrast Media*Decision MakingFemaleFollow-Up Studies*Gadolinium DTPAHumansLiver Neoplasms/*pathology/radiography/therapyMagnetic Resonance ImagingMaleMiddle Aged*Multidetector Computed TomographyNeoplasm StagingPrognosisRetrospective Studies2013Sep1534-4681 (Electronic) 1068-9265 (Linking)23649931http://www.ncbi.nlm.nih.gov/pubmed/2364993110.1245/s10434-013-3001-yRao201912121217Rao, S. X.Wang, J.Wang, J.Jiang, X. Q.Long, L. L.Li, Z. P.Li, Z. L.Shen, W.Zhao, X. M.Hu, D. Y.Zhang, H. M.Zhang, L.Huan, Y.Liang, C. H.Song, B.Zeng, M. S.Department of Radiology, Zhongshan Hospital, Fudan University, and Shanghai Institute of Medical Imaging, Shanghai, China. Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China. Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, China. Department of Radiology, Guangzhou First People's Hospital, Guangzhou, Guangdong Province, China. Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China. Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Department of Radiology, Tianjin First Central Hospital, Tianjin, China. Department of Diagnostic Imaging, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. Department of Radiology, The First Hospital of Jilin University, Changchun, Jilin Province, China. Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China. Department of Radiology, Guangdong Provincial People's Hospital, Guanggong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodiumJ Dig DisJournal of digestive diseasesJ Dig DisJournal of digestive diseasesJ Dig DisJournal of digestive diseases54-612022019/01/30Chinaconsensusgadolinium ethoxybenzyl DTPAimaging techniquesmagnetic resonance imaging2019Feb1751-29723069365910.1111/1751-2980.12707NLMeng|4DZeng201314141417Zeng, M. S.Ye, H. Y.Guo, L.Peng, W. J.Lu, J. P.Teng, G. J.Huan, Y.Li, P.Xu, J. R.Liang, C. H.Breuer, J.Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. zeng.mengsu@zs-hospital.sh.cn.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase III studyHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INTHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INTHepatobiliary Pancreat Dis IntHepatobiliary & pancreatic diseases international : HBPD INT607-16126AdultAged*Asian Continental Ancestry GroupChinaContrast Media/administration & dosageFemale*Gadolinium DTPA/administration & dosageHumansInjections, IntravenousLiver Neoplasms/*diagnosis/epidemiology/*pathologyMagnetic Resonance Imaging/*methodsMaleMiddle AgedPatient SafetySensitivity and SpecificityTreatment Outcome2013Dec1499-3872 (Print)24322746http://www.ncbi.nlm.nih.gov/pubmed/24322746Ichikawa201099917Ichikawa, T.Saito, K.Yoshioka, N.Tanimoto, A.Gokan, T.Takehara, Y.Kamura, T.Gabata, T.Murakami, T.Ito, K.Hirohashi, S.Nishie, A.Saito, Y.Onaya, H.Kuwatsuru, R.Morimoto, A.Ueda, K.Kurauchi, M.Breuer, J.Department of Radiology, University of Yamanashi, School of Medicine, Yamanashi, Japan. ichikawa@yamanashi.ac.jpDetection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver diseaseInvest RadiolInvestigative radiologyInvest RadiolInvestigative radiologyInvest RadiolInvestigative radiology133-41453AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*diagnosis/pathology/radiographyChronic DiseaseContrast MediaDextransFemale*Ferrosoferric Oxide*Gadolinium DTPAHumansImage Enhancement/*methodsJapanLiver Diseases/*complicationsLiver Neoplasms/*diagnosis/pathology/radiographyMagnetic Resonance Imaging/*methodsMagnetite NanoparticlesMaleMiddle AgedProspective StudiesTomography, Spiral Computed/*methods2010Mar1536-0210 (Electronic) 0020-9996 (Linking)20098330http://www.ncbi.nlm.nih.gov/pubmed/2009833010.1097/RLI.0b013e3181caea5b丁莺201333317Ding YingChen Cai-zhongR. A. O. Sheng-xiangZeng Meng-su<style face="normal" font="default" size="100%">Gd+-EOB-DTPA</style><style face="normal" font="default" charset="134" size="100%">与</style><style face="normal" font="default" size="100%">Gd+-DTPA</style><style face="normal" font="default" charset="134" size="100%">增强磁共振检查肝细胞癌的对照研究</style>中华普通外科杂志682-685289癌肝细胞磁共振成像对比噪声比20131007-631Xhttp://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhptwk20130901010.3760/cma.j.issn.1007-631X.2013.09.010chiYoo201313131317Yoo, S. H.Choi, J. Y.Jang, J. W.Bae, S. H.Yoon, S. K.Kim, D. G.Yoo, Y. K.Rha, S. E.Lee, Y. J.Jung, E. S.Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncology2893-900209Carcinoma, Hepatocellular/*pathology/radiography/therapy*Contrast Media*Decision MakingFemaleFollow-Up Studies*Gadolinium DTPAHumansLiver Neoplasms/*pathology/radiography/therapyMagnetic Resonance ImagingMaleMiddle Aged*Multidetector Computed TomographyNeoplasm StagingPrognosisRetrospective Studies2013Sep1534-4681 (Electronic) 1068-9265 (Linking)23649931http://www.ncbi.nlm.nih.gov/pubmed/2364993110.1245/s10434-013-3001-yRao201912121217Rao, S. X.Wang, J.Wang, J.Jiang, X. Q.Long, L. L.Li, Z. P.Li, Z. L.Shen, W.Zhao, X. M.Hu, D. Y.Zhang, H. M.Zhang, L.Huan, Y.Liang, C. H.Song, B.Zeng, M. S.Department of Radiology, Zhongshan Hospital, Fudan University, and Shanghai Institute of Medical Imaging, Shanghai, China. Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China. Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, China. Department of Radiology, Guangzhou First People's Hospital, Guangzhou, Guangdong Province, China. Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China. Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Department of Radiology, Tianjin First Central Hospital, Tianjin, China. Department of Diagnostic Imaging, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. Department of Radiology, The First Hospital of Jilin University, Changchun, Jilin Province, China. Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China. Department of Radiology, Guangdong Provincial People's Hospital, Guanggong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodiumJ Dig DisJournal of digestive diseasesJ Dig DisJournal of digestive diseasesJ Dig DisJournal of digestive diseases54-612022019/01/30Chinaconsensusgadolinium ethoxybenzyl DTPAimaging techniquesmagnetic resonance imaging2019Feb1751-29723069365910.1111/1751-2980.12707NLMenguDyK  _ENREF_11T DMarrero201833333317Marrero, J. A.Kulik, L. M.Sirlin, C. B.Zhu, A. X.Finn, R. S.Abecassis, M. M.Roberts, L. R.Heimbach, J. K.UT Southwestern Medical Center, Dallas, TX. Northwestern Medicine, Chicago, IL. University of California SanDiego, San Diego, CA. Massachusets General Hospital, Boston, MA. UCLA Medical Center, Los Angeles, CA. Mayo Clinic, Rochester, MN.Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)723-7506822018/04/07Antineoplastic Agents/therapeutic useCarcinoma, Hepatocellular/*diagnosis/therapyEarly Detection of Cancer/methodsFemaleHepatectomy/methodsHumansLiver/*pathologyLiver Neoplasms/*diagnosis/therapyLiver Transplantation/methodsMaleNeoplasm StagingUnited States2018Aug0270-91392962469910.1002/hep.29913NLMeng201817171717EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology182-2366912018/04/102018Jul0168-82782962828110.1016/j.jhep.2018.03.019NLMengOmata201736363617Omata, M.Cheng, A. L.Kokudo, N.Kudo, M.Lee, J. M.Jia, J.Tateishi, R.Han, K. H.Chawla, Y. K.Shiina, S.Jafri, W.Payawal, D. A.Ohki, T.Ogasawara, S.Chen, P. J.Lesmana, C. R. A.Lesmana, L. A.Gani, R. A.Obi, S.Dokmeci, A. K.Sarin, S. K.Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-city, Yamanashi, Japan. aug8808@yahoo.co.jp. The University of Tokyo, Tokyo, Japan. aug8808@yahoo.co.jp. Department of Oncology and Internal Medicine, National Taiwan University Hospital, National Taiwan University Cancer Center and Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan. Hepato-Biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka-Sayama, Osaka, Japan. Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Beijing Key Laboratory of Translational Medicine on Cirrhosis, National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Department of Gastroenterology, Juntendo University, Tokyo, Japan. Department of Medicine, Aga Khan University and Hospital, Karachi, Pakistan. Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines. Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia. Third Department of Internal Medicine, Teikyo University School of Medicine, Chiba, Japan. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatol IntHepatology internationalHepatol IntHepatology internationalHepatol IntHepatology international317-3701142017/06/18AsiaCarcinoma, Hepatocellular/*epidemiology/therapy/virologyCoinfection/epidemiologyDisease ManagementEvidence-Based MedicineHepatitis B/*epidemiology/therapyHepatitis C/*epidemiology/therapyHumansLiver Neoplasms/*epidemiology/therapy/virologyMeta-Analysis as TopicPractice Guidelines as TopicApaslAsia-PacificHepatocellular carcinomaTreatment algorithm2017Jul1936-053328620797PMC549169410.1007/s12072-017-9799-9NLMeng`T DMarrero201833333317Marrero, J. A.Kulik, L. M.Sirlin, C. B.Zhu, A. X.Finn, R. S.Abecassis, M. M.Roberts, L. R.Heimbach, J. K.UT Southwestern Medical Center, Dallas, TX. Northwestern Medicine, Chicago, IL. University of California SanDiego, San Diego, CA. Massachusets General Hospital, Boston, MA. UCLA Medical Center, Los Angeles, CA. Mayo Clinic, Rochester, MN.Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)723-7506822018/04/07Antineoplastic Agents/therapeutic useCarcinoma, Hepatocellular/*diagnosis/therapyEarly Detection of Cancer/methodsFemaleHepatectomy/methodsHumansLiver/*pathologyLiver Neoplasms/*diagnosis/therapyLiver Transplantation/methodsMaleNeoplasm StagingUnited States2018Aug0270-91392962469910.1002/hep.29913NLMeng201817171717EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology182-2366912018/04/102018Jul0168-82782962828110.1016/j.jhep.2018.03.019NLMengOmata201736363617Omata, M.Cheng, A. L.Kokudo, N.Kudo, M.Lee, J. M.Jia, J.Tateishi, R.Han, K. H.Chawla, Y. K.Shiina, S.Jafri, W.Payawal, D. A.Ohki, T.Ogasawara, S.Chen, P. J.Lesmana, C. R. A.Lesmana, L. A.Gani, R. A.Obi, S.Dokmeci, A. K.Sarin, S. K.Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-city, Yamanashi, Japan. aug8808@yahoo.co.jp. The University of Tokyo, Tokyo, Japan. aug8808@yahoo.co.jp. Department of Oncology and Internal Medicine, National Taiwan University Hospital, National Taiwan University Cancer Center and Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan. Hepato-Biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka-Sayama, Osaka, Japan. Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Beijing Key Laboratory of Translational Medicine on Cirrhosis, National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Department of Gastroenterology, Juntendo University, Tokyo, Japan. Department of Medicine, Aga Khan University and Hospital, Karachi, Pakistan. Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines. Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia. Third Department of Internal Medicine, Teikyo University School of Medicine, Chiba, Japan. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatol IntHepatology internationalHepatol IntHepatology internationalHepatol IntHepatology international317-3701142017/06/18AsiaCarcinoma, Hepatocellular/*epidemiology/therapy/virologyCoinfection/epidemiologyDisease ManagementEvidence-Based MedicineHepatitis B/*epidemiology/therapyHepatitis C/*epidemiology/therapyHumansLiver Neoplasms/*epidemiology/therapy/virologyMeta-Analysis as TopicPractice Guidelines as TopicApaslAsia-PacificHepatocellular carcinomaTreatment algorithm2017Jul1936-053328620797PMC549169410.1007/s12072-017-9799-9NLMeng`uDyK  _ENREF_16DCho201523232317Cho, E. S.Choi, J. Y.Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea. Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea.MRI features of hepatocellular carcinoma related to biologic behaviorKorean J RadiolKorean journal of radiologyKorean J RadiolKorean journal of radiologyKorean J RadiolKorean journal of radiology449-641632015/05/23AgedBiological ProductsBiomarkers, TumorCarcinoma, Hepatocellular/diagnosis/*diagnostic imaging/pathologyContrast MediaGadolinium DTPAHumansLiver Neoplasms/diagnosis/*diagnostic imaging/pathologyMagnetic Resonance Imaging/*methodsMaleMiddle AgedNeoplasm Staging/methodsPrognosisRadiographyHepatocellular carcinomaMagnetic resonance imaging2015May-Jun1229-692925995679PMC443598010.3348/kjr.2015.16.3.449NLMeng`DCho201523232317Cho, E. S.Choi, J. Y.Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea. Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea.MRI features of hepatocellular carcinoma related to biologic behaviorKorean J RadiolKorean journal of radiologyKorean J RadiolKorean journal of radiologyKorean J RadiolKorean journal of radiology449-641632015/05/23AgedBiological ProductsBiomarkers, TumorCarcinoma, Hepatocellular/diagnosis/*diagnostic imaging/pathologyContrast MediaGadolinium DTPAHumansLiver Neoplasms/diagnosis/*diagnostic imaging/pathologyMagnetic Resonance Imaging/*methodsMaleMiddle AgedNeoplasm Staging/methodsPrognosisRadiographyHepatocellular carcinomaMagnetic resonance imaging2015May-Jun1229-692925995679PMC443598010.3348/kjr.2015.16.3.449NLMeng`uDyK  _ENREF_19, DHwang201529292917Hwang, J.Kim, Y. K.Jeong, W. K.Choi, D.Rhim, H.Lee, W. J.From the Department of Radiology, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea (J.H.); and Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea (Y.K.K., W.K.J., D.C., H.R., W.J.L.).Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for CharacterizationRadiologyRadiologyRadiologyRadiology137-4627612015/03/04AdultAgedCarcinoma, Hepatocellular/*diagnosisChronic Disease*Contrast MediaDiffusion Magnetic Resonance Imaging/methodsFemale*Gadolinium DTPAHumansLiver Diseases/*diagnosisLiver Neoplasms/*diagnosisMagnetic Resonance Imaging/*methodsMaleMiddle AgedRetrospective Studies2015Jul0033-84192573455110.1148/radiol.15141350NLMeng`, DHwang201529292917Hwang, J.Kim, Y. K.Jeong, W. K.Choi, D.Rhim, H.Lee, W. J.From the Department of Radiology, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea (J.H.); and Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea (Y.K.K., W.K.J., D.C., H.R., W.J.L.).Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for CharacterizationRadiologyRadiologyRadiologyRadiology137-4627612015/03/04AdultAgedCarcinoma, Hepatocellular/*diagnosisChronic Disease*Contrast MediaDiffusion Magnetic Resonance Imaging/methodsFemale*Gadolinium DTPAHumansLiver Diseases/*diagnosisLiver Neoplasms/*diagnosisMagnetic Resonance Imaging/*methodsMaleMiddle AgedRetrospective Studies2015Jul0033-84192573455110.1148/radiol.15141350NLMeng`uDyK  _ENREF_20 DRenzulli201838383817Renzulli, M.Biselli, M.Brocchi, S.Granito, A.Vasuri, F.Tovoli, F.Sessagesimi, E.Piscaglia, F.D'Errico, A.Bolondi, L.Golfieri, R.Radiology Unit, Department of Diagnostic Medicine and Prevention, Sant'Orsola Hospital, University of Bologna, Bologna, Italy. Department of Medical and Surgical Sciences, Sant'Orsola Hospital, University of Bologna, Bologna, Italy. Unit of Internal Medicine, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. 'F Addarii' Institute of Oncology and Transplantation Pathology, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithmGutGutGutGut1674-16826792018/02/14AgedAlgorithmsCarcinoma, Hepatocellular/*diagnosisCell Transformation, Neoplastic*Contrast MediaDisease ProgressionEarly Detection of CancerFemale*Gadolinium DTPAHumansLiver Cirrhosis/complications/*diagnosisLiver Neoplasms/*diagnosisMagnetic Resonance Imaging/*methodsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProspective StudiesSensitivity and Specificity*mri*dysplasia*hepatobiliary radiology*hepatocellular carcinoma2018Sep0017-57492943791210.1136/gutjnl-2017-315384NLMeng DRenzulli201838383817Renzulli, M.Biselli, M.Brocchi, S.Granito, A.Vasuri, F.Tovoli, F.Sessagesimi, E.Piscaglia, F.D'Errico, A.Bolondi, L.Golfieri, R.Radiology Unit, Department of Diagnostic Medicine and Prevention, Sant'Orsola Hospital, University of Bologna, Bologna, Italy. Department of Medical and Surgical Sciences, Sant'Orsola Hospital, University of Bologna, Bologna, Italy. Unit of Internal Medicine, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. 'F Addarii' Institute of Oncology and Transplantation Pathology, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithmGutGutGutGut1674-16826792018/02/14AgedAlgorithmsCarcinoma, Hepatocellular/*diagnosisCell Transformation, Neoplastic*Contrast MediaDisease ProgressionEarly Detection of CancerFemale*Gadolinium DTPAHumansLiver Cirrhosis/complications/*diagnosisLiver Neoplasms/*diagnosisMagnetic Resonance Imaging/*methodsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProspective StudiesSensitivity and Specificity*mri*dysplasia*hepatobiliary radiology*hepatocellular carcinoma2018Sep0017-57492943791210.1136/gutjnl-2017-315384NLMenguDyK  _ENREF_21DXu201922262226222617Xu, X.Zhang, H. L.Liu, Q. P.Sun, S. W.Zhang, J.Zhu, F. P.Yang, G.Yan, X.Zhang, Y. D.Liu, X. S.Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China. MR Scientific Marketing, Siemens Healthcare, Shanghai, China. Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address: njmu_zyd@163.com. Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address: njmu_lxs@163.com.Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinomaJ HepatolJ Hepatol1133-11447062019/03/17Clinical outcomeHccLiver imaging scoreMicrovascular invasionRadiomics2019Jun1600-0641 (Electronic) 0168-8278 (Linking)30876945https://www.ncbi.nlm.nih.gov/pubmed/3087694510.1016/j.jhep.2019.02.023Lei201622272227222717Lei, Z.Li, J.Wu, D.Xia, Y.Wang, Q.Si, A.Wang, K.Wan, X.Lau, W. Y.Wu, M.Shen, F.Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Chinese Traditional Medicine, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China3Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan CriteriaJAMA SurgJama SurgJama SurgeryJama SurgJama SurgeryJama Surg356-6315142015/11/19Carcinoma, Hepatocellular/epidemiology/*pathology/surgeryChina/epidemiologyDisease-Free SurvivalFemale*HepatectomyHepatitis B Surface Antigens/immunologyHepatitis B virus/*immunologyHepatitis B, Chronic/*complications/epidemiology/virologyHumansIncidenceLiver Neoplasms/epidemiology/*pathology/surgeryMaleMiddle AgedNeoplasm Invasiveness*NomogramsPreoperative PeriodRetrospective StudiesRisk FactorsSurvival Rate/trends2016Apr2168-6262 (Electronic) 2168-6254 (Linking)26579636https://www.ncbi.nlm.nih.gov/pubmed/2657963610.1001/jamasurg.2015.4257EnglishPeng201822282228222817Peng, J.Zhang, J.Zhang, Q.Xu, Y.Zhou, J.Liu, L.Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China. Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinomaDiagn Interv RadiolDiagn Interv RadiolDiagnostic and Interventional RadiologyDiagn Interv RadiolDiagnostic and Interventional RadiologyDiagn Interv Radiol121-1272432018/05/18AdolescentAdultAgedAlgorithmsCarcinoma, Hepatocellular/blood supply/*diagnostic imaging/pathology/virologyFemaleHepatitis B virus/immunologyHumansLiver Neoplasms/*blood supply/pathologyMaleMicrovessels/*pathologyMiddle AgedNeoplasm Invasiveness/diagnostic imaging/pathology*NomogramsPortal Vein/diagnostic imaging/pathologyPredictive Value of TestsPreoperative PeriodRetrospective StudiesRisk FactorsTomography, X-Ray Computed/methodsYoung Adultalpha-Fetoproteins/analysis2018May-Jun1305-3612 (Electronic) 1305-3825 (Linking)29770763https://www.ncbi.nlm.nih.gov/pubmed/29770763PMC595119910.5152/dir.2018.17467English@0DXu201922262226222617Xu, X.Zhang, H. L.Liu, Q. P.Sun, S. W.Zhang, J.Zhu, F. P.Yang, G.Yan, X.Zhang, Y. D.Liu, X. S.Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China. MR Scientific Marketing, Siemens Healthcare, Shanghai, China. Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address: njmu_zyd@163.com. Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address: njmu_lxs@163.com.Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinomaJ HepatolJ Hepatol1133-11447062019/03/17Clinical outcomeHccLiver imaging scoreMicrovascular invasionRadiomics2019Jun1600-0641 (Electronic) 0168-8278 (Linking)30876945https://www.ncbi.nlm.nih.gov/pubmed/3087694510.1016/j.jhep.2019.02.023Lei201622272227222717Lei, Z.Li, J.Wu, D.Xia, Y.Wang, Q.Si, A.Wang, K.Wan, X.Lau, W. Y.Wu, M.Shen, F.Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Chinese Traditional Medicine, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China3Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan CriteriaJAMA SurgJama SurgJama SurgeryJama SurgJama SurgeryJama Surg356-6315142015/11/19Carcinoma, Hepatocellular/epidemiology/*pathology/surgeryChina/epidemiologyDisease-Free SurvivalFemale*HepatectomyHepatitis B Surface Antigens/immunologyHepatitis B virus/*immunologyHepatitis B, Chronic/*complications/epidemiology/virologyHumansIncidenceLiver Neoplasms/epidemiology/*pathology/surgeryMaleMiddle AgedNeoplasm Invasiveness*NomogramsPreoperative PeriodRetrospective StudiesRisk FactorsSurvival Rate/trends2016Apr2168-6262 (Electronic) 2168-6254 (Linking)26579636https://www.ncbi.nlm.nih.gov/pubmed/2657963610.1001/jamasurg.2015.4257EnglishPeng201822282228222817Peng, J.Zhang, J.Zhang, Q.Xu, Y.Zhou, J.Liu, L.Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China. Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinomaDiagn Interv RadiolDiagn Interv RadiolDiagnostic and Interventional RadiologyDiagn Interv RadiolDiagnostic and Interventional RadiologyDiagn Interv Radiol121-1272432018/05/18AdolescentAdultAgedAlgorithmsCarcinoma, Hepatocellular/blood supply/*diagnostic imaging/pathology/virologyFemaleHepatitis B virus/immunologyHumansLiver Neoplasms/*blood supply/pathologyMaleMicrovessels/*pathologyMiddle AgedNeoplasm Invasiveness/diagnostic imaging/pathology*NomogramsPortal Vein/diagnostic imaging/pathologyPredictive Value of TestsPreoperative PeriodRetrospective StudiesRisk FactorsTomography, X-Ray Computed/methodsYoung Adultalpha-Fetoproteins/analysis2018May-Jun1305-3612 (Electronic) 1305-3825 (Linking)29770763https://www.ncbi.nlm.nih.gov/pubmed/29770763PMC595119910.5152/dir.2018.17467English@0uDyK  _ENREF_22DPark200837373717Park, J. W.Kim, J. H.Kim, S. K.Kang, K. W.Park, K. W.Choi, J. I.Lee, W. J.Kim, C. M.Nam, B. H.Center for Liver Cancer, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea. jwpark@ncc.re.krA prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinomaJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine1912-214912*AcetatesAdult*Carbon*Carcinoma, Hepatocellular/diagnosis/mortality/secondaryFemale*Fluorodeoxyglucose F18HumansIncidenceKorea/epidemiologyLiver Neoplasms/*diagnosis/*mortalityMaleMiddle AgedPositron-Emission Tomography/*statistics & numerical dataPrognosisProspective StudiesRadiopharmaceuticalsReproducibility of ResultsRisk Assessment/methodsRisk FactorsSensitivity and SpecificitySubtraction Technique/statistics & numerical dataSurvival AnalysisSurvival RateTomography, X-Ray Computed/*statistics & numerical data2008Dec0161-5505 (Print) 0161-5505 (Linking)18997056http://www.ncbi.nlm.nih.gov/pubmed/1899705610.2967/jnumed.108.055087Lin201232323217Lin, C. Y.Chen, J. H.Liang, J. A.Lin, C. C.Jeng, L. B.Kao, C. H.Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan.18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysisEur J RadiolEuropean journal of radiologyEur J RadiolEuropean journal of radiologyEur J RadiolEuropean journal of radiology2417-22819Carcinoma/*diagnosis/*secondary*Fluorodeoxyglucose F18HumansLiver Neoplasms/*diagnosisMultimodal Imaging/*methodsNeoplasm Recurrence, Local/*diagnosis*Positron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and Specificity*Tomography, X-Ray Computed2012Sep1872-7727 (Electronic) 0720-048X (Linking)21899970http://www.ncbi.nlm.nih.gov/pubmed/2189997010.1016/j.ejrad.2011.08.004uDyK  _ENREF_25uDyK  _ENREF_260DBoellaard201519191917Boellaard, R.Delgado-Bolton, R.Oyen, W. J.Giammarile, F.Tatsch, K.Eschner, W.Verzijlbergen, F. J.Barrington, S. F.Pike, L. C.Weber, W. A.Stroobants, S.Delbeke, D.Donohoe, K. J.Holbrook, S.Graham, M. M.Testanera, G.Hoekstra, O. S.Zijlstra, J.Visser, E.Hoekstra, C. J.Pruim, J.Willemsen, A.Arends, B.Kotzerke, J.Bockisch, A.Beyer, T.Chiti, A.Krause, B. J.European Association of Nuclear, MedicineDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands, r.boellaard@vumc.nl.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0Eur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging328-54422*Fluorodeoxyglucose F18HumansMultimodal Imaging/*methodsNeoplasms/*radionuclide imagingPositron-Emission Tomography/*methods*RadiopharmaceuticalsTomography, X-Ray Computed/*methods2015Feb1619-7089 (Electronic) 1619-7070 (Linking)25452219http://www.ncbi.nlm.nih.gov/pubmed/25452219431552910.1007/s00259-014-2961-xBoellaard201020202017Boellaard, R.O'Doherty, M. J.Weber, W. A.Mottaghy, F. M.Lonsdale, M. N.Stroobants, S. G.Oyen, W. J.Kotzerke, J.Hoekstra, O. S.Pruim, J.Marsden, P. K.Tatsch, K.Hoekstra, C. J.Visser, E. P.Arends, B.Verzijlbergen, F. J.Zijlstra, J. M.Comans, E. F.Lammertsma, A. A.Paans, A. M.Willemsen, A. T.Beyer, T.Bockisch, A.Schaefer-Prokop, C.Delbeke, D.Baum, R. P.Chiti, A.Krause, B. J.Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. r.boellaard@vumc.nlFDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0Eur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging181-200371Europe*Fluorodeoxyglucose F18HumansNeoplasms/*diagnosisNuclear Medicine/*standardsPositron-Emission Tomography/*standards*Practice Guidelines as TopicRadiopharmaceuticalsSubtraction Technique/*standardsTomography, X-Ray Computed/*standards2010Jan1619-7089 (Electronic) 1619-7070 (Linking)19915839http://www.ncbi.nlm.nih.gov/pubmed/19915839279147510.1007/s00259-009-1297-4uDyK  _ENREF_27uDyK  _ENREF_28$DWahl200942424217Wahl, R. L.Jacene, H.Kasamon, Y.Lodge, M. A.Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0817, USA. rwahl@jhmi.eduFrom RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumorsJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine122S-50S50 Suppl 1*Fluorodeoxyglucose F18*ForecastingHumansInternationalityNeoplasms/*diagnosis/*therapyOutcome Assessment (Health Care)/*standardsPositron-Emission Tomography/*standards*Practice Guidelines as TopicPrognosisRadiopharmaceuticalsTreatment OutcomeWorld Health Organization2009May0161-5505 (Print) 0161-5505 (Linking)19403881http://www.ncbi.nlm.nih.gov/pubmed/19403881275524510.2967/jnumed.108.057307Chalian201121212117Chalian, H.Tore, H. G.Horowitz, J. M.Salem, R.Miller, F. H.Yaghmai, V.Department of Radiology, Northwestern Memorial Hospital, Northwestern University-Feinberg School of Medicine, 676 N St Clair St, Suite 800, Chicago, IL 60611, USA.Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0RadiographicsRadiographics : a review publication of the Radiological Society of North America, IncRadiographicsRadiographics : a review publication of the Radiological Society of North America, IncRadiographicsRadiographics : a review publication of the Radiological Society of North America, Inc2093-105317Diagnostic Imaging/*standardsHumansNeoplasms/*diagnosis/*therapyOutcome Assessment (Health Care)/*standards*Practice Guidelines as TopicPrognosisRadiology/*standardsTreatment OutcomeUnited States2011Nov-Dec1527-1323 (Electronic) 0271-5333 (Linking)22084190http://www.ncbi.nlm.nih.gov/pubmed/2208419010.1148/rg.317115050uDyK  _ENREF_29uDyK  _ENREF_300DBoellaard201519191917Boellaard, R.Delgado-Bolton, R.Oyen, W. J.Giammarile, F.Tatsch, K.Eschner, W.Verzijlbergen, F. J.Barrington, S. F.Pike, L. C.Weber, W. A.Stroobants, S.Delbeke, D.Donohoe, K. J.Holbrook, S.Graham, M. M.Testanera, G.Hoekstra, O. S.Zijlstra, J.Visser, E.Hoekstra, C. J.Pruim, J.Willemsen, A.Arends, B.Kotzerke, J.Bockisch, A.Beyer, T.Chiti, A.Krause, B. J.European Association of Nuclear, MedicineDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands, r.boellaard@vumc.nl.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0Eur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging328-54422*Fluorodeoxyglucose F18HumansMultimodal Imaging/*methodsNeoplasms/*radionuclide imagingPositron-Emission Tomography/*methods*RadiopharmaceuticalsTomography, X-Ray Computed/*methods2015Feb1619-7089 (Electronic) 1619-7070 (Linking)25452219http://www.ncbi.nlm.nih.gov/pubmed/25452219431552910.1007/s00259-014-2961-xBoellaard201020202017Boellaard, R.O'Doherty, M. J.Weber, W. A.Mottaghy, F. M.Lonsdale, M. N.Stroobants, S. G.Oyen, W. J.Kotzerke, J.Hoekstra, O. S.Pruim, J.Marsden, P. K.Tatsch, K.Hoekstra, C. J.Visser, E. P.Arends, B.Verzijlbergen, F. J.Zijlstra, J. M.Comans, E. F.Lammertsma, A. A.Paans, A. M.Willemsen, A. T.Beyer, T.Bockisch, A.Schaefer-Prokop, C.Delbeke, D.Baum, R. P.Chiti, A.Krause, B. J.Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. r.boellaard@vumc.nlFDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0Eur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging181-200371Europe*Fluorodeoxyglucose F18HumansNeoplasms/*diagnosisNuclear Medicine/*standardsPositron-Emission Tomography/*standards*Practice Guidelines as TopicRadiopharmaceuticalsSubtraction Technique/*standardsTomography, X-Ray Computed/*standards2010Jan1619-7089 (Electronic) 1619-7070 (Linking)19915839http://www.ncbi.nlm.nih.gov/pubmed/19915839279147510.1007/s00259-009-1297-4uDyK  _ENREF_27uDyK  _ENREF_28.:DFerda201525252517Ferda, J.Ferdova, E.Baxa, J.Kreuzberg, B.Daum, O.Treska, V.Skalicky, T.Department of Imaging Methods, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic Biomedical Centre, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic ferda@fnplzen.cz. Department of Imaging Methods, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic. Institute of Pathology, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic. Department of Surgery, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic Biomedical Centre, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Department of Surgery, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic.The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiographyAnticancer ResAnticancer researchAnticancer ResAnticancer researchAnticancer ResAnticancer research2241-63542015/04/12AdultAgedAged, 80 and overAngiographyCarcinoma, Hepatocellular/diagnostic imaging/drug therapy/*pathologyFemale*Fluorodeoxyglucose F18HumansLiver Neoplasms/*diagnostic imaging/drug therapy/*pathologyMaleMiddle AgedPositron-Emission TomographyTomography, X-Ray Computed18F-fluorodeoxyglucoseHepatocellular carcinomaPet/ctpositron emission tomography2015Apr0250-700525862885NLMengLee201631313117Lee, J. W.Oh, J. K.Chung, Y. A.Na, S. J.Hyun, S. H.Hong, I. K.Eo, J. S.Song, B. I.Kim, T. S.Kim do, Y.Kim, S. U.Moon, D. H.Lee, J. D.Yun, M.Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Department of Radiology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Seoul, Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. Department of Nuclear Medicine, National Cancer Center Research Institute and Hospital, Gyeonggi-do, Korea. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Department of Radiology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea; and yunmijin@yuhs.ac jdlee@ish.or.kr. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea yunmijin@yuhs.ac jdlee@ish.or.kr.Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort StudyJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine509-165742016Apr1535-5667 (Electronic) 0161-5505 (Linking)26742711http://www.ncbi.nlm.nih.gov/pubmed/2674271110.2967/jnumed.115.167338Hyun201623723723717Hyun, S. H.Eo, J. S.Lee, J. W.Choi, J. Y.Lee, K. H.Na, S. J.Hong, I. K.Oh, J. K.Chung, Y. A.Song, B. I.Kim, T. S.Kim, K. S.Moon, D. H.Yun, M.Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea. Department of Nuclear Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Republic of Korea. Department of Nuclear Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. Department of Nuclear Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea. dhmoon@amc.seoul.kr. Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. yunmijin@yuhs.ac.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort studyEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging1638-454392016/03/05AgedBiological TransportCarcinoma, Hepatocellular/*diagnostic imaging/*pathologyCohort StudiesDisease-Free SurvivalFemale*Fluorodeoxyglucose F18HumansKaplan-Meier EstimateLiver Neoplasms/*diagnostic imaging/*pathologyMaleMiddle AgedNeoplasm Staging*Positron Emission Tomography Computed TomographyRetrospective Studies*fdg pet/ct*Hepatocellular carcinoma*Multicenter trial*Prognosis*Standardized uptake value2016Mar 21619-7089 (Electronic) 1619-7070 (Linking)26936852http://www.ncbi.nlm.nih.gov/pubmed/2693685210.1007/s00259-016-3348-yNa201734343417Na, S. J.Oh, J. K.Hyun, S. H.Lee, J. W.Hong, I. K.Song, B. I.Kim, T. S.Eo, J. S.Lee, S. W.Yoo, I. R.Chung, Y. A.Yun, M.Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. Department of Nuclear Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; and. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea yunmijin@yuhs.ac yongan@catholic.ac.kr. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea yunmijin@yuhs.ac yongan@catholic.ac.kr.(18)F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort StudyJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine730-7365852016/10/30AdultAgedCarcinoma, Hepatocellular/*diagnostic imaging/*mortality/therapyCohort StudiesFemaleFluorodeoxyglucose F18HumansImage Interpretation, Computer-Assisted/methodsLiver Neoplasms/*diagnostic imaging/*mortality/therapyMaleMiddle AgedPositron Emission Tomography Computed Tomography/methods/*statistics & numericaldataPrevalencePrognosisProportional Hazards ModelsRadiopharmaceuticalsReproducibility of ResultsRepublic of Korea/epidemiologyRetrospective StudiesRisk AssessmentSensitivity and Specificity*Survival Analysis*18f-fdg*pet/ct*hepatocellular carcinoma*prognosis*survival2017May0161-55052778971410.2967/jnumed.116.182022NLMengp.:DFerda201525252517Ferda, J.Ferdova, E.Baxa, J.Kreuzberg, B.Daum, O.Treska, V.Skalicky, T.Department of Imaging Methods, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic Biomedical Centre, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic ferda@fnplzen.cz. Department of Imaging Methods, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic. Institute of Pathology, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic. Department of Surgery, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic Biomedical Centre, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Department of Surgery, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic.The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiographyAnticancer ResAnticancer researchAnticancer ResAnticancer researchAnticancer ResAnticancer research2241-63542015/04/12AdultAgedAged, 80 and overAngiographyCarcinoma, Hepatocellular/diagnostic imaging/drug therapy/*pathologyFemale*Fluorodeoxyglucose F18HumansLiver Neoplasms/*diagnostic imaging/drug therapy/*pathologyMaleMiddle AgedPositron-Emission TomographyTomography, X-Ray Computed18F-fluorodeoxyglucoseHepatocellular carcinomaPet/ctpositron emission tomography2015Apr0250-700525862885NLMengLee201631313117Lee, J. W.Oh, J. K.Chung, Y. A.Na, S. J.Hyun, S. H.Hong, I. K.Eo, J. S.Song, B. I.Kim, T. S.Kim do, Y.Kim, S. U.Moon, D. H.Lee, J. D.Yun, M.Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Department of Radiology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Seoul, Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. Department of Nuclear Medicine, National Cancer Center Research Institute and Hospital, Gyeonggi-do, Korea. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Department of Radiology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea; and yunmijin@yuhs.ac jdlee@ish.or.kr. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea yunmijin@yuhs.ac jdlee@ish.or.kr.Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort StudyJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine509-165742016Apr1535-5667 (Electronic) 0161-5505 (Linking)26742711http://www.ncbi.nlm.nih.gov/pubmed/2674271110.2967/jnumed.115.167338Hyun201623723723717Hyun, S. H.Eo, J. S.Lee, J. W.Choi, J. Y.Lee, K. H.Na, S. J.Hong, I. K.Oh, J. K.Chung, Y. A.Song, B. I.Kim, T. S.Kim, K. S.Moon, D. H.Yun, M.Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea. Department of Nuclear Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Republic of Korea. Department of Nuclear Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. Department of Nuclear Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea. dhmoon@amc.seoul.kr. Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. yunmijin@yuhs.ac.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort studyEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imagingEur J Nucl Med Mol ImagingEuropean journal of nuclear medicine and molecular imaging1638-454392016/03/05AgedBiological TransportCarcinoma, Hepatocellular/*diagnostic imaging/*pathologyCohort StudiesDisease-Free SurvivalFemale*Fluorodeoxyglucose F18HumansKaplan-Meier EstimateLiver Neoplasms/*diagnostic imaging/*pathologyMaleMiddle AgedNeoplasm Staging*Positron Emission Tomography Computed TomographyRetrospective Studies*fdg pet/ct*Hepatocellular carcinoma*Multicenter trial*Prognosis*Standardized uptake value2016Mar 21619-7089 (Electronic) 1619-7070 (Linking)26936852http://www.ncbi.nlm.nih.gov/pubmed/2693685210.1007/s00259-016-3348-yNa201734343417Na, S. J.Oh, J. K.Hyun, S. H.Lee, J. W.Hong, I. K.Song, B. I.Kim, T. S.Eo, J. S.Lee, S. W.Yoo, I. R.Chung, Y. A.Yun, M.Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Nuclear Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea. Department of Nuclear Medicine, Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Korea. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. Department of Nuclear Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; and. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea yunmijin@yuhs.ac yongan@catholic.ac.kr. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea yunmijin@yuhs.ac yongan@catholic.ac.kr.(18)F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort StudyJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine730-7365852016/10/30AdultAgedCarcinoma, Hepatocellular/*diagnostic imaging/*mortality/therapyCohort StudiesFemaleFluorodeoxyglucose F18HumansImage Interpretation, Computer-Assisted/methodsLiver Neoplasms/*diagnostic imaging/*mortality/therapyMaleMiddle AgedPositron Emission Tomography Computed Tomography/methods/*statistics & numericaldataPrevalencePrognosisProportional Hazards ModelsRadiopharmaceuticalsReproducibility of ResultsRepublic of Korea/epidemiologyRetrospective StudiesRisk AssessmentSensitivity and Specificity*Survival Analysis*18f-fdg*pet/ct*hepatocellular carcinoma*prognosis*survival2017May0161-55052778971410.2967/jnumed.116.182022NLMengpuDyK  _ENREF_31DBertagna201418181817Bertagna, F.Bertoli, M.Bosio, G.Biasiotto, G.Sadeghi, R.Giubbini, R.Treglia, G.Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy. francesco.bertagna@unibs.it. Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy. Biomedical Technology Department, University of Brescia, Brescia, Italy. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysisHepatol IntHepatology internationalHepatol IntHepatology internationalHepatol IntHepatology international493-500842014Oct1936-0541 (Electronic) 1936-0533 (Linking)26202754http://www.ncbi.nlm.nih.gov/pubmed/2620275410.1007/s12072-014-9566-0Cheung201322222217Cheung, T. T.Ho, C. L.Lo, C. M.Chen, S.Chan, S. C.Chok, K. S.Fung, J. Y.Yan Chan, A. C.Sharr, W.Yau, T.Poon, R. T.Fan, S. T.Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. tantocheung@hotmail.com11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspectiveJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine192-200542AdultAged*Carbon RadioisotopesCarcinoma, Hepatocellular/*surgery/therapyContrast MediaDiagnostic Imaging/methodsFemale*Fluorodeoxyglucose F18HumansLiver Neoplasms/*surgery/therapyLiver Transplantation/*methodsMaleMedical Oncology/methodsMiddle AgedNeoplasm Staging/*methodsNuclear Medicine/methodsPositron-Emission Tomography/*methodsReproducibility of ResultsSensitivity and SpecificityTomography, X-Ray Computed/*methods2013Feb1535-5667 (Electronic) 0161-5505 (Linking)23321459http://www.ncbi.nlm.nih.gov/pubmed/2332145910.2967/jnumed.112.107516uDyK  _ENREF_35uDyK  _ENREF_36uDyK  _ENREF_37 DHectors201828282817Hectors, S. J.Wagner, M.Besa, C.Huang, W.Taouli, B.Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY 10029, USA. Sorbonne Universites, UPMC, Department of Radiology, Hopital Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, 47-83 Boulevard de l'Hopital, 75013 Paris, France. Department of Radiology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile. Advanced Imaging Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd L452, Portland, OR 97239, USA. Department of Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY 10029, USA.Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial ExperienceContrast Media Mol ImagingContrast media & molecular imagingContrast Media Mol ImagingContrast media & molecular imagingContrast Media Mol ImagingContrast media & molecular imaging563828320182018/11/08AgedCarcinoma, Hepatocellular/*diagnostic imagingFemaleFluorodeoxyglucose F18HumansLiver/cytologyLiver Neoplasms/*diagnostic imagingMagnetic Resonance Imaging/*methods/standardsMaleMiddle AgedMultimodal Imaging/methods/standardsParenchymal TissuePilot ProjectsPositron-Emission Tomography/*methods/standardsProspective Studies20181555-430930402045PMC619212410.1155/2018/5638283NLMeng DHectors201828282817Hectors, S. J.Wagner, M.Besa, C.Huang, W.Taouli, B.Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY 10029, USA. Sorbonne Universites, UPMC, Department of Radiology, Hopital Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, 47-83 Boulevard de l'Hopital, 75013 Paris, France. Department of Radiology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile. Advanced Imaging Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd L452, Portland, OR 97239, USA. Department of Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY 10029, USA.Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial ExperienceContrast Media Mol ImagingContrast media & molecular imagingContrast Media Mol ImagingContrast media & molecular imagingContrast Media Mol ImagingContrast media & molecular imaging563828320182018/11/08AgedCarcinoma, Hepatocellular/*diagnostic imagingFemaleFluorodeoxyglucose F18HumansLiver/cytologyLiver Neoplasms/*diagnostic imagingMagnetic Resonance Imaging/*methods/standardsMaleMiddle AgedMultimodal Imaging/methods/standardsParenchymal TissuePilot ProjectsPositron-Emission Tomography/*methods/standardsProspective Studies20181555-430930402045PMC619212410.1155/2018/5638283NLMenguDyK  _ENREF_388DForner200826262617Forner, A.Vilana, R.Ayuso, C.Bianchi, L.Sole, M.Ayuso, J. R.Boix, L.Sala, M.Varela, M.Llovet, J. M.Bru, C.Bruix, J.BCLC group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinomaHepatologyHepatologyHepatologyHepatology97-104471AdultAgedAged, 80 and overAlgorithmsBiopsyCarcinoma, Hepatocellular/diagnosis/etiology/*ultrasonographyContrast MediaFemaleHumansLiver/*pathology/ultrasonographyLiver Cirrhosis/*complicationsLiver Neoplasms/diagnosis/etiology/*ultrasonography*Magnetic Resonance ImagingMaleMiddle AgedProspective Studies2008Jan1527-3350 (Electronic) 0270-9139 (Linking)18069697http://www.ncbi.nlm.nih.gov/pubmed/1806969710.1002/hep.21966Roberts201839393917Roberts, L. R.Sirlin, C. B.Zaiem, F.Almasri, J.Prokop, L. J.Heimbach, J. K.Murad, M. H.Mohammed, K.Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN. Liver Imaging Group, Department of Radiology, University of California San Diego, San Diego, CA. Evidence-Based Practice Center, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic College of Medicine and Science, Rochester, MN.Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysisHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)401-4216712017/09/01AdultCarcinoma, Hepatocellular/*diagnostic imaging/pathology*Contrast MediaFemaleHumans*Image Interpretation, Computer-AssistedLiver Neoplasms/*diagnostic imaging/pathologyMagnetic Resonance Imaging/methodsMaleMiddle AgedMultimodal Imaging/*methodsReproducibility of ResultsTomography, X-Ray Computed/methods2018Jan0270-91392885923310.1002/hep.29487NLMenguDyK  _ENREF_39uDyK  _ENREF_40uDyK  _ENREF_41DZhou201144444417Zhou, J.Yu, L.Gao, X.Hu, J.Wang, J.Dai, Z.Wang, J. F.Zhang, Z.Lu, S.Huang, X.Wang, Z.Qiu, S.Wang, X.Yang, G.Sun, H.Tang, Z.Wu, Y.Zhu, H.Fan, J.Liver Cancer Institute, Zhongshan Hospital, Fudan University, People's Republic of China.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinomaJ Clin OncolJ Clin Oncol4781-829362011/11/23AdultCarcinoma, Hepatocellular/blood/*diagnosisEarly Detection of CancerFemaleGene Expression ProfilingHepatitis B, Chronic/*complicationsHumansLiver Neoplasms/blood/*diagnosisMaleMicroRNAs/*bloodMiddle AgedROC Curve2011Dec 201527-7755 (Electronic) 0732-183X (Linking)22105822https://www.ncbi.nlm.nih.gov/pubmed/2210582210.1200/JCO.2011.38.2697pDZhou201144444417Zhou, J.Yu, L.Gao, X.Hu, J.Wang, J.Dai, Z.Wang, J. F.Zhang, Z.Lu, S.Huang, X.Wang, Z.Qiu, S.Wang, X.Yang, G.Sun, H.Tang, Z.Wu, Y.Zhu, H.Fan, J.Liver Cancer Institute, Zhongshan Hospital, Fudan University, People's Republic of China.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinomaJ Clin OncolJ Clin Oncol4781-829362011/11/23AdultCarcinoma, Hepatocellular/blood/*diagnosisEarly Detection of CancerFemaleGene Expression ProfilingHepatitis B, Chronic/*complicationsHumansLiver Neoplasms/blood/*diagnosisMaleMicroRNAs/*bloodMiddle AgedROC Curve2011Dec 201527-7755 (Electronic) 0732-183X (Linking)22105822https://www.ncbi.nlm.nih.gov/pubmed/2210582210.1200/JCO.2011.38.2697puDyK  _ENREF_42uDyK  _ENREF_43DNara201235353517Nara, S.Shimada, K.Sakamoto, Y.Esaki, M.Kishi, Y.Kosuge, T.Ojima, H.Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan. sanara@ncc.go.jpPrognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomiesSurgerySurgerySurgerySurgerySurgerySurgery526-361514AdultAgedAged, 80 and overCarcinoma, Hepatocellular/complications/diagnosis/*surgeryDisease-Free SurvivalFemaleHumansLiver/pathologyLiver Cirrhosis/complicationsLiver Neoplasms/complications/diagnosis/*surgeryMaleMiddle Aged*Neoplasm Recurrence, LocalPrognosisYoung Adult2012Apr1532-7361 (Electronic) 0039-6060 (Linking)22244181http://www.ncbi.nlm.nih.gov/pubmed/2224418110.1016/j.surg.2011.12.002@DNara201235353517Nara, S.Shimada, K.Sakamoto, Y.Esaki, M.Kishi, Y.Kosuge, T.Ojima, H.Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan. sanara@ncc.go.jpPrognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomiesSurgerySurgerySurgerySurgerySurgerySurgery526-361514AdultAgedAged, 80 and overCarcinoma, Hepatocellular/complications/diagnosis/*surgeryDisease-Free SurvivalFemaleHumansLiver/pathologyLiver Cirrhosis/complicationsLiver Neoplasms/complications/diagnosis/*surgeryMaleMiddle Aged*Neoplasm Recurrence, LocalPrognosisYoung Adult2012Apr1532-7361 (Electronic) 0039-6060 (Linking)22244181http://www.ncbi.nlm.nih.gov/pubmed/2224418110.1016/j.surg.2011.12.002@uDyK  _ENREF_44ZnDd X  s 4A? VGr 1Rm1Cz\Tm+xFm1Cz\TJFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222S-" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( *)`<+*OIcVQ,PkFEyT-A|?-Bz,ը^~7y[8W=k4ʣ,s^T ?iOrP\#2%o^K As漞i>,hL-8!F"O%ҔuhN( Eyf2b|Z>nZ6# $OX柸zZ)2 -QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQUoM6ٮ/.#%,@)`q2D;`WN}U͗tuKpf*DQUΫƓ2;ͬdkOz־)zu,wCncB fj"{3{RnXڜ^ϓk3ځ\rGLbϋ^/Olk"m /xDKbn ρ5OV'ӬS]3>MyykmF nc'.YߍZkDZcfLhqc_DZm{KxZ:ʒ-6Rk/a_k)s@ҼIgxv?̅8Xjϊ|97,m lϥHGg4jw<4x CJVd"Iխu.P}NJ|8.R0:~nwU/{Cn}HzD>f?qI^I6ЮkA8V,"WOCգW- l5#Q.3p0d0ߥU{^ wLr60 0 )k̹P.bCZi>+k:doKG;+.9df,끶%=Y9ڤ/;kxH-g G?(b?+ֵ]:qvAo ҿ`+_ xumI6mkh i}}!:Տ5izIZ uc9ڹ1L  b+G6Sῴhq!lvH"}VF=f./0>6[]m.QYv>~Q@Q@s87Ifc'+gZw40$tPC}?TѴQf4huo9?#7l&&}.xұ/}i7RҬ QmO?vno_Zh&PHEV@o;]F$S!굟hZ牬5 ]fK{(ZĕQ@õa:׾!R-s'ַ( F[S6@b9;T#џ^'ӣ1pµ~°]x@xz[#3|֖a :B9cM^9m7zs^j\t<<~Q92ExCүwWF_s]u[m!ɍtg2%l"l$L9-;>,7Mvwk=:C) 'TjHM%4-ZkYdb[85 Z5nz>ڔ>bHJ[ 6Tmt{ZB8M4H»zLsCs|5JO xO Cu5XšI?7<+U_',@%3 } 'u:k[;}康U> N7|-Oۼe|>[~]:lYF#PaS2i{bB}ZͳĖW҇ }j2=H9%ڄM'xp~Wx$! .;z]/ Ex?xٖLw="Y.TxVrņӕƃSEYoXҚ>WsvQ}*+KxQel,Ve3\zg>"Rst4lU,{Vυg\\rfT'[)=B3DZf3``1\ ? 0[kMf]T)r5N-u=:if[K}XGH#ҫ7~0w'֬I,cx ["5k,25?<½xWx;V7O=2 ff…nzWOxWASp FݻI92AI҇ʷy+5{b𖋶SjW'ͻ,}s7yjxHNyʹO,#ק-Q@-u+9-/ IaA|6ω|)i.lO,ƠIRԳtP_M[:@InC>=ToB3:+)fǪ¤F?Zՠ((l@U$>)L[ې3?A[~#.5 O68e~mؼO]h3D\%Q-"޵EQEb(3@4&._|5Ebj: ޾GUNO^mP3Sb4P{$6a4' gr>-47$V)Znii~$1~6jc*܌湭sW]/37%l8+<kQ;Mw)F;ղtOmPWk&us;[7RVuxY-w7>݃^Y,lqvMvϨ𧍯; ИTo23he wP0((((((( ͼ~-ucfܫ٣7ʑǩ#b!w>*'U}uuSOɂGx'W hZ qzA|SY[(O!dvRO b[,one#hR6v6߽>u,e]nh31CdI1/% Y-^xǚ9jikMƝrΰλX֥Mӡq&㓁h `?q8-i?p:M\ʿ#S\8#UkC,{8S@xװhM[Q @PWŮJirUx^r[x˿W|8OY ߘ?WÖ=gݜ< 5fsjv7Rv@;5{&kg]Rqڝ9tKH]$ޡTjz<|1 DeLj7qo>@i6z&oXıPW4_Zme14ψ>Y &:z( 2*d5>hmqxW‘jpu( Ѹh#gK(n/3 to?=*H~-ЫZ+ʿ!B U_*H~-ЫJy_$?UZWOWCk]?ïj)V좵:wy޿J+M<;F  N [ tf@O@Q4)(P5%b(( r; J)- ( ( ( ( ( (f @&%i-BPW`+}_x7>:"P8Vf^-1F|G;^Jglb v) ('|O#vz>'eϵt6Z tКTee9W#Ķn]iu%{M:`3]vvD-uo_5Q,27}ǵ{"H$hyOԔ "&`҅ qɬ_xZ Q̏ ׻[(bRxW;+-|QiSxbsYz<>T2H0DzqTuO AokBzUw5#g*}}@##84Zwc58+3XR?J>xbOq9 U$TХdwh|FxW':}Xj6xt84k"6B8N"}x6{ Z7m`ڒ]HLe1#'v67*H@/w|a_?wub_?t?HHmV/?O??[TQECws2Gch֙msy㛧*# \TL#v<@d'}}9_$.zX4_h+~/V~7o~V*Y#?*Z(<4WNtt9{ʋ=Dep48X/i,n+`4g,M-N-E (O× ጔCMPST<7m{Qv(((K𷊭tso6'ҽ2ŽTeiL ʙB#r s+A rY3}MZ9m~g^GNKf'tz扦EնNx%zjچioocQUORk<= >QldH@Ǹ?]x_f<-ZdžG}kDSUu:QxJ)0;Sq 먢QEQEQEQE|Q&ؒu-IBFz!v 1=R|A{y:fMfgy ? [ڄjDwglMV!nGдk[WePԝ6^H}?XoG|)`(ָ俭y텭χ|]=O{t2^᫝VE]jmođ:}ϯjl1y #Eƿ2KoK_=zFK}3n縮7I=B=ٱmH=rtT'WCEK@W|Jƛ >3..5^LJz Ojw_R da@;fxO/-XHo\t57|o -/%竹ϥu4^w; cDyr9%'ʹ x8a/HT+/ !S^?4o5+`\}ɓC o++AxV^2){m\\.ĺUXzW|Sn\}@a/g& ߶I #ǵs^:jz|!j[y&a3nkR+;GPZE 72=}/m&{coo羺/Tgkcᖮ`:?ȟפʶ?'+ξ4 qO<+My_~&a \I珥ys-+߆bks+,yN}svQ|?knNoOk1hAV^3"ޣ;P^U Nn_X>?su}W f"I#ϏB3p1X|DgǎnVʪCZKK)oRS* Я*<~?t_GiZV_.9NsT(H8̎J#R@.[wwx-klΠaEQHK\exl_lo\D5|=wL͊ZJ l@ nkVw鵉Qδ钆h! C@5# D ±3}Ԣ]Ÿr{늞}>4<)⩥呢9gQ|99M),uX#7,ay[g8dnzWY^e5oN-5d p:Z^7PkV,wZ ;( ( ( (8/< urm I=k:`V w I ŮhhI3/sĖ,KB'`^zxo>]5֒e|2͙-O2@=GzOSxM[6dS:ޛs0Xw=qz].<rz7zҀ:: ڍ Cz\o ݴx ɬ_ѫ@=+'CмA&#igY+QEQEG<[BM"1$i$lXd|>H_SMN损l2[/oG&瑶>C\}\ݞvzP|-}ﭤt@vktշ'Y-|3(\̪?. qG 4A>)Gu }:,s?~xCP=C+9tFsAӡi~eۜd  jOQE<C19D_?GOP^vƏ^vƯ$ED_?@?{w?{wE<y$EP kwxRHe $~j8w~D_?NTTU QEW'|ӿ'򮲹=3K`?{eQ@Q@yW(>k&A/~@EPY0 9$7:Nq<}7q"+\ŝjHk RkDWSEַ'DaHX8y4訢Z Ki h_oY ( (0WX>&6Ϧo:WX>evڨTϽkW?->[S8qހ8xo]_}{vF?k_Ǿ MrHqC&m:?-w9<0{5{HfqLG)Lh-upCʼ߆oȒ#%Nk趺t =q@*(Q@s64֥#~.Wz INc!vo bug|+mCz{zf~@ tNok:/TeHev¤{&%^Y=ЏY¾:wA9bl%6eIx#Ne7o& kPkH5ڊ}:E__7n蓻)^ z,ZM3آ#!O`ucOFxMKI~B獻+rQ@Q@-*X6w XpirD@,AگQ@ +5 24Oi}ʛzk=|:mmr&7nEe-\rLkIH\BVX|Ok a y'ע~*x uMoU$xt @FiVs}s(g89/ xP jtƑ HQT` uei^%ѵZ-;PE*+V ( (#@nu3Bg Z+-mn%X¹vWARii q}k~|A,`sWL_?ʽRgTQEU4MN/`I2 O I)jU>) $;ZYa="̅ ! 20e=9")4..9`ӶHjݠ޵JhpW8Պ(dHefn_.K|0* \/4 B_ [Ƕ+p Ru|K*<=dhvzW?xi7,2yVqW;澀*O"v1Cƛ:%=,n rCRE EHd zE^ol`B pG (=( K N| ȽI=}lFnnc+ھ4fѢ ]l|UT)hՋ:Y[d#?((򿉟P| _WWL_?ʀ=R(((((((JdN#p## N]=ԦWy'>;ZoKe(DOݟƀ8Y"\Z̧Ԋf>(/{]oQu+S[fdpH^ׁa=5' D_ '@IqN֬ORvi_Ei7+ATy|PJB>U>'G88H-8uNL}~sVl(xXӘZkga%j>C@}e1,$ RAլnZ<0ɞ]=':߆$Dh[@. 0d7c\߅t}K>k;϶]E:ĜsTEܷ][\4N`vQE њ%zχ9l}7JԛmtXIuX>eZs|7[if WwjڠaEPEPEPxOK?^^U?..hzW߉fy& ɲૹ&"*kZue?]eQEJRp:+"t^?HHmV/?O??[TW+/I^+oZ[fTEi>>n𦨖0+2ȯ|g/,>&[DHȿ^ xZ]ōn.Vi|Ό>\<7mm4L{@Q@xO?tWWCGOvQE_4OL>O@T5}OlSKf qW=>.6 G?]5g[-VD@j+&A/~^^W3J*J( ( ( ( ( NuzP{\)!Ҁ9_,6eY I0Z[ڗ0Bڸ#2LTĚOGK;hWm#P2}k.tj25ԛ!%PQE2hc&Xц 5[/𝶣-ґCr}vTPpAK1$qU((G}3c_js*YEs^;9,Hʸa]-yWxu^תI~/hȡ zW? 3@d3Юҭ+1>1h UZ׉FX],q<[>yxS3)<+)־YOW0!vv?*2?]erzG*((OWzYU5=2W屼MJ0PM=SOO*0AA}kg[M_Us1<j!ih!ikUxcy\G* +hڿZ?Z_U^W? m7Əm7ƼWW?4ª=[M_s1{Ve9w* +kw@M:7A1˗mQ@rzg;*+/7>77%EQ^G S+Tz@CQI,d_kp(ի&A/~I oXX`jֵox^s}B+< {Q@Q@Q@Q@Q@Q@Q@V,|˘8#`f?<7xJ};S- ?r2#+{aN8"M '[(31MhI{xHEk}[Ŷ7,[ǯKjľ'V+M"JSD/ďGy ^G ?<-}8JCDWsys˜l?A^yro ly}+ |qv> 6 s? 0O.I7rh;YsohWR kum2aXCk|!icu'\FDy]MuxӮB%8wqNz1ѴKU)뒘_^TKHaEP//ny ʹVi ]A((F!T@5{'_KBH }q|]yFTY.O$xSiFqǹ G[ ʨ cEyWxu^ת%uu95I1#@; ֜gW51潚<=gLM?KX ^ëR{֭P__5OR>?]eQEQEQEQEQEQEQEQPAgOs*f45As{kfn#U {vO#A@xkԤH=F~uZ743H J =z@-q{'eҴ|/ ly׍[ 4O +xm$1$j:*((<ܭɛP^V[ݷ: @-R cQEU gQҮ/|f"8,Uc4= 7h4'o@hϴ=LkOet'ϩ{Yg#B9cP$\aW|S'Q뷨1^薚dbu=X'ށTQE (9mcZhb)rsv~5ӣe`yCXvɭuX9-l|G9@]gDL,߾(Vn"92`~U=GRm ]dd2NePiͫp[x= wX ,i]-$R\Z)`oսIa5k-:;\HlXc#~U>%onuۯ~#]z^:WӦNEt3.p΄ o@ᾲ'=  ,~Wԭ/ֲ_'N'"c`S@u<햷xM;B[mMzJQs}kȾK-6|xّWnx^#>&x8(a\l5յԣdwq] #P,'Ө ( =}et OZhx0Sltx P|C%޿CcpvAGXmI58e>EQEPN)7 #>QEQE tRE`k^i[KIz5?z%zl6:.k7gw}7s$0F2W߆'T_2+&NJHLo ŗI_%6!eԐ3zA)cωtgC wx{7͡:UҀSt5OĚn褊hʺmwpb|wkSԊ2MXbS#`g8v߉-+IXŖܧ'U+ t]EOml)Du>^X:ׄtmlV.#?rZI'DTՁ+Tr}/ ц+R#֕e[G=2H28 RȥOs@_Os@_{(?Z#T][_ܫԁ@^>i&pAOS^*niC,6[_,->[kuv#9@ EPMWA\'+_U>9_BJ(((k/մ+úE}Z)X`W|GmWÓGjGi&\zU h6ɩ3G_ڗW$|WkÃ~ uIyӱnyK]/5i4F^(Kxo$YboZZ gMҤfHHA96Oɱ6*qQZ-%wj X!%Oʍkp^8oŸ|=}J[;glnqbOʁQHQGEQRW9V1 S@8 j?ٶzè( sP3f(qh[ݟ*$'ך 5-Mn2%s"m:=! m(H;n=ա+XdY#ae9U oBӼCIc$8Ð}G,)?w; }޲[e$c.Vh\v<#;^׬<7K3,P3V>vށ)-jw *ɽ?&9|ԐxJPr3K@VچnJ]xwQG{M#q~? Уk rG7 |!IF2Ǡ6G_PEWkϊ<&Xds"ˎ@L#4󿀾5[gBD{A7E|FojwoKmanurOOJ+]i6r˜hM_CioX( g*_^Mp?䜯~PQEQEQEQE`zQEQEQE/ڼ4[q㿭MURylQ̄$giY:v]J̌qpǗ۵lEaEj4tp-LPQ@Xwz"=)6҆Hu/WԯvIoyx^~ƳKFWB-9,_Og:;vzF=zzW"^-E9\o3yjl[Ynr}2 6)e/$}ڤ/yRQwҼ5ۡzYh|V6$ *( llᴶG (vQE ( ke*FAu> aχ'ݶ~hOB{W~ F|=M3[en\6gm8 ,_EOKko1@:j MkFL.> .CSٱҼsK_h6:];CgNB>a f"iZ孛^!$n0z >+dZ[)kCzF}+@n.721\+kxϑ[?Hb xBƞ,,:|f^J=}HH"XP p:REbIh@ 2Ss%ˏWD]4dgb9$<-I/cbw\iQּz~"-Wg?2=M}'?h2ե7V?ZxQi;\qoZoKHm]k^[2[)0:`v5ZG35DM1LmnZb#}k2AހaYt"xu-deui_j:s\kke.^o [_H}Dl+¯K=_Iw#%гۥ[ b=k>92tյ O"AKn#@6!IdtX˺^ݔ8{UgO:LvvمclYFA֮h׼Gọ3v p`u'֬xkNE/k"k ǰHƿ$#HK![j~3m7(RlW[Y[Y!KX#IDj'֧RCeRx֦,Kw[NSԎ zM浜Ms+<Q'C(I Z(ʿE?@~!Dqx-bD#I2=t_C?G ?O~W@U?(ߡ$z7oͻ'J>@6OS20*bWa/ 7'%WEL2ְ6FcS_>iKMUn]狮Rh~zt-_);Jh4ݰ *"޵tor^ǪRTwz +DtKaomkօ;2(5$TEUQ>)QEQEQE[9/?>ӯa#9*~$0xB-IT>m;P#μS u{Vi Btrp)fxƚ-t6Fmjg>Ũ-8Z-=J=Dh4p=nm ?jK5[ޙgg\jGP'mއҫY7;jj?(6:Dڶutw|mgfGPV;Xu#Z|+yZát6Rqc yR;Op~0l.?5`0gT7S kYg=#Fs מGC}uP_Mzʹ)"?B1@1xOIZF{ɟQ^ix/^oƶiq6 x k9'߉z.4BNj[ZѼI=<'Rb c}Gv?'WNԼ*m{HKMJ6HCVbxšWֲÌ|W‹OLaQz7{%W [wR\d@izaO*sOԴ]VkD.0-AGQ̃Ö_+h,cb5 Q@U{m:K#gsX<; #xg,ж]v=@=~ ( ( (\Isxdb@y *zn+|z=i?=c7z5ʋ`k(# ޸[{wrLTkdx{@OY5wW*[!q¶(TeבXOy&Z8c.y$^sS֭t[RmKPBzE3m"Zo*d9%HMr5lO@^^i;~R>fA-Ie%m$.oxoek奇lg5uLzi{H[WQ1]Cx)wOf{rQ*\;M>/R!u,MO{-t;@7 ԼKėtP AYN;V~;5WvyF>;[^$U~rVG"B0T$+~"WHVhb~%yh&p.n✞G^v9k[.5qH4TQ(9x'Axl#IHo񮊊(QEQEQEQEQEQE|=xX-N<Ƶ$kx}ߝȧLgCC .p|X%Ǡ_JxZs>~77j`7K!#&訅&%O8 =q@EW 34k=2;tI7ʒgz]x#Ι{,奂+S]Gb+((J}GV,,?X`.Yj܋;)YH\VFAp7vD1I;Gz^%3`W`;Dy8W5ķzm(9+RxS=5J]#ޛ'&XKRI4jk +A'',H'^oymt,!Vkigo-)]\P_O͋Wl|tΪ=\gzv*PBj.sdݶH{uԅq\ݞ95s Tq~1a@7]@k0@ =[ҁO/ˮR:v-s3_#g,UׁE"uV#ڻ^OIkϛrk%m.~8g OUM|y&)cQozqP[[71$L0 7e*9OrY<Kmvͧr@Zʓ]?nZź+Zw ; /4.ۘͣ]W,1OĈ޼G7doi|w20zĺ|w}ja%aT]uoFW@Q7Wp>(sug0qZ_C[j3[X[FɱkkQa|]7lwb  mtZ#k[Ks]^YEƥ}($⸆:q6Py:ѼU}o) ud]ӧZ]kO<æi&D𗎴hsj6|yN9ȹ[aO@իy/ O#Qjv^›SC@O.-Yae]NA/M}1ߌ<3=gib9=A SD]^B%|Dͅ}@ҊHԭ @gwԶZkK<42\BZ!*{pmlgTbB}p++Zxlm̌')YDHA,3_eC#MqNu:0)i#jW=o]ۘ|.tޤɨjri;}!4P[I7qځ\1s-/dςXK \)z_xzHxmRAwiGx-!_@X  #j[beO|CFubUfF dMm;XP&Ӵkvuo?fj^% jaI/w;OZSi?td $t7QW4Y7UW:p5O~VX?GQb*D]sm _i [o{{ob>%d^wOG Ļx yT.G n|s0-1Fl/+DMԑRI_zx,LK^ivxQUM'+qpgEʚkx_glN1F|2ӿUq"0Ѷ=}?|8ңI-(  ,}O4@}mh7D{]>€0^23/ƷF=@z-nj5OIe'qqm W=x &pMd\{+OaM#|᛻w]cu@ΝyWٵ}:{j&֊@Nlx4Y\h:2rD^ 7zi_Er)Dnm%dآv y[|ju :U{[x r4 v[=~GHbί|R]!7̀x>C=eEU>hGɤi/"9R0;a}A1)J#!n Z9h z5<`4O i0ϩkGJo<Vn)3Zp͡BMjh;bhb1g=~,/.4Oji%K_’LkNi?X_;_ j}(mR_k]7FI>v:T]KH{Z#k._x|,LLJ|N7z 갍(_0έ}|7R~OcG09;KQ2>+{L]/=*9?s_C.}|a㊌ho .λ8#YZH %M.<>ԂBG0Z+gKO=2uX;>qE" hA q@-bLQZ(1KEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEFI፾ P}Scheuer199140404017Scheuer, P. J.Department of Histopathology, Royal Free Hospital and School of Medicine, London, United Kingdom.Classification of chronic viral hepatitis: a need for reassessmentJ HepatolJournal of hepatology372-4133BiopsyChronic DiseaseHepatitis C/*classification/diagnosis/pathologyHepatitis, Viral, Human/*classification/pathologyHumansLiver/pathology1991Nov0168-8278 (Print) 0168-8278 (Linking)1808228http://www.ncbi.nlm.nih.gov/pubmed/1808228200122722722717病毒性肝炎防治方案中华传染病杂志中华传染病杂志56-62191病毒性肝炎原发性肝细胞癌乙类传染病寄生虫病学乙型健康危害肝炎患者丁型传播途径丙型医学会可发展肝硬化发病率传染性演变修订西安戊型人民20011000-6680http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhcrbzz20010102710.3760/j.issn:1000-6680.2001.01.027北京万方数据股份有限公司chiLasser201516161617Lasser, C.University of Gothenburg, Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy , Box 424, 405 30, Gothenburg , Sweden +46 031 786 67 11 ; +46 31 786 67 30 ; cecilia.lasser@gu.se.Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicleExpert Opin Biol TherExpert Opin Biol Ther103-171512014/11/05Biomarkers/metabolismCancer Vaccines/therapeutic useDrug Delivery Systems/*methodsExosomes/*physiology/transplantation*Gene Transfer TechniquesHumansNeoplasms/*diagnosis/*therapyProteins/metabolism*RNA Interference/physiologybiomarkerdiagnosisdrug deliveryexosomesextracellular vesiclesgene therapysmall interfering RNAtherapyvaccine2015Jan1744-7682 (Electronic) 1471-2598 (Linking)25363342https://www.ncbi.nlm.nih.gov/pubmed/25363342https://www.tandfonline.com/doi/pdf/10.1517/14712598.2015.977250?needAccess=true10.1517/14712598.2015.977250@DScheuer199140404017Scheuer, P. J.Department of Histopathology, Royal Free Hospital and School of Medicine, London, United Kingdom.Classification of chronic viral hepatitis: a need for reassessmentJ HepatolJournal of hepatology372-4133BiopsyChronic DiseaseHepatitis C/*classification/diagnosis/pathologyHepatitis, Viral, Human/*classification/pathologyHumansLiver/pathology1991Nov0168-8278 (Print) 0168-8278 (Linking)1808228http://www.ncbi.nlm.nih.gov/pubmed/1808228200122722722717病毒性肝炎防治方案中华传染病杂志中华传染病杂志56-62191病毒性肝炎原发性肝细胞癌乙类传染病寄生虫病学乙型健康危害肝炎患者丁型传播途径丙型医学会可发展肝硬化发病率传染性演变修订西安戊型人民20011000-6680http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhcrbzz20010102710.3760/j.issn:1000-6680.2001.01.027北京万方数据股份有限公司chiLasser201516161617Lasser, C.University of Gothenburg, Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy , Box 424, 405 30, Gothenburg , Sweden +46 031 786 67 11 ; +46 31 786 67 30 ; cecilia.lasser@gu.se.Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicleExpert Opin Biol TherExpert Opin Biol Ther103-171512014/11/05Biomarkers/metabolismCancer Vaccines/therapeutic useDrug Delivery Systems/*methodsExosomes/*physiology/transplantation*Gene Transfer TechniquesHumansNeoplasms/*diagnosis/*therapyProteins/metabolism*RNA Interference/physiologybiomarkerdiagnosisdrug deliveryexosomesextracellular vesiclesgene therapysmall interfering RNAtherapyvaccine2015Jan1744-7682 (Electronic) 1471-2598 (Linking)25363342https://www.ncbi.nlm.nih.gov/pubmed/25363342https://www.tandfonline.com/doi/pdf/10.1517/14712598.2015.977250?needAccess=true10.1517/14712598.2015.977250@uDyK  _ENREF_46uDyK  _ENREF_492 D中国抗癌协会肝癌专业委员会201522082208220817中国抗癌协会肝癌专业委员会中华医学会肝病学分会肝癌学组中国抗癌协会病理专业委员会中华医学会病理学分会消化病学组中华医学会外科学分会肝脏外科学组中国抗癌协会临床肿瘤学协作专业委员会全国肝胆肿瘤及移植病理协作组Chinese Societies of Liver, CancerChinese, Anti-CaLiver Cancer Study, GroupChinese Society of, HepatChinese Societies of, PathologyChinese, Anti-CancerDigestive Disease, GroupChinese Society of, PatholoLiver Surgery, GroupChinese Society of, SurgeryChinese Societies of Clinical, OncologyChinese, AnChinese Pathological Group of Hepatobiliary, Tumor原发性肝癌规范化病理诊断指南(2015年版)中华肝胆外科杂志中华肝胆外科杂志145-151213肝癌病理学诊断指南20151007-8118http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk20150300110.3760/cma.j.issn.1007-8118.2015.03.001北京万方数据股份有限公司chi2 D中国抗癌协会肝癌专业委员会201522082208220817中国抗癌协会肝癌专业委员会中华医学会肝病学分会肝癌学组中国抗癌协会病理专业委员会中华医学会病理学分会消化病学组中华医学会外科学分会肝脏外科学组中国抗癌协会临床肿瘤学协作专业委员会全国肝胆肿瘤及移植病理协作组Chinese Societies of Liver, CancerChinese, Anti-CaLiver Cancer Study, GroupChinese Society of, HepatChinese Societies of, PathologyChinese, Anti-CancerDigestive Disease, GroupChinese Society of, PatholoLiver Surgery, GroupChinese Society of, SurgeryChinese Societies of Clinical, OncologyChinese, AnChinese Pathological Group of Hepatobiliary, Tumor原发性肝癌规范化病理诊断指南(2015年版)中华肝胆外科杂志中华肝胆外科杂志145-151213肝癌病理学诊断指南20151007-8118http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk20150300110.3760/cma.j.issn.1007-8118.2015.03.001北京万方数据股份有限公司chiDEguchi201024242417Eguchi, S.Takatsuki, M.Hidaka, M.Soyama, A.Tomonaga, T.Muraoka, I.Kanematsu, T.Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. sueguchi@nagasaki-u.ac.jpPredictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resectionWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgery1034-8345AdultAgedAged, 80 and overBiomarkers/bloodBiomarkers, Tumor/bloodCarcinoma, Hepatocellular/blood/*pathology/surgeryFemaleHepatectomyHumansLiver Neoplasms/blood/*pathology/surgeryMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, Local/*bloodPortal Vein/*pathologyPredictive Value of TestsPrognosisProtein Precursors/bloodProthrombinRetrospective StudiesVascular Neoplasms/blood/*pathologyYoung Adultalpha-Fetoproteins/analysis2010May1432-2323 (Electronic) 0364-2313 (Linking)20127241http://www.ncbi.nlm.nih.gov/pubmed/2012724110.1007/s00268-010-0424-5Fujita201127272717Fujita, N.Aishima, S.Iguchi, T.Mano, Y.Taketomi, A.Shirabe, K.Honda, H.Tsuneyoshi, M.Oda, Y.Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinomaHum PatholHuman pathologyHum PatholHuman pathologyHum PatholHuman pathology1531-84210AgedAnalysis of VarianceCarcinoma, Hepatocellular/diagnosis/*pathologyDisease-Free SurvivalFemaleHumansLiver Neoplasms/diagnosis/*pathologyMaleNeoplasm InvasivenessPortal Vein/*pathologyPrognosisSurvival Rate2011Oct1532-8392 (Electronic) 0046-8177 (Linking)21496875http://www.ncbi.nlm.nih.gov/pubmed/2149687510.1016/j.humpath.2010.12.016Iguchi201530303017Iguchi, T.Shirabe, K.Aishima, S.Wang, H.Fujita, N.Ninomiya, M.Yamashita, Y.Ikegami, T.Uchiyama, H.Yoshizumi, T.Oda, Y.Maehara, Y.1 Department of Surgery and Science, Kyushu University, Fukuoka, Japan. 2 Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan. 3 Department of Molecular Imaging and Diagnosis, Kyushu University, Fukuoka, Japan.New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver TransplantationTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation1236-42996AdultAgedBiomarkers/metabolismCarcinoma, Hepatocellular/blood supply/pathology/*surgeryDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLiver Neoplasms/blood supply/pathology/*surgery*Liver TransplantationLiving DonorsLogistic ModelsMaleMicrovessels/pathologyMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm Recurrence, Local/blood supply/pathologyPrognosisProtein Precursors/metabolismProthrombin/metabolismRetrospective Studiesalpha-Fetoproteins/metabolism2015Jun1534-6080 (Electronic) 0041-1337 (Linking)25427164http://www.ncbi.nlm.nih.gov/pubmed/2542716410.1097/TP.0000000000000489DEguchi201024242417Eguchi, S.Takatsuki, M.Hidaka, M.Soyama, A.Tomonaga, T.Muraoka, I.Kanematsu, T.Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. sueguchi@nagasaki-u.ac.jpPredictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resectionWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgery1034-8345AdultAgedAged, 80 and overBiomarkers/bloodBiomarkers, Tumor/bloodCarcinoma, Hepatocellular/blood/*pathology/surgeryFemaleHepatectomyHumansLiver Neoplasms/blood/*pathology/surgeryMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, Local/*bloodPortal Vein/*pathologyPredictive Value of TestsPrognosisProtein Precursors/bloodProthrombinRetrospective StudiesVascular Neoplasms/blood/*pathologyYoung Adultalpha-Fetoproteins/analysis2010May1432-2323 (Electronic) 0364-2313 (Linking)20127241http://www.ncbi.nlm.nih.gov/pubmed/2012724110.1007/s00268-010-0424-5Fujita201127272717Fujita, N.Aishima, S.Iguchi, T.Mano, Y.Taketomi, A.Shirabe, K.Honda, H.Tsuneyoshi, M.Oda, Y.Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinomaHum PatholHuman pathologyHum PatholHuman pathologyHum PatholHuman pathology1531-84210AgedAnalysis of VarianceCarcinoma, Hepatocellular/diagnosis/*pathologyDisease-Free SurvivalFemaleHumansLiver Neoplasms/diagnosis/*pathologyMaleNeoplasm InvasivenessPortal Vein/*pathologyPrognosisSurvival Rate2011Oct1532-8392 (Electronic) 0046-8177 (Linking)21496875http://www.ncbi.nlm.nih.gov/pubmed/2149687510.1016/j.humpath.2010.12.016Iguchi201530303017Iguchi, T.Shirabe, K.Aishima, S.Wang, H.Fujita, N.Ninomiya, M.Yamashita, Y.Ikegami, T.Uchiyama, H.Yoshizumi, T.Oda, Y.Maehara, Y.1 Department of Surgery and Science, Kyushu University, Fukuoka, Japan. 2 Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan. 3 Department of Molecular Imaging and Diagnosis, Kyushu University, Fukuoka, Japan.New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver TransplantationTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation1236-42996AdultAgedBiomarkers/metabolismCarcinoma, Hepatocellular/blood supply/pathology/*surgeryDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLiver Neoplasms/blood supply/pathology/*surgery*Liver TransplantationLiving DonorsLogistic ModelsMaleMicrovessels/pathologyMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm Recurrence, Local/blood supply/pathologyPrognosisProtein Precursors/metabolismProthrombin/metabolismRetrospective Studiesalpha-Fetoproteins/metabolism2015Jun1534-6080 (Electronic) 0041-1337 (Linking)25427164http://www.ncbi.nlm.nih.gov/pubmed/2542716410.1097/TP.0000000000000489uDyK  _ENREF_51 DShi201941414117Shi, L.Zhang, S. J.Chen, J.Lu, S. X.Fan, X. J.Tong, J. H.Chow, C.Tin, E. K.Chan, S. L.Chong, C. C.Lai, P. B.To, K. F.Wong, N.Chan, A. W.Department of Pathology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Department of Pathology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Department of Pathology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. awh_chan@cuhk.edu.hk.A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinomaMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019/06/252019Jun 230893-39523123112610.1038/s41379-019-0307-8NLMengp DShi201941414117Shi, L.Zhang, S. J.Chen, J.Lu, S. X.Fan, X. J.Tong, J. H.Chow, C.Tin, E. K.Chan, S. L.Chong, C. C.Lai, P. B.To, K. F.Wong, N.Chan, A. W.Department of Pathology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Department of Pathology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Department of Pathology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. awh_chan@cuhk.edu.hk.A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinomaMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMod PatholModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019/06/252019Jun 230893-39523123112610.1038/s41379-019-0307-8NLMengpuDyK  _ENREF_54rDXie201921492149214917Xie, D. Y.Fan, H. K.Ren, Z. G.Fan, J.Gao, Q.Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China. Institute of Biomedical Sciences, Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical ImplicationsClin Transl GastroenterolClin Transl Gastroenterole000061022019/03/052019Feb2155-384X (Electronic) 2155-384X (Linking)30829920https://www.ncbi.nlm.nih.gov/pubmed/30829920PMC640781710.14309/ctg.0000000000000006Wen201821502150215017Wen, T.Jin, C.Facciorusso, A.Donadon, M.Han, H. S.Mao, Y.Dai, C.Cheng, S.Zhang, B.Peng, B.Du, S.Jia, C.Xu, F.Shi, J.Sun, J.Zhu, P.Nara, S.Millis, J. M.M. D. T. of West China Hospital*Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, China. Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Department of Hepatobiliary & General Surgery, Humanitas University, Humanitas Clinical and Research Center, Milan, Italy. Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea. Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. Department of Hepatobiliary and Splenic Surgery, Shengjing Hospital, China Medical University, Shenyang 110000, China. Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China. Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China. Department of Liver Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan. Department of Surgery, University of Chicago, Chicago, IL, USA.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensusHepatobiliary Surg NutrHepatobiliary Surg Nutr353-371752018/12/01Recurrent hepatocellular carcinoma (RHCC)consensusmultidisciplinary management2018Oct2304-3881 (Print) 2304-3881 (Linking)30498711https://www.ncbi.nlm.nih.gov/pubmed/30498711PMC623083810.21037/hbsn.2018.08.01uDyK  _ENREF_55uDyK  _ENREF_56RDWang201321512151215117Wang, B.Xia, C. Y.Lau, W. Y.Lu, X. Y.Dong, H.Yu, W. L.Jin, G. Z.Cong, W. M.Wu, M. C.Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgeryJ Am Coll SurgJ Am Coll Surg1054-6221762013/11/20AdultCarcinoma, Hepatocellular/*genetics/mortality/pathology/surgeryClone CellsFemaleGenetic Markers*HepatectomyHumansLiver Neoplasms/*genetics/mortality/pathology/surgery*Loss of HeterozygosityMale*Microsatellite RepeatsMiddle AgedNeoplasm Recurrence, Local/*genetics/mortality/pathology/surgeryPolymorphism, Single-Stranded ConformationalPrecision Medicine/*methodsRetrospective StudiesSurvival AnalysisTreatment OutcomeHccImLohMoPcrRhcchepatocellular carcinomaintrahepatic metastasisloss of heterozygositymulticentric occurrencepolymerase chain reactionrecurrent hepatocellular carcinoma2013Dec1879-1190 (Electronic) 1072-7515 (Linking)24246620https://www.ncbi.nlm.nih.gov/pubmed/2424662010.1016/j.jamcollsurg.2013.07.402Cong201521522152215217Cong, W. M.Wu, M. C.Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address: wmcong@smmu.edu.cn. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.New insights into molecular diagnostic pathology of primary liver cancer: Advances and challengesCancer LettCancer Lett14-1936812015/08/16AnimalsAntineoplastic Agents/therapeutic useBiomarkers, Tumor/*geneticsCarcinoma, Hepatocellular/drug therapy/*genetics/*pathologyCholangiocarcinoma/drug therapy/*genetics/*pathologyGenetic Predisposition to DiseaseHumansLiver Neoplasms/drug therapy/*genetics/*pathology*Molecular Diagnostic TechniquesMolecular Targeted TherapyPhenotypePrecision MedicinePredictive Value of TestsDiagnosisLiver cancerMolecular pathologyTreatment model2015Nov 11872-7980 (Electronic) 0304-3835 (Linking)26276723https://www.ncbi.nlm.nih.gov/pubmed/2627672310.1016/j.canlet.2015.07.043RDWang201321512151215117Wang, B.Xia, C. Y.Lau, W. Y.Lu, X. Y.Dong, H.Yu, W. L.Jin, G. Z.Cong, W. M.Wu, M. C.Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgeryJ Am Coll SurgJ Am Coll Surg1054-6221762013/11/20AdultCarcinoma, Hepatocellular/*genetics/mortality/pathology/surgeryClone CellsFemaleGenetic Markers*HepatectomyHumansLiver Neoplasms/*genetics/mortality/pathology/surgery*Loss of HeterozygosityMale*Microsatellite RepeatsMiddle AgedNeoplasm Recurrence, Local/*genetics/mortality/pathology/surgeryPolymorphism, Single-Stranded ConformationalPrecision Medicine/*methodsRetrospective StudiesSurvival AnalysisTreatment OutcomeHccImLohMoPcrRhcchepatocellular carcinomaintrahepatic metastasisloss of heterozygositymulticentric occurrencepolymerase chain reactionrecurrent hepatocellular carcinoma2013Dec1879-1190 (Electronic) 1072-7515 (Linking)24246620https://www.ncbi.nlm.nih.gov/pubmed/2424662010.1016/j.jamcollsurg.2013.07.402Cong201521522152215217Cong, W. M.Wu, M. C.Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address: wmcong@smmu.edu.cn. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.New insights into molecular diagnostic pathology of primary liver cancer: Advances and challengesCancer LettCancer Lett14-1936812015/08/16AnimalsAntineoplastic Agents/therapeutic useBiomarkers, Tumor/*geneticsCarcinoma, Hepatocellular/drug therapy/*genetics/*pathologyCholangiocarcinoma/drug therapy/*genetics/*pathologyGenetic Predisposition to DiseaseHumansLiver Neoplasms/drug therapy/*genetics/*pathology*Molecular Diagnostic TechniquesMolecular Targeted TherapyPhenotypePrecision MedicinePredictive Value of TestsDiagnosisLiver cancerMolecular pathologyTreatment model2015Nov 11872-7980 (Electronic) 0304-3835 (Linking)26276723https://www.ncbi.nlm.nih.gov/pubmed/2627672310.1016/j.canlet.2015.07.043uDyK  _ENREF_57uDyK  _ENREF_58DdK0*  A? HHCCʋeAm zVVGr 5C:\Users\ganys\Desktop\HCCʋeAm zV.jpgRw+)8@H{S8xFK+)8@H{JFIF``C     C   " }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?S((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((f٧?gZ:xSJq4#FYݘ,I$M}=^U'ɬ3FhN!Do?jdF/cƫk('OV_-?,<;Wwm~_'|7 {5G2w#U[%冭u]÷zdzM#.c,qNd:\2`/xK6hz׏otMkm2'D[+ٞ+YN!Do?jdF/cƫk_> <,4x94jI-j֦;f/6HPRYĖ~_x=xHՒeWtmGFHdsoP1I$?ᓾ;KO?6^VO~?dE }7*mO'v'AYlk~%=j4Q=ĚČiN/ ^Au'|7 {5G2w#UE'~n~*xSAO[VbX_ȶ;$Tctd$W.Aڣ|eicŶvumkÖK 5ݳi7V6Ha-Ĩv 'R2w#T'|7 {5_2_]"`Hkƿi$?li6_.lYsizvuK%.XTjZDee{-'W+LR Hm~&h?ZOlm>gTЉ[3(fTn(bB} C%??^W_LOO0t?ï }6\[C-ωEYv/s#H Q)$CJ׃Jq4&}jommdJN!O2w#T'|7 {5_/vw[eC#VI_aѵ1#p#I˵C5$~S?G}o i'akh 5A$ ??^Q C%d>)a#!.ilttЭC"ېH k*N!Do?jdF/cƫ|qo?i~k-RԼtm>I ͌SFv̟͐:'OPw쫦\]x<|[Ѯu}Tš]+|M43$!6׍ '|7 {5G2w#U={A<3}> O-S]Ks)̌|a8> 2'ɟm}'g~mN!Do?jdF/cƫM?>ցh'aqsoExdv/&Q )$ ~=^'M7៎e։i^ZͫE 2\ f[@1Lװ|nfg}gP?jZH/,brGKkyO'=;K?ᓾU /x߃tO ?T֧ᤞp5 mwiH"H;K?ᓾ!O|\;^+{k)עiSU-hC"ev0ƭk\o_ <6 To^*Fu$_k4l!XOʀ} C%??^WOkgI}\KN$-_'N#)B7~*N!Do?jm_^ |"|B׋iY Jmq׿WxN&=V(((((((((((((((((((((((((((((((((((((((((>5xxO7 y%U|vpz;(z_|o;\(z_|o;\(z_|o;\(z_|o;\(z_|o;\(z_|o;\(z_|o;\(z_|o;\(z_|o;\(zX5"m26Z͘"y$d޶ᶗl#&((((((+ʿd5&hC zyW&oHaU*~2ؙ P䕟1SIEeD~#Huguq\CKknAYiѓSژ';K2a|3<_ xCE!) gig&쵙LѢ+P_xz&=mԉeWz)0V# [N_?|/a+}uhMchV->kuQ6۝}E~S~ֿm?/Ti|SoFtMCOi䧘gn#2D>xm(L~'xRm=;^:3_qƢ0X췋x>SW|@m?gO=OeO[|A4Z^tR6#NDKYe[+E~u~ҟ q㿍)&/t#vD8YWi׼_z|CoF/7Z n,6[=[]2I-D_O\Vx○4mCJ| ӵ{Y!'r_߱X́Yr|V>#~_u~.4xZcV Ö]siXO7~饗ˍLH?3~@_̿*?!#џ?gg?vy[>ov^a,(~ך_My[-~aEukj[HUdy(VbWwQ\owVO4| \8%C .ZMtݲ}P&VGet9?V(ȏW῅-|ioou[+{ mBX;i ^\C;p$p#Ժ O^6+/6Kqiڝ}k'cff<,7Z(į_3CuGW&M파ĭ!V%_+>CoO炥E>%x{Zwu7-߈4%W_I^6urEWS1_eg[?~8_zIo^_ou;y|]Z( Z]HPU*wHUSig5/+iwבZH@ *՞:PҴ_ot^HIjV(`u VG\_J@Dԟ 鰷u->1[s)Ctnx`11G[c% >W~1αoC> еwrd{n-eC2oC3 ǁUPoHNJ]CDjڨN-eRCҩ{W:(t?L7h5^#ybgAU(((((((((|jyQO<3[{9d%wJXdq}+!E?v=VkY>Qch!E?v=VkY>Qch!E?v=VkY>Qch!E?v=VkY>Qch!E?v=VkY>Qch!E?v=VkY>Qch!E?v=VkY>Qch!E?v=Vϊ4ohvׇ{wG 2.-!*`G"((((((((((((((((((((((((ʿk5&k?C5zyWc&gHfU(()x?xf,tD]"SW}]]i ID1.牾?xrX:n ӵz6Wv~/>kFJ˵e;Ū|/pWOHM+lg # ^/ok^ 񅕬 _hve_K}k$1-xfCK&B}ߎ>,x+Oԭ4WoRn-y#}7͗&96~2Oh7 Wφ?g/C·zZA Ih"xr6fS}?.Z2OUo戱Apyҫ49;5ៃ4 \koCKgYjQˣYi&-Z͹q$I%QZ[ڳ cI m|_|_z4tMn{X6"<\"mڹ_ ~6og} sF?5)lZR7[đ/07)_M;dž~>?/ğZտu[^tZĒ[bWfVvDmgi ?gxK j%GYCv$= ,y*Y,O#|~u Iy;P:߉5->Kէ( f3ż<6>]#$;K_v?mnN̵f7-5S^ S?{=7SxCkC{g<ݻM0UXRa3?/ ~_V|%n%BA$F"v Yy4=?>+xcOg^M#lcO$bQĜ+_( 7|A| *ƕt dy3 m.ȻQEQE_O_?COῊ񗊵MAmbKS(^K;y`k<0La(pg.Lu48dZ}(5h"?q458#!]b)xOYU`#چGvn]Ť2Ö;pN(+ʿM*7.?Uߋ|@S~.|=ʪZ+ʿM*7.?Uߋ|@S~.|=ʪZ+ʿM*7.?Uߋ|@S~.|=ʪZ~x'?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jdF/cƨ7.?ߋ|@dF/cƨN!Do?jS~.|=ʪ?M*N!Do?jwTR|1]FhM&mg3YX)*YTeA\)v>U]E{TW›woUQ o] U@EyW)v>U]E{TW›woUQ o] U@EyW)v>U]E{TW›woUQ o] U@EyW)v>U]E{TW›woUQ o] U@EyW)v>U]E{Txw:oɥiײ%͕q8 1Q C:$B AE|#ׁm.1PhZV뛋0t 7I+$cp *~2;y_3ԟEԎ/Lpx-Dcc8R[aPo:o&xgKZ|C3?]WEP^3㧅>uj5=B߹帶(f` '+(/>"7/Fw ˩b$raԌ8i__O'Kw$-.7?ۍo,4;EZtҋd7wEB5~.FP,\2Xڭh|b| ҵKxGӵ+-2]V=MJ-J$W!mD23n:3 g| _#?t]CIi<1p=]yj L ~$z Ǎn Ɠ4"R]j@e3HQC~*j9RF<+Zfoa,CuPE }A+oM{Z7C.hs?A7C.hs?A=VG>7C.hs?A=VG>7C.hs?A٧I֯c?!kk?߆6z_Zٵ/5ㄅ\ 5EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPE*@U֧ksJG}J%ImvẫtWKxG?xh>  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@U[xVCЭY{\E" e_ x_Þ,<@|Em[Ag.y,S0h|F⟀k Z?\x;]Hܧ20=|d 7'~n.!u m"R34ad ~^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljt?״֑i ݭ>4̰"2>@@,EwQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEUkYq_H@o.6ؒ"HUE WKxG?xhh*>  -|@qAU[??G4 Lj=Vio# G7!Z+ʿ᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 LjO/ޖWIoq ay"U,`m` ( ( ( ( ( ( ( ( ( ( ( ( ( ( |C3?]WΏ$2$r]@%N882]"ՌoludTdsB+w|-.h$[[ݤ"Vh7lPQEQEQEQEUcCӼCico[G<7KaeE':#ب5z((((((((((+ʼ9'M v^<dFҔR8: ~Bx֭|Ih~m%_y4OȪ/!Ϝm4uQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@rRY5vY<8n3S^UXɬd3Yχ^_I>7<)h*χ^_I>7<)k>1~П~1>?vḦw2]\ʤoiebs@|oy SW5cωg [ >}VNwvOId9=HT;NJmۏ 9o\|&f>{z"ӵ vPkh)Ao8w/x񇂮>%ΥKo4{.c @t|oy SQ ''5t>>h^=Ƶhڕ\Adf3pr ) uibKll?n[@ky SEaI//MG$|?[źt;}kzΟ wwQ˵l2px ֠*χ^_|}coڿßˤmΫy/vYjB>8ֽμYbf3PEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEWcy  iOnimR%4=KPk7*0Vo0[6t -qjuR !>o:n>↋o~9/ῈYe SH[??ZoX]Zgﴭ%cmB_ 1#lBon#'RxKkQh/M,W^= 7@|2q)A%L#'88<?cxFnl/$dO(Uǯ<S -|@qAᗁm/nGlv C]F}y7xqM̼ >~?7_ Q7I.ү/ n&鵘Fsk!V|)5;~0 ֚%ձdF8#4f\YA [??G4 Lj|DQjz$h%IS l/*3;i'e!-.pmR$Rpͷ}qE~xPO|K7;㾡iEhķDTaI, ٯ5?dW_8+[wvyl-Xb&YT*ʀUbדoT[5{oz IN"0 k̉%2G#0C?߰ͤ ZFT,Rpnr?}$+f g࿌UKkiu[;HحQTE=}EW~?k??LjZMg'@EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP^UJ/kkʾ2EczQ@|Sc>m; uOVV*`?56n!.WR@u E|A+'^S7 quweA+movpN2"z7e8(i^1ěI,=Ew|^v@~x'\Zxsœ+%ozЫX!$ M |?OޓT04"ibT &W8/#@G׆xZC藷 .iQ*orK{B`\K"~Õ3Wd'5mI. %V `Rv 2A'^-)u(ТiR ($g$]K6?هSi&gvs;s(&~x%mq]{=_OO%C|7ѭyvk[mU1'Ij(٧I֯c?!kkʿf'Z~,ԇQU(((((((((((((*~2ؙ _O5!V?"nόy@|V_bz;M?J5[^$e@LG׃^W|D5:?,>&Ix<q6Ѯ־+ ßtzEơjZ֧{INFnm^yO~jvY`}:ksunѡǛ Z% Y_n7Uާ=x{!bޟtu;hH Hwsğ&f e^xK4 A0#G-.s#ߎtO ^]_hijϥȑ/2J|рr~ilZ.e@#HAbA8Jw I{ោ 3tBGyKlZ6 ѧyo~1|0|9R#}ZmmSńƤK `Bŗ3n_8澁~Fj>.𯈴vFt2[E9 ς { izwZd{bڍScpD>6g,jw!x(<;y5HVXP@,Q@<ٯ]oX 6\|fJ>Hv%/2T@UoJ/oѫkʾ Ec5zQEQEQEQEQEQEQEQEQEQEyW(s{F^*/uꒈt&k h]E5;oGj> xB[ž&}C@a=\Kksek]k:]J#%8B#2 $O_Kx{K<-bD2GkG'Mv^#UUUt?L7h4QEQEQEQEQEQEQEQEQEWT.MԬ :exJnee$F$EyW2w#T'|7 {5^EyW2w#T'|7 {5^EyW2w#U_f߄:?>Y|&쯣O XjotPWU_? QfdF/cƨN!Do?jVdF/cƨN!Do?jVM< iֺkmKNgL$ȖE]H!A(2w#T/EXsATKxG?xh>  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qA[??@EyW4 Ljio# z_G7!?᥼#@n  ^U -|@qAAKx*K Yvo-!ռyʰ  -|@qAU[??G4 Lj=Vio# G7!Z+ʿ᥼#@n  -|@qAU[??G4 Lj=Vio# G7!Z+ʿ᥼#@n  -|@qAU[??G4 Lj=Vio# G7!Z+ʿ᥼#@n  -|@qAU[??G4 Lj:>4xF ? x͙]wnFq9 s^i4Α o}Z+VQ4xZ_|o;\(z_|o;\)VC_|e 3-W!$^ݷ~7mp:W_w4o!G>7C.hs?AVG>7C.hs?AV>='/Gi ּMq6mK5"{Y2<+((((((((((]wy8!󯅿=xַǃJLv> kѕ\3-.|ɤ; }5^UoJ/oѨi 'Q  @ÏNU<??Z_xA60utk6mbD*ee8<#J <+j VΧoe<%ΐ0}yME]襃'}JKj5XV8LkG67doVMKP覓íiVz\Gow O]Im2(`)^6C) Eq^ ס_ZׁorͅRrMÚ?j xwÇo{_cK|W<}M }|ˉf1 4V?xχfk)+_ lgyt*K2i$M%`%~ǂ>/x_nOR /lۿ]wmޙqsWxw!?|?;?j:ՌZvSyN sE/ 73n7^ov} Tl3lt4ů~0?*-;RHM3m`s+/{N㏀_ ZO-rHP\ jO?Q%7~=|ASė#V n<'iDL)xԋ%IԖ0?>5 ஔ5xG4&vtig|/%>i7 ?~axZ-HdI(e$b'"XەqQn[LL[5Zim]7Ok3"m؍.>ߊ_/T,~iQs$Y[j!̰*Ь(g/^/MO^27_k<~d|+9ȃ8Ots:ǎ=?WR~Flc]3y|G<gxPִkVѵoeaW Gmu)Gs_׌~\NxgK-k[jf>mT+N8.}&{ $x_]tˍgRMUP,(ܪ:)9 W~u=^[eOojDxr=RėWvq/\[@$\*/1Ho6O0@ 0ku? b}4 WsZ9 {#Qі'>i#!AIhװZj9ih6HBHB7Oس-nXZ5GZQ-hŽNp0ƥ2d_vI_ٛ7TdKg\I'XѫF}O_Yt*ԡgk6ד$AL#v!C: X[I֑c!ӫ¿,~#x{Q; N[ku-[[[ɹdz4\yio'ZG~ԇNU((((((((((((*%Ow?k5_? Qf=V((_9=Wו|;oGj|mmGºTWzg<&%hԫ!7w&T. )#[O^N5[ ^7U ?u3[ΧI*<č$ H!-5xvS]z Mq;!]#,YBd  WG~}/7ЯQV-ާ=c 1lulE H 鴖+Ყ* ~.Gմ~m~X֢X|?.f3p0 rsҭ|-e?X^>\{}gHkǀw ayv1JW˒RGHumȬ6t^/ۓúoOJ5++KZWYF XM10@ryRMy"Yoti)7vz:`¤FYƧ^f־/ E/Fc=66ڣ}%^,4[n&gOT=Ťq' qN /sZ|eá{O n/&Gp* 3 PIJ M[> [Fլ45aHQ[w JH@yO)?ooId,m%{W) r#h\@4+KjxBGn#:^u}q$rRfHJ U=~~2iX<NMڔחDؾۋf_57#ewoyf׉|M2,<7fM'UM."xY$jEk>/񝶣KO|iw|x5RҮDZۿ?_y<-(_?|d/ kwi,X&5q hZ;R}3Eckq~mqsqqTͲ^.7ot%%F0K'nnj^OY RVk|1I'9i.mⶆ2[3 gsǯ~ ҮI]iyI)ΗZFL@-^EҾx]%zw-S]QG4$i@߲9֟qab]~q)!y8ěxdʮ9S\?Meēc+mKijywVAo<5 k^|Q;@ȶﭓJ;Lp ǗOkwvG&tMo%!ުʎ>NҠ<+'5"xn'R^֓, @}c1:V,(.B+4 x׉:uDžu:V{cuc41 >r a7Mqk? Ma9|I%&[msO2<7č{ǿ·OMS:'~!_xB}2)L|6=Bx]rA_Zl}+]̐F~mVf %k˻QHo Z/kXͩM28ntI/4ѕUH47eQ~<y}jZ;Mg7G$|?~k?LѿNN^~2~"T( dWn#7*C8S/ 'YkhxbEV\D<69c\W e⯍:Ώh^mR%[R+׳][؃ERۄ"zs~6_ x?ŞW$c-x罹d7B,6yg6e(~xO:Wm-;oxHnVT'la?"~u3;>VJ )5Z}+;:}y>l1]ə$wm|e~Ϳ|}o/]Kb[.+7{"&]<'_/W 0g|.3Wֺ-4t)-ީv` ,$\ ܚK?N<5DP&-ė")b Mߘ<0: ~:OY꺯_-M`#5K|g|_|w/h6~%xSBtejMj&}6[D<4l~|'/*~ oѬ^W>ElwlOZ ϊ[|ac׍}I%3*.'h8"Y7 /;R_$ >F pt|6y>?gO?hǂyb?~<ϵ<4v?kV:m=C5VI쥻{gq>xÂB,1/>GŐxCҚiVg%J"H}qioÍ_[O -aߨ%A-Xt_3|(`c|,׃[urPebYcSmeO_W4 3ᾗNu zH&:-qt Y+瘞~'$?éu? mE3f ȾuѨY颀>u/>N 𯏼@n,3;I$ y܅AbU@Q[~kXh--lT[q\XXW71}{?l|#wN a $fsqs]R/Fr >OؖAêx |exS.u= jDO#$ف),m.}qE|Wƾ|;'Kty+l(h u@ݧt;7BI}>Y^c$d0f'5S|+a=_G|Y j"{]6$H.o,j,U3 [ȼe? t|44K }V侓J]9b&KfKaI.f;rp~ҢGKOmknŬא4Фk[YWFeu_gXYq8WG>O+hqkjny*ZK(8!s#)$7/G>7C.hh*s?AG>7C.hkʾ Ec5t\&ԭ#e'I3Hv 1લQO̺eo _SrgogJr2YZD]O"@ EʌBx~ux>&j ֮xIɈl#gޤN V_ _>;?eRM|! Ѥ{ɴix$iV%MT/fjgS]Ƶ VkvVi4QXY30NĘI `_T¿K^[ k^Ѽ}|ᵊQy܉`mLO^2!~WG~4W|FK8,Y{a"I!%b_x*W*%xg?[J8h{Msx85anʛ fM|$gg}?|VxB7'MS]P6nK , Q vkm@n/x>,;? ke[o:/"Еs`dac~i:]Yi1yVpn-4P2I'Iy/co^.O~_?m!x^K (?Z׮nn'BĖF> _i/YtH5ӼOu !Yg{>;y}` +(ggE[o⫋6أ v+Oq4DC2C7( R Z?؍+( <g<7QΐU7 OE=5*0|1Դ=cY?# '"z:ilO(rs@){4߉~2:tkY.$Y$Uef}*V4ƻ?x|A|FKX1bdtG!p#1+hY?E@*ϿO ֭Q?VZ&%#,H&rcYhsqL|>_K xvkk(kh!lnhf ,I&% {Wڷluό?i?-NM\hZ.q 6&:EBFL׼S [^(ƣ<:܊#S$c05cH0HEPNutٿR_[ -kX}Q^JR/:Anb`W@?24Q>m.zՖ8KI]BeUV^o_e7._?'?}v͞W@#w~xnjOxuKJ;{hM]<bҲ4+!D?$|;]环5|ߗ.o;sp i_U|t>*| oxo,궄iz-@Ĵ$089YL1ʿd5&hC y;0F㟊W.G$ t7M*/;Mg7@EPEPEPEPEPEPEPEPEPEPEPEPEPEPEP^UoJ/oѫkʾ Ec5zQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@yWO(s{YU*%Ow?k42[,H#&7e#ێ*J(NY7bf0תו~k?LѿWgkk5~_ibcqgdp|bdM.y!>o_|9i|)-6W:~#RԣbkO8 ʥe_O Jog>(RZfo {rXl%P ,Ԏ <(xR/i$r\%ʰ|#KK A¶q@<+g=s?/*~>5yiḼ9&j$1Ea}3FL~~?񖭣xcg DS喷 ]Lt`Y [Fj<Ys[Ggq%|(,~UnP)i\pIâ.4(s +6(\aI$p79-6ZƑFBg ?dgv2s*\ B>83C㿈AO RvӼ~yz=+:,j#Kx#h1dr#ࣚiqK\ V{6&YZ >NU<[w}r"ӵ+:x䘽B(DDc$_UOᏃ^_V=r\]ȬUUTf,@ Mx^3o>kO>Tm ,C3rw2 ^+Ω>^c1ڭLUt8{@RSu_7ֺni\57q d qJ+A@? *ԟ>#Ӯ5+K$p.$b!⼫O#?kzރMgL6Z] 4}i.˙ RBg .ӴU{]BO9Ml ci͢o4b0-Ѝ W9kž!㿅z/mtĖ"Cs&΀dp|:&j>烴 ~Zh.7Fԥcehz+柈^"seg;yoz1,D!(g#3G֮t+kB;ah>$a7$,`7H@j+~*~ C 57]_B[/eW_.8FԜRjG~Ki-Heױ{֍4ljtƍo@W|+Ř9.JpsZ&&Cu6{gP[ǾE{#u\oqր=u?Ht3AOxt\e4[Ik|6#G$Rz1A i9OR:=V(((((((((((('_?9=תו|d';GZ( ( Q~;m^^UoJ/oѨVOvῈGYP΀i#T|b9'_~.;? 8x8^S Ь$->6i_woJN kXHU Ŷ*Uio9 Y41IGnĦI㈁/Ǚ9l?:eu⏇G.Jm Z]c{{`ҩ(J =g#/ ,~84? x[iQFp+ehee?woyrҽ?Ph''o ukkxT k?3'pEv?Gan_x׆Ww *O$R-A`|Rw}ъ_R_WѾ,jNo|7ծ4 5Y^Mm{v"hSm兝vn&1 ^L,7-ҵְZZ+k$e|j#PaC)[mvO]x~ ܞ*Mo,Nnj6񴍭ݏ> <6]:bI _Im]}޴Ş75/C8ci YBA(Kn[+f6UW|a^  2h^!~Xx_Orui"[XX:F3@֖TO]$q7A?>8hV_~Q i6ј)4q#i爵_ʧӬC}%G22'o( Yp ῇ_~\|D5 'R;z=ha2x!YvC0lx4~?? K6ӿ0<"o'܍)ݻ&>GC<{텟۾-hϨϏߵ?xkVRꋦ ^ *%ZC<}ÄL+fg%Z~s\4j:M -MXK7pC`eXr~<~/[ŷ? BZ[!yy{h0񭇂)oiLn`IWpX w",/q2*ŸO a^O?/⯆I5}'K֬7j6w Hb1˘g (ʿd5&hC zyW&oHaU(NY7bf0תו~k?LѿZ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( Q~;m^^UoJ/oѨh(((((((((((((+ʾ2EczyWO(s{YU(*~ ؙ 5M|K>+#M|']Y^x)K8@ QssFXձm~JG={qJ 'OƲ %3%h>Wx|v/ /_OömYΠ}Le$asgkF|H[j;m޻=8BіT3@rx_$;&M T<+"8Ẽ=k>KO?\h=Ԥ‡B}M3$+>0bd:^,7k j:HH/6oh>ozw'ď4^i^\7ޚR1vl@ ^I{kt|jZjtC]Y$֐Y*CcnlnKd*K_iKKQ,CϡQ KIFwc\ֳ[xRy0m{?_>5]"o&R-DVщ )mw|aƿf_ZlZw}Z|2ֵ2$0>w?GF߆:jO5:X HrI<~ߵ'q?uc*ெt[wqv8--|c=p}+gM8 u luTF5 J]chn'Nw!mx|Pf5ֵ-ii6ˈLf,1-83@_"ji`bіk`|pzH+ oؐG#NoOG|-OkPl2Cg P_ uoMC&Sxk$MR/k^u%ծF >T?þ/>!>h桧j>=>iQds4Q Ѱ  IM{~!o5MVF^J7 }ytb{;Ubq D QR1խ}gm-ARYSlYf-麾>9:u? oudiԮ52KhĖ $ӓR~,~:<2?c/Xy-M*6R\V܇H|1?;~_1/<*<oߦ ?D>{#> lavX6:ot߰[i7n[s1/_x}Q៏_w/O|EYhv56.Is夁rĒx<.PK*3MrY1}I@;Xye%ŭ~і~^0ȣ;ls7b?ud(l܃9~dEOTXJQςN}O׺~ ]6Mekun#7e1ŵ un~_#M+XwaӤa :ttF,9°??|?¢ cC'*,x='(mwIےgԾ >+wO^TMv2<{fkY>Qch!E?v6~7?J+66+" Wǟ o|/V_]~ &;˸"d&ll,UU cC'*,??|?¢w#ᛙ "9At~;~|g⷏:kPuuwɖEow@Đ/OTX?~dE~6~-ImozچeRیܼYvVҐ EbX;KrN2~Bf?d}3ڦui0&œs{!6PX2An00J !E?vkY>Qchٳm[⭞ok6/$f9I,Mʪ q޲fSt[A9n4mxI8X\ ɢ]ڴ6 EcĿh J+U~X ;G5,v'Wp~z|7t-K+ jg5JtVS%ֵ}#L;x+Ynto:6c ꗳ]]қDWdY8W cC'*,??|?¢i*_RO > 6Ԍu^E|ᯊ~*x _{Aik;^xNh`V !,+!E?v;Mg7^^U'_g#x3FV ( ;Mg7^^U'ɬ3Fhh((((((((((((((+ʾ Ec5zyW(s{FU((((((((((((((*%Ow?k5_? Qf=V(((((((((((((((((((((((((((('_?9=תו|d';GZ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ;Mg7^^U'ɬ3Fhh((((((((((((((+ʾ Ec5zyW(s{FU((((((((((((((*%Ow?k5 1-'-ahחɩA!{i%v zMq@tV/uhxKQ5hQKqy>+j ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( 򯌟Q~s^_+?Ÿb]k~7tS~+W.g Zh6{#E2ij0%ե`'G\pA֝QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE_w4o!~_b 94n㵼]>dVL lߵ>_M1~:| 4k? _tI]L6 '>(((((((((((((((*7%vh_vQ=V(((((((((( xGnu(kCRK{xA!AyPIԊkY>Qcj_2{/LI Z&*J>GfV*GpH^@U cC'*,??|?¢ת@U cC'*,??|?¢ת@U cC'*,??|?¢ת@U cC'*,s^*6Zƭ|Osxj.y.-tF{JW#'2>N!Do?jdF/cƨӬlm{;8#a*FUP:{T_??^Q C%z_??^Q C%z_??^Q C%z_??^Q C%z_??^Q C%z_??^Q C%z?i'tXl41Vǯ QUT( ((ɿjςvRa rdpAo cC'*,K,Ϩ~noK4Yse ,I$MzyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^EyW5,X ;^Ex?o?.?)lSu#r7SOk6kI,Pܹ,ybp 8PkY>Qch!E?vVkY>Qch!E?vVkY>Qch!E?vVkY>Qch!E?vV}C]^J>*x'U/%X-lEg4 !fbz2k+ʿio'ZG~ԇNU((((((((((_9=Wו|;oGjZ( ( ( ( ( ( ( ( ( (<u?HtZ[I֑c!ӫh((((((((((((*7?<3zyW?!ؙ.רh(((((((((((((٧I֯c?!kkʿf'Z~,ԇQU(((((((((((*j9RFViuHuZ((;Mg7^^U'ɬ3Fkh((((((((((((((ʿio'ZG~ԇNU*i9OR:V ( ( ( ( ( ( ( ( ( ( Q~;m^^UoJ/oѨh(((((((((>|?t Ŗ:?3}l,a ,pLă,ҽO U𭯉<%AhWLo.RQpGs 9՞<]QZ0iȩ9nـEKW||, h-VVj(f9b{Oz袊(((((((((((+ʼ9'M v^<1$2xRЂ0E~R||oE5T5x[{_Yiž|He ȟ܀~EQEQEQEQEQEQEQEQEQEQEQEQEQEy 47x;Eڛn"B`y#sw ٧I֯c?!kk_&OM w>t iwڎ>4y dΗ'QEQEQEQEQEQEQEQEQEQEQ^sCWŞ237׆dmm&@t6g=CiuHuZI񭯌|[3^G;cQve;mIkn ( (n/L_VE[k1p&ѓ"B@_&oHaU7gqhb|/kGD;qXjV ( ( ( ( ( ( ( ( ( ( ( ( ( (<u?HtZ|-|]}Bt>EY$plgPr#/kK3oj3ho.fi^ysvf E ;PQEQEQEQEQEQEQEQEQEQEW|;oGjZQ~;m@EPEPEPEPEPEPEP K~3~]wL[/0%Vٻˏv1dF/cƨ7?<3zyW2w#T'|7 {5^EyW2w#T'|7 {5^E|o_]V-3/]JhEvz݆g3YHERT8݌eHhO/V. V &K=I" d) n2wƯе៊:#ϩ+gڿdjmbʻlx h]|G7?Wk _1!Hy[70f]۷qP??^Q C%z_??^Q C%z_??^Wς>X#x;~q⻫I=Ya:&xIBѣm'E=@+ʾ2EczQ@Q@Q@Q@Q@Q@|W] ]?o[V}KVЭne _Ɓ2͵Td NiuHu?ᓾ;KZ(ʿᓾ;KZ(ʿᓾ;K⟆q|Z> GO3K uUU$WX)h?ǁ5VҴ]{I__x]:л]_yvo5gH} C%??^W)4CMYH,%%Xr]"f ~*N!Do?jdF/cƫh*N!Do?jdF/cƫh|/x'/:e(VM-#U˻噏Rkkʾ Ec5zQEQEQEQEQEQE|9/Yϥ:mΩvS 4mp ^UXɬd3Y!??;'@ֽV\.=Z?rxO-kh*!??;o^-u*<~F7ʭzr:ex5F3 }:/mۏ3vݸf@Wψ)졿ԬK($DL5?*9\ 8o Wjy A<3w6^qm#l '@֏\.=ZZ(ʿrxO-h!??;U<'@ֻ7|9)fM/^mKEPge@mq 繭;Mg7@EPEPEPEPEPEPx_|m#Z_j:&g h1A$r}Q]w+)(a@ok<z4Zծ4[kg[k.(i [ɉ ?]E{TxN&V<ߋ|@S~.|=ʪZ(ʿM*7.?Uq5̾`^tb30bB|>Jf7 E⟍\i>;m6K&e >Zg]s YGwxݕVI$=yS@^YcA´?$DUOO>y}j?$DUOO>y}j?$DU*%Ow?k4I//MYW㟈xoѼ3ϫ6{FmeƱ>X( ( ( ( ( ( ٧I֯c?!kk> oA=s*m{QQүO\Aw]&cf9!H94WwZ B~ wk@EyW.O <]D'x{j|3qxCgD_vGkB UwZ~BkT)+i.Io=4$zƃ݅b~_'?$}?G?<7/nێ1_@WwZ B~ wk@EyW.O <]D'x{WwZ B~ wk@(s{FU*{:"4zOi-ȁ4:лYfKYp7 8U((((((Ybf3Wו~?k??LjZ( ( ګ76Z&5kkZNiK!$IjD1Q Ϻו~ԟ>#_e>7QOznϕ n8~~Ͼ2Mg_< =Jm LLzG->n4\5Ԅ&CcCg/}g6SIl֌vq2o;ȣg0% |? tjF4{Oz[[JyclɃw }+@Q@Q@yW&oHaU*~ ؙ 4QEQEQEQEQEQEyW&oHaU*~ ؙ 5QEW?kXQIG5#0Y-Z]6keđۂ `W{~"+Iu*&tL} '|ṼATk$WIC.:%cۀӻp n<c)_ 3h 6ea=EE)u@O)`Ee*𾹦JoxfMeܸs$+8۰H; Q@Q@yW(s{FU*7%vhQEQEQEQEQEQEQEQEQEQEyWؙo.kk~*x<%ҼA{NB/o*kHDVMo1#9_io# z_G7!?᥼#@n  ~|>jzs?׎E%5ޯEfDqHדcC ^ |M_|Aî[z_^m1aPͪݰi'fuv! )@|' Cm4 =p,;Og ,g%#bxSZƯƽkwٺzK/5BKtP  'MEҬwdT(/,#`rŘI&וKxG?xh>  ^U -|@qA[??@^UK:?s:uG7!,Y&h:h>7RŞݜ)ݕ<$qEK0_Z*(((((((_9=Wו|;oGjZ( ( ( ( ( ( ( ( ( (<u?HtZ[I֑c!ӫh((((((((((((*i9OR:Vu?HtZ( ( ( ( ( ( ( ( ( ( __XkWO.A*MC  Ej@U  @ÏN??^EyW3O/?:f_uz_>8!?|#AqCPZ_ jM[i:%-=ƣ!nXA]3O/?:|C3?]W4G?i 'W@U  @ÏN??^EyW3O/?:ž<}Ú%tm">;?H#71,pXq5EQEQEQEQEQEQEy*xB2ng [ABqEU4G?h*i 'Q  @ÏNU<??G3O/?:V-4aa@6rS"͖4G?7%vh_>8!?|#AqCP4G?i 'W@U  @ÏN-}mǨBTn+K$ ꨠ(((((((((((((*%Ow?k5_? QfV ( ( ( ( ( ( ( ( ( ( Q~;m^^UoJ/oѨh((((((((([I֑c!ӫkʿio'ZG~ԇNU(((((((((tM{y_WZ暷ߊ.떸MB+ 3I>7<)h*χ^_I>7<)h*χ^_I>7<)k kVoS{[+-FW2F=Cv$D:Ciơm,W>8uYbe:/GD`{7g |-^'ͫ_H'8,cL&OO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DUOO>y}j?$DU+ŏ? |_j >i:V:i("i]P6T8d;Q E2 DW!XϠ@QEQE^bg^U*7?<3zQEQEQEQEQEQEQEQEQEQEQEQEyW(s{FU*7%vhQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE_? QfV&no_ ~9x~$mjSUԂ躅oO_`x3V8+.[Hm㽈0E Fy ( ( ( ( ( ( ( ( ( ( Q~;m^^UoJ/oѨh((((((((([I֑c!ӫkʿio'ZG~ԇNU((((((((+h/ϊ|oϤj:}P{k}A۽T0T@?f'Z~,ԇQU/$Oxn>>έnt-;K.deH&r,g=rzGh((((((((((((((ʿk5&k?C5z|k@"9cxcŖwofEN{vHPAeQU꿱~_|{X]u;?-,̶v_uAu{Q@Ts  % J#6 xsNzV9~E`푩zᆽo[i}>{cuIs,qV쓎@j ( ( ( ( ( ( ( ( ( ( ( (<_9=Wו|m,3L\hRWEPEPEPEPEPEPEPEPEPEPEx&ONxWԼImm?[áRS|БZ\D$$ExNzof_uz_>8!?|#AqCW4G?i 'P^U  @ÏN??@EyW3O/?:f_uz_>8!?|#AqC念3~ӟ~x hV u 9wJ䉀N$@B(UT : f_u>8!Z+ʿ|#AqC4G?h*i 'Q  @ÏNU??G3O/?:=Vf_uri~ JuFyc>]cP)b\I Yr((((((+ʾ Ec5zyW(s{FU((((((((((ʿio'ZG~ԇNU*i9OR:V ( ( ( ( ( o|e'x 5,]RItآ[ n ,֓d|C3?]P B~ wkG.O zxǏ|Ij,񷊵 GAnoRUdR=W9'=mwZ B~ wk]'/E񷄯Cb!idxՃ) '0 V~pS#'9$z.O <]D'x{χMkǿھD&oi#Z3oW`0Fď+/W~.uqźKao|:9'$W$4\.=Z_α_]+j~Inb,4x(eTH;Cex+׾Zׅ5gb^c#ok=W ,KF+3 @=W'@֏\.=ZVc>#mGgEU XRGJ mʹa?ઞ4<uw{3Vae{y=-wRݤF#,PȥVs>mu)>XbV[ꗞa`h$ncnZ)c1MEwZ B~ wkY:wů hz47o,EkIoeࣈT \̞}3Ox{^\G''ua5["BbmNX4v&7W!??;'@ֺK>"}*cnsQ7oݏ/E}ӝs=]q &'Ĉ@[ /PlE1Hkiu  Evu_vQV ( ( ( ( ( ( ( (2Qm7~A]-{t!$/#Rp  Ӡ%xL7זjmXaF{47" ,`3zyW-$HQEQEQEQEQEQEQEQEQEQEyW_>5fkʾ 56^@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@U:o&xgKZ|C3?]WEPEPEPEPEPEPEPEPEP^UXɬd3Ykʿk5&k?C5zQ@Q@Q@Q@Q@Q@yW(s{FU*7%vhQEQEQEQEQEQEQEQEQEQEyW-$H_#? CWEPEPEPX/}f55Keuǣ7Z=1 RHGہ܊ۯ.q,?ri7nEV :?6eT᥼#@n'-'C𵧄>8x( Cii$+2Cc5o|<𧉵_-bv[]ϱswȅ2p3/o~?>xc/?h j%|[ca ܙK(dW'Ȍv’O5?_^ԧ5??[Z6\$Vv`sz3^ tX hZg4=?IXP8_|-^+_xCAeק!{@ޠa}hAga4Vu-?ZMGׄ[nicUG H|'_)|ϋ>SWu乒V\fZO~h=W_'>>P[H=el7H|#E>-x^%ﵩuu{] AO0,X8xioʬj"*|]Γ|JOZx&O]MY-]O U?he:ZC?X&[[_֫ai:_l~nnEcHnhTMUm}A6lͬi:!5m6$O:+8L&tXx6PcE?iWݰ$k>&_h>!_tȮoo‘x%уuXsYg"7%~fKrs/^例YD5W:*TN0ye~ /^/T$o]G];$[y6BF=|?~φonajSh>-զv-fa1 Ev'"5_/Þ>1Zm犾+w8{K ɡ!Kr#Y=y`1)I𮕣ZxsHߋWvnv;%4] 3D4 IPl>_E/^ij> QQI7Z=ݤjs{cVNšևoeqndPU]Ԗm?k/ xuxtVZNm {R]I\=I(;CH#ތS$^dnw>xGSX 4dqw ۷WG _IáKj-^i2i3G iq-ZHOAi̊A^x \#24!U$ d k7//Bu #Wv^߆%ojvv>u+[˶H|nYUi__ğP80,#xtXæ.o $byH.9_HJ? ~ xzMu{N'l|3lutxjrKHc&0ad`Ruk{J}GM.mo-%Ya'P":YH!_ƙg 5KH|[hޛ3x^kkMzE-7Z#q*`_ 7n<9۶&wsVq4im5jE2JߚL2T[I֑c!ӫkʿio'ZG~ԇNU((((((((((ʾ 56^^UWGO_9Z((((((((K?xze{RE洹r>DȠ.q`+ʿrxO-h!??;UG9 .BȠ8.!??;'@ր>+ Xwi00}OZJdXq ί-w௏H!I UXT+h(((|W@|.>o>VOյ[[(e-RhOTX?~dEUOTX?~dEUa_=Z?,u xzHisn2u ?OTX2|X9|1|IOkV /Xy0! 2ʌ@~_|{X]u;?-,̶v_uAu{xh'L?X"(@ !E?v=VkY>Qch!E?v=VkY>Qck4JYӭu > {{iMA,EQEQEW|;oGjZQ~;m@EPEPEPEPEPEPEPEPEPEP~N'^^UK:?s:uzQEQEQE_? QfV'_?9=EWϊzxY>[ A$I"\D& $ywP4G?i 'W@U  @ÏN??^EyW3O/?: /m'Gz^DfĤ͎ID4W<-x\z^ y6lt 9gbBfH|"~5eƚ{8qKCbq2ұ*f_ur>ֆ|E%5ޛğ mAnU*o+ k߇0h%֥%ͭe|/h^jޥsq?!{d8"@7`]UPEPEPEPEPEPEPEPEP~?k??LjZ6&WxCMQiV]3,),DA!C8'g? ''5zy"ioB%.w=|KYdh-ͼ'̆4rW%[9_|oy SQ ''5O|x]k,P5Ammm$,ɾWLHpDf|r'<1ba/cB }F%3FyaRc4I//MU5o|at˭GRGÍ?OyPƣ,ͣI4[yo L]xZƹᖎ5wQ'>_ݳgۻqeI//MG$|?G |-qam`~k S[ΐۥ0cF )jU/M#ۿ0|JmS~uU}mxꐶvanPfEs{Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@UC73OQ(zyW/'+h(((((((*j9RFViuHuZjpUp[BȖ\ʪX5g8DRp$VꦭâW\Ioi "Z[Is3*b(՞FK1|C?a kX:ºΝq =1c뱚9Wi?VOҼqowvf`Y*F#|H׼{lz/G<#x'"slc'%lYؼ>xPgoMz_#V~5^k4fþ\0Sjt^)u,ռYQXCwKm4E0O19'#vP||,7ŏ=پ$Mϴဍyx~<>+'~);5-WKfിwĒ \"8eM{My |V㆟mkd`n D`/đ@о ¾(n5obi +H=fzc!(Hܞ /}_Euyjo}[|=[ᯍ}n<'\Df4KBN,Զ.ὂ~9%~7Ѿ'8|=xJm'A5B wk$Rɶ4\pZUn“Ɨv[LEWyGPrV袀<Ybf3Wו~?k??LjZ(((+ʾ Ec5zyW(s{FU(SB|,>ux_?ZS^r]񼁗*#5o?|Je<# Rs%^LU2؅ 7c`;W 1|E7iq_ i<[OG-̳E,<\[=B+-$Pf9_ٿG;𷏴^Ѽ'M"̗E+WL NʾjAe◆<'7UO}ھU(Qs (Z?3LJyn/o˷v5+R' Mx{WBԼ=eGi ٥B.fxaQ٫??ÿb_F?ᣵyj'^P/^/MO^27_k<~d|+9ȃ8Oey__eKqMO`n 3Ꮓ?YY?uyJnEwKbFI ~Uׂ}DލEi][[ù\3Kֵ_w4o!VNY7bf0EQEQEW|;oGjZQ~;m@EPEPEPEPEPEPEPEPEPEP~N'^^UK:?s:uzQEQEQE_? QfV'_?9=EQEQEQEymgP[ỹ쥺nKZ9Y45(}ۛG(Y8*)h> E9>R2Ω([䋳JNjsGҴHl4B HQv (*]]ڍ7ŵXde<A ^MTKo> JWkWN] E,|y7 %X,+S^\_o 蚓MfIo[e͍l_, N0AQ^s&?$6< vCdCn U.c] ;AoF((((((((((((+|irx O4/WeӴUaU I@:Oz}ڣs}!MFlgʂ rI8TgePH4:N[ȷgXظ9IndyQJz\W&W|C|_|xonH9w˞<u?Ht~ 7&i1Yk0H%\6r/,'ep A* _#? CWi5߄w' &`Ӽy KĜ$W>[Y C! Kx?h+El1Vc$( B~ wkG.O p+MC_`;Lq\__O 2Ksp#~dEOTX洿>8xw~+߃/w$/-uDKy"5xSq+6bOm?[W>ey~dEOTXZ`_٧g-EY]x~Kuo.hڛ F^C%XټscͲ*0*mdG\"7 `kLJ~!j$P66C kc4#Ɍ˝LK멡"5)e#z/׼I Zxf^8(aٙ".sJ( ( ( ( ( ( ( ( ( ( ( >{㶵Yf$h,ǀk#AgGkM( xTC 8uאOn|?URun% RaC`#ox}7W>|l1ٶT^릣3?n0G1+dJh_=:-3NqIؖF9fv%I&UB`QE_#? CWו~N'^@Q@[ne,,nCfkF-c^ l?W|d';GZ(((((((((+>|6g.wKm yR^RO M^UXɬd3Yh(((((+ʾ Ec5zyW(s{FU((((((((((ʿio'ZG~ԇNU*i9OR:V ( (<3K_3?o ;C!4fkg2chcS~.|=ʪ> Ec5j~ťYWϴt؈r&xߴ߸ e›woUQ o] U_| |\3ÞԴ i]HkW.nmԺmLE_3q!.hRo_^"x-qjl6v:]J.DRI ̖m`›woUQ o] U_ .|Oc&>vt{}8&"_>X6 ċ8' 3|<;O # =k^ m9- GzU]E{T›woUWW]8A|Ai?kV6 5N|rHDNvƒ,5} kRZgc[J[Ү4*7c62`pA*Wߋ|@S~.|=ʪƿ(|pׄ$z~MwTM;/|/{a\iH֨ڴ6%3#VW|E}Y%O$]RF7~7.? &&9xºU֟AK[ۏ[y t\K#,m@  @ÏN??_*?[Yj:o75fRD.2t`>Mv?MW쥬h:x>(杯i-btX%GEK ~DlvWKE4G?i 'W¿>'jI}7Þ'𾡠j͝g=W6K vYV&[^ N>)Co⾡xgմHGN+5Ũr,I!UP??G3O/?:8|)D~v𽆩6yyq=ab/^2IqnA"TS\H~'kO$>}\M7Mm?^ԮuxKNp 6n2o \,j/3O/?:f_u|mK  a}΁uތl|y:v6G~Ŀ^O M~]o- e; 6ܰHi 'Sfd_<Wڑ/.5;o.>oA<ҳI&Ȣ7;!FIS*j9RF=V(((((sS_ #^0|$ٵN !9\neeݍ˜tOOTXZ+ʿ~dEOTXMp\do^}/^>vQch!E?v=V|)@|.៉>8fOu[f+r8PIk?j߂p(JAuykY>Qchi9OR:V)ߴǝ-/-'V&^6-խ؍ }ھ?ho 3m7I!hj,vD;cu tWX ;G5,WX ;Z>x\EğX3E:āT9 ($p4xg4[Z]*&%)VR0Ey~1.㟆ot:yÄ?j߂p(JAuy>& Z]_HMm{g()ViWg\|?t+ j0$yhWjzlwjm"EZp$ru(|A2:oj˨D0+i$BOE_??|?¢ cC'*,z_??|?¢ cC'*,z_??|?¢צiZ}7Q,V "6с!# Y((((((ʾGwOm^^U#B?s{jZ((((((((((򯌟Q~s^^UJ/kh(((((((((*~2ؙ _O5!=V((((((_9=Wו|;oGjZ( ( ( ( ( ( ( ( ( (<u?HtZ[I֑c!ӫh((ʾ Ec5r |@wLջdžuKJ{~|ʷT'y2IB]_(s{FJմ{J5;+}GMYa'RYIH@~._㯈fZTG? _x>Ƨj7wZ[KLh-~|0|Y+7_#~Cgk(u瞫 W-rTcFȔv|=敠|?5Ώg%M, -Ю"hׄdbum&^ү4NQoa{k;XgԫVRAR0A _Ox>+ES^kz=Z WIqysƍHaadg2v_:>I{^g/~YHk֥o#qM /&AҬ2NlKk[;H(`*FUPP0UO xOC>kxoF?4.-dhY%h/u_e ' >*k~> jvF2I#O/93- LbLk OocԬ-RG.-wa[մ{J5;+}GMYa'RYIH@o࿌Iyx? h7ף&tg+gȆx07&⎡r^PյK2-VzXhEkMbFOuO 5ҥ<#ºl,KyJ F D(TxZoY&X4'2GL]6]a#@]yW?!ؙ.׫kʼ9'M v@EP~k?Lѿo۳V?>!1%k2m/ ڭty U4kHy[!S&&oHaUwMGύ~"vzMW6WVڏ>infHpG.̎ Zo\/o΋jI=ơ$jD;9 z#9R_TPFԟj~E354+է4;7YX!gC#;2NDkkgk$u-2m[_xaW cKA˫W*O?_ O4w]^P{(mGHxxA?$Z_6?n;Uc-+KK ̲\HtBv@գV7#THXL#* hdvE_O_?Cתו~?NY@EPEPEPEPEPxN&Vt?L7h5|L4 xSlqZn um!UUl9Pǂ/[4]rt+QT fE@en%c ֯YA7 nyt6mbD%[ uNMFIo5i.i>4k/>*~G쿲_u믉QqogoH̲Z4{624v)յkJ;};Mn.X$R#UA%FXU^[:m)skyi* :IԐA  fcy~xYռ!+ۗռi~?j#SM3]G$RFҼh/w4Rv .>$jZx{DGu]wj~#u}bwELO86(*%Ow?k5_? QfV`XPMGŚi%kZǝ\]$wRɌlR ֯_YxA+SᥞJUm7(MܒC%R(f .[3Sn,|E|{cO~/嶽km6K"&z3c+.(>,k~$t趻|GTKkxw0E#eQ`:5hz>hΟekwnqt^J_&2wIHfrp+_گþ'q7Wx3~B].{ԐB%D~YnI/mS<+XGƞ/~i6+۝2|-ֻsᯄRreyys~#ybgA_:|K&u-kGΧXk'?_go'..Vx1Y-KVryViȌ|c3 o =/U ^x30|?4"'_-|uYk^ 2R JF6Tŝdi|%X+߲W,;< /4y?"(" bȄ~k?toŏS4еtx>5 Kk+xt"dRl#VY!H쬌?>-msB񖏯.(džQk%1I펵wj[t[ I@sZ(<'_?9=תו|d';GZ;Mg7\Ǐ3|URܾ ſo6&I'fXms.]A+~ ؙ 5OZ_X|3>W|>hVqksaio]!k;j4wS)ḥʎmԌU@] Zx43KY4.  ~(8$[YCo.a(GE!>._H?e<mVmɬ仂9c2ĎcUV[(HڿN >#(ѼA⯈l#UVU&0 I Pld'激/xšh4Ns6]\ZGp$'dPa]_t|8Ӿ/OwcN̥X.YPrKW|d';GZ򯌟Q~s@^U'ɬ3Fkkʿd5&hC   M7^0wP%W#8+?g|8v#YyO5&B_2)B0ZV؞*'[xúnZIfT#$ӡ+y *6;e[ _|_kZߊ<5q@CPlWznk ?ii™>|!*꿵kfM'Hn>"&Դ/xx/sZzmmoi-\G#Z4*PRH~N|KY#+g_k^$Ѵ e|MJz)$ױAoi͔_%BWz[Vm?3JqjZޭWT=;LM6 cHVL_3xV W^U'ɬ3Fkkʿd5&hC zQ@Q@Q@Q@Q@Q@U/yjͭ]jm_*"SbLl9 s@EyW#?49 s@EyW#?49 s@^eo^Ǿ及LNIlo9;\GX6A(fxxwTu][*;]p'3úڼO|mxkwӵ{lu achE"K#by7' G;|%5\Nۢ>鐙dٽU8Roҵ2:<o&,㰉aԥv%ĭ"ѩ|=i 6ˠE%SbRPm\av1@>.~K[o6L7B/f}z5iZO:_BjW۔#2{l w3@QEyWO(s{YU*%Ow?k5_w4o!ݯ1?tZecf.1-ח B\Ecd5&hC zVU晩[:m/mugw :xH*F$OhxGƗu;[<4k{X+xAOqxU3"eHn$-`~;~O0 $1uԱ-)%XJ(y@+|¿ ttgG4K=+8^RBQg a]~.|S~#x7]kdhKCuk$G*V' ~k?Lѿe{Y] Hkke8T)R C o xr– M{&m։-n .m3HOm"Hȓ6M^iVwq,Wс `AKuu Ha]),V(2 j q 8m=jZ֯ l4{W4,fkke̲_%12> kØtX]:J[6Sgy($SY>?/MOѿdԯR]I2]oc|ø?'Oz=& b!@HN4<'Ѵ趻;KKkxw1vfcbz֠NY7bf0תו~k?LѿZ( ( ( ( ( (</^^Sj?zӯV(((((( OO|;@mv0KG$T29ʾ Ec5??|?¢ cC'*,zr<'&x [/oz@5,X ;^Y>)f}[&E:[[ù.\*K cC'*,??|?¢תNX׵}YuӭK/5KF,FE~O@|#G|=W>,x;?ǥxĖ$YK^7{N^+;?wzk厓Zgim,v j~PzYKY4Q̷a;%]r6ddsVmZAү5=NNl{˹V(`UPIbp$X ;G5,ZNciVzyo鷰ͭ夫,3$GRC+)08 (յkJ;};Mn.X$R#UA%@k cC'*,??|?¢ץi:Yze徣—6dI t_??|?¢ cC'*,u^^Zxo^ՓjPA\֫1Qhї(u+V>x\EğX3E:āT9 ($p5W|d';GZ((,|Ziľg/%=ƷcD${D܌8"  @ÏNU??G3O/?:=Vf_u>8!Z WZ= ^_M{ig;i g ⯡|#AqC?f_MG&FY[7H }8?ླWulQ{}`kj\!{+O5?H?zԿg>ͷQ>wfv|kkھa^Z?[QפT^tcPpȠk??\>,}[v5o5mN{MRp ̑-.nP`rQEQE_vQV_9=PEQEQEQEQEQEQEQEQEQE_#? CWו~N'^@Q@Q@Q@Q@Q@Q@Q@Q@U:o&xgK[VtOSӴ(^U"E,;UTX 5bg^JդJLԖk[{e)؏"R9W^?%[]_<-z|3 =pc>ɕc8VeF%s|!?tmc~!lo~Xd3'ųL&If$|+ ŭ|)c^/Leim}BtBVC$7,n<R~|1ڽ&`MUQҭ/4H's*.٣#P}WsVh:/o&_]G\?ekxvȤ&crgA|A. y-wfZRJTLD6_^ݿglݻ|Bh~@k$ծ59$<]zeM$f#4Y2Uy'#^0*o?l?6m_+;6U⟳ƽsG-]>?,<[_+ywfSvŠ>?x+ϊ_?XͲkGS,g K$7c5gb"@~ ~}ɼ3H?"G-2 H29ҪOُ^ݮk [–?Ȟe弻ݳ)TaEpῄ^5յ M/2ͯHzqϺYeˌIIC/Ï{7}7mn%ohڔbm}#9 6}UCF^,V a;ǘ{W1J6 D7(zywu4}/ŞgP(%џ`p$%NڧOW;xnonΫs![Kq۬fb O\◆W^?i"fecXQ,@vW~?k??LjZMg'@EPEPEPT x  -|@qAU<[??G4 LjV|FCx%^&o5_je&v8evIqֽ(_^.O? ?IP%8-+,Tc t'@ֽV\.=Z f|Z{gw M 7_e`GֽNY7bf0 B~ wkG.O z_<]D'x{꺯>%|H[$ |OM7ƭ}kwCB#QUUFc-C1đZ( }_xk:_Mhek%灯g$22 s:W@ ;T᷋-Hf1,j97rarG4Yt>Kխ/ߊ1Ddek >,T}8ṋ(*c+3e{[5SM>"|'~&Zx-miS5z,6VWCpP.3:Ēp>]񖋫~2Ҵ+X_ jv/tˋ ^X-)ύg3Ȋ(PWQ=SeU'#ZaΟixtLm\P|tسDmSu/[eu,3G4A132 #^ uoZo%+}NUqsA[F?2BF<U>bY ٯ$z⯈1ޝ}s=Z%CxGEoUyjl?Pth|Io-zauk Xod5 #[gB d'mfO~ x'S:.q-KgdI İm$gk>53o<'M lKIui7VL1]JL"wÛxߙoZMHR; |:eWxTD߳=Zj[_ iw{8",7J cz¯w@t? WmښIWU2ۋϻ'?k' xF#BZ.5)to¤Zt cFsyWO(s{YU*%Ow?k5QE_#? CWו~N'^@>o/,3y=|Wk[I sԁ70 9  ߴÿWռw-^;m~G&K1m?.+iNoڃõ[X]&w:ˈn$McU 0k[ ~I|aK :6J먺{gYIAUh.UI8 u%;mWyFKin|+&~|C(e F/^ K_χJA1__@o.kpook3\ . XA?c7=G[n.A,[V]PۋZ[W}^M{LwVv"%h.[!rMs4o ZּOxJtO k7vZ&=2甪l*~L^ ֧ҵ7'Dn +(?U#ڼl|WOOšsZٳi ydk$W*Zvx`e xzۏX5O j6j1:\^ϥz rf *}g|GSY<_]3i!'xڣ"K ,EQ3Rxςx7O) Ƥ|o-S^ ҼǤj߼ˤivk3+|D|IK{}~.̺7lmWy0g fo ~.xH_kJ4yt]Psqumokwm 57썧|Xt; ?t1|M^CЇPkIs Viy9s^> ?.}b-:K}RMGHmcTI .fd؋qw{E_o|IQ4ຕ!7:eʗ&xf#ȒBEU<V𵿃t]yO_&=鶾 I/E)W!25">2A?oxx^˝Xԟ -ULiXm3K9`~˶^8'/i::}wxUң[|Ҫcwmݼ_|-?þ׭u{ KvGxY-*wqw$OnS0@ +ʾ2EczyWO(s{YU((*7%vh_vQ=V((((((((((*i9OR:Vu?HtZ((((((((|C3?]WוxsNza+Oئ?myglݻw˷9>(ែ0:]j 񾙮[2X1iP g#sɐ\۾b~j7\S? x~xt!m,i#qͨGI$$K( }?#⯈<%{zgKvhvvfV uk6ɹ(3~hhΪl'?lC,amb;<>M3_}7ڿTǍ>-GźwBP#I45 =2xؑhbr&i㏈>s÷pk/qcneI!O,DљNbO|?j:vq]OPxF"9"O{YMhycx^9,[ +εP:m ׌#f<+a+Ec-18 J-'IPyx6oi:ƿi~#?"Gnfبm$cDڲ/&?h~wb:o}'_kmnZuEkpR9dWUT>&k7_ h,ynjmOp.hbN_|dw8IaYYkeI?fgFv巣 |3af7α|EmA/4 [Lң .U'H(hEmOh;ceye M/e%ėOv/rr`P>>~*4/ Po x/CծagMy#yEl% ,4U"S :oĈ/?|=WP&>kwjzjye#j *!H3!  xVis|Mgux;[-Ngç%ԇʅe_>ݢf&oxW½Vc*U֭5֔C'l6K;AZe^rǟ~2ؙ |--,t};M ?IX [c FFs?Xɬd3Yh((((((((+ʿd5&hC zyW&oHaU((͵[k+V/T3A"2:4 cC'*,O_?Cw{&{Lޑ*=y p#4/R1D|@=Cƾ2 oY2xKகj/.,-}NOKM:kU(+xvf>^H>)AH0kuOk`G fU< okY>Qch!E?v~%|wg={Z'/uּI;Kѯu;ϳ<#FՎ@'8>wg{ĺ'uּ7om;Tѯtˋ?+㺆6!E?vkY>Qck[K< xφ/7엿g3˕UWxr8^ Iڥ }F}kS#d n'C};[Jm,PNx$-z5,X ;]Sº74KŔ:ϖKpr3Zk:uC}auoum )`]H 8 ՚;Mg7^@Q@Q@Q@Q@U>;9Pkkʿgx=cJ zQEQEQEQEQEQE_vQV_9=PkoiҢ5;mbI &{0&+Hu\)ʅNX5]/#mZ'ㄾ ռeớ[ AUYA2|Vlt|wgQkixRvw-[/(+96XcHw!T&#>/#K}K i}d(ԌBpx$ExAJ~~?v x:Hm˜ܩ1U g1x" "֣$O_ m/.շ&Y\a߈.>ԟFkOŲΡ^5u'k7y;xXwVZlQKƓf;8XT!?B-|'MvMOe{R;\[}6\䑴WG~6{/^Ծ(_Dw|5:#x(hoR#,n v9t?OO2|H_Ith<uM1mU* k-FhFUg>Ysǟi:O/ gDa>v)ĊZ]%ha$qƐkx~k>&eso9CZ@KO Y:, dxO)FM+>߈~z|wS8o<*]P2)&؇7>\~OFA0a>a빿y1ğ ~>;g\-zIcxI5=3\Ȳ}8m>l@?@> ~Пhkg>|'_^xoYկ5N+U͜!+b= 1Yc2k{s^d4xaHJy岕+k_|Ih3|U74V!6p['LG4=idW2m97մ&IQhO.3ƛUZt!7lW9UO~F>kj٣]3n|=Z}&k{(eΊ63Imd Wg~^7z 5j^/XotL7/r[4qX  bC} Z ~6xFmrBOp\G<6|Q !vƀ^UWM|><![mW7zpq]D@g ryb$Lm>6;qoyh6>-.N]9dm􆴖(g#2$oRѼsIм3UZ$ȱXItjȡ(ŋ3|*Yx¯h8R4-+Xʚ򆝋 RR^70t_|%ǿWj>"kxjm( 6 zb[I7"oAj$`C.)ր<'_?9=תו|d';GZ([I֑c!ӫkʿio'ZG~ԇNU)?kϊ ~? >E.wzVyMuqww-ro X-٤i 8R>bKc|5WObCg--yZ k ^!g`2neXdG^TiP_|G/9?ܽxZ_xi1MԡӇnw&նkPE- G`v5O[T 6 cv HB~ٟ ~;|uoN ^!"q:|!$U|7 Ǽt{yom|AztPe6l!f9O|uwH~ jmCR["'xQ|8'k-rO/?g񍌒jjˆ:->U#X7|?ۃALӉĆYf6<%|M?Z|xq`5*n.Z1{FfmF 2%7(aL?su xB}#U76V:p#4j!xeRLN[G'i_~?|qKK~:hɫA myiʳ)4,~"WFg|3> XQiFn}-cWi ͜}V#o}\x ? +wFu+K8mcf X<1,@J2:;‹E[/Yl.[ՖY8{T@C0Gm >"O ~z+]k%kG,2YlV ̖֫Lʦ;*L'uq^ |G|' ß> iZ_#6C6yeG̽\3 *~ȚI?PFv.ĚjDfc]".dYUĞg-~]0#EV20y5 Œ?X[@%I.d\n nBDͽ#>*r x/m_ M?޽#ng=SKHV\Hb[XF@?B<-^xAu]û~Gn (A 6Ƽ(NI?k5&k?C5w54]^BvM6OXqʜ# xMg'@EPEPEPEPEPEPEPEPEP^U'ɬ3Fkkʿd5&hC zQ@Q@U4:sg:p'ǧooK٧[oNOc\OŎKi#&y>_C((c]$Wş5~ҟiS—<_ɼ33_k1B' be#o8@%2B^28e֩x]Ɔu ",Wh Qh|3y7?? -| mxY}FIKV#i  ƊWtqRk?Iz ߍ|{ˁq7||bN3u$םg>l_jT]Ϋ+mz#lWmJwxc3ğ_쟮s Z-jY"X\(#;lxwUt/[X!;.uY| ͋"@ xb;ag,Z{x,EbSME|)4=E.b ^&#iA 𯅺/:O/,TA·9tmOW6bl4sCYd2}[~Z ]%Konk<v[Pxn%a@$VF,i] ?~+ 𮝣/>rkҴ_Ϣ^mqM<6ږ{^7*>*k_~$hT/ًUЯ4Z5MC fm ;",qeZk*GV5_h‹4r77qAΆ;Y.6M^ٗ_ |hڝƷpj:ݻK+wp UT| ⯉ ΍c?讦X=.i:x/jh5؝.(_OCu=# xŷ"$.m- FvhaaLnc*vyW/Aռ%m ^ׇti1q+4;eHZ;Mg7^^U'ɬ3Fkh((((ʿgx=cJ zyW AU((((((_9=Wו|;oGjZVaTy<@4ɥm7ĺB.o=Kg"m@>/MW/2KK/!խ1]j9 $1ĤR<{>OOub^[x+mE!n;x 1<&u}sυ(?'cID6i,pƖ7~\0V%góyW/t_xOwq'-~֗ Foum"-,!ktAs;Kr$7 #F|m}؟M א jkG 5^N:J2n >@7?-\e-ݨvKD*噥.\W{ݾ \5sj:t?ZPQ[kk9 m?UŵŠܕF/<5ʁ;XևVE)/x4 ?ThBBycuv-Sៈ>uMJ@jѺjyowi ^EB -W?:|uO^7zSK2kCHHI!<ʱ~ox3h$Q, %R+/e5ee+{-k}obe{m]Hnb  JWZ5 h'Կ|IMCej>|=&̐}άۘ95gŏ'nk C{˨w^{EgCF-*8șP]|U/^0gj^+ծj1mf yTmA{t1O\M~ۗ^'Í?5\. ͼ /`alN0|=ŋ-Cz\ ޳{ .5Eޛs+D!70,co**%Ow?k5_? QfV (<u?HtZ0xW&jVmy MeoxYb.H) s|o;\ם~'S[ԼA\\ZkP}4NeL)vmufF% Zs?AG>7C.hE^{7C.h=KQIxž6/|.t7XD+G.HX.+5_|o;\(z_|o;\(zVíiW}Gow 2[LT6Wxt`pAY^7I}T"I$Iff%ؖfff$O(|o;\uhVQB?1tY²J, Y漫ύP}˚?EwU*%Ow?k49 sUc_^񿂵NmV+·6O3]ـKv$h袊(+ʾ Ec5zyW(s{FU((((((((((ʿio'ZG~ԇNU*i9OR:V ( ( ( ( ( ( ( (<ßtLkZwiWzBkqwnNxк* ˜57?<3z~M?ޑ|g&׾"x]kuvdq+ %O$_?o@_[/OE?o.5mn&ea*U O4T|-炾:|2Ծ# 1%W){}h]<(l/MҴ=5ƭ~] ݴyW7zFXى& u~3⟍?oOQWZ\Ѽ5&[HVsIsS3ĆMXLEf"?2_|[xkxO/k[Kxxg. h-u摢5?1ޏ}~|I,|gGfZMƑ%7s\q:)0^4_*( |#'z5 {gږLkAy\IE%o0-퟊_b^%n+> |)ޟ>׎?퟈44M_Ck &I֞fd9ܶ+!|+E7^xSx{WZO_No_*mH[{8+'"Hjb2|-kOh6:mƟp6S 9S20FAO5!VYbf3PEQEQEQEQEQEQEQEQEW~k?LѿZ;Mg7@EPEP~?NY_+R x/kc}}&R#[K`V'l.Ӕu,٧I֯c?!ko(>$|`=Ḽm}C076\Amdm,%YYT#A}S; -(O. ֡kizuq0U`y#i5?DZ|pOė>(Z^,u΁+:\fx(b_^A7KvOhx~=.-f܉22+ok`*6|;b4c0Kxg]? 6ݭ5?%Quʹp~1xZWþ'Zm#/ 4ˋ$lt|F0b/2Fb{| us ٺ-mFt2륗~RJ8;~|ws_{ywm]?\oSʹ{'YI&$2..1("c9 ]hV{:(9Pl2U`@*(((*~ ؙ 5_w4o!V ( ( ( (3ݺO^^U:Ȼ8^@Q@Q@Q@Q@Q@Q@yW(s{FU*7%vhJ[Oo_b֮t~lHA\ Cm,F_K?|WMVSPFK9iLDUT (go j.$ $NV 8'^sZη]Ҳ{/>O E}$4߹kDk2 $Keb}Eq_|#kǷ:n&]--.|,Sq6]J?b ~^_no,hiVI ]|X8M wO)|_]u^#z^Q@6MvnHHBPk*?e? N׵=SEy7xozx\G/S h- k] Xas j_b|7tt/ WD-RoK.$Vyi|UE}E|M&Gi~(Դ_5=n2fmDwM`Us*"m,ٿ?b+SJh^L#oP!` Z(gW>;|0VwMӿ{_ rmvg%H?oN]x1wUkֽ&he?@Q@  -|@qAU<[??G4 LjVio# G7!Z(ʿ᥼#@n  -|@qAU<[??\E?^=kYΧX~mֲGo{ ebI ( ( ( ( ( ( ( ( ( ;Mg7^^U'ɬ3Fhh(٧I֯c?!kkʿf'Z~,ԇQU(((((*~ ؙ 5_w4o!V ( ( ( (U]E{UP›woUQ o] U^EyW)v>U]E{UP›woUQ o] U^EyW)v>U]E{UP›woUQ o] U^EyW)v>U]E{UPi.ν|NPX4Oj]2Eu6dAU(((((((((((+ʾ Ec5zyW(s{FU((((((((((ʿio'ZG~ԇNU*i9OR:V ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ;Mg7^^U'ɬ3Fhh(?fͽNjϷ^\j[^8쭼ytč7#e44G?h*i 'Q  @ÏNU<??G3O/?:Vf_u>8!Z(ʿ|#AqC4G?h*i 'Q  @ÏNU2)}39ZF,mC0D8s e'ZQ@Q@Q@Q@Q@U:Ȼ8^^U:|dC)TתEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP^UoJ/oѫkʾ Ec5zQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@UK:?s:uzyW-$HQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW~k?LѿZ;Mg7@EPEPEPEPEPEPEPEPEPEPEPEPEP~%?Vo/9O7QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW|;oGjBJ;HWtH4_VcZ_><6"n'ZLӨeqyR;*( ( ( ( ( (!kO6e^cTby.eϨ&,2(,g"=z\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր>7|-|]}Bt>EY$plgPr#/kK3oj3ho.fi^ysvf E ;VtqkA?@?;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր=V\.=Z?rxO-hh*!??;'@ր8ླu׬/{}akiM<2O$Jw-!ua^W+|>wo/5O沴l[uDbBoqh<]D'x{0x8@UUZz+ʿrxO-h!??;U'@֏\.=ZZ+ʿrxO-h!??;U'@֏\.=ZZ+ʿrxO-h!??;U'@֏\.=ZZ+ʿrxO-h!??;U'@֏\.=ZZ+ʿrxO-h!??;U'@֏\.=ZZ+ʿrxO-h!??;U'@֏\.=ZZ8|;7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_=VI>7<)χ^_= ӼaSA-RId|"u>Iu_ԚO.gL}e@}"qYWW|oy SQ ''5z_|oy SQ ''5z_|oy SQ ''5z0O?|3N66 ⛍BXfKZ)tpPC^=z ( ( ٧I֯c?!kkʿf'Z~,ԇQU(((((((((((((((((4sĞ4_ O[c4J. D2< dfk^(?l>!y|)G[2{hBSu%2Co vG QN@G(Džhmɭ*c-+ZᇙfE %8˕SJ~vu/xSLεKE׌K:y ̳BC{2|7|1O~/ ׳uQz[i-c|=ʶEF$͎Y*WTSj>J4XM-Ao}qAۅ˰@14? +px'ÚOk/&(J,i[Y"I%6q]ߏ 8OOIiڒ9Gn|bvFZRo xDEi}^BItKpƋt U(T;C_-4|1aa %|Y M?Z^nnn>+DMp Lj>-oD4>ҠƓ.xQX[9%~Rr^*c2?G>MH5'Ş)杨g@=:cUɚJqw_5Vqw3L*|n+ -{⏄tIDvbn}\Qvdx--mҲe__/V<kt Ծ QtjGr7R=> @>S⯊58|7K.K4%6Hc+(`} jO:_<+xDnYCXo*# چsxLKWE5kD C`a +L~][goZO$ !olVlmW u崂X}8[o%K-KP-&"K]Im\(2OT.&5$~%]G)?=SŞ'hhb8t;]yfuc)rjAπxP4Vf|W] XHJeyX׮GMxtxV$m)Gb.c?qr,HT*pNė:]ؒW~:k84භK%p?4h叅K?)uO5*R]bGg^ҵ7^|ZE{wne,QSW Z[k:˦[Og~'[ݽ5IoڣZ½gvah:47Ycom"g( hU[q@៍M-L5Լ] :Լ3XCE{60ˏ3Zw4=c^K gOִ'KNI.,/;ޠpMs׋x?E'u >xuM8m<e"k'O6o$K$bqҫ/.M6$_ ܪDlZ6#ܥ @V<%x~./Co>i3MlV2gg{g ?M+G,5bM#ZK]/RºV¬=Ic $u؊Bgj_/68 ]|!^q}+6,yo2-ìcU>HE-*xM)u{ \RZ|ͭ RϹy<}@>oIxPot}WPc_~^On4"o̥@-kx?(t!M-}pafrA 8(,>??d[fk o~"j2]Z[׺hFY 0[eb(`~zVA?gM+JJ?Pϲ][lp6f@^h?Z޹Zx{HѮ/XP8WbȊrT@|do|O|?צEո ʈmE'F@cR|0>,Ek|׷ZlvX]=[@VEs,1I `RNj;|OqP/z>_=<1kvR:>S#xzbx/Ay-͂ ͐p&*=<$|Yx]Jj!+% grq3׾xKmƧ cIԼ j_jF[i|`CDR8* p#>7ÿP_[{yoBDdC8;[7rȻFI_~7h߄T]n]VVӥQjKqpvv[iO,HF?h_!߈t}Fo(ϻ 踚@HPJd1_ګ^9<6~OIQyc9le#,)WlHDT/_/{X{MF=.+zN ٗ C4~T3fGQ~ԟ|=*ݟ鷞!fGdVW6Jí󘦌f%GBp@>յkJ;};Mn.X$R#UA%_9|߈^ AMse{YMmW76&{LleƲKcZ?~w/ۼ-n^-ōŲHʹXsM$$#j s);LAHi_\ݭ%ΦזQ XgĐ~ 6m-A_6Vk>/<~d-%ƥͷ]r˗X~/ƭNov~_kZí^SF!KlnmPnp߳^/ o xH-SRv☵m59˛k m"%!U555>4SiFGm/ K4Q -FE|F|q >x~<&x{}2)t|܊0؞+9}CUڗ[A{|Ԭ!>#ӧ'Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uzr( 5棧7UZg |CxuxQoDHRVxBt_]E{T›woUP?kx M_Vk:ßYK1#Ms{&nу,O+N[ @Z~,5`YPޙz/|3v"`·PDH!ޱdY_]E{T›woUP?~VPе.@+-(tZHm/$(J:G#*VQ7.?ߋ|@=+Vlu*L6exJnee$# x&xA~ uK0myinsxs׎<]~ZxWQW4 Ń"GKo>4So ^W,g*J4y  ܲb,wM*7.?P~|Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>Uz_]E{T›woUP^U o] UG)v>UzyW-$H›woUU[Tפc.:mc2E崺DHWR@ph袊;Mg7^^+OZ?hap6@ɷq6Te'kWߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@: ࿂?qY,|?o&kO[Z?.Y­*q+*.yῂ?kZf znٵK=7F-\Iaw5›woUQ o] U@~:k˩G4&KF,c/)*Y2jM^iVwq,Wс `A57.?ߋ|@-I2J$Owm 6噆)dXI<+:f$Fю ? ^<zǑG' G܊r]E{T›woUPkkKxG:?t٦72YYU2T*7c8P; oEUzr ~cශ47Lޛ/#X8+7.?ߋ|@:Ii~=^ɬnUZԾ2|\OxG70kХSC vE 2#B?;<^-Px֮Pͥz௙k<.Z8s o] UG)v>Uy.YU5ⅺwu֟rװ澆;m*\ج1bW\> x]O^6L#u-bkgE%C.Ғ1tyK8F-›woUQ o] U@<';s˨xr?iwgYHi47=MvRvrV# S~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*h*7.?ߋ|@=VS~.|=ʪ?M*%Ow?k5ZK3k_Go$,tV &+qpڗcka ]M p+h(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((Dd<0*]  A ? B*gh-1VGr 3C:\Users\ganys\Desktop\*gh-1.jpgR5FcvI9ʚH xFš5FcvI9JFIF``RExifMM*bj(1r2i''Adobe Photoshop CS3 Windows2019:12:04 09:08:17 &(.HHJFIFHH Adobe_CMAdobed            p" ?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?TkkC[ ޕ4f}a^fl"lY.i"Ô=zOm-OU%;i,k_KwUV.}&fZ )I$JRI$I$$I)I ^ 7-t7vl,Z=Fm&ݎس[eFِ61ztUHzJv$x졝) <Pdz_Cg&H[`,FgNr)50-5tפdz@۸ݼk/ٳq^|L4*clzl,`?IMuGS!j~I{mL.5uێ9>eWWg疐q͏ĸnl~vIOka%D .cm~ڟugm;mV 1m 8mCp=i)/~ ,qo0R2k -kC$\׳w+i)I$JRI$HG"7KLc[-~n; 1VuyWm8d[͑fڙo(,e6+Nm6{;wWO;&ke/!mI,yoUg%4[S˭eN]Vݵmom{ORmC*h{ 0-)fodϥW 6UA&u])Ta7SUunot*˽K>ݽel6<ȘT%~mԱW8h]űŅ7: x$;]| k?E_ױ Hmhy~R+gѯݵ_c(h-=4.Q^NIKosQsC\\l VVZƆ&,GIO1 C#o4cGkXыHma`V]-ǽV-{lwlIz{c,kO=]RSGOϥTlh,l Ʀ r,fzPoIJIEVHGYpIICF?Vo}=pǸ{lILێom!4Ih|_j>92@`"`3T};)f5۝eQ_+5s_ C,x1$xo}5mhiu8lU{K75qmm[2'BIqeVl\YSȻnOI)B;sXY_M\Sad %$iݬgs7s\}nK3 riY1X^IqUV1Y]6{Rk6Y1@*ұڹ\Sqst0LmoY*2qnRW_e_oXm949p6ew?{,U_etlo z?Jvx,̶[v;*8 ]uD4mnmC߰o߳l;/]_%>1\,.su~m -ulr̷ۢR .P--{F?H㼊kˏ}^6mYf]a0n`ksumu^mUz)S1u:Z.[uX?m-R뢪KXe׽u?νj C5_oIIP w"QIIP&3؊6QĔ wչ wչ%*) )%?QKݽ:$h5< *4oӽ 4>*L$cK6olkl~4lpSv,m-hD4kvTΦ.eZ͕Zʽ:ëͮz eYkhms{ݎv{,v$@fki>c\1&[/pDlrV t哗ցfX =]ʵesscKZAFbJbo6bHAwlꭵZ=NݼϢ3՛ew*Xa+ޠqs/vnش='nlKRc3 {F,VbSkEwWmm{lkk:C,=px~9?BlZLs)5NH۵w$ ݅mOUeLs-sKC98Y6c^4[[lWM}K"rFk]nvKkwcJuU|Kj\j{^kaw򚁕e7:oٷ- T獠5<<~kYne.vEaEUl{} 3jJwP0Qk/cK>{?k[^ָ_{}EVWI;@v2֟7Ĕݽnn׻}KZHov] ݛzuz:Ϋ `7#!?)/xn^?GbIOk,cvD5\dOJkzS 9 74?vUZc?t})}dXь wb"˶mv\ߺSQ^;_skp[:ٷ{?~P?sʥΪEάC m{o$KdYMĮ6pvH6wQX'4:FUq-罾6gU?wElmx#!cN50V=~wmĔ7ƶ C2fחݞMZVY]pc&Ʒݻ'LgOc {/s\麯Gӯ1kkuOi}/q Lg4ϭiiȩ%֛hwu6=ggEz>FgP~Y94[lksks鮪ZΗԪ3T,sӼ[[?Ы[#vF!~U$Ynp}vkl} ;oL'SM`o{7麶o|{6V3]rOǛd]kJe5\j}jsNFX^\39ޟ_)kv[s9HanOԺ}y‚e=չؗ;f[ZKYmfS-s+ok]sVTW1:]vf5U;e9g-}/nu>)ήEc& .;gҲƵͪ_oɺ\MaUkkkY{S_F.]&XnvE'6^q1f (sA w%E6~i)},渶H<}G2c߉K>a,9UX<7cemt'Ϳ+?dZzNm[f_ߠsM۽IN>WU;#bH~9k=q@ON.gݙSu{6TYOk?3'UD|STI%,Em܁UaT>5 "vc*pnv]ˋ cM??2ͳ cmmskckw;mDcF=~M2Ľriʩ;kZo%Tn7Y ;"\ưdg=v¢џ]qc_X} {vW*WȠfX*&Zǚ+L{mv#k7JJr9efjh ۳ ~oGBѶlVײ2o̚M5nimnݟe~{:n.4Z쫍L!ېc%o?{IRLX0=º .g~kYAnWPþĿ9GcHks;E cuedUmpGZncmTtVkzk3nh~߷)Iq#f븶ng?ͪX]%nkChq~YL=EUtC-[mk;UfJmW%[ĝ\RR!MmV81Kˬ{%o-Ahz?c~?"^.,;S^*l==G}no菂iK\$vIOPhotoshop 3.08BIM%8BIM``8BIM&?8BIM x8BIM8BIM 8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM@@8BIM8BIM? g*h-1 nullboundsObjcRct1Top longLeftlongBtomlongRghtlong slicesVlLsObjcslicesliceIDlonggroupIDlongoriginenum ESliceOrigin autoGeneratedTypeenum ESliceTypeImg boundsObjcRct1Top longLeftlongBtomlongRghtlong urlTEXTnullTEXTMsgeTEXTaltTagTEXTcellTextIsHTMLboolcellTextTEXT horzAlignenumESliceHorzAligndefault vertAlignenumESliceVertAligndefault bgColorTypeenumESliceBGColorTypeNone topOutsetlong leftOutsetlong bottomOutsetlong rightOutsetlong8BIM( ?8BIM8BIM 8pJFIFHH Adobe_CMAdobed            p" ?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?TkkC[ ޕ4f}a^fl"lY.i"Ô=zOm-OU%;i,k_KwUV.}&fZ )I$JRI$I$$I)I ^ 7-t7vl,Z=Fm&ݎس[eFِ61ztUHzJv$x졝) <Pdz_Cg&H[`,FgNr)50-5tפdz@۸ݼk/ٳq^|L4*clzl,`?IMuGS!j~I{mL.5uێ9>eWWg疐q͏ĸnl~vIOka%D .cm~ڟugm;mV 1m 8mCp=i)/~ ,qo0R2k -kC$\׳w+i)I$JRI$HG"7KLc[-~n; 1VuyWm8d[͑fڙo(,e6+Nm6{;wWO;&ke/!mI,yoUg%4[S˭eN]Vݵmom{ORmC*h{ 0-)fodϥW 6UA&u])Ta7SUunot*˽K>ݽel6<ȘT%~mԱW8h]űŅ7: x$;]| k?E_ױ Hmhy~R+gѯݵ_c(h-=4.Q^NIKosQsC\\l VVZƆ&,GIO1 C#o4cGkXыHma`V]-ǽV-{lwlIz{c,kO=]RSGOϥTlh,l Ʀ r,fzPoIJIEVHGYpIICF?Vo}=pǸ{lILێom!4Ih|_j>92@`"`3T};)f5۝eQ_+5s_ C,x1$xo}5mhiu8lU{K75qmm[2'BIqeVl\YSȻnOI)B;sXY_M\Sad %$iݬgs7s\}nK3 riY1X^IqUV1Y]6{Rk6Y1@*ұڹ\Sqst0LmoY*2qnRW_e_oXm949p6ew?{,U_etlo z?Jvx,̶[v;*8 ]uD4mnmC߰o߳l;/]_%>1\,.su~m -ulr̷ۢR .P--{F?H㼊kˏ}^6mYf]a0n`ksumu^mUz)S1u:Z.[uX?m-R뢪KXe׽u?νj C5_oIIP w"QIIP&3؊6QĔ wչ wչ%*) )%?QKݽ:$h5< *4oӽ 4>*L$cK6olkl~4lpSv,m-hD4kvTΦ.eZ͕Zʽ:ëͮz eYkhms{ݎv{,v$@fki>c\1&[/pDlrV t哗ցfX =]ʵesscKZAFbJbo6bHAwlꭵZ=NݼϢ3՛ew*Xa+ޠqs/vnش='nlKRc3 {F,VbSkEwWmm{lkk:C,=px~9?BlZLs)5NH۵w$ ݅mOUeLs-sKC98Y6c^4[[lWM}K"rFk]nvKkwcJuU|Kj\j{^kaw򚁕e7:oٷ- T獠5<<~kYne.vEaEUl{} 3jJwP0Qk/cK>{?k[^ָ_{}EVWI;@v2֟7Ĕݽnn׻}KZHov] ݛzuz:Ϋ `7#!?)/xn^?GbIOk,cvD5\dOJkzS 9 74?vUZc?t})}dXь wb"˶mv\ߺSQ^;_skp[:ٷ{?~P?sʥΪEάC m{o$KdYMĮ6pvH6wQX'4:FUq-罾6gU?wElmx#!cN50V=~wmĔ7ƶ C2fחݞMZVY]pc&Ʒݻ'LgOc {/s\麯Gӯ1kkuOi}/q Lg4ϭiiȩ%֛hwu6=ggEz>FgP~Y94[lksks鮪ZΗԪ3T,sӼ[[?Ы[#vF!~U$Ynp}vkl} ;oL'SM`o{7麶o|{6V3]rOǛd]kJe5\j}jsNFX^\39ޟ_)kv[s9HanOԺ}y‚e=չؗ;f[ZKYmfS-s+ok]sVTW1:]vf5U;e9g-}/nu>)ήEc& .;gҲƵͪ_oɺ\MaUkkkY{S_F.]&XnvE'6^q1f (sA w%E6~i)},渶H<}G2c߉K>a,9UX<7cemt'Ϳ+?dZzNm[f_ߠsM۽IN>WU;#bH~9k=q@ON.gݙSu{6TYOk?3'UD|STI%,Em܁UaT>5 "vc*pnv]ˋ cM??2ͳ cmmskckw;mDcF=~M2Ľriʩ;kZo%Tn7Y ;"\ưdg=v¢џ]qc_X} {vW*WȠfX*&Zǚ+L{mv#k7JJr9efjh ۳ ~oGBѶlVײ2o̚M5nimnݟe~{:n.4Z쫍L!ېc%o?{IRLX0=º .g~kYAnWPþĿ9GcHks;E cuedUmpGZncmTtVkzk3nh~߷)Iq#f븶ng?ͪX]%nkChq~YL=EUtC-[mk;UfJmW%[ĝ\RR!MmV81Kˬ{%o-Ahz?c~?"^.,;S^*l==G}no菂iK\$vIO8BIM!UAdobe PhotoshopAdobe Photoshop CS38BIMhttp://ns.adobe.com/xap/1.0/ XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)KmAdobed@     !1xYA"W89QqX a2BR#3$'(b&)т%7IGCDt56 ?@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( A@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( "-ب6IDi"7b KC-mfJ(: 4IqFhmù ,ns"n+_]ֵe{U_=gYZ޽[\oH; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կAfK,#,6ELPf~^ ͱ4b5ooA\V !Twfs"1OIҸo;Hf#T7mNd̪Sm_uۭ AEI;L%v[T^7b+Ћ:n>FhđJ\\@Kǘ^ڋl>-\rZ:r"C7Γ+-oY Eą7qHAwzc6oDŽV2ܙs nGӣ fEf(Me3zp+{0980 @<~V|̏A?}s@P( @P( @P(?@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( YW2>5ooALo׽+vcm׶ݔoBt;߬h|T Fdea9ϒvq'ozh @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( r[x^e<$ xw-{g~]-+[[f7˒{tlۻݶ=޽{>^߲cŗy@qe,DucP<\Yy +^rG_5ŗy@qe,DucP<\Yy +^rG_5ŗyA1ύ@PhNAan$F$%{UUJ6%xPLSsaB^"mVr+ZzZ{e{;_+_L{ֶ6æ^K^e@P( @P( @P(?@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P(s˻ӭomnoPF58u]I5(-,dz]M //1*2S؁$h ,p4Сy {P( @P( @P( @P@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( M^ޖv_/k8߽+m*=| 1HPGJټ"+dk2f-)B$x|ӤIӍPWPi𧽬?m`(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE:|okÞ?NJWexgx/kaԇh ;;̽oɜZ ZF2(T֐JZK$}#aѻݎj woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE:|r-Tz;1/sF6FEʊFɗiX˒.Y9ʔ=߹ yrhԆ>GqA !w,@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( 2[t?goo|6A y j ߔLOv,,]5־J|L,~E"z S5[ݵAgek_$$<}3F%0~,7j,&?#h'( 34#X6n@p5qu @P( @P( @P( Ag2e]{:vZ >vry- mK]-6>)$.Zz"f̳;7\dʝ"f,|G*%Ϝ7env_ؿ<;BG!J+חU3<زlOr2=@ā[B9RJi׽q*fvl6g0x?;/~Vwr^rl[.yZ(>_&wǟޖR&wǟޖR&wǟޖR&wǟޖRrR;4ݝqϕRwᕺ㖜xm+v_6Ќ,lr?7͛&Mδ*k5=La xU$^wX"\\%Ze>Uc"TCHƵA&`5!6#JQvAbw8y2وиod}dΗMB-FE+LXG6|k۰Ԏ~d0NF;b03N4ڗ>oQD^x:ߪJK0loɄ;;7UX4.ě;h` M#¾}o?Y" dS 8'Kp3‘./¢ߞ@hJkfZD$aIiP\:j& ZG X25`9II&ʍ,-5b<[)Lǥekx[B]vbFGw9 0_ʊE0z@r \KD\ۉ4:QDfȪFnQj=?XƝp{:kם;x!kt5GQ̺)T?<m, {׫BcP(bnK.4'@P( @P( @P( @P( @P( @P( @P( @P(  PO\ kenl7,qY_okvh)%`4~`qM:Ʃc3q|L%q[rN* #u6t.G]DM/6|y P4QMW@5 `Rs#'`MBFP|:=|rP3y;(N>\DVJG瑉0(Tܗ26l@0pǓܧ,p[Dj+EI,RWS@0!T{ە=Yu@gM̖>5گ\gO3* 2hR|d⫖>. Z뵄 M3fw"ҙ7q1Uj# _"e6 (*lFcFe9^? I-({.F9-"^WɠJ'3طG ό2oh j܆7)*I5oXT죅ZCS `Whw#eBWYHg@tJO 0݅[m}uT quqbSfEP( @P(_A2dx傂P(\]6Vya{uu׆9gۍ/^h?=W!eo;Dp { 9};0EiQܶL9f@7Im݆u׺q8A 2H=nV wu1IͶFd1CQKf̐LR6(ӝX/7eh66KG7H]@f ֺk]DVRWx^wN܅hxcp׽\s tr3Y pqvAp'gmٱn#T(Jǟ[L5D$ 3!iz_{^ֿN_e_AP(᷈%_x''A!+/N(>=W;;uǹϽ=/Ջ0Ð8 f =0Jē ͓X ^~NfD5T$2mU@ c÷ 0PÏ5 R1E$I ͳT1AX5hD 8ܙϡbL$-m'F'&1bwX =Rl!_~Ef3q;cOtl ac$Z8IBil?pweS-*ף}M8lS,9❱#1ϯ!aB ˷>&(ԽcHvPQtAOHJQʋĘi540?c$jÍ:ʯ*vSR1p/wnI\b :!A$cOW RxOmS-hfGC,nаG,JہSsqxSL0 PTąI*4:l8pQr"$z´ X+%MZFK9:F O]9-614tS'`0ڍ0J8ʆ$r=iTUؙV+J'vo (`L pNjCW,^?eƝP( @P( @P( @P( @P( @P( @P( @P( Sݛ @띺~[~K[~Kt?0Cv*8|Òh9K7IEJ/QpӴ4EmfVH ᕶw+܇|/\ORiF%?l: Bb:Hk^jvH/vy-YO.'r8[$mPŪ3 PHi= NQk]F6>rKCJcGIn eh0pTDg^mfxv |:B)2ZJ+᪩+ۡt\]tIҍB{H [,,# ZEùhDVvd H%4! K/7!ny pQ(!Y28"ۃ*̑y@¾C9 vR rdr@{WkF"^X6})NE-UƇnk~A;|J}&EoT\r\A&!MNB\E Rݨ=,Cnמ E06P(?2('@P( @ i#OO,@1aaNzva[nX,p~,okvm\$װp Y< ]\nRk#,㛞x;$%Wm1oq~j> `\#94/fj>BbL9+IĸlV <u2(1yDŽ.2`r!0,Ar@:u"kB)@UTm68ƪOvZGBЀ t-~x*:E%cVeLHS[HKF΋zxܘ'"XV8-Vȷ fd۞<4y > [J7 xp݊ ܉1,q 0ۼhOE]2m\Vj##I\HvIsDD ɓ!Xp}߬( G)#('9. S|vD%+=N0 @ avV>Y[7~;on=-~eۅǥփP(᷈%_x''󵯕{tϭ-ܶ>_{PRC6i|d,m t{5b$7~;A HWէfl6V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj2凋+%P+JON8kǁ UIN!o/߿4 V(xh2Y {`^xG?aýT14ulrlǾye׵Ovh>Ǖ/9d#bY?ƠyX@":1:yc{cd":_~okݽOm?k?ErPnd\Fb_qJpk|"u H^ݧgMt AP( @P( @P( @P( @P( @P( @P( @P( m}yZK9t|3Z{-nW{h(Lxo "WM+TrV jIZb$ʭ:z9NN0:={1X쵂pX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj9b^rY{ݞ nY[zߥZ R]E#)FDE&(z*r^JR^MaLQo\|@|F7H7m 06aXe+( @P( - Z]|oKv{{:yg$z6xB80CYXo,dR>8 :ʼnK);7ўvkK3/;OD);OD);OD);OD);OD);OD);OD);OD);OD);OD);OD);OD);OD);OD)rW/V8 8/ֶW:ZuIH#ndR!s$WpZƔZ}8@&($,Ԗ-^Ż v{c{P(?@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( A;u+vۧgf]}eDbƍZ].xI*BiX,KC``'aلY{г['V{PK:@P( @P( @P( +;mkw{{6W1ZFAa@Fs )bFʻ½ D_lGm` @P(@P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( ^ Kۯ^m~v4z`Gy5͖a+HkBsA;q@#3l[l,uk* iೖx1uc;tᓿ3O9nLIQMS>_wen+0iG*mx@P( @P( @P( @{,- @P( @P( @P( @P( @P( @P( @P( @P( @P( @P( @Pt{[ ko{|nvނ)'Ks \y)bK6F3!bҚT-G:@48݅q {. woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~woE(ܧFJ_~9Q^4R߹" lD!U\N0Gs=;1<~w{ez<(dqtr|ȣȄ֡ {YW+b Q 68Ny h F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SrqyN7ݗVDw+u(>Z$`@:gb+D`J;iIjvZ^縖q*{q4kBP( @P( A_#Yr[A` @P(@P( @P( @P( @P( @P( @P( @P( @P( @P( @띭|okx:_{ۻNn] `E eT!0#'hkfD&X Jf0pN .,V1f >{/VϨk_*siUppЄmaP]%\T ,:q92 p]EZݞ9nU@P( @P( @P( ukߥof;m KM|^F_Q }K9vzNH=^$ CZ=Q2ӆ[,(7[_my8r&UvlsƮzyrƈ:.+aA2x6gb@P( @P(+d}qK.Kh,@P( ⃮};wǥ]qc돱ӷAPmyLiAѣ{`KnSL욑Aeu7A6Kf5uDYYvc !zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKbuύHlrylkWIϦV\ol3[p9Zͯq]ݍI/C^UkF|dۈ+9xxP=TU4I#;6ߖ͛Ϩ @P( @P( @P( @P( @P( @鳧s+-ku1ַe_(%"av.jH$9漃mQf .֖;y阡&YlkmZ@}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנy,7uŮ8ߧonVW;o{xmk߲ 1X#:Hտa4zƤiی \*%dhve Z@ z FͿSiaG>CF; ӬEI P"/f`9Sf@ 5) [rLv7 ` @P( ?~{z[oku k_j c 40%H(]:1{HnjЩU;%EU$q@3/X|uF'+?xk>+?xkb׌܏gv!u8 S5E-Z@h:}CQh|Ž-ZN[p /sXAsY J5Ron=L] wuӴ\p<\YpVK-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Zj2ik$Q\͕ >gH3F#Ε KX]ʕ`ӼyŦ t xs"4;1 яKǽlkwt}o:ǶVk^׶TfG/䶂( @P(?A!+/N(rqk_cA74JFL|exBxArd+^gI& vQ6qhlV3Pi@gd{yA[__ɱ|K,Z6RⶲͯSW,wo.׽AkM̡ٟ+DG7DHiTGY0J%X3o&)ldP< <>L6[FCFR|ľl_ rﻠ <,|C8i "O),x߿d$!  3՞OO|m 8U2dj@I.4-.NJ]E>/86K'u$' I =Ia@S0 [rGn@(#F'^6 x#<8I59s>ׁmE[oN&sQh.+ "+G %ā^5a e#L^~SPn~(s2C/t),8 h /M2<@xA? @P( @P( @P( @P( @P( @P@4ή7,_lȠs~:ӯַK_~dž?9h0qǻT:anOaD)D;2hЄ{HUhmi9Pb7N AXv#1 FUf$% #utӜ({Lǩ?]ۧv͹ 9g>Y&bC:IFdy?j=DeDNF)[~H s~L7B*pNV<2,Va|Ȥ6 l爃4,maMͧ$b k|7a`\sIeҒ5<[mr@k$Ӑt!UDjD&Q`UdvF(&eWHY$ZhneUH)V>:rlju<=a $N8۳`ݛ忟8P>-flBUꖩ':'V#$kc龢)=A (QPe O RI)CBz#aI T;r3U01 :l+Vӷ^4H@E2MVn~q0I<‚`# .'3߻l9wB,^6JLA?/=YC BmII&'X f)慪3H{wﶻ_AQ(ru&'nMͧh$FuRRؕ,}$RR5gU=3fݣUcD-ь-T<@B`wrә}#,C3RY$Q6.=(Uxs0@_s~Ac\ƩɳoCS$=1,K5.3}vCݲe7l8y.0zBۿPPKs@i\oXTّA? @P( iƧ97.t~ [vPW%䟏(Ź1z oƓJ;kqbM!Pd\n /E/0{ekk;j@Hz[)+j!'Sz;՚@!rH~#i^Et{lo|Ø) "o ( '!:906$ coovmPd*-yU>BroG|sMY!b) -⑷iE'K3Dڌ2n7`P{Nl¦Tj'OH!tK;$ bY'c)5$E/Ǹ" ooa ӆ[1 g9z@7U^|yJ%P6%36@յщ]vpM{ExBvw#~NϑgiFHJDUųnz#Jd,vjy[׆7jٯ1p&Gm58yMW mɓ{cK7op\9;BmўX {~5'su'>=fS I1Yj.C\fPII^ KNH*jSi^eCĖmf+Vͨe U0zz6AIN'Ȍ˃ 0J%SC6ţv~w+<~V|̏A?}sA_#Yr[A` @P(A!+/N(s~ΖΝh?LKY-:^ͭĉ wT1MXt!DH`3&VkZ؈P丽|˃b\qKym~1ߑ :[m|/:f6ќ ucORr=r^?C:oG ʜW sэйF1Slع`&$&h* 1rqNB%/R{إY .鹬jҽNGy P-Qmc&6촫Zdmʄc!$ImVCvRVkrI #^Fas!x3/a3eiT8l$bd0pF;s&sQh.+ "+G %ā^5a e#L^~SPn~(s2C/t),8 h /M2<@xA? @P( @P( @P( @P( @P( @P@4ή7,_lȠםg|uۮyZݹc;h5ޟHy#9Dgei#c0|Y6-$u-ngPd.^*a/-+~zCin!ur9].#pAF ~;p.,#ʓI7م,- $AUE~q2hdax4i<[hT3$K'y<-v1Ȼ =w6lAyY_!˿\̣5dOrkw+q 8lIAu?^!i0̲ڜ]Vs Tpyy*՚Ad.sъF`w ʆ3=l'Iƣ? 2U\תB%Iw J/MHf@|W!4A6|lϠT hZw9p, ΠMQ"(ٌdd!t,olXF&+u`21 u7vQɈMZJ2A]CRnJ5ooȀ_?/emP( @P⃦_kkwZ~7kxokڂ۩ҋe]N]N|z %MvNbWP {͚iýWn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{\+=̻[^'yJZalmn*.Ċ M&Q5dg3ȘѱBo^G,kڵ24QxA o _ucZ@P( @P( @P( @P( @P( @P(smoo<=m{^ַm  [h5dވ떘]L:rQoW)_-T$b?If!6|vF}BayX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1>-e}Yܕ.vfDx]:۽{[S̯k{߭ࠌ2Lp;:YL8FIti2$ )X~U$] {@TbVA 7~y6yG:=İ:)8JD_ %_GtѾhA!@"ݖ[bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj9b^rY{ݞ nY[zߥZ R]E#)FDE&(z*r^JR^MaLQo\|@|F7H7m 06aXe+( @P(>=k_/klu쵻_{>31ま㗏*HP\"4THQ)Z&թ%jqB*:!8 Vc bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj/9d#bY?ƠNx\%H!{/VϨk_*siUppЄmaP]%\T ,:q92 p]EZݞ9nU@P( @P( @P( @P( rYun|Saߺƒ@P(2>|Ox8%@P( A@P( @P( @P( @P( @P( @P( @P( @P( Ael2wݾW7amz `%.yR#1ro4Hg,jً̇JiPI?4tvT|)k`l37)ѿ꟠|r+~7)ѿ꟠|r+~7)ѿ꟠|r+~7)ѿ꟠|r+~ܧ~,/y+o~E9VDvwBgYC(^tsR'pXq=vQkvztAU@P( @P( @P( ~/b{/ӭC)La4Qx%HfZ2i+Ebj^Rމ86jAs " n0珶S;O'>7ѩHis'L$-k6mжe+(/N!\0߇UNP( @P( ;z ou4 @P(+d}qK.Kh,@P( ⃮};wǥ]qc돱ӷAPmyLiAѣ{`KnSL욑Aeu7A6Kf5uDYYvc !zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKbuύX7N4yWJϯ[ܼzῂ "|4T1=nI &;_D\+?xk>+?xk>+?xkuțc{ߕK>Nx[t׷|=m||/:0vYfREz^: r@jSn@嘘)%+ n7k 37 @P( @P(:l\2[ۯg[[+ݶsW escpt;>h#gy6S&RϏ#y!ai1] B whq@ڶa57+_½xXhӯH-!$;sǮϢX0P48]ɪ;e҉$n%kߞB߸^S?/@9;ѩ"lS?/@9;ѩ"lS?/@9;ѩ"l3mL c@ 6RE߽o 񽼬6cf ۳A4RzBFy(bM{_$bF/P':M$$Ì6F`34ݣ0{l P( gչwM ~ h @PWE=\X@P( A!+/N(:gӻ{ߥk{:[ek[卭ݵ T$9ulLdLsCFQ$#3߸VT! [?$R+'AGF&+')|:<(!RAW3S2x<7WSI}+#5:eu(ʏ*J傃h #`-9.n+84q)< MYuʠf>0fllQ]0͒s2M BӀ`}h}~ Io%2Sd(Mܙ4\/S\7iqǙK*"2ry)]` 4f ,҆K6j"yދ%C(B'N'MR<1tJ̈́i4!ZAceyi1A$<6] UNPVFx*hMeRqY>dVt-¶- YHs4p"0ŢpF UguF`PFY4yQ.r?pP)cz҉F,hWSӔ'D:q&a *f[j.Br^27 e$MG`rU0]+34NG ` {]#)%~AV92 T*m$A'G |d,.m0Fl&=A!+/N( @P( @P( @P( @P( @P@4ή7,_lȠ M{{{{nc"ķtZf5ߙ $J>!J'_x@*pJa&c( NKi|^E-oѨXp֪;,FNDg$FKOxn3gBz~rE 7 Zr[ {n#=y6xS.6% t@K2[Cրq76@,jՍRؖGMB 𦬂 vv @P(?2('@P( @P( __P@&L .[ĄYlTRTajo*w ᅃiD>L"FZk?:='.-1`#%{f`Onqn1v#v'fh /M2<@xA? rYun|Saߺƒ@P(2>|Ox8%@P( AA!+/N(:׹~c{oVK=G jOr悘ኹnO,98̛K]2)u^7/0dt:D)bzTٺhV)8T(QHћFKPj.W-ĥm}2۝ǻӮ"҄S٢QL'[xʄn66MӬJh偐n/[h ok,^Df:c,V)\s\Bd䲎?dN"sܑ (%]T]rrTgPo=eiٞsgf.d8'f6,n^^)R:qLF ؃1l`-@ˋ"~O0I)ő*߲jR(V&@tV7G.HvPVѣ` @8^(Jj,}cD/3WM+Ga*~ 7EoaJ[]XD,0hpԭ\wed8otKо0ZE"hJʖjRƤ`*;MTGv!12.#tk 'Hh3܉qQr@{ҟ B{<)\$7ٸrKӮNz@i\oXTّA? @P( @P(8‚7?dSP(>=/~/:{[^=S-^H_)Q [A)Ѽ9;N vԬT-mѤz'R!BuÚVq[X"&&CZiY#TۓO YoV$lW7|ɿ+WJ{뼪M-k:mmAA &GxX('@P@K>έϏl7[[Ps@P( G/䶂( @P(?⃦_kkwZ~7kxokڂ۩ҋe]N]N|z %MvNbWP {͚iýWn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{MG^:e~(yIûp-vwnoA?_ D;ȔS6*'xZMqsU0FB7Nb-.n|THm,ߞ gp:@P( @P( @P( @P( @P(smoo<=m{^ַm  [h5dވ떘]L:rQoW)_-T$b?If!6|vF}BayX@":1V.,Ȏj/9d#Xx+Wtqo[ x}? r*-3\n]'8ɹV.!:Ck/84H{׎Vƃ#yX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj9b^rY{ݞ nY[zߥZ R]E#)FDE&(z*r^JR^MaLQo\|@|F7H7m 06aXe+( @P( @Pqun4ɑƧ' @P(1!e];'k\TՌ~0M\Gs'" mn!5 v ӏIKI)M8[DmFkN6 \f^6(.zTO :<@[uז卲[fWcn]ܯk];q{߻{( /M2<@xA? rYun|Saߺƒ@P(2>|Ox8%@P( A@P( @P( @P( @P( @P( @P( @P( @P( A;u+vۧgf]}eDbƍZ].xI*BiX,KC``'aلY{г['V{PK:@P( @P( @P(:l/[uwngZhg%EY#)! +Tl V驊@FNU 2gin4eߗx1?w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xY.;{^~7x^N^Pg*)ETkxmFk=Lk:4ՙ'ngz[)ܔ?|::*=$5@P@K>έϏl7[[Ps@P( G/䶂( @P(?@P( @P( @P( @P( @P( @P( @P( @P( v~n]:_vPB~B%7}P EXЙ`5)sDBhQ:\0-[0Q쿹[>~E9VDvwBgYC(^tsR'pXq=vQkvztAU@P( @P( @P( @P(:l\2^^8q쿶᠅}~G\q'Sɉ]Y@7ceR|Ox8%@P( A@P( @P( @P( @P( @P( @P( @P(:lW{\q=Y^ַmoAQO9Dtr.BP( @P(2>|Ox8%@P( @}['ToA?@P( ̏_?/emP( @P@P( @P( @P( @P( @P( @P( @Pu־7</ӽm˧K.jOQ"ﲪȴP\RKZ,3~pȈ^ 8Z'Kef3=+g59ȴG*8H8hB6ఌk(e ЮpP\8 _8g"xnN7*P( @P( @P( @P( 2__ؽNdzA1E!%kXɧAyJz$"*PQOM>F1"Fu̞Z%2xbDTsٶ{KBvŖdX;p~Vm9@P( @P(+d}qK.Kh,@P( A9,:>?Nނ[ooA@P( h'_˒ P( @⃦ub;h*.^GN3LGd{(6EoY 0LL3693~3S/_C̶n F<^H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կA8o#1Ǖ<[wo+ZZZ~V˧{zPwJ7g5lhq vG)l@ ܇58ΦxM & f-f ϩb߉vZ4onz0 @P( @P( @P( @鳧s+-ku1ַe_(%"av.jH$9漃mQf .֖;y阡&YlkmZ@}MW}kנ}MW}kנ}MW}kנy,7uŮ8ߧonVW;o{xmk߲ 1X#:Hտa4zƤiی \*%dhve Z@ z FͿSiaG>CF; ӬEI P"/f`9Sf@ 5) [rLv7 ` @P( @鳧s+-ku1ַe_(%"av.jH$9漃mQf .֖;y阡&YlkmZ@}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנu }'))S@B~V8ٯyQAm oW ˌVj,3W{pDnG.Bh^sիh 2dAcg1fIv)pkI߿7`lBMW}kנ}MW}kנ76+gN|mk~鍯n617zA^9$u`8'N&';#%B'u%oM9Ԧ܁m11RJV @6nOgo( @{,- @P( ;z ou4 @P(+d}qK.Kh,@P( A!+/N(86v۲?փSSyzg\RdhG0\v"H8ctK#4_!]tfڳv 1 D39,K,W2B6@4ǷӺ@$2 acTX44,HE I&};J()C+n4qR^1%_"tc7@@m=hD##xY*Ј&uv:\?PbYNjvػ h0QoM'*Rt$a[ 00#j 虓T[bIlP~39] Z-檦iO0ż/Qnw`Yw b8Sib 3&oG5nL/aƩ$괋xlܡDoU?o\gc|H-[$+߰ ,xCuCȊ0NbKxk'ቦQZSASd@+dk!+ LF8pMbƞ/ll,U$BkD%+g10R̭& Ƚ(T5ʈ6|8`zp6md@sYqA? @P( @P( @P( A8:?~"(6Zӥ__[w}ip~d'*(fPFj)H/C:m,i0F 1yXvѿFaZȱ:yc]c.=$͟ M 4܃skʿl /h`3Lؔ1i.nZhKsV4KbZ5 pf^TZN/š 0=5$=@P@4ή7,_lȠ @P( @P@4ή7,_lȠ \k߭K_+[q/v ։8>MliX2Hә53=U'tk?I.lM` _{PRC6i|d,m t{5b$7~;A HWէfl6V.,Ȏj/9d#bY?ƠyX@":1:m凋+R~1_gK[7u_*>AdWI]88Tm ߒWJEScOmsvVnv:YyC|(^:Dlh9Qr*r:ٿg쬻H($W8\69597*57Tme.A5cOVcA^ܒLCHq+? *H@u Kɀ* ӫYX3%5 4Fo{,8Ɋ\ev bm8]>I2{dö18_:PMkbK$'mY]o (f\h]Bs##¨O+ps 'n;-F3Xx.Iz/1L<=qᝯ~loZX@":1V.,Ȏj/9d#\qg7<@2#k-kvc9]Fs?tYg%6JelV)K'tnFIβ'P/q;m`-vt߫g@@P( @P( @P( @o{x/kmnv~޶M$bG{&Dg\*fӒzOj% [( O1 }^6k ŗy@qe,DucP<\Yy 6ŕo)\\on̈|׳|:߯PcAdW/M_8xT9miev> Mʰp,:YyC&tz4ŗy@qe,DucP<\Yy +^rG_5ŗy@qe,DucPtÒLhKw޿rN-~\< )QJ2%-i6yDVS"UZRm/ d∳x1E hQa -y\,@P( @P(smoo<=m{^ַm  [h5dވ떘]L:rQoW)_-T$b?If!6|vF}BayX@":1V.,Ȏj/9d#Xx+Wtqo[ t#Uru%KɤqR+. 'W97*5GD]eёMXlal(;&"qD*廿v -W.w"Lk8jS"2Qs,Xf^yA\Yy +^rG_5ŗy@qe,DucPtÒLhKw޿rN-~\< )QJ2%-i6yDVS"UZRm/ d∳x1E hQa -y\,@P( ̏_?/emP( @P( %gV6Ox-(9P( A_#Yr[A` @P(@P( @P( @P( @P( @P( @P( @P(sLznNwvwmoPF4j]p-#/5&r>4X"SEDR:C+?xkuțc{ߖ onnmkltz"kdr㫼OQ=z%bǨN6 C*ش_…|xfN,^Z0:XZȜnW7vNf-w'EygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzy7 t-n^5ߥjCǪpcѮÄx-RZr[\1>Wᑌ#xj-m6MnY²RFu^ @P( @P(᷈%_x''@P( @PWE=\X@P( rYun|Saߺƒ@P(2>|Ox8%@P( A@P( @P( @P( @Puϭ˧m~̯km4M< 󆈋U=M7%+aequC;Cj` II7Peݖ9`ތWl&ٳn!{efܭn~@P( @P( v{u׶m޷fX߶ݟ䏆PMD\2w9G&=+C5b6y3D5JZay`[hzt&­j LڑCR k!t[T(>I%= Kӻ0H%X=@ucosZ@wq:@P( @P( x//nzuE+8EWm6Z   Ύ˓r!8tf/uamFܱկ<)YlՌgʹӆNNlƽc{u/kEg dL}@ނYy: q?^*ÝZ+(-Dk >6a%E^ -vN5-~-}Z-}Z33o|y_߮=1sŷvr>~lx4vsV{dr R sSm~9Bo+Rba|k 9meFݳ P( @PB^KJI hu-^1NJRb8!6/qY "Cճ wjέϏl7[[Ps@P( G/䶂( @P(?A!+/N(:oo[׽džJzd|k@ڌj^ZG'8ވnY##@8]LrЉHV!,PZ~AhRv+N,9,B`DŽ\KA~,Զkh8b]WKZoIpr95X4tsYFn8a*>}qx(B'AcDkxGv#->[QҔ$r ۇ1G;Tm¡2ke@wB^Z<`mRNj8` ldTQR&Cֻ+{; 2,$ˆ%;"Վ-$o!K5Z=Fi[)WeKYVcp݇W FWlҽ%󨣑4@8FjY Y V%KFgg\([hIoUy9?q36)4o1e ph| 9`dy66+b97~;ǚL]˦XNkX2:\8tޗ)~kH;S/*ʷ>OҽZbhzsbH@A#vw &8u׆!xT /M2<@xA? /( sL5>?@l=}ӯN6;<rnbA!+/N( @P( ,%~ 3#POfumo{Zuoc L,7,0յj؜kՋ~]21Y9k-iQ:/VMnolCmīO|Q5:/-Nkdӏyn4E[7K[U@ !V9 ,NvѤ8|&0llK6l?GZM 8kږ$v"|1 s{Ƃx49__ 3tv&+:hdPIZcMR+HF[|##vaB-l2.;ϗ$HE&hTnA*rb DL+Ln^d%S3d[XqIz #ֹJ]x6KI86S۟6]B%Ϗ.QuI1v{ۼPjq?Zq~P( /M2<@xA?iALj ;#e[v,S Bw=u|+ۻpփwC|v7@v |GL$rRmZ6N3$YXيmM`= MGHUwԦ[Ӌm)j#E!|,H W=Xj #^͔ Y;}Dul>S*$t,r$ReD8F<*h{+N˯9`f/rZh b& wxȏI.~5j0\N#70uL6*Qfi G@ i#OO,@P( q4mW' @P( @P(2>|Ox8%@P( @}['ToA?@P( ̏_?/emP( @PA!+/N(:ۍ}-{;zha.T.@ܽo' aO/3e6?k4h9 dlKfxZnǕc=w6\=ۄk6WQs>T7&n.~%|XYE`6DV);<Ў"ɩPf0D91{F! k&aې{jNp/Y,{S`.S'eh NL%t8HԪ*$|%mĢ3ϰbV;!QqUz iZ#жQ(׈!C׉@O h!Znzc jCfg$FMz8 BuM,XNBSXV wvWf{/p  \x?t@P( Ay`+wg~77ۆV{ue{ke}k{(5}M>U |aaJJqJ{'hIwS,'f׋XmN\X$H2-;O7 mt  XE 9A*=d^rI†A+2_@ݧbp9Qmm0SǬUKɯ9sص1t%rhx=FWuk/q{c(/%7!|feS/"56o#0 PsڴjE#uאk-ofps_u_sMP( iƧ97@P(8‚7?dSPFIzLDm;vn`0͑#; H+`-#RV@pRt3;ZW/$ހc%yTO'D(%EC8,L[)WjI")zlp0 ~z&>(^) ˸o hI&G8]<-sۚ1MxDPPb~9B($96CV5`&i*ьjjjs̮&0"B?NB^11n]c91__P@&L o*abC򇒗ZS7 @(Kot{Ow$'/9d#bY?ƠyX@":1:w%p\ǷABxajrZݮa6rG]ĺ JToEc/jؿS4?g#ok}w0Fqe,DucP<\Yy r僋<I/[]Ƿn_5s9(7qTOu.#bNЊ_88sr5H>u:Yx{mnӳ[:( @P(!&i%R@ЈTlr"G% T*bHį ɔ@agt6ۆxeVo*abC򇒗ZS7 @(Kot{Ow$'/9d#bY?ƠyX@":1V.,Ȏj/9d#+5%|S!W<¶D E5W+*,K((S*daIxfAӴ(s׷ 7ɟhi$b!@NG$Rr3ҩ$p1)]4@PLD$+8At .5׎=7/9d#bY?Ơ,{C^ej,J1~pTHtfu;%dSmoqVW E@P( @P( @Pc;hERNyUڵbB8@dN.!ひwI{Efmy{|'g.l߾;Ј&;v+ڞj蔅j(2PXX[N} LcAFc~޾}lmo߲P( @P( @Pu˶׷{vu{^׵x?ւ']ř 07ʹQN`>5f4 .J'0 ߝA, @P( 8\6P( @P( h'_˒ P( @P@K>έϏl7[[Ps@P( G/䶂( @P(?@P( @P( @P(:l>5=IJ$ӄ8Iʖ^9B I/R\<9al2ָ}uܤo+Ȭqֶ](_e?7)ѿ꟠|r+~7)ѿ꟠|r+~.rӶqnt\wN'~PS3[O`vy0UZnheJYN7f{dRP21i a}hׅP( A &GxX('@P( @P@K }x @P( A_#Yr[A` @P( gչwM ~ h @PWE=\X@P( @P( @P( @P(>=yve[t㟹~ǻ_}xh5&nR%/?6zs\X#qinID@J:8w/,ݘ=\{=oԔ=rKu=n0gŻkPi>))> "DlDT{u2iJmܨs*~Fa-Ajy lwLta{6m Eʍi%^4E28lTÎRT Tգ"oV2c6נʴ @Pt׹\ۍrnk{[Ы8W'0wGt+9"VUJU~RH34xnp3oҞ>ٖWXmJyi[&]$(4֡Bs51$0b{Gmbx8G-nWP @P( ӷ;;m8c pd8Jp3 +)8C\Ra [HB@lq+,޵Ө@_]{' ,nF6C" `sx% OV*oX&9=]6~P( A &GxX('@P( @P@K }x @P( A_#Yr[A` @P( gչwM ~ h @PWE=\X@P( ⃮};wǥ]qc돱ӷAPmyLiAѣ{`KnSL욑Aeu7A6Kf5uDYYvc !zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKb<zXyKbuύX7N4yWJϯ[ܼzῂ "|4T1=nI &;_D\d ‰Ee烍^Yc0{0ϒζ'z7L{m|qN?R~mk_uZ_8=KJ @52)"6@p?>mT)h%kġjh919tmѾk >0 aE׍+c|7jկ+Z2Lh>7)ѿ꟠|r+~7)ѿ꟠|r+~͑V>"5w51Cz:?Kf9he yM8uz_mטYsekue^._n6_=x{n|z{jS"$c}&p]ƚBG= gIt{YG1@x%NT*eԚ,F 9pOrאynS~?%r/?@F;7W"SnS~?%r/?@F;7W"SdrxEefV\m~(q[_~ᠪAB9CH E  90/ nИJJyfZPE eqP .J5lwrϧ^|z|(ܧFJ_~~Smk=9*Al{^*>afH*pB@,bG"LQ =xp4&7Y= GXFz :Ptݗ{[fX^^ZonPS(i|1*G-FդCܬ"D+?xk>+?xk>+?xk>+?xk~: >*r#ҏzQ!>$3l8ZpJpaqY=i("vjݯ|HPdSJiȳRu)󚂍'lh"OR>dʥe񫛙<mT'j,dӭl\D}a\'W {]ģ xF*@6&-Y<ԢtM[TPۼmI[-k`1 .3- oKh2dYioZ)+x `fileqf#<('6uNhR!I7ex1@Dn yyIP78 @P@o,Ӡϒvq'oz3ku~_m/zݝ} qXݻZ2P $>m#HǏsFЍ`}U) BQM9Z74| n~xPF47k(qܚA`)cJQ&+#UG݂y/ƣ}d|zak;u˯۳_;,n7]=N{@P@K>έϏl7[[P@K }x:/ӧ^tokt/A[#$s3,[X񱳩wH/-b R*h.8$:9M)2J[/Jx,MKXXd(3$/YNѶP6P#ͩUjX8)GQPM$*;QvGM+ &ſsxE: Mnچ%q]哆-QQfҘkVw^/^ޢ3D0UXX* JZYj6YռVfp۴y#pY- Q9EP['JnV)IlZ.Y(7&aYNcK6ѠpŇѼ2 vKD.(KWY0,rF^\Rjg%K^0pl4:B %gV6Ox-( oJ5.BfRj|hƉ8]:r@F;^wd]4DҮQYF| s~&v!JWa\,K Mn~a$&#(EƫXʷ=ۨL=%Je8EpS+XDf pBqkʪK2 q4FEil1ukPmL#Ңi8P6 sa6 ]x`Qߕ,HiF[*I6@!]v!''r|-;h՝$5-""NcT g[jQ5xuD%nPHu0=Fޖ@$i>  %l((ZB"LÍ%⣢VǦ jb҅*d@SNҋR48hgsn: m~:q ;A_.xrUz( __P@&L 廐f07fy!QJv( .P,Z%Q2TqK-d@Q;;T/3^dXOϓN8|~^2 ,8^Ɓmنrȇ&tlvHa,D]B8+PFV"-o&ܧIng"wRn͙ P( 7Er\isg_ 8ٿY "97& {Yjn~#ϋn[1G&}q߫f 7gDy1& N!'2uyi,D5M< :Üszq)b^j+=_@@VMQK҈v@Oaܡ kOn8dtz cRo x:}[vLq(@b<*Ӛ7I%[${ u LYʿ$Ll/ߑnߑ2!02cp=O"\9`7bju]li7^ DvMm.ͶPf(JYo#qU7)xGEJ n:OJk=ՠhpRhXpAJfdag_g\{wh '%gV6Ox-( oJi3*.)Kqi[)l&ꍛߺr@2g!^()hdx=|*^8LB-X?Q76zR֕3 UvڠgF?nZ@}C&"~Wp>/qS0+z:MvBH䛪`K;(CE`7۷ Vm ҽJ-TsBQ\`p+h@R-7nE4"8[:էﯴ/q?Zq~P(  PgX~KbVRu X=ܭmdP :o LۖJlPo|o~ TƝ7xy[b /kَ6cSމp;;DDR6\PNɮVLM50 ivjݿ/{vڂYun|Saߺ‚\6q{ӳ,|?bLJ >ژ?!V!bq F)NI&EX8pI8R""YX!C&8#&ay(+xʋ,<{1+'d!U\J+ 2D^;qe΋_-qcLn]$h rp%h\Y4zP~)NjcNbpVװˏ9m/8&vPeJ8MO'cMM[5e]2[XFAtpn#O1K$vQzYRK1Jr|Ox8%@P( A⃦_kkwZ~7kxokڂ۩ҋe]N]N|z %MvNbWP {͚iýWn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{Wn'{MG^:e~(yIûp-vwnoA?_ D;ȔS6*'xZMqsU0FB7Nb-.n|THm,ߞ gp~V|̏A?}y TM떋IyvEjt'W#2 4BSX[C՝kxlM㋏v`p! W (;YM~j5l4Ubn@M!VΛ>[ZP*u#NerV+y 8<nkaᆬvYȬ;ix>L.1h%-n4I~@k6j yú~`2O!x-C6|%{K.d;F)AAis^8{Yڃ@4 @ #4>'F$XZ$3OK-DZ\>rp,1g[~[[o;?蠀\}['ToA?./ @9*=A?6+^_N|>?A zR%B4 B%$}[dqȌK )8sFY'HZk14_Is2{ݷKqzm _/kk~bug_PiW(p+Jc 0,.7'(V7iٳFya sk^C0q{A=fZİ>l`F)؉1ӻ@u]e:&k2]l0^BpLͨ#J5X~ mZڦcQD͋& Z9"@Ȳ65vk:E&aѠ ߿fͽve|&q?Zq~P|{m{ֿoe_˥{׶kwrv7AD|grc}/U EBhZRMRJ'Q&Ui!uDBppAi$(Yٍeŗy@qe,DucP<\Yy +^rG_5ŗy@qe,DucP<\Yy lrFŝk)^'9O?x4ܵYpj,Hy2 Sˑ$RkSeӤNJ}vzw[owl{:ۭ{| r |6 g yI^)ե>.%('ǃ /nB6㏹ bY?ƠyX@":1V.,Ȏj/9d#bY?ƠyX@":1V.,Ȏj/9d#XxZܕ߲-2#^c^m;zP`tò5I&C`͌xf̕R#Ֆo-IӦσ-\ @Pqun4ɑƧ' @P( @P(᷈%_x''@P( @PWE=\X@P( rYun|Saߺƒ@P(2>|Ox8%@P( A@P( @P( @dz)tT ^ظI͊Qd#K"6 /Uwײ`Xq2F=[+e[̞6׾>kJɩq-ɩq-ɩq-R;׿4NޞVRoZſeA+ oiެoܴji~UrvEjz̐HPe,I {׾oɩq-ɩq-OYL^.^y ygy\'ܦt%V]"JjX8&#@ٖ'w[2߽Zt^~ m=mA_I5S~ruK6zE,i+$c24 qHJѩN ^gXL7ݯg[%jGya/@jGya/Ag 2'~m)ǥl}vbۗv߲נ"F?]*O"{$'ϖ~QomϏ5o 1-ڑ!u 5ξMH?,<1hMH?,<1hMH?,<1hMH?,<1h8ˍH<僔obOm᠗m3bd՗kl$9n875:A'$66P ~"(  /m۷nWᑨ @ů̫8B^wWbdjl% J}x_̌4oH{^ݲïmKo׷g[{nϥۖ=A( A?߶{^ek߭ǥ҃&$ DڦB> -|fU Ri JDVS11prg4 @P( __P@&L ?Nނ[ooA@P( h'_˒ P( @@P( @P( @P( q?Zq~P( e|26ݵc,l7oku;bBV n\bT+tHc0BoT}ɬ=$3פV:#s-nfOJ@P( @<~V|̏A?}s@P( __P@&L 8ѫ^9Yyo4$^m8_;ŗNfs@NeӀټu\ m!]@P( @P(H.#x، 5āAVZ =a;[-ۆZP?XNaDMtfL2o R*`04%b7& (o;u߯qvg{Yatw~]2_+mA @P(PS#ѬP!Dvu$(YhnvջVw,P?KlF֯]W&E%d%Y㞿1gTըd)Uj  ӘlKV=3:[,׷NZַ_kg{V{/ޖ@P( @cnKeo{[gocgZ6nK?"kZDIN V9+zpL3M1泐Xp) _`Nc|2KC \ x- p`k & ݎXׇN˯KZݴ@P( @Pt׹\ۍrnk{[Ы8W'0wGt+9"VUJU~RH34xnp3oҞ>ٖWXmJyi[&]$(4֡Bs51$0b{Gmbx8G-nWP @P(\P`:j-~nmjoØq:pم8獯nPv;[۽\~1v5@P(s^/ֵ/{;-k}\‡߸0tvb m8mos~s@P( Aߏ{VXkuۮ7Zz^9ldzǥmIzibe[###eo|t2\L4 d; K ޠȑep5F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?A7Xozwo׹\<8tz[փG9_';vMh\&o0촁UHz E QA7F8s  ^v[~"$c}&p]ƚBG= gIt{YG1@x%NT*eԚ,F 9pOrאynS~?%r/?@F;7W"SnS~?%r/?@F;7W"Sο#Opi܈3ǚs44aL3Y 8İ~]rL \lLUSIb+/ M:y ,X[~gc / nd(+5v#,E)W#DɪKHƦ8$)ׅG<2#P O01f̱*wp /bߒˮw2⏦X߭qrߏI\O>QNȿTߏI\O>QNȿTŽ'~7^?ѻ nHgO۽lKٵPC37RJ&Džyn@[ngbay\!ڊӄoWLNoGoOߏI\O>QNȿTߏI\O>QNȿT8CxzrU"/?{=޽;h3T|$TY 4D]gz6hLn;mz{u0 Aevek^aۭ{{66ROJ\Xj%('ݙ S%c <6b1muޠrR܆*_Ŧ nNn厍 jYt*$ qKè .0HMz^Y^Y6ۤǀ=o[^Eelە ~ֿ޹swRE('<Y5$_swRE('<Y5$_^ݳͩ"k~/EX?8pEeƜvС 6Uen_swRE('<Y5$_swRE('<Y5$_m)d@ cnƬKZuh3(z2ZĹ-(%VљzDC nV]j1d;Q9y!1$@,Pӻ~kۥ=DJF{HBhnބ(5"*9H.SAեI/ʍ$q]m^m/|r+~7)ѿ꟠|r+~7)ѿ꟠7)/xJUO~1F^#.IOi+h|ig8ntwoE(ܧFJ_~woE(ܧFJ_~^S86:\c{2ǯ׷\on%1"ҏRh\b$M{PgbN#ԉʭ`iڕ %4-f@w=na/v߻;k{ߥ|qZo{P@7:J6Fx:CF%|*U/! H +}gٔnƢLDSmV^[`F;7W"SnS~?%r/?@F;7W"SnS~?%r/?A'{e KۥnJUk_ݖA/9Eߴ6ˏBPlrM"veFaxma~;ٽF;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"S)g"}",E*kjcԇM4yu|̈́sN):ZqR46)M}a0=xk|k[+c쯖=׽|tA _9 q=pZLAG[$BT݁pN%NbE|ڥ߹F/lHj0̵m.Oo"{ߚ<;qk:խ{nܭ?ݵH; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կ@H; 9կA(o"mܰ\qk{tex޶҃b 2qr% Y̖iziP:* .8#ZK[뛓s )u% 2ڌTiLISUH@L6o 8p1Nw %.V} żC(U"1.n6hp#^aqڸ|x+ͩm@w-P=k &dJuB0a@ç 68 PIbIGБX8~3'/ ?mFr?mFr|Ox8%@}['ToA?A\2K[zݷ{l-Xۯ+vnΝh)0۝JX)2Gpo$[kwk2ĻF&:3Z#j:kւi䢑BNQ/HN!)`jQhIؕx 77*./~ىo4|y41H#lw-+dH$t\D`iuv& "#xܙccpK,e3Ae^8Ar-PiH᭭tD ,ӊ|ynZ j+!f/@P@'+N5<@!ٸ ƟMA.f7cwRmƂ^dV"n;9 :YX?{6-m+%IAm(c1P #dcjwOFtK(m#a*], ^[6 |}^ m9gkC.B%ucNHzQ )S b-.BZj@`PdXj4nX9$)ljT:{њ'q.7[,͞ɲqp^2hZ6LGBsrz(@| Z6Z2Ya{/mk[ _.{Zۧ{}__P@&L ׏Ypƞg{f-'$řo#f>6&Skߤ*UC+5mE@h`2o}m~Ćۍ)9l1C<ۇa_ihe\Y.f5e$5sD q@e768f`>lO7lմfK9Mes` Ƴ=*m J9ѳIJecՖB50 hn!pG9-߻e ZT#B t{ C'oqws|5k CP( 7Er\iO/( sL5>V^_3w>Ғő8XܯzdG>a4ɦ*beh\9ݡ8{d [r}BidP &cVi4@泈'9mf9+[SfT,!;r՞V'7<zU \_ Zw>zVa+hô*P2Rf 9߮+RLWߊ&~JŧM9oR'%^-Wgme'r|n.W'׻Xf@}['ToA?rYun|SaߺƒL|pV^ݶl|l{x-AR\Nz B!yPo+9$} sOX&́,ܗU}m{<<Fs8mN<${^mԉĉ H:IVKR^-kF=t)1#_GV!9ge= 5:=n|H\'&AT7Aws5(̣p.E(T*QMRrr@~2lHqac#$Y"e`ێBPAysѐiDM)"9OSgutr:VGhU(Wr`\O_G|ٳ0*/( sL5>өXP=/P{шVԩLj۫_td~J㠚L,SN%Y- G% `ZBc 8Grĥ؇J, f\Sp7*ޥ`~mܞ}4Ӻ!ruw%_#Z k=G*n:M.2i9'vx<5j@l&V~q9%$XJP'brVinN5P4Q). |pۮDcl~Dߛ0kҽڔi\T|&|nfB zh1Be0b2*vx+(0xb8rθp6W?9Co##&.j,) tYF=I2Tdu F%C.8^XO8ҽɊY=ʱ; !&BVaj9 ^ex4m$|ݰ`qG 9% \]_+PSdjIiUŜ1=6PPs$ٗd)1CLD!@an,pbE l`\0~?Yyd'˧_JYv;!9: Jѳ=j23!A,lj.8Psk,z:|޶te~ A &GxX(8q4mW' @PkQ6\o8`l{zCs׿_-Xio|y!y7\D8bُ \bæ<rq'%Gj`Xm̸!yLQ~'wX ^JwIIl+X5usˑɄ*E,9<$a hta\L7^#FaG08wX (x߽ǖaqrY$ Җ]H|N*@c;Rlzxxjv7 q{5<6쎭ź+w]2íY_zP(2>|Ox8%@}['ToA?@grb<$c `oEf=lE2CVTjls8 M4'X8en0l .fƁ&<~te*/=R*2rs s-%NJ%+3n/us'Mf=l`5[PoR*?!Dh^T1,MsIuq1)}31eL|1W1}k}T,w+^4Ք(9dXtlS'H$:?29X0n@P(  POOx̊ @P8Cc{--!!V땯|o^־l^n}xlwxe1*rّOʶ\ )^*5F뒦[ ٝ iLQ.kEmA! 8z)uyxAZ.cډzd)O !3SIr0΂LH5<4P-"B+IJAQ;h9u$ &2-=H(_O|Fo_ڃ__P@&L 8 G, rp<.@$ DșI:0ēJAv8IChj4$sVgNbk 'Ÿ"egcl9r\޴SnJ5pc!&5/6Z@4*~Og91LĔx܆ysGZmA =^uh([m⥞%DOy"@sh4$Ib$yEXx9އ "%\"3€p!i? C4 ;z ou4ϳs '(:kXۧ\[[e{tk<PP'=LqkwGj.u7(RBO|t@VkM܁^2}Eۮ2 v-Md|SyH|- fD29n#^,\4Q'7MK 9嘽2B8#3;1KC*YDCHiJ/ ACw9p6vv;Q}b$(FiVrxK.D朌v9̎*K&?ģ`7=y_7@cpL|XUwXlшm.e3Z _wfX궼g\sֵP@ i#OO,@P( A!+/N(<"_hue8DLSjԂJS'ClrDOPvFh_fAD٣~;woz @XCFG &qiu*Qn.!܋u.BڱݳΙ&|Fl*-fR .lPm9%Bw+œaAoral&+ rPa|n/FѢxoџQ](A4N:6Ee 1"31n &ȶ)XQ6 f^V8HVvmAQ [hKq3Q{#Vwq0֪8%˖[TLXvWmll5'?pge,ٸ8bE>uL#->#4=ӑjH+8f##H*|]#%\WkWf+B:dm98=M{Vg2~ :6q SF-\NNg\<"N,W P*GĜnWA?P/FkNLT-U/Ӟ ^.RHEBMkhP:(qS{-kQ `2)v՞o k~T*JH5(řqʼn"mۖY2E__P@&L El+3tZ 0hHeYxqEP}[p k(seW w2&b65-l pdr}tQUJ4Afpk017)K`G'gLQ4)+ p(pEVI  F;yJ UC?P/FkNLT-U/Ӟ ^.RHEBMkhP:(qS{-kQ `2)v՞o k~T*JH5(řqʼn"mۖY2EA_#Yr[A` gչwM ~ h6[0?o:JSW#OkSA; Sݛ @i\oXTّA? M^ߥ|{m|m~wko{ײup=7ru@Fki|9I"E[ J]Hܷ)1@%)sbR==_ j)W2 n>.0+ηdDZ rfZ _/yA!15kec{w+w.nW.޸ݽp /M2<@xA? %gV6Ox-(9P(u^K/d20@D %5XL^K+RBʙ>niI|nУAӴ0s׷ 啮>0)v pŴȦ FUH10ʪڲ-!J$QE{O(y8l>8ݠZΞ/ɋ}v.u6WٵUcc;.ؙc}3 q?Zq~OVjxCqA? \~ξO}#. R%#ϷͤV( 󲆽< ӹ|f74k/i*Ї IŏȻB1"dO72֤$VV.2\ڊqm ]nA2BHn̉@C1/V8Qgb<5lZԙCS!j.)/=Fo,`s&F 6:4xBEohfCW,^?eƝ‚7?dSP( :M-jdye*t٠ĢPT.< hr["σ`͉#^63~ a1 F $уjy=N)Cˬ~~VT"l8MJ⹴%LoIcġSyŘ(jxfAbXZQV+LnJXa,h gչwM ~ h+Re W U! 5\^+ Q]&LoJu2hr8 X`tnx,-.WL{e18m[{w|l+ۮ7keA<\Yy +^rG_5ŗy@qe,DucPq,"K=jwLQCvUeSZF 6 n[AGgZ,C9E鴪I,- J@M/' ]: zㆻtMbY?ƠyX@":1V.,ȎjŞXy+WkZL|okv[׿O߳\u{W U xI,g)$ե()a$9„2xn#XŅٖ>_P:@P(?⃦u{nmnzm;h+w^e;^DnߵDBdLC s ^vf-&EHk;7ӫs/EygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygzEygz/ WO͆xquŵ~5o-Q4S"ZH?Yxldt|K6{hBA*֖]9bpvM8-j$) TjqYA:E q/ğkǕRqw+뙲㳥6~MH?,<1hMH?,<1hMH?,<1hMH?,<1h8ֽQvb-/~AXPxNc~SK2>S+T#dD,&d^rHeFֽl[~MH?,<1hMH?,<1hMH?,<1hMH?,<1h8ˍH<僔obOm᠗m3bd՗kl$9n875:A'$66P ~"(  /m۷nWᑨ>=kxon~}-{߷ok۲nJ/l9UK>+ۄFyhЙ.]qO[Q$Pi5cqku)_+[Î81Yen[/!Em̒1NA:&sT9ORđw e[Lf":elaGee_&wǟޖR&wǟޖR&wǟޖR&wǟޖRsR>,3q@0cCl9ms?7%S$]gys S{^p#.{eO&wǟޖR&wǟޖR&wǟޖR&wǟޖRrV;ۧ,e{_ؽĽӥ:_AcfhbܝNs~=O[X.rC0秎;rףlHʃhޡ^/ N=comkt{(!'+w4z ؝)X}/JBV"U1k?]5" }cɩq-ɩq-ɩq-ɩq-ɩq-.x!EdEKEۛprC=h@,G17YH'7Zvdk. W^@l~Z;4|)۹G\{:eڃjGya/@jGya/@jGya/@jGya/@Ƅ_n;97!׭Bu9=Ayj )==m Do՗HC :ve+j m=2,xk;e|W+tnçK[o{P}@P(:lL2Ӷַzlqe{x-ރknd$ n78–$l l+X[zEnxv @P( @P( @P( @P( @P( quqbSfEP( @P( q?Zq~P( @P( ̏_?/emP( @P( CW,^?eƝP( @P( ipO@P( @P( %gV6Ox-(9P( @P( ̏_?/emP( @P( @P( @P( @P( quqbSfEP( @P( q?Zq~P( @P( ̏_?/emP( @P( CW,^?eƝP( @P( ipO@P( @P( %gV6Ox-(9P( @P( ̏_?/emP( @P( @P( @P( @P( x//nzuE+8EWm6Z   Ύ˓r!8tf/uamFܱկ<)YlՌgʹӆN `=[0]lї6`]Ѫvӿ@-|6m>{olە~ѠP( @P(>=yve[t㟹~ǻ_}xh5&nR%/?6zs\X#qinID@J:8w/,ݘ=\{=oԔ[w(2@P( @P@P( @P( @P( sc/Zghh^[Kd 9~YZc~vek)σ~EOZ?iryb hGi3} ߑ醛cO#avl ŠP( D56WD)LQ$O`w^PNP\`"w熝uy[oz)+ZᖻyJ%̈덺w{危pkckkǻna9ojbY?ƠyX@":1V.,Ȏj/9d#b˥rW/b\~c7[udlx8d@L֞ze r~g \DŅwlNGy B LQ<^ {pgvh4k*fbn:j*fbrj(5Aհ.XX6nqe,DucP<\Yy +^rG_5ŗy@qe,DucPq~X8J{1Wuv5Pd&( . &BlD>f j4-C76ZHG-*Xѝѳf}0 }@P( :oӷΗ_mnw{ &Ŕn !RbFLU)@?v^ Q{{q `̓wcInX7H}@TF(vM"N>T^{Z~[ރP( MWӻnkobgm"WU3lR 9 kiLb]ZQąL?^ X´`#^_nyX@":1V.,Ȏj/9d#bY?ƠyX@":1B\NZ2j|HmK 6{a^yJOr:yJOr:yJOr:yJOr:.Jvu?alfYg98o{᠅ic|w"C2s D&O`Mo/!PVDAU M0N@2lp}51:Ѹ~n'Jݕ+7=_+7=_+7=_+7=_ꃮ\Nj{YNg)c{V9_gK{4 g߄Ӑ-rSoFJQ"#Ԙ 5Jyc-%E\j @P( ⃦םoc|{;;ӯmgZ ei\9˔5AUEvTgq'?_$& J%Ae7k q7A'Yyo4$^m8_;ŗNfsA>'xZj@ ^Ѽvm~Pc0#Vb*N|AbI w $Xt܄>C,ckټ5k<2&|Ng|2Ԁxnۥ 7i>8aW/F'U9m,4cc5 H(u|X@;׳xkl׆yPd=Oqemyɩ߮09+tk[7+W0R[emfABϻ~Osr4C>\|JN`qha+ / =t= >ڥWt#LToK'7Ԁ=mn6ݏVn#Lyvfv>qҴeċV7|B"3WL" BTfr"g1bC׳/sz1Bmr{,w= ^ AQ^FJV'0$U'=<uay'xi:.h<꿌")5:qR1>rX,B2'$xILP 'Jn4`C =3 o{}XC$}H'Si&#D.hmfQ^J ē( ,XA8iQa7 T:c1e@ӆrܳї: Kk gX2 b$kY&ۄ'yTv# {Pؘ@u A"Zn6JxX7m ~[VbTI¨c~?q6;rڊfxTt?:iˋoτ ,j/F$p-[ qT؃eo9x\svt NeӀټu\tVmo{~ςqٶlTͷHfFddr$SD [Ivt&0%)f!U߿g]v^y`+wg~77볯ݿKm~;oݶ^׽ݗ[Zu*9r 8/I ' d1?81ڄ4Bu$+Xdr5m!JtRBXq]1 #7 $lwgI$Ep>8gg(,0 Vx\v@Lt;,`*8++xd}\,3,|~QZKO-,|LJVDe/'_~_u}y 9FjdL6:08r(IO+&@70o\D~HHsviY`2 ӷWaee/!),4$οKn7독l_k(OW{/XwTscd r$p}  m 8gP83ħ -(},3 GU[^L3Wʟ;4waYtL\ |ӏn2[uKcmv{\_n_ڠP(+f}8o/ş%^n~t-AZ0>Q$Y1i 3)]!=ԫpOfҖ+m\ zGt3|NgݿwHl-kM^8ݟ 2 4~Pd|:-Ő(`0 mP6 H %a\>,.Xs1ܵSq>LݐQ؅6txeYǣҎ8鸇i^El0RLۨJF[`pp\aɕl!'91C* LF92OQBS6dfRuepEhSJ0!f໶\%hOPyr/ hvPhLż(԰l뤋B$^P u 7+F%eNvϪ;VnST߸Z^KW dgsV[ʰwX+SB'w͚wsUL4en6*3Z>DȮToRS[1U = Vv{:P~ϴs] *O{}^Ih0)DխNT+u^uHk j߰I׿]Վ 0zdkty|tL,p658h@ģ^2B0&jEV󠚁 pcl0>w ㏼F'i##ZHlEjz5| XI6cNm@ q =/$f:ykq[.b0d܄^~y0̀H\/&{2ӍZA|Hej+|J<9L ȣEn:7_t@Pqun4ɑƧ' #Yr[A= Dh mŊPp‡ז߷Fi+< [kZUyg3ru`Ժ6V@xj5\ ULΎ+>4 +v3/52z̞b(qJG"64L!ujK VA#t8Nm kdf C"Ʃm]qQ(`f^p2A/EPJNNdi}*'0ӻF!w|>GaY,|W+b;úb|ܲ+x{z}{| d}ݜj [ނW,^?eƝ~^vZtkߦ6go_;WdnkZBbhY6Sz%O(TW9fzlI(鐏 [lH$F0GY v9Oz>/$k.&LC@4YD <q5`sBHL !&ə:s2@& ٖBܤUJ*`:ę.h.-qrr}d)S`TѥÇA߯PB9ͫ-#azmɔW@BɐXhûKA ,J $YHXs2#ksEhfRQUff`Z|=/KVJ9RBnRo;N;Zs>(D`PJWqGCHl8kDFp7⫂R'cI1`;NN$wh\4HZ^5e٪p304ۄQ\>q&82kDR,G٣;[f`7Fl '-iљ|f #qg1М2dci ޶> vW.ٻ1C Hc.k%~T4o%LkVɇLp e$!Lrp]$>(Sfz Mq1`xNjq4mW' @sYqA?sLrNgf>׮WwlzEw[5KIc4U&̬!I-`偃]GE5'ݖҁf:j٠Nh=O2bR!!WSD7FΘ>eNritD?v9;mc|UJ\$2^Y@c@aP  j]Iߗ4H! w^h2âj;5hT͜ItzTda!@! c ,n$΢9ZX(\N?R-nrVn&H-sBylj"%2$YgIzRr2D0+8QLў( ̍wOpMŖf<+W2lgBrr9\K/~@l˽e'so,(x=.xd-" |0{Xb22dJLMu H ļ~[m/@R U=,Sn5_u28 c&O%;Hy<W-|N(+W#Ȕ,f϶ F:*5d9SœE\,l_8镜^e}v{ۭA <"P+ғ:MԜ{+ѽo$%J֒`ndh%Fe@Mj2YK0Dk978o \r7'VCa&c I;pVuq[!!vhskiٕ^{uiXa|2;-~eٍǥvCW,^?eƝ<~V|̏A>|?)A5u9. $je q.M PI,0=X씢ƀI.gFC\hЃ~/Mq3\I0b?iTwÑRiJ 2!\:Dl@RL r5G@;/i,|܋yD';Vӗ >Ib(Aq*=U D/#!; &;FND*'5"dŒg%Ϝl,O8.aBF-xYMm8>Q7Q;cbZ$ <{SbZM NhNu([g#SDn2+1fdS: k+9Iْ}ZZ 6Xxj#0ާF%! }ShX)B 0=:(+rUӄ .͕/ֹ;n JL.A0 \.Pb v9 'h"wj"a1M" KF4E$D >MHhDըEFZ4FS'I%iL1P9@6D0m;SvkbB5 IrWd.#ȢAѓq{y@&&$^.?ȢНowlx@ܔ W&J۔`A:E*#a!LO5r!N CfP(+dqK.Kh;?dWE8K䃴 -qnv1U6L\[B_4Cbz :ʲ=x;nO cKYȌ=OЖKs7xx[edGcNɟa]}ֿx op-aޫ[Q*Ix_.9Rwthey"HYxc̋o%audID;MѴhh.GfK˵t:-bE=]g#]PSNƈz"̈́L^ֶcO ߼IB.Gc7l;ǽų{ a˭kt]5莎C&`0SfkAng5()hVo^ BÄ(BXTp+.j!Jhfc2] Ŕ*IDH{۸n~lh\8]Hh"FT>OzNNŎ(2ݝ?X-P &<_V/nCi*l4kVjrd"TkLOx-# N)r $5wK]@LwmJ+ZF9nγ@IԒ"1Qg'D-ꕾO /VA.l%]@ i#OO,fG/䶂e$.-HA Yza\L1>| If%Em׎5|elkB.6xюW06qҊDTnH:W(JDMD H.3vaBo||s؉kԕ^Sxf-f3L$ _UK4e ԫӖ=[};~/$YP*BPPEEvV[7*h^< p-;D9 (NX-+=+J"%efȎ3W3LHmIqIr[[L)RJ$/1/D8pBi˅d9P1Wdj?&9c[^ꡐȹп쪎U52>ŠoO8Ц*!ʿ-gcIwh!BY rc: ;qOi7NnеQ*_iܶC܆\p@(EQdD+rq|D4uƇ~I;zbA?O )Xw%!|dpn^pk2|n7VMG((ó`.3OP6DaT×' YЏ)zUaʂ84xQ `՛d#^?O- -*x> ٽ7VefܬcQbbRZUiZEʕ"|c9IVn04P'N.(jZ:N$Mĭ>s|imjwbgnID~>ntx仕H$ Ƀ"Q{BCCG#v\=ڋ"r*rJB]KjܕP$TRl*!kAF;v|kSߨz$/xa(2/A8\6P( A!+/N(:{ӦYu{Z^uON9߰S;Y4Ѷo;_4iыƳRuU&5kWRK ODo!`}``_PpXa, > PZҵ fPr2Hxro. P&0%ܫE#b4,tPthT~ COY&n ӉS"fr0ҚF|˩nлGgG)(;6lqXBb 5H80s@qo>LHiz`vQC3sQ@@ wj(PJz__P@&L |Ox8%A;酺{obo Zᠩ7ȗ˕?1\6d:nD Oro({*x, AJ܀j*\~ͮjhX\bI6˸T?jD䣀L/&H>tЅ{XF( o^3XBdUI4HhkQ0{o* QxR j/Z7-)  zLHbj-Y v&/1S4&-oUJiMVI&p,1l Brex3^l`Yxw161~AَLbNI!(%zqdϢt$ځGpDE%S*RUA7a(X⭨t;FH;QM[4dP`)&J(@lhbPh`I~| #&21i!v̩:,'G-uy lhgAh|v5 j`ϕ/H.xQ^ NKl9p`Kcc_=E)UlNdq0.3]TBp ˩Q~3[`V7{+ۥn?˿Xu~oJA!+/NX?+>J@fGƠu:mf^x;mk {goJ ~KX Q|TNNeAJӭrLCCvzن@y|c\MSG,RI{wY+Yen߻qنZ2ϳ+uנ7km[7~X&OZ4ȄNFץ3FnQȐZ7XVݙd# gCVx2'2]h%R:-t$QDsƵW؃M"iuj٣ ޔJ|ԙ\CV8/!1.rUu@EzEX9Hdn >AZs,o[ RFsj._7e՗@)w-vK9Z6 6#M%2F'1$2[Y#-XZ%ç8xyWcb#Va lYa!Ɖh5`*To r7>q4rdQ 1X-O&jܙܣKRm44bi H1ۏͭV ǵ.]24 =o_ _C DŠ_}6g{pȴ LW?7emvL @T .ΠOuZ m*ZRTz8ORWFۧX<קuAYx_#rcdk`Y*kb AJlvNm Hlٖukxcgqj{)[.' eZeإP=D?JϕOde95?,VG'u1jig OqTl,7τi}흂*I^>y\FgT]dkhH25XY8k  TMGܙǘPqP+9yU覰{jȧFA3)|")d$J |4 Ύw AOiI4?,|;E! vZ>%%ǩ.V!A\:D @LѤvZj}[@m `։38%O_d5C͏zO%|N|zeyn!JXxq< x.AqJ3ԝثrʂL䑻*7f.:TXk\ME-_^G1)Y;3,N!ݏ%|Y W%Vb?57VjfJ+%5otĸ!zXȅe~R! tAsDKE$ UZ39I5k-Ѡ p!j t8xGJJ=N)Q^)v%Sh8@ KOk]fa`A4(᷈%_x''@P(⃮}]^1gektjy!d $mVY}&Anš?_ afK]=X1rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(}rdWz}#qk(ȑW{9fqkֿ[ݷoxh<]/f|Dcw")kc($zՑFU*Nx@G'*, .*o4XD>XhI2>|Ox8%@P( @P( 7Er\isg_ 8ٿ4 @P( A_'Yr[Aݹ&GxX('@P( @{,- ƟMེ^{=-Wzݝ-nA_O* !odq ?b@+X8_p,fmݶ?Ͽl-nK뽰Ywrٕ,ý~Yuc҃r-דR?{>3'oڋ+nȮR 5d6}z[~~͌DtNhU qGRP jzctNꭔɷ Too`n1ؿ!yX%M/( sL5>#af.(~<#59`YܿU\^s >X`kd/2/pQ-3X@9[: nk%kfկӪʜQˌfece5s}D-N]5O2vt9S[e.zB2N71ׇާ#n+^KF;oc{#.OQkLlpHlċZr|}] _er7#(w7p}wt9QbĬmH Jp`{P@z.L%() Oz(Jœ' FEqEvfZA ,%~ 3#POfbnK.4']{k^ůu{[.KDfpUI8-ַiZu-RE/JT*jv, &#FGL%Eyfk[ 㓞'_H5cِa..֔hH*MҽO)[xT4{@݄1ӆrMT}!yҽچoqCqcnܽW*US# 2ljfP[ `0 5F#pX$,GÖ+G/f t)r=G!RfPZyZF}r C@P( oJLi ЭdKCis "#xF~p`0iƟшSȜkU8`]آW4z'\hoıBl O#,ݱ @L5$H rPněA鰠2߰y> Gʹ):l@U@wjkD,wpm@T8  @sYqA,%~ 3#POolr۹{~{gcugZ 3(rpG.@]jX}D&`͜Q[U6Si}xrLJ dw.OߌYυy l٢/Lt9` &@q zpc"^Mf]6О`˵Z'HHdOR^<ſGɌӠ@Bh-cKD>Z7[NFf; 8P0ܯ|r\I~q|cD@]Ey{X,>M@;, eJ] Y<2P[g_-B 4!AV .|ta1r H4فX=|MjHPO ~Pu>[eSą/xr0U|̔ A_#Yr[A`ƽG'"mn+_+ǔّ{wcݿAf,ۡkd,)OyrRMerԦIc;/J`?^75&m=v}:œ{UDLpV(GPǖ!ꝪRf=M'ruxǛi4 %=Ь6YA'x%m !z9~GD6:`L5b Ac iUxzh츁Ụ6z$y2~U5^3.[%G4tcΫ>V'j|pi2LXM! A &GxX(:̏_?/emq||{v^+o-nR8Ca!j:F-+)@᥮O=Z\5 IB:.iRkt*Y<$3PM}3bfA 9:N,|BWH6p{٦}ph!8a~K:?ԌeoYp+dFM|]D:&2-n28L&bGA'<\0geEZZC vnr)ɑ!=5H$?UI "@ZWŴ4: 2qQfc"O$dCIwG׸ u|~I)~= 6i&~:u1KS21lJp% w X2#ʸT$n^isN{f1.õG.O8M]rw$aŜ2.N Ŝn[ôA>~JBIȫ #ciN!BYR= y<榈DIy5wR˄~;nq>X#%ڰ@Bb beޟPV!w/VkFޗ`a+jxjj:B(>\BtfU6B 琽'"uh e~]ok^KZkϻk~kK_Nϒvq'oz \x?tm^wvm/bֶYa{ܱAi (hG&¨T(K$be`ɌX e5*ɭf :N"p L1MXu#ىZJ+K3fSXњtD;S.XɐɇTpU|f "n5hC& ^3,di&UwsEHvC]"E~d)T[%`/6J@N,*4F9eZxhD۶$lml1lNPj5B^;7330:jd3pnx5:"7j7VE4ePqh-tW QjLALR8Qc<6bS0voayNG\;2G c L.|Lk s^7Řv ̈́s\fY D@%B^;!mH}!}yw(4oքsޑL0̈Jw 'HKX00b٫N[ Y( ipOA_'.(o^k>4g o" 9oQ|(dQrKo3V+W_8Ko{r~3]^ma/rMv"p%kA8D(m*3' )|0q:>Fxփr4еS嚀yq 1^de9v("4#u*Dq7kTRUA~2IZ<4sm2UzhTKA!H\> Ӡ\oKrh8yGcTӞkjA/ePlkZ= b11P6L0r A8 ؍ &qs2hCEبUɈj5XL: 4Ĩ' Qk$ ܂,\Jn2KE"N?%n,>~`KDjjaaF+ >Dz7K KpynjQ@j:tR-wH+Y'3Yk,1aV#l0^# dxK򡶗H)8ÏiB7j*J>I-S0`Ť~CN7NSx4gnF](k^Xݺ(ʄ .L8gQ cTuZn֨OND~5ˮyy$8Ji#HD ʔWL9-d¨΋H˅g(86^P@K }x @P@P( @P( @{,-Vvݿ[eloX۷,sv=ٗ^AKohH?sRik.ɝK^T;d[vpBm0<z%QEu }{~cdZ 05H0ۑ9 trF=.x闿ݧ4`0ŻLyy^ ccԶx'lc-f-`]jq$R"IP,-% _7Y$W$$&$[d䔞BfNl\]0@P(bnK.49d}ݜj {w._Ӷ{׷śf{6B ѹ@z+NJI=.+&[_esX$H>G8ȥv^BTcF;U.$lsq/l $~Ap2r"5I}%>sݵ1|K .RivOqA$N'q%k!X7ye q2=s(,4HC%\fMhF#b</urd\yC'11%;Tim%J^Xe@< ݁S%Ppm7\LlC[@Ac1hr pVmgW䝺||NO||k&@3OƏ_7u_pz)P( O+䶃sL5>/ӏS+\1QʎNcVJ>HK1Ä>f6ڷj m/-?qJ $bap6D_E& !.bU6T╰ѕCf5I2f1JVi߈=KF.wr>,![*0- r &|Yi™pN%j!cS|L5X Z=Nv,} j24u I#t궩ҊD4)hbMjU$'iq0a~7lJj/M2<@xAd}qK.Kh,,C*$U Jt:4X4XH{N)!ҭ`#ЎjC996y SLD4tNJ4hz ԨRA) )Zo mE^uZilZ'GN7-X[T%Roq"gU20ݹK\!n *MLT ȮEuڠ.M#Clz8\6P( @P( @P( @{,- @P( A!+/NX?+>J@fGƠu9P( @P( ?h'\o˒2<@xA? @P( ̏_?/emP@4ή7,_lȠ @P( __P@&L |Ox8%@P( @P( ,%~ 3#POfbnK.4'[-Y{_+eݵ{׳/i^uC}V&oE- lZU29] GL@Ժugɲ8}@ Nwn 5Ղ죦<vII ApCM˥S 7'6pJsv XDLE-O{H!CP9 'IQW QlOHcRr*e.@䏅'L`0tAAޓEʓEٕ? /C}\Ff,j؉Tj$K$7zɤ21|Fb\6HR: ˇ^0]G LY,i(MΣqjLv$~7i(M+~Mhqx]FMAE1JEv.y fKHWFpŵ'"Z@^1› 8Թ/m#@5F X I"x7Bt~24NVu_F3']@/ @9*=A?bnK.4'@P( @/ @9*=A? @@P( @P( @{,- @P( A!+/NX?+>J@fGƠuJ3 ,ì=㵐?Zemr؆a:1{A>Ux4@- -{-KDl 0D%%[ L3`r!W)RNz W$q喘_Z_y%@LL džZf0SH\Ȥ0޷f..'!հ{cRltk*E䚖٘-b :s֞s*ȸ@<DžInBMgQӰP4vM-$jB<>2с^ 0^e BT$IX! fȯFsG ,"2'o;roAFJm.on~{_?AkU hM(I|1Х&I-CH9v//vd=~u"4 H|idwnb܎y.d3h w1o9tey65h4^Qp  v\>9c?%p%q_nk`p_e)bO,|=W=%&G2C 6Yv)j`'B/JEGPn͆32He4K6x) Jv:O#Ahm9(*_k4Ma^&wbGxF9Q{i2::.A\TJ%$sS'$U }hedPϓ%?ɯE1:Ϙ/ ?b=b+,k8K=pRې"b8$T`W\ E/Q9Ķ7>cK*bKk=pSQZ6 ,)#jL|r([JW w#d.tюׇ~HPDaC@.=n;xf'&e; .p$㿛e)u5n9,Mj~Ob2'dZbD㞎^9P-7fJ_9q#\fyƾ S4Dg͢CI5JU"r0F3G3ѹ kf k-:~(fi Ttb#yA#>Z.-sY|bHMF PهG/䶂(+󍏳~[q{r2/kۿ{a?Y貊Xk=8ER [ 2IL Kvs',"n 27kу"'I>ftpdHRI#Hl"N|10_xmD,%ɺDŽ2A0HWcM'" Mѭ/#?q]vwyāJR U\a:k?g;o,ҭ[ـs#lI_ȤB#@l/VA\~]lZ)M2-ҝ# FJ8iGnLe&x&vz`:Hb (^Y  r\UpnN輠)rC*\ZPY9fЃ>`} .*SKþ-5[&ԡHSdex \K[3\h_K~j9 OSj *[ -hՌi: TZ7B,\GcaFEp}!lT_A2dx傃E=\XMe~{~3҃H%JHD,iC +Sd)D pt{@hg\ g(](XkV%U rXT~@?jNdVkZN7 &S[b7EBʞ@EZ˔*,~k4z(Af" ҂#-ʙUV*$x?rR(\}Inz<|Sh;>hV_ڠP( ,%~ 3#POfbnK.4'@P( @/ @9*=A?7=zxoo%}mnv07-ta&1ӀmIժ2t!FFB4upkfxp qw "Z3跞qܗIeF[3tn{_# @2 –kAa<Уruտ^d#`fswXKsϧ\ktT'|\Pp#"Tu%?a'T0=pGI%[A;܃7A}IA!f.\=;`DTPy'H  J(=qւa!8X<їs<: Z KqͶ>uU UϬEWG-uٶܿ3-2ESܟ<|lK PS)qaFֺHC75ХcSFG;!}ڄJ x&SNՂ]8S3}LpeM=Q-l›n`ğꖝn3uA )}fp- "^ث~z7d7~[5 %P(᷈%_x''@P(@P( @P( @{,- @P( A!+/NX?+>J@fGƠy2vuݷ[_bPR[ڐW,#J9 hdljȳl`b8J2Fc5& ?Eε{-xHd˘MI$VAY=V JXe<;'c.9ܦa5 (Yⴓs).*4fw 0],f\02V_3[j}BUnI|%O/{]!)%'NL6t QZ{CUn MD[Q% M2lfn^rz藄˓,[(%3S5ʘeV)mQs@ zA qRXHBאL2<2t_BN/\ٚcqVK5ln1 eޜLX2H*W^$M{FH>ZHL1F.fxbJm(+D}-+&`^f!0r@w7fH5FgUc'dM ka3* SP*F'τ.(J1(PV GĄDG[-ed~E>$pՇw;V) yOĢ#y@"HS=/xp]&Zʘ\A0DzYQtFKBw /n1a  %\dv }STײd\˶HLiykQizIG'q0Nrvܲ2ELW?7emvL K|ߵFA0ikchwv7APMS< 6Nk#1,"y:g츑Į[8%T' )qoml5jp?~ͫھKsxrڈ˘q1Ei"R8^8z%oTCN>&1% #pDD[Jxn?6eG|_-v6S;^y\NaYۭ2y ^Ҝ6|=[%#zjfF.a%+`QƧhB=)^&5+qx41j2KS *C+G ! _2w!>ɦ&b !T'=+ZGv$*[8`AdS#Yr[A`ƷmfGk{~mA \nN0Xz9F+d!isDJD# 6" <״&`f%Mˍԏx>&ĝ2_dQF1)IŔc4[C~0'5n(68/VP058h@ݷrD}x˄`L;fӏԔqp#! ;t#D.!˴n8ͪ TXs}!h܋H,N[r/_0N83)a}!pOj`eZJTߡ7h3Nb/ӀXb:L SGىl1qMm9TfQwr"'Σb9 2*48AMU}M98}$l |^s "[ņ5]C\U4i\]aKl< M؄-V-Z% /iF!ο$`]Pr&! ˂/ےi2r$a60VDRVW%ﳛSY$hg2L4x$Ky&r;~6{pʋܴYxaESL~N88,k[$ MH=餤S 0%N8i%l%P%Hڇ#?Heqgb> kٶ?6CtoX 0p&E|Ox8%Ag2_K/{ߥӭou_~2\8ozJ#}AcsI#''5܏4!B#Ċj`bQ mhC")6bf d 7"˺..3PܴVԯQaqvg$ڢ]kNYA2*\zp`CFIKI^EbAdMYa%ڕ hB}AfCX% oR-SP2ZdpKGW$,N(e*eMYxٳݷe kh!Lqų:`Qf3FdI+X%CֻРiZidž:E'ZBRJ l1.e#R>L",{ C+y:lpXN^:tuǿ~<-{h>Ay`+wg~770sYqA?s[pm9ۥؿLF135Oعx!TEx#EKKEH;2Gi2J41gV)gN{ -ʐ>4wkn_+&"!| 6"[A`x9acI ;Hr6׶z ? ŽێD$r{aT&YKro0e"̙:P5'e Rv}h$+ק}=hbjl9YOEdfBӕB5cPLEPCҴDiK4ZB5)2|C@Acuk\½lC#۶͞aFgyuqp8 4WJ(ruQ'Y:HF!;WKت旋վ0H,81ъZad'J_TaQ21jD^$"AAWhme3 p=12L-ㅰǭݽt@P@K }x v!coqַ|i^ ^;oӷ+{ n2(sNJZd8InC"a4;IP +e[Xtѷ资lS"\Srb~b-W34 ]3J5.5 𙾆X7)Jk6[27w0yaDraW"K0MHTE&"QuBB ?Naj/CD96#(CJ`X)5,5沵ܕ\3O:C7vr 1w'1XB7:;qhyNj5tB:wcp8XG9. "FBHhC.WrR(BgJ;:sbC̋31$g [mk}Dp9Ȣ>uY]X>5d*+5HtYה^.6MܝkU& ue;0frзbi^{w0aeOUJ@fGƠy2{1k^^G5gQ3 ]DfyIA݀B/"F'6XqՏՏ{,:g8:cȎ,mH|2RkQ\|ܧ'ZB ѨO #qص!F@l.+v񟥱WsF!R ^=tǷmmk{}7ƫ楮unQl+xv[(+-u Ii5[V.;2|n[;ރ=ӟ(bU:3JZ»V wW뀌?H 4/Yg1:/[@v1BD &usG\'&ᱹZ2ԉxPDzKA9!]r1EX7MxӤ]vsEٓ8[&ZQ&+-:>ۈDv |TM0eo)LE3dAm5p9Z M_9aPAj4`C+q)vWHBcc[(xOfG8 >6AL,6pbtrH3]kw<+уOmN*L@1F`Bߐ0`'"(vz΅0U y,}b{n*<jO1*Rub,! O#lBrVt)ƑX3@xb-/)Iщ d0o&M] IħVqUeaVi@fd#}ˁ}ׅ #Yr[A`?2('Mk-e{_,ol/ٟL^xekcƭkXAZʶhLXG'TG'f H)RҒ "4kBn=A[,zV|f}2=ywKAcMk*٠Z1c{@!S(Nq"HKJHJ,h|p,phѮ ٺgD0 e ^z piĒtM ,;v9>Ltl%?# ]Dv#(9eإF[ 9 6߷7ZAqr[pa-vݽZmzA &GxX(:̏_?/emP~QBt@5,"!#,pxvt8)a919`]LMGax-߻vzj,m{5v}yU=Ky7dpJDBnSu: 眕_#%cvɩUHߦ)Jʼnd`sWcy;FXYX0gܢIze  *qICR)01lZEz֨qECrr K,H5^#-  B%'89Bgd)y$0j4Rjgґ\V MH*Gk5j=Gy2ȳc|I.-<1]%-a&-SzK&h6[*[%Iޒ@RY >i6Z \{h,:Ft|F1Hc:Kǩ#f& `!MWnf@P( ,%~ 3#POfbnK.4'@P( @/ @9*=A?bnK.4'wWmn[+mZKGPN[}a~ c 5YMg_%ػ'srlr| l ooj@Եr*VP46WݧqT(鯻Mkbu@Ag v5ᕃ'y(hd:Qr6hf 6YZ% Q'‚Fj=2duQ.I*tujY'Rj@VE )A a'iҁ+FCm^{0\>TT.&)N&Dit!!8-`II KRTT]iկH}8c0 A_.xrUz( A@P( @P( @{,- @P( A!+/NX?+>J@fGƠu5(姆9`o{c8֑ }fekWk۲9Ky$+7Z)ő3x69 yO:.4GS0r!$KAD` 0[ef׆+!4 LxY滋3)LHz]&sQqItS2KMЄ"хC발l+rx+)0x Bu:9@ ey F2zXܲE7i6X"%"5L@ byxDjlto(W/Ϫ ҕʸutHGwL51Nhe [W]H:kOmf\2јRԊb*PmB␭piҬ'trvjI#DO=y8%O{iߧ`σ6!4x܅E,O-"H둔Ue@[Wal3zhߊ^ w4  @ i#OO,fG/䶂(:lf]zt׶ۻ_kt ĺǛgҌxٓ)$:SIG:A)'e|~ ֫ NMtX}I'Na-(I0Qg,cstYJ8Q>jnX]4mߕX$Ivo+nb6O$ɭ~BdhbϓD $דxsKB NKmۥ(EoSr =h8 gӍ)g" PVQ6ƚfj % ;,fqJ@fGƠu 7Er\iO?ocob+u͑&YE|9Xj7_Y=Ɩ9on ~y]b49gE#?|kӘAG!%2ĞF8R{  7"lVjٖ)]y=v׎YnP嶙 ;6C6e['P-Zmx8ĦD%襊aG+u-51RG5eqx\cr)GaN8Ѻ*kFeL.HmEKF8fMӠ emX,8Q E. EN < ރK|vj杀ֶyarj6얺ͷ' *#wC'N|^WAF55VSf'(4f[-9smHɬLb˦[#C%sΫ{AL Eb0I)F>蝋iŒF`~6ͳ_ 7 IZS)O(nBjhM HG7VA`$F~D~dX+0ӱBuKb뚹w [N`ط.\'UPM.^18瘮yq4mW' @sYqA?1Cјt_`ZugЪWlq*u(V Z6 a4 ٯN< QGRMG~Đ'nBڃA( =$ 1׀dfSz%$bv^D,OZ!Ol``hfxn%>dG'Z"Oy D1. LGj4rW/N 4v.6Cg' 5fs2MF'z]8^jDHnR "g7as+f<`da n&/t:9*>V46>KJ"VbT=J `ŗi9'ݦ* pcFՌ$ 6h=Nt?e4߬Pcl^ӑN6g(*l\'*]VI1bZ3Lvwmտ P( oJJ@fGƠ7mA6{ |9{)nfX",ej݅ٯ@gL4qZ'Hk'0&_ҩ@&S*U`S0u0V69{89m^bhv"S"Hv)eT`lHtl׎xl1BBd)BD̋~(ƽVL;c8`8%ւ Tڇm^jtz,Ex\tcS6\|\J:(DcyHeVp^-kk2##l 0IGF%`';Γ,^jg -z`L'!-o ~o߫` ߻7P( A_'Yr[Aݹ&GxX('@P( @{,- ƟM.^ӧ(#/bǬ,`IS_$֘p9Q)X3\E7`8nD`"u/j!8f9 ̇+lqM.T9׿qb[ [r6E Iȃmc,=I86-́pWjv6uԖ֎ (bZA iUlRhȬ`` 80ER;k$|H4[htV8nm)f>y @@i&(P[mȌ/pPLs *=s+Veo\u_gYx+Fab+<)@j|z{@dux`2iE$Г9ܓH.-7Ҡ-6O#@{]53T.#ta} @jPP;ݠF7 alqBծ#bJ#O5Rb5U\s~P8۹v3ҤCI}+"È=@Pqun4ɑƧ' #Yr[A`6t_-~/rkx/쿂8IX6!c}b&zVjF\i%B"bn"6=1|$05ټ20))Aamp[Te+FA"G'I4C,`G@f4`!upDXehٺ$/lV:72-WvØ*Y1%T E4FrרD- )H,,tڒ\'T7i; W^[5e raʼnzͳ*I2=ιfDSkB03ѻ>Edه0J7.ѱkK xʞq^h۵ tycv0롍q Փ!!7ns]aa4b$.YD=/Y}+NCtۯ<-]lU~8*̷z!D*%Fmݪ)*-[+M+wqvjѪ#rۯ^xB ݖＵRERw1KIa넥?Rf+26qg0LO 2|s"En!C&Z #b*!0un+J% 9rN(V܊X1.`|mۻ~A᷈%_x''CW,^?eƝ˧Nuk=:P/9*> Fi1 1펕{۰V{vӗθ_+PEJ20;/S |zr8qc_ h-.уm"XNA^GF5_;mFǀs򽄫xȊr X&R.:La)I#V;ٯ-WīCc2b!넇TRN VcJęF1R/a&e 65M4);L5W!EZ/8X6`$WkƵt^0:j[M ti zdCEB Y@eΉ"|2lLn]o`lm|2nIy? L4ָPbݸw?K4 q4mW' @P( @P( @P( @{,- @P( A!+/NX?+>J@fGƠu9P( @P( ?h'\o˒2<@xA? @P( ̏_?/emP@4ή7,_lȠ6[[ׯgoKwm|~Ηz ib=2rv3حx:n29sH< upDb}X Wewvt7iZJ1q %"@х>IB9lnx+>fl^DUB㠝P"W(0@h9`țx{3ٖ6vv\<~rf6:7e1Qv40yv9Q#1# \GՑ`5d_n>7&P%A-&,6&lp}bNYfVYlX TJ+ (j2qBTx!$\Xl=. T4eӊpf^*څk 3NP4 __P@&L |Ox8%A;uǧmq[e|ztֿev_bq9+Rͧ\7Rrڇvx(|AJ,\jPgBLX0}ۂb^]9zc'w<]-rh4a#-2X ,`VjkӯbwB'^5NHC))6腓 EgW0''iU)P:l'N\ە{k p͡1mr^-qcbHMo28BTnZ,Q=EN6 =3 {TR2R + Q )B/.g׻aCg*ArNG'J _yȬm!UrdbU\X)'uG*^jh2LjZtah=8*ݘf[TK "HPQh=,^MA8C=a#pJYW2>5ooAa+/N~lmm핯o3o{DwzzAܾ6)2.b&h[UR;gR]j(=^k ׿-6q{ ИHm ɜ7hE4B3@DZ~VړJ@ vayelr WdNQk2BA^8I*S4)SGB(HNj`]4ӶaMh0"BlCe)BKH̴~(IWS`Nf'*LS: m}eztbzEg\ )(ˠ 6-EV)?-Ĥpqz-6w # _/t2#!"oBɏ& uS%`O(Q'J" ncVwe( 8\6P@o,Ӡd4dΊWp/K>m0(]CF'@A%Zhײמи+l#Jphfwd5lA%&lVdxnۆ63h[ ێǯPLt͵rCE4-MId~a(s͉AI!Ó 4#}8+ֵ;;Ph"x4Cސ@\4B؀7F5os2δo(|Zm7:@tӊ4N?A 4̘nѳ~NsǦ]/`ǀ!J(eLa<\QuBI \AV9J@fGƠu9P( @P( ?h'\o˒2<@xA? @P( ̏_?/emP@4ή7,_lȠ嗠UCX*ۚ):䬏!׎ ua 埐c,hR#e|0=ͼp{%eh<XzĬQȋJMǍ,dThPnn(ͽ0sHD~H[ԛħ0d,QaA2>R4$]ҥmU3-rLy"̕bjM)"j&c<)H`J@E%)2# sG]pzUFp,)vGT#XU;KN&znCa -J;HȵsM (6'*%0"8C84a,ź-Y.Z*$6cdt+Ѩ59 bEէf"`\R(A}Q=Xoo~RXt49ك.|ͻl\-c2hF:rm<P(_A2dx傃E=\X?_A$d"e&}otLH%2 *tP`X :+fv?lov + H.?ĸvTl;f>zB(Rv(\qP{j {lALŷz0cCLC S)#S'A$*TNҍfQ,v}!0#2l!#,hHX8q.,"ZRv,FIpp#w}Xb/lՆܰ~V|̏A?}W:叻;-5~\KE"j3q ƎC lO(h3=+eVK#~6,D蠁_㑏2IGvG|,?}GMcpC 7dRz)xr!{冡ѐm5l6_ #iKƌOUhcb|\bVN włlãE/=b&+c36իfXog'wrv U;ɧXL}笄RfRl/ 4(ឮ͸UT}Z4(Z׮Jmxc${pL1'qVU`\aa+,= Z҂HF`{ہeC cQ &&ջp.zmf87;5am)ƺ<#rA v7QFFYL,9ՠ0T)drLJVN{15էv]5,"@P( oJJ@fGƠu9P( @P( ?h'\o˒2<@xA? @P( ̏_?/emP@4ή7,_lȠeץx}ݶh!Ǵ zN{b(6z9q^Or- b("4h!aZ%5bI F0$L7X2`<>bLHAHA 9\=/aj±@O]Fn۔T yAp5`Ҏ׿fyXXAt{{ڃێ^>,:vXds \ `{R' #K}-l2f*ҷdUE1;`Pb(Z)Ȁ P\1A2z5Ngoq82/,(.j^̴FBaAH Zd2^sL;P(_A2dx傃E=\X'n:4nݞ;3N厝;:܃`:cp׎Y~qZD j׋3RxhTT3Ԫ"v#?G <840@[mݼF-tork>܈\1ZVr`Ŵ!ZsU+?^yB (<4iMQ'10- r+I.UHTnDȟ\k+2jVQ P,\,7 ͷ7 ]#R`9$VKMݣ%1 t!D)ԢXH"ۍOH z >{HG' /\Ei{ ,1Y'D`JQ^훸pS srBE{ˬJ(nBgefCL?Xy:"'mT%w>B.$ԋeG%T!-3/1@1b/rF4\|x$M}{1x\DF4':H{º*BJRYR3l ;7ZCijlmtB!{M{s fD4/&ALLsYhr.epoV1ɖ#t{,KH6)s4ٹc AX-ۖϒvq'oz \x?tmHJ8ڐ~t'V6"D Rρ̕io6Oh" DLasfX<m 6+zF.+McMZ4y"Fx\v>AMݹP}y[^Dz ^?;_&0,oHrL*5%$B,pOnxF"3~!? -O},Լg*Npژk1օ'K6"T7v, 0vbBcpƙ/X,KNK7N@Xw%,R\G* h-#Fzƙ a6fZ Աo2Y|hXXo5 dK)*%.VWq„_4 8\6P@o,Ӡ @P( 8\6P( @P( @P( Ak7k.YDiK҄Ul-b(v7 nZmۇt=Ltdduk#x#,df J<ǵ2EK|`^$rTW&ӖE;o)kوez/nS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?@F;7W"SnS~?%r/?A7{^@ Z-{d[u8_gg쿂@OWgߵ7kTW:7%I+dS#(12nдƟMwݾ];{k{;K[/{ֵ7Q2&\D :D)& >iȸ uTjw@\,7nzC1 Ak`yG2 |N'M|.J2mXV~'B>͌ށ 2`jR nhqA1RM,ǩO9T_r!H9  ዯTYPT{62{s @ vZE ׸1?n$iͤ}r2ft5܌S'YJqTj'Ng9YRi&z-0$aݱ|eK6L1v\䩆%[j6mW,iBhIa@q{7_XF6 qwalp+Zڰ]9gvZ<7^YP}__P@&L |Ox8%x#H@`,P >m߼N5hV/0׾YZֽȓUU?1m"ƝsD0ҽ#Le!t@p"8ձ;2`@ ՘kBM>ly%|jqxiyN]-^T>ͮfl4FH9{ a FbBͽ 7f9oSJ3a.,[oG%e`8U!5RX!Fchrf֯=S~jd,k fI[ȞU /zBήgS4 b``% h%(RCCOEDxs(I\Bl zjWr<@# +T K8RTT-sH-F>}u& ˉ)d$kmgMixN ->fc1#$O /)L25*T"tЈ|qKJIݻp.(?~8]z/09ImgҜVe,-Љ.F,_ JQ45#@#]*[T#2 QoGp;V(Ь${LiٖZ6dM,5q_5VsF b[}Kc6dŞ 2'|Ѿ"aG٦j:l 8l&JyzT#59n~Ҩ,ZDi%7i0@ʀu:[VoVjc^80dҧ!/+j$x Ўpv7 tl4C+ӅFxRQ6T"HR$n'Rn'K%P2XkT f? K'0.,ZtIi%FmBA,aB`XGEC)b%9;TzP$8yRf/)N$ suFf8ij` 9q$mTusD$(qp)%t2D-i\[`JB18 >v ŗ/Y5<+Sh|֞2h4ae#VۘRyxO8k9#)/2,خ dƶD*1r]v'2؜ȑ>ge4+{}c@d$0~aobD$x| Fсun߻vט~[#;rѧfx[{PAL |Ox8%1A&Frحm5F8\W`ia8CĂ1qPF{u>9Z*$pW#g zTD[3ua Q 1FvSdEiR;5mݰÄ{AT\#CTzY*< NHr P܅nVмaQkBHkYPy!/^[mK 䟢mY`gZf;!ǖ63,m P)5  5aX@12 J)(*`9}3|'syA\I8ly}20o\Qy;.%n| ['厎K1//C*|;@HZ;tPm]AH4@Qd(HF%3Ta`Q\ȎN^9&9 )5bq~"t2#ɑ;/Ze[1aJpN锄( q0̴=r''zOWTQ Ԭ{ 'Km$U@f%H '60aEu,pl=onqklײs;( R[Xx"ЕT{&:[{🺦QU)LEd"-;f;&9'#%, R,%2 eUӗ6x[K' rc|T0Pv͙[mD+B 2!\UWfD+D**HZ`-?mF8\Vkd#FJyz qnG 銜f»YӎZۀj. +##*g˔MbY@Oqh)BT95FAHh[-1NeI.W/P >qWy{StiTeY49m - }-e έϏl7[[P@4ή7,_lȠὯ{_k_|r-{_MJ[4(Hk";tK"﯆q{@cJ@*Nd>}6Za`Z|>)%=;ehמm=:_㊳vB8HI-$T 법q)TI*YpjƓS Xj7& 2bs5>[Y \۪!FV,X6u ]xҬ lӲ'e8.P$H-#^)[u[!QBNppKQ*qCsQ$pWh"2dP鎽U`hGɛTC0$ 2x,ZU U|cvffPմx|o{9fX~4OLoa[go1V9QzeA;dߵle(nG±vzCwSDDvIa[dJ4Lz6`$„r5gqm8!ރA6~~!ar3G2=Jf0N2;ĎfӡAU@ѥA}J `tS3`  3d(lN[pc*ׁ<ߴD1q$P<`)ҵ"M90Mna#4R4y+56`6蒧(r3^!ѣ)i N>#h=yl~bI&GxX(:̏_?/emPu0 e ^z tiĒtM *;8)y*ϲ4S[Qs,Xf^yAn_tǻ޽k[k5 rzܺ ٿT9*˴"@pk`\*?CuN3 ";4el2^WُL}W-t8(k|ݵ@]6iK58YշoqT챝=b-q}흀jY_w4Y>b۪5]tX} ~>~1#ƦY<͵D CHޤJ(^T-y>^ԚAf pb'v;1{Q,L&P}F$ш(U&M%!KSȊ] zㆻtQ@<~V|̏A?}@o,Ӡ @P( 8\6P@o,Ӡ @P( 8\6P( @P( @P( @/ @9*=A? @P( tm)=N!TکHXVԪ#G2gqx:Vu׆WAw{'A\K'I Q7Cr}N^$GPL)LBuѦ96ێÅ0^h;zݾi##6@KdLbl0[V u^R:/: irZ'iNudT9+68J(!KIW(jLִbPNT8 !9<\0<|Ij6:1'ej[tt:Z8yc,x/THVjԹq.LnBw-vceh\ 4)6M7xCޚ8oR-kZi6Qn`Pl@e^'#'T?g}9UP:U2.* pݴ`AZq|߿ *QZԬ֭X{ !M%HW jZ 6~=IY:XްVps=g|a|.[[>ICY]_KROmu ËjJWۀXr flv Xp~tlϫ:ӺWcob}:pw}uҾLTD2p-2qC+9G"YZJD5ҏV" ,˱{vͽ{nr`*)Y$_J>g®6yMV* ɢaBpXeU1DhBh`ʬ R̆ M[PA(Ɯ 5O p ӯ;) @P( rYun|Saߺ‚uqbSfEP( @P(8‚7?dSY{,-;0ޙumn[ۭ?ASA 't<* LhHF9nLuP!dAiq0c7XA9e̷L9vDM#)z7[i!Aȕ;\2A:jrvZ ua,i vB!LU9m6{"lD}rv#5rWRuK'59:l~)tEfir_9"\Y /ad,NG-6'[$.i$\|S@P.|pkTP1FNt글BB`T˥J39V*|r:g5:,Q˄n*EǛ;'piF9,@P(ϒvq'oz \x?t@P( @P@K }x  \x?t@P( @P@K }x @P@P( @P( @/ @9*=A? @P( \{cӭzu{(##6k̤3\^g̖JPtp ݔu@C̋Kȏ7k4g2'fb8{3s`n K"JQ'!. dXE[w)\pBȿF|?okl3{^UA[`&T<{HaönŻ{rE;.l).=xGRTa LH*Q"IOIdXBae6h .ȝ&RD}K'ikcK.߮ӿ 'N~W$E ~+ng^lW{{1鏶_X5 oʵTsj,MOY3VݽUw( [>mT"@P|{L:c^쵭ߵ~{_AϚ\n]slߪփeg@ 8\p NrnFE:^op׎X[ @P( @P( gչwM ~ ƟM@P( @ i#OO,fG/䶂b(n6i-KRTR3TH4j0i IuB/~'Vrݸi:-t>;aϒN6;>|Fȷ9:~/^7 J2eBR.#bF!D 0b$ PR3ٙQAܫ'eBL Jhz8:dXH$sTho1%CcVN3qI[Dd<{g fE U=G~@XXPFwnF;D(Bvf@ (|kGyV1q_WAF,(M5 8BA S@P( g_ 8ٿhX۟ˍ: @P( @P( oJ[{{{ouz|"\hNV'[x> xkIf_`@=w=7ϯc0?w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xy'xi:.hI,p7˚w/6ͧ?xot#DQ*j!Xtڱ& ԁJPȏB`] V;5l&߽ӹvc޵|mӮ7 so.ܺP@4ή7,_lȠ @P( __P@&L |Ox8%oVۧL{ook{(1kV+WhuI%5>plrp pN.nݪ@ =DYl yŋPtz4j~@H^G5Um>acjDL-O"6m ..`3䜁Dz\wf3)]8L!3U]R`XbV4q:഼Nyp!*ED!teosjKRn;fg>AVVQHT?F$bm-z|Xl,m˹ە|p˧w={o{o{c{>@P( ,%~ 3#POfbnK.4'@P( @/ @9*=A?bnK.4'@P( @/ @9*=A? @@P( @P( @P( @P( @P( @P( @P( @P( o{vuǭ|[ֽ|k[:`( BZh9)hF-A+$UH7yr8Rr\gxM&bBێw_VZ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנEtgW\[[ٷ[ {2N{+d%\Dž6'Jv#@cTj D)?'0#4Pcokd242tL_{6C/vyG#xT,6xn3u`o&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR&wǟޖR}YdO\%h‚n-Qk#dU2M\PP~Sϥ5|fЃ Ѹ sӻ 7 lwm{[g{.vû]̯{_( )UK:%v^& kЉHxeIk[LX=!:voѧW>_-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Z-}Ze Wvya{_m{tlnh?u(G9"\yw&к$SɤYY2K-&g o[ >th29(:l\/n^K׭nݿO7uvZY/J6M\JD&K,0O?^fb2dZĆ9 ӳ~:>MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ}MW}kנ(m" knKۥw{elntA59B?)˹7'օe M$:ɒ]m03<75`Sxd4(PcFv @P( \:DImamura200354545417Imamura, H.Seyama, Y.Kokudo, N.Maema, A.Sugawara, Y.Sano, K.Takayama, T.Makuuchi, M.Division of Hepato-Biliary-Pancreatic Surgery and Artificial Organ and Transplantation, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.One thousand fifty-six hepatectomies without mortality in 8 yearsArch SurgArchives of surgeryArch SurgArch SurgArchives of surgery1198-206; discussion 120613811AdolescentAdultAgedAged, 80 and overCohort StudiesFemaleHepatectomy/methods/*mortality/statistics & numerical dataHumansJapan/epidemiologyLiver Diseases/*surgeryLiver Transplantation/methodsMalePerioperative Care/*methodsPostoperative Complications/epidemiology/*mortalityRetrospective StudiesTreatment Outcome2003Nov0004-0010 (Print) 0004-0010 (Linking)14609867http://www.ncbi.nlm.nih.gov/pubmed/1460986710.1001/archsurg.138.11.1198Kubota199756565617Kubota, K.Makuuchi, M.Kusaka, K.Kobayashi, T.Miki, K.Hasegawa, K.Harihara, Y.Takayama, T.Second Department of Surgery, Faculty of Medicine, University of Tokyo, Japan.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumorsHepatologyHepatologyHepatologyHepatology1176-81265AgedBilirubin/blood*Decision MakingEmbolization, TherapeuticHepatectomy/*methodsHumansLiver/*physiopathology/*radiographyLiver Neoplasms/*physiopathology/*radiography/surgeryMiddle AgedPortal VeinTomography, X-Ray Computed1997Nov0270-9139 (Print) 0270-9139 (Linking)9362359http://www.ncbi.nlm.nih.gov/pubmed/936235910.1053/jhep.1997.v26.pm0009362359Bruix199646464617Bruix, J.Castells, A.Bosch, J.Feu, F.Fuster, J.Garcia-Pagan, J. C.Visa, J.Bru, C.Rodes, J.Liver Unit, Hospital Clinic i Provincial, University of Barcelona, Spain.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressureGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterology1018-221114AgedCarcinoma, Hepatocellular/mortality/physiopathology/*surgeryFemaleHumansLiver Cirrhosis/complications/*surgeryLiver Neoplasms/mortality/physiopathology/*surgeryMaleMiddle Aged*Portal PressurePostoperative ComplicationsPrognosis1996Oct0016-5085 (Print) 0016-5085 (Linking)8831597http://www.ncbi.nlm.nih.gov/pubmed/8831597Cescon201247474717Cescon, M.Colecchia, A.Cucchetti, A.Peri, E.Montrone, L.Ercolani, G.Festi, D.Pinna, A. D.Department of General Surgery and Organ Transplantation, University of Bologna, Italy.Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery706-12; discussion 712-32565AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*surgery/*ultrasonographyComorbidityElasticity Imaging Techniques/*methodsFemaleHepatectomyHumansLiver Cirrhosis/ultrasonographyLiver Neoplasms/*surgery/*ultrasonographyMaleMiddle AgedPostoperative ComplicationsPredictive Value of TestsProspective StudiesROC CurveSensitivity and Specificity2012Nov1528-1140 (Electronic) 0003-4932 (Linking)23095613http://www.ncbi.nlm.nih.gov/pubmed/2309561310.1097/SLA.0b013e3182724ce8Shen201711211121112117Shen, Y.Zhou, C.Zhu, G.Shi, G.Zhu, X.Huang, C.Zhou, J.Fan, J.Ding, H.Ren, N.Sun, H. C.Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. The Third Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. ren.ning@zs-hospital.sh.cn. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. ren.ning@zs-hospital.sh.cn. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. sun.huichuan@zs-hospital.sh.cn. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. sun.huichuan@zs-hospital.sh.cn.Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular CarcinomaJ Gastrointest SurgJ Gastrointest Surg1471-14792192017/05/17Liver stiffnessPortal hypertensionPostoperative liver failureShear wave elastography2017Sep1873-4626 (Electronic) 1091-255X (Linking)28510795https://www.ncbi.nlm.nih.gov/pubmed/28510795https://link.springer.com/content/pdf/10.1007%2Fs11605-017-3443-9.pdf10.1007/s11605-017-3443-9Rajakannu201763636317Rajakannu, M.Cherqui, D.Ciacio, O.Golse, N.Pittau, G.Allard, M. A.Antonini, T. M.Coilly, A.Sa Cunha, A.Castaing, D.Samuel, D.Guettier, C.Adam, R.Vibert, E.Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of anatomo-pathologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France; Inserm, Unite UMR-S 776, Villejuif, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Electronic address: muthukumarassamy@yahoo.com.Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinomaSurgerySurgerySurgerySurgerySurgerySurgery766-77416242017/07/18AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*diagnostic imaging/*surgeryCohort Studies*Elasticity Imaging TechniquesFemaleHepatectomy/*adverse effectsHumansLiver Failure/diagnosis/*etiologyLiver Neoplasms/*diagnostic imaging/*surgeryMaleMiddle AgedPostoperative Complications/*etiologyPredictive Value of TestsROC CurveTime FactorsTreatment Outcome2017Oct0039-60602871132010.1016/j.surg.2017.06.006NLMeng@\:DImamura200354545417Imamura, H.Seyama, Y.Kokudo, N.Maema, A.Sugawara, Y.Sano, K.Takayama, T.Makuuchi, M.Division of Hepato-Biliary-Pancreatic Surgery and Artificial Organ and Transplantation, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.One thousand fifty-six hepatectomies without mortality in 8 yearsArch SurgArchives of surgeryArch SurgArch SurgArchives of surgery1198-206; discussion 120613811AdolescentAdultAgedAged, 80 and overCohort StudiesFemaleHepatectomy/methods/*mortality/statistics & numerical dataHumansJapan/epidemiologyLiver Diseases/*surgeryLiver Transplantation/methodsMalePerioperative Care/*methodsPostoperative Complications/epidemiology/*mortalityRetrospective StudiesTreatment Outcome2003Nov0004-0010 (Print) 0004-0010 (Linking)14609867http://www.ncbi.nlm.nih.gov/pubmed/1460986710.1001/archsurg.138.11.1198Kubota199756565617Kubota, K.Makuuchi, M.Kusaka, K.Kobayashi, T.Miki, K.Hasegawa, K.Harihara, Y.Takayama, T.Second Department of Surgery, Faculty of Medicine, University of Tokyo, Japan.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumorsHepatologyHepatologyHepatologyHepatology1176-81265AgedBilirubin/blood*Decision MakingEmbolization, TherapeuticHepatectomy/*methodsHumansLiver/*physiopathology/*radiographyLiver Neoplasms/*physiopathology/*radiography/surgeryMiddle AgedPortal VeinTomography, X-Ray Computed1997Nov0270-9139 (Print) 0270-9139 (Linking)9362359http://www.ncbi.nlm.nih.gov/pubmed/936235910.1053/jhep.1997.v26.pm0009362359Bruix199646464617Bruix, J.Castells, A.Bosch, J.Feu, F.Fuster, J.Garcia-Pagan, J. C.Visa, J.Bru, C.Rodes, J.Liver Unit, Hospital Clinic i Provincial, University of Barcelona, Spain.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressureGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterology1018-221114AgedCarcinoma, Hepatocellular/mortality/physiopathology/*surgeryFemaleHumansLiver Cirrhosis/complications/*surgeryLiver Neoplasms/mortality/physiopathology/*surgeryMaleMiddle Aged*Portal PressurePostoperative ComplicationsPrognosis1996Oct0016-5085 (Print) 0016-5085 (Linking)8831597http://www.ncbi.nlm.nih.gov/pubmed/8831597Cescon201247474717Cescon, M.Colecchia, A.Cucchetti, A.Peri, E.Montrone, L.Ercolani, G.Festi, D.Pinna, A. D.Department of General Surgery and Organ Transplantation, University of Bologna, Italy.Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery706-12; discussion 712-32565AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*surgery/*ultrasonographyComorbidityElasticity Imaging Techniques/*methodsFemaleHepatectomyHumansLiver Cirrhosis/ultrasonographyLiver Neoplasms/*surgery/*ultrasonographyMaleMiddle AgedPostoperative ComplicationsPredictive Value of TestsProspective StudiesROC CurveSensitivity and Specificity2012Nov1528-1140 (Electronic) 0003-4932 (Linking)23095613http://www.ncbi.nlm.nih.gov/pubmed/2309561310.1097/SLA.0b013e3182724ce8Shen201711211121112117Shen, Y.Zhou, C.Zhu, G.Shi, G.Zhu, X.Huang, C.Zhou, J.Fan, J.Ding, H.Ren, N.Sun, H. C.Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. The Third Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China. Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. ren.ning@zs-hospital.sh.cn. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. ren.ning@zs-hospital.sh.cn. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. sun.huichuan@zs-hospital.sh.cn. Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. sun.huichuan@zs-hospital.sh.cn.Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular CarcinomaJ Gastrointest SurgJ Gastrointest Surg1471-14792192017/05/17Liver stiffnessPortal hypertensionPostoperative liver failureShear wave elastography2017Sep1873-4626 (Electronic) 1091-255X (Linking)28510795https://www.ncbi.nlm.nih.gov/pubmed/28510795https://link.springer.com/content/pdf/10.1007%2Fs11605-017-3443-9.pdf10.1007/s11605-017-3443-9Rajakannu201763636317Rajakannu, M.Cherqui, D.Ciacio, O.Golse, N.Pittau, G.Allard, M. A.Antonini, T. M.Coilly, A.Sa Cunha, A.Castaing, D.Samuel, D.Guettier, C.Adam, R.Vibert, E.Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France. Department of hepatologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of anatomo-pathologie, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France; Inserm, Unite UMR-S 776, Villejuif, France. Department of chirurgie hepatique et transplantation, Centre Hepato-Biliaire, AH-HP Hopital Paul Brousse, Villejuif, France; Inserm, Unite UMR-S 1193, Villejuif, France; Universite Paris-Sud, Faculte de Medecine, Le Kremlin-Bicetre, France. Electronic address: muthukumarassamy@yahoo.com.Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinomaSurgerySurgerySurgerySurgerySurgerySurgery766-77416242017/07/18AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*diagnostic imaging/*surgeryCohort Studies*Elasticity Imaging TechniquesFemaleHepatectomy/*adverse effectsHumansLiver Failure/diagnosis/*etiologyLiver Neoplasms/*diagnostic imaging/*surgeryMaleMiddle AgedPostoperative Complications/*etiologyPredictive Value of TestsROC CurveTime FactorsTreatment Outcome2017Oct0039-60602871132010.1016/j.surg.2017.06.006NLMeng@uDyK  _ENREF_59DDZhong201421532153215317Zhong, J. H.Ke, Y.Gong, W. F.Xiang, B. D.Ma, L.Ye, X. P.Peng, T.Xie, G. S.Li, L. Q.*Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University daggerHepatobiliary Surgery Department, The First Affiliated Hospital of Guangxi Medical University double daggerGeneral Surgery Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinomaAnn SurgAnn Surg329-4026022013/10/08AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryChemoembolization, TherapeuticChina/epidemiologyFemaleHepatectomy/*methods/mortalityHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm StagingPropensity ScoreRetrospective StudiesSurvival AnalysisTreatment Outcome2014Aug1528-1140 (Electronic) 0003-4932 (Linking)24096763https://www.ncbi.nlm.nih.gov/pubmed/2409676310.1097/SLA.0000000000000236Xiao201521542154215417Xiao, H.Zhang, B.Mei, B.Zuo, C.Wei, G.Wang, R.Zhang, B.Chen, X.From the Hepatic Surgery Center (HX, Binhao Z, BM, GW, RW, Bixiang Z, XC), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; and Department of Gastroduodenal and Pancreatic Surgery (HX, CZ), the Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablationMedicine (Baltimore)Medicine (Baltimore)e4959472015/02/24Ablation Techniques/methodsAdultCarcinoma, Hepatocellular/*epidemiology/surgery/*therapyChemoembolization, Therapeutic/methodsFemaleHumansHypertension, Portal/*epidemiologyLiver Neoplasms/*epidemiology/surgery/*therapyMaleMiddle AgedPrognosisRetrospective StudiesSurvival Rate2015Feb1536-5964 (Electronic) 0025-7974 (Linking)25700311https://www.ncbi.nlm.nih.gov/pubmed/25700311PMC455417710.1097/MD.0000000000000495uDyK  _ENREF_65uDyK  _ENREF_66DBosch200921572157215717Bosch, J.Abraldes, J. G.Berzigotti, A.Garcia-Pagan, J. C.Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic and CIBERehd, University of Barcelona, Barcelona, Spain. jbosch@clinic.ub.esThe clinical use of HVPG measurements in chronic liver diseaseNat Rev Gastroenterol HepatolNat Rev Gastroenterol Hepatol573-826102009/09/03Carcinoma, Hepatocellular/diagnosis/epidemiology/physiopathologyCentral Venous Pressure/*physiologyChronic DiseaseHumansHypertension, Portal/*diagnosis/etiology/physiopathologyLiver Diseases/complications/*physiopathologyLiver Neoplasms/diagnosis/epidemiology/physiopathologyRisk Factors2009Oct1759-5053 (Electronic) 1759-5045 (Linking)19724251https://www.ncbi.nlm.nih.gov/pubmed/1972425110.1038/nrgastro.2009.149engChen201221582158215817Chen, X.Zhai, J.Cai, X.Zhang, Y.Wei, L.Shi, L.Wu, D.Shen, F.Lau, W. Y.Wu, M.Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosisBr J SurgBr J SurgThe British journal of surgery1701-1099122012/11/08AdolescentAdultAgedCarcinoma, Hepatocellular/physiopathology/*surgeryHepatectomy/methodsHumansHypertension, Portal/*complications/physiopathologyLiver Cirrhosis/*complications/physiopathologyLiver Failure, Acute/*etiology/physiopathologyLiver Neoplasms/physiopathology/*surgeryMiddle AgedPortal Pressure/physiologyPostoperative Complications/*etiology/physiopathologyPrognosisProspective StudiesROC CurveRisk FactorsYoung Adult2012Dec1365-2168 (Electronic) 0007-1323 (Linking)23132418https://www.ncbi.nlm.nih.gov/pubmed/2313241810.1002/bjs.8951eng`DBosch200921572157215717Bosch, J.Abraldes, J. G.Berzigotti, A.Garcia-Pagan, J. C.Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic and CIBERehd, University of Barcelona, Barcelona, Spain. jbosch@clinic.ub.esThe clinical use of HVPG measurements in chronic liver diseaseNat Rev Gastroenterol HepatolNat Rev Gastroenterol Hepatol573-826102009/09/03Carcinoma, Hepatocellular/diagnosis/epidemiology/physiopathologyCentral Venous Pressure/*physiologyChronic DiseaseHumansHypertension, Portal/*diagnosis/etiology/physiopathologyLiver Diseases/complications/*physiopathologyLiver Neoplasms/diagnosis/epidemiology/physiopathologyRisk Factors2009Oct1759-5053 (Electronic) 1759-5045 (Linking)19724251https://www.ncbi.nlm.nih.gov/pubmed/1972425110.1038/nrgastro.2009.149engChen201221582158215817Chen, X.Zhai, J.Cai, X.Zhang, Y.Wei, L.Shi, L.Wu, D.Shen, F.Lau, W. Y.Wu, M.Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosisBr J SurgBr J SurgThe British journal of surgery1701-1099122012/11/08AdolescentAdultAgedCarcinoma, Hepatocellular/physiopathology/*surgeryHepatectomy/methodsHumansHypertension, Portal/*complications/physiopathologyLiver Cirrhosis/*complications/physiopathologyLiver Failure, Acute/*etiology/physiopathologyLiver Neoplasms/physiopathology/*surgeryMiddle AgedPortal Pressure/physiologyPostoperative Complications/*etiology/physiopathologyPrognosisProspective StudiesROC CurveRisk FactorsYoung Adult2012Dec1365-2168 (Electronic) 0007-1323 (Linking)23132418https://www.ncbi.nlm.nih.gov/pubmed/2313241810.1002/bjs.8951eng`uDyK  _ENREF_67uDyK  _ENREF_68uDyK  _ENREF_60DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8@0DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8@0uDyK  _ENREF_69 DMohkam201861616117Mohkam, K.Dumont, P. N.Manichon, A. F.Jouvet, J. C.Boussel, L.Merle, P.Ducerf, C.Lesurtel, M.Rode, A.Mabrut, J. Y.Department of General Surgery and Liver Transplantation, Hopital de la Croix-Rousse, Hospices Civils de Lyon, EMR3738, Universite Lyon 1, Lyon, France. Department of Diagnostic and Interventional Radiology, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France. Department of Hepatology, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France. Department of General Surgery and Liver Transplantation, Hopital de la Croix-Rousse, Hospices Civils de Lyon, EMR3738, Universite Lyon 1, Lyon, France. Electronic address: jean-yves.mabrut@chu-lyon.fr.No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cmJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology1172-11806862018/02/08*Ablation*Hepatectomy*Hepatocellular carcinoma*Local neoplasm recurrence*Radiofrequency2018Jun0168-82782941028710.1016/j.jhep.2018.01.014NLMeng@ DMohkam201861616117Mohkam, K.Dumont, P. N.Manichon, A. F.Jouvet, J. C.Boussel, L.Merle, P.Ducerf, C.Lesurtel, M.Rode, A.Mabrut, J. Y.Department of General Surgery and Liver Transplantation, Hopital de la Croix-Rousse, Hospices Civils de Lyon, EMR3738, Universite Lyon 1, Lyon, France. Department of Diagnostic and Interventional Radiology, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France. Department of Hepatology, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France. Department of General Surgery and Liver Transplantation, Hopital de la Croix-Rousse, Hospices Civils de Lyon, EMR3738, Universite Lyon 1, Lyon, France. Electronic address: jean-yves.mabrut@chu-lyon.fr.No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cmJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology1172-11806862018/02/08*Ablation*Hepatectomy*Hepatocellular carcinoma*Local neoplasm recurrence*Radiofrequency2018Jun0168-82782941028710.1016/j.jhep.2018.01.014NLMeng@uDyK  _ENREF_70hDLiu201659595917Liu, P. H.Hsu, C. Y.Hsia, C. Y.Lee, Y. H.Huang, Y. H.Chiou, Y. Y.Lin, H. C.Huo, T. I.*Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan daggerDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan double daggerDepartment of Biostatistics, UCLA, Los Angeles, CA section signDepartment of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan paragraph signInstitute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan ||Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan **Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma </= 2 cm in a Propensity Score ModelAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery538-452633AgedCarcinoma, Hepatocellular/*surgeryCatheter Ablation/*methodsFemaleHepatectomy/*methodsHumansLiver Neoplasms/*surgeryMaleMiddle AgedPropensity ScoreRadio WavesRetrospective StudiesSurvival RateTreatment Outcome2016Mar1528-1140 (Electronic) 0003-4932 (Linking)25775062http://www.ncbi.nlm.nih.gov/pubmed/2577506210.1097/SLA.0000000000001178Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Xu201471717117Xu, Q.Kobayashi, S.Ye, X.Meng, X.1] Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China [2] bioMerieux (Shanghai) Co. Ltd., Shanghai, China. cole Polytechnique ParisTech, Paris, France.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patientsSci RepScientific reportsSci RepScientific reportsSci RepScientific reports72524AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryCatheter Ablation/methodsDisease-Free SurvivalFemaleHepatectomy/methodsHumansLiver/*surgeryLiver Neoplasms/mortality/*surgeryMaleMiddle AgedSurvival RateTreatment OutcomeYoung Adult20142045-2322 (Electronic) 2045-2322 (Linking)25429732http://www.ncbi.nlm.nih.gov/pubmed/25429732424621210.1038/srep07252@hDLiu201659595917Liu, P. H.Hsu, C. Y.Hsia, C. Y.Lee, Y. H.Huang, Y. H.Chiou, Y. Y.Lin, H. C.Huo, T. I.*Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan daggerDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan double daggerDepartment of Biostatistics, UCLA, Los Angeles, CA section signDepartment of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan paragraph signInstitute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan ||Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan **Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma </= 2 cm in a Propensity Score ModelAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery538-452633AgedCarcinoma, Hepatocellular/*surgeryCatheter Ablation/*methodsFemaleHepatectomy/*methodsHumansLiver Neoplasms/*surgeryMaleMiddle AgedPropensity ScoreRadio WavesRetrospective StudiesSurvival RateTreatment Outcome2016Mar1528-1140 (Electronic) 0003-4932 (Linking)25775062http://www.ncbi.nlm.nih.gov/pubmed/2577506210.1097/SLA.0000000000001178Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Xu201471717117Xu, Q.Kobayashi, S.Ye, X.Meng, X.1] Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China [2] bioMerieux (Shanghai) Co. Ltd., Shanghai, China. cole Polytechnique ParisTech, Paris, France.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patientsSci RepScientific reportsSci RepScientific reportsSci RepScientific reports72524AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryCatheter Ablation/methodsDisease-Free SurvivalFemaleHepatectomy/methodsHumansLiver/*surgeryLiver Neoplasms/mortality/*surgeryMaleMiddle AgedSurvival RateTreatment OutcomeYoung Adult20142045-2322 (Electronic) 2045-2322 (Linking)25429732http://www.ncbi.nlm.nih.gov/pubmed/25429732424621210.1038/srep07252@uDyK  _ENREF_71DYin201474747417Yin, L.Li, H.Li, A. J.Lau, W. Y.Pan, Z. Y.Lai, E. C.Wu, M. C.Zhou, W. P.The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. The Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai 200438, China. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China; Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address: EHPHWP@126.com.Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCTJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology82-8611AdultCarcinoma, Hepatocellular/mortality/*surgery/*therapy*Chemoembolization, Therapeutic/adverse effectsFemale*Hepatectomy/adverse effectsHumansKaplan-Meier EstimateLiver Neoplasms/mortality/*surgery/*therapyMaleMiddle AgedNeoplasms, Multiple Primary/mortality/*surgery/*therapyPractice Guidelines as TopicPrognosisRisk FactorsTreatment Outcome2014Jul1600-0641 (Electronic) 0168-8278 (Linking)24650695http://www.ncbi.nlm.nih.gov/pubmed/2465069510.1016/j.jhep.2014.03.012Torzilli201366666617Torzilli, G.Belghiti, J.Kokudo, N.Takayama, T.Capussotti, L.Nuzzo, G.Vauthey, J. N.Choti, M. A.De Santibanes, E.Donadon, M.Morenghi, E.Makuuchi, M.Liver Surgery Unit, Department of Surgery, University of Milan-School of Medicine, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. guido.torzilli@unimi.itA snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study groupAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery929-372575AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryChildFemaleFollow-Up StudiesGuideline Adherence/*statistics & numerical dataHepatectomy/mortality/*statistics & numerical dataHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPostoperative Complications/epidemiologyPractice Guidelines as TopicPractice Patterns, Physicians'/*statistics & numerical dataPreoperative Care/methodsRetrospective StudiesSurvival AnalysisTertiary Care Centers/*statistics & numerical dataTreatment OutcomeYoung Adult2013May1528-1140 (Electronic) 0003-4932 (Linking)23426336http://www.ncbi.nlm.nih.gov/pubmed/2342633610.1097/SLA.0b013e31828329b8`DYin201474747417Yin, L.Li, H.Li, A. J.Lau, W. Y.Pan, Z. Y.Lai, E. C.Wu, M. C.Zhou, W. P.The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. The Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai 200438, China. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China; Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Electronic address: EHPHWP@126.com.Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCTJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology82-8611AdultCarcinoma, Hepatocellular/mortality/*surgery/*therapy*Chemoembolization, Therapeutic/adverse effectsFemale*Hepatectomy/adverse effectsHumansKaplan-Meier EstimateLiver Neoplasms/mortality/*surgery/*therapyMaleMiddle AgedNeoplasms, Multiple Primary/mortality/*surgery/*therapyPractice Guidelines as TopicPrognosisRisk FactorsTreatment Outcome2014Jul1600-0641 (Electronic) 0168-8278 (Linking)24650695http://www.ncbi.nlm.nih.gov/pubmed/2465069510.1016/j.jhep.2014.03.012Torzilli201366666617Torzilli, G.Belghiti, J.Kokudo, N.Takayama, T.Capussotti, L.Nuzzo, G.Vauthey, J. N.Choti, M. A.De Santibanes, E.Donadon, M.Morenghi, E.Makuuchi, M.Liver Surgery Unit, Department of Surgery, University of Milan-School of Medicine, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. guido.torzilli@unimi.itA snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study groupAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery929-372575AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryChildFemaleFollow-Up StudiesGuideline Adherence/*statistics & numerical dataHepatectomy/mortality/*statistics & numerical dataHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPostoperative Complications/epidemiologyPractice Guidelines as TopicPractice Patterns, Physicians'/*statistics & numerical dataPreoperative Care/methodsRetrospective StudiesSurvival AnalysisTertiary Care Centers/*statistics & numerical dataTreatment OutcomeYoung Adult2013May1528-1140 (Electronic) 0003-4932 (Linking)23426336http://www.ncbi.nlm.nih.gov/pubmed/2342633610.1097/SLA.0b013e31828329b8`uDyK  _ENREF_74uDyK  _ENREF_75 DWang201621592159215917Wang, K.Guo, W. X.Chen, M. S.Mao, Y. L.Sun, B. C.Shi, J.Zhang, Y. J.Meng, Y.Yang, Y. F.Cong, W. M.Wu, M. C.Lau, W. Y.Cheng, S. Q.From the Department of Hepatic Surgery (KW, WXG, JS, MCW, WYL, SQC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai; Faculty of Medicine (WYL), The Chinese University of Hong Kong, Shatin, Hong Kong SAR; Department of Hepatobiliary Surgery (MSC, YJZ), SunYat-sen University Cancer Center; Department of Liver Surgery (YLM), Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing; Liver Transplantation Center of the First Affiliated Hospital (BCS), Nanjing Medical University, Nanjing, Jiangsu Province; Department of Radiotherapy (YM); Department of Invasive Technology (YFY); and Department of Pathology (WMC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score AnalysisMedicine (Baltimore)Medicine (Baltimore)e301595112016/03/18Antineoplastic Agents/*therapeutic useCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticChina/epidemiologyCombined Modality TherapyFemaleHumansLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePhenylurea Compounds/*therapeutic usePortal VeinPropensity ScoreRadiotherapyRetrospective StudiesSorafenibVenous Thrombosis/etiology2016Mar1536-5964 (Electronic) 0025-7974 (Linking)26986115https://www.ncbi.nlm.nih.gov/pubmed/26986115PMC483989610.1097/MD.0000000000003015eng@0 DWang201621592159215917Wang, K.Guo, W. X.Chen, M. S.Mao, Y. L.Sun, B. C.Shi, J.Zhang, Y. J.Meng, Y.Yang, Y. F.Cong, W. M.Wu, M. C.Lau, W. Y.Cheng, S. Q.From the Department of Hepatic Surgery (KW, WXG, JS, MCW, WYL, SQC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai; Faculty of Medicine (WYL), The Chinese University of Hong Kong, Shatin, Hong Kong SAR; Department of Hepatobiliary Surgery (MSC, YJZ), SunYat-sen University Cancer Center; Department of Liver Surgery (YLM), Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing; Liver Transplantation Center of the First Affiliated Hospital (BCS), Nanjing Medical University, Nanjing, Jiangsu Province; Department of Radiotherapy (YM); Department of Invasive Technology (YFY); and Department of Pathology (WMC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score AnalysisMedicine (Baltimore)Medicine (Baltimore)e301595112016/03/18Antineoplastic Agents/*therapeutic useCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticChina/epidemiologyCombined Modality TherapyFemaleHumansLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePhenylurea Compounds/*therapeutic usePortal VeinPropensity ScoreRadiotherapyRetrospective StudiesSorafenibVenous Thrombosis/etiology2016Mar1536-5964 (Electronic) 0025-7974 (Linking)26986115https://www.ncbi.nlm.nih.gov/pubmed/26986115PMC483989610.1097/MD.0000000000003015eng@0uDyK  _ENREF_76 DWei201969696917Wei, X.Jiang, Y.Zhang, X.Feng, S.Zhou, B.Ye, X.Xing, H.Xu, Y.Shi, J.Guo, W.Zhou, D.Zhang, H.Sun, H.Huang, C.Lu, C.Zheng, Y.Meng, Y.Huang, B.Cong, W.Lau, W. Y.Cheng, S.1 Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, People's Republic of China. 2 Department of Health Statistics, Navy Military Medical University, Shanghai, People's Republic of China. 3 Fujian Provincial Cancer Hospital, Fuzhou, People's Republic of China. 4 Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 5 The Chinese University of Hong Kong, Sha Tin, People's Republic of China.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled StudyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJco18021842019/07/102019Jul 80732-183x3128340910.1200/jco.18.02184NLMeng DWei201969696917Wei, X.Jiang, Y.Zhang, X.Feng, S.Zhou, B.Ye, X.Xing, H.Xu, Y.Shi, J.Guo, W.Zhou, D.Zhang, H.Sun, H.Huang, C.Lu, C.Zheng, Y.Meng, Y.Huang, B.Cong, W.Lau, W. Y.Cheng, S.1 Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, People's Republic of China. 2 Department of Health Statistics, Navy Military Medical University, Shanghai, People's Republic of China. 3 Fujian Provincial Cancer Hospital, Fuzhou, People's Republic of China. 4 Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 5 The Chinese University of Hong Kong, Sha Tin, People's Republic of China.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled StudyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJco18021842019/07/102019Jul 80732-183x3128340910.1200/jco.18.02184NLMenguDyK  _ENREF_77uDyK  _ENREF_78DYang201872727217Yang, J.Tao, H. S.Cai, W.Zhu, W.Zhao, D.Hu, H. Y.Liu, J.Fang, C. H.Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Department of Surgical Oncology, Xinyang Central Hospital, Henan, China.Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imagingJ Surg OncolJournal of surgical oncologyJ Surg OncolJ Surg OncolJournal of surgical oncology1081-108711872018/10/08Carcinoma, Hepatocellular/diagnostic imaging/secondary/surgeryCholangiocarcinoma/diagnostic imaging/secondary/surgeryFemaleFluorescent DyesHepatectomy/*methodsHumans*Imaging, Three-DimensionalIndocyanine GreenLiver/*diagnostic imagingLiver Neoplasms/*diagnostic imaging/secondary/*surgeryMaleMiddle Aged*Optical ImagingPreoperative CareProspective StudiesStaining and LabelingTomography, X-Ray Computed3danatomical liver resections (ALRs)indocyanine green fluorescence imaging (IGFI)2018Dec0022-47903029324910.1002/jso.25258NLMengMise201860606017Mise, Y.Hasegawa, K.Satou, S.Shindoh, J.Miki, K.Akamatsu, N.Arita, J.Kaneko, J.Sakamoto, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.How Has Virtual Hepatectomy Changed the Practice of Liver Surgery?: Experience of 1194 Virtual Hepatectomy Before Liver Resection and Living Donor Liver TransplantationAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery127-13326812017/03/142018Jul0003-49322828806510.1097/sla.0000000000002213NLMenguDyK  _ENREF_79uDyK  _ENREF_80DJiang201555555517Jiang, H. T.Cao, J. Y.Department of General Surgery, Ningbo No. 2 Hospital, Ningbo 315010, Zhejiang, China. Department of Hepatobiliary Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinomaChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical SciencesChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical SciencesChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences80-3302AdultAgedAged, 80 and overFemaleHepatectomy/*methodsHumansLaparoscopy/*methodsLength of StayLiver Neoplasms/*surgeryMaleMiddle AgedPostoperative Complications/prevention & control2015Jun1001-9294 (Print) 1001-9294 (Linking)26148997http://www.ncbi.nlm.nih.gov/pubmed/26148997@DJiang201555555517Jiang, H. T.Cao, J. Y.Department of General Surgery, Ningbo No. 2 Hospital, Ningbo 315010, Zhejiang, China. Department of Hepatobiliary Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinomaChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical SciencesChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical SciencesChin Med Sci JChinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences80-3302AdultAgedAged, 80 and overFemaleHepatectomy/*methodsHumansLaparoscopy/*methodsLength of StayLiver Neoplasms/*surgeryMaleMiddle AgedPostoperative Complications/prevention & control2015Jun1001-9294 (Print) 1001-9294 (Linking)26148997http://www.ncbi.nlm.nih.gov/pubmed/26148997@uDyK  _ENREF_81" DWu201970707017Wu, X.Huang, Z.Lau, W. Y.Li, W.Lin, P.Zhang, L.Chen, Y.Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China. Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. zhanglei646@126.com. Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. cyj0509@126.com.Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching studySurg EndoscSurgical endoscopySurg EndoscSurgical endoscopySurg EndoscSurgical endoscopy206-2153312018/07/11CirrhosisHepatocellular carcinomaLaparoscopic liver resectionLong-term outcomesMultivariate analysisPropensity score matching2019Jan0930-27942998756510.1007/s00464-018-6296-8NLMeng" DWu201970707017Wu, X.Huang, Z.Lau, W. Y.Li, W.Lin, P.Zhang, L.Chen, Y.Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China. Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. zhanglei646@126.com. Department of Hepato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yanjiang West Road, Guangzhou, 510120, Guangdong, People's Republic of China. cyj0509@126.com.Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching studySurg EndoscSurgical endoscopySurg EndoscSurgical endoscopySurg EndoscSurgical endoscopy206-2153312018/07/11CirrhosisHepatocellular carcinomaLaparoscopic liver resectionLong-term outcomesMultivariate analysisPropensity score matching2019Jan0930-27942998756510.1007/s00464-018-6296-8NLMenguDyK  _ENREF_82 DCheung201849494917Cheung, T. T.Han, H. S.She, W. H.Chen, K. H.Chow, P. K. H.Yoong, B. K.Lee, K. F.Kubo, S.Tang, C. N.Wakabayashi, G.Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong (SAR), China. Department of Surgery, Seoul National University Bundang Hospital, Seoul National College of Medicine, Seoul, South Korea. Department of Surgery, Far-Eastern Memorial Hospital, New Taipei City, Taiwan, China. National Cancer Center, Singapore, Singapore. Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia. Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong (SAR), China. Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong (SAR), China. Department of Surgery, Ageo Central General Hospital, Ageo, Japan.The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong KongLiver CancerLiver cancerLiver CancerLiver Cancer28-39712018/04/183D laparoscopyCirrhosisEvidenceHepatectomyHepatocellular carcinomaInternational consensus conferenceInternational consensus guidelinesLiver resection2018Mar2235-1795 (Print) 1664-555329662831PMC589235910.1159/000481834NLMeng DCheung201849494917Cheung, T. T.Han, H. S.She, W. H.Chen, K. H.Chow, P. K. H.Yoong, B. K.Lee, K. F.Kubo, S.Tang, C. N.Wakabayashi, G.Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong (SAR), China. Department of Surgery, Seoul National University Bundang Hospital, Seoul National College of Medicine, Seoul, South Korea. Department of Surgery, Far-Eastern Memorial Hospital, New Taipei City, Taiwan, China. National Cancer Center, Singapore, Singapore. Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia. Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong (SAR), China. Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong (SAR), China. Department of Surgery, Ageo Central General Hospital, Ageo, Japan.The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong KongLiver CancerLiver cancerLiver CancerLiver Cancer28-39712018/04/183D laparoscopyCirrhosisEvidenceHepatectomyHepatocellular carcinomaInternational consensus conferenceInternational consensus guidelinesLiver resection2018Mar2235-1795 (Print) 1664-555329662831PMC589235910.1159/000481834NLMenguDyK  _ENREF_83`DShi200721602160216017Shi, M.Guo, R. P.Lin, X. J.Zhang, Y. Q.Chen, M. S.Zhang, C. Q.Lau, W. Y.Li, J. Q.State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, P.R. China.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trialAnn SurgAnn Surg36-4324512007/01/02AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSingle-Blind MethodSurvival RateTreatment Outcome2007Jan0003-4932 (Print) 0003-4932 (Linking)17197963https://www.ncbi.nlm.nih.gov/pubmed/17197963PMC186793410.1097/01.sla.0000231758.07868.71`DShi200721602160216017Shi, M.Guo, R. P.Lin, X. J.Zhang, Y. Q.Chen, M. S.Zhang, C. Q.Lau, W. Y.Li, J. Q.State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, P.R. China.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trialAnn SurgAnn Surg36-4324512007/01/02AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSingle-Blind MethodSurvival RateTreatment Outcome2007Jan0003-4932 (Print) 0003-4932 (Linking)17197963https://www.ncbi.nlm.nih.gov/pubmed/17197963PMC186793410.1097/01.sla.0000231758.07868.71uDyK  _ENREF_84 DYang201973737317Yang, P.Si, A.Yang, J.Cheng, Z.Wang, K.Li, J.Xia, Y.Zhang, B.Pawlik, T. M.Lau, W. Y.Shen, F.Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Surgical Oncology, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province China. Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of General Surgery, the Affiliated Zhongda Hospital, Southeast University, Nanjing, China. Department of Hepatic Surgery II, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: zhangbaohuaehbh@163.com. Department of Surgery, Ohio State University, The Wexner Medical Center, Columbus, OH, USA. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: shenfengehbh@sina.com.A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasionSurgerySurgerySurgerySurgerySurgerySurgery721-73016542018/12/182019Apr0039-60603055472410.1016/j.surg.2018.09.016NLMengp DYang201973737317Yang, P.Si, A.Yang, J.Cheng, Z.Wang, K.Li, J.Xia, Y.Zhang, B.Pawlik, T. M.Lau, W. Y.Shen, F.Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Surgical Oncology, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province China. Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of General Surgery, the Affiliated Zhongda Hospital, Southeast University, Nanjing, China. Department of Hepatic Surgery II, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Department of Minimally Invasive Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: zhangbaohuaehbh@163.com. Department of Surgery, Ohio State University, The Wexner Medical Center, Columbus, OH, USA. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: shenfengehbh@sina.com.A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasionSurgerySurgerySurgerySurgerySurgerySurgery721-73016542018/12/182019Apr0039-60603055472410.1016/j.surg.2018.09.016NLMengpuDyK  _ENREF_85uDyK  _ENREF_86J DZhou201976767617Zhou, C.Peng, Y.Zhou, K.Zhang, L.Zhang, X.Yu, L.Hu, J.Chen, F.Qiu, S.Zhou, J.Fan, J.Ren, Z.Wang, Z.Liver Cancer Institute and Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Institute of Biomedical Sciences, School of Life Sciences, Fudan University, Shanghai 200032, China. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200032, China.Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinomaHepatobiliary Surg NutrHepatobiliary surgery and nutritionHepatobiliary Surg NutrHepatobiliary Surg NutrHepatobiliary surgery and nutrition19-28812019/03/19Hepatocellular carcinoma (HCC)radiofrequency ablation (RFA)surgical resection (SR)survival ratetransarterial chemoembolization (TACE)2019Feb2304-3881 (Print) 2304-388130881962PMC638300710.21037/hbsn.2018.11.19NLMeng@0J DZhou201976767617Zhou, C.Peng, Y.Zhou, K.Zhang, L.Zhang, X.Yu, L.Hu, J.Chen, F.Qiu, S.Zhou, J.Fan, J.Ren, Z.Wang, Z.Liver Cancer Institute and Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Institute of Biomedical Sciences, School of Life Sciences, Fudan University, Shanghai 200032, China. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200032, China.Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinomaHepatobiliary Surg NutrHepatobiliary surgery and nutritionHepatobiliary Surg NutrHepatobiliary Surg NutrHepatobiliary surgery and nutrition19-28812019/03/19Hepatocellular carcinoma (HCC)radiofrequency ablation (RFA)surgical resection (SR)survival ratetransarterial chemoembolization (TACE)2019Feb2304-3881 (Print) 2304-388130881962PMC638300710.21037/hbsn.2018.11.19NLMeng@0uDyK  _ENREF_87 DZhang201575757517Zhang, Z. M.Lai, E. C.Zhang, C.Yu, H. W.Liu, Z.Wan, B. J.Liu, L. M.Tian, Z. H.Deng, H.Sun, Q. H.Chen, X. P.Department of General Surgery, Beijing Electric Power Hospital, Capital Medical University, Beijing, China. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Chaiwan, Hong Kong, China. Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. Electronic address: chenxpchenxp@163.com.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombusInt J SurgInternational journal of surgeryInt J SurgInternational journal of surgeryInt J SurgInternational journal of surgery8-1620Carcinoma, Hepatocellular/*therapyCatheter Ablation*Chemoembolization, TherapeuticCombined Modality Therapy*Hepatectomy/methodsHigh-Intensity Focused Ultrasound AblationHumansLiver Neoplasms/*therapyMaleMiddle Aged*Neoplastic Cells, Circulating*Portal Vein/pathologyPrognosisQuality of Life*Radiotherapy, ConformalThrombosis/*surgeryTreatment Outcome2015Aug1743-9159 (Electronic) 1743-9159 (Linking)26026424http://www.ncbi.nlm.nih.gov/pubmed/2602642410.1016/j.ijsu.2015.05.009 DZhang201575757517Zhang, Z. M.Lai, E. C.Zhang, C.Yu, H. W.Liu, Z.Wan, B. J.Liu, L. M.Tian, Z. H.Deng, H.Sun, Q. H.Chen, X. P.Department of General Surgery, Beijing Electric Power Hospital, Capital Medical University, Beijing, China. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Chaiwan, Hong Kong, China. Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. Electronic address: chenxpchenxp@163.com.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombusInt J SurgInternational journal of surgeryInt J SurgInternational journal of surgeryInt J SurgInternational journal of surgery8-1620Carcinoma, Hepatocellular/*therapyCatheter Ablation*Chemoembolization, TherapeuticCombined Modality Therapy*Hepatectomy/methodsHigh-Intensity Focused Ultrasound AblationHumansLiver Neoplasms/*therapyMaleMiddle Aged*Neoplastic Cells, Circulating*Portal Vein/pathologyPrognosisQuality of Life*Radiotherapy, ConformalThrombosis/*surgeryTreatment Outcome2015Aug1743-9159 (Electronic) 1743-9159 (Linking)26026424http://www.ncbi.nlm.nih.gov/pubmed/2602642410.1016/j.ijsu.2015.05.009uDyK  _ENREF_88~DFu201082828217Fu, S. Y.Lau, W. Y.Li, A. J.Yang, Y.Pan, Z. Y.Sun, Y. M.Lai, E. C.Zhou, W. P.Wu, M. C.Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Liver resection under total vascular exclusion with or without preceding Pringle manoeuvreBr J SurgThe British journal of surgeryBr J SurgBr J SurgThe British journal of surgery50-5971Blood Loss, Surgical/*prevention & controlConstrictionEmbolization, Therapeutic/*methodsFemaleHemostatic TechniquesHepatectomy/*methodsHumansIntraoperative Care/methodsLiver/*blood supplyLiver Diseases/*surgeryMaleMiddle AgedProspective Studies2010Jan1365-2168 (Electronic) 0007-1323 (Linking)20013928http://www.ncbi.nlm.nih.gov/pubmed/2001392810.1002/bjs.6841@0~DFu201082828217Fu, S. Y.Lau, W. Y.Li, A. J.Yang, Y.Pan, Z. Y.Sun, Y. M.Lai, E. C.Zhou, W. P.Wu, M. C.Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.Liver resection under total vascular exclusion with or without preceding Pringle manoeuvreBr J SurgThe British journal of surgeryBr J SurgBr J SurgThe British journal of surgery50-5971Blood Loss, Surgical/*prevention & controlConstrictionEmbolization, Therapeutic/*methodsFemaleHemostatic TechniquesHepatectomy/*methodsHumansIntraoperative Care/methodsLiver/*blood supplyLiver Diseases/*surgeryMaleMiddle AgedProspective Studies2010Jan1365-2168 (Electronic) 0007-1323 (Linking)20013928http://www.ncbi.nlm.nih.gov/pubmed/2001392810.1002/bjs.6841@0uDyK  _ENREF_89DSatoh200010010010017Satoh, S.Ikai, I.Honda, G.Okabe, H.Takeyama, O.Yamamoto, Y.Yamamoto, N.Iimuro, Y.Shimahara, Y.Yamaoka, Y.Department of Gastroenterological Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombiSurgerySurgerySurgerySurgerySurgerySurgery779-831285AdultAgedBile Duct Diseases/*diagnosis/etiology/pathology/surgeryBile Ducts/pathologyCarcinoma, Hepatocellular/complications/*diagnosisFemaleHumansLiver Neoplasms/complications/*diagnosisMaleMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm StagingThrombosis/*diagnosis/etiology/pathology/surgeryTreatment Outcome2000Nov0039-6060 (Print) 0039-6060 (Linking)11056440http://www.ncbi.nlm.nih.gov/pubmed/1105644010.1067/msy.2000.108659@0DSatoh200010010010017Satoh, S.Ikai, I.Honda, G.Okabe, H.Takeyama, O.Yamamoto, Y.Yamamoto, N.Iimuro, Y.Shimahara, Y.Yamaoka, Y.Department of Gastroenterological Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombiSurgerySurgerySurgerySurgerySurgerySurgery779-831285AdultAgedBile Duct Diseases/*diagnosis/etiology/pathology/surgeryBile Ducts/pathologyCarcinoma, Hepatocellular/complications/*diagnosisFemaleHumansLiver Neoplasms/complications/*diagnosisMaleMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm StagingThrombosis/*diagnosis/etiology/pathology/surgeryTreatment Outcome2000Nov0039-6060 (Print) 0039-6060 (Linking)11056440http://www.ncbi.nlm.nih.gov/pubmed/1105644010.1067/msy.2000.108659@0uDyK  _ENREF_90DTang199564646417Tang, Z. Y.Uy, Y. Q.Zhou, X. D.Ma, Z. C.Lu, J. Z.Lin, Z. Y.Liu, K. D.Ye, S. L.Yang, B. H.Wang, H. W.et al.,Liver Cancer Institute, Shanghai Medical University, People's Republic of China.Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patientsWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgery784-9196AdolescentAdultAgedCarcinoma, Hepatocellular/surgery/*therapyCombined Modality TherapyFemaleHumansLiver Neoplasms/surgery/*therapyMaleMiddle AgedMultivariate AnalysisPrognosis1995Nov-Dec0364-2313 (Print) 0364-2313 (Linking)8553666http://www.ncbi.nlm.nih.gov/pubmed/8553666Tang199565656517Tang, Z. Y.Yu, Y. Q.Zhou, X. D.Ma, Z. C.Yang, B. H.Lin, Z. Y.Lu, J. Z.Liu, K. D.Fan, Z.Zeng, Z. C.Liver Cancer Institute, Shanghai Medical University, People's Republic of China.Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resectionWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgeryWorld J SurgWorld journal of surgery47-52191AdolescentAdultAgedAntineoplastic Agents/administration & dosageChemotherapy, AdjuvantEmbolization, TherapeuticFemaleHepatectomyHepatic Artery/surgeryHumansInfusions, Intra-ArterialLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedNeoplasm StagingRadioimmunotherapyRadiotherapy, AdjuvantSurvival Rate1995Jan-Feb0364-2313 (Print) 0364-2313 (Linking)7740810http://www.ncbi.nlm.nih.gov/pubmed/7740810uDyK  _ENREF_91uDyK  _ENREF_92uDyK  _ENREF_93NDOgata200662626217Ogata, S.Belghiti, J.Farges, O.Varma, D.Sibert, A.Vilgrain, V.Department of Hepato-Pancreato-Biliary Surgery, Hospital Beaujon-University Paris VII, Clichy, France.Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinomaBr J SurgThe British journal of surgeryBr J SurgBr J SurgThe British journal of surgery1091-8939AgedCarcinoma, Hepatocellular/*therapyChemoembolization, Therapeutic/methodsEmbolization, Therapeutic/*methodsHepatectomy/*methodsHumansLiver Cirrhosis/*therapyLiver Neoplasms/*therapyMaleMiddle Aged*Portal VeinPostoperative Complications/etiologyTreatment Outcome2006Sep0007-1323 (Print) 0007-1323 (Linking)16779884http://www.ncbi.nlm.nih.gov/pubmed/1677988410.1002/bjs.5341pNDOgata200662626217Ogata, S.Belghiti, J.Farges, O.Varma, D.Sibert, A.Vilgrain, V.Department of Hepato-Pancreato-Biliary Surgery, Hospital Beaujon-University Paris VII, Clichy, France.Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinomaBr J SurgThe British journal of surgeryBr J SurgBr J SurgThe British journal of surgery1091-8939AgedCarcinoma, Hepatocellular/*therapyChemoembolization, Therapeutic/methodsEmbolization, Therapeutic/*methodsHepatectomy/*methodsHumansLiver Cirrhosis/*therapyLiver Neoplasms/*therapyMaleMiddle Aged*Portal VeinPostoperative Complications/etiologyTreatment Outcome2006Sep0007-1323 (Print) 0007-1323 (Linking)16779884http://www.ncbi.nlm.nih.gov/pubmed/1677988410.1002/bjs.5341puDyK  _ENREF_94 DWang201868686817Wang, Z.Peng, Y.Hu, J.Wang, X.Sun, H.Sun, J.Shi, Y.Xiao, Y.Ding, Z.Yang, X.Tang, M.Tang, Z.Wang, J.Lau, W. Y.Fan, J.Zhou, J.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hepatobiliary Cancer Division of Surgical Oncology, Brigham and Women's Hospital, Boston, MA. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Honk King, China. Institute of Biomedical Sciences, Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 PatientsAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery2018/07/122018Jul 100003-49322999568110.1097/sla.0000000000002942NLMeng@0 DWang201868686817Wang, Z.Peng, Y.Hu, J.Wang, X.Sun, H.Sun, J.Shi, Y.Xiao, Y.Ding, Z.Yang, X.Tang, M.Tang, Z.Wang, J.Lau, W. Y.Fan, J.Zhou, J.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hepatobiliary Cancer Division of Surgical Oncology, Brigham and Women's Hospital, Boston, MA. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Honk King, China. Institute of Biomedical Sciences, Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 PatientsAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery2018/07/122018Jul 100003-49322999568110.1097/sla.0000000000002942NLMeng@0uDyK  _ENREF_95 DD'Haese201650505017D'Haese, J. G.Neumann, J.Weniger, M.Pratschke, S.Bjornsson, B.Ardiles, V.Chapman, W.Hernandez-Alejandro, R.Soubrane, O.Robles-Campos, R.Stojanovic, M.Dalla Valle, R.Chan, A. C.Coenen, M.Guba, M.Werner, J.Schadde, E.Angele, M. K.Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany. Department of Pathology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. Department of Surgery, County Council of Ostergotland, Linkoping University, Linkoping, Sweden. HPB Surgery and Liver Transplant Unit, Italian Hospital Buenos Aires, Buenos Aires, Argentina. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. Medical Center London, Western University, Ontario, Canada. Department of HPB Surgery and Liver Transplant, Beaujon Hospital, Clichy, France. Virgen de la Arrixaca University Hospital, Murcia, Spain. Department of Surgery, University Clinical Center, Nis, Serbia. Department of Surgery, Parma University Hospital, Parma, Italy. Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China. Department of Medical Informatics, Biometry, and Epidemiology-IBE, Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. Department of Surgery, Cantonal Hospital Winterthur, Institute of Physiology, University of Zurich, Zurich, Switzerland. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany. martin.angele@med.uni-muenchen.de. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Campus Grosshadern, Ludwig Maximilians-University, Munich, Germany. martin.angele@med.uni-muenchen.de.Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC?Ann Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncology1335-432342016Apr1534-4681 (Electronic) 1068-9265 (Linking)26646946http://www.ncbi.nlm.nih.gov/pubmed/2664694610.1245/s10434-015-5007-0@ DD'Haese201650505017D'Haese, J. G.Neumann, J.Weniger, M.Pratschke, S.Bjornsson, B.Ardiles, V.Chapman, W.Hernandez-Alejandro, R.Soubrane, O.Robles-Campos, R.Stojanovic, M.Dalla Valle, R.Chan, A. C.Coenen, M.Guba, M.Werner, J.Schadde, E.Angele, M. K.Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany. Department of Pathology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. Department of Surgery, County Council of Ostergotland, Linkoping University, Linkoping, Sweden. HPB Surgery and Liver Transplant Unit, Italian Hospital Buenos Aires, Buenos Aires, Argentina. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. Medical Center London, Western University, Ontario, Canada. Department of HPB Surgery and Liver Transplant, Beaujon Hospital, Clichy, France. Virgen de la Arrixaca University Hospital, Murcia, Spain. Department of Surgery, University Clinical Center, Nis, Serbia. Department of Surgery, Parma University Hospital, Parma, Italy. Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China. Department of Medical Informatics, Biometry, and Epidemiology-IBE, Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. Department of Surgery, Cantonal Hospital Winterthur, Institute of Physiology, University of Zurich, Zurich, Switzerland. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany. martin.angele@med.uni-muenchen.de. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Campus Grosshadern, Ludwig Maximilians-University, Munich, Germany. martin.angele@med.uni-muenchen.de.Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC?Ann Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncology1335-432342016Apr1534-4681 (Electronic) 1068-9265 (Linking)26646946http://www.ncbi.nlm.nih.gov/pubmed/2664694610.1245/s10434-015-5007-0@uDyK  _ENREF_96 D郑树国201445454517郑树国李建伟肖乐曹利郭鹏Zheng, ShuguoLi, JianweiXiao, LeCao, LiGuo, Peng第三军医大学西南医院全军肝胆外科研究所中国人民解放军西南肝胆外科医院, 重庆,400038全腹腔镜联合肝脏离断和门静脉结扎的二步肝切除术治疗肝硬化肝癌中华消化外科杂志中华消化外科杂志502-507137肝肿瘤 肝硬化 腹腔镜检查 联合肝脏离断和门静脉结扎的二步肝切除术 Liver neoplasms Liver cirrhosis Laparoscopy Associating liver partition and portal vein ligation for staged hepatectomy20141673-9752http://d.g.wanfangdata.com.cn/Periodical_xhwk201407002.aspx10.3760/cma.j.issn.1673-9752.2014.07.002北京万方数据股份有限公司chiHong de201653535317Hong de, F.Zhang, Y. B.Peng, S. Y.Huang, D. S.Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.Percutaneous Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver Regeneration: A Minimally Invasive First Step of ALPPS for Hepatocellular CarcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgerye1-226412016Jul1528-1140 (Electronic) 0003-4932 (Linking)26967629http://www.ncbi.nlm.nih.gov/pubmed/26967629490231910.1097/SLA.0000000000001707uDyK  _ENREF_98uDyK  _ENREF_91DShi201410210210217Shi, H. Y.Wang, S. N.Wang, S. C.Chuang, S. C.Chen, C. M.Lee, K. T.Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung, Taiwan.Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictorsJ Surg OncolJournal of surgical oncologyJ Surg OncolJ Surg OncolJournal of surgical oncology487-931095AdultAgedCarcinoma, Hepatocellular/*drug therapy/surgery*Chemoembolization, Therapeutic/methods/statistics & numerical dataConfounding Factors (Epidemiology)Databases, FactualDisease-Free SurvivalFemale*Hepatectomy/statistics & numerical data*Hepatic ArteryHepatitis B/complicationsHepatitis C/complicationsHospitals/statistics & numerical dataHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapy/surgeryMaleMiddle AgedNeoadjuvant Therapy/*methodsPredictive Value of TestsPrognosisPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk FactorsTaiwanTreatment Outcome2014Apr1096-9098 (Electronic) 0022-4790 (Linking)24293372http://www.ncbi.nlm.nih.gov/pubmed/2429337210.1002/jso.23521Zhou200911211211217Zhou, W. P.Lai, E. C.Li, A. J.Fu, S. Y.Zhou, J. P.Pan, Z. Y.Lau, W. Y.Wu, M. C.The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery195-2022492AdultCarcinoma, Hepatocellular/surgery/*therapy*Chemoembolization, TherapeuticFemaleHepatectomyHumansLiver Neoplasms/surgery/*therapyMaleMiddle AgedNeoadjuvant TherapyProspective StudiesTreatment Outcome2009Feb1528-1140 (Electronic) 0003-4932 (Linking)19212170http://www.ncbi.nlm.nih.gov/pubmed/1921217010.1097/SLA.0b013e3181961c16uDyK  _ENREF_99wDyK  _ENREF_100DYin201310910910917Yin, J.Li, N.Han, Y.Xue, J.Deng, Y.Shi, J.Guo, W.Zhang, H.Wang, H.Cheng, S.Cao, G.Jianhua Yin, Yifang Han, Yang Deng, Hongwei Zhang, and Guangwen Cao, Second Military Medical University; Nan Li, Jie Xue, Jie Shi, Weixing Guo, Hongyang Wang, and Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical studyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3647-553129Antiviral Agents/*therapeutic useCarcinoma, Hepatocellular/*mortality/surgery/virologyHepatectomyHepatitis B, Chronic/*drug therapyHumansLiver Neoplasms/*mortality/surgery/virologyLongitudinal StudiesNucleosides/chemistry/*therapeutic useNucleotides/chemistry/*therapeutic usePrognosisProportional Hazards Models2013Oct 101527-7755 (Electronic) 0732-183X (Linking)24002499http://www.ncbi.nlm.nih.gov/pubmed/2400249910.1200/JCO.2012.48.5896Huang201585858517Huang, G.Lau, W. Y.Wang, Z. G.Pan, Z. Y.Yuan, S. X.Shen, F.Zhou, W. P.Wu, M. C.*Eastern Hepatobiliary Surgery Hospital, National Innovation Alliance for Hepatitis & Liver Cancer, Shanghai, China; and daggerFaculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trialAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery56-662611Adenine/*analogs & derivatives/therapeutic useAdolescentAdultAgedAntiviral Agents/*therapeutic useCarcinoma, Hepatocellular/mortality/*surgery/*virologyDNA, Viral/bloodHepatitis B/geneticsHepatitis B, Chronic/*drug therapyHumansLiver Failure/etiologyLiver Neoplasms/mortality/*surgery/*virologyMiddle AgedNeoplasm Recurrence, Local/*prevention & controlOrganophosphonates/*therapeutic useProspective StudiesSurvival AnalysisVirus ActivationYoung Adult2015Jan1528-1140 (Electronic) 0003-4932 (Linking)25072444http://www.ncbi.nlm.nih.gov/pubmed/2507244410.1097/SLA.0000000000000858wDyK  _ENREF_101wDyK  _ENREF_102DWang201810710710717Wang, Z.Ren, Z.Chen, Y.Hu, J.Yang, G.Yu, L.Yang, X.Huang, A.Zhang, X.Zhou, S.Sun, H.Wang, Y.Ge, N.Xu, X.Tang, Z.Lau, W.Fan, J.Wang, J.Zhou, J.Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, HKSAR, China. Institute of Biomedical Sciences, Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China. zhou.jian@zs-hospital.sh.cn jwang39@bwh.harvard.edu. Division of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled StudyClin Cancer ResClin Cancer Res2074-20812492018/02/092018May 11078-0432 (Print) 1078-0432 (Linking)29420221https://www.ncbi.nlm.nih.gov/pubmed/2942022110.1158/1078-0432.CCR-17-2899Wei201810810810817Wei, W.Jian, P. E.Li, S. H.Guo, Z. X.Zhang, Y. F.Ling, Y. H.Lin, X. J.Xu, L.Shi, M.Zheng, L.Chen, M. S.Guo, R. P.State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. Department of Medical Imaging, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. guorp@sysucc.org.cn. Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. guorp@sysucc.org.cn.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safetyCancer Commun (Lond)Cancer communications (London, England)Cancer Commun (Lond)Cancer communications (London, England)Cancer Commun (Lond)Cancer communications (London, England)613812018/10/12AdolescentAdultAgedCarcinoma, Hepatocellular/*drug therapy/pathologyChemoembolization, Therapeutic/*methodsFemaleHumansLiver Neoplasms/*drug therapy/pathologyMaleMiddle AgedTreatment OutcomeYoung Adult*Adjuvant therapy*Hepatectomy alone*Hepatocellular carcinoma*Microvascular invasion*Solitary tumor*Transcatheter arterial chemoembolization2018Oct 102523-354830305149PMC623539310.1186/s40880-018-0331-yNLMengwDyK  _ENREF_103wDyK  _ENREF_104DChen201878787817Chen, Q.Shu, C.Laurence, A. D.Chen, Y.Peng, B. G.Zhen, Z. J.Cai, J. Q.Ding, Y. T.Li, L. Q.Zhang, Y. B.Zheng, Q. C.Xu, G. L.Li, B.Zhou, W. P.Cai, S. W.Wang, X. Y.Wen, H.Peng, X. Y.Zhang, X. W.Dai, C. L.Bie, P.Xing, B. C.Fu, Z. R.Liu, L. X.Mu, Y.Zhang, L.Zhang, Q. S.Jiang, B.Qian, H. X.Wang, Y. J.Liu, J. F.Qin, X. H.Li, Q.Yin, P.Zhang, Z. W.Chen, X. P.Division of Gastroenterology, Department of Internal Medicine at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China. Department of Epidemiology and Biostatistics and State Key Laboratory of Environment Health, School of Public Health, Tongji Medical College, HUST, Wuhan, China. Hepatic Surgery Centre at Tongji Hospital, Tongji Medical College, HUST, Wuhan, China. Surgery administrator office at Tongji Hospital, Tongji Medical College, Hust, Wuhan, China. Hematology Department, The Newcastle upon Tyne Hospitals NHS Foundation Trust at Freeman Hospital, Newcastle, UK. Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Public Health, Wuhan, China. Hubei Province for the Clinical Medicine Research Center of Hepatic Surgery, Wuhan, China. Surgery Department, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Surgery Department, First People's Hospital, Foshan, China. Surgery Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. Surgery Department, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China. Surgery Department, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China. Surgery Department, Third Affiliated Hospital of Harbin Medical University, Harbin, China. Surgery Department, Wuhan Union Hospital of HUST, Wuhan, China. Surgery Department, Shengli Hospital Affiliated to Anhui Medical University, Hefei, China. Surgery Department, West China Hospital of Sichuan University, Chengdu, China. Surgery Department, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Surgery Department, Chinese PLA General Hospital of Medical School of Chinese PLA, Beijing, China. Surgery Department, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. Surgery Department, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Surgery Department, First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, China. Surgery Department, China and Japan Union Hospital of Jilin Hospital, Changchun, China. Surgery Department, Shengjing Hospital of China Medial University, Shenyang, China. Surgery Department, Southwest University Hospital, Chongqing, China. Surgery Department, Beijing Cancer Hospital, Beijing, China. Surgery Department, Shanghai Changzheng Hospital, Shanghai, China. Surgery Department, First Affiliated Hospital of Harbin Medical University, Harbin, China. Surgery Department, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, China. Surgery Department, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Surgery Department, Guangxi Liuzhou Worker's Hospital, Liuzhou, China. Surgery Department, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan, China. Surgery Department, First Affiliated Hospital of Suzhou Medical University, Suzhou, China. Surgery Department, Tianjin No.3 Hospital, Tianjin, China. Surgery Branch at the Hospital of Infectious and Contagious Diseases Affiliated to Fujian Medical University, Fuzhou, China. Surgery Department, Third People's Hospital of Changzhou, Changzhou, China. Surgery Department, Tianjin Medical University Cancer Institute and Hospital (TMUCIH), Tianjin, China.Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trialGutGutGutGut2006-201667112018/05/29AgedCarcinoma, Hepatocellular/*drug therapy/mortality/surgeryChemotherapy, AdjuvantComplex Mixtures/adverse effects/*therapeutic useFemaleHepatectomy/*adverse effectsHumansLiver/pathology/surgeryLiver Neoplasms/*drug therapy/mortality/surgeryMaleMiddle AgedNeoplasm Recurrence, Local/drug therapySurvival AnalysisTreatment Outcome*adjuvant treatment*hepatocellular carcinoma2018Nov0017-57492980217410.1136/gutjnl-2018-315983NLMengDChen201878787817Chen, Q.Shu, C.Laurence, A. D.Chen, Y.Peng, B. G.Zhen, Z. J.Cai, J. Q.Ding, Y. T.Li, L. Q.Zhang, Y. B.Zheng, Q. C.Xu, G. L.Li, B.Zhou, W. P.Cai, S. W.Wang, X. Y.Wen, H.Peng, X. Y.Zhang, X. W.Dai, C. L.Bie, P.Xing, B. C.Fu, Z. R.Liu, L. X.Mu, Y.Zhang, L.Zhang, Q. S.Jiang, B.Qian, H. X.Wang, Y. J.Liu, J. F.Qin, X. H.Li, Q.Yin, P.Zhang, Z. W.Chen, X. P.Division of Gastroenterology, Department of Internal Medicine at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China. Department of Epidemiology and Biostatistics and State Key Laboratory of Environment Health, School of Public Health, Tongji Medical College, HUST, Wuhan, China. Hepatic Surgery Centre at Tongji Hospital, Tongji Medical College, HUST, Wuhan, China. Surgery administrator office at Tongji Hospital, Tongji Medical College, Hust, Wuhan, China. Hematology Department, The Newcastle upon Tyne Hospitals NHS Foundation Trust at Freeman Hospital, Newcastle, UK. Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Public Health, Wuhan, China. Hubei Province for the Clinical Medicine Research Center of Hepatic Surgery, Wuhan, China. Surgery Department, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Surgery Department, First People's Hospital, Foshan, China. Surgery Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. Surgery Department, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China. Surgery Department, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China. Surgery Department, Third Affiliated Hospital of Harbin Medical University, Harbin, China. Surgery Department, Wuhan Union Hospital of HUST, Wuhan, China. Surgery Department, Shengli Hospital Affiliated to Anhui Medical University, Hefei, China. Surgery Department, West China Hospital of Sichuan University, Chengdu, China. Surgery Department, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Surgery Department, Chinese PLA General Hospital of Medical School of Chinese PLA, Beijing, China. Surgery Department, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. Surgery Department, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Surgery Department, First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, China. Surgery Department, China and Japan Union Hospital of Jilin Hospital, Changchun, China. Surgery Department, Shengjing Hospital of China Medial University, Shenyang, China. Surgery Department, Southwest University Hospital, Chongqing, China. Surgery Department, Beijing Cancer Hospital, Beijing, China. Surgery Department, Shanghai Changzheng Hospital, Shanghai, China. Surgery Department, First Affiliated Hospital of Harbin Medical University, Harbin, China. Surgery Department, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, China. Surgery Department, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Surgery Department, Guangxi Liuzhou Worker's Hospital, Liuzhou, China. Surgery Department, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan, China. Surgery Department, First Affiliated Hospital of Suzhou Medical University, Suzhou, China. Surgery Department, Tianjin No.3 Hospital, Tianjin, China. Surgery Branch at the Hospital of Infectious and Contagious Diseases Affiliated to Fujian Medical University, Fuzhou, China. Surgery Department, Third People's Hospital of Changzhou, Changzhou, China. Surgery Department, Tianjin Medical University Cancer Institute and Hospital (TMUCIH), Tianjin, China.Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trialGutGutGutGut2006-201667112018/05/29AgedCarcinoma, Hepatocellular/*drug therapy/mortality/surgeryChemotherapy, AdjuvantComplex Mixtures/adverse effects/*therapeutic useFemaleHepatectomy/*adverse effectsHumansLiver/pathology/surgeryLiver Neoplasms/*drug therapy/mortality/surgeryMaleMiddle AgedNeoplasm Recurrence, Local/drug therapySurvival AnalysisTreatment Outcome*adjuvant treatment*hepatocellular carcinoma2018Nov0017-57492980217410.1136/gutjnl-2018-315983NLMengwDyK  _ENREF_105DHuang201821692169216917Huang, G.Li, P. P.Lau, W. Y.Pan, Z. Y.Zhao, L. H.Wang, Z. G.Wang, M. C.Zhou, W. P.Eastern Hepatobiliary Surgery Hospital, National Innovation Alliance for Hepatitis and Liver Cancer, Shanghai, China. Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China.Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled TrialAnn SurgAnn Surg943-95426862018/03/10Antiviral Agents/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/*virologyDNA, Viral/*bloodFemaleHepatitis B virus/geneticsHumansLiver Neoplasms/*drug therapy/pathology/surgery/*virologyMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlProspective StudiesSurvival RateTelbivudine/*therapeutic use2018Dec1528-1140 (Electronic) 0003-4932 (Linking)29521740https://www.ncbi.nlm.nih.gov/pubmed/2952174010.1097/SLA.0000000000002727engYin201310910910917Yin, J.Li, N.Han, Y.Xue, J.Deng, Y.Shi, J.Guo, W.Zhang, H.Wang, H.Cheng, S.Cao, G.Jianhua Yin, Yifang Han, Yang Deng, Hongwei Zhang, and Guangwen Cao, Second Military Medical University; Nan Li, Jie Xue, Jie Shi, Weixing Guo, Hongyang Wang, and Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical studyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3647-553129Antiviral Agents/*therapeutic useCarcinoma, Hepatocellular/*mortality/surgery/virologyHepatectomyHepatitis B, Chronic/*drug therapyHumansLiver Neoplasms/*mortality/surgery/virologyLongitudinal StudiesNucleosides/chemistry/*therapeutic useNucleotides/chemistry/*therapeutic usePrognosisProportional Hazards Models2013Oct 101527-7755 (Electronic) 0732-183X (Linking)24002499http://www.ncbi.nlm.nih.gov/pubmed/2400249910.1200/JCO.2012.48.5896Huang201585858517Huang, G.Lau, W. Y.Wang, Z. G.Pan, Z. Y.Yuan, S. X.Shen, F.Zhou, W. P.Wu, M. C.*Eastern Hepatobiliary Surgery Hospital, National Innovation Alliance for Hepatitis & Liver Cancer, Shanghai, China; and daggerFaculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, People's Republic of China.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trialAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery56-662611Adenine/*analogs & derivatives/therapeutic useAdolescentAdultAgedAntiviral Agents/*therapeutic useCarcinoma, Hepatocellular/mortality/*surgery/*virologyDNA, Viral/bloodHepatitis B/geneticsHepatitis B, Chronic/*drug therapyHumansLiver Failure/etiologyLiver Neoplasms/mortality/*surgery/*virologyMiddle AgedNeoplasm Recurrence, Local/*prevention & controlOrganophosphonates/*therapeutic useProspective StudiesSurvival AnalysisVirus ActivationYoung Adult2015Jan1528-1140 (Electronic) 0003-4932 (Linking)25072444http://www.ncbi.nlm.nih.gov/pubmed/2507244410.1097/SLA.0000000000000858wDyK  _ENREF_101wDyK  _ENREF_102wDyK  _ENREF_106 DFan200580808017Fan, J.Zhou, J.Wu, Z. Q.Qiu, S. J.Wang, X. Y.Shi, Y. H.Tang, Z. Y.Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yixueyuan Road, Shanghai 200032, China. jiafan99@yahoo.comEfficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosisWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterology1215-9118AdultAgedAntineoplastic Agents/therapeutic useCarcinoma, Hepatocellular/complications/drug therapy/mortality/*surgeryChemoembolization, TherapeuticCombined Modality TherapyFemaleHumansLiver Neoplasms/complications/drug therapy/mortality/*surgeryMaleMiddle Aged*Portal VeinPrognosisProportional Hazards ModelsThrombosis/*etiology/mortality2005Feb 281007-9327 (Print) 1007-9327 (Linking)15754408http://www.ncbi.nlm.nih.gov/pubmed/157544084250717@ DFan200580808017Fan, J.Zhou, J.Wu, Z. Q.Qiu, S. J.Wang, X. Y.Shi, Y. H.Tang, Z. Y.Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yixueyuan Road, Shanghai 200032, China. jiafan99@yahoo.comEfficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosisWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterology1215-9118AdultAgedAntineoplastic Agents/therapeutic useCarcinoma, Hepatocellular/complications/drug therapy/mortality/*surgeryChemoembolization, TherapeuticCombined Modality TherapyFemaleHumansLiver Neoplasms/complications/drug therapy/mortality/*surgeryMaleMiddle Aged*Portal VeinPrognosisProportional Hazards ModelsThrombosis/*etiology/mortality2005Feb 281007-9327 (Print) 1007-9327 (Linking)15754408http://www.ncbi.nlm.nih.gov/pubmed/157544084250717@wDyK  _ENREF_1070DLo200793939317Lo, C. M.Liu, C. L.Chan, S. C.Lam, C. M.Poon, R. T.Ng, I. O.Fan, S. T.Wong, J.Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. chungmlo@hkucc.hku.hkA randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery831-422456AdultAgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyFemaleHepatectomyHepatitis B/complicationsHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRecombinant ProteinsStatistics, NonparametricSurvival RateTreatment Outcome2007Jun0003-4932 (Print) 0003-4932 (Linking)17522506http://www.ncbi.nlm.nih.gov/pubmed/17522506187694710.1097/01.sla.0000245829.00977.45Sun200610410410417Sun, H. C.Tang, Z. Y.Wang, L.Qin, L. X.Ma, Z. C.Ye, Q. H.Zhang, B. H.Qian, Y. B.Wu, Z. Q.Fan, J.Zhou, X. D.Zhou, J.Qiu, S. J.Shen, Y. F.Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, People's Republic of China.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology458-651327Analysis of VarianceAntineoplastic Agents/adverse effects/*therapeutic useAntiviral Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyFemale*HepatectomyHepatitis B virus/*isolation & purificationHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlSurvival AnalysisTreatment Outcome2006Jul0171-5216 (Print) 0171-5216 (Linking)16557381http://www.ncbi.nlm.nih.gov/pubmed/1655738110.1007/s00432-006-0091-yNishiguchi200595959517Nishiguchi, S.Tamori, A.Kubo, S.Department of Hepatology, Osaka City University Medical School, Osaka, Japan. snishiguch@med.osaka-cu.ac.jpEffect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinomaIntervirologyIntervirologyIntervirologyIntervirologyIntervirologyIntervirology71-5481AgedAlanine Transaminase/bloodAntiviral Agents/administration & dosage/pharmacology/therapeutic useCarcinoma, Hepatocellular/*surgeryHepacivirus/drug effectsHepatitis C, Chronic/*complications/*drug therapyHumansInterferon-alpha/administration & dosage/pharmacology/*therapeutic useLiver Neoplasms/*surgeryMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlRNA, Viral/bloodSurvival RateTreatment OutcomeViral Load20050300-5526 (Print) 0300-5526 (Linking)15785093http://www.ncbi.nlm.nih.gov/pubmed/1578509310.1159/000082098@00DLo200793939317Lo, C. M.Liu, C. L.Chan, S. C.Lam, C. M.Poon, R. T.Ng, I. O.Fan, S. T.Wong, J.Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. chungmlo@hkucc.hku.hkA randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery831-422456AdultAgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyFemaleHepatectomyHepatitis B/complicationsHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRecombinant ProteinsStatistics, NonparametricSurvival RateTreatment Outcome2007Jun0003-4932 (Print) 0003-4932 (Linking)17522506http://www.ncbi.nlm.nih.gov/pubmed/17522506187694710.1097/01.sla.0000245829.00977.45Sun200610410410417Sun, H. C.Tang, Z. Y.Wang, L.Qin, L. X.Ma, Z. C.Ye, Q. H.Zhang, B. H.Qian, Y. B.Wu, Z. Q.Fan, J.Zhou, X. D.Zhou, J.Qiu, S. J.Shen, Y. F.Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, People's Republic of China.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology458-651327Analysis of VarianceAntineoplastic Agents/adverse effects/*therapeutic useAntiviral Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyFemale*HepatectomyHepatitis B virus/*isolation & purificationHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlSurvival AnalysisTreatment Outcome2006Jul0171-5216 (Print) 0171-5216 (Linking)16557381http://www.ncbi.nlm.nih.gov/pubmed/1655738110.1007/s00432-006-0091-yNishiguchi200595959517Nishiguchi, S.Tamori, A.Kubo, S.Department of Hepatology, Osaka City University Medical School, Osaka, Japan. snishiguch@med.osaka-cu.ac.jpEffect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinomaIntervirologyIntervirologyIntervirologyIntervirologyIntervirologyIntervirology71-5481AgedAlanine Transaminase/bloodAntiviral Agents/administration & dosage/pharmacology/therapeutic useCarcinoma, Hepatocellular/*surgeryHepacivirus/drug effectsHepatitis C, Chronic/*complications/*drug therapyHumansInterferon-alpha/administration & dosage/pharmacology/*therapeutic useLiver Neoplasms/*surgeryMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlRNA, Viral/bloodSurvival RateTreatment OutcomeViral Load20050300-5526 (Print) 0300-5526 (Linking)15785093http://www.ncbi.nlm.nih.gov/pubmed/1578509310.1159/000082098@0wDyK  _ENREF_108( DMazzaferro200694949417Mazzaferro, V.Romito, R.Schiavo, M.Mariani, L.Camerini, T.Bhoori, S.Capussotti, L.Calise, F.Pellicci, R.Belli, G.Tagger, A.Colombo, M.Bonino, F.Majno, P.Llovet, J. M.H. C. C. Italian Task ForceDepartment of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy. vincenzo.mazzaferro@istitutotumori.mi.itPrevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatologyHepatologyHepatologyHepatology1543-54446AdultAgedCarcinoma, Hepatocellular/pathology/*prevention & control/secondaryComorbidityFemaleHepatectomyHepatitis B Core Antigens/analysisHepatitis B, Chronic/complicationsHepatitis C, Chronic/complications/*drug therapy/surgeryHumansInterferon-alpha/*therapeutic useLiver Cirrhosis/*drug therapy/surgeryLiver Neoplasms/pathology/*prevention & controlMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/*prevention & controlRecombinant ProteinsRiskalpha-Fetoproteins/analysis2006Dec0270-9139 (Print) 0270-9139 (Linking)17133492http://www.ncbi.nlm.nih.gov/pubmed/1713349210.1002/hep.21415@( DMazzaferro200694949417Mazzaferro, V.Romito, R.Schiavo, M.Mariani, L.Camerini, T.Bhoori, S.Capussotti, L.Calise, F.Pellicci, R.Belli, G.Tagger, A.Colombo, M.Bonino, F.Majno, P.Llovet, J. M.H. C. C. Italian Task ForceDepartment of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy. vincenzo.mazzaferro@istitutotumori.mi.itPrevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatologyHepatologyHepatologyHepatology1543-54446AdultAgedCarcinoma, Hepatocellular/pathology/*prevention & control/secondaryComorbidityFemaleHepatectomyHepatitis B Core Antigens/analysisHepatitis B, Chronic/complicationsHepatitis C, Chronic/complications/*drug therapy/surgeryHumansInterferon-alpha/*therapeutic useLiver Cirrhosis/*drug therapy/surgeryLiver Neoplasms/pathology/*prevention & controlMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/*prevention & controlRecombinant ProteinsRiskalpha-Fetoproteins/analysis2006Dec0270-9139 (Print) 0270-9139 (Linking)17133492http://www.ncbi.nlm.nih.gov/pubmed/1713349210.1002/hep.21415@wDyK  _ENREF_111 DJi200987878717Ji, J.Shi, J.Budhu, A.Yu, Z.Forgues, M.Roessler, S.Ambs, S.Chen, Y.Meltzer, P. S.Croce, C. M.Qin, L. X.Man, K.Lo, C. M.Lee, J.Ng, I. O.Fan, J.Tang, Z. Y.Sun, H. C.Wang, X. W.Liver Carcinogenesis Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.MicroRNA expression, survival, and response to interferon in liver cancerN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicine1437-4736115AdolescentAdultAgedAged, 80 and overAntiviral Agents/*therapeutic useCarcinoma, Hepatocellular/drug therapy/*genetics/mortalityCohort StudiesFemale*Gene ExpressionGene Expression ProfilingGene Regulatory NetworksHepatitis B/complicationsHumansInterferon-alpha/*therapeutic useLiver Cirrhosis/complicationsLiver Neoplasms/drug therapy/*genetics/mortalityMaleMicroRNAs/*metabolismMiddle AgedPharmacogeneticsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionSex FactorsSurvival AnalysisYoung Adult2009Oct 81533-4406 (Electronic) 0028-4793 (Linking)19812400http://www.ncbi.nlm.nih.gov/pubmed/19812400278693810.1056/NEJMoa0901282@0 DJi200987878717Ji, J.Shi, J.Budhu, A.Yu, Z.Forgues, M.Roessler, S.Ambs, S.Chen, Y.Meltzer, P. S.Croce, C. M.Qin, L. X.Man, K.Lo, C. M.Lee, J.Ng, I. O.Fan, J.Tang, Z. Y.Sun, H. C.Wang, X. W.Liver Carcinogenesis Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.MicroRNA expression, survival, and response to interferon in liver cancerN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicine1437-4736115AdolescentAdultAgedAged, 80 and overAntiviral Agents/*therapeutic useCarcinoma, Hepatocellular/drug therapy/*genetics/mortalityCohort StudiesFemale*Gene ExpressionGene Expression ProfilingGene Regulatory NetworksHepatitis B/complicationsHumansInterferon-alpha/*therapeutic useLiver Cirrhosis/complicationsLiver Neoplasms/drug therapy/*genetics/mortalityMaleMicroRNAs/*metabolismMiddle AgedPharmacogeneticsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionSex FactorsSurvival AnalysisYoung Adult2009Oct 81533-4406 (Electronic) 0028-4793 (Linking)19812400http://www.ncbi.nlm.nih.gov/pubmed/19812400278693810.1056/NEJMoa0901282@0wDyK  _ENREF_112DBruix201577777717Bruix, J.Takayama, T.Mazzaferro, V.Chau, G. Y.Yang, J.Kudo, M.Cai, J.Poon, R. T.Han, K. H.Tak, W. Y.Lee, H. C.Song, T.Roayaie, S.Bolondi, L.Lee, K. S.Makuuchi, M.Souza, F.Berre, M. A.Meinhardt, G.Llovet, J. M.Storm investigatorsBCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es. Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. Liver Unit, Hepato-Oncology Group, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Taipei Veterans General Hospital, Department of Surgery, Beitou District, Taipei City, Taiwan. Eastern Hepatobiliary Hospital, Shanghai District, Shanghai, China. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China. Queen Mary Hospital, Pok Fu Lam, Hong Kong, China. Severance Hospital, Seodaemun-gu, Seoul, South Korea. Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Jung-gu, Daegu, Korea. Asan Medical Center, Songpa-gu, Seoul, South Korea. Tianjin Medical University Cancer Hospital Huanhuxilu, Hexi District, Tianjin, China. Liver Cancer Program, Hofstra-North Shore-LIJ School of Medicine, Lenox Hill Hospital, New York, NY, USA. University of Bologna, Bologna, Italy. Gangnam Severance Hospital, Gangnam-gu, Seoul, South Korea. University of Tokyo, Bunkyo, Tokyo, Japan. Bayer HealthCare Pharmaceuticals, Socorro, Sao Paulo, Brazil. Bayer HealthCare Pharmaceuticals, Loos, France. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain; Liver Cancer Program, Mount Sinai Medical Center, New York, NY, USA.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology1344-541613AdultAgedAged, 80 and overAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useAsiaAustraliaCarcinoma, Hepatocellular/*drug therapy/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalDouble-Blind MethodEuropeFemale*Hepatectomy/adverse effects/mortalityHumansIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalNew ZealandNiacinamide/administration & dosage/adverse effects/*analogs &derivatives/therapeutic useNorth AmericaPhenylurea Compounds/administration & dosage/adverse effects/*therapeutic useProtein Kinase Inhibitors/administration & dosage/adverse effects/*therapeuticuseRisk FactorsSouth AmericaTime FactorsTreatment OutcomeYoung Adult2015Oct1474-5488 (Electronic) 1470-2045 (Linking)26361969http://www.ncbi.nlm.nih.gov/pubmed/2636196910.1016/S1470-2045(15)00198-9DBruix201577777717Bruix, J.Takayama, T.Mazzaferro, V.Chau, G. Y.Yang, J.Kudo, M.Cai, J.Poon, R. T.Han, K. H.Tak, W. Y.Lee, H. C.Song, T.Roayaie, S.Bolondi, L.Lee, K. S.Makuuchi, M.Souza, F.Berre, M. A.Meinhardt, G.Llovet, J. M.Storm investigatorsBCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es. Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. Liver Unit, Hepato-Oncology Group, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Taipei Veterans General Hospital, Department of Surgery, Beitou District, Taipei City, Taiwan. Eastern Hepatobiliary Hospital, Shanghai District, Shanghai, China. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China. Queen Mary Hospital, Pok Fu Lam, Hong Kong, China. Severance Hospital, Seodaemun-gu, Seoul, South Korea. Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Jung-gu, Daegu, Korea. Asan Medical Center, Songpa-gu, Seoul, South Korea. Tianjin Medical University Cancer Hospital Huanhuxilu, Hexi District, Tianjin, China. Liver Cancer Program, Hofstra-North Shore-LIJ School of Medicine, Lenox Hill Hospital, New York, NY, USA. University of Bologna, Bologna, Italy. Gangnam Severance Hospital, Gangnam-gu, Seoul, South Korea. University of Tokyo, Bunkyo, Tokyo, Japan. Bayer HealthCare Pharmaceuticals, Socorro, Sao Paulo, Brazil. Bayer HealthCare Pharmaceuticals, Loos, France. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain; Liver Cancer Program, Mount Sinai Medical Center, New York, NY, USA.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology1344-541613AdultAgedAged, 80 and overAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useAsiaAustraliaCarcinoma, Hepatocellular/*drug therapy/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalDouble-Blind MethodEuropeFemale*Hepatectomy/adverse effects/mortalityHumansIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalNew ZealandNiacinamide/administration & dosage/adverse effects/*analogs &derivatives/therapeutic useNorth AmericaPhenylurea Compounds/administration & dosage/adverse effects/*therapeutic useProtein Kinase Inhibitors/administration & dosage/adverse effects/*therapeuticuseRisk FactorsSouth AmericaTime FactorsTreatment OutcomeYoung Adult2015Oct1474-5488 (Electronic) 1470-2045 (Linking)26361969http://www.ncbi.nlm.nih.gov/pubmed/2636196910.1016/S1470-2045(15)00198-9wDyK  _ENREF_113wDyK  _ENREF_114wDyK  _ENREF_115 DZheng200811011011017Zheng, S. S.Xu, X.Wu, J.Chen, J.Wang, W. L.Zhang, M.Liang, T. B.Wu, L. M.Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. zyzss@zju.edu.cnLiver transplantation for hepatocellular carcinoma: Hangzhou experiencesTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation1726-328512AdultAgedCarcinoma, Hepatocellular/ethnology/pathology/*surgeryChinaFemaleHumansKaplan-Meier EstimateLiver/metabolism/pathologyLiver Neoplasms/ethnology/pathology/*surgery*Liver TransplantationMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/epidemiologyPredictive Value of TestsRetrospective StudiesRisk FactorsTreatment Outcomealpha-Fetoproteins/metabolism2008Jun 270041-1337 (Print) 0041-1337 (Linking)18580463http://www.ncbi.nlm.nih.gov/pubmed/1858046310.1097/TP.0b013e31816b67e4 DZheng200811011011017Zheng, S. S.Xu, X.Wu, J.Chen, J.Wang, W. L.Zhang, M.Liang, T. B.Wu, L. M.Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. zyzss@zju.edu.cnLiver transplantation for hepatocellular carcinoma: Hangzhou experiencesTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation1726-328512AdultAgedCarcinoma, Hepatocellular/ethnology/pathology/*surgeryChinaFemaleHumansKaplan-Meier EstimateLiver/metabolism/pathologyLiver Neoplasms/ethnology/pathology/*surgery*Liver TransplantationMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/epidemiologyPredictive Value of TestsRetrospective StudiesRisk FactorsTreatment Outcomealpha-Fetoproteins/metabolism2008Jun 270041-1337 (Print) 0041-1337 (Linking)18580463http://www.ncbi.nlm.nih.gov/pubmed/1858046310.1097/TP.0b013e31816b67e4wDyK  _ENREF_116F DFan200979797917Fan, J.Yang, G. S.Fu, Z. R.Peng, Z. H.Xia, Q.Peng, C. H.Qian, J. M.Zhou, J.Xu, Y.Qiu, S. J.Zhong, L.Zhou, G. W.Zhang, J. J.Liver Cancer Institute, Shanghai Medical School, Zhong Shan Hospital, Fudan University, 200032 Shanghai, People's Republic of China. jiafan99@yahoo.comLiver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, ChinaJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1403-1213510AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryChinaFemaleFollow-Up StudiesHumansLiver Neoplasms/mortality/*surgery*Liver TransplantationMaleMiddle AgedPrognosisRecurrenceSurvival RateTreatment OutcomeYoung Adultalpha-Fetoproteins/metabolism2009Oct1432-1335 (Electronic) 0171-5216 (Linking)19381688http://www.ncbi.nlm.nih.gov/pubmed/1938168810.1007/s00432-009-0584-6F DFan200979797917Fan, J.Yang, G. S.Fu, Z. R.Peng, Z. H.Xia, Q.Peng, C. H.Qian, J. M.Zhou, J.Xu, Y.Qiu, S. J.Zhong, L.Zhou, G. W.Zhang, J. J.Liver Cancer Institute, Shanghai Medical School, Zhong Shan Hospital, Fudan University, 200032 Shanghai, People's Republic of China. jiafan99@yahoo.comLiver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, ChinaJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1403-1213510AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryChinaFemaleFollow-Up StudiesHumansLiver Neoplasms/mortality/*surgery*Liver TransplantationMaleMiddle AgedPrognosisRecurrenceSurvival RateTreatment OutcomeYoung Adultalpha-Fetoproteins/metabolism2009Oct1432-1335 (Electronic) 0171-5216 (Linking)19381688http://www.ncbi.nlm.nih.gov/pubmed/1938168810.1007/s00432-009-0584-6wDyK  _ENREF_117DLi200989898917Li, J.Yan, L. N.Yang, J.Chen, Z. Y.Li, B.Zeng, Y.Wen, T. F.Zhao, J. C.Wang, W. T.Yang, J. Y.Xu, M. Q.Ma, Y. K.Division of Liver Transplantation, West China Hospital, West China Medical School of Sichuan University, Chengdu 610041, Sichuan Province, China.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patientsWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterology4170-61533AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryFemaleHumansLiver/pathologyLiver Neoplasms/mortality/pathology/*surgery*Liver TransplantationLymphatic MetastasisMaleMiddle AgedPrognosis2009Sep 72219-2840 (Electronic) 1007-9327 (Linking)19725152http://www.ncbi.nlm.nih.gov/pubmed/197251522738814pDLi200989898917Li, J.Yan, L. N.Yang, J.Chen, Z. Y.Li, B.Zeng, Y.Wen, T. F.Zhao, J. C.Wang, W. T.Yang, J. Y.Xu, M. Q.Ma, Y. K.Division of Liver Transplantation, West China Hospital, West China Medical School of Sichuan University, Chengdu 610041, Sichuan Province, China.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patientsWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterologyWorld J GastroenterolWorld journal of gastroenterology4170-61533AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryFemaleHumansLiver/pathologyLiver Neoplasms/mortality/pathology/*surgery*Liver TransplantationLymphatic MetastasisMaleMiddle AgedPrognosis2009Sep 72219-2840 (Electronic) 1007-9327 (Linking)19725152http://www.ncbi.nlm.nih.gov/pubmed/197251522738814pwDyK  _ENREF_118DLlovet201892929217Llovet, J. M.Pavel, M.Rimola, J.Diaz, M. A.Colmenero, J.Saavedra-Perez, D.Fondevila, C.Ayuso, C.Fuster, J.Gines, P.Bruix, J.Garcia-Valdecasas, J. C.Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Barcelona, Catalonia, Spain. Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, NY. Institucio Catalana de Recerca i Estudis Avancats, Barcelona, Catalonia, Spain. Liver Transplant Unit, Barcelona, Catalonia, Spain. Pathology Department, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain. Liver Unit, Digestive and Metabolic Diseases Institute, Barcelona, Catalonia, Spain.Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)Liver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society369-3792432017/11/16AgedCarcinoma, Hepatocellular/diagnostic imaging/mortality/secondary/*surgeryClinical Decision-Making*Decision Support TechniquesFemaleHumansKaplan-Meier EstimateLiver Neoplasms/diagnostic imaging/mortality/pathology/*surgeryLiver Transplantation/adverse effects/*methods/mortality*Living DonorsMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPilot ProjectsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk FactorsTime FactorsTreatment OutcomeTumor Burden2018Mar1527-64652914060110.1002/lt.24977NLMengDLlovet201892929217Llovet, J. M.Pavel, M.Rimola, J.Diaz, M. A.Colmenero, J.Saavedra-Perez, D.Fondevila, C.Ayuso, C.Fuster, J.Gines, P.Bruix, J.Garcia-Valdecasas, J. C.Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Barcelona, Catalonia, Spain. Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, NY. Institucio Catalana de Recerca i Estudis Avancats, Barcelona, Catalonia, Spain. Liver Transplant Unit, Barcelona, Catalonia, Spain. Pathology Department, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain. Liver Unit, Digestive and Metabolic Diseases Institute, Barcelona, Catalonia, Spain.Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)Liver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society369-3792432017/11/16AgedCarcinoma, Hepatocellular/diagnostic imaging/mortality/secondary/*surgeryClinical Decision-Making*Decision Support TechniquesFemaleHumansKaplan-Meier EstimateLiver Neoplasms/diagnostic imaging/mortality/pathology/*surgeryLiver Transplantation/adverse effects/*methods/mortality*Living DonorsMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPilot ProjectsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk FactorsTime FactorsTreatment OutcomeTumor Burden2018Mar1527-64652914060110.1002/lt.24977NLMengwDyK  _ENREF_120DPinheiro201797979717Pinheiro, R. S.Waisberg, D. R.Nacif, L. S.Rocha-Santos, V.Arantes, R. M.Ducatti, L.Martino, R. B.Lai, Q.Andraus, W.D'Albuquerque, L. A. C.Digestive Organs Transplant Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil. Transplant Unit, Department of Surgery, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy.Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?Transl Gastroenterol HepatolTranslational gastroenterology and hepatologyTransl Gastroenterol HepatolTranslational gastroenterology and hepatologyTransl Gastroenterol HepatolTranslational gastroenterology and hepatology6822017/09/15Far EastLiver transplantation (LT)Middle EastWestern Worldhepatocellular carcinoma (HCC)living donors20172415-1289 (Print) 2415-128928905009PMC559001410.21037/tgh.2017.08.02NLMeng`DPinheiro201797979717Pinheiro, R. S.Waisberg, D. R.Nacif, L. S.Rocha-Santos, V.Arantes, R. M.Ducatti, L.Martino, R. B.Lai, Q.Andraus, W.D'Albuquerque, L. A. C.Digestive Organs Transplant Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil. Transplant Unit, Department of Surgery, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy.Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?Transl Gastroenterol HepatolTranslational gastroenterology and hepatologyTransl Gastroenterol HepatolTranslational gastroenterology and hepatologyTransl Gastroenterol HepatolTranslational gastroenterology and hepatology6822017/09/15Far EastLiver transplantation (LT)Middle EastWestern Worldhepatocellular carcinoma (HCC)living donors20172415-1289 (Print) 2415-128928905009PMC559001410.21037/tgh.2017.08.02NLMeng`wDyK  _ENREF_121wDyK  _ENREF_1224 DSegev200810110110117Segev, D. L.Sozio, S. M.Shin, E. J.Nazarian, S. M.Nathan, H.Thuluvath, P. J.Montgomery, R. A.Cameron, A. M.Maley, W. R.Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. dorry@jhmi.eduSteroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trialsLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society512-251442008/04/03Adrenal Cortex Hormones/*administration & dosageGraft Rejection/prevention & controlHumansImmunosuppressive Agents/*therapeutic useLiver Transplantation/*immunology/mortalityPatient SelectionRandomized Controlled Trials as TopicRegression AnalysisRisk FactorsSurvival Analysis2008Apr1527-64651838308110.1002/lt.21396NLMeng@04 DSegev200810110110117Segev, D. L.Sozio, S. M.Shin, E. J.Nazarian, S. M.Nathan, H.Thuluvath, P. J.Montgomery, R. A.Cameron, A. M.Maley, W. R.Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. dorry@jhmi.eduSteroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trialsLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society512-251442008/04/03Adrenal Cortex Hormones/*administration & dosageGraft Rejection/prevention & controlHumansImmunosuppressive Agents/*therapeutic useLiver Transplantation/*immunology/mortalityPatient SelectionRandomized Controlled Trials as TopicRegression AnalysisRisk FactorsSurvival Analysis2008Apr1527-64651838308110.1002/lt.21396NLMeng@0wDyK  _ENREF_123 DRodriguez-Peralvarez201398989817Rodriguez-Peralvarez, M.Tsochatzis, E.Naveas, M. C.Pieri, G.Garcia-Caparros, C.O'Beirne, J.Poyato-Gonzalez, A.Ferrin-Sanchez, G.Montero-Alvarez, J. L.Patch, D.Thorburn, D.Briceno, J.De la Mata, M.Burroughs, A. K.Hepatology and Liver Transplant Unit, Reina Sofia University Hospital, IMIBIC, CIBERehd, Cordoba, Spain.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology1193-9596Aged*Calcineurin InhibitorsCarcinoma, Hepatocellular/mortality/*surgeryFemaleHumansImmunosuppressive Agents/*administration & dosageLiver Neoplasms/mortality/*surgery*Liver TransplantationMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlProportional Hazards ModelsRetrospective StudiesTOR Serine-Threonine Kinases/antagonists & inhibitors2013Dec1600-0641 (Electronic) 0168-8278 (Linking)23867318http://www.ncbi.nlm.nih.gov/pubmed/2386731810.1016/j.jhep.2013.07.012 DRodriguez-Peralvarez201398989817Rodriguez-Peralvarez, M.Tsochatzis, E.Naveas, M. C.Pieri, G.Garcia-Caparros, C.O'Beirne, J.Poyato-Gonzalez, A.Ferrin-Sanchez, G.Montero-Alvarez, J. L.Patch, D.Thorburn, D.Briceno, J.De la Mata, M.Burroughs, A. K.Hepatology and Liver Transplant Unit, Reina Sofia University Hospital, IMIBIC, CIBERehd, Cordoba, Spain.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology1193-9596Aged*Calcineurin InhibitorsCarcinoma, Hepatocellular/mortality/*surgeryFemaleHumansImmunosuppressive Agents/*administration & dosageLiver Neoplasms/mortality/*surgery*Liver TransplantationMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlProportional Hazards ModelsRetrospective StudiesTOR Serine-Threonine Kinases/antagonists & inhibitors2013Dec1600-0641 (Electronic) 0168-8278 (Linking)23867318http://www.ncbi.nlm.nih.gov/pubmed/2386731810.1016/j.jhep.2013.07.012wDyK  _ENREF_12444DLiang201291919117Liang, W.Wang, D.Ling, X.Kao, A. A.Kong, Y.Shang, Y.Guo, Z.He, X.Organ Transplant Center, First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Er Road, Guangzhou, China.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysisLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society62-9181Carcinoma, Hepatocellular/*surgeryFemaleHumansImmunosuppressive Agents/adverse effects/therapeutic useLiver Neoplasms/*surgeryLiver Transplantation/*immunology/mortalityMaleNeoplasm Recurrence, Local/prevention & controlRisk FactorsSirolimus/adverse effects/*therapeutic useSurvival Rate2012Jan1527-6473 (Electronic) 1527-6465 (Linking)21964956http://www.ncbi.nlm.nih.gov/pubmed/2196495610.1002/lt.22441Zhou200811111111117Zhou, J.Wang, Z.Wu, Z. Q.Qiu, S. J.Yu, Y.Huang, X. W.Tang, Z. Y.Fan, J.Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteriaTransplant ProcTransplantation proceedingsTransplant ProcTransplantation proceedingsTransplant ProcTransplantation proceedings3548-534010AdolescentAdultCarcinoma, Hepatocellular/mortality/pathology/*surgeryDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunosuppressive Agents/adverse effects/*therapeutic useLiver Neoplasms/mortality/pathology/*surgeryLiver Transplantation/*immunology/mortalityMaleNeoplasm Invasiveness/pathologyNeoplasm Metastasis/pathologyPatient SelectionRetrospective StudiesSirolimus/adverse effects/*therapeutic useSurvival AnalysisSurvivorsTacrolimus/therapeutic use2008Dec0041-1345 (Print) 0041-1345 (Linking)19100435http://www.ncbi.nlm.nih.gov/pubmed/1910043510.1016/j.transproceed.2008.03.165Geissler201683838317Geissler, E. K.Schnitzbauer, A. A.Zulke, C.Lamby, P. E.Proneth, A.Duvoux, C.Burra, P.Jauch, K. W.Rentsch, M.Ganten, T. M.Schmidt, J.Settmacher, U.Heise, M.Rossi, G.Cillo, U.Kneteman, N.Adam, R.van Hoek, B.Bachellier, P.Wolf, P.Rostaing, L.Bechstein, W. O.Rizell, M.Powell, J.Hidalgo, E.Gugenheim, J.Wolters, H.Brockmann, J.Roy, A.Mutzbauer, I.Schlitt, A.Beckebaum, S.Graeb, C.Nadalin, S.Valente, U.Turrion, V. S.Jamieson, N.Scholz, T.Colledan, M.Fandrich, F.Becker, T.Soderdahl, G.Chazouilleres, O.Makisalo, H.Pageaux, G. P.Steininger, R.Soliman, T.de Jong, K. P.Pirenne, J.Margreiter, R.Pratschke, J.Pinna, A. D.Hauss, J.Schreiber, S.Strasser, S.Klempnauer, J.Troisi, R. I.Bhoori, S.Lerut, J.Bilbao, I.Klein, C. G.Konigsrainer, A.Mirza, D. F.Otto, G.Mazzaferro, V.Neuhaus, P.Schlitt, H. J.1 Department of Surgery and Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany. 2 Klinik fur Allgemein- und Viszeralchirurgie, Universitatsklinikum Frankfurt, Frankfurt am Main, Germany. 3 Unite d'Hepatologie et de Transplantation Hepatique, Centre Hospitalier Universitaire Henri-Mondor, Service d'Hepatologie et de Gastroenterologie, Universite Paris-Est Creteil Val-de-Marne, Paris, France. 4 Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG), Universita degli Studi di Padova, Padova, Italy. 5 Klinik fur Allgemeine, Viszeral, Transplantations- Gefass- und Thoraxchirurgie, Klinikum der Ludwig-Maximilians-Universitat Munchen-Grosshadern, Munchen, Germany. 6 Innere Medizin IV, Sektion Lebertransplantation, Universitatsklinikum Heidelberg, Heidelberg, Germany. 7 Klinik fur Allgemein-, Viszeral- und Gefasschirurgie, Universitatsklinikum Jena, Jena, Germany. 8 Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany. 9 Centro Trapianti Fegato, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico IRCCS di Milano, Milan, Italy. 10 Chirurgia Epatobiliare e Trapianto Epatico, Azienda Ospedaliera di Padova, Universita di Padova, Padova, Italy. 11 Alberta Health Services Liver Transplant Program, University of Alberta, Edmonton, Alberta, Canada. 12 Centre Hepato Biliaire, Hopital Paul Brousse, Villejuif Cedex, Paris, France. 13 Department of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, Netherlands. 14 Service de Chirurgie Generale, Hepatique, Endocrinienne, et Transplantation, Hopital de Hautepierre, Les Hopitaux Universitaires de Strasbourg, Strasbourg, France. 15 Service de Nephrologie-HTA-Dialyse-Transplantation, CHU Toulouse-Rangueil, Toulouse, France. 16 Department of Surgery and Transplantation, Sahlgrenska University Hospital, Goteborg, Sweden. 17 Hepatic-PaSirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation116-2510012015/11/12AdultAge FactorsAgedAustraliaCanadaCarcinoma, Hepatocellular/mortality/pathology/*surgeryDisease ProgressionDisease-Free SurvivalDrug Therapy, CombinationEuropeFemaleHumansImmunosuppressive Agents/*therapeutic useIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/mortality/pathology/*surgery*Liver Transplantation/adverse effects/mortalityMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRisk AssessmentRisk FactorsSirolimus/*therapeutic useTOR Serine-Threonine Kinases/antagonists & inhibitors/metabolismTime FactorsTreatment OutcomeYoung Adult2016Jan0041-133726555945PMC468303310.1097/tp.0000000000000965NLMengThorat201710510510517Thorat, A.Jeng, L. B.Yang, H. R.Yeh, C. C.Hsu, S. C.Chen, T. H.Poon, K. S.Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan. Department of Surgery, China Medical University Hospital, Taichung, Taiwan. Department of Anaesthesiology, China Medical University Hospital, Taichung, Taiwan.Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitorsAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgeryAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgeryAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgery205-2112142017/12/22EverolimusHepatic artery thrombosisHepatocellular carcinomaLiving donor liver transplantation2017Nov2508-5778 (Print) 2508-585929264583PMC573674010.14701/ahbps.2017.21.4.205NLMeng`44DLiang201291919117Liang, W.Wang, D.Ling, X.Kao, A. A.Kong, Y.Shang, Y.Guo, Z.He, X.Organ Transplant Center, First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Er Road, Guangzhou, China.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysisLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLiver TransplLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society62-9181Carcinoma, Hepatocellular/*surgeryFemaleHumansImmunosuppressive Agents/adverse effects/therapeutic useLiver Neoplasms/*surgeryLiver Transplantation/*immunology/mortalityMaleNeoplasm Recurrence, Local/prevention & controlRisk FactorsSirolimus/adverse effects/*therapeutic useSurvival Rate2012Jan1527-6473 (Electronic) 1527-6465 (Linking)21964956http://www.ncbi.nlm.nih.gov/pubmed/2196495610.1002/lt.22441Zhou200811111111117Zhou, J.Wang, Z.Wu, Z. Q.Qiu, S. J.Yu, Y.Huang, X. W.Tang, Z. Y.Fan, J.Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteriaTransplant ProcTransplantation proceedingsTransplant ProcTransplantation proceedingsTransplant ProcTransplantation proceedings3548-534010AdolescentAdultCarcinoma, Hepatocellular/mortality/pathology/*surgeryDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunosuppressive Agents/adverse effects/*therapeutic useLiver Neoplasms/mortality/pathology/*surgeryLiver Transplantation/*immunology/mortalityMaleNeoplasm Invasiveness/pathologyNeoplasm Metastasis/pathologyPatient SelectionRetrospective StudiesSirolimus/adverse effects/*therapeutic useSurvival AnalysisSurvivorsTacrolimus/therapeutic use2008Dec0041-1345 (Print) 0041-1345 (Linking)19100435http://www.ncbi.nlm.nih.gov/pubmed/1910043510.1016/j.transproceed.2008.03.165Geissler201683838317Geissler, E. K.Schnitzbauer, A. A.Zulke, C.Lamby, P. E.Proneth, A.Duvoux, C.Burra, P.Jauch, K. W.Rentsch, M.Ganten, T. M.Schmidt, J.Settmacher, U.Heise, M.Rossi, G.Cillo, U.Kneteman, N.Adam, R.van Hoek, B.Bachellier, P.Wolf, P.Rostaing, L.Bechstein, W. O.Rizell, M.Powell, J.Hidalgo, E.Gugenheim, J.Wolters, H.Brockmann, J.Roy, A.Mutzbauer, I.Schlitt, A.Beckebaum, S.Graeb, C.Nadalin, S.Valente, U.Turrion, V. S.Jamieson, N.Scholz, T.Colledan, M.Fandrich, F.Becker, T.Soderdahl, G.Chazouilleres, O.Makisalo, H.Pageaux, G. P.Steininger, R.Soliman, T.de Jong, K. P.Pirenne, J.Margreiter, R.Pratschke, J.Pinna, A. D.Hauss, J.Schreiber, S.Strasser, S.Klempnauer, J.Troisi, R. I.Bhoori, S.Lerut, J.Bilbao, I.Klein, C. G.Konigsrainer, A.Mirza, D. F.Otto, G.Mazzaferro, V.Neuhaus, P.Schlitt, H. J.1 Department of Surgery and Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany. 2 Klinik fur Allgemein- und Viszeralchirurgie, Universitatsklinikum Frankfurt, Frankfurt am Main, Germany. 3 Unite d'Hepatologie et de Transplantation Hepatique, Centre Hospitalier Universitaire Henri-Mondor, Service d'Hepatologie et de Gastroenterologie, Universite Paris-Est Creteil Val-de-Marne, Paris, France. 4 Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG), Universita degli Studi di Padova, Padova, Italy. 5 Klinik fur Allgemeine, Viszeral, Transplantations- Gefass- und Thoraxchirurgie, Klinikum der Ludwig-Maximilians-Universitat Munchen-Grosshadern, Munchen, Germany. 6 Innere Medizin IV, Sektion Lebertransplantation, Universitatsklinikum Heidelberg, Heidelberg, Germany. 7 Klinik fur Allgemein-, Viszeral- und Gefasschirurgie, Universitatsklinikum Jena, Jena, Germany. 8 Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany. 9 Centro Trapianti Fegato, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico IRCCS di Milano, Milan, Italy. 10 Chirurgia Epatobiliare e Trapianto Epatico, Azienda Ospedaliera di Padova, Universita di Padova, Padova, Italy. 11 Alberta Health Services Liver Transplant Program, University of Alberta, Edmonton, Alberta, Canada. 12 Centre Hepato Biliaire, Hopital Paul Brousse, Villejuif Cedex, Paris, France. 13 Department of Gastroenterology and Hepatology, Leiden University Medical Center (LUMC), Leiden, Netherlands. 14 Service de Chirurgie Generale, Hepatique, Endocrinienne, et Transplantation, Hopital de Hautepierre, Les Hopitaux Universitaires de Strasbourg, Strasbourg, France. 15 Service de Nephrologie-HTA-Dialyse-Transplantation, CHU Toulouse-Rangueil, Toulouse, France. 16 Department of Surgery and Transplantation, Sahlgrenska University Hospital, Goteborg, Sweden. 17 Hepatic-PaSirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialTransplantationTransplantationTransplantationTransplantationTransplantationTransplantation116-2510012015/11/12AdultAge FactorsAgedAustraliaCanadaCarcinoma, Hepatocellular/mortality/pathology/*surgeryDisease ProgressionDisease-Free SurvivalDrug Therapy, CombinationEuropeFemaleHumansImmunosuppressive Agents/*therapeutic useIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/mortality/pathology/*surgery*Liver Transplantation/adverse effects/mortalityMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRisk AssessmentRisk FactorsSirolimus/*therapeutic useTOR Serine-Threonine Kinases/antagonists & inhibitors/metabolismTime FactorsTreatment OutcomeYoung Adult2016Jan0041-133726555945PMC468303310.1097/tp.0000000000000965NLMengThorat201710510510517Thorat, A.Jeng, L. B.Yang, H. R.Yeh, C. C.Hsu, S. C.Chen, T. H.Poon, K. S.Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan. Department of Surgery, China Medical University Hospital, Taichung, Taiwan. Department of Anaesthesiology, China Medical University Hospital, Taichung, Taiwan.Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitorsAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgeryAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgeryAnn Hepatobiliary Pancreat SurgAnnals of hepato-biliary-pancreatic surgery205-2112142017/12/22EverolimusHepatic artery thrombosisHepatocellular carcinomaLiving donor liver transplantation2017Nov2508-5778 (Print) 2508-585929264583PMC573674010.14701/ahbps.2017.21.4.205NLMeng`wDyK  _ENREF_125wDyK  _ENREF_129~DAu201821702170217017Au, K. P.Chok, K. S. H.Department of Surgery, Queen Mary Hospital, Hong Kong, China. Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China. chok6275@hku.hk.Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithmWorld J GastroenterolWorld J Gastroenterol5081-509424452018/12/21Carcinoma, Hepatocellular/mortality/pathology/*therapyClinical ProtocolsCombined Modality Therapy/methodsHumansLiver Neoplasms/mortality/pathology/*therapy*Liver TransplantationNeoplasm Recurrence, Local/mortality/pathology/*therapyPatient Care Team/*organization & administrationSurvival RateTreatment OutcomeHepatocellular carcinomaLiver transplantationRecurrence2018Dec 72219-2840 (Electronic) 1007-9327 (Linking)30568386https://www.ncbi.nlm.nih.gov/pubmed/30568386PMC628865310.3748/wjg.v24.i45.5081eng~DAu201821702170217017Au, K. P.Chok, K. S. H.Department of Surgery, Queen Mary Hospital, Hong Kong, China. Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China. chok6275@hku.hk.Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithmWorld J GastroenterolWorld J Gastroenterol5081-509424452018/12/21Carcinoma, Hepatocellular/mortality/pathology/*therapyClinical ProtocolsCombined Modality Therapy/methodsHumansLiver Neoplasms/mortality/pathology/*therapy*Liver TransplantationNeoplasm Recurrence, Local/mortality/pathology/*therapyPatient Care Team/*organization & administrationSurvival RateTreatment OutcomeHepatocellular carcinomaLiver transplantationRecurrence2018Dec 72219-2840 (Electronic) 1007-9327 (Linking)30568386https://www.ncbi.nlm.nih.gov/pubmed/30568386PMC628865310.3748/wjg.v24.i45.5081engwDyK  _ENREF_1302DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xLi201290909017Li, L.Zhang, J.Liu, X.Li, X.Jiao, B.Kang, T.Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysisJ Gastroenterol HepatolJournal of gastroenterology and hepatologyJ Gastroenterol HepatolJ Gastroenterol HepatolJournal of gastroenterology and hepatology51-8271AdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChi-Square DistributionDisease-Free SurvivalEvidence-Based MedicineFemale*Hepatectomy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2012Jan1440-1746 (Electronic) 0815-9319 (Linking)22004366http://www.ncbi.nlm.nih.gov/pubmed/2200436610.1111/j.1440-1746.2011.06947.xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656Feng201581818117Feng, Q.Chi, Y.Liu, Y.Zhang, L.Liu, Q.The Key Laboratory of Molecular Biology for Infectious Disease, Chinese Ministry of Education, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 74 Lin Jiang Road, Chongqing, 400010, China.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studiesJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1-914112014/06/04Carcinoma, Hepatocellular/*therapy*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*therapySafetyTreatment Outcome2015Jan0171-52162488950510.1007/s00432-014-1708-1NLMengp2DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xLi201290909017Li, L.Zhang, J.Liu, X.Li, X.Jiao, B.Kang, T.Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysisJ Gastroenterol HepatolJournal of gastroenterology and hepatologyJ Gastroenterol HepatolJ Gastroenterol HepatolJournal of gastroenterology and hepatology51-8271AdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChi-Square DistributionDisease-Free SurvivalEvidence-Based MedicineFemale*Hepatectomy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2012Jan1440-1746 (Electronic) 0815-9319 (Linking)22004366http://www.ncbi.nlm.nih.gov/pubmed/2200436610.1111/j.1440-1746.2011.06947.xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656Feng201581818117Feng, Q.Chi, Y.Liu, Y.Zhang, L.Liu, Q.The Key Laboratory of Molecular Biology for Infectious Disease, Chinese Ministry of Education, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 74 Lin Jiang Road, Chongqing, 400010, China.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studiesJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1-914112014/06/04Carcinoma, Hepatocellular/*therapy*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*therapySafetyTreatment Outcome2015Jan0171-52162488950510.1007/s00432-014-1708-1NLMengpuDyK  _ENREF_69uDyK  _ENREF_72wDyK  _ENREF_131$DPeng201396969617Peng, Z. W.Zhang, Y. J.Chen, M. S.Xu, L.Liang, H. H.Lin, X. J.Guo, R. P.Zhang, Y. Q.Lau, W. Y.State Key Laboratory of Oncology in Southern China, Guangzhou, PR China.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trialJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology426-32314AdultAgedCarcinoma, Hepatocellular/blood/mortality/pathology/surgery/*therapy*Catheter Ablation/adverse effects*Chemoembolization, Therapeutic/adverse effectsChinaCombined Modality TherapyDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLiver Neoplasms/blood/mortality/pathology/surgery/*therapyMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsProspective Studies2013Feb 11527-7755 (Electronic) 0732-183X (Linking)23269991http://www.ncbi.nlm.nih.gov/pubmed/2326999110.1200/JCO.2012.42.9936Morimoto201012512512517Morimoto, M.Numata, K.Kondou, M.Nozaki, A.Morita, S.Tanaka, K.Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. morimoto@urahp.yokohama-cu.ac.jpMidterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolizationCancerCancerCancerCancerCancerCancer5452-6011623AgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*therapyCatheter Ablation/*methodsChemoembolization, Therapeutic/*methodsCombined Modality Therapy/adverse effectsDisease ProgressionFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedTreatment Outcome2010Dec 10008-543X (Print) 0008-543X (Linking)20672352http://www.ncbi.nlm.nih.gov/pubmed/2067235210.1002/cncr.25314Chen201611611611617Chen, Q. W.Ying, H. F.Gao, S.Shen, Y. H.Meng, Z. Q.Chen, H.Chen, Z.Teng, W. J.Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China; Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China. Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Department of Traditional Chinese Medicine, 200025 Shanghai, PR China. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. Electronic address: cz120@mail.sh.cn. University of Traditional Chinese Medicine, Post Graduate School of Shandong, Weifang Hospital of Traditional Chinese Medicine, Cancer Treatment Center, First Department, 250355 Jinan, Shandong Province, PR China.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysisClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterologyClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterologyClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterology309-3144032015/10/03Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyHumansLiver Neoplasms/mortality/*therapyNeoplasm Recurrence, Local2016Jun2210-74012642866010.1016/j.clinre.2015.07.008NLMeng$DPeng201396969617Peng, Z. W.Zhang, Y. J.Chen, M. S.Xu, L.Liang, H. H.Lin, X. J.Guo, R. P.Zhang, Y. Q.Lau, W. Y.State Key Laboratory of Oncology in Southern China, Guangzhou, PR China.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trialJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology426-32314AdultAgedCarcinoma, Hepatocellular/blood/mortality/pathology/surgery/*therapy*Catheter Ablation/adverse effects*Chemoembolization, Therapeutic/adverse effectsChinaCombined Modality TherapyDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLiver Neoplasms/blood/mortality/pathology/surgery/*therapyMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsProspective Studies2013Feb 11527-7755 (Electronic) 0732-183X (Linking)23269991http://www.ncbi.nlm.nih.gov/pubmed/2326999110.1200/JCO.2012.42.9936Morimoto201012512512517Morimoto, M.Numata, K.Kondou, M.Nozaki, A.Morita, S.Tanaka, K.Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. morimoto@urahp.yokohama-cu.ac.jpMidterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolizationCancerCancerCancerCancerCancerCancer5452-6011623AgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*therapyCatheter Ablation/*methodsChemoembolization, Therapeutic/*methodsCombined Modality Therapy/adverse effectsDisease ProgressionFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedTreatment Outcome2010Dec 10008-543X (Print) 0008-543X (Linking)20672352http://www.ncbi.nlm.nih.gov/pubmed/2067235210.1002/cncr.25314Chen201611611611617Chen, Q. W.Ying, H. F.Gao, S.Shen, Y. H.Meng, Z. Q.Chen, H.Chen, Z.Teng, W. J.Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China; Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China. Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Department of Traditional Chinese Medicine, 200025 Shanghai, PR China. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China. Electronic address: cz120@mail.sh.cn. University of Traditional Chinese Medicine, Post Graduate School of Shandong, Weifang Hospital of Traditional Chinese Medicine, Cancer Treatment Center, First Department, 250355 Jinan, Shandong Province, PR China.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysisClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterologyClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterologyClin Res Hepatol GastroenterolClinics and research in hepatology and gastroenterology309-3144032015/10/03Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyHumansLiver Neoplasms/mortality/*therapyNeoplasm Recurrence, Local2016Jun2210-74012642866010.1016/j.clinre.2015.07.008NLMengwDyK  _ENREF_135DBruix201577777717Bruix, J.Takayama, T.Mazzaferro, V.Chau, G. Y.Yang, J.Kudo, M.Cai, J.Poon, R. T.Han, K. H.Tak, W. Y.Lee, H. C.Song, T.Roayaie, S.Bolondi, L.Lee, K. S.Makuuchi, M.Souza, F.Berre, M. A.Meinhardt, G.Llovet, J. M.Storm investigatorsBCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es. Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. Liver Unit, Hepato-Oncology Group, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Taipei Veterans General Hospital, Department of Surgery, Beitou District, Taipei City, Taiwan. Eastern Hepatobiliary Hospital, Shanghai District, Shanghai, China. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China. Queen Mary Hospital, Pok Fu Lam, Hong Kong, China. Severance Hospital, Seodaemun-gu, Seoul, South Korea. Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Jung-gu, Daegu, Korea. Asan Medical Center, Songpa-gu, Seoul, South Korea. Tianjin Medical University Cancer Hospital Huanhuxilu, Hexi District, Tianjin, China. Liver Cancer Program, Hofstra-North Shore-LIJ School of Medicine, Lenox Hill Hospital, New York, NY, USA. University of Bologna, Bologna, Italy. Gangnam Severance Hospital, Gangnam-gu, Seoul, South Korea. University of Tokyo, Bunkyo, Tokyo, Japan. Bayer HealthCare Pharmaceuticals, Socorro, Sao Paulo, Brazil. Bayer HealthCare Pharmaceuticals, Loos, France. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain; Liver Cancer Program, Mount Sinai Medical Center, New York, NY, USA.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology1344-541613AdultAgedAged, 80 and overAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useAsiaAustraliaCarcinoma, Hepatocellular/*drug therapy/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalDouble-Blind MethodEuropeFemale*Hepatectomy/adverse effects/mortalityHumansIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalNew ZealandNiacinamide/administration & dosage/adverse effects/*analogs &derivatives/therapeutic useNorth AmericaPhenylurea Compounds/administration & dosage/adverse effects/*therapeutic useProtein Kinase Inhibitors/administration & dosage/adverse effects/*therapeuticuseRisk FactorsSouth AmericaTime FactorsTreatment OutcomeYoung Adult2015Oct1474-5488 (Electronic) 1470-2045 (Linking)26361969http://www.ncbi.nlm.nih.gov/pubmed/2636196910.1016/S1470-2045(15)00198-9DBruix201577777717Bruix, J.Takayama, T.Mazzaferro, V.Chau, G. Y.Yang, J.Kudo, M.Cai, J.Poon, R. T.Han, K. H.Tak, W. Y.Lee, H. C.Song, T.Roayaie, S.Bolondi, L.Lee, K. S.Makuuchi, M.Souza, F.Berre, M. A.Meinhardt, G.Llovet, J. M.Storm investigatorsBCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es. Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. Liver Unit, Hepato-Oncology Group, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Taipei Veterans General Hospital, Department of Surgery, Beitou District, Taipei City, Taiwan. Eastern Hepatobiliary Hospital, Shanghai District, Shanghai, China. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China. Queen Mary Hospital, Pok Fu Lam, Hong Kong, China. Severance Hospital, Seodaemun-gu, Seoul, South Korea. Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Jung-gu, Daegu, Korea. Asan Medical Center, Songpa-gu, Seoul, South Korea. Tianjin Medical University Cancer Hospital Huanhuxilu, Hexi District, Tianjin, China. Liver Cancer Program, Hofstra-North Shore-LIJ School of Medicine, Lenox Hill Hospital, New York, NY, USA. University of Bologna, Bologna, Italy. Gangnam Severance Hospital, Gangnam-gu, Seoul, South Korea. University of Tokyo, Bunkyo, Tokyo, Japan. Bayer HealthCare Pharmaceuticals, Socorro, Sao Paulo, Brazil. Bayer HealthCare Pharmaceuticals, Loos, France. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain; Liver Cancer Program, Mount Sinai Medical Center, New York, NY, USA.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology1344-541613AdultAgedAged, 80 and overAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useAsiaAustraliaCarcinoma, Hepatocellular/*drug therapy/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalDouble-Blind MethodEuropeFemale*Hepatectomy/adverse effects/mortalityHumansIntention to Treat AnalysisKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalNew ZealandNiacinamide/administration & dosage/adverse effects/*analogs &derivatives/therapeutic useNorth AmericaPhenylurea Compounds/administration & dosage/adverse effects/*therapeutic useProtein Kinase Inhibitors/administration & dosage/adverse effects/*therapeuticuseRisk FactorsSouth AmericaTime FactorsTreatment OutcomeYoung Adult2015Oct1474-5488 (Electronic) 1470-2045 (Linking)26361969http://www.ncbi.nlm.nih.gov/pubmed/2636196910.1016/S1470-2045(15)00198-9wDyK  _ENREF_1132DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xFeng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Li201290909017Li, L.Zhang, J.Liu, X.Li, X.Jiao, B.Kang, T.Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysisJ Gastroenterol HepatolJournal of gastroenterology and hepatologyJ Gastroenterol HepatolJ Gastroenterol HepatolJournal of gastroenterology and hepatology51-8271AdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChi-Square DistributionDisease-Free SurvivalEvidence-Based MedicineFemale*Hepatectomy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2012Jan1440-1746 (Electronic) 0815-9319 (Linking)22004366http://www.ncbi.nlm.nih.gov/pubmed/2200436610.1111/j.1440-1746.2011.06947.xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656Feng201581818117Feng, Q.Chi, Y.Liu, Y.Zhang, L.Liu, Q.The Key Laboratory of Molecular Biology for Infectious Disease, Chinese Ministry of Education, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 74 Lin Jiang Road, Chongqing, 400010, China.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studiesJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1-914112014/06/04Carcinoma, Hepatocellular/*therapy*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*therapySafetyTreatment Outcome2015Jan0171-52162488950510.1007/s00432-014-1708-1NLMengp2DChen200648484817Chen, M. S.Li, J. Q.Zheng, Y.Guo, R. P.Liang, H. H.Zhang, Y. Q.Lin, X. J.Lau, W. Y.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, Guangzhou, China. Cms64@21cn.comA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinomaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery321-82433AdolescentAdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*methodsFemaleFollow-Up StudiesHepatectomy/*methodsHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedProspective StudiesSurvival RateTreatment Outcome2006Mar0003-4932 (Print) 0003-4932 (Linking)16495695http://www.ncbi.nlm.nih.gov/pubmed/16495695144894710.1097/01.sla.0000201480.65519.b8Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xFeng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Li201290909017Li, L.Zhang, J.Liu, X.Li, X.Jiao, B.Kang, T.Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysisJ Gastroenterol HepatolJournal of gastroenterology and hepatologyJ Gastroenterol HepatolJ Gastroenterol HepatolJournal of gastroenterology and hepatology51-8271AdultAgedCarcinoma, Hepatocellular/mortality/pathology/*surgery*Catheter Ablation/adverse effects/mortalityChi-Square DistributionDisease-Free SurvivalEvidence-Based MedicineFemale*Hepatectomy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm Recurrence, LocalOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2012Jan1440-1746 (Electronic) 0815-9319 (Linking)22004366http://www.ncbi.nlm.nih.gov/pubmed/2200436610.1111/j.1440-1746.2011.06947.xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656Feng201581818117Feng, Q.Chi, Y.Liu, Y.Zhang, L.Liu, Q.The Key Laboratory of Molecular Biology for Infectious Disease, Chinese Ministry of Education, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 74 Lin Jiang Road, Chongqing, 400010, China.Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studiesJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology1-914112014/06/04Carcinoma, Hepatocellular/*therapy*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*therapySafetyTreatment Outcome2015Jan0171-52162488950510.1007/s00432-014-1708-1NLMengpuDyK  _ENREF_69uDyK  _ENREF_72wDyK  _ENREF_131lDPeng201212712712717Peng, Z. W.Lin, X. J.Zhang, Y. J.Liang, H. H.Guo, R. P.Shi, M.Chen, M. S.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Rd East, Guangzhou 510060, China.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative studyRadiologyRadiologyRadiologyRadiology1022-3326232012/02/24AdultAgedCarcinoma, Hepatocellular/pathology/*surgeryCatheter Ablation/*methodsChi-Square DistributionFemaleHumansKaplan-Meier EstimateLiver Neoplasms/pathology/*surgeryMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPostoperative ComplicationsPrognosisProportional Hazards ModelsRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeUltrasonography2012Mar0033-84192235790210.1148/radiol.11110817NLMengLivraghi200812112112117Livraghi, T.Meloni, F.Di Stasi, M.Rolle, E.Solbiati, L.Tinelli, C.Rossi, S.Department of Radiology, Ospedale Civile, Vimercate, Milano, Italy. tito.livraghi@aovimercate.orgSustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?HepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)82-94712007/11/17AdultAgedAged, 80 and overCarcinoma, Hepatocellular/etiology/*therapy*Catheter Ablation/adverse effectsCohort StudiesFemaleHumansLiver Cirrhosis/*complicationsLiver Neoplasms/etiology/*therapyMaleMiddle AgedRetrospective StudiesSurvival AnalysisTreatment Outcome2008Jan0270-91391800835710.1002/hep.21933NLMeng@0lDPeng201212712712717Peng, Z. W.Lin, X. J.Zhang, Y. J.Liang, H. H.Guo, R. P.Shi, M.Chen, M. S.Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-Sen University, 651 Dongfeng Rd East, Guangzhou 510060, China.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative studyRadiologyRadiologyRadiologyRadiology1022-3326232012/02/24AdultAgedCarcinoma, Hepatocellular/pathology/*surgeryCatheter Ablation/*methodsChi-Square DistributionFemaleHumansKaplan-Meier EstimateLiver Neoplasms/pathology/*surgeryMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPostoperative ComplicationsPrognosisProportional Hazards ModelsRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeUltrasonography2012Mar0033-84192235790210.1148/radiol.11110817NLMengLivraghi200812112112117Livraghi, T.Meloni, F.Di Stasi, M.Rolle, E.Solbiati, L.Tinelli, C.Rossi, S.Department of Radiology, Ospedale Civile, Vimercate, Milano, Italy. tito.livraghi@aovimercate.orgSustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?HepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)82-94712007/11/17AdultAgedAged, 80 and overCarcinoma, Hepatocellular/etiology/*therapy*Catheter Ablation/adverse effectsCohort StudiesFemaleHumansLiver Cirrhosis/*complicationsLiver Neoplasms/etiology/*therapyMaleMiddle AgedRetrospective StudiesSurvival AnalysisTreatment Outcome2008Jan0270-91391800835710.1002/hep.21933NLMeng@0wDyK  _ENREF_138wDyK  _ENREF_139DWeis201313113113117Weis, S.Franke, A.Mossner, J.Jakobsen, J. C.Schoppmeyer, K.Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstrasse 20, Leipzig, Germany, 04103.Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinomaCochrane Database Syst RevThe Cochrane database of systematic reviewsCochrane Database Syst RevThe Cochrane database of systematic reviewsCochrane Database Syst RevThe Cochrane database of systematic reviewsCd003046122013/12/21Acetic Acid/administration & dosageAdministration, CutaneousCarcinoma, Hepatocellular/mortality/*therapyCatheter Ablation/*methods/mortalityEthanol/administration & dosageHepatectomy/mortalityHumansLiver Neoplasms/mortality/*therapyMicrowaves/therapeutic useRandomized Controlled Trials as TopicTreatment Outcome2013Dec 191361-61372435745710.1002/14651858.CD003046.pub3NLMengKim201311911911917Kim, Y. S.Lim, H. K.Rhim, H.Lee, M. W.Choi, D.Lee, W. J.Paik, S. W.Koh, K. C.Lee, J. H.Choi, M. S.Gwak, G. Y.Yoo, B. C.Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factorsJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology89-975812012/10/02AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*mortality/pathology/*surgeryCatheter Ablation/*methods/*mortalityDatabases, FactualEarly DiagnosisFemaleFollow-Up StudiesHumansLiver Neoplasms/*mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/mortalityPrognosisRisk FactorsTreatment Outcome2013Jan0168-82782302300910.1016/j.jhep.2012.09.020NLMengZhang201522192219221917Zhang, L.Ge, N. L.Chen, Y.Xie, X. Y.Yin, X.Gan, Y. H.Zhang, B. H.Zhang, J. B.Chen, R. X.Wang, Y. H.Ye, S. L.Ren, Z. G.Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Xue Yuan Road, Shanghai, 200032, China.Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patientsMed OncolMed Oncol773232015/02/24AgedAsian Continental Ancestry GroupCarcinoma, Hepatocellular/*mortality/pathology/*surgeryCatheter Ablation/adverse effects/*methodsDisease-Free SurvivalFemaleFollow-Up StudiesHepatitis B/complicationsHumansLiver Neoplasms/*mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/epidemiologyPrognosisSurvival RateTreatment Outcome2015Mar1559-131X (Electronic) 1357-0560 (Linking)25698535https://www.ncbi.nlm.nih.gov/pubmed/2569853510.1007/s12032-015-0532-zDWeis201313113113117Weis, S.Franke, A.Mossner, J.Jakobsen, J. C.Schoppmeyer, K.Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstrasse 20, Leipzig, Germany, 04103.Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinomaCochrane Database Syst RevThe Cochrane database of systematic reviewsCochrane Database Syst RevThe Cochrane database of systematic reviewsCochrane Database Syst RevThe Cochrane database of systematic reviewsCd003046122013/12/21Acetic Acid/administration & dosageAdministration, CutaneousCarcinoma, Hepatocellular/mortality/*therapyCatheter Ablation/*methods/mortalityEthanol/administration & dosageHepatectomy/mortalityHumansLiver Neoplasms/mortality/*therapyMicrowaves/therapeutic useRandomized Controlled Trials as TopicTreatment Outcome2013Dec 191361-61372435745710.1002/14651858.CD003046.pub3NLMengKim201311911911917Kim, Y. S.Lim, H. K.Rhim, H.Lee, M. W.Choi, D.Lee, W. J.Paik, S. W.Koh, K. C.Lee, J. H.Choi, M. S.Gwak, G. Y.Yoo, B. C.Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factorsJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology89-975812012/10/02AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*mortality/pathology/*surgeryCatheter Ablation/*methods/*mortalityDatabases, FactualEarly DiagnosisFemaleFollow-Up StudiesHumansLiver Neoplasms/*mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/mortalityPrognosisRisk FactorsTreatment Outcome2013Jan0168-82782302300910.1016/j.jhep.2012.09.020NLMengZhang201522192219221917Zhang, L.Ge, N. L.Chen, Y.Xie, X. Y.Yin, X.Gan, Y. H.Zhang, B. H.Zhang, J. B.Chen, R. X.Wang, Y. H.Ye, S. L.Ren, Z. G.Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Xue Yuan Road, Shanghai, 200032, China.Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patientsMed OncolMed Oncol773232015/02/24AgedAsian Continental Ancestry GroupCarcinoma, Hepatocellular/*mortality/pathology/*surgeryCatheter Ablation/adverse effects/*methodsDisease-Free SurvivalFemaleFollow-Up StudiesHepatitis B/complicationsHumansLiver Neoplasms/*mortality/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, Local/epidemiologyPrognosisSurvival RateTreatment Outcome2015Mar1559-131X (Electronic) 1357-0560 (Linking)25698535https://www.ncbi.nlm.nih.gov/pubmed/2569853510.1007/s12032-015-0532-zwDyK  _ENREF_140wDyK  _ENREF_143 DShibata200212812812817Shibata, T.Iimuro, Y.Yamamoto, Y.Maetani, Y.Ametani, F.Itoh, K.Konishi, J.Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54-Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan. ksj@kuhp.kyoto-u.ac.jpSmall hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapyRadiologyRadiologyRadiologyRadiology331-722322002/05/09AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*therapy*Catheter AblationChi-Square DistributionElectrocoagulation/*methodsHumansLiver Neoplasms/*therapyMicrowaves/*therapeutic useMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRadiography, InterventionalStatistics, NonparametricTomography, X-Ray ComputedTreatment Outcome2002May0033-8419 (Print) 0033-84191199753410.1148/radiol.2232010775NLMeng DShibata200212812812817Shibata, T.Iimuro, Y.Yamamoto, Y.Maetani, Y.Ametani, F.Itoh, K.Konishi, J.Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54-Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan. ksj@kuhp.kyoto-u.ac.jpSmall hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapyRadiologyRadiologyRadiologyRadiology331-722322002/05/09AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*therapy*Catheter AblationChi-Square DistributionElectrocoagulation/*methodsHumansLiver Neoplasms/*therapyMicrowaves/*therapeutic useMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRadiography, InterventionalStatistics, NonparametricTomography, X-Ray ComputedTreatment Outcome2002May0033-8419 (Print) 0033-84191199753410.1148/radiol.2232010775NLMengwDyK  _ENREF_144 DDi Vece201411811811817Di Vece, F.Tombesi, P.Ermili, F.Maraldi, C.Sartori, S.Section of Interventional Ultrasound, Department of Internal Medicine, St. Anna Hospital, Via a. Moro 8, Cona, 44100, Ferrara, Italy, fradiv12@libero.it.Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot studyCardiovasc Intervent RadiolCardiovascular and interventional radiologyCardiovasc Intervent RadiolCardiovascular and interventional radiologyCardiovasc Intervent RadiolCardiovascular and interventional radiology723-9373Carcinoma, Hepatocellular/*surgery/*ultrasonographyCatheter Ablation/instrumentation/*methodsContrast MediaFemaleHumansLiver Neoplasms/secondary/*surgery/*ultrasonographyMaleMicrowavesMiddle AgedPilot ProjectsProspective StudiesRadio WavesTreatment Outcome2014Jun1432-086X (Electronic) 0174-1551 (Linking)24196263http://www.ncbi.nlm.nih.gov/pubmed/2419626310.1007/s00270-013-0733-9@ DDi Vece201411811811817Di Vece, F.Tombesi, P.Ermili, F.Maraldi, C.Sartori, S.Section of Interventional Ultrasound, Department of Internal Medicine, St. Anna Hospital, Via a. Moro 8, Cona, 44100, Ferrara, Italy, fradiv12@libero.it.Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot studyCardiovasc Intervent RadiolCardiovascular and interventional radiologyCardiovasc Intervent RadiolCardiovascular and interventional radiologyCardiovasc Intervent RadiolCardiovascular and interventional radiology723-9373Carcinoma, Hepatocellular/*surgery/*ultrasonographyCatheter Ablation/instrumentation/*methodsContrast MediaFemaleHumansLiver Neoplasms/secondary/*surgery/*ultrasonographyMaleMicrowavesMiddle AgedPilot ProjectsProspective StudiesRadio WavesTreatment Outcome2014Jun1432-086X (Electronic) 0174-1551 (Linking)24196263http://www.ncbi.nlm.nih.gov/pubmed/2419626310.1007/s00270-013-0733-9@wDyK  _ENREF_145wDyK  _ENREF_143+DLiu201659595917Liu, P. H.Hsu, C. Y.Hsia, C. Y.Lee, Y. H.Huang, Y. H.Chiou, Y. Y.Lin, H. C.Huo, T. I.*Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan daggerDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan double daggerDepartment of Biostatistics, UCLA, Los Angeles, CA section signDepartment of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan paragraph signInstitute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan ||Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan **Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma </= 2 cm in a Propensity Score ModelAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery538-452633AgedCarcinoma, Hepatocellular/*surgeryCatheter Ablation/*methodsFemaleHepatectomy/*methodsHumansLiver Neoplasms/*surgeryMaleMiddle AgedPropensity ScoreRadio WavesRetrospective StudiesSurvival RateTreatment Outcome2016Mar1528-1140 (Electronic) 0003-4932 (Linking)25775062http://www.ncbi.nlm.nih.gov/pubmed/2577506210.1097/SLA.0000000000001178Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Xu201471717117Xu, Q.Kobayashi, S.Ye, X.Meng, X.1] Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China [2] bioMerieux (Shanghai) Co. Ltd., Shanghai, China. cole Polytechnique ParisTech, Paris, France.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patientsSci RepScientific reportsSci RepScientific reportsSci RepScientific reports72524AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryCatheter Ablation/methodsDisease-Free SurvivalFemaleHepatectomy/methodsHumansLiver/*surgeryLiver Neoplasms/mortality/*surgeryMaleMiddle AgedSurvival RateTreatment OutcomeYoung Adult20142045-2322 (Electronic) 2045-2322 (Linking)25429732http://www.ncbi.nlm.nih.gov/pubmed/25429732424621210.1038/srep07252Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656+DLiu201659595917Liu, P. H.Hsu, C. Y.Hsia, C. Y.Lee, Y. H.Huang, Y. H.Chiou, Y. Y.Lin, H. C.Huo, T. I.*Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan daggerDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan double daggerDepartment of Biostatistics, UCLA, Los Angeles, CA section signDepartment of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan paragraph signInstitute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan ||Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan **Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma </= 2 cm in a Propensity Score ModelAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery538-452633AgedCarcinoma, Hepatocellular/*surgeryCatheter Ablation/*methodsFemaleHepatectomy/*methodsHumansLiver Neoplasms/*surgeryMaleMiddle AgedPropensity ScoreRadio WavesRetrospective StudiesSurvival RateTreatment Outcome2016Mar1528-1140 (Electronic) 0003-4932 (Linking)25775062http://www.ncbi.nlm.nih.gov/pubmed/2577506210.1097/SLA.0000000000001178Feng201251515117Feng, K.Yan, J.Li, X.Xia, F.Ma, K.Wang, S.Bie, P.Dong, J.Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology794-802574AdolescentAdultAgedAged, 80 and overBlood Loss, SurgicalCarcinoma, Hepatocellular/*pathology/*surgery*Catheter Ablation/adverse effectsDisease-Free SurvivalFemaleFollow-Up Studies*Hepatectomy/adverse effectsHumansIndocyanine Green/pharmacokineticsKaplan-Meier EstimateLength of StayLiver Neoplasms/*pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, Local/*pathologyNeoplasms, Multiple Primary/pathology/*surgeryProportional Hazards ModelsSurvival RateYoung Adult2012Oct1600-0641 (Electronic) 0168-8278 (Linking)22634125http://www.ncbi.nlm.nih.gov/pubmed/2263412510.1016/j.jhep.2012.05.007Xu201471717117Xu, Q.Kobayashi, S.Ye, X.Meng, X.1] Fudan University Shanghai Cancer Center - Institut Merieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China [2] bioMerieux (Shanghai) Co. Ltd., Shanghai, China. cole Polytechnique ParisTech, Paris, France.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patientsSci RepScientific reportsSci RepScientific reportsSci RepScientific reports72524AdolescentAdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/*surgeryCatheter Ablation/methodsDisease-Free SurvivalFemaleHepatectomy/methodsHumansLiver/*surgeryLiver Neoplasms/mortality/*surgeryMaleMiddle AgedSurvival RateTreatment OutcomeYoung Adult20142045-2322 (Electronic) 2045-2322 (Linking)25429732http://www.ncbi.nlm.nih.gov/pubmed/25429732424621210.1038/srep07252Hasegawa201484848417Hasegawa, K.Aoki, T.Ishizawa, T.Kaneko, J.Sakamoto, Y.Sugawara, Y.Kokudo, N.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinomaAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyAnn Surg OncolAnnals of surgical oncologyS348-5521 Suppl 3Carcinoma, Hepatocellular/mortality/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/mortality/*surgeryPrognosisRandomized Controlled Trials as TopicSurvival Rate2014Jun1534-4681 (Electronic) 1068-9265 (Linking)24566865http://www.ncbi.nlm.nih.gov/pubmed/2456686510.1245/s10434-014-3585-xHuang201086868617Huang, J.Yan, L.Cheng, Z.Wu, H.Du, L.Wang, J.Xu, Y.Zeng, Y.Department of Hepato-Biliary-Pancreatic Surgery, Treatment Centre of Liver Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, China.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteriaAnn SurgAnnals of surgeryAnn SurgAnn SurgAnnals of surgery903-122526Carcinoma, Hepatocellular/*surgery*Catheter Ablation*HepatectomyHumansLiver Neoplasms/*surgery*Neoplasm Recurrence, LocalPatient SelectionSurvival AnalysisTreatment Outcome2010Dec1528-1140 (Electronic) 0003-4932 (Linking)21107100http://www.ncbi.nlm.nih.gov/pubmed/2110710010.1097/SLA.0b013e3181efc656uDyK  _ENREF_71wDyK  _ENREF_131wDyK  _ENREF_133(DAhmed201421722172217217Ahmed, M.Solbiati, L.Brace, C. L.Breen, D. J.Callstrom, M. R.Charboneau, J. W.Chen, M. H.Choi, B. I.de Baere, T.Dodd, G. D., 3rdDupuy, D. E.Gervais, D. A.Gianfelice, D.Gillams, A. R.Lee, F. T., Jr.Leen, E.Lencioni, R.Littrup, P. J.Livraghi, T.Lu, D. S.McGahan, J. P.Meloni, M. F.Nikolic, B.Pereira, P. L.Liang, P.Rhim, H.Rose, S. C.Salem, R.Sofocleous, C. T.Solomon, S. B.Soulen, M. C.Tanaka, M.Vogl, T. J.Wood, B. J.Goldberg, S. N.International Working Group on Image-guided Tumor, AblationInterventional Oncology Sans Frontieres Expert, PanelTechnology Assessment Committee of the Society of Interventional, RadiologyStandard of Practice Committee of the, CardiovascularInterventional Radiological Society of, EuropeDepartment of Radiology, Beth Israel Deaconess Medical Center 1 Deaconess Rd, WCC-308B, Boston, MA 02215 (M.A.); Department of Radiology, Ospedale Generale, Busto Arsizio, Italy (L.S.); Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wis (C.L.B.); Department of Radiology, Southampton University Hospitals, Southampton, England (D.J.B.); Department of Radiology, Mayo Clinic, Rochester, Minn (M.R.C., J.W.C.); Department of Ultrasound, School of Oncology, Peking University, Beijing, China (M.H.C.); Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (B.I.C.); Department of Imaging, Institut de Cancerologie Gustave Roussy, Villejuif, France (T.d.B.); Department of Radiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo (G.D.D.); Department of Diagnostic Radiology, Rhode Island Hospital, Providence, RI (D.E.D.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (D.A.G.); Medical Imaging, University Health Network, Laval, Quebec, Canada (D.G.); Imaging Department, the London Clinic, London, England (A.R.G.); Department of Radiology, University of Wisconsin Hospital and Clinics, Madison, Wis (F.T.L.); Department of Radiology, Royal Infirmary, Glasgow, Scotland (E.L.); Department of Diagnostic Imaging and Intervention, Cisanello Hospital, Pisa University Hospital and School of Medicine, University of Pisa, Pisa, Italy (R.L.); Department of Radiology, Karmonos Cancer Institute, Wayne State University, Detroit, Mich (P.J.L.); Busto Arsizio, Italy (T.L.); Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, Calif (D.S.L.); Department of Radiology, Ambulatory Care Center, UC Davis Medical Center, Sacramento, Calif (J.P.M.); Department of Radiology, Ospedale Valduce, Como, Italy (M.F.M.); Department of Radiology, Albert Einstein Medical Center, PhilImage-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year updateRadiologyRadiology241-6027312014/06/14Ablation Techniques/*methodsHumansNeoplasms/pathology/*surgery*Radiography, InterventionalResearch Design/*standards*Terminology as Topic2014Oct1527-1315 (Electronic) 0033-8419 (Linking)24927329https://www.ncbi.nlm.nih.gov/pubmed/24927329PMC426361810.1148/radiol.14132958eng`(DAhmed201421722172217217Ahmed, M.Solbiati, L.Brace, C. L.Breen, D. J.Callstrom, M. R.Charboneau, J. W.Chen, M. H.Choi, B. I.de Baere, T.Dodd, G. D., 3rdDupuy, D. E.Gervais, D. A.Gianfelice, D.Gillams, A. R.Lee, F. T., Jr.Leen, E.Lencioni, R.Littrup, P. J.Livraghi, T.Lu, D. S.McGahan, J. P.Meloni, M. F.Nikolic, B.Pereira, P. L.Liang, P.Rhim, H.Rose, S. C.Salem, R.Sofocleous, C. T.Solomon, S. B.Soulen, M. C.Tanaka, M.Vogl, T. J.Wood, B. J.Goldberg, S. N.International Working Group on Image-guided Tumor, AblationInterventional Oncology Sans Frontieres Expert, PanelTechnology Assessment Committee of the Society of Interventional, RadiologyStandard of Practice Committee of the, CardiovascularInterventional Radiological Society of, EuropeDepartment of Radiology, Beth Israel Deaconess Medical Center 1 Deaconess Rd, WCC-308B, Boston, MA 02215 (M.A.); Department of Radiology, Ospedale Generale, Busto Arsizio, Italy (L.S.); Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wis (C.L.B.); Department of Radiology, Southampton University Hospitals, Southampton, England (D.J.B.); Department of Radiology, Mayo Clinic, Rochester, Minn (M.R.C., J.W.C.); Department of Ultrasound, School of Oncology, Peking University, Beijing, China (M.H.C.); Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (B.I.C.); Department of Imaging, Institut de Cancerologie Gustave Roussy, Villejuif, France (T.d.B.); Department of Radiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo (G.D.D.); Department of Diagnostic Radiology, Rhode Island Hospital, Providence, RI (D.E.D.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (D.A.G.); Medical Imaging, University Health Network, Laval, Quebec, Canada (D.G.); Imaging Department, the London Clinic, London, England (A.R.G.); Department of Radiology, University of Wisconsin Hospital and Clinics, Madison, Wis (F.T.L.); Department of Radiology, Royal Infirmary, Glasgow, Scotland (E.L.); Department of Diagnostic Imaging and Intervention, Cisanello Hospital, Pisa University Hospital and School of Medicine, University of Pisa, Pisa, Italy (R.L.); Department of Radiology, Karmonos Cancer Institute, Wayne State University, Detroit, Mich (P.J.L.); Busto Arsizio, Italy (T.L.); Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, Calif (D.S.L.); Department of Radiology, Ambulatory Care Center, UC Davis Medical Center, Sacramento, Calif (J.P.M.); Department of Radiology, Ospedale Valduce, Como, Italy (M.F.M.); Department of Radiology, Albert Einstein Medical Center, PhilImage-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year updateRadiologyRadiology241-6027312014/06/14Ablation Techniques/*methodsHumansNeoplasms/pathology/*surgery*Radiography, InterventionalResearch Design/*standards*Terminology as Topic2014Oct1527-1315 (Electronic) 0033-8419 (Linking)24927329https://www.ncbi.nlm.nih.gov/pubmed/24927329PMC426361810.1148/radiol.14132958eng`wDyK  _ENREF_146-DLencioni201612012012017Lencioni, R.de Baere, T.Soulen, M. C.Rilling, W. S.Geschwind, J. F.Division of Vascular and Interventional Radiology, University of Miami Miller School of Medicine, Miami, FL. Department of Interventional Radiology, Institut Gustav-Roussy, Villejuif Cedex, France. Division of Interventional Radiology, University of Pennsylvania, Radnor, PA. Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety dataHepatologyHepatologyHepatologyHepatology106-166412016Jul1527-3350 (Electronic) 0270-9139 (Linking)26765068http://www.ncbi.nlm.nih.gov/pubmed/2676506810.1002/hep.28453Pelletier199812612612617Pelletier, G.Ducreux, M.Gay, F.Luboinski, M.Hagege, H.Dao, T.Van Steenbergen, W.Buffet, C.Rougier, P.Adler, M.Pignon, J. P.Roche, A.Liver Unit, Hopital de Bicetre, Le Kremlin-Bicetre, France.Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHCJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology129-34291AdultAgedAntineoplastic Agents/administration & dosage/therapeutic useCarcinoma, Hepatocellular/drug therapy/*therapy*Chemoembolization, TherapeuticCisplatin/administration & dosageFemaleHumansIodized Oil/administration & dosageLiver Neoplasms/drug therapy/*therapyMaleMiddle AgedSurvival AnalysisTamoxifen/administration & dosage/therapeutic use1998Jul0168-8278 (Print) 0168-8278 (Linking)9696501http://www.ncbi.nlm.nih.gov/pubmed/9696501Lo200212412412417Lo, C. M.Ngan, H.Tso, W. K.Liu, C. L.Lam, C. M.Poon, R. T.Fan, S. T.Wong, J.Center for the Study of Liver Disease, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China. chungmlo@hkucc.hku.hkRandomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatologyHepatologyHepatologyHepatology1164-71355AgedCarcinoma, Hepatocellular/*drug therapy/mortality*Chemoembolization, TherapeuticContrast Media/*administration & dosage/adverse effectsFemaleHumansInjections, Intra-ArterialIodized Oil/*administration & dosage/adverse effectsLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedPrognosisTreatment Outcome2002May0270-9139 (Print) 0270-9139 (Linking)11981766http://www.ncbi.nlm.nih.gov/pubmed/1198176610.1053/jhep.2002.33156Llovet200212312312317Llovet, J. M.Real, M. I.Montana, X.Planas, R.Coll, S.Aponte, J.Ayuso, C.Sala, M.Muchart, J.Sola, R.Rodes, J.Bruix, J.Barcelona Liver Cancer, GroupLiver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialLancetLancetLancetLancet1734-93599319AgedAntineoplastic Agents/*administration & dosageCarcinoma, Hepatocellular/mortality/pathology/*therapyCause of DeathChemoembolization, Therapeutic/*methodsDoxorubicin/*administration & dosageFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedSurvival Analysis2002May 180140-6736 (Print) 0140-6736 (Linking)12049862http://www.ncbi.nlm.nih.gov/pubmed/1204986210.1016/S0140-6736(02)08649-XCamma200211511511517Camma, C.Schepis, F.Orlando, A.Albanese, M.Shahied, L.Trevisani, F.Andreone, P.Craxi, A.Cottone, M.National Council of Research, Istituto Metodologie Diagnostiche Avanzate, Palermo, Italy. camma@ismeda.pa.cnr.itTransarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trialsRadiologyRadiologyRadiologyRadiology47-542241Carcinoma, Hepatocellular/drug therapy/mortality/*therapy*Chemoembolization, TherapeuticHumansLiver Neoplasms/drug therapy/mortality/*therapyRandomized Controlled Trials as TopicSafetySurvival RateTreatment Outcome2002Jul0033-8419 (Print) 0033-8419 (Linking)12091661http://www.ncbi.nlm.nih.gov/pubmed/1209166110.1148/radiol.2241011262Llovet200312212212217Llovet, J. M.Bruix, J.Barcelona-Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain. jmllovet@clinic.ub.esSystematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatologyHepatologyHepatologyHepatology429-42372Carcinoma, Hepatocellular/*therapy*Chemoembolization, TherapeuticHumansLiver Neoplasms/*therapyRandomized Controlled Trials as TopicSurvival Analysis2003Feb0270-9139 (Print) 0270-9139 (Linking)12540794http://www.ncbi.nlm.nih.gov/pubmed/1254079410.1053/jhep.2003.50047-DLencioni201612012012017Lencioni, R.de Baere, T.Soulen, M. C.Rilling, W. S.Geschwind, J. F.Division of Vascular and Interventional Radiology, University of Miami Miller School of Medicine, Miami, FL. Department of Interventional Radiology, Institut Gustav-Roussy, Villejuif Cedex, France. Division of Interventional Radiology, University of Pennsylvania, Radnor, PA. Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety dataHepatologyHepatologyHepatologyHepatology106-166412016Jul1527-3350 (Electronic) 0270-9139 (Linking)26765068http://www.ncbi.nlm.nih.gov/pubmed/2676506810.1002/hep.28453Pelletier199812612612617Pelletier, G.Ducreux, M.Gay, F.Luboinski, M.Hagege, H.Dao, T.Van Steenbergen, W.Buffet, C.Rougier, P.Adler, M.Pignon, J. P.Roche, A.Liver Unit, Hopital de Bicetre, Le Kremlin-Bicetre, France.Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHCJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology129-34291AdultAgedAntineoplastic Agents/administration & dosage/therapeutic useCarcinoma, Hepatocellular/drug therapy/*therapy*Chemoembolization, TherapeuticCisplatin/administration & dosageFemaleHumansIodized Oil/administration & dosageLiver Neoplasms/drug therapy/*therapyMaleMiddle AgedSurvival AnalysisTamoxifen/administration & dosage/therapeutic use1998Jul0168-8278 (Print) 0168-8278 (Linking)9696501http://www.ncbi.nlm.nih.gov/pubmed/9696501Lo200212412412417Lo, C. M.Ngan, H.Tso, W. K.Liu, C. L.Lam, C. M.Poon, R. T.Fan, S. T.Wong, J.Center for the Study of Liver Disease, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China. chungmlo@hkucc.hku.hkRandomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatologyHepatologyHepatologyHepatology1164-71355AgedCarcinoma, Hepatocellular/*drug therapy/mortality*Chemoembolization, TherapeuticContrast Media/*administration & dosage/adverse effectsFemaleHumansInjections, Intra-ArterialIodized Oil/*administration & dosage/adverse effectsLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedPrognosisTreatment Outcome2002May0270-9139 (Print) 0270-9139 (Linking)11981766http://www.ncbi.nlm.nih.gov/pubmed/1198176610.1053/jhep.2002.33156Llovet200212312312317Llovet, J. M.Real, M. I.Montana, X.Planas, R.Coll, S.Aponte, J.Ayuso, C.Sala, M.Muchart, J.Sola, R.Rodes, J.Bruix, J.Barcelona Liver Cancer, GroupLiver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialLancetLancetLancetLancet1734-93599319AgedAntineoplastic Agents/*administration & dosageCarcinoma, Hepatocellular/mortality/pathology/*therapyCause of DeathChemoembolization, Therapeutic/*methodsDoxorubicin/*administration & dosageFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedSurvival Analysis2002May 180140-6736 (Print) 0140-6736 (Linking)12049862http://www.ncbi.nlm.nih.gov/pubmed/1204986210.1016/S0140-6736(02)08649-XCamma200211511511517Camma, C.Schepis, F.Orlando, A.Albanese, M.Shahied, L.Trevisani, F.Andreone, P.Craxi, A.Cottone, M.National Council of Research, Istituto Metodologie Diagnostiche Avanzate, Palermo, Italy. camma@ismeda.pa.cnr.itTransarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trialsRadiologyRadiologyRadiologyRadiology47-542241Carcinoma, Hepatocellular/drug therapy/mortality/*therapy*Chemoembolization, TherapeuticHumansLiver Neoplasms/drug therapy/mortality/*therapyRandomized Controlled Trials as TopicSafetySurvival RateTreatment Outcome2002Jul0033-8419 (Print) 0033-8419 (Linking)12091661http://www.ncbi.nlm.nih.gov/pubmed/1209166110.1148/radiol.2241011262Llovet200312212212217Llovet, J. M.Bruix, J.Barcelona-Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain. jmllovet@clinic.ub.esSystematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatologyHepatologyHepatologyHepatology429-42372Carcinoma, Hepatocellular/*therapy*Chemoembolization, TherapeuticHumansLiver Neoplasms/*therapyRandomized Controlled Trials as TopicSurvival Analysis2003Feb0270-9139 (Print) 0270-9139 (Linking)12540794http://www.ncbi.nlm.nih.gov/pubmed/1254079410.1053/jhep.2003.50047wDyK  _ENREF_147wDyK  _ENREF_147 DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@ DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@wDyK  _ENREF_154 D胡鸿涛201211311311317H. U. Hong-taoL. I. Hai-liangG. U. O. Chen-yangY. A. O. Quan-junMeng Yan-liL. U. O. Jun-pengCheng Hong-taoYang HuiL. I. Wen-liang<style face="normal" font="default" size="100%">125I</style><style face="normal" font="default" charset="134" size="100%">粒子植入联合动脉化学栓塞治疗原发性肝癌合并门静脉癌栓</style>中华放射学杂志552-556466癌肝细胞门静脉化学栓塞治疗性碘20121005-1201http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfsx20120601610.3760/cma.j.issn.1005-1201.2012.06.016chi D胡鸿涛201211311311317H. U. Hong-taoL. I. Hai-liangG. U. O. Chen-yangY. A. O. Quan-junMeng Yan-liL. U. O. Jun-pengCheng Hong-taoYang HuiL. I. Wen-liang<style face="normal" font="default" size="100%">125I</style><style face="normal" font="default" charset="134" size="100%">粒子植入联合动脉化学栓塞治疗原发性肝癌合并门静脉癌栓</style>中华放射学杂志552-556466癌肝细胞门静脉化学栓塞治疗性碘20121005-1201http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfsx20120601610.3760/cma.j.issn.1005-1201.2012.06.016chiwDyK  _ENREF_156wDyK  _ENREF_147 DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@ DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@wDyK  _ENREF_154 DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@ DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@wDyK  _ENREF_154 DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@ DYang201413213213217Yang, M.Fang, Z.Yan, Z.Luo, J.Liu, L.Zhang, W.Wu, L.Ma, J.Yang, Q.Liu, Q.Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology211-91402*Blood Vessel Prosthesis ImplantationCarcinoma, Hepatocellular/complications/mortality/*therapy*Chemoembolization, TherapeuticCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine Radioisotopes/*therapeutic useLiver Neoplasms/complications/mortality/*therapyMaleMiddle AgedNeoplasm Staging*Portal VeinPrognosisProspective StudiesSurvival RateVenous Thrombosis/etiology/mortality/*therapy2014Feb1432-1335 (Electronic) 0171-5216 (Linking)24374800http://www.ncbi.nlm.nih.gov/pubmed/2437480010.1007/s00432-013-1568-0@wDyK  _ENREF_154( DJang200422202220222017Jang, J. W.Choi, J. Y.Bae, S. H.Kim, C. W.Yoon, S. K.Cho, S. H.Yang, J. M.Ahn, B. M.Lee, C. D.Lee, Y. S.Chung, K. W.Sun, H. S.Division of Hepatology, Department of Internal Medicine, College of Medicine, WHO collaborating Center on Viral Hepatitis, Catholic University of Korea, #505 Banpodong, Seocho-ku, 137-040 Seoul, South Korea.Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinomaJ HepatolJ Hepatol427-354132004/09/01AgedAntineoplastic Agents/administration & dosage/adverse effectsCarcinoma, Hepatocellular/complications/*therapyChemoembolization, Therapeutic/*adverse effectsCisplatin/administration & dosage/adverse effectsEpirubicin/administration & dosage/adverse effectsFemaleHepatitis B virus/drug effectsHepatitis B, Chronic/complications/*etiology/virologyHumansIodized Oil/administration & dosageLiver Neoplasms/complications/*therapyMaleMiddle AgedRecurrenceRetrospective StudiesVirus Activation/drug effects2004Sep0168-8278 (Print) 0168-8278 (Linking)15336446https://www.ncbi.nlm.nih.gov/pubmed/1533644610.1016/j.jhep.2004.05.014@0( DJang200422202220222017Jang, J. W.Choi, J. Y.Bae, S. H.Kim, C. W.Yoon, S. K.Cho, S. H.Yang, J. M.Ahn, B. M.Lee, C. D.Lee, Y. S.Chung, K. W.Sun, H. S.Division of Hepatology, Department of Internal Medicine, College of Medicine, WHO collaborating Center on Viral Hepatitis, Catholic University of Korea, #505 Banpodong, Seocho-ku, 137-040 Seoul, South Korea.Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinomaJ HepatolJ Hepatol427-354132004/09/01AgedAntineoplastic Agents/administration & dosage/adverse effectsCarcinoma, Hepatocellular/complications/*therapyChemoembolization, Therapeutic/*adverse effectsCisplatin/administration & dosage/adverse effectsEpirubicin/administration & dosage/adverse effectsFemaleHepatitis B virus/drug effectsHepatitis B, Chronic/complications/*etiology/virologyHumansIodized Oil/administration & dosageLiver Neoplasms/complications/*therapyMaleMiddle AgedRecurrenceRetrospective StudiesVirus Activation/drug effects2004Sep0168-8278 (Print) 0168-8278 (Linking)15336446https://www.ncbi.nlm.nih.gov/pubmed/1533644610.1016/j.jhep.2004.05.014@0wDyK  _ENREF_157Wahl201613013013017Wahl, D. R.Stenmark, M. H.Tao, Y.Pollom, E. L.Caoili, E. M.Lawrence, T. S.Schipper, M. J.Feng, M.Daniel R. Wahl, Matthew H. Stenmark, Yebin Tao, Erqi L. Pollom, Elaine M. Caoili, Theodore S. Lawrence, Matthew J. Schipper, and Mary Feng, University of Michigan Medical Center; and Matthew H. Stenmark, Veterans Affairs Medical Center, Ann Arbor, MI. Daniel R. Wahl, Matthew H. Stenmark, Yebin Tao, Erqi L. Pollom, Elaine M. Caoili, Theodore S. Lawrence, Matthew J. Schipper, and Mary Feng, University of Michigan Medical Center; and Matthew H. Stenmark, Veterans Affairs Medical Center, Ann Arbor, MI. maryfeng@med.umich.edu.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular CarcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology452-93452015/12/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*mortalityFemaleFollow-Up StudiesHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiosurgery/*mortalityRetrospective StudiesSurvival Rate2016Feb 100732-183x26628466PMC4872011 online at www.jco.org. Author contributions are found at the end of this article.10.1200/jco.2015.61.4925NLMengChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMengShen201915115115117Shen, P. C.Chang, W. C.Lo, C. H.Yang, J. F.Lee, M. S.Dai, Y. H.Lin, C. S.Fan, C. Y.Huang, W. Y.Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. School of Public Health, National Defense Medical Center, Taipei, Taiwan. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: hwyyi@yahoo.com.tw.Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular CarcinomaInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics2019/06/092019Jun 50360-30163117590310.1016/j.ijrobp.2019.05.066NLMengHara201913913913917Hara, K.Takeda, A.Tsurugai, Y.Saigusa, Y.Sanuki, N.Eriguchi, T.Maeda, S.Tanaka, K.Numata, K.Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Japan. Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score AnalysisHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)2533-25456962019/02/262019Jun0270-91393080595010.1002/hep.30591NLMengBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengSu201715315315317Su, T. S.Liang, P.Liang, J.Lu, H. Z.Jiang, H. Y.Cheng, T.Huang, Y.Tang, Y.Deng, X.Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China; Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Electronic address: sutingshi@163.com. Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China; Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Medical Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular CarcinomaInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics639-6469832017/06/06AdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*radiotherapy/*surgeryDisease-Free SurvivalFemaleFiducial Markers*Hepatectomy/adverse effects/methods/mortalityHumansKaplan-Meier EstimateLiver Cirrhosis/pathologyLiver Neoplasms/mortality/pathology/*radiotherapy/*surgeryMaleMatched-Pair AnalysisMiddle AgedNeoplasm Recurrence, Local/therapyPostoperative ComplicationsPropensity Score*Radiosurgery/adverse effects/mortalityRetrospective StudiesTime Factors2017Jul 10360-30162858140610.1016/j.ijrobp.2017.02.095NLMengKim201914314314317Kim, N.Kim, H. J.Won, J. Y.Kim, D. Y.Han, K. H.Jung, I.Seong, J.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Radiology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Biostatistics & Medical Informatics, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jsseong@yuhs.ac.Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinomaRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology81-871312019/02/19Hepatocellular carcinomaRadiofrequency ablationStereotactic body radiotherapy2019Feb0167-81403077319210.1016/j.radonc.2018.12.013NLMengRim201914814814817Rim, C. H.Kim, H. J.Seong, J.Department of Radiation Oncology, Korea University Ansan Hospital, Republic of Korea. Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, Republic of Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jsseong@yuhs.ac.Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studiesRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology135-1441312019/02/19Hepatocellular carcinomaLiver neoplasmMeta-analysisRadiation therapyStereotactic body radiotherapy2019Feb0167-81403077318010.1016/j.radonc.2018.12.005NLMeng@Wahl201613013013017Wahl, D. R.Stenmark, M. H.Tao, Y.Pollom, E. L.Caoili, E. M.Lawrence, T. S.Schipper, M. J.Feng, M.Daniel R. Wahl, Matthew H. Stenmark, Yebin Tao, Erqi L. Pollom, Elaine M. Caoili, Theodore S. Lawrence, Matthew J. Schipper, and Mary Feng, University of Michigan Medical Center; and Matthew H. Stenmark, Veterans Affairs Medical Center, Ann Arbor, MI. Daniel R. Wahl, Matthew H. Stenmark, Yebin Tao, Erqi L. Pollom, Elaine M. Caoili, Theodore S. Lawrence, Matthew J. Schipper, and Mary Feng, University of Michigan Medical Center; and Matthew H. Stenmark, Veterans Affairs Medical Center, Ann Arbor, MI. maryfeng@med.umich.edu.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular CarcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology452-93452015/12/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*surgeryCatheter Ablation/*mortalityFemaleFollow-Up StudiesHumansLiver Neoplasms/mortality/pathology/*surgeryMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiosurgery/*mortalityRetrospective StudiesSurvival Rate2016Feb 100732-183x26628466PMC4872011 online at www.jco.org. Author contributions are found at the end of this article.10.1200/jco.2015.61.4925NLMengChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMengShen201915115115117Shen, P. C.Chang, W. C.Lo, C. H.Yang, J. F.Lee, M. S.Dai, Y. H.Lin, C. S.Fan, C. Y.Huang, W. Y.Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. School of Public Health, National Defense Medical Center, Taipei, Taiwan. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: hwyyi@yahoo.com.tw.Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular CarcinomaInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics2019/06/092019Jun 50360-30163117590310.1016/j.ijrobp.2019.05.066NLMengHara201913913913917Hara, K.Takeda, A.Tsurugai, Y.Saigusa, Y.Sanuki, N.Eriguchi, T.Maeda, S.Tanaka, K.Numata, K.Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Japan. Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score AnalysisHepatologyHepatology (Baltimore, Md.)HepatologyHepatologyHepatology (Baltimore, Md.)2533-25456962019/02/262019Jun0270-91393080595010.1002/hep.30591NLMengBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengSu201715315315317Su, T. S.Liang, P.Liang, J.Lu, H. Z.Jiang, H. Y.Cheng, T.Huang, Y.Tang, Y.Deng, X.Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China; Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Electronic address: sutingshi@163.com. Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China; Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Medical Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular CarcinomaInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics639-6469832017/06/06AdultAgedAged, 80 and overCarcinoma, Hepatocellular/mortality/pathology/*radiotherapy/*surgeryDisease-Free SurvivalFemaleFiducial Markers*Hepatectomy/adverse effects/methods/mortalityHumansKaplan-Meier EstimateLiver Cirrhosis/pathologyLiver Neoplasms/mortality/pathology/*radiotherapy/*surgeryMaleMatched-Pair AnalysisMiddle AgedNeoplasm Recurrence, Local/therapyPostoperative ComplicationsPropensity Score*Radiosurgery/adverse effects/mortalityRetrospective StudiesTime Factors2017Jul 10360-30162858140610.1016/j.ijrobp.2017.02.095NLMengKim201914314314317Kim, N.Kim, H. J.Won, J. Y.Kim, D. Y.Han, K. H.Jung, I.Seong, J.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Radiology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Biostatistics & Medical Informatics, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jsseong@yuhs.ac.Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinomaRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology81-871312019/02/19Hepatocellular carcinomaRadiofrequency ablationStereotactic body radiotherapy2019Feb0167-81403077319210.1016/j.radonc.2018.12.013NLMengRim201914814814817Rim, C. H.Kim, H. J.Seong, J.Department of Radiation Oncology, Korea University Ansan Hospital, Republic of Korea. Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, Republic of Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jsseong@yuhs.ac.Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studiesRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology135-1441312019/02/19Hepatocellular carcinomaLiver neoplasmMeta-analysisRadiation therapyStereotactic body radiotherapy2019Feb0167-81403077318010.1016/j.radonc.2018.12.005NLMeng@wDyK  _ENREF_158`DChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMengOhri201614614614617Ohri, N.Dawson, L. A.Krishnan, S.Seong, J.Cheng, J. C.Sarin, S. K.Kinkhabwala, M.Ahmed, M. M.Vikram, B.Coleman, C. N.Guha, C.Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD. Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD. cguhamd@gmail.com.Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future StudyJ Natl Cancer InstJournal of the National Cancer InstituteJ Natl Cancer InstJournal of the National Cancer InstituteJ Natl Cancer InstJournal of the National Cancer Institute10892016/07/06Biomarkers, TumorCarcinoma, Hepatocellular/*radiotherapy/therapyCombined Modality TherapyHumansImmunotherapyLiver Neoplasms/*radiotherapy/therapyLiver TransplantationRadiation-Sensitizing Agents/*therapeutic useRadiosurgery2016Sep0027-887427377923PMC627929610.1093/jnci/djw133NLMengHuo201514114114117Huo, Y. R.Eslick, G. D.The Whiteley-Martin Research Centre, Discipline of Surgery, The University of Sydney, Sydney, Australia.Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysisJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology756-65162015/07/17Carcinoma, Hepatocellular/mortality/pathology/*therapy*Chemoembolization, Therapeutic/adverse effects/mortality*Chemoradiotherapy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*therapyOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2015Sep2374-24372618220010.1001/jamaoncol.2015.2189NLMengZeng200415715715717Zeng, Z. C.Tang, Z. Y.Fan, J.Zhou, J.Qin, L. X.Ye, S. L.Sun, H. C.Wang, B. L.Yu, Y.Wang, J. H.Guo, W.Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. zcheng@zshospital.netA comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinomaCancer JCancer journalCancer JCancer journalCancer JCancer journal307-16105AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarcinoma, Hepatocellular/mortality/radiography/*therapyChemoembolization, Therapeutic/adverse effects/*methodsCisplatin/administration & dosage/adverse effectsContrast Media/administration & dosage/adverse effectsFemaleFluorouracil/administration & dosage/adverse effectsHumansIodized Oil/administration & dosage/adverse effectsLiver Failure/epidemiologyLiver Neoplasms/mortality/radiography/*therapyMaleMiddle AgedMitomycin/administration & dosage/adverse effectsMultivariate AnalysisRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisTreatment Outcomealpha-Fetoproteins/analysisgamma-Glutamyltransferase/blood2004Sep-Oct1528-9117 (Print) 1528-9117 (Linking)15530260http://www.ncbi.nlm.nih.gov/pubmed/15530260Meng200914514514517Meng, M. B.Cui, Y. L.Lu, Y.She, B.Chen, Y.Guan, Y. S.Zhang, R. M.Division of Thoracic Cancer, West China Hospital, West China School of Medicine, Sichuan University, #37 Guoxue Lane, Chengdu, China.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysisRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology184-94922Alanine Transaminase/bloodBilirubin/bloodCarcinoma, Hepatocellular/mortality/*therapy*Chemoembolization, Therapeutic/adverse effectsCombined Modality TherapyHumansLiver Neoplasms/mortality/*therapyPublication Bias2009Aug1879-0887 (Electronic) 0167-8140 (Linking)19042048http://www.ncbi.nlm.nih.gov/pubmed/1904204810.1016/j.radonc.2008.11.002Yoon201815515515517Yoon, S. M.Ryoo, B. Y.Lee, S. J.Kim, J. H.Shin, J. H.An, J. H.Lee, H. C.Lim, Y. S.Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical TrialJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology661-669452018/03/162018May 12374-243729543938PMC588524610.1001/jamaoncol.2017.5847NLMengYoon201815515515517Yoon, S. M.Ryoo, B. Y.Lee, S. J.Kim, J. H.Shin, J. H.An, J. H.Lee, H. C.Lim, Y. S.Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical TrialJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology661-669452018/03/162018May 12374-243729543938PMC588524610.1001/jamaoncol.2017.5847NLMengShen201815015015017Shen, L.Xi, M.Zhao, L.Zhang, X.Wang, X.Huang, Z.Chen, Q.Zhang, T.Shen, J.Liu, M.Huang, J.Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. shenlj@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. shenlj@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. ximian@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. ximian@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhaolei@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhaolei@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhangxuh@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhangxuh@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. wangxiuch@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. wangxiuch@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. huangzhm@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. huangzhm@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. chenqf25@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. chenqf25@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhangtq@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhangtq@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. shenjx@sysucc.org.cn. Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. shenjx@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. liumzh@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. liumzh@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. huangjh@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. huangjh@sysucc.org.cn.Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus SorafenibCancers (Basel)CancersCancers (Basel)CancersCancers (Basel)Cancers10122018/12/19hepatocellular carcinomamacrovascular invasionsorafenibstereotactic body radiotherapytransarterial chemoembolization2018Dec 142072-6694 (Print) 2072-669430558224PMC631555710.3390/cancers10120516NLMengZeng200515615615617Zeng, Z. C.Fan, J.Tang, Z. Y.Zhou, J.Qin, L. X.Wang, J. H.Sun, H. C.Wang, B. L.Zhang, J. Y.Jiang, G. L.Wang, Y. Q.Radiation Oncology, Fudan University, Zhongshan Hospital, Shanghai 200032, China. zczeng@zshospital.netA comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombusInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics432-43612AdolescentAdultAgedAntineoplastic Combined Chemotherapy Protocols/administration & dosageCarcinoma, Hepatocellular/pathology/radiotherapy/surgery/*therapyChemoembolization, Therapeutic/*methodsChildFemaleHumansLiver Neoplasms/pathology/radiotherapy/surgery/*therapyMaleMiddle Aged*Portal VeinRegression AnalysisRetrospective StudiesStatistics as TopicTreatment Failure*Vena Cava, InferiorVenous Thrombosis/etiology/mortality/*radiotherapy2005Feb 10360-3016 (Print) 0360-3016 (Linking)15667964http://www.ncbi.nlm.nih.gov/pubmed/1566796410.1016/j.ijrobp.2004.05.025@0`DChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMengOhri201614614614617Ohri, N.Dawson, L. A.Krishnan, S.Seong, J.Cheng, J. C.Sarin, S. K.Kinkhabwala, M.Ahmed, M. M.Vikram, B.Coleman, C. N.Guha, C.Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD. Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD. cguhamd@gmail.com.Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future StudyJ Natl Cancer InstJournal of the National Cancer InstituteJ Natl Cancer InstJournal of the National Cancer InstituteJ Natl Cancer InstJournal of the National Cancer Institute10892016/07/06Biomarkers, TumorCarcinoma, Hepatocellular/*radiotherapy/therapyCombined Modality TherapyHumansImmunotherapyLiver Neoplasms/*radiotherapy/therapyLiver TransplantationRadiation-Sensitizing Agents/*therapeutic useRadiosurgery2016Sep0027-887427377923PMC627929610.1093/jnci/djw133NLMengHuo201514114114117Huo, Y. R.Eslick, G. D.The Whiteley-Martin Research Centre, Discipline of Surgery, The University of Sydney, Sydney, Australia.Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysisJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology756-65162015/07/17Carcinoma, Hepatocellular/mortality/pathology/*therapy*Chemoembolization, Therapeutic/adverse effects/mortality*Chemoradiotherapy/adverse effects/mortalityHumansLiver Neoplasms/mortality/pathology/*therapyOdds RatioRisk AssessmentRisk FactorsSurvival AnalysisTime FactorsTreatment Outcome2015Sep2374-24372618220010.1001/jamaoncol.2015.2189NLMengZeng200415715715717Zeng, Z. C.Tang, Z. Y.Fan, J.Zhou, J.Qin, L. X.Ye, S. L.Sun, H. C.Wang, B. L.Yu, Y.Wang, J. H.Guo, W.Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. zcheng@zshospital.netA comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinomaCancer JCancer journalCancer JCancer journalCancer JCancer journal307-16105AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarcinoma, Hepatocellular/mortality/radiography/*therapyChemoembolization, Therapeutic/adverse effects/*methodsCisplatin/administration & dosage/adverse effectsContrast Media/administration & dosage/adverse effectsFemaleFluorouracil/administration & dosage/adverse effectsHumansIodized Oil/administration & dosage/adverse effectsLiver Failure/epidemiologyLiver Neoplasms/mortality/radiography/*therapyMaleMiddle AgedMitomycin/administration & dosage/adverse effectsMultivariate AnalysisRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisTreatment Outcomealpha-Fetoproteins/analysisgamma-Glutamyltransferase/blood2004Sep-Oct1528-9117 (Print) 1528-9117 (Linking)15530260http://www.ncbi.nlm.nih.gov/pubmed/15530260Meng200914514514517Meng, M. B.Cui, Y. L.Lu, Y.She, B.Chen, Y.Guan, Y. S.Zhang, R. M.Division of Thoracic Cancer, West China Hospital, West China School of Medicine, Sichuan University, #37 Guoxue Lane, Chengdu, China.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysisRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology184-94922Alanine Transaminase/bloodBilirubin/bloodCarcinoma, Hepatocellular/mortality/*therapy*Chemoembolization, Therapeutic/adverse effectsCombined Modality TherapyHumansLiver Neoplasms/mortality/*therapyPublication Bias2009Aug1879-0887 (Electronic) 0167-8140 (Linking)19042048http://www.ncbi.nlm.nih.gov/pubmed/1904204810.1016/j.radonc.2008.11.002Yoon201815515515517Yoon, S. M.Ryoo, B. Y.Lee, S. J.Kim, J. H.Shin, J. H.An, J. H.Lee, H. C.Lim, Y. S.Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical TrialJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology661-669452018/03/162018May 12374-243729543938PMC588524610.1001/jamaoncol.2017.5847NLMengYoon201815515515517Yoon, S. M.Ryoo, B. Y.Lee, S. J.Kim, J. H.Shin, J. H.An, J. H.Lee, H. C.Lim, Y. S.Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical TrialJAMA OncolJAMA oncologyJAMA OncolJAMA OncolJAMA oncology661-669452018/03/162018May 12374-243729543938PMC588524610.1001/jamaoncol.2017.5847NLMengShen201815015015017Shen, L.Xi, M.Zhao, L.Zhang, X.Wang, X.Huang, Z.Chen, Q.Zhang, T.Shen, J.Liu, M.Huang, J.Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. shenlj@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. shenlj@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. ximian@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. ximian@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhaolei@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhaolei@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhangxuh@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhangxuh@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. wangxiuch@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. wangxiuch@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. huangzhm@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. huangzhm@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. chenqf25@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. chenqf25@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. zhangtq@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. zhangtq@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. shenjx@sysucc.org.cn. Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. shenjx@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. liumzh@sysucc.org.cn. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. liumzh@sysucc.org.cn. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. huangjh@sysucc.org.cn. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China. huangjh@sysucc.org.cn.Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus SorafenibCancers (Basel)CancersCancers (Basel)CancersCancers (Basel)Cancers10122018/12/19hepatocellular carcinomamacrovascular invasionsorafenibstereotactic body radiotherapytransarterial chemoembolization2018Dec 142072-6694 (Print) 2072-669430558224PMC631555710.3390/cancers10120516NLMengZeng200515615615617Zeng, Z. C.Fan, J.Tang, Z. Y.Zhou, J.Qin, L. X.Wang, J. H.Sun, H. C.Wang, B. L.Zhang, J. Y.Jiang, G. L.Wang, Y. Q.Radiation Oncology, Fudan University, Zhongshan Hospital, Shanghai 200032, China. zczeng@zshospital.netA comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombusInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics432-43612AdolescentAdultAgedAntineoplastic Combined Chemotherapy Protocols/administration & dosageCarcinoma, Hepatocellular/pathology/radiotherapy/surgery/*therapyChemoembolization, Therapeutic/*methodsChildFemaleHumansLiver Neoplasms/pathology/radiotherapy/surgery/*therapyMaleMiddle Aged*Portal VeinRegression AnalysisRetrospective StudiesStatistics as TopicTreatment Failure*Vena Cava, InferiorVenous Thrombosis/etiology/mortality/*radiotherapy2005Feb 10360-3016 (Print) 0360-3016 (Linking)15667964http://www.ncbi.nlm.nih.gov/pubmed/1566796410.1016/j.ijrobp.2004.05.025@0wDyK  _ENREF_159wDyK  _ENREF_166.D中华医学会放射肿瘤学分会201623002300230017中华医学会放射肿瘤学分会中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会中国研究型医院学会放射肿瘤学分会肝癌学组2016年原发性肝癌放疗共识中华放射肿瘤学杂志中华放射肿瘤学杂志1141-11502511肝肿瘤/放射疗法肝肿瘤原发性共识20161004-4221http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfszl20161100110.3760/cma.j.issn.1004-4221.2016.11.001北京万方数据股份有限公司chiJihye201221742174217417Jihye, C.Jinsil, S.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Republic of Korea.Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular CarcinomaLiver CancerLiver Cancer216-2513-42013/10/26Hepatocellular carcinomaRadiotherapyTreatment guidelines2012Nov2235-1795 (Print) 1664-5553 (Linking)24159586https://www.ncbi.nlm.nih.gov/pubmed/24159586PMC376045610.1159/000343836engSoliman201315215215217Soliman, H.Ringash, J.Jiang, H.Singh, K.Kim, J.Dinniwell, R.Brade, A.Wong, R.Brierley, J.Cummings, B.Zimmermann, C.Dawson, L. A.Hany Soliman, Odette Sunnybrook Cancer Centre, University of Toronto; Jolie Ringash, Haiyan Jiang, John Kim, Robert Dinniwell, Anthony Brade, Rebecca Wong, James Brierley, Bernard Cummings, Camilla Zimmermann, and Laura A. Dawson, Princess Margaret Cancer Centre, University of Toronto; and Jolie Ringash and Kawalpreet Singh, University of Toronto, Toronto, Ontario, Canada.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastasesJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3980-631312013/09/26AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*radiotherapyFemaleHumansLiver Neoplasms/*radiotherapy/secondaryMaleMiddle AgedPalliative Care/*methodsQuality of LifeRadiotherapy/adverse effects/*methodsTreatment Outcome2013Nov 10732-183x2406239410.1200/jco.2013.49.9202NLMeng.D中华医学会放射肿瘤学分会201623002300230017中华医学会放射肿瘤学分会中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会中国研究型医院学会放射肿瘤学分会肝癌学组2016年原发性肝癌放疗共识中华放射肿瘤学杂志中华放射肿瘤学杂志1141-11502511肝肿瘤/放射疗法肝肿瘤原发性共识20161004-4221http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfszl20161100110.3760/cma.j.issn.1004-4221.2016.11.001北京万方数据股份有限公司chiJihye201221742174217417Jihye, C.Jinsil, S.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Republic of Korea.Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular CarcinomaLiver CancerLiver Cancer216-2513-42013/10/26Hepatocellular carcinomaRadiotherapyTreatment guidelines2012Nov2235-1795 (Print) 1664-5553 (Linking)24159586https://www.ncbi.nlm.nih.gov/pubmed/24159586PMC376045610.1159/000343836engSoliman201315215215217Soliman, H.Ringash, J.Jiang, H.Singh, K.Kim, J.Dinniwell, R.Brade, A.Wong, R.Brierley, J.Cummings, B.Zimmermann, C.Dawson, L. A.Hany Soliman, Odette Sunnybrook Cancer Centre, University of Toronto; Jolie Ringash, Haiyan Jiang, John Kim, Robert Dinniwell, Anthony Brade, Rebecca Wong, James Brierley, Bernard Cummings, Camilla Zimmermann, and Laura A. Dawson, Princess Margaret Cancer Centre, University of Toronto; and Jolie Ringash and Kawalpreet Singh, University of Toronto, Toronto, Ontario, Canada.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastasesJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3980-631312013/09/26AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*radiotherapyFemaleHumansLiver Neoplasms/*radiotherapy/secondaryMaleMiddle AgedPalliative Care/*methodsQuality of LifeRadiotherapy/adverse effects/*methodsTreatment Outcome2013Nov 10732-183x2406239410.1200/jco.2013.49.9202NLMengDWang201515415415417Wang, W. H.Wang, Z.Wu, J. X.Zhang, T.Rong, W. Q.Wang, L. M.Jin, J.Wang, S. L.Song, Y. W.Liu, Y. P.Ren, H.Fang, H.Wang, W. Q.Liu, X. F.Yu, Z. H.Li, Y. X.Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. Department of Abdominal Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vesselsLiver IntLiver international : official journal of the International Association for the Study of the LiverLiver IntLiver IntLiver international : official journal of the International Association for the Study of the Liver2603-1035122015Dec1478-3231 (Electronic) 1478-3223 (Linking)25939444http://www.ncbi.nlm.nih.gov/pubmed/2593944410.1111/liv.12857Sapisochin201714914914917Sapisochin, G.Barry, A.Doherty, M.Fischer, S.Goldaracena, N.Rosales, R.Russo, M.Beecroft, R.Ghanekar, A.Bhat, M.Brierley, J.Greig, P. D.Knox, J. J.Dawson, L. A.Grant, D. R.Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Electronic address: gonzalo.sapisochin@uhn.ca. Radiation Medicine Program, Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. Department of Medical Oncology, University of Toronto, Canada. Department of Pathology, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada. Division of Interventional Radiology, University of Toronto, Canada.Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysisJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology92-996712017/03/05Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyFemaleHumans*Intention to Treat AnalysisLiver Neoplasms/mortality/*therapy*Liver TransplantationMaleMiddle Aged*Radiosurgery*Hepatocellular carcinoma*Stereotactic body radiotherapy*Transarterial chemoembolization2017Jul0168-82782825790210.1016/j.jhep.2017.02.022NLMeng中华医学会放射肿瘤学分会201623002300230017中华医学会放射肿瘤学分会中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会中国研究型医院学会放射肿瘤学分会肝癌学组2016年原发性肝癌放疗共识中华放射肿瘤学杂志中华放射肿瘤学杂志1141-11502511肝肿瘤/放射疗法肝肿瘤原发性共识20161004-4221http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfszl20161100110.3760/cma.j.issn.1004-4221.2016.11.001北京万方数据股份有限公司chiDWang201515415415417Wang, W. H.Wang, Z.Wu, J. X.Zhang, T.Rong, W. Q.Wang, L. M.Jin, J.Wang, S. L.Song, Y. W.Liu, Y. P.Ren, H.Fang, H.Wang, W. Q.Liu, X. F.Yu, Z. H.Li, Y. X.Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. Department of Abdominal Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vesselsLiver IntLiver international : official journal of the International Association for the Study of the LiverLiver IntLiver IntLiver international : official journal of the International Association for the Study of the Liver2603-1035122015Dec1478-3231 (Electronic) 1478-3223 (Linking)25939444http://www.ncbi.nlm.nih.gov/pubmed/2593944410.1111/liv.12857Sapisochin201714914914917Sapisochin, G.Barry, A.Doherty, M.Fischer, S.Goldaracena, N.Rosales, R.Russo, M.Beecroft, R.Ghanekar, A.Bhat, M.Brierley, J.Greig, P. D.Knox, J. J.Dawson, L. A.Grant, D. R.Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Electronic address: gonzalo.sapisochin@uhn.ca. Radiation Medicine Program, Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. Department of Medical Oncology, University of Toronto, Canada. Department of Pathology, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada. Division of Interventional Radiology, University of Toronto, Canada.Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysisJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology92-996712017/03/05Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyFemaleHumans*Intention to Treat AnalysisLiver Neoplasms/mortality/*therapy*Liver TransplantationMaleMiddle Aged*Radiosurgery*Hepatocellular carcinoma*Stereotactic body radiotherapy*Transarterial chemoembolization2017Jul0168-82782825790210.1016/j.jhep.2017.02.022NLMeng中华医学会放射肿瘤学分会201623002300230017中华医学会放射肿瘤学分会中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会中国研究型医院学会放射肿瘤学分会肝癌学组2016年原发性肝癌放疗共识中华放射肿瘤学杂志中华放射肿瘤学杂志1141-11502511肝肿瘤/放射疗法肝肿瘤原发性共识20161004-4221http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfszl20161100110.3760/cma.j.issn.1004-4221.2016.11.001北京万方数据股份有限公司chiwDyK  _ENREF_176wDyK  _ENREF_177JDWang201515415415417Wang, W. H.Wang, Z.Wu, J. X.Zhang, T.Rong, W. Q.Wang, L. M.Jin, J.Wang, S. L.Song, Y. W.Liu, Y. P.Ren, H.Fang, H.Wang, W. Q.Liu, X. F.Yu, Z. H.Li, Y. X.Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. Department of Abdominal Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vesselsLiver IntLiver international : official journal of the International Association for the Study of the LiverLiver IntLiver IntLiver international : official journal of the International Association for the Study of the Liver2603-1035122015Dec1478-3231 (Electronic) 1478-3223 (Linking)25939444http://www.ncbi.nlm.nih.gov/pubmed/2593944410.1111/liv.12857Sapisochin201714914914917Sapisochin, G.Barry, A.Doherty, M.Fischer, S.Goldaracena, N.Rosales, R.Russo, M.Beecroft, R.Ghanekar, A.Bhat, M.Brierley, J.Greig, P. D.Knox, J. J.Dawson, L. A.Grant, D. R.Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Electronic address: gonzalo.sapisochin@uhn.ca. Radiation Medicine Program, Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. Department of Medical Oncology, University of Toronto, Canada. Department of Pathology, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada. Division of Interventional Radiology, University of Toronto, Canada.Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysisJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology92-996712017/03/05Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyFemaleHumans*Intention to Treat AnalysisLiver Neoplasms/mortality/*therapy*Liver TransplantationMaleMiddle Aged*Radiosurgery*Hepatocellular carcinoma*Stereotactic body radiotherapy*Transarterial chemoembolization2017Jul0168-82782825790210.1016/j.jhep.2017.02.022NLMengJDWang201515415415417Wang, W. H.Wang, Z.Wu, J. X.Zhang, T.Rong, W. Q.Wang, L. M.Jin, J.Wang, S. L.Song, Y. W.Liu, Y. P.Ren, H.Fang, H.Wang, W. Q.Liu, X. F.Yu, Z. H.Li, Y. X.Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. Department of Abdominal Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vesselsLiver IntLiver international : official journal of the International Association for the Study of the LiverLiver IntLiver IntLiver international : official journal of the International Association for the Study of the Liver2603-1035122015Dec1478-3231 (Electronic) 1478-3223 (Linking)25939444http://www.ncbi.nlm.nih.gov/pubmed/2593944410.1111/liv.12857Sapisochin201714914914917Sapisochin, G.Barry, A.Doherty, M.Fischer, S.Goldaracena, N.Rosales, R.Russo, M.Beecroft, R.Ghanekar, A.Bhat, M.Brierley, J.Greig, P. D.Knox, J. J.Dawson, L. A.Grant, D. R.Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Electronic address: gonzalo.sapisochin@uhn.ca. Radiation Medicine Program, Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. Department of Medical Oncology, University of Toronto, Canada. Department of Pathology, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada; Department of General Surgery, University of Toronto, Canada. Multi-Organ Transplant, Toronto General Surgery, Canada. Division of Interventional Radiology, University of Toronto, Canada.Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysisJ HepatolJournal of hepatologyJ HepatolJournal of hepatologyJ HepatolJournal of hepatology92-996712017/03/05Carcinoma, Hepatocellular/mortality/*therapy*Catheter Ablation*Chemoembolization, TherapeuticCombined Modality TherapyFemaleHumans*Intention to Treat AnalysisLiver Neoplasms/mortality/*therapy*Liver TransplantationMaleMiddle Aged*Radiosurgery*Hepatocellular carcinoma*Stereotactic body radiotherapy*Transarterial chemoembolization2017Jul0168-82782825790210.1016/j.jhep.2017.02.022NLMengwDyK  _ENREF_176wDyK  _ENREF_177TDBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengByun201913613613617Byun, H. K.Kim, H. J.Im, Y. R.Kim, D. Y.Han, K. H.Seong, J.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, South Korea. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: jsseong@yuhs.ac.Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinomaRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology1-81332019/04/03Hepatic arterial infusion chemotherapyHepatocellular carcinomaIntensity modulated radiotherapyRadiation dose-response relationship2019Apr0167-81403093556310.1016/j.radonc.2018.12.025NLMengTDBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengByun201913613613617Byun, H. K.Kim, H. J.Im, Y. R.Kim, D. Y.Han, K. H.Seong, J.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, South Korea. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: jsseong@yuhs.ac.Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinomaRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRadiother OncolRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology1-81332019/04/03Hepatic arterial infusion chemotherapyHepatocellular carcinomaIntensity modulated radiotherapyRadiation dose-response relationship2019Apr0167-81403093556310.1016/j.radonc.2018.12.025NLMengwDyK  _ENREF_162wDyK  _ENREF_178 DWei201969696917Wei, X.Jiang, Y.Zhang, X.Feng, S.Zhou, B.Ye, X.Xing, H.Xu, Y.Shi, J.Guo, W.Zhou, D.Zhang, H.Sun, H.Huang, C.Lu, C.Zheng, Y.Meng, Y.Huang, B.Cong, W.Lau, W. Y.Cheng, S.1 Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, People's Republic of China. 2 Department of Health Statistics, Navy Military Medical University, Shanghai, People's Republic of China. 3 Fujian Provincial Cancer Hospital, Fuzhou, People's Republic of China. 4 Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 5 The Chinese University of Hong Kong, Sha Tin, People's Republic of China.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled StudyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJco18021842019/07/102019Jul 80732-183x3128340910.1200/jco.18.02184NLMeng DWei201969696917Wei, X.Jiang, Y.Zhang, X.Feng, S.Zhou, B.Ye, X.Xing, H.Xu, Y.Shi, J.Guo, W.Zhou, D.Zhang, H.Sun, H.Huang, C.Lu, C.Zheng, Y.Meng, Y.Huang, B.Cong, W.Lau, W. Y.Cheng, S.1 Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, People's Republic of China. 2 Department of Health Statistics, Navy Military Medical University, Shanghai, People's Republic of China. 3 Fujian Provincial Cancer Hospital, Fuzhou, People's Republic of China. 4 Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 5 The Chinese University of Hong Kong, Sha Tin, People's Republic of China.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled StudyJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJco18021842019/07/102019Jul 80732-183x3128340910.1200/jco.18.02184NLMenguDyK  _ENREF_778 DBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengp8 DBujold201313513513517Bujold, A.Massey, C. A.Kim, J. J.Brierley, J.Cho, C.Wong, R. K.Dinniwell, R. E.Kassam, Z.Ringash, J.Cummings, B.Sykes, J.Sherman, M.Knox, J. J.Dawson, L. A.Princess Margaret Hospital, University Health Network, University of Toronto, Canada. abujold.hmr@ssss.gouv.qc.caSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1631-931132013/04/03AdultAgedAged, 80 and overCarcinoma, Hepatocellular/diagnosis/*surgeryFemaleHumansLiver Neoplasms/diagnosis/*surgeryMaleMiddle AgedProspective StudiesRadiosurgery/methods2013May 10732-183x2354707510.1200/jco.2012.44.1659NLMengpwDyK  _ENREF_162wDyK  _ENREF_180DChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMeng@DChino201813813813817Chino, F.Stephens, S. J.Choi, S. S.Marin, D.Kim, C. Y.Morse, M. A.Godfrey, D. J.Czito, B. G.Willett, C. G.Palta, M.Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Gastroenterology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Duke University Medical Center, Durham, North Carolina. Department of Radiology, Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Department of Medicine, Medical Oncology, Duke University Medical Center, Durham, North Carolina.The role of external beam radiotherapy in the treatment of hepatocellular cancerCancerCancerCancerCancerCancerCancer3476-3489124172018/04/13hepatocellular carcinomaimage-guided radiotherapyradioembolizationradiotherapystereotactic body radiotherapy2018Sep 10008-543x2964507610.1002/cncr.31334NLMeng@wDyK  _ENREF_159HDJihye201221742174217417Jihye, C.Jinsil, S.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Republic of Korea.Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular CarcinomaLiver CancerLiver Cancer216-2513-42013/10/26Hepatocellular carcinomaRadiotherapyTreatment guidelines2012Nov2235-1795 (Print) 1664-5553 (Linking)24159586https://www.ncbi.nlm.nih.gov/pubmed/24159586PMC376045610.1159/000343836engCheung201322222217Cheung, T. T.Ho, C. L.Lo, C. M.Chen, S.Chan, S. C.Chok, K. S.Fung, J. Y.Yan Chan, A. C.Sharr, W.Yau, T.Poon, R. T.Fan, S. T.Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. tantocheung@hotmail.com11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspectiveJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine192-200542AdultAged*Carbon RadioisotopesCarcinoma, Hepatocellular/*surgery/therapyContrast MediaDiagnostic Imaging/methodsFemale*Fluorodeoxyglucose F18HumansLiver Neoplasms/*surgery/therapyLiver Transplantation/*methodsMaleMedical Oncology/methodsMiddle AgedNeoplasm Staging/*methodsNuclear Medicine/methodsPositron-Emission Tomography/*methodsReproducibility of ResultsSensitivity and SpecificityTomography, X-Ray Computed/*methods2013Feb1535-5667 (Electronic) 0161-5505 (Linking)23321459http://www.ncbi.nlm.nih.gov/pubmed/2332145910.2967/jnumed.112.107516Soliman201315215215217Soliman, H.Ringash, J.Jiang, H.Singh, K.Kim, J.Dinniwell, R.Brade, A.Wong, R.Brierley, J.Cummings, B.Zimmermann, C.Dawson, L. A.Hany Soliman, Odette Sunnybrook Cancer Centre, University of Toronto; Jolie Ringash, Haiyan Jiang, John Kim, Robert Dinniwell, Anthony Brade, Rebecca Wong, James Brierley, Bernard Cummings, Camilla Zimmermann, and Laura A. Dawson, Princess Margaret Cancer Centre, University of Toronto; and Jolie Ringash and Kawalpreet Singh, University of Toronto, Toronto, Ontario, Canada.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastasesJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3980-631312013/09/26AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*radiotherapyFemaleHumansLiver Neoplasms/*radiotherapy/secondaryMaleMiddle AgedPalliative Care/*methodsQuality of LifeRadiotherapy/adverse effects/*methodsTreatment Outcome2013Nov 10732-183x2406239410.1200/jco.2013.49.9202NLMengHDJihye201221742174217417Jihye, C.Jinsil, S.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Republic of Korea.Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular CarcinomaLiver CancerLiver Cancer216-2513-42013/10/26Hepatocellular carcinomaRadiotherapyTreatment guidelines2012Nov2235-1795 (Print) 1664-5553 (Linking)24159586https://www.ncbi.nlm.nih.gov/pubmed/24159586PMC376045610.1159/000343836engCheung201322222217Cheung, T. T.Ho, C. L.Lo, C. M.Chen, S.Chan, S. C.Chok, K. S.Fung, J. Y.Yan Chan, A. C.Sharr, W.Yau, T.Poon, R. T.Fan, S. T.Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. tantocheung@hotmail.com11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspectiveJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear MedicineJ Nucl MedJournal of nuclear medicine : official publication, Society of Nuclear Medicine192-200542AdultAged*Carbon RadioisotopesCarcinoma, Hepatocellular/*surgery/therapyContrast MediaDiagnostic Imaging/methodsFemale*Fluorodeoxyglucose F18HumansLiver Neoplasms/*surgery/therapyLiver Transplantation/*methodsMaleMedical Oncology/methodsMiddle AgedNeoplasm Staging/*methodsNuclear Medicine/methodsPositron-Emission Tomography/*methodsReproducibility of ResultsSensitivity and SpecificityTomography, X-Ray Computed/*methods2013Feb1535-5667 (Electronic) 0161-5505 (Linking)23321459http://www.ncbi.nlm.nih.gov/pubmed/2332145910.2967/jnumed.112.107516Soliman201315215215217Soliman, H.Ringash, J.Jiang, H.Singh, K.Kim, J.Dinniwell, R.Brade, A.Wong, R.Brierley, J.Cummings, B.Zimmermann, C.Dawson, L. A.Hany Soliman, Odette Sunnybrook Cancer Centre, University of Toronto; Jolie Ringash, Haiyan Jiang, John Kim, Robert Dinniwell, Anthony Brade, Rebecca Wong, James Brierley, Bernard Cummings, Camilla Zimmermann, and Laura A. Dawson, Princess Margaret Cancer Centre, University of Toronto; and Jolie Ringash and Kawalpreet Singh, University of Toronto, Toronto, Ontario, Canada.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastasesJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3980-631312013/09/26AdultAgedAged, 80 and overCarcinoma, Hepatocellular/*radiotherapyFemaleHumansLiver Neoplasms/*radiotherapy/secondaryMaleMiddle AgedPalliative Care/*methodsQuality of LifeRadiotherapy/adverse effects/*methodsTreatment Outcome2013Nov 10732-183x2406239410.1200/jco.2013.49.9202NLMenguDyK  _ENREF_36wDyK  _ENREF_174wDyK  _ENREF_175DLlovet200814414414417Llovet, J. M.Ricci, S.Mazzaferro, V.Hilgard, P.Gane, E.Blanc, J. F.de Oliveira, A. C.Santoro, A.Raoul, J. L.Forner, A.Schwartz, M.Porta, C.Zeuzem, S.Bolondi, L.Greten, T. F.Galle, P. R.Seitz, J. F.Borbath, I.Haussinger, D.Giannaris, T.Shan, M.Moscovici, M.Voliotis, D.Bruix, J.Sharp Investigators Study GroupBarcelona Clinic Liver Cancer Group, Institut d'Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepaticas y Digestivas Hospital Clinic Barcelona, Barcelona. jmllovet@clinic.ub.esSorafenib in advanced hepatocellular carcinomaN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicine378-903594AgedBenzenesulfonates/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortality/surgeryChemotherapy, AdjuvantDisease ProgressionDouble-Blind MethodFemaleHumansLiver Neoplasms/*drug therapy/mortality/surgeryMaleMiddle AgedNeoplasm StagingNiacinamide/analogs & derivativesPhenylurea CompoundsProportional Hazards ModelsProtein Kinase Inhibitors/adverse effects/*therapeutic usePyridines/adverse effects/*therapeutic useSurvival Analysisraf Kinases/*antagonists & inhibitors2008Jul 241533-4406 (Electronic) 0028-4793 (Linking)18650514http://www.ncbi.nlm.nih.gov/pubmed/1865051410.1056/NEJMoa0708857Cheng200913713713717Cheng, A. L.Kang, Y. K.Chen, Z.Tsao, C. J.Qin, S.Kim, J. S.Luo, R.Feng, J.Ye, S.Yang, T. S.Xu, J.Sun, Y.Liang, H.Liu, J.Wang, J.Tak, W. Y.Pan, H.Burock, K.Zou, J.Voliotis, D.Guan, Z.National Taiwan University Hospital, Taipei, Taiwan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology25-341012008/12/20AdultAgedAged, 80 and overAntineoplastic Agents/*therapeutic useBenzenesulfonates/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapyCost-Benefit AnalysisDouble-Blind MethodFemaleHumansLiver Neoplasms/*drug therapyMaleMiddle AgedNiacinamide/analogs & derivativesPhenylurea CompoundsProtein Kinase Inhibitors/*therapeutic usePyridines/adverse effects/*therapeutic useSorafenib2009Jan1470-20451909549710.1016/s1470-2045(08)70285-7NLMengwDyK  _ENREF_182wDyK  _ENREF_183 DPressiani201314714714717Pressiani, T.Boni, C.Rimassa, L.Labianca, R.Fagiuoli, S.Salvagni, S.Ferrari, D.Cortesi, E.Porta, C.Mucciarini, C.Latini, L.Carnaghi, C.Banzi, M.Fanello, S.De Giorgio, M.Lutman, F. R.Torzilli, G.Tommasini, M. A.Ceriani, R.Covini, G.Tronconi, M. C.Giordano, L.Locopo, N.Naimo, S.Santoro, A.Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnn OncolAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOAnn OncolAnnals of oncology : official journal of the European Society for Medical OncologyAnn OncolAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO406-11242AgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortalityDisease-Free SurvivalFeasibility StudiesFemaleHumansLiver/metabolism/pathologyLiver Neoplasms/*drug therapy/mortalityMaleNiacinamide/adverse effects/*analogs & derivatives/therapeutic usePhenylurea Compounds/adverse effects/*therapeutic useProspective StudiesProtein Kinase Inhibitors/adverse effects/therapeutic useSeverity of Illness IndexSurvival RateTreatment Outcome2013Feb1569-8041 (Electronic) 0923-7534 (Linking)23041587http://www.ncbi.nlm.nih.gov/pubmed/2304158710.1093/annonc/mds343 DPressiani201314714714717Pressiani, T.Boni, C.Rimassa, L.Labianca, R.Fagiuoli, S.Salvagni, S.Ferrari, D.Cortesi, E.Porta, C.Mucciarini, C.Latini, L.Carnaghi, C.Banzi, M.Fanello, S.De Giorgio, M.Lutman, F. R.Torzilli, G.Tommasini, M. A.Ceriani, R.Covini, G.Tronconi, M. C.Giordano, L.Locopo, N.Naimo, S.Santoro, A.Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnn OncolAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOAnn OncolAnnals of oncology : official journal of the European Society for Medical OncologyAnn OncolAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO406-11242AgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortalityDisease-Free SurvivalFeasibility StudiesFemaleHumansLiver/metabolism/pathologyLiver Neoplasms/*drug therapy/mortalityMaleNiacinamide/adverse effects/*analogs & derivatives/therapeutic usePhenylurea Compounds/adverse effects/*therapeutic useProspective StudiesProtein Kinase Inhibitors/adverse effects/therapeutic useSeverity of Illness IndexSurvival RateTreatment Outcome2013Feb1569-8041 (Electronic) 0923-7534 (Linking)23041587http://www.ncbi.nlm.nih.gov/pubmed/2304158710.1093/annonc/mds343wDyK  _ENREF_184DKudo201816916916917Kudo, M.Finn, R. S.Qin, S.Han, K. H.Ikeda, K.Piscaglia, F.Baron, A.Park, J. W.Han, G.Jassem, J.Blanc, J. F.Vogel, A.Komov, D.Evans, T. R. J.Lopez, C.Dutcus, C.Guo, M.Saito, K.Kraljevic, S.Tamai, T.Ren, M.Cheng, A. L.Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: m-kudo@med.kindai.ac.jp. Geffen School of Medicine at UCLA, Santa Monica, CA, USA. Nanjing Bayi Hospital, Nanjing, Jiangsu, China. Severance Hospital, Yonsei University, Seoul, South Korea. Toranomon Hospital, Tokyo, Japan. University of Bologna, Bologna, Italy. California Pacific Medical Center, San Francisco, CA, USA. National Cancer Center Korea, Goyang-si, South Korea. Xijing Hospital, Fourth Military Medical University, Xi'an, China. Medical University of Gdansk, Gdansk, Poland. University of Bordeaux, Bordeaux, France. Hannover Medical School, Hannover, Germany. N N Blokhin Cancer Research Center, Moscow, Russia. University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. Marques de Valdecilla University Hospital, Santander, Spain. Eisai, Woodcliff Lake, NJ, USA. Eisai, Hatfield, UK. National Taiwan University Hospital, Taipei, Taiwan.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialLancetLancet (London, England)LancetLancetLancet (London, England)1163-1173391101262018/02/13AgedAntineoplastic Agents/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortalityFemaleHumansLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePhenylurea Compounds/*therapeutic useQuinolines/*therapeutic useSorafenibSurvival RateTreatment Outcome2018Mar 240140-67362943385010.1016/s0140-6736(18)30207-1NLMengDKudo201816916916917Kudo, M.Finn, R. S.Qin, S.Han, K. H.Ikeda, K.Piscaglia, F.Baron, A.Park, J. W.Han, G.Jassem, J.Blanc, J. F.Vogel, A.Komov, D.Evans, T. R. J.Lopez, C.Dutcus, C.Guo, M.Saito, K.Kraljevic, S.Tamai, T.Ren, M.Cheng, A. L.Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: m-kudo@med.kindai.ac.jp. Geffen School of Medicine at UCLA, Santa Monica, CA, USA. Nanjing Bayi Hospital, Nanjing, Jiangsu, China. Severance Hospital, Yonsei University, Seoul, South Korea. Toranomon Hospital, Tokyo, Japan. University of Bologna, Bologna, Italy. California Pacific Medical Center, San Francisco, CA, USA. National Cancer Center Korea, Goyang-si, South Korea. Xijing Hospital, Fourth Military Medical University, Xi'an, China. Medical University of Gdansk, Gdansk, Poland. University of Bordeaux, Bordeaux, France. Hannover Medical School, Hannover, Germany. N N Blokhin Cancer Research Center, Moscow, Russia. University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. Marques de Valdecilla University Hospital, Santander, Spain. Eisai, Woodcliff Lake, NJ, USA. Eisai, Hatfield, UK. National Taiwan University Hospital, Taipei, Taiwan.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialLancetLancet (London, England)LancetLancetLancet (London, England)1163-1173391101262018/02/13AgedAntineoplastic Agents/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortalityFemaleHumansLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePhenylurea Compounds/*therapeutic useQuinolines/*therapeutic useSorafenibSurvival RateTreatment Outcome2018Mar 240140-67362943385010.1016/s0140-6736(18)30207-1NLMengwDyK  _ENREF_185t$DQin201317217217217Qin, S.Bai, Y.Lim, H. Y.Thongprasert, S.Chao, Y.Fan, J.Yang, T. S.Bhudhisawasdi, V.Kang, W. K.Zhou, Y.Lee, J. H.Sun, Y.Shukui Qin, People's Liberation Army Cancer Centre, Bayi Hospital, Nanjing; Yuxian Bai, Third Affiliated Hospital, Harbin Medical University, Harbin; Jia Fan, Zhongshan Hospital, Fudan University; Yu Zhou, sanofi-aventis Asia, Shanghai; Yan Sun, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China; Ho Yeong Lim and Won Ki Kang, Samsung Medical Centre; Won Ki Kang, Sungkyunkwan University School of Medicine; Jee Hyun Lee, sanofi-aventis Korea, Seoul, Korea; Sumitra Thongprasert, Chiang Mai University, Chiang Mai; Vajarabhongsa Bhudhisawasdi, Khon Kaen University, Khon Kaen, Thailand; Yee Chao, Taipei Veterans General Hospital, Taipei; and Tsai-Shen Yang, Chang Gung Memorial Hospital, LinKou Medical Center, Chang Gung University, Taoyuan, Taiwan.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from AsiaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3501-83128AdolescentAdultAgedAntineoplastic Combined Chemotherapy Protocols/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyDoxorubicin/administration & dosageFemaleFluorouracil/administration & dosageFollow-Up StudiesHumansInternational AgenciesLeucovorin/administration & dosageLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedNeoplasm StagingOrganoplatinum Compounds/administration & dosage*Palliative CarePrognosisProspective StudiesSurvival RateYoung Adult2013Oct 11527-7755 (Electronic) 0732-183X (Linking)23980077http://www.ncbi.nlm.nih.gov/pubmed/2398007710.1200/JCO.2012.44.5643Qin201417317317317Qin, S.Cheng, Y.Liang, J.Shen, L.Bai, Y.Li, J.Fan, J.Liang, L.Zhang, Y.Wu, G.Rau, K. M.Yang, T. S.Jian, Z.Liang, H.Sun, Y.People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China qinsk@csco.org.cn. People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyOncologistThe oncologistOncologistThe oncologistOncologistThe oncologist1169-7819112014/09/17AdultAntineoplastic Combined Chemotherapy Protocols/*therapeutic useAsian Continental Ancestry GroupCarcinoma, Hepatocellular/*drug therapy/mortalityDoxorubicin/*therapeutic useFemaleFluorouracil/therapeutic useHumansLeucovorin/therapeutic useLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedOrganoplatinum Compounds/therapeutic useSurvival AnalysisTreatment OutcomeFOLFOX4 regimenHepatocellular carcinomaOxaliplatinSystemic chemotherapy2014Nov1083-715925223462PMC422137010.1634/theoncologist.2014-0190NLMengt$DQin201317217217217Qin, S.Bai, Y.Lim, H. Y.Thongprasert, S.Chao, Y.Fan, J.Yang, T. S.Bhudhisawasdi, V.Kang, W. K.Zhou, Y.Lee, J. H.Sun, Y.Shukui Qin, People's Liberation Army Cancer Centre, Bayi Hospital, Nanjing; Yuxian Bai, Third Affiliated Hospital, Harbin Medical University, Harbin; Jia Fan, Zhongshan Hospital, Fudan University; Yu Zhou, sanofi-aventis Asia, Shanghai; Yan Sun, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China; Ho Yeong Lim and Won Ki Kang, Samsung Medical Centre; Won Ki Kang, Sungkyunkwan University School of Medicine; Jee Hyun Lee, sanofi-aventis Korea, Seoul, Korea; Sumitra Thongprasert, Chiang Mai University, Chiang Mai; Vajarabhongsa Bhudhisawasdi, Khon Kaen University, Khon Kaen, Thailand; Yee Chao, Taipei Veterans General Hospital, Taipei; and Tsai-Shen Yang, Chang Gung Memorial Hospital, LinKou Medical Center, Chang Gung University, Taoyuan, Taiwan.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from AsiaJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology3501-83128AdolescentAdultAgedAntineoplastic Combined Chemotherapy Protocols/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyDoxorubicin/administration & dosageFemaleFluorouracil/administration & dosageFollow-Up StudiesHumansInternational AgenciesLeucovorin/administration & dosageLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedNeoplasm StagingOrganoplatinum Compounds/administration & dosage*Palliative CarePrognosisProspective StudiesSurvival RateYoung Adult2013Oct 11527-7755 (Electronic) 0732-183X (Linking)23980077http://www.ncbi.nlm.nih.gov/pubmed/2398007710.1200/JCO.2012.44.5643Qin201417317317317Qin, S.Cheng, Y.Liang, J.Shen, L.Bai, Y.Li, J.Fan, J.Liang, L.Zhang, Y.Wu, G.Rau, K. M.Yang, T. S.Jian, Z.Liang, H.Sun, Y.People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China qinsk@csco.org.cn. People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyOncologistThe oncologistOncologistThe oncologistOncologistThe oncologist1169-7819112014/09/17AdultAntineoplastic Combined Chemotherapy Protocols/*therapeutic useAsian Continental Ancestry GroupCarcinoma, Hepatocellular/*drug therapy/mortalityDoxorubicin/*therapeutic useFemaleFluorouracil/therapeutic useHumansLeucovorin/therapeutic useLiver Neoplasms/*drug therapy/mortalityMaleMiddle AgedOrganoplatinum Compounds/therapeutic useSurvival AnalysisTreatment OutcomeFOLFOX4 regimenHepatocellular carcinomaOxaliplatinSystemic chemotherapy2014Nov1083-715925223462PMC422137010.1634/theoncologist.2014-0190NLMengwDyK  _ENREF_186wDyK  _ENREF_187b DAssenat201916416416417Assenat, E.Pageaux, G. P.Thezenas, S.Peron, J. M.Becouarn, Y.Seitz, J. F.Merle, P.Blanc, J. F.Bouche, O.Ramdani, M.Poujol, S.de Forges, H.Ychou, M.Boige, V.Institut du Cancer de Montpellier (ICM), Universite de Montpellier, Montpellier, France. eric.assenat@icm.unicancer.fr. Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Montpellier, France. eric.assenat@icm.unicancer.fr. Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Montpellier, France. Institut du Cancer de Montpellier (ICM), Universite de Montpellier, Montpellier, France. Centre Hospitalier Universitaire de Toulouse, Toulouse, France. Bergonie Institute, Bordeaux, France. Centre Hospitalier Universitaire de Marseille, Marseille, France. Centre Hospitalier Universitaire de Lyon, Lyon, France. Saint-Andre Hospital, Bordeaux, France. Centre Hospitalier Universitaire de Reims, Reims, France. Centre Hospitalier Universitaire de Beziers, Beziers, France. Gustave Roussy, Villejuif, France.Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trialBr J CancerBritish journal of cancerBr J CancerBritish journal of cancerBr J CancerBritish journal of cancer896-90212092019/04/052019Apr0007-09203094445810.1038/s41416-019-0443-4NLMengb DAssenat201916416416417Assenat, E.Pageaux, G. P.Thezenas, S.Peron, J. M.Becouarn, Y.Seitz, J. F.Merle, P.Blanc, J. F.Bouche, O.Ramdani, M.Poujol, S.de Forges, H.Ychou, M.Boige, V.Institut du Cancer de Montpellier (ICM), Universite de Montpellier, Montpellier, France. eric.assenat@icm.unicancer.fr. Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Montpellier, France. eric.assenat@icm.unicancer.fr. Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Montpellier, France. Institut du Cancer de Montpellier (ICM), Universite de Montpellier, Montpellier, France. Centre Hospitalier Universitaire de Toulouse, Toulouse, France. Bergonie Institute, Bordeaux, France. Centre Hospitalier Universitaire de Marseille, Marseille, France. Centre Hospitalier Universitaire de Lyon, Lyon, France. Saint-Andre Hospital, Bordeaux, France. Centre Hospitalier Universitaire de Reims, Reims, France. Centre Hospitalier Universitaire de Beziers, Beziers, France. Gustave Roussy, Villejuif, France.Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trialBr J CancerBritish journal of cancerBr J CancerBritish journal of cancerBr J CancerBritish journal of cancer896-90212092019/04/052019Apr0007-09203094445810.1038/s41416-019-0443-4NLMengwDyK  _ENREF_188 D屈凤莲201116116116117Q. U. Feng-lianH. A. O. Xue-zhiQ. I. N. Shu-kuiL. I. U. Ji-weiS. U. I. Guang-jieChen QiangQ. U. TaoZhang He-pingS. U. N. Yan<style face="normal" font="default" charset="134" size="100%">亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究</style>中华肿瘤杂志697-701339亚砷酸注射液肝肿瘤治疗效果药代动力学20110253-3766http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhzl20110901310.3760/cma.j.issn.0253-3766.2011.09.013chi D屈凤莲201116116116117Q. U. Feng-lianH. A. O. Xue-zhiQ. I. N. Shu-kuiL. I. U. Ji-weiS. U. I. Guang-jieChen QiangQ. U. TaoZhang He-pingS. U. N. Yan<style face="normal" font="default" charset="134" size="100%">亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究</style>中华肿瘤杂志697-701339亚砷酸注射液肝肿瘤治疗效果药代动力学20110253-3766http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhzl20110901310.3760/cma.j.issn.0253-3766.2011.09.013chiDBruix201716616616617Bruix, J.Qin, S.Merle, P.Granito, A.Huang, Y. H.Bodoky, G.Pracht, M.Yokosuka, O.Rosmorduc, O.Breder, V.Gerolami, R.Masi, G.Ross, P. J.Song, T.Bronowicki, J. P.Ollivier-Hourmand, I.Kudo, M.Cheng, A. L.Llovet, J. M.Finn, R. S.LeBerre, M. A.Baumhauer, A.Meinhardt, G.Han, G.Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain. Electronic address: jbruix@clinic.ub.es. Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China. Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France. Department of Medical and Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy. Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. St Laszlo Teaching Hospital, Budapest, Hungary. Service d'Oncologie Medicale, Centre Eugene Marquis, Rennes, France. Department of Gastroenterology and Nephrology, Chiba University, Chiba, Japan. Department of Hepatology, Hopital de la Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris and Universite Pierre et Marie Curie, Sorbonne Universites, Paris, France. Russian Cancer Research Center n.a.N.Blokhin, Moscow, Russia. CHU Timone, Universite de la Mediterranee, Marseille, France. Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. King's College Hospital NHS Foundation Trust, London, UK. Tianjin Medical University Cancer Hospital, Tianjin, China. INSERM 954, CHU de Nancy, Universite de Lorraine, Nancy, France. Service d'Hepatogastroenterologie, CHU, Caen, France. Kindai University Faculty of Medicine, Osaka, Japan. Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan. Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain. Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Bayer HealthCare SAS, Loos, France. Bayer Pharmaceuticals, Bayer Vital GmbH, Leverkusen, Germany. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. The First Affiliated Hospital (Xijing Hospital) of the Fourth Military Medical University, Xi'an, China.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancetLancet (London, England)LancetLancetLancet (London, England)56-66389100642016/12/10AgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapyDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapyMaleMiddle AgedNiacinamide/analogs & derivatives/therapeutic usePhenylurea Compounds/adverse effects/*therapeutic usePyridines/adverse effects/*therapeutic useSorafenibTreatment Outcome2017Jan 70140-67362793222910.1016/s0140-6736(16)32453-9NLMengDBruix201716616616617Bruix, J.Qin, S.Merle, P.Granito, A.Huang, Y. H.Bodoky, G.Pracht, M.Yokosuka, O.Rosmorduc, O.Breder, V.Gerolami, R.Masi, G.Ross, P. J.Song, T.Bronowicki, J. P.Ollivier-Hourmand, I.Kudo, M.Cheng, A. L.Llovet, J. M.Finn, R. S.LeBerre, M. A.Baumhauer, A.Meinhardt, G.Han, G.Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain. Electronic address: jbruix@clinic.ub.es. Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China. Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France. Department of Medical and Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy. Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. St Laszlo Teaching Hospital, Budapest, Hungary. Service d'Oncologie Medicale, Centre Eugene Marquis, Rennes, France. Department of Gastroenterology and Nephrology, Chiba University, Chiba, Japan. Department of Hepatology, Hopital de la Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris and Universite Pierre et Marie Curie, Sorbonne Universites, Paris, France. Russian Cancer Research Center n.a.N.Blokhin, Moscow, Russia. CHU Timone, Universite de la Mediterranee, Marseille, France. Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. King's College Hospital NHS Foundation Trust, London, UK. Tianjin Medical University Cancer Hospital, Tianjin, China. INSERM 954, CHU de Nancy, Universite de Lorraine, Nancy, France. Service d'Hepatogastroenterologie, CHU, Caen, France. Kindai University Faculty of Medicine, Osaka, Japan. Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan. Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain. Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Bayer HealthCare SAS, Loos, France. Bayer Pharmaceuticals, Bayer Vital GmbH, Leverkusen, Germany. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. The First Affiliated Hospital (Xijing Hospital) of the Fourth Military Medical University, Xi'an, China.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancetLancet (London, England)LancetLancetLancet (London, England)56-66389100642016/12/10AgedAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapyDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapyMaleMiddle AgedNiacinamide/analogs & derivatives/therapeutic usePhenylurea Compounds/adverse effects/*therapeutic usePyridines/adverse effects/*therapeutic useSorafenibTreatment Outcome2017Jan 70140-67362793222910.1016/s0140-6736(16)32453-9NLMengwDyK  _ENREF_190j DEl-Khoueiry201716716716717El-Khoueiry, A. B.Sangro, B.Yau, T.Crocenzi, T. S.Kudo, M.Hsu, C.Kim, T. Y.Choo, S. P.Trojan, J.Welling, T. H. RdMeyer, T.Kang, Y. K.Yeo, W.Chopra, A.Anderson, J.Dela Cruz, C.Lang, L.Neely, J.Tang, H.Dastani, H. B.Melero, I.USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: elkhouei@med.usc.edu. Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain. University of Hong Kong, Hong Kong Special Administrative Region, China. Providence Cancer Center, Portland, OR, USA. Kindai University Faculty of Medicine, Osaka, Japan. National Taiwan University Hospital, Taipei, Taiwan. Seoul National University Hospital, Seoul, South Korea. National Cancer Center, Singapore. Goethe University Hospital and Cancer Center, Frankfurt, Germany. University of Michigan School of Medicine, Ann Arbor, MI, USA. Royal Free Hospital, London, UK. Asan Medical Center, University of Ulsan, Seoul, South Korea. Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Johns Hopkins Singapore International Medical Centre, Singapore. Bristol-Myers Squibb, Princeton, NJ, USA. Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain; Center for Applied Medical Research (CIMA), Pamplona, Spain.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancetLancet (London, England)LancetLancetLancet (London, England)2492-2502389100882017/04/25AgedAntibodies, Monoclonal/*administration & dosage/adverse effectsAntineoplastic Agents/*administration & dosage/adverse effectsB7-H1 Antigen/metabolismBiomarkers, Tumor/metabolismCarcinoma, Hepatocellular/*drug therapy/pathologyDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLiver Neoplasms/*drug therapy/pathologyMaleNivolumabResponse Evaluation Criteria in Solid TumorsTime FactorsTreatment OutcomeTumor Burden2017Jun 240140-67362843464810.1016/s0140-6736(17)31046-2NLMengZhu201817517517517Zhu, A. X.Finn, R. S.Edeline, J.Cattan, S.Ogasawara, S.Palmer, D.Verslype, C.Zagonel, V.Fartoux, L.Vogel, A.Sarker, D.Verset, G.Chan, S. L.Knox, J.Daniele, B.Webber, A. L.Ebbinghaus, S. W.Ma, J.Siegel, A. B.Cheng, A. L.Kudo, M.Department of Medicine, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: azhu@mgh.harvard.edu. Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. Department of Medical Oncology and Gastroenterology, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France. Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Medical Oncology, University of Liverpool, Liverpool, UK. Department of Hepatology, University Hospital Gasthuisberg, Leuven, Leuven, Belgium. Istituto Oncologico Veneto-Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padua, Italy. Department of Gastroenterology and Hepatology, Hopital Universitaire Pitie-Salpetriere, Paris, France. Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule, Hannover, Germany. Department of Medical Oncology, King's College Hospital, London, UK. Gastrointestinal Oncology Unit, Hopital Erasme, Brussels, Belgium. Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Shatin, Hong Kong. Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Department of Oncology, Azienda Ospedaliera Gaetano Rummo, Benevento, Italy. Department of Global Clinical Development, Merck & Co, Kenilworth, NJ, USA. Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan. Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology940-9521972018/06/08AgedAntibodies, Monoclonal, Humanized/*administration & dosageCarcinoma, Hepatocellular/*drug therapy/*mortality/pathologyDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousInternationalityLiver Neoplasms/*drug therapy/*mortality/pathologyMaleMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm StagingPrognosisRemission InductionSorafenib/administration & dosageSurvival Rate2018Jul1470-20452987506610.1016/s1470-2045(18)30351-6NLMengwDyK  _ENREF_191wDyK  _ENREF_192d"DBrahmer201816516516517Brahmer, J. R.Lacchetti, C.Schneider, B. J.Atkins, M. B.Brassil, K. J.Caterino, J. M.Chau, I.Ernstoff, M. S.Gardner, J. M.Ginex, P.Hallmeyer, S.Holter Chakrabarty, J.Leighl, N. B.Mammen, J. S.McDermott, D. F.Naing, A.Nastoupil, L. J.Phillips, T.Porter, L. D.Puzanov, I.Reichner, C. A.Santomasso, B. D.Seigel, C.Spira, A.Suarez-Almazor, M. E.Wang, Y.Weber, J. S.Wolchok, J. D.Thompson, J. A.Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1714-176836172018/02/152018Jun 100732-183x29442540PMC6481621NIHMS100880810.1200/jco.2017.77.6385NLMengHaanen201821352135213517Haanen, JbagCarbonnel, F.Robert, C.Kerr, K. M.Peters, S.Larkin, J.Jordan, K.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn OncolAnnals of oncology : official journal of the European Society for Medical OncologyAnn Oncoliv264-iv26629Supplement_42018/06/202018Oct 10923-75342991704610.1093/annonc/mdy162NLMengPuzanov201717117117117Puzanov, I.Diab, A.Abdallah, K.Bingham, C. O., 3rdBrogdon, C.Dadu, R.Hamad, L.Kim, S.Lacouture, M. E.LeBoeuf, N. R.Lenihan, D.Onofrei, C.Shannon, V.Sharma, R.Silk, A. W.Skondra, D.Suarez-Almazor, M. E.Wang, Y.Wiley, K.Kaufman, H. L.Ernstoff, M. S.Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. University of Texas MD Anderson Cancer Center, Houston, TX, USA. Merck & Co., Inc., Upper Gwynedd, PA, USA. Johns Hopkins University, Baltimore, MD, USA. Bristol-Myers Squibb Company, New York, NY, USA. Memorial Sloan Kettering Cancer Center, New York, NY, USA. Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Washington University in St Louis, St Louis, MO, USA. Indiana University, Indianapolis, IN, USA. Massachusetts General Hospital, Boston, MA, USA. University of Chicago, Chicago, IL, USA. Oncology Nursing Society, Pittsburgh, PA, USA. Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. Marc.Ernstoff@RoswellPark.org.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJ Immunother CancerJournal for immunotherapy of cancerJ Immunother CancerJournal for immunotherapy of cancerJ Immunother CancerJournal for immunotherapy of cancer95512017/11/23Clinical Decision-MakingEvidence-Based MedicineHumansImmunotherapy/*adverse effects/methodsNeoplasms/*therapyNeurotoxicity Syndromes/etiologyPractice Guidelines as TopicSocieties, Medical*Immune checkpoint inhibitor*Immune-related adverse events*Toxicity2017Nov 212051-142629162153PMC569716210.1186/s40425-017-0300-zNLMengd"DBrahmer201816516516517Brahmer, J. R.Lacchetti, C.Schneider, B. J.Atkins, M. B.Brassil, K. J.Caterino, J. M.Chau, I.Ernstoff, M. S.Gardner, J. M.Ginex, P.Hallmeyer, S.Holter Chakrabarty, J.Leighl, N. B.Mammen, J. S.McDermott, D. F.Naing, A.Nastoupil, L. J.Phillips, T.Porter, L. D.Puzanov, I.Reichner, C. A.Santomasso, B. D.Seigel, C.Spira, A.Suarez-Almazor, M. E.Wang, Y.Weber, J. S.Wolchok, J. D.Thompson, J. A.Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical OncologyJ Clin OncolJ Clin OncolJournal of clinical oncology : official journal of the American Society of Clinical Oncology1714-176836172018/02/152018Jun 100732-183x29442540PMC6481621NIHMS100880810.1200/jco.2017.77.6385NLMengHaanen201821352135213517Haanen, JbagCarbonnel, F.Robert, C.Kerr, K. M.Peters, S.Larkin, J.Jordan, K.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn OncolAnnals of oncology : official journal of the European Society for Medical OncologyAnn Oncoliv264-iv26629Supplement_42018/06/202018Oct 10923-75342991704610.1093/annonc/mdy162NLMengPuzanov201717117117117Puzanov, I.Diab, A.Abdallah, K.Bingham, C. O., 3rdBrogdon, C.Dadu, R.Hamad, L.Kim, S.Lacouture, M. E.LeBoeuf, N. R.Lenihan, D.Onofrei, C.Shannon, V.Sharma, R.Silk, A. W.Skondra, D.Suarez-Almazor, M. E.Wang, Y.Wiley, K.Kaufman, H. L.Ernstoff, M. S.Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. University of Texas MD Anderson Cancer Center, Houston, TX, USA. Merck & Co., Inc., Upper Gwynedd, PA, USA. Johns Hopkins University, Baltimore, MD, USA. Bristol-Myers Squibb Company, New York, NY, USA. Memorial Sloan Kettering Cancer Center, New York, NY, USA. Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Washington University in St Louis, St Louis, MO, USA. Indiana University, Indianapolis, IN, USA. Massachusetts General Hospital, Boston, MA, USA. University of Chicago, Chicago, IL, USA. Oncology Nursing Society, Pittsburgh, PA, USA. Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. Marc.Ernstoff@RoswellPark.org.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJ Immunother CancerJournal for immunotherapy of cancerJ Immunother CancerJournal for immunotherapy of cancerJ Immunother CancerJournal for immunotherapy of cancer95512017/11/23Clinical Decision-MakingEvidence-Based MedicineHumansImmunotherapy/*adverse effects/methodsNeoplasms/*therapyNeurotoxicity Syndromes/etiologyPractice Guidelines as TopicSocieties, Medical*Immune checkpoint inhibitor*Immune-related adverse events*Toxicity2017Nov 212051-142629162153PMC569716210.1186/s40425-017-0300-zNLMengwDyK  _ENREF_1934DSun200610410410417Sun, H. C.Tang, Z. Y.Wang, L.Qin, L. X.Ma, Z. C.Ye, Q. H.Zhang, B. H.Qian, Y. B.Wu, Z. Q.Fan, J.Zhou, X. D.Zhou, J.Qiu, S. J.Shen, Y. F.Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, People's Republic of China.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology458-651327Analysis of VarianceAntineoplastic Agents/adverse effects/*therapeutic useAntiviral Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyFemale*HepatectomyHepatitis B virus/*isolation & purificationHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlSurvival AnalysisTreatment Outcome2006Jul0171-5216 (Print) 0171-5216 (Linking)16557381http://www.ncbi.nlm.nih.gov/pubmed/1655738110.1007/s00432-006-0091-y程树群200415815815817<style face="normal" font="default" charset="134" size="100%">胸腺肽</style><style face="normal" font="default" charset="161" size="100%">α</style><style face="normal" font="default" size="100%">1</style><style face="normal" font="default" charset="134" size="100%">对原发性肝癌术后复发的影响</style><style face="normal" font="default" size="100%"> </style>中华肝胆外科杂志592-593109癌肝细胞复发胸腺肽20041007-8118http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk20040900610.3760/cma.j.issn.1007-8118.2004.09.006chi4DSun200610410410417Sun, H. C.Tang, Z. Y.Wang, L.Qin, L. X.Ma, Z. C.Ye, Q. H.Zhang, B. H.Qian, Y. B.Wu, Z. Q.Fan, J.Zhou, X. D.Zhou, J.Qiu, S. J.Shen, Y. F.Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, People's Republic of China.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trialJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncologyJ Cancer Res Clin OncolJournal of cancer research and clinical oncology458-651327Analysis of VarianceAntineoplastic Agents/adverse effects/*therapeutic useAntiviral Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/pathology/surgery/virologyFemale*HepatectomyHepatitis B virus/*isolation & purificationHumansInterferon-alpha/adverse effects/*therapeutic useLiver Neoplasms/*drug therapy/pathology/surgery/virologyMaleMiddle AgedNeoplasm Recurrence, Local/*prevention & controlSurvival AnalysisTreatment Outcome2006Jul0171-5216 (Print) 0171-5216 (Linking)16557381http://www.ncbi.nlm.nih.gov/pubmed/1655738110.1007/s00432-006-0091-y程树群200415815815817<style face="normal" font="default" charset="134" size="100%">胸腺肽</style><style face="normal" font="default" charset="161" size="100%">α</style><style face="normal" font="default" size="100%">1</style><style face="normal" font="default" charset="134" size="100%">对原发性肝癌术后复发的影响</style><style face="normal" font="default" size="100%"> </style>中华肝胆外科杂志592-593109癌肝细胞复发胸腺肽20041007-8118http://wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk20040900610.3760/cma.j.issn.1007-8118.2004.09.006chiwDyK  _ENREF_109wDyK  _ENREF_197 DLee201517017017017Lee, J. H.Lee, J. H.Lim, Y. S.Yeon, J. E.Song, T. J.Yu, S. J.Gwak, G. Y.Kim, K. M.Kim, Y. J.Lee, J. W.Yoon, J. H.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. The Liver Center, Korea University Guro Hospital, Seoul, Korea. Department of Surgery, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea. Department of Statistics, Korea University, Seoul, Korea. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address: yoonjh@snu.ac.kr.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinomaGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterology1383-91 e61487AgedCarcinoma, Hepatocellular/immunology/mortality/secondary/*therapyCatheter AblationCytokine-Induced Killer Cells/immunology/*transplantationDisease ProgressionDisease-Free SurvivalEthanol/administration & dosageFemaleHepatectomyHumansImmunotherapy, Adoptive/adverse effects/*methodsKaplan-Meier EstimateLiver Neoplasms/immunology/mortality/pathology/*therapyMaleMiddle AgedNeoplasm Recurrence, LocalProportional Hazards ModelsRepublic of KoreaRisk FactorsTime FactorsTransplantation, AutologousTreatment Outcome2015Jun1528-0012 (Electronic) 0016-5085 (Linking)25747273http://www.ncbi.nlm.nih.gov/pubmed/2574727310.1053/j.gastro.2015.02.055 DLee201517017017017Lee, J. H.Lee, J. H.Lim, Y. S.Yeon, J. E.Song, T. J.Yu, S. J.Gwak, G. Y.Kim, K. M.Kim, Y. J.Lee, J. W.Yoon, J. H.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. The Liver Center, Korea University Guro Hospital, Seoul, Korea. Department of Surgery, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea. Department of Statistics, Korea University, Seoul, Korea. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address: yoonjh@snu.ac.kr.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinomaGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterologyGastroenterology1383-91 e61487AgedCarcinoma, Hepatocellular/immunology/mortality/secondary/*therapyCatheter AblationCytokine-Induced Killer Cells/immunology/*transplantationDisease ProgressionDisease-Free SurvivalEthanol/administration & dosageFemaleHepatectomyHumansImmunotherapy, Adoptive/adverse effects/*methodsKaplan-Meier EstimateLiver Neoplasms/immunology/mortality/pathology/*therapyMaleMiddle AgedNeoplasm Recurrence, LocalProportional Hazards ModelsRepublic of KoreaRisk FactorsTime FactorsTransplantation, AutologousTreatment Outcome2015Jun1528-0012 (Electronic) 0016-5085 (Linking)25747273http://www.ncbi.nlm.nih.gov/pubmed/2574727310.1053/j.gastro.2015.02.055wDyK  _ENREF_198DAbou-Alfa201816316316317Abou-Alfa, G. K.Meyer, T.Cheng, A. L.El-Khoueiry, A. B.Rimassa, L.Ryoo, B. Y.Cicin, I.Merle, P.Chen, Y.Park, J. W.Blanc, J. F.Bolondi, L.Klumpen, H. J.Chan, S. L.Zagonel, V.Pressiani, T.Ryu, M. H.Venook, A. P.Hessel, C.Borgman-Hagey, A. E.Schwab, G.Kelley, R. K.From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (G.K.A.-A.); Royal Free Hospital and University College London, London (T.M.); National Taiwan University Hospital, Taipei (A.-L.C.), and the Department of Medical Oncology, Liouying Chi Mei Hospital, Tainan (Y.C.) - both in Taiwan; USC Norris Comprehensive Cancer Center, Los Angeles (A.B.E.-K.), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (A.P.V., R.K.K.), and Exelixis, Alameda (C.H., A.E.B.-H., G.S.) - all in California; Humanitas Cancer Center, Humanitas Clinical and Research Center, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano (L.R., T.P.), the Department of Medical and Surgical Sciences, University of Bologna, Bologna (L.B.), and Medical Oncology Unit 1, Istituto Oncologico Veneto, IRCCS, Padua (V.Z.) - all in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul (B.-Y.R., M.-H.R.), and the National Cancer Center, Goyang (J.-W.P.) - both in South Korea; Trakya University School of Medicine, Edirne, Turkey (I.C.); Groupement Hospitalier Nord, Lyon (P.M.), and Hopital Haut-Leveque, Centre Hospitalier Universitaire Bordeaux, Bordeaux (J.-F.B.) - both in France; the Department of Medical Oncology, Academic Medical Center, Amsterdam (H.-J.K.); and the Chinese University of Hong Kong, State Key Laboratory in Oncology in South China, Hong Kong (S.L.C.).Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicine54-6337912018/07/05AdultAgedAged, 80 and overAnilides/adverse effects/*therapeutic useAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapyDisease-Free SurvivalDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapyMaleMiddle AgedPyridines/adverse effects/*therapeutic useReceptor Protein-Tyrosine Kinases/*antagonists & inhibitors2018Jul 50028-47932997275910.1056/NEJMoa1717002NLMengDAbou-Alfa201816316316317Abou-Alfa, G. K.Meyer, T.Cheng, A. L.El-Khoueiry, A. B.Rimassa, L.Ryoo, B. Y.Cicin, I.Merle, P.Chen, Y.Park, J. W.Blanc, J. F.Bolondi, L.Klumpen, H. J.Chan, S. L.Zagonel, V.Pressiani, T.Ryu, M. H.Venook, A. P.Hessel, C.Borgman-Hagey, A. E.Schwab, G.Kelley, R. K.From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (G.K.A.-A.); Royal Free Hospital and University College London, London (T.M.); National Taiwan University Hospital, Taipei (A.-L.C.), and the Department of Medical Oncology, Liouying Chi Mei Hospital, Tainan (Y.C.) - both in Taiwan; USC Norris Comprehensive Cancer Center, Los Angeles (A.B.E.-K.), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (A.P.V., R.K.K.), and Exelixis, Alameda (C.H., A.E.B.-H., G.S.) - all in California; Humanitas Cancer Center, Humanitas Clinical and Research Center, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano (L.R., T.P.), the Department of Medical and Surgical Sciences, University of Bologna, Bologna (L.B.), and Medical Oncology Unit 1, Istituto Oncologico Veneto, IRCCS, Padua (V.Z.) - all in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul (B.-Y.R., M.-H.R.), and the National Cancer Center, Goyang (J.-W.P.) - both in South Korea; Trakya University School of Medicine, Edirne, Turkey (I.C.); Groupement Hospitalier Nord, Lyon (P.M.), and Hopital Haut-Leveque, Centre Hospitalier Universitaire Bordeaux, Bordeaux (J.-F.B.) - both in France; the Department of Medical Oncology, Academic Medical Center, Amsterdam (H.-J.K.); and the Chinese University of Hong Kong, State Key Laboratory in Oncology in South China, Hong Kong (S.L.C.).Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicineN Engl J MedThe New England journal of medicine54-6337912018/07/05AdultAgedAged, 80 and overAnilides/adverse effects/*therapeutic useAntineoplastic Agents/adverse effects/*therapeutic useCarcinoma, Hepatocellular/*drug therapyDisease-Free SurvivalDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapyMaleMiddle AgedPyridines/adverse effects/*therapeutic useReceptor Protein-Tyrosine Kinases/*antagonists & inhibitors2018Jul 50028-47932997275910.1056/NEJMoa1717002NLMengwDyK  _ENREF_199lDZhu201517717717717Zhu, A. X.Park, J. O.Ryoo, B. Y.Yen, C. J.Poon, R.Pastorelli, D.Blanc, J. F.Chung, H. C.Baron, A. D.Pfiffer, T. E.Okusaka, T.Kubackova, K.Trojan, J.Sastre, J.Chau, I.Chang, S. C.Abada, P. B.Yang, L.Schwartz, J. D.Kudo, M.Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: azhu@partners.org. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Asan Medical Center, University of Ulsan School of Medicine, Seoul, South Korea. National Cheng Kung University Hospital, Tainan City, Taiwan. The University of Hong Kong, Hong Kong. Istituto Oncologico Veneto IRCCS, Padova, Italy. Hopital Saint-Andre, Bordeaux, France. Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. California Pacific Medical Center, San Francisco, CA, USA. Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. National Cancer Center Hospital, Tokyo, Japan. University Hospital in Motol, Prague, Czech Republic. University Hospital Cancer Center, Frankfurt, Germany. Hospital Clinico San Carlos, Madrid, Spain. Royal Marsden Hospital, Surrey, UK. Eli Lilly and Company, Indianapolis, IN, USA. Eli Lilly and Company, Bridgewater, NJ, USA. Stemline Therapeutics Inc, New York, NY, USA. Kinki University School of Medicine, Osaka-Sayama City, Osaka, Japan.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology859-701672015/06/23AdultAgedAged, 80 and overAntibodies, Monoclonal/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyConfidence IntervalsDisease-Free SurvivalDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePatient SelectionPhenylurea Compounds/*therapeutic useProportional Hazards ModelsRemission InductionSorafenibSurvival AnalysisTime FactorsTreatment Outcome2015Jul1470-20452609578410.1016/s1470-2045(15)00050-9NLMengZhu201917617617617Zhu, A. X.Kang, Y. K.Yen, C. J.Finn, R. S.Galle, P. R.Llovet, J. M.Assenat, E.Brandi, G.Pracht, M.Lim, H. Y.Rau, K. M.Motomura, K.Ohno, I.Merle, P.Daniele, B.Shin, D. B.Gerken, G.Borg, C.Hiriart, J. B.Okusaka, T.Morimoto, M.Hsu, Y.Abada, P. B.Kudo, M.Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA. Electronic address: azhu@mgh.harvard.edu. Asan Medical Center, University of Ulsan, Seoul, South Korea. Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Tainan, Taiwan; College of Medicine, National Cheng Kung University, Tainan, Taiwan. Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. University Medical Center, Mainz, Germany. Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institut d'Investigations Biomediques, August Pi i Sunyer-Hospital Clinic Barcelona, Barcelona, Spain. CHU de Montpellier, Montpellier, France. University Hospital S Orsola, Bologna, Italy. Centre Eugene Marquis, Rennes, France. Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea. Chang Gung Memorial Hospital-Kaohsiung Branch, Kaohsiung City, Taiwan; Hematology-Oncology Department, E-Da Cancer Hospital, Kaohsiung, Taiwan. Aso Iizuka Hospital-Hepatology, Iizuka, Fukuoka, Japan. National Cancer Center Hospital East-Hepatobiliary and Pancreatic Oncology, Kashiwa, Chiba, Japan. Hopital de la Croix Rousse, Lyon, France. Azienda Ospedaliera G Rummo, Benevento, Benevento, Italy; Ospedale del Mare, Naples, Italy. Gachon University Gil Medical Center, Incheon, South Korea. Universtitatsklinikum Essen AoR, Essen, North Rhine-Westphalia, Germany. University Hospital of Besancon, Besancon, France. CHU de Bordeaux, Pessac, France. National Cancer Center Hospital, Tokyo, Japan. Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. Eli Lilly, New York, NY, USA. Eli Lilly, Indianapolis, IN, USA. Kindai University, Osaka-Sayama, Japan.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology282-2962022019/01/232019Feb1470-20453066586910.1016/s1470-2045(18)30937-9NLMenglDZhu201517717717717Zhu, A. X.Park, J. O.Ryoo, B. Y.Yen, C. J.Poon, R.Pastorelli, D.Blanc, J. F.Chung, H. C.Baron, A. D.Pfiffer, T. E.Okusaka, T.Kubackova, K.Trojan, J.Sastre, J.Chau, I.Chang, S. C.Abada, P. B.Yang, L.Schwartz, J. D.Kudo, M.Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: azhu@partners.org. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Asan Medical Center, University of Ulsan School of Medicine, Seoul, South Korea. National Cheng Kung University Hospital, Tainan City, Taiwan. The University of Hong Kong, Hong Kong. Istituto Oncologico Veneto IRCCS, Padova, Italy. Hopital Saint-Andre, Bordeaux, France. Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. California Pacific Medical Center, San Francisco, CA, USA. Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil. National Cancer Center Hospital, Tokyo, Japan. University Hospital in Motol, Prague, Czech Republic. University Hospital Cancer Center, Frankfurt, Germany. Hospital Clinico San Carlos, Madrid, Spain. Royal Marsden Hospital, Surrey, UK. Eli Lilly and Company, Indianapolis, IN, USA. Eli Lilly and Company, Bridgewater, NJ, USA. Stemline Therapeutics Inc, New York, NY, USA. Kinki University School of Medicine, Osaka-Sayama City, Osaka, Japan.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology859-701672015/06/23AdultAgedAged, 80 and overAntibodies, Monoclonal/*therapeutic useCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyConfidence IntervalsDisease-Free SurvivalDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedNiacinamide/*analogs & derivatives/therapeutic usePatient SelectionPhenylurea Compounds/*therapeutic useProportional Hazards ModelsRemission InductionSorafenibSurvival AnalysisTime FactorsTreatment Outcome2015Jul1470-20452609578410.1016/s1470-2045(15)00050-9NLMengZhu201917617617617Zhu, A. X.Kang, Y. K.Yen, C. J.Finn, R. S.Galle, P. R.Llovet, J. M.Assenat, E.Brandi, G.Pracht, M.Lim, H. Y.Rau, K. M.Motomura, K.Ohno, I.Merle, P.Daniele, B.Shin, D. B.Gerken, G.Borg, C.Hiriart, J. B.Okusaka, T.Morimoto, M.Hsu, Y.Abada, P. B.Kudo, M.Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA. Electronic address: azhu@mgh.harvard.edu. Asan Medical Center, University of Ulsan, Seoul, South Korea. Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Tainan, Taiwan; College of Medicine, National Cheng Kung University, Tainan, Taiwan. Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. University Medical Center, Mainz, Germany. Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institut d'Investigations Biomediques, August Pi i Sunyer-Hospital Clinic Barcelona, Barcelona, Spain. CHU de Montpellier, Montpellier, France. University Hospital S Orsola, Bologna, Italy. Centre Eugene Marquis, Rennes, France. Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea. Chang Gung Memorial Hospital-Kaohsiung Branch, Kaohsiung City, Taiwan; Hematology-Oncology Department, E-Da Cancer Hospital, Kaohsiung, Taiwan. Aso Iizuka Hospital-Hepatology, Iizuka, Fukuoka, Japan. National Cancer Center Hospital East-Hepatobiliary and Pancreatic Oncology, Kashiwa, Chiba, Japan. Hopital de la Croix Rousse, Lyon, France. Azienda Ospedaliera G Rummo, Benevento, Benevento, Italy; Ospedale del Mare, Naples, Italy. Gachon University Gil Medical Center, Incheon, South Korea. Universtitatsklinikum Essen AoR, Essen, North Rhine-Westphalia, Germany. University Hospital of Besancon, Besancon, France. CHU de Bordeaux, Pessac, France. National Cancer Center Hospital, Tokyo, Japan. Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. Eli Lilly, New York, NY, USA. Eli Lilly, Indianapolis, IN, USA. Kindai University, Osaka-Sayama, Japan.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology282-2962022019/01/232019Feb1470-20453066586910.1016/s1470-2045(18)30937-9NLMengwDyK  _ENREF_200wDyK  _ENREF_201D成远201721772177217717成远华海清南京中医药大学附属八一医院全军肿瘤中心内科;榄香烯治疗原发性肝癌的研究进展临床肿瘤学杂志临床肿瘤学杂志950-9532210原发性肝癌榄香烯临床应用作用机制20171009-046032-1577/RCnki路大鹏201722912291229117路大鹏王玉强赵卫林齐增平河北省民政总医院医学影像科,河北邢台,054000 河北省民政总医院肿瘤内科,河北邢台,054000康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究世界临床医学世界临床医学70,72115肝动脉化疗栓塞术康莱特注射液肝癌20171009-3389http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=sjlcyx201705059北京万方数据股份有限公司chi高继良201422922292229217高继良G. A. O. Ji-liang杭州市萧山区中医院肿瘤内科,浙江杭州311201肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究中国中药杂志中国中药杂志2367-23693912原发性肝癌肝复乐方剂化疗临床研究20141001-5302http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzyzz20141204410.4268/cjcmm20141243北京万方数据股份有限公司chi范隼201922862286228617范隼李庆源周志涛何伟良巫兆国钟鹏中山大学附属第三医院粤东医院;TACE联合金龙胶囊治疗原发性肝癌的效果研究中国实用医药中国实用医药42-441421原发性肝癌肝动脉化疗栓塞术金龙胶囊生活质量20191673-755511-5547/RCnki蔡文辉201822872287228717蔡文辉尹春丽范庆秋江苏省盐城市第二人民医院中西医结合肝病科;艾迪联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察中国医师杂志中国医师杂志1723-17252011肝肿瘤/治疗抗肿瘤剂(中药)/投药和剂量化学栓塞,治疗性肝动脉20181008-137243-1274/RCnki杨新华201722882288228817杨新华解放军第一五二中心医院肿瘤内科;TACE联合鸦胆子油乳液静脉滴注对肝癌患者的临床疗效及VEGF水平的影响海峡药学海峡药学176-1772909鸦胆子油乳液TACE肝癌VEGF20171006-376535-1173/RCnki彭文达201122892289228917彭文达湖南省马王堆疗养院;复方斑蝥胶囊联合化疗治疗中晚期原发性肝癌的临床疗效观察肿瘤药学肿瘤药学518-519+543106复方斑蝥胶囊中晚期肝癌临床疗效观察20112095-126443-1507/RCnkiD成远201721772177217717成远华海清南京中医药大学附属八一医院全军肿瘤中心内科;榄香烯治疗原发性肝癌的研究进展临床肿瘤学杂志临床肿瘤学杂志950-9532210原发性肝癌榄香烯临床应用作用机制20171009-046032-1577/RCnki路大鹏201722912291229117路大鹏王玉强赵卫林齐增平河北省民政总医院医学影像科,河北邢台,054000 河北省民政总医院肿瘤内科,河北邢台,054000康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究世界临床医学世界临床医学70,72115肝动脉化疗栓塞术康莱特注射液肝癌20171009-3389http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=sjlcyx201705059北京万方数据股份有限公司chi高继良201422922292229217高继良G. A. O. Ji-liang杭州市萧山区中医院肿瘤内科,浙江杭州311201肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究中国中药杂志中国中药杂志2367-23693912原发性肝癌肝复乐方剂化疗临床研究20141001-5302http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzyzz20141204410.4268/cjcmm20141243北京万方数据股份有限公司chi范隼201922862286228617范隼李庆源周志涛何伟良巫兆国钟鹏中山大学附属第三医院粤东医院;TACE联合金龙胶囊治疗原发性肝癌的效果研究中国实用医药中国实用医药42-441421原发性肝癌肝动脉化疗栓塞术金龙胶囊生活质量20191673-755511-5547/RCnki蔡文辉201822872287228717蔡文辉尹春丽范庆秋江苏省盐城市第二人民医院中西医结合肝病科;艾迪联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察中国医师杂志中国医师杂志1723-17252011肝肿瘤/治疗抗肿瘤剂(中药)/投药和剂量化学栓塞,治疗性肝动脉20181008-137243-1274/RCnki杨新华201722882288228817杨新华解放军第一五二中心医院肿瘤内科;TACE联合鸦胆子油乳液静脉滴注对肝癌患者的临床疗效及VEGF水平的影响海峡药学海峡药学176-1772909鸦胆子油乳液TACE肝癌VEGF20171006-376535-1173/RCnki彭文达201122892289228917彭文达湖南省马王堆疗养院;复方斑蝥胶囊联合化疗治疗中晚期原发性肝癌的临床疗效观察肿瘤药学肿瘤药学518-519+543106复方斑蝥胶囊中晚期肝癌临床疗效观察20112095-126443-1507/RCnki@ D201524024024017中华医学会肝病学分会;中华医学会感染病学分会;丙型肝炎防治指南(2015年更新版)中华实验和临床感染病杂志(电子版)中华实验和临床感染病杂志(电子版)590-607905肝炎,丙型,慢性治疗预防指南20151674-135811-9284/RCnkiEuropean Association for the Study of the Liver. Electronic address201824124124117European Association for the Study of the Liver. Electronic address, easloffice easloffice euEuropean Association for the Study of the, LiverEASL Recommendations on Treatment of Hepatitis C 2018J HepatolJ HepatolJournal of hepatology461-5116922018/04/142018Aug1600-0641 (Electronic) 0168-8278 (Linking)29650333https://www.ncbi.nlm.nih.gov/pubmed/2965033310.1016/j.jhep.2018.03.026@ D201524024024017中华医学会肝病学分会;中华医学会感染病学分会;丙型肝炎防治指南(2015年更新版)中华实验和临床感染病杂志(电子版)中华实验和临床感染病杂志(电子版)590-607905肝炎,丙型,慢性治疗预防指南20151674-135811-9284/RCnkiEuropean Association for the Study of the Liver. Electronic address201824124124117European Association for the Study of the Liver. Electronic address, easloffice easloffice euEuropean Association for the Study of the, LiverEASL Recommendations on Treatment of Hepatitis C 2018J HepatolJ HepatolJournal of hepatology461-5116922018/04/142018Aug1600-0641 (Electronic) 0168-8278 (Linking)29650333https://www.ncbi.nlm.nih.gov/pubmed/2965033310.1016/j.jhep.2018.03.026wDyK  _ENREF_212wDyK  _ENREF_213DDSeymour201721782178217817Seymour, L.Bogaerts, J.Perrone, A.Ford, R.Schwartz, L. H.Mandrekar, S.Lin, N. U.Litiere, S.Dancey, J.Chen, A.Hodi, F. S.Therasse, P.Hoekstra, O. S.Shankar, L. K.Wolchok, J. D.Ballinger, M.Caramella, C.de Vries, E. G. E.Recist working groupCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada. Electronic address: lseymour@ctg.queensu.ca. EORTC Headquarters, Brussels, Belgium. Translational Medicine, Merck & Co, Kenilworth, NJ, USA. Clinical Trials Imaging Consulting, LLC, Belle Mead, NJ, USA. Department of Radiology, Columbia University Medical Center, New York, NY, USA; New York Presbyterian Hospital, New York, NY, USA. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada. Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. Institut de Recherche International Servier, Paris, France. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands. Diagnostic Imaging Branch, National Cancer Institute, Bethesda, MD, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Weill Cornell Medical and Graduate Colleges, New York, NY, USA; Ludwig Institute for Cancer Research, New York, NY, USA; Genentech Inc, San Francisco, CA, USA. Department of Radiology, Gustav Roussy Cancer Campus, Villejuif, France. Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands.iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet OncolLancet OncolThe Lancet. Oncologye143-e1521832017/03/09Disease ProgressionHumansImmunotherapyNeoplasms/*therapyPractice Guidelines as Topic/*standards*Response Evaluation Criteria in Solid TumorsTumor Burden2017Mar1474-5488 (Electronic) 1470-2045 (Linking)28271869https://www.ncbi.nlm.nih.gov/pubmed/28271869PMC564854410.1016/S1470-2045(17)30074-8engDDSeymour201721782178217817Seymour, L.Bogaerts, J.Perrone, A.Ford, R.Schwartz, L. H.Mandrekar, S.Lin, N. U.Litiere, S.Dancey, J.Chen, A.Hodi, F. S.Therasse, P.Hoekstra, O. S.Shankar, L. K.Wolchok, J. D.Ballinger, M.Caramella, C.de Vries, E. G. E.Recist working groupCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada. Electronic address: lseymour@ctg.queensu.ca. EORTC Headquarters, Brussels, Belgium. Translational Medicine, Merck & Co, Kenilworth, NJ, USA. Clinical Trials Imaging Consulting, LLC, Belle Mead, NJ, USA. Department of Radiology, Columbia University Medical Center, New York, NY, USA; New York Presbyterian Hospital, New York, NY, USA. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada. Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. Institut de Recherche International Servier, Paris, France. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands. Diagnostic Imaging Branch, National Cancer Institute, Bethesda, MD, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Weill Cornell Medical and Graduate Colleges, New York, NY, USA; Ludwig Institute for Cancer Research, New York, NY, USA; Genentech Inc, San Francisco, CA, USA. Department of Radiology, Gustav Roussy Cancer Campus, Villejuif, France. Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands.iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet OncolLancet OncolThe Lancet. Oncologye143-e1521832017/03/09Disease ProgressionHumansImmunotherapyNeoplasms/*therapyPractice Guidelines as Topic/*standards*Response Evaluation Criteria in Solid TumorsTumor Burden2017Mar1474-5488 (Electronic) 1470-2045 (Linking)28271869https://www.ncbi.nlm.nih.gov/pubmed/28271869PMC564854410.1016/S1470-2045(17)30074-8engwDyK  _ENREF_214DYoshida201620520520517Yoshida, H.Mamada, Y.Taniai, N.Uchida, E.Department of Surgery, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan. Department of Surgery, Nippon Medical School, Tokyo, Japan.Spontaneous ruptured hepatocellular carcinomaHepatol. Res.Hepatol. Res.13-214612016Jan1386-63462563129010.1111/hepr.12498engZhong201621832183218317Zhong, F.Cheng, X. S.He, K.Sun, S. B.Zhou, J.Chen, H. M.Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, 510515 Guangdong Province China ; Department of Hepatobiliary Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, 518100 Guangdong Province China. Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, 510515 Guangdong Province China. Department of General Surgery, Jiangmen People's Hospital, Jiangmen, 529000 Guangdong Province China.Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock: a multicenter studySpringerplusSpringerplus1101512016/07/29Conservative treatmentHemorrhagic shockHepatectomyHepatocellular carcinomaRuptureTranscatheter arterial embolization20162193-1801 (Print) 2193-1801 (Linking)27468402https://www.ncbi.nlm.nih.gov/pubmed/27468402PMC494746510.1186/s40064-016-2762-8engMoris201821842184218417Moris, D.Chakedis, J.Sun, S. H.Spolverato, G.Tsilimigras, D. I.Ntanasis-Stathopoulos, I.Spartalis, E.Pawlik, T. M.Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Department of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Laboratory of Experimental Surgery and Surgical Research, National and Kapodistrian University of Athens, Athens, Greece.Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic reviewJ Surg OncolJ Surg OncolJournal of surgical oncology341-35311732017/11/09Ablation TechniquesCarcinoma, Hepatocellular/*pathology/surgery/*therapyChemoembolization, TherapeuticFemaleHepatectomyHumansLiver Neoplasms/*pathology/surgery/*therapyMaleMiddle AgedRetrospective StudiesRupture, SpontaneousTreatment Outcomehepatocellular carcinomamanagementrupturesurvivalsystematic review2018Mar1096-9098 (Electronic) 0022-4790 (Linking)29116644https://www.ncbi.nlm.nih.gov/pubmed/2911664410.1002/jso.24869engSahu201921852185218517Sahu, S. K.Chawla, Y. K.Dhiman, R. K.Singh, V.Duseja, A.Taneja, S.Kalra, N.Gorsi, U.Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Department of Radio Diagnosis, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.Rupture of Hepatocellular Carcinoma: A Review of LiteratureJ Clin Exp HepatolJ Clin Exp Hepatol245-256922019/04/27CTP, Child Turcotte PughHBV, Hepatitis B VirusHCC, Hepatocellular CarcinomaHCV, Hepatitis C VirusTACE, Trans-arterial Chemo-embolizationTAE, Transarterial EmbolizationVEGF, Vascular Endothelial Growth Factorhemoperitoneumhepatocellular carcinomaspontaneous rupturetransarterial embolization2019Mar-Apr0973-6883 (Print) 0973-6883 (Linking)31024207https://www.ncbi.nlm.nih.gov/pubmed/31024207PMC647694310.1016/j.jceh.2018.04.002engDYoshida201620520520517Yoshida, H.Mamada, Y.Taniai, N.Uchida, E.Department of Surgery, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan. Department of Surgery, Nippon Medical School, Tokyo, Japan.Spontaneous ruptured hepatocellular carcinomaHepatol. Res.Hepatol. Res.13-214612016Jan1386-63462563129010.1111/hepr.12498engZhong201621832183218317Zhong, F.Cheng, X. S.He, K.Sun, S. B.Zhou, J.Chen, H. M.Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, 510515 Guangdong Province China ; Department of Hepatobiliary Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, 518100 Guangdong Province China. Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Guangzhou, 510515 Guangdong Province China. Department of General Surgery, Jiangmen People's Hospital, Jiangmen, 529000 Guangdong Province China.Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock: a multicenter studySpringerplusSpringerplus1101512016/07/29Conservative treatmentHemorrhagic shockHepatectomyHepatocellular carcinomaRuptureTranscatheter arterial embolization20162193-1801 (Print) 2193-1801 (Linking)27468402https://www.ncbi.nlm.nih.gov/pubmed/27468402PMC494746510.1186/s40064-016-2762-8engMoris201821842184218417Moris, D.Chakedis, J.Sun, S. H.Spolverato, G.Tsilimigras, D. I.Ntanasis-Stathopoulos, I.Spartalis, E.Pawlik, T. M.Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Department of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Laboratory of Experimental Surgery and Surgical Research, National and Kapodistrian University of Athens, Athens, Greece.Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic reviewJ Surg OncolJ Surg OncolJournal of surgical oncology341-35311732017/11/09Ablation TechniquesCarcinoma, Hepatocellular/*pathology/surgery/*therapyChemoembolization, TherapeuticFemaleHepatectomyHumansLiver Neoplasms/*pathology/surgery/*therapyMaleMiddle AgedRetrospective StudiesRupture, SpontaneousTreatment Outcomehepatocellular carcinomamanagementrupturesurvivalsystematic review2018Mar1096-9098 (Electronic) 0022-4790 (Linking)29116644https://www.ncbi.nlm.nih.gov/pubmed/2911664410.1002/jso.24869engSahu201921852185218517Sahu, S. K.Chawla, Y. K.Dhiman, R. K.Singh, V.Duseja, A.Taneja, S.Kalra, N.Gorsi, U.Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Department of Radio Diagnosis, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.Rupture of Hepatocellular Carcinoma: A Review of LiteratureJ Clin Exp HepatolJ Clin Exp Hepatol245-256922019/04/27CTP, Child Turcotte PughHBV, Hepatitis B VirusHCC, Hepatocellular CarcinomaHCV, Hepatitis C VirusTACE, Trans-arterial Chemo-embolizationTAE, Transarterial EmbolizationVEGF, Vascular Endothelial Growth Factorhemoperitoneumhepatocellular carcinomaspontaneous rupturetransarterial embolization2019Mar-Apr0973-6883 (Print) 0973-6883 (Linking)31024207https://www.ncbi.nlm.nih.gov/pubmed/31024207PMC647694310.1016/j.jceh.2018.04.002engwDyK  _ENREF_215DAoki201421812181218117Aoki, T.Kokudo, N.Matsuyama, Y.Izumi, N.Ichida, T.Kudo, M.Ku, Y.Sakamoto, M.Nakashima, O.Matsui, O.Makuuchi, M.Liver Cancer Study Group of, Japan*Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan daggerDepartment of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan double daggerDepartment of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Musashino, Japan section signDepartment of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Izunokuni, Japan paragraph signDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka Sayama, Japan ||Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan **Department of Pathology, Keio University School of Medicine, Tokyo, Japan daggerdaggerDepartment of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan double daggerdouble daggerDepartment of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan section sign section signSurgery, Japanese Red Cross Medical Center, Tokyo, Japan.Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide surveyAnn SurgAnn Surg532-4225932013/03/13Carcinoma, Hepatocellular/*diagnosis/epidemiologyFemaleHumansIncidenceJapan/epidemiologyKaplan-Meier EstimateLiver Neoplasms/*diagnosis/epidemiologyMaleMiddle AgedNeoplasm Staging/*methods*Population SurveillancePrognosisRetrospective StudiesRisk FactorsRupture, Spontaneous/epidemiologySex FactorsSurvival Rate/trends2014Mar1528-1140 (Electronic) 0003-4932 (Linking)23478524https://www.ncbi.nlm.nih.gov/pubmed/2347852410.1097/SLA.0b013e31828846deengLai200621792179217917Lai, E. C.Lau, W. Y.Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong.Spontaneous rupture of hepatocellular carcinoma: a systematic reviewArch SurgArch SurgArchives of surgery191-814122006/02/24Antineoplastic Agents/administration & dosageCarcinoma, Hepatocellular/mortality/pathology/*therapyChemoembolization, Therapeutic/*methodsHepatectomy/*methodsHumans*LaparoscopyLiver Neoplasms/mortality/pathology/*therapyRupture, SpontaneousSurvival RateTreatment Outcome2006Feb0004-0010 (Print) 0004-0010 (Linking)16490898https://www.ncbi.nlm.nih.gov/pubmed/1649089810.1001/archsurg.141.2.191engwDyK  _ENREF_219wDyK  _ENREF_220n DShin201121802180218017Shin, B. S.Park, M. H.Jeon, G. S.Department of Radiology, Chungnam National University Hospital, Daejeon, South Korea.Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolizationActa RadiolActa Radiol331-55232011/04/19AdultAgedAged, 80 and overBiomarkers, Tumor/analysisCarcinoma, Hepatocellular/mortality/pathology/*therapyChemoembolization, Therapeutic/methodsEmbolization, Therapeutic/*methodsFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedMultivariate AnalysisPortal Vein/pathologyPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsRupture, Spontaneous/diagnostic imaging/mortality/therapySurvival RateTomography, X-Ray ComputedTreatment OutcomeVenous Thrombosis/diagnostic imaging/pathology2011Apr 11600-0455 (Electronic) 0284-1851 (Linking)21498371https://www.ncbi.nlm.nih.gov/pubmed/2149837110.1258/ar.2010.100369engn DShin201121802180218017Shin, B. S.Park, M. H.Jeon, G. S.Department of Radiology, Chungnam National University Hospital, Daejeon, South Korea.Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolizationActa RadiolActa Radiol331-55232011/04/19AdultAgedAged, 80 and overBiomarkers, Tumor/analysisCarcinoma, Hepatocellular/mortality/pathology/*therapyChemoembolization, Therapeutic/methodsEmbolization, Therapeutic/*methodsFemaleHumansLiver Neoplasms/mortality/pathology/*therapyMaleMiddle AgedMultivariate AnalysisPortal Vein/pathologyPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsRupture, Spontaneous/diagnostic imaging/mortality/therapySurvival RateTomography, X-Ray ComputedTreatment OutcomeVenous Thrombosis/diagnostic imaging/pathology2011Apr 11600-0455 (Electronic) 0284-1851 (Linking)21498371https://www.ncbi.nlm.nih.gov/pubmed/2149837110.1258/ar.2010.100369engwDyK  _ENREF_221 DAoki201421812181218117Aoki, T.Kokudo, N.Matsuyama, Y.Izumi, N.Ichida, T.Kudo, M.Ku, Y.Sakamoto, M.Nakashima, O.Matsui, O.Makuuchi, M.Liver Cancer Study Group of, Japan*Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan daggerDepartment of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan double daggerDepartment of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Musashino, Japan section signDepartment of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Izunokuni, Japan paragraph signDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka Sayama, Japan ||Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan **Department of Pathology, Keio University School of Medicine, Tokyo, Japan daggerdaggerDepartment of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan double daggerdouble daggerDepartment of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan section sign section signSurgery, Japanese Red Cross Medical Center, Tokyo, Japan.Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide surveyAnn SurgAnn Surg532-4225932013/03/13Carcinoma, Hepatocellular/*diagnosis/epidemiologyFemaleHumansIncidenceJapan/epidemiologyKaplan-Meier EstimateLiver Neoplasms/*diagnosis/epidemiologyMaleMiddle AgedNeoplasm Staging/*methods*Population SurveillancePrognosisRetrospective StudiesRisk FactorsRupture, Spontaneous/epidemiologySex FactorsSurvival Rate/trends2014Mar1528-1140 (Electronic) 0003-4932 (Linking)23478524https://www.ncbi.nlm.nih.gov/pubmed/2347852410.1097/SLA.0b013e31828846deeng DAoki201421812181218117Aoki, T.Kokudo, N.Matsuyama, Y.Izumi, N.Ichida, T.Kudo, M.Ku, Y.Sakamoto, M.Nakashima, O.Matsui, O.Makuuchi, M.Liver Cancer Study Group of, Japan*Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan daggerDepartment of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan double daggerDepartment of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Musashino, Japan section signDepartment of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Izunokuni, Japan paragraph signDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka Sayama, Japan ||Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan **Department of Pathology, Keio University School of Medicine, Tokyo, Japan daggerdaggerDepartment of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan double daggerdouble daggerDepartment of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan section sign section signSurgery, Japanese Red Cross Medical Center, Tokyo, Japan.Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide surveyAnn SurgAnn Surg532-4225932013/03/13Carcinoma, Hepatocellular/*diagnosis/epidemiologyFemaleHumansIncidenceJapan/epidemiologyKaplan-Meier EstimateLiver Neoplasms/*diagnosis/epidemiologyMaleMiddle AgedNeoplasm Staging/*methods*Population SurveillancePrognosisRetrospective StudiesRisk FactorsRupture, Spontaneous/epidemiologySex FactorsSurvival Rate/trends2014Mar1528-1140 (Electronic) 0003-4932 (Linking)23478524https://www.ncbi.nlm.nih.gov/pubmed/2347852410.1097/SLA.0b013e31828846deengwDyK  _ENREF_219$$If!vh#v#v #vB #v #v #v\:V l4 t0|6+,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l4 t0|6+,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytj$$If!vh#v#v #vB #v #v #v\:V l t0|6,55 5B 5 5 5\ytjwDyK  _ENREF_222DZhou201144444417Zhou, J.Yu, L.Gao, X.Hu, J.Wang, J.Dai, Z.Wang, J. F.Zhang, Z.Lu, S.Huang, X.Wang, Z.Qiu, S.Wang, X.Yang, G.Sun, H.Tang, Z.Wu, Y.Zhu, H.Fan, J.Liver Cancer Institute, Zhongshan Hospital, Fudan University, People's Republic of China.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinomaJ Clin OncolJ Clin Oncol4781-829362011/11/23AdultCarcinoma, Hepatocellular/blood/*diagnosisEarly Detection of CancerFemaleGene Expression ProfilingHepatitis B, Chronic/*complicationsHumansLiver Neoplasms/blood/*diagnosisMaleMicroRNAs/*bloodMiddle AgedROC Curve2011Dec 201527-7755 (Electronic) 0732-183X (Linking)22105822https://www.ncbi.nlm.nih.gov/pubmed/2210582210.1200/JCO.2011.38.2697pDZhou201144444417Zhou, J.Yu, L.Gao, X.Hu, J.Wang, J.Dai, Z.Wang, J. F.Zhang, Z.Lu, S.Huang, X.Wang, Z.Qiu, S.Wang, X.Yang, G.Sun, H.Tang, Z.Wu, Y.Zhu, H.Fan, J.Liver Cancer Institute, Zhongshan Hospital, Fudan University, People's Republic of China.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinomaJ Clin OncolJ Clin Oncol4781-829362011/11/23AdultCarcinoma, Hepatocellular/blood/*diagnosisEarly Detection of CancerFemaleGene Expression ProfilingHepatitis B, Chronic/*complicationsHumansLiver Neoplasms/blood/*diagnosisMaleMicroRNAs/*bloodMiddle AgedROC Curve2011Dec 201527-7755 (Electronic) 0732-183X (Linking)22105822https://www.ncbi.nlm.nih.gov/pubmed/2210582210.1200/JCO.2011.38.2697puDyK  _ENREF_42DGuo201821992199219917Guo, W.Sun, Y. F.Shen, M. N.Ma, X. L.Wu, J.Zhang, C. Y.Zhou, Y.Xu, Y.Hu, B.Zhang, M.Wang, G.Chen, W. Q.Guo, L.Lu, R. Q.Zhou, C. H.Zhang, X.Shi, Y. H.Qiu, S. J.Pan, B. S.Cao, Y.Zhou, J.Yang, X. R.Fan, J.Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University; and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, P.R. China. Department of Clinical Laboratory, Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China. Department of Clinical Laboratory, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. Department of Laboratory Medicine, Shanghai Cancer Center, Fudan University, Shanghai, P.R. China. Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. Cancer Research Institute, Xiangya School of Medicine, Central South University; and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China. Institute of Biomedical Sciences, Fudan University, Shanghai, P.R. China. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University; and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, P.R. China. fan.jia@zs-hospital.sh.cn yang.xinrong@zs-hospital.sh.cn.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular CarcinomaClin Cancer ResClin Cancer Res2203-22132492018/01/28AdultAgedBiomarkersCarcinoma, Hepatocellular/*diagnosis/genetics/metabolism/*mortalityFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumans*ImmunophenotypingKaplan-Meier EstimateLiver Neoplasms/*diagnosis/genetics/metabolism/*mortalityMaleMiddle AgedNeoplasm GradingNeoplasm StagingNeoplastic Cells, Circulating/*metabolism/pathologyNeoplastic Stem Cells/*metabolism/pathologyPrognosisROC CurveRecurrence2018May 11078-0432 (Print) 1078-0432 (Linking)29374055https://www.ncbi.nlm.nih.gov/pubmed/2937405510.1158/1078-0432.CCR-17-1753engZhou201621912191219117Zhou, Y.Wang, B.Wu, J.Zhang, C.Zhou, Y.Yang, X.Zhou, J.Guo, W.Fan, J.Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China. Liver Cancer Institute, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China. Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China. guo.wei@zs-hospital.sh.cn. Liver Cancer Institute, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China. fan.jia@zs-hospital.sh.cn.Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resectionBMC CancerBMC Cancer506162016/07/22AdultAgedAged, 80 and overCarcinoma, Hepatocellular/genetics/pathology/*surgeryEpithelial Cell Adhesion Molecule/blood/*geneticsFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLiver/metabolism/pathology/surgeryLiver Neoplasms/genetics/pathology/*surgeryMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplastic Cells, Circulating/*metabolismOutcome Assessment (Health Care)/methods/statistics & numerical dataPreoperative PeriodPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionT-Lymphocytes, Regulatory/*metabolismTime Factors*Circulating tumor cells*Epithelial cell adhesion molecule*Hepatocellular carcinoma*Regulatory T cells*Tumor recurrence2016Jul 201471-2407 (Electronic) 1471-2407 (Linking)27439521https://www.ncbi.nlm.nih.gov/pubmed/27439521PMC495526610.1186/s12885-016-2526-4engwDyK  _ENREF_223wDyK  _ENREF_224 DSun201321882188218817Sun, Y. F.Xu, Y.Yang, X. R.Guo, W.Zhang, X.Qiu, S. J.Shi, R. Y.Hu, B.Zhou, J.Fan, J.Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, PR China.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resectionHepatologyHepatology1458-685742012/11/24AC133 AntigenATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette Transporters/metabolismAntigens, CD/metabolismAntigens, Neoplasm/*metabolismBiomarkers, Tumor/metabolismCarcinoma, Hepatocellular/*metabolism/*pathology/surgeryCell Adhesion Molecules/*metabolismCell CountEpithelial Cell Adhesion MoleculeEpithelial-Mesenchymal TransitionFemaleFollow-Up StudiesGlycoproteins/metabolism*HepatectomyHumansLiver Neoplasms/*metabolism/*pathology/surgeryMaleMiddle AgedNeoplasm Proteins/metabolismNeoplasm Recurrence, Local/*epidemiologyPeptides/metabolismPredictive Value of TestsPrognosisProspective StudiesRisk Factors2013Apr1527-3350 (Electronic) 0270-9139 (Linking)23175471https://www.ncbi.nlm.nih.gov/pubmed/2317547110.1002/hep.26151engwDyK  _ENREF_225 DGuo201421892189218917Guo, W.Yang, X. R.Sun, Y. F.Shen, M. N.Ma, X. L.Wu, J.Zhang, C. Y.Zhou, Y.Xu, Y.Hu, B.Zhang, X.Zhou, J.Fan, J.Department of Liver Surgery, Liver cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China. Department of Laboratory Medicine, Zhongshan hospital, Fudan University. Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China. Department of Liver Surgery, Liver cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China. Department of Laboratory Medicine, Zhongshan hospital, Fudan University. Department of Liver Surgery, Liver cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China. Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China. Department of Liver Surgery, Liver cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China. Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China. jiafan99@yahoo.com.Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platformClin Cancer ResClin Cancer Res4794-80520182014/07/11Antigens, Neoplasm/*metabolismBiomarkers, Tumor/analysis/metabolismCarcinoma, Hepatocellular/*blood/mortality/pathologyCell Adhesion Molecules/*metabolismEpithelial Cell Adhesion MoleculeFemaleHumansKaplan-Meier EstimateLiver Neoplasms/*blood/mortality/pathologyMaleMiddle AgedNeoplastic Cells, Circulating/*metabolism/pathologyRNA, MessengerReal-Time Polymerase Chain Reaction/*methodsSensitivity and Specificity2014Sep 151078-0432 (Print) 1078-0432 (Linking)25009297https://www.ncbi.nlm.nih.gov/pubmed/2500929710.1158/1078-0432.CCR-14-0251engwDyK  _ENREF_226j DSun201821982198219817Sun, Y. F.Guo, W.Xu, Y.Shi, Y. H.Gong, Z. J.Ji, Y.Du, M.Zhang, X.Hu, B.Huang, A.Chen, G. G.Lai, P. B. S.Cao, Y.Qiu, S. J.Zhou, J.Yang, X. R.Fan, J.Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, P.R. China. Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China. Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China. Cancer Research Institute, Xiangya School of Medicine, Central South University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China. Institute of Biomedical Sciences, Fudan University, Shanghai, P.R. China. Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, P.R. China. fan.jia@zs-hospital.sh.cn yang.xinrong@zs-hospital.sh.cn.Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular CarcinomaClin Cancer ResClin Cancer Res547-5592432017/10/27Biomarkers, TumorCarcinoma, Hepatocellular/*diagnosis/etiology/mortalityCell Count*Epithelial-Mesenchymal Transition/geneticsFlow CytometryGene Expression ProfilingHemodynamicsHumansImmunohistochemistryLiver Neoplasms/*diagnosis/etiology/mortalityNeoplastic Cells, Circulating/*metabolism/*pathologyNeovascularization, Pathologic/genetics/metabolismPhenotypePrognosisShear Strength2018Feb 11078-0432 (Print) 1078-0432 (Linking)29070526https://www.ncbi.nlm.nih.gov/pubmed/2907052610.1158/1078-0432.CCR-17-1063engwDyK  _ENREF_227B DQu201922002200220017Qu, C.Wang, Y.Wang, P.Chen, K.Wang, M.Zeng, H.Lu, J.Song, Q.Diplas, B. H.Tan, D.Fan, C.Guo, Q.Zhu, Z.Yin, H.Jiang, L.Chen, X.Zhao, H.He, H.Wang, Y.Li, G.Bi, X.Zhao, X.Chen, T.Tang, H.Lv, C.Wang, D.Chen, W.Zhou, J.Zhao, H.Cai, J.Wang, X.Wang, S.Yan, H.Zeng, Y. X.Cavenee, W. K.Jiao, Y.State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China; quchf@cicams.ac.cn wcavenee@ucsd.edu jiaoyuchen@126.com. Immunology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. National Cancer Registration Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, P. R. China. Qidong Liver Cancer Institute/Qidong People's Hospital, Qidong, 226200 Jiangsu Province, China. The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710. Genetron Health (Beijing) Co. Ltd., 102206 Beijing, China. Lingbi Center for Disease Control and Prevention, 234200 Anhui Province, China. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. Department of Ultrasonography, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Center for Bioinformatics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, 100005 Beijing, China. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, China. Office for Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 Beijing, P. R. China. Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093-0660 quchf@cicams.ac.cn wcavenee@ucsd.edu jiaoyuchen@126.com.Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsyProc Natl Acad Sci U S AProc Natl Acad Sci U S A6308-6312116132019/03/13Biomarkers, Tumor/*bloodCarcinoma, Hepatocellular/blood/*diagnosis/pathologyCell-Free Nucleic AcidsEarly Detection of Cancer/*methodsHepatitis B Surface Antigens/*bloodHepatitis B virusHepatitis B, ChronicHumansLiquid Biopsy/*methodsLiver Neoplasms/blood/*diagnosis/pathologySensitivity and SpecificityUltrasonography*HBsAg-seropositive*cell free DNA*early detection of cancer*hepatocellular carcinomaHealth (Beijing) Co. Ltd. Y.J. is one of the cofounders of Genetron Health(Beijing) Co. Ltd. B.H.D. is a consultant for Genetron Health (Beijing) Co. Ltd.Y.J., Q.C., P.W., Yuting Wang, K.C., Q.S., S.W., and H. Yan have filedpatents/patent applications based on the data generated from this work. Otherauthors declare no conflict of interest.2019Mar 261091-6490 (Electronic) 0027-8424 (Linking)30858324https://www.ncbi.nlm.nih.gov/pubmed/30858324PMC644262910.1073/pnas.1819799116engHuang201621922192219217Huang, A.Zhang, X.Zhou, S. L.Cao, Y.Huang, X. W.Fan, J.Yang, X. R.Zhou, J.Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University. Cancer Research Institute, Central South University. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Institute of Biomedical Sciences, Fudan University, Shanghai, 200032, China. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University; State Key Laboratory of Genetic Engineering Fudan University, Shanghai, 200433, China.Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular CarcinomaJ CancerJ Cancer1798-18037132016/10/05cfDNAcirculating cell-free DNAhepatocellular carcinoma.integrity20161837-9664 (Print) 1837-9664 (Linking)27698918https://www.ncbi.nlm.nih.gov/pubmed/27698918PMC503936210.7150/jca.15618engwDyK  _ENREF_228wDyK  _ENREF_229DHuang201721952195219517Huang, A.Zhao, X.Yang, X. R.Li, F. Q.Zhou, X. L.Wu, K.Zhang, X.Sun, Q. M.Cao, Y.Zhu, H. M.Wang, X. D.Yang, H. M.Wang, J.Tang, Z. Y.Hou, Y.Fan, J.Zhou, J.Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai 200032, China. BGI-Shenzhen, Shenzhen 518083, China; China National Genebank-Shenzhen, BGI-Shenzhen, Shenzhen 518083, China. Cancer Research Institute, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha 410078, China. BGI-Shenzhen, Shenzhen 518083, China; BGI-Tianjin, Tianjin 300308, China. Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China. BGI-Shenzhen, Shenzhen 518083, China; James D. Watson Institute of Genome Sciences, Hangzhou 310058, China. BGI-Shenzhen, Shenzhen 518083, China; China National Genebank-Shenzhen, BGI-Shenzhen, Shenzhen 518083, China. Electronic address: houyong@genomics.cn. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai 200032, China; Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China; State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200433, China. Electronic address: fan.jia@zs-hospital.sh.cn. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai 200032, China; Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China; State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200433, China. Electronic address: zhou.jian@zs-hospital.sh.cn.Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinomaJ HepatolJ Hepatol293-3016722017/03/23Carcinoma, Hepatocellular/*genetics/*therapyDNA Copy Number VariationsDNA Mutational AnalysisDNA, Neoplasm/blood/geneticsFemaleHigh-Throughput Nucleotide SequencingHumansLiver Neoplasms/*genetics/*therapyMale*Molecular Targeted Therapy*MutationPhylogenySequence Analysis, DNAWhole Exome Sequencing*Circulating cell-free DNA (cfDNA)*Hepatocellular carcinoma (HCC)*Intratumoral heterogeneity (ITH)*Target therapy*Targeted deep sequencing (TDS)2017Aug1600-0641 (Electronic) 0168-8278 (Linking)28323123https://www.ncbi.nlm.nih.gov/pubmed/2832312310.1016/j.jhep.2017.03.005engHuang201621942194219417Huang, A.Zhang, X.Zhou, S. L.Cao, Y.Huang, X. W.Fan, J.Yang, X. R.Zhou, J.Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University. Cancer Research Institute, Central South University. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Institute of Biomedical Sciences, Fudan University, Shanghai, No.130, Dong'an Rd, 200032, China. Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University; State Key Laboratory of Genetic Engineering Fudan University, No.220, Handan Rd, Shanghai, 200433, China.Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral HeterogeneityJ CancerJ Cancer1907-19147132016/10/05circulating tumor DNAdroplet digital PCRhepatocellular carcinomaintratumoral heterogeneity.liquid biopsy20161837-9664 (Print) 1837-9664 (Linking)27698932https://www.ncbi.nlm.nih.gov/pubmed/27698932PMC503937610.7150/jca.15823engwDyK  _ENREF_230wDyK  _ENREF_231JDCai201922012201220117Cai, J.Chen, L.Zhang, Z.Zhang, X.Lu, X.Liu, W.Shi, G.Ge, Y.Gao, P.Yang, Y.Ke, A.Xiao, L.Dong, R.Zhu, Y.Yang, X.Wang, J.Zhu, T.Yang, D.Huang, X.Sui, C.Qiu, S.Shen, F.Sun, H.Zhou, W.Zhou, J.Nie, J.Zeng, C.Stroup, E. K.Zhang, X.Chiu, B. C.Lau, W. Y.He, C.Wang, H.Zhang, W.Fan, J.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University & Ministry of Education, Shanghai, China. Key Laboratory of Medical Epigenetics and Metabolism, Institute of Biomedical Sciences, Fudan University, Shanghai, China. The International Cooperation Laboratory on Signal Transduction, The Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China. National Center for Liver Cancer, Shanghai, China. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Shanghai Epican Genetech Co. Ltd., Shanghai, China. Department of Laboratory Medicine, The Tenth People's Hospital of Shanghai, Tongji University, Shanghai, China. School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Department of Hepatobiliary Surgery, The Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China. Department of Laboratory Medicine, Shanghai Jiao Tong University, Shanghai, China. Shanghai Public Health Clinic Center, Fudan University, Shanghai, China. Department of Laboratory Medicine, Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China. Department of Chemistry, University of Chicago, Chicago, Illinois, USA. Driskill Graduate Program in Life Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Chicago. Department of Medicine, University of Illinois, Chicago, Illinois, USA. Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA. Faculty of Medicine, The Chinese University of Hong Kong, New Territories, Hong Kong, China. Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA. Institute for Biophysical Dynamics, University of Chicago, Chicago, Illinois, USA. The Howard Hughes Medical Institute, University of Chicago, Chicago, Illinois, USA. Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer, The Second Military Medical University & Ministry of Education, Shanghai, China. The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinomaGutGut2195-220568122019/07/31*cancer*hepatobiliary cancer*hepatocellular carcinomaby Shanghai Epican Genetech Co. Ltd. for clinical applications in human diseasesfrom the University of Chicago. XL is a co-founder of Shanghai Epican GenetechCo. Ltd. CH and WZ are shareholders of Shanghai Epican Genetech Co. Ltd. CH is ascientific founder of Accent Therapeutics, Inc. and a member of its scientificadvisory board. All other authors report no potential conflicts of interest.2019Dec1468-3288 (Electronic) 0017-5749 (Linking)31358576https://www.ncbi.nlm.nih.gov/pubmed/3135857610.1136/gutjnl-2019-318882engwDyK  _ENREF_232dDLi201721972197219717Li, W.Zhang, X.Lu, X.You, L.Song, Y.Luo, Z.Zhang, J.Nie, J.Zheng, W.Xu, D.Wang, Y.Dong, Y.Yu, S.Hong, J.Shi, J.Hao, H.Luo, F.Hua, L.Wang, P.Qian, X.Yuan, F.Wei, L.Cui, M.Zhang, T.Liao, Q.Dai, M.Liu, Z.Chen, G.Meckel, K.Adhikari, S.Jia, G.Bissonnette, M. B.Zhang, X.Zhao, Y.Zhang, W.He, C.Liu, J.Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China. Section of Hematology/Oncology, Department of Medicine, University of Illinois, Chicago, IL 60612, USA. Department of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA. Shanghai Epican Genetech, Co. Ltd., Zhangjiang Hi-Tech Park, Shanghai 201203, China. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China. Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai 200032, China. Department of Digestive Diseases, Pudong Hospital, Fudan University, Shanghai 201399, China. Department of Oncology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China. Beijing National Laboratory for Molecular Sciences, College of Chemistry, Peking University, Beijing 100871, China. Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Peking University, Beijing 100871, China. Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. Department of Chemical Biology, Structure and Function Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China. Department of Preventive Medicine and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Department of Immunology, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Fudan University, Shanghai 200433, China.5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancersCell ResCell Res1243-125727102017/09/205-Methylcytosine/*analogs & derivatives/bloodAdolescentAdultAgedBiomarkers, Tumor/*bloodCell-Free Nucleic Acids/blood/geneticsCirculating Tumor DNA/*bloodDNA Methylation/geneticsEpigenomicsFemaleGene Expression Regulation, Neoplastic/geneticsHumansLiquid BiopsyMaleMiddle AgedNeoplasms/*blood/classification/genetics/pathologyYoung Adult2017Oct1748-7838 (Electronic) 1001-0602 (Linking)28925386https://www.ncbi.nlm.nih.gov/pubmed/28925386PMC563068310.1038/cr.2017.121engwDyK  _ENREF_233 DLlovet201822812281228117Llovet, J. M.Montal, R.Sia, D.Finn, R. S.Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Josep.Llovet@mssm.edu. Liver Cancer Translational Lab, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Josep.Llovet@mssm.edu. Liver Cancer Translational Lab, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.Molecular therapies and precision medicine for hepatocellular carcinomaNat Rev Clin OncolNature Reviews Clinical OncologyNat Rev Clin Oncol599-61615102018/08/01Anilides/therapeutic useAntibodies, Monoclonal/therapeutic useCarcinoma, Hepatocellular/*drug therapy/genetics/pathologyHumansImmunotherapyLiver Neoplasms/*drug therapy/genetics/pathology*Molecular Targeted TherapyPhenylurea Compounds/therapeutic use*Precision MedicinePyridines/therapeutic useQuinolines/therapeutic useSorafenib/therapeutic use2018Oct1759-4782 (Electronic) 1759-4774 (Linking)30061739https://www.ncbi.nlm.nih.gov/pubmed/3006173910.1038/s41571-018-0073-4wDyK  _ENREF_234DGao201922802280228017Gao, Q.Zhu, H.Dong, L.Shi, W.Chen, R.Song, Z.Huang, C.Li, J.Dong, X.Zhou, Y.Liu, Q.Ma, L.Wang, X.Zhou, J.Liu, Y.Boja, E.Robles, A. I.Ma, W.Wang, P.Li, Y.Ding, L.Wen, B.Zhang, B.Rodriguez, H.Gao, D.Zhou, H.Fan, J.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, 180 Fenglin Road, Shanghai 200032, China. Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. OrigiMed, Shanghai 201114, China. State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China. Department of Molecular and Human Genetics, Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston,TX 77030, USA. Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, 180 Fenglin Road, Shanghai 200032, China; Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. Department of Pharmacology, Cancer Biology Institute, Yale University School of Medicine, West Haven, CT 06516, USA. Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institutel, NIH, Bethesda, MD 20892, USA. Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Department of Medicine, McDonnell Genome Institute, Siteman Cancer Center, Washington University, St. Louis, MO 63108, USA. State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China. Electronic address: dgao@sibcb.ac.cn. Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China. Electronic address: zhouhu@simm.ac.cn. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, 180 Fenglin Road, Shanghai 200032, China; Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. Electronic address: fan.jia@zs-hospital.sh.cn.Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaCellCell561-577 e2217922019/10/05AA signatureAldoaCtnnb1hepaotcellular carcinomametabolismneoantigenprognosisproteogenomicsproteomics2019Oct 31097-4172 (Electronic) 0092-8674 (Linking)31585088https://www.ncbi.nlm.nih.gov/pubmed/3158508810.1016/j.cell.2019.08.052wDyK  _ENREF_235DJiang201922822282228217Jiang, Y.Sun, A.Zhao, Y.Ying, W.Sun, H.Yang, X.Xing, B.Sun, W.Ren, L.Hu, B.Li, C.Zhang, L.Qin, G.Zhang, M.Chen, N.Zhang, M.Huang, Y.Zhou, J.Zhao, Y.Liu, M.Zhu, X.Qiu, Y.Sun, Y.Huang, C.Yan, M.Wang, M.Liu, W.Tian, F.Xu, H.Zhou, J.Wu, Z.Shi, T.Zhu, W.Qin, J.Xie, L.Fan, J.Qian, X.He, F.Chinese Human Proteome Project, ConsortiumState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China. College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China. Department of Liver Surgery & Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China. Center for Bioinformatics and Computational Biology, and the Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China. Shanghai Center for Bioinformation Technology, Shanghai Academy of Science and Technology, Shanghai, China. Department of Liver Surgery & Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China. fan.jia@zs-hospital.sh.cn. State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China. qianxh1@163.com. College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China. qianxh1@163.com. State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China. hefc@nic.bmi.ac.cn.Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinomaNatureNature257-26156777472019/03/01AnimalsCarcinoma, Hepatocellular/*drug therapy/*metabolism/pathology/virologyCell Growth ProcessesCell MovementHepatitis B virus/pathogenicityHumansLiver Neoplasms/*drug therapy/*metabolism/pathology/virologyMaleMiceMice, Inbred NODMice, SCIDMolecular Targeted Therapy/*trendsNeoplasm StagingPrognosis*ProteomicsSterol O-Acyltransferase/genetics2019Mar1476-4687 (Electronic) 0028-0836 (Linking)30814741https://www.ncbi.nlm.nih.gov/pubmed/3081474110.1038/s41586-019-0987-8wDyK  _ENREF_236wDyK  _ENREF_237$$If!vh#v#v#vb:V l t065ytg$$If!vh#v#v#vb:V l t065ytg$$If!vh#v#v#vb:V l t065ytg$$If!vh#v#v#vb:V l t065ytg$$If!vh#v8:V  t!,58/ /  / / 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4$$If!vh#vp:V  t!,5p/ 4p($$If!vh#vp:V  t!,5p/ 4p($$If!vh#vp:V  t!,5p/ 4p($$If!vh#vp:V  t!,5p/ 4p($$If!vh#vp:V  t!,5p/ 4p(X$$If!vh#v!:V J t!,5!/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v:V  t!,5/ 4X$$If!vh#v!:V  t!,5!/ 4 DShi201022952295229517Shi, J.Lai, E. C.Li, N.Guo, W. X.Xue, J.Lau, W. Y.Wu, M. C.Cheng, S. Q.Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombusAnn Surg OncolAnn Surg Oncol2073-801782010/02/05AdultCarcinoma, Hepatocellular/complications/mortality/*surgeryFemaleFollow-Up StudiesHepatectomy/*adverse effectsHospital MortalityHumansLiver Neoplasms/complications/mortality/*surgeryMaleMesenteric Vascular Occlusion/*surgeryMesenteric Veins/pathology/surgeryMiddle AgedPortal Vein/pathology/*surgeryRetrospective StudiesSeverity of Illness IndexSurvival RateThrombectomy/adverse effectsTreatment OutcomeVenous Thrombosis/complications/mortality/*surgery2010Aug1534-4681 (Electronic) 1068-9265 (Linking)20131013https://www.ncbi.nlm.nih.gov/pubmed/2013101310.1245/s10434-010-0940-4wDyK  _ENREF_238wDyK  _ENREF_239|5DLyu201822022202220217Lyu, N.Lin, Y.Kong, Y.Zhang, Z.Liu, L.Zheng, L.Mu, L.Wang, J.Li, X.Pan, T.Xie, Q.Liu, Y.Lin, A.Wu, P.Zhao, M.Division of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Minimally Invasive Interventional and Target Treatment, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, China. Department of Interventional Radiology, First People's Hospital, Guangzhou, China. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinomaGutGut395-3966722017/06/09Antineoplastic Combined Chemotherapy Protocols*Carcinoma, HepatocellularCisplatinFluorouracilHumans*LeucovorinLiver NeoplasmsOrganoplatinum CompoundsOxaliplatinTreatment Outcome*Advanced HCC*folfox*haic2018Feb1468-3288 (Electronic) 0017-5749 (Linking)28592441https://www.ncbi.nlm.nih.gov/pubmed/2859244110.1136/gutjnl-2017-314138engLyu201822032203220317Lyu, N.Kong, Y.Mu, L.Lin, Y.Li, J.Liu, Y.Zhang, Z.Zheng, L.Deng, H.Li, S.Xie, Q.Guo, R.Shi, M.Xu, L.Cai, X.Wu, P.Zhao, M.Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China. Medical Imaging Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: zhaoming@sysucc.org.cn.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinomaJ HepatolJ Hepatol60-696912018/02/23AdolescentAdultAgedAged, 80 and overAntineoplastic Agents/administration & dosageCarcinoma, Hepatocellular/diagnosis/*drug therapy/mortalityChina/epidemiologyDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFluorouracil/*administration & dosageFollow-Up StudiesHepatic ArteryHumansImmunosuppressive Agents/administration & dosageInfusions, Intra-ArterialLeucovorin/*administration & dosageLiver Neoplasms/diagnosis/*drug therapy/mortalityMaleMiddle Aged*Neoplasm StagingOxaliplatin/*administration & dosageRetrospective StudiesSorafenib/*administration & dosageSurvival Rate/trendsTreatment OutcomeVitamin B Complex/administration & dosageYoung Adult*Arterial infusion chemotherapy*folfox*Fluorouracil*Hepatocellular carcinoma*Oxaliplatin*Sorafenib2018Jul1600-0641 (Electronic) 0168-8278 (Linking)29471013https://www.ncbi.nlm.nih.gov/pubmed/2947101310.1016/j.jhep.2018.02.008engHe201922062206220617He, M.Li, Q.Zou, R.Shen, J.Fang, W.Tan, G.Zhou, Y.Wu, X.Xu, L.Wei, W.Le, Y.Zhou, Z.Zhao, M.Guo, Y.Guo, R.Chen, M.Shi, M.Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Ultrasonography, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Kaiping Central Hospital, KaiPing, China. First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Guangzhou No.12 People's Hospital, Guangzhou, China. The First Affiliated Hospital of the University of South China, HengYang, China. Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical TrialJAMA OncolJAMA OncolJAMA oncology953-960572019/05/102019Jul 12374-2445 (Electronic) 2374-2437 (Linking)31070690https://www.ncbi.nlm.nih.gov/pubmed/31070690PMC651227810.1001/jamaoncol.2019.0250engLyu201922052205220517Lyu, N.Kong, Y.Pan, T.Mu, L.Li, S.Liu, Y.Deng, H.Li, J.Shi, M.Xu, L.Guo, R.Chen, M.Wu, P.Zhao, M.Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Breast Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Vascular Interventional Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Department of Medical Imaging, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China; Department of Medical Imaging, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Electronic address: zhaoming@sysucc.org.cn.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic SpreadJ Vasc Interv RadiolJ Vasc Interv Radiol349-357 e23032019/03/02AdultAgedAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useCarcinoma, Hepatocellular/diagnostic imaging/*drug therapy/mortality/secondaryChinaClinical Decision-MakingFemaleFluorouracil/*administration & dosage/adverse effects*Hepatic ArteryHumansInfusions, Intra-ArterialLeucovorin/*administration & dosage/adverse effectsLiver Neoplasms/diagnostic imaging/*drug therapy/mortality/pathologyLung Neoplasms/mortality/secondaryMaleMiddle AgedOxaliplatin/*administration & dosage/adverse effectsPatient SelectionRetrospective StudiesTime FactorsTreatment OutcomeYoung Adult2019Mar1535-7732 (Electronic) 1051-0443 (Linking)30819477https://www.ncbi.nlm.nih.gov/pubmed/3081947710.1016/j.jvir.2018.09.004eng|5DLyu201822022202220217Lyu, N.Lin, Y.Kong, Y.Zhang, Z.Liu, L.Zheng, L.Mu, L.Wang, J.Li, X.Pan, T.Xie, Q.Liu, Y.Lin, A.Wu, P.Zhao, M.Division of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Minimally Invasive Interventional and Target Treatment, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, China. Department of Interventional Radiology, First People's Hospital, Guangzhou, China. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinomaGutGut395-3966722017/06/09Antineoplastic Combined Chemotherapy Protocols*Carcinoma, HepatocellularCisplatinFluorouracilHumans*LeucovorinLiver NeoplasmsOrganoplatinum CompoundsOxaliplatinTreatment Outcome*Advanced HCC*folfox*haic2018Feb1468-3288 (Electronic) 0017-5749 (Linking)28592441https://www.ncbi.nlm.nih.gov/pubmed/2859244110.1136/gutjnl-2017-314138engLyu201822032203220317Lyu, N.Kong, Y.Mu, L.Lin, Y.Li, J.Liu, Y.Zhang, Z.Zheng, L.Deng, H.Li, S.Xie, Q.Guo, R.Shi, M.Xu, L.Cai, X.Wu, P.Zhao, M.Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China. Medical Imaging Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: zhaoming@sysucc.org.cn.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinomaJ HepatolJ Hepatol60-696912018/02/23AdolescentAdultAgedAged, 80 and overAntineoplastic Agents/administration & dosageCarcinoma, Hepatocellular/diagnosis/*drug therapy/mortalityChina/epidemiologyDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFluorouracil/*administration & dosageFollow-Up StudiesHepatic ArteryHumansImmunosuppressive Agents/administration & dosageInfusions, Intra-ArterialLeucovorin/*administration & dosageLiver Neoplasms/diagnosis/*drug therapy/mortalityMaleMiddle Aged*Neoplasm StagingOxaliplatin/*administration & dosageRetrospective StudiesSorafenib/*administration & dosageSurvival Rate/trendsTreatment OutcomeVitamin B Complex/administration & dosageYoung Adult*Arterial infusion chemotherapy*folfox*Fluorouracil*Hepatocellular carcinoma*Oxaliplatin*Sorafenib2018Jul1600-0641 (Electronic) 0168-8278 (Linking)29471013https://www.ncbi.nlm.nih.gov/pubmed/2947101310.1016/j.jhep.2018.02.008engHe201922062206220617He, M.Li, Q.Zou, R.Shen, J.Fang, W.Tan, G.Zhou, Y.Wu, X.Xu, L.Wei, W.Le, Y.Zhou, Z.Zhao, M.Guo, Y.Guo, R.Chen, M.Shi, M.Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Ultrasonography, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Kaiping Central Hospital, KaiPing, China. First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Guangzhou No.12 People's Hospital, Guangzhou, China. The First Affiliated Hospital of the University of South China, HengYang, China. Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical TrialJAMA OncolJAMA OncolJAMA oncology953-960572019/05/102019Jul 12374-2445 (Electronic) 2374-2437 (Linking)31070690https://www.ncbi.nlm.nih.gov/pubmed/31070690PMC651227810.1001/jamaoncol.2019.0250engLyu201922052205220517Lyu, N.Kong, Y.Pan, T.Mu, L.Li, S.Liu, Y.Deng, H.Li, J.Shi, M.Xu, L.Guo, R.Chen, M.Wu, P.Zhao, M.Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Breast Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Vascular Interventional Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Department of Medical Imaging, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Clinical Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China; Department of Medical Imaging, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Department of Minimally Invasive Interventional Radiology, Center of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. Electronic address: zhaoming@sysucc.org.cn.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic SpreadJ Vasc Interv RadiolJ Vasc Interv Radiol349-357 e23032019/03/02AdultAgedAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useCarcinoma, Hepatocellular/diagnostic imaging/*drug therapy/mortality/secondaryChinaClinical Decision-MakingFemaleFluorouracil/*administration & dosage/adverse effects*Hepatic ArteryHumansInfusions, Intra-ArterialLeucovorin/*administration & dosage/adverse effectsLiver Neoplasms/diagnostic imaging/*drug therapy/mortality/pathologyLung Neoplasms/mortality/secondaryMaleMiddle AgedOxaliplatin/*administration & dosage/adverse effectsPatient SelectionRetrospective StudiesTime FactorsTreatment OutcomeYoung Adult2019Mar1535-7732 (Electronic) 1051-0443 (Linking)30819477https://www.ncbi.nlm.nih.gov/pubmed/3081947710.1016/j.jvir.2018.09.004engwDyK  _ENREF_240DWang201922042204220417Wang, Q.Xia, D.Bai, W.Wang, E.Sun, J.Huang, M.Mu, W.Yin, G.Li, H.Zhao, H.Li, J.Zhang, C.Zhu, X.Wu, J.Li, J.Gong, W.Li, Z.Lin, Z.Pan, X.Shi, H.Shao, G.Liu, J.Yang, S.Zheng, Y.Xu, J.Song, J.Wang, W.Wang, Z.Zhang, Y.Ding, R.Zhang, H.Yu, H.Zheng, L.Gu, W.You, N.Wang, G.Zhang, S.Feng, L.Liu, L.Zhang, P.Li, X.Chen, J.Xu, T.Zhou, W.Zeng, H.Zhang, Y.Huang, W.Jiang, W.Zhang, W.Shao, W.Li, L.Niu, J.Yuan, J.Li, X.Lv, Y.Li, K.Yin, Z.Xia, J.Fan, D.Han, G.China, H. C. C. Tace Study GroupDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Department of Hepatobiliary and Pancreatic Interventional Cancer, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Department of Minimally Invasive International Therapy, The Third Affiliated Hospital of Kunming University, Tumour Hospital of Yunnan Province, Kunming, China. Department of Radiology, The Southwest Hospital, Third Military Medical University, Chongqing, China. Department of Interventional Radiology, Jiangsu Provincial Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Department of Interventional Radiology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. Department of Interventional Radiology, The Affiliated Hospital of Nantong University, Nantong, China. Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. Department of Gastroenterology and Hepatology, Shandong Province Hospital Affiliated to Shandong University, Jinan, China. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China. Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Interventional Medical Centre of the Affiliated Hospital of Qingdao University, Qingdao, China. Department of Interventional Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Clinical Liver Diseases Research Centre, Nanjing Military Command, 180th Hospital of PLA, Quanzhou, China. Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China. Department of Interventional Radiology and Vascular Surgery, Hunan Provincial People's Hospital, Changsha, China. Department of Interventional Radiology, The Affiliated Tumour Hospital of Xinjiang Medical University, Urumqi, China. Department of Interventional Radiology, Yantai Yuhuangding Hospital, Yantai, China. Department of Medical Imaging, Nanjing General Hospital of the Nanjing Military Command, Nanjing, China. Department of Interventional Therapy, Shandong Tumour Hospital, Jinan, China. Department of Interventional Medicine, The First Affiliated Hospital of Lanzhou University, Lanzhou, China. Department of Health Statistics, Fourth Military Medical University, Xi'an, China. State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Department of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Electronic address: hangh@fmmu.edu.cn.Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational studyJ HepatolJ Hepatol893-9037052019/01/21Hepatocellular carcinomaIndividual predictionRisk stratificationTransarterial chemoembolization2019May1600-0641 (Electronic) 0168-8278 (Linking)30660709https://www.ncbi.nlm.nih.gov/pubmed/3066070910.1016/j.jhep.2019.01.013engDWang201922042204220417Wang, Q.Xia, D.Bai, W.Wang, E.Sun, J.Huang, M.Mu, W.Yin, G.Li, H.Zhao, H.Li, J.Zhang, C.Zhu, X.Wu, J.Li, J.Gong, W.Li, Z.Lin, Z.Pan, X.Shi, H.Shao, G.Liu, J.Yang, S.Zheng, Y.Xu, J.Song, J.Wang, W.Wang, Z.Zhang, Y.Ding, R.Zhang, H.Yu, H.Zheng, L.Gu, W.You, N.Wang, G.Zhang, S.Feng, L.Liu, L.Zhang, P.Li, X.Chen, J.Xu, T.Zhou, W.Zeng, H.Zhang, Y.Huang, W.Jiang, W.Zhang, W.Shao, W.Li, L.Niu, J.Yuan, J.Li, X.Lv, Y.Li, K.Yin, Z.Xia, J.Fan, D.Han, G.China, H. C. C. Tace Study GroupDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Department of Hepatobiliary and Pancreatic Interventional Cancer, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Department of Minimally Invasive International Therapy, The Third Affiliated Hospital of Kunming University, Tumour Hospital of Yunnan Province, Kunming, China. Department of Radiology, The Southwest Hospital, Third Military Medical University, Chongqing, China. Department of Interventional Radiology, Jiangsu Provincial Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Department of Interventional Radiology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. Department of Interventional Radiology, The Affiliated Hospital of Nantong University, Nantong, China. Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. Department of Gastroenterology and Hepatology, Shandong Province Hospital Affiliated to Shandong University, Jinan, China. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China. Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Interventional Medical Centre of the Affiliated Hospital of Qingdao University, Qingdao, China. Department of Interventional Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Clinical Liver Diseases Research Centre, Nanjing Military Command, 180th Hospital of PLA, Quanzhou, China. Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China. Department of Interventional Radiology and Vascular Surgery, Hunan Provincial People's Hospital, Changsha, China. Department of Interventional Radiology, The Affiliated Tumour Hospital of Xinjiang Medical University, Urumqi, China. Department of Interventional Radiology, Yantai Yuhuangding Hospital, Yantai, China. Department of Medical Imaging, Nanjing General Hospital of the Nanjing Military Command, Nanjing, China. Department of Interventional Therapy, Shandong Tumour Hospital, Jinan, China. Department of Interventional Medicine, The First Affiliated Hospital of Lanzhou University, Lanzhou, China. Department of Health Statistics, Fourth Military Medical University, Xi'an, China. State Key Laboratory of Cancer Biology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Department of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Electronic address: hangh@fmmu.edu.cn.Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational studyJ HepatolJ Hepatol893-9037052019/01/21Hepatocellular carcinomaIndividual predictionRisk stratificationTransarterial chemoembolization2019May1600-0641 (Electronic) 0168-8278 (Linking)30660709https://www.ncbi.nlm.nih.gov/pubmed/3066070910.1016/j.jhep.2019.01.013engwDyK  _ENREF_244L DXu201524224224217Xu, L.Peng, Z. W.Chen, M. S.Shi, M.Zhang, Y. J.Guo, R. P.Lin, X. J.Lau, W. Y.Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road II, Guangzhou, China. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. Electronic address: Chminsh@mail.sysu.edu.cn. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region.Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolizationJ HepatolJ HepatolJournal of hepatology122-306312015/03/01AdolescentAdultAgedAntineoplastic Agents/*administration & dosageCarcinoma, Hepatocellular/pathology/*therapyCatheterization, PeripheralChemoembolization, Therapeutic/*methodsFemaleFollow-Up StudiesHumansInjections, Intra-ArterialLiver Neoplasms/pathology/*therapyMaleMiddle Aged*Neoplasm Staging*NomogramsPrognosisProspective StudiesYoung AdultHepatocellular carcinomaPrognostic nomogramStaging systemTransarterial chemoembolization2015Jul1600-0641 (Electronic) 0168-8278 (Linking)25725438https://www.ncbi.nlm.nih.gov/pubmed/2572543810.1016/j.jhep.2015.02.034L DXu201524224224217Xu, L.Peng, Z. W.Chen, M. S.Shi, M.Zhang, Y. J.Guo, R. P.Lin, X. J.Lau, W. Y.Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road II, Guangzhou, China. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. Electronic address: Chminsh@mail.sysu.edu.cn. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region.Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolizationJ HepatolJ HepatolJournal of hepatology122-306312015/03/01AdolescentAdultAgedAntineoplastic Agents/*administration & dosageCarcinoma, Hepatocellular/pathology/*therapyCatheterization, PeripheralChemoembolization, Therapeutic/*methodsFemaleFollow-Up StudiesHumansInjections, Intra-ArterialLiver Neoplasms/pathology/*therapyMaleMiddle Aged*Neoplasm Staging*NomogramsPrognosisProspective StudiesYoung AdultHepatocellular carcinomaPrognostic nomogramStaging systemTransarterial chemoembolization2015Jul1600-0641 (Electronic) 0168-8278 (Linking)25725438https://www.ncbi.nlm.nih.gov/pubmed/2572543810.1016/j.jhep.2015.02.034wDyK  _ENREF_2450!DKudo201922982298229817Kudo, M.Ueshima, K.Ikeda, M.Torimura, T.Tanabe, N.Aikata, H.Izumi, N.Yamasaki, T.Nojiri, S.Hino, K.Tsumura, H.Kuzuya, T.Isoda, N.Yasui, K.Aino, H.Ido, A.Kawabe, N.Nakao, K.Wada, Y.Yokosuka, O.Yoshimura, K.Okusaka, T.Furuse, J.Kokudo, N.Okita, K.Johnson, P. J.Arai, Y.Tactics study groupDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan m-kudo@med.kindai.ac.jp. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Department of Gastroenterology and Hepatology, Kurume University School of Medicine, Kurume, Japan. Department of Gastroenterology, National Hospital Organisation Sendai Medical Center, Sendai, Japan. Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan. Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube-Yamaguchi, Japan. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki, Japan. Department of Gastroenterology and Hepatology, Hyogo Cancer Center, Akashi, Japan. Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa Hospital, Tagawa, Japan. Department of Gastroenterology and Hepatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University School of Medicine, Aichi, Japan. Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. Department of Gastroenterology, School of Medicine, Chiba University, Chiba, Japan. Center for Integrated Medical Research, Hiroshima University, Hiroshima, Japan. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan. Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan. Deapartment of Medicine, Shunan Memorial Hospital, Kudamatsu, Yamaguchi, Japan. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialGutGut2019/12/06combination therapy with transarterial chemoembolisation and sorafenibhepatocellular carcinomaprogression-free survivalsorafenibtransarterial chemoembolizationor advisory role for Kowa, MSD, BMS, Bayer, Chugai, Taiho. Research funding fromChugai, Otuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai,Bayer, Abbvie. IM: Honoraria from Novartis Pharma, Bayer Yakuhin, Bristol-MyersSquibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli Lilly Japan,Daiichi-Sankyo, Yakult, Otsuka Pharmaceutical, Nobelpharma, EA Pharma, TeijinPharma. Consulting or advisory role for Nano Carrier, Bayer Yakuhin, Eisai, KyowaHakko Kirin, Novartis Pharma, Shire, MSD, Bristol Myers Sqiibb, Eli Lilly Japan,Sumitomo Dainippon, Daiichi-Sankyo, Teijin Pharma, Takara Bio. Research fundingfrom Bayer Yakuhin, Kyowa Hakko Kirin, Yakult, Taiho Pharmaceutical, Eli LillyJapan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria Pharmaceutical, Chugai,Bristol Myers Sqiibb, Merck Serono, Kowa, Nano Carrier, ASLAN, Daiichi-Sankyo.,Sumitomo Dainippon, Novartis Pharma, Baxalta, Boehringer Ingelheim, Takara Bio.Board membership: ASLAN, Chugai. IN: Honoraria from Bayer, Gilead, Abbvie, Otuka.IN: Research funding from Abbvie GK. HK: Honoraria from MSD, Abbvie,Bristrol-Myers Squibb, Dainippon Sumitomo and Otsuka, Research funding fromGilead, Bristrol-Myers Squibb, MSD. IA: Honoraria from AbbVie GK, Bristol MyersSquibb, Gilead, Eisai. Research funding from AbbVie GK, Otsuka, MSD, Chugai,Eisai, Astellas, Takeda. KN: Research funding from Abbvie GK.Nakao K: Honorariafrom Gilead. YO: Research funding from AstraZeneca, Asteras, Ajinomoto,AsahiKasei-Kurare Medical, Bayer Yakuhin, Bristol Myers Sqiibb, Chugai,Daiichi-Sankyo, Eisai, Kyowa Hakko Kirin, Kowa, Nihon Kayaku, MSD, Otsuka, Ono,Taiho, Tanabe-Mitsubishi, Takeda, Torii, Tsumura, Zeria. YK: Honoraria fromChugai, Eli Lilly, Taiho, Nippon Shinyaku. OT: Honoraria from Novartis, Taiho,Eli Lilly, Dainippon Sumitomo, Bayer, Yakult, FUJIFILM, AstraZeneca, OnoPharmaceutical, EA Pharma, Nippon Chemiphar, Celgene, Chugai, Bristol Myers,Eisai, Pfizer, Teijin, Daiichi Sankyo, MSD, Shire, AbbVie, Takeda. Consulting oradvisory role for Eli Lilly, Dainippon Sumitomo, Taiho, Zeria Pharmaceutical,Daiichi Sankyo, Bristol Myers. Research Funding from Eli Lilly, Eisai, Novartis,Yakult Honsha, Taiho, Kowa, Kyowa Hakko Kirin, Merck Serono, Ono Pharmaceutical,Bayer, Pfizer Japan, AstraZeneca, Dainippon Sumitomo, Chugai, Bristol Myers,Zeria Pharmaceutical. KN: Honoraria from Eisai. AY: Royalties from SumitomoBakelite. Research funding from Canon Medical Systems, Taiho Pharmaceutical,Eisai. Honoraria from Merit Medical Systems., Fuji Pharma, Terumo InternationalSystems, Nippon Kayaku, Canon Medical Systems, Bristol Meyer Squibb, SumitomoBakelite, Bayer Pharmaceuticals, Boston Scientific Japan, Taiho Pharmaceutical,Guerbet Japan, Guerbet Asia Pacific.2019Dec 41468-3288 (Electronic) 0017-5749 (Linking)31801872https://www.ncbi.nlm.nih.gov/pubmed/3180187210.1136/gutjnl-2019-3189340!DKudo201922982298229817Kudo, M.Ueshima, K.Ikeda, M.Torimura, T.Tanabe, N.Aikata, H.Izumi, N.Yamasaki, T.Nojiri, S.Hino, K.Tsumura, H.Kuzuya, T.Isoda, N.Yasui, K.Aino, H.Ido, A.Kawabe, N.Nakao, K.Wada, Y.Yokosuka, O.Yoshimura, K.Okusaka, T.Furuse, J.Kokudo, N.Okita, K.Johnson, P. J.Arai, Y.Tactics study groupDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan m-kudo@med.kindai.ac.jp. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Department of Gastroenterology and Hepatology, Kurume University School of Medicine, Kurume, Japan. Department of Gastroenterology, National Hospital Organisation Sendai Medical Center, Sendai, Japan. Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan. Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube-Yamaguchi, Japan. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki, Japan. Department of Gastroenterology and Hepatology, Hyogo Cancer Center, Akashi, Japan. Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Japan. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa Hospital, Tagawa, Japan. Department of Gastroenterology and Hepatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University School of Medicine, Aichi, Japan. Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. Department of Gastroenterology, School of Medicine, Chiba University, Chiba, Japan. Center for Integrated Medical Research, Hiroshima University, Hiroshima, Japan. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan. Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan. Deapartment of Medicine, Shunan Memorial Hospital, Kudamatsu, Yamaguchi, Japan. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialGutGut2019/12/06combination therapy with transarterial chemoembolisation and sorafenibhepatocellular carcinomaprogression-free survivalsorafenibtransarterial chemoembolizationor advisory role for Kowa, MSD, BMS, Bayer, Chugai, Taiho. Research funding fromChugai, Otuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai,Bayer, Abbvie. IM: Honoraria from Novartis Pharma, Bayer Yakuhin, Bristol-MyersSquibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli Lilly Japan,Daiichi-Sankyo, Yakult, Otsuka Pharmaceutical, Nobelpharma, EA Pharma, TeijinPharma. Consulting or advisory role for Nano Carrier, Bayer Yakuhin, Eisai, KyowaHakko Kirin, Novartis Pharma, Shire, MSD, Bristol Myers Sqiibb, Eli Lilly Japan,Sumitomo Dainippon, Daiichi-Sankyo, Teijin Pharma, Takara Bio. Research fundingfrom Bayer Yakuhin, Kyowa Hakko Kirin, Yakult, Taiho Pharmaceutical, Eli LillyJapan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria Pharmaceutical, Chugai,Bristol Myers Sqiibb, Merck Serono, Kowa, Nano Carrier, ASLAN, Daiichi-Sankyo.,Sumitomo Dainippon, Novartis Pharma, Baxalta, Boehringer Ingelheim, Takara Bio.Board membership: ASLAN, Chugai. IN: Honoraria from Bayer, Gilead, Abbvie, Otuka.IN: Research funding from Abbvie GK. HK: Honoraria from MSD, Abbvie,Bristrol-Myers Squibb, Dainippon Sumitomo and Otsuka, Research funding fromGilead, Bristrol-Myers Squibb, MSD. IA: Honoraria from AbbVie GK, Bristol MyersSquibb, Gilead, Eisai. Research funding from AbbVie GK, Otsuka, MSD, Chugai,Eisai, Astellas, Takeda. KN: Research funding from Abbvie GK.Nakao K: Honorariafrom Gilead. YO: Research funding from AstraZeneca, Asteras, Ajinomoto,AsahiKasei-Kurare Medical, Bayer Yakuhin, Bristol Myers Sqiibb, Chugai,Daiichi-Sankyo, Eisai, Kyowa Hakko Kirin, Kowa, Nihon Kayaku, MSD, Otsuka, Ono,Taiho, Tanabe-Mitsubishi, Takeda, Torii, Tsumura, Zeria. YK: Honoraria fromChugai, Eli Lilly, Taiho, Nippon Shinyaku. OT: Honoraria from Novartis, Taiho,Eli Lilly, Dainippon Sumitomo, Bayer, Yakult, FUJIFILM, AstraZeneca, OnoPharmaceutical, EA Pharma, Nippon Chemiphar, Celgene, Chugai, Bristol Myers,Eisai, Pfizer, Teijin, Daiichi Sankyo, MSD, Shire, AbbVie, Takeda. Consulting oradvisory role for Eli Lilly, Dainippon Sumitomo, Taiho, Zeria Pharmaceutical,Daiichi Sankyo, Bristol Myers. Research Funding from Eli Lilly, Eisai, Novartis,Yakult Honsha, Taiho, Kowa, Kyowa Hakko Kirin, Merck Serono, Ono Pharmaceutical,Bayer, Pfizer Japan, AstraZeneca, Dainippon Sumitomo, Chugai, Bristol Myers,Zeria Pharmaceutical. KN: Honoraria from Eisai. AY: Royalties from SumitomoBakelite. Research funding from Canon Medical Systems, Taiho Pharmaceutical,Eisai. Honoraria from Merit Medical Systems., Fuji Pharma, Terumo InternationalSystems, Nippon Kayaku, Canon Medical Systems, Bristol Meyer Squibb, SumitomoBakelite, Bayer Pharmaceuticals, Boston Scientific Japan, Taiho Pharmaceutical,Guerbet Japan, Guerbet Asia Pacific.2019Dec 41468-3288 (Electronic) 0017-5749 (Linking)31801872https://www.ncbi.nlm.nih.gov/pubmed/3180187210.1136/gutjnl-2019-318934wDyK  _ENREF_246DMarks201022142214221417Marks, L. B.Yorke, E. D.Jackson, A.Ten Haken, R. K.Constine, L. S.Eisbruch, A.Bentzen, S. M.Nam, J.Deasy, J. O.Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA. marks@med.unc.eduUse of normal tissue complication probability models in the clinicInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS10-9763 Suppl2010/03/05AdultChildDose Fractionation, RadiationDose-Response Relationship, RadiationHumans*Models, Biological*Models, StatisticalOrgan Specificity*Practice Guidelines as TopicRadiation Injuries/*prevention & control*Radiation OncologyRadiation Tolerance2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171502https://www.ncbi.nlm.nih.gov/pubmed/20171502PMC404154210.1016/j.ijrobp.2009.07.1754engPan201022152215221517Pan, C. C.Kavanagh, B. D.Dawson, L. A.Li, X. A.Das, S. K.Miften, M.Ten Haken, R. K.Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109-5010, USA. cpan@umich.eduRadiation-associated liver injuryInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS94-100763 Suppl2010/03/05HumansLiver/*radiation effectsLiver Neoplasms/*radiotherapy/secondaryModels, BiologicalRadiation DosageRadiation Injuries/*complications/therapyRadiation ToleranceRisk2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171524https://www.ncbi.nlm.nih.gov/pubmed/20171524PMC438803310.1016/j.ijrobp.2009.06.092engDMarks201022142214221417Marks, L. B.Yorke, E. D.Jackson, A.Ten Haken, R. K.Constine, L. S.Eisbruch, A.Bentzen, S. M.Nam, J.Deasy, J. O.Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA. marks@med.unc.eduUse of normal tissue complication probability models in the clinicInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS10-9763 Suppl2010/03/05AdultChildDose Fractionation, RadiationDose-Response Relationship, RadiationHumans*Models, Biological*Models, StatisticalOrgan Specificity*Practice Guidelines as TopicRadiation Injuries/*prevention & control*Radiation OncologyRadiation Tolerance2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171502https://www.ncbi.nlm.nih.gov/pubmed/20171502PMC404154210.1016/j.ijrobp.2009.07.1754engPan201022152215221517Pan, C. C.Kavanagh, B. D.Dawson, L. A.Li, X. A.Das, S. K.Miften, M.Ten Haken, R. K.Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109-5010, USA. cpan@umich.eduRadiation-associated liver injuryInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS94-100763 Suppl2010/03/05HumansLiver/*radiation effectsLiver Neoplasms/*radiotherapy/secondaryModels, BiologicalRadiation DosageRadiation Injuries/*complications/therapyRadiation ToleranceRisk2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171524https://www.ncbi.nlm.nih.gov/pubmed/20171524PMC438803310.1016/j.ijrobp.2009.06.092engwDyK  _ENREF_247wDyK  _ENREF_248R DChon201122162216221617Chon, Y. E.Seong, J.Kim, B. K.Cha, J.Kim, S. U.Park, J. Y.Ahn, S. H.Han, K. H.Chon, C. Y.Shin, S. K.Kim, D. Y.Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factorsInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics1343-518152010/10/12AdultAntimetabolites, Antineoplastic/administration & dosageCarcinoma, Hepatocellular/*therapyChemoradiotherapy/*adverse effects/methodsDuodenal Ulcer/diagnosis/epidemiologyDuodenitis/diagnosis/epidemiologyDuodenum/*radiation effects*Endoscopy, GastrointestinalFemaleFluorouracil/administration & dosageGastritis/diagnosis/epidemiologyGastrointestinal Hemorrhage/etiologyHumansLiver Neoplasms/*therapyMaleMiddle AgedNausea/epidemiology/etiologyPrevalenceProspective StudiesRadiation Injuries/*diagnosis/epidemiologyRadiotherapy DosageRisk FactorsStomach/*radiation effectsStomach Ulcer/diagnosis/epidemiologyVomiting/epidemiology/etiology2011Dec 11879-355X (Electronic) 0360-3016 (Linking)20934268https://www.ncbi.nlm.nih.gov/pubmed/2093426810.1016/j.ijrobp.2010.07.1986engR DChon201122162216221617Chon, Y. E.Seong, J.Kim, B. K.Cha, J.Kim, S. U.Park, J. Y.Ahn, S. H.Han, K. H.Chon, C. Y.Shin, S. K.Kim, D. Y.Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factorsInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physics1343-518152010/10/12AdultAntimetabolites, Antineoplastic/administration & dosageCarcinoma, Hepatocellular/*therapyChemoradiotherapy/*adverse effects/methodsDuodenal Ulcer/diagnosis/epidemiologyDuodenitis/diagnosis/epidemiologyDuodenum/*radiation effects*Endoscopy, GastrointestinalFemaleFluorouracil/administration & dosageGastritis/diagnosis/epidemiologyGastrointestinal Hemorrhage/etiologyHumansLiver Neoplasms/*therapyMaleMiddle AgedNausea/epidemiology/etiologyPrevalenceProspective StudiesRadiation Injuries/*diagnosis/epidemiologyRadiotherapy DosageRisk FactorsStomach/*radiation effectsStomach Ulcer/diagnosis/epidemiologyVomiting/epidemiology/etiology2011Dec 11879-355X (Electronic) 0360-3016 (Linking)20934268https://www.ncbi.nlm.nih.gov/pubmed/2093426810.1016/j.ijrobp.2010.07.1986engwDyK  _ENREF_249 DHanna201822172217221717Hanna, G. G.Murray, L.Patel, R.Jain, S.Aitken, K. L.Franks, K. N.van As, N.Tree, A.Hatfield, P.Harrow, S.McDonald, F.Ahmed, M.Saran, F. H.Webster, G. J.Khoo, V.Landau, D.Eaton, D. J.Hawkins, M. A.Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK. Electronic address: g.hanna@qub.ac.uk. Department of Clinical Oncology, St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK. National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK. Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK. Department of Radiotherapy, Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK. Department of Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, UK. Department of Radiotherapy, Worcester Oncology Centre, Worcester, UK. Department of Oncology, Guy's and St Thomas' Hospital, London, UK. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.UK Consensus on Normal Tissue Dose Constraints for Stereotactic RadiotherapyClin Oncol (R Coll Radiol)Clin Oncol (R Coll Radiol)5-143012017/10/17ConsensusGuidelines as TopicHumansRadiosurgery/*methodsUnited KingdomConstraintsOarSabrSbrtnormal tissuestereotactic radiotherapy2018Jan1433-2981 (Electronic) 0936-6555 (Linking)29033164https://www.ncbi.nlm.nih.gov/pubmed/2903316410.1016/j.clon.2017.09.007eng DHanna201822172217221717Hanna, G. G.Murray, L.Patel, R.Jain, S.Aitken, K. L.Franks, K. N.van As, N.Tree, A.Hatfield, P.Harrow, S.McDonald, F.Ahmed, M.Saran, F. H.Webster, G. J.Khoo, V.Landau, D.Eaton, D. J.Hawkins, M. A.Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK. Electronic address: g.hanna@qub.ac.uk. Department of Clinical Oncology, St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK. National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK. Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK. Department of Radiotherapy, Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK. Department of Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, UK. Department of Radiotherapy, Worcester Oncology Centre, Worcester, UK. Department of Oncology, Guy's and St Thomas' Hospital, London, UK. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.UK Consensus on Normal Tissue Dose Constraints for Stereotactic RadiotherapyClin Oncol (R Coll Radiol)Clin Oncol (R Coll Radiol)5-143012017/10/17ConsensusGuidelines as TopicHumansRadiosurgery/*methodsUnited KingdomConstraintsOarSabrSbrtnormal tissuestereotactic radiotherapy2018Jan1433-2981 (Electronic) 0936-6555 (Linking)29033164https://www.ncbi.nlm.nih.gov/pubmed/2903316410.1016/j.clon.2017.09.007engwDyK  _ENREF_250wDyK  _ENREF_248DMarks201022142214221417Marks, L. B.Yorke, E. D.Jackson, A.Ten Haken, R. K.Constine, L. S.Eisbruch, A.Bentzen, S. M.Nam, J.Deasy, J. O.Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA. marks@med.unc.eduUse of normal tissue complication probability models in the clinicInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS10-9763 Suppl2010/03/05AdultChildDose Fractionation, RadiationDose-Response Relationship, RadiationHumans*Models, Biological*Models, StatisticalOrgan Specificity*Practice Guidelines as TopicRadiation Injuries/*prevention & control*Radiation OncologyRadiation Tolerance2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171502https://www.ncbi.nlm.nih.gov/pubmed/20171502PMC404154210.1016/j.ijrobp.2009.07.1754engDMarks201022142214221417Marks, L. B.Yorke, E. D.Jackson, A.Ten Haken, R. K.Constine, L. S.Eisbruch, A.Bentzen, S. M.Nam, J.Deasy, J. O.Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA. marks@med.unc.eduUse of normal tissue complication probability models in the clinicInt J Radiat Oncol Biol PhysInt J Radiat Oncol Biol PhysInternational journal of radiation oncology, biology, physicsS10-9763 Suppl2010/03/05AdultChildDose Fractionation, RadiationDose-Response Relationship, RadiationHumans*Models, Biological*Models, StatisticalOrgan Specificity*Practice Guidelines as TopicRadiation Injuries/*prevention & control*Radiation OncologyRadiation Tolerance2010Mar 11879-355X (Electronic) 0360-3016 (Linking)20171502https://www.ncbi.nlm.nih.gov/pubmed/20171502PMC404154210.1016/j.ijrobp.2009.07.1754engwDyK  _ENREF_247DEl-Khoueiry201716716716717El-Khoueiry, A. B.Sangro, B.Yau, T.Crocenzi, T. S.Kudo, M.Hsu, C.Kim, T. Y.Choo, S. P.Trojan, J.Welling, T. H. RdMeyer, T.Kang, Y. K.Yeo, W.Chopra, A.Anderson, J.Dela Cruz, C.Lang, L.Neely, J.Tang, H.Dastani, H. B.Melero, I.USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: elkhouei@med.usc.edu. Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain. University of Hong Kong, Hong Kong Special Administrative Region, China. Providence Cancer Center, Portland, OR, USA. Kindai University Faculty of Medicine, Osaka, Japan. National Taiwan University Hospital, Taipei, Taiwan. Seoul National University Hospital, Seoul, South Korea. National Cancer Center, Singapore. Goethe University Hospital and Cancer Center, Frankfurt, Germany. University of Michigan School of Medicine, Ann Arbor, MI, USA. Royal Free Hospital, London, UK. Asan Medical Center, University of Ulsan, Seoul, South Korea. Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Johns Hopkins Singapore International Medical Centre, Singapore. Bristol-Myers Squibb, Princeton, NJ, USA. Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain; Center for Applied Medical Research (CIMA), Pamplona, Spain.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancetLancet (London, England)LancetLancetLancet (London, England)2492-2502389100882017/04/25AgedAntibodies, Monoclonal/*administration & dosage/adverse effectsAntineoplastic Agents/*administration & dosage/adverse effectsB7-H1 Antigen/metabolismBiomarkers, Tumor/metabolismCarcinoma, Hepatocellular/*drug therapy/pathologyDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLiver Neoplasms/*drug therapy/pathologyMaleNivolumabResponse Evaluation Criteria in Solid TumorsTime FactorsTreatment OutcomeTumor Burden2017Jun 240140-67362843464810.1016/s0140-6736(17)31046-2NLMengDEl-Khoueiry201716716716717El-Khoueiry, A. B.Sangro, B.Yau, T.Crocenzi, T. S.Kudo, M.Hsu, C.Kim, T. Y.Choo, S. P.Trojan, J.Welling, T. H. RdMeyer, T.Kang, Y. K.Yeo, W.Chopra, A.Anderson, J.Dela Cruz, C.Lang, L.Neely, J.Tang, H.Dastani, H. B.Melero, I.USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: elkhouei@med.usc.edu. Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain. University of Hong Kong, Hong Kong Special Administrative Region, China. Providence Cancer Center, Portland, OR, USA. Kindai University Faculty of Medicine, Osaka, Japan. National Taiwan University Hospital, Taipei, Taiwan. Seoul National University Hospital, Seoul, South Korea. National Cancer Center, Singapore. Goethe University Hospital and Cancer Center, Frankfurt, Germany. University of Michigan School of Medicine, Ann Arbor, MI, USA. Royal Free Hospital, London, UK. Asan Medical Center, University of Ulsan, Seoul, South Korea. Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Johns Hopkins Singapore International Medical Centre, Singapore. Bristol-Myers Squibb, Princeton, NJ, USA. Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain; Center for Applied Medical Research (CIMA), Pamplona, Spain.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancetLancet (London, England)LancetLancetLancet (London, England)2492-2502389100882017/04/25AgedAntibodies, Monoclonal/*administration & dosage/adverse effectsAntineoplastic Agents/*administration & dosage/adverse effectsB7-H1 Antigen/metabolismBiomarkers, Tumor/metabolismCarcinoma, Hepatocellular/*drug therapy/pathologyDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLiver Neoplasms/*drug therapy/pathologyMaleNivolumabResponse Evaluation Criteria in Solid TumorsTime FactorsTreatment OutcomeTumor Burden2017Jun 240140-67362843464810.1016/s0140-6736(17)31046-2NLMengwDyK  _ENREF_191DZhu201817517517517Zhu, A. X.Finn, R. S.Edeline, J.Cattan, S.Ogasawara, S.Palmer, D.Verslype, C.Zagonel, V.Fartoux, L.Vogel, A.Sarker, D.Verset, G.Chan, S. L.Knox, J.Daniele, B.Webber, A. L.Ebbinghaus, S. W.Ma, J.Siegel, A. B.Cheng, A. L.Kudo, M.Department of Medicine, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: azhu@mgh.harvard.edu. Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. Department of Medical Oncology and Gastroenterology, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France. Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Medical Oncology, University of Liverpool, Liverpool, UK. Department of Hepatology, University Hospital Gasthuisberg, Leuven, Leuven, Belgium. Istituto Oncologico Veneto-Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padua, Italy. Department of Gastroenterology and Hepatology, Hopital Universitaire Pitie-Salpetriere, Paris, France. Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule, Hannover, Germany. Department of Medical Oncology, King's College Hospital, London, UK. Gastrointestinal Oncology Unit, Hopital Erasme, Brussels, Belgium. Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Shatin, Hong Kong. Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Department of Oncology, Azienda Ospedaliera Gaetano Rummo, Benevento, Italy. Department of Global Clinical Development, Merck & Co, Kenilworth, NJ, USA. Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan. Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology940-9521972018/06/08AgedAntibodies, Monoclonal, Humanized/*administration & dosageCarcinoma, Hepatocellular/*drug therapy/*mortality/pathologyDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousInternationalityLiver Neoplasms/*drug therapy/*mortality/pathologyMaleMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm StagingPrognosisRemission InductionSorafenib/administration & dosageSurvival Rate2018Jul1470-20452987506610.1016/s1470-2045(18)30351-6NLMengDZhu201817517517517Zhu, A. X.Finn, R. S.Edeline, J.Cattan, S.Ogasawara, S.Palmer, D.Verslype, C.Zagonel, V.Fartoux, L.Vogel, A.Sarker, D.Verset, G.Chan, S. L.Knox, J.Daniele, B.Webber, A. L.Ebbinghaus, S. W.Ma, J.Siegel, A. B.Cheng, A. L.Kudo, M.Department of Medicine, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: azhu@mgh.harvard.edu. Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. Department of Medical Oncology and Gastroenterology, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France. Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Department of Medical Oncology, University of Liverpool, Liverpool, UK. Department of Hepatology, University Hospital Gasthuisberg, Leuven, Leuven, Belgium. Istituto Oncologico Veneto-Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padua, Italy. Department of Gastroenterology and Hepatology, Hopital Universitaire Pitie-Salpetriere, Paris, France. Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule, Hannover, Germany. Department of Medical Oncology, King's College Hospital, London, UK. Gastrointestinal Oncology Unit, Hopital Erasme, Brussels, Belgium. Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Shatin, Hong Kong. Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Department of Oncology, Azienda Ospedaliera Gaetano Rummo, Benevento, Italy. Department of Global Clinical Development, Merck & Co, Kenilworth, NJ, USA. Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan. Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. OncologyLancet OncolThe Lancet. Oncology940-9521972018/06/08AgedAntibodies, Monoclonal, Humanized/*administration & dosageCarcinoma, Hepatocellular/*drug therapy/*mortality/pathologyDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousInternationalityLiver Neoplasms/*drug therapy/*mortality/pathologyMaleMiddle AgedNeoplasm Invasiveness/pathologyNeoplasm StagingPrognosisRemission InductionSorafenib/administration & dosageSurvival Rate2018Jul1470-20452987506610.1016/s1470-2045(18)30351-6NLMengwDyK  _ENREF_192wDyK  _ENREF_251DXu201922972297229717Xu, J.Zhang, Y.Jia, R.Yue, C.Chang, L.Liu, R.Zhang, G.Zhao, C.Zhang, Y.Chen, C.Wang, Y.Yi, X.Hu, Z.Zou, J.Wang, Q.Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China. xujm@bmi.ac.cn. Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China. CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterial and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China. Geneplus-Beijing Institute, Beijing, China. Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China.Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion StudyClin Cancer ResClin Cancer Res515-5232522018/10/242019Jan 151078-0432 (Print) 1078-0432 (Linking)30348638https://www.ncbi.nlm.nih.gov/pubmed/3034863810.1158/1078-0432.CCR-18-2484wDyK  _ENREF_252$$If!vh#v.#vB#v#v2:V l  t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytr'$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V lx t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V lw t 6`0~.5.5B552/ ytj$$If!vh#v.#vB#v#v2:V lx t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V lx t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V lx t 6`0~.,5.5B552/ ytj$$If!vh#v.#vB#v#v2:V l t 6`0~.5.5B552/ ytji[Ci[Ci[Ci[Ci[Ci[Ci[Ci[C?x666666666vvvvvvvvv66<<6>6666666666666666666666666666666666666666666666<>H66666 6666666666>6666666666666666666666666666666666666666666666>620 0@P`p2(00 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@66666 OJPJQJ_HmH nHsH tH\`\ ecke$dh1$a$(CJKHOJQJ_HaJmH nHsH tH`@` eh 1ddd1$@&[$\$a$5CJ0KH$OJQJ\^JaJ0^^ 0eh 2$$d@&"5CJ OJQJ\aJ mHsHtH$A`$ ؞k=W[SOBi@B 0nfh*B*phOr*U * e0c >*B*ph(' ( eybl_(uCJaJ>/> e0u w CharCJOJPJQJ^JaJ>/> e0u CharCJOJPJQJ^JaJ>/> e ybleW[ CharOJPJQJ^JaJD/D e0 yblFhe,g CharCJOJPJQJ^JaJ0@0 e RQk=WD``D/D e0 ybl;N Char5OJPJQJ\^JaJ  ejrnlh"h #eEndNote Bibliography Title "a$CJmHsHtHr/1r "eEndNote Bibliography Title CharKHOJQJaJmHsHtH`OB` %eEndNote Bibliography$$da$CJmHsHtHf/Qf $eEndNote Bibliography CharKHOJQJaJmHsHtHdbd e RQk=1$&d1$G$H$WD``a$CJKHOJPJQJ^JaJ^s^ epQ/> e0*gYtvcS10B*ph`^\q >/> e0*gYtvcS11B*ph`^\q >/> e0*gYtvcS12B*ph`^\q >/> e0*gYtvcS13B*ph`^\q R/R o0Unresolved MentionB*ph`^\q H HYo0O=(CJKHOJQJ_HaJmH nHsH tH:v!: x-0*gYtvcSB*ph`^\q PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VCݓvUA 6F͌n|QsAX\ >8O( b\'X77?ڐ!@5?2XY}XFKp GH%Vވ b׫|G_9Ѣ`(B-)( b"{G|07`]PEB_?1r!?S`m-ʥV_\ĵJNS.j4Cw\+ZxC筲/-xkP//z֯A)_BJP5f CFr]]*Q Yv)CeCP@$=9I!_vHB%(fV va ߒ602- "O9IdͿ Z}r'=ySZ%{W<wo~ omͩv{_8}:oq3]ac.`/& 1%@)+-Z ȁcۏ9T" X;adwuƝ^lnmM]\('PbKe#bc{lcwK 6qKzV6B$L\!ޖov{uF]n# ]L-7Bc".$C΄M\KHt)Z,Kf~APܜaߥFrIF.;1dFą84(twk>VϮšQw[Yۙ!®R#nq̎8R{ccާuX>IlcWbFv fNall \ᙠ8B|=V>LI}:^ DVSn<<s< /,ݔyoZ"-XETsbc~h0pd<F7qsGqǭتUtՒfn~i0> LDCY,XW#HGe lܸd|0duޑChϐPڑw>ufІE%=qvQ90`ǙȰR@x pf]6H:EuvVd^(gpL%Ste5@(ً0$$E$} Ns;{/,,+P-jYTk~" q0TPϢ>#̙V=ˀ<ݥvH[$tIhO-xj<4.<= mR+Q.5qͯ!e(C82Q#W.Dxҗ<}/SY.d0u.:i5ܣ$jYhkV\[򡑃A!K3Ɗtz >λZ`%N88zt"Hr8 ^So YsiZvwQ:uDM;YS.}jd{jSnuҮ{Q4iU5U̲0ks\7X\ 5i/Z77'd]u j1bXU͞ڽc3IU2S;緬G8:?g-, gs~unfC(MrT Jxi D=deCn PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Rtheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] pmb '''* f f:>#"$h%p&' )&*@++-|-/0021223h445^67@88BvCDEFFK N:RSUVf]^:``d@hj8tNuNvw}ȆއP@r.vĚJxاܫҬd&&@FpFr:@~`jH0jDRx  #b%*&&.01d23i;@==,?&CE^G|HII KbL@M2N OOX[\H]f hijkmn.q2suvTwxz|(čTʜtltBTXdXPRD4\xFJl,jP0 FX ,  v l^Lp$& !!Z"',L0>f?RAGHJ~MtNNQRS8TT^UU$WFWWRZ ^ `iplmno\qrsu"#%&'H(r) *D+,,-/34 78t:>;<<>?@tA2BBQ S^T|TU8WWb\]r`aFijkkl4m\oXqFstuNwFxyJ{}V|f\dJ"$T:XT r#). 307<CHHNUZafrk:pvB|.&fTnTpPTl ^;=>?@ABCDEFGHIJKLNOPQRSTUVWXYZ[\]^_`abcdefghijklmnpqrstuvxyz{|}~      !"#$%&'()*+,-./012456789:;<=>?ABCDEFGHIJKLMNOPQRSTUVWXYZ[]^_`bcdefghijklmnopqtz}~     !"#$%'()*+,-.0!SalN$?0qP) AFWWWDXXYY|ZZp\\2]]##B$$&'')f))))**++,d-rTl(mvnnNooBppqqqFrs ttt:uuu8wDw,~"-ZL&*^<Mow3@\arsuvwxy{|}~ &/Xh~#3IKM})+-aD F x z |  ACEvxP`vxz 357jpr"2HJL{~y/EGIy,-/_bd7:<qtv/24Rbxy{+-/`fh!$&X[]t#v####$*$@$B$D$w$z$|$$$$$$%%%R%U%W%%))))),,,--3-6-8-033333444444455d8f8s8v8x8:.:D:F:H:{::::BBBBCxCCCCCCCCCCDDD9D?DADDGGGGGHHHHHI!I#IJJ4J5J7JhJkJmJJJJ%K5KKKMKOKKKKKKK UU/U1U3UfUlUnUUUUUU VVVDVGVIV]VmVVVVVVVVVV?W^_2_5_7__ `!`#`%`U`X`Z````````aa/aEaGaIaxa~aaab%b'b)bXb[b]bbbblc|cccccccdd)d+d-d\d_dademmmmm5nEn[n\n^nnnnnnnnn oooAoDoFohoxoooooooKp[pqpspuppppppqqqCqFqHqequqqqqqqqq^y`yyyyyyyyyzzzEzUzkzmzozzzzzzzzz {#{%{{{{{{{{{Z|j||||||||||.}ik ;>@҅ԅօ Yiֆ DGI=HJz}(,.ϑߑ)-/aeg1AWXZÓǓɓ "$UY[SWY /13bjlzۖߖ&(*Y]_!BFHªĪ$4JLNNRTZ')6:<O_uwy޲=ACsNPϻ "?OegiGOQ.24y58:jmo 357hpr!$&[ce FJL/#')$(*\lDJL,.0dhj:J`bdVX/35aq TXZwHLN  fv\l7;=uy{(*,^bd6:<\"" ###6#F#\#^#`####1$A$W$Y$[$$$$%1+3+c+g+i+++++++++,11111"222H2J2L2~222222222W366666:::::;; ;<;@;B;;;;;;< < <<<<<<&=*=,===>>>E>I>K>|>>>>>>>>'?+?-?????????&@6@L@N@P@@@@AAAA"B'B;BKBaBbBdBBBBBBBCDDDDODWDYDDDDDDDDDDDDEMM;M?MAMTMdMzM|M~MMMMMRNWNhNxNNNNNNNNQOZOvOOOOOOOOP PPP S SSS SgW+^-^:^>^@^s^^^^^^^^"`cccccxccccccccGdKdMdQfafwfyf{ffffkh{hhhhhhhh i#i$i&iYi]i_iiiiiiiii#j'j)jxjjjjjjjjGovvwwwwwwwwxxxxxxxxxxxyyyJyZypyqysyyyyyyyyy,z0z2zEzUzkzlznzzzz{{.{/{1{b{f{h{{{{{{{{{ |||G|K|M|g|w||||||||||||)}-}/}}}}}}}}}~(~>~?~A~s~w~y~~~~~~~~~ bdbrÇ>݊ߊ^nŒČݍzԎ؎ڎ,<RTV brÑő0@VXZ y#9;=quwě:?{ޜXΝӝaqŸݠT^!#ǦȦʦۧPZjߪ<?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~  ީީɮɮɮVE۷Lc%q : 6Qoo_$$w tI0v2h@"Y(ND\eukO>-+~+qA &R $aC I      l vL7WC*eU/-e& 0!!"~#4$%%&&)(|(])**h+@, --.a/C0012b3f465)66D7789::;'<<=_>;??@%AA>B%CDDEFG HHSII KLGLLLM^MMMCNNNNOP%QQR'SSwT0UUVWiXUYXZ[[\]W^__2``rabbcDd5?5C5E5N5P5Q5R5S5T5U5V5W5\5`5b5c5e5f5h5i5v5w5}5~555555555555y888888888889999!9&9*9-9.91999999::::::::CC C CCCCC C$C&C'C)C*C.C:C=C@CCCDCFCGCJCLCOCXChCsCvCxCCCCCCDGDIDJDaDDDDDDDDDDDDDDGGGGGGGGGGHH H H HHHHHHH,H4H5H:H;HWHXH[HdHjHlHHHHHHHHHHH$I%I)IaIhIIIIJJJJJKKKKKKKKKLL LCLNLnLrLLLLLLLLLL M M M MMM4M8M9M?MBMLMOMVMYM^M`MfMoMqMzM|MMMMMMMMMMMMMMM&N,N-N8N9NQNRNSNTNZNfNiNzNNNNNNNNO!O"O#O$O(O)O0O7OQPQTQ]Q^QoQqQrQwQxQyQzQQQQQQQQQQQQQQQQQQQQQQQQQQQRRRRRRR"R#R@RARFRGRHRIR[RaRvRzR{RRRRRRRRRRRRRRRRRRRRR_S`SdSkSSSSSSTT$T)T,T?TBTRTeTTTTTTTTTTToUrUJV]VVVVWWW!W&W8_9_L_N_U_V_Y_f_x___________________\```b``aa aaaaaaaaaaaaaa\b]bbbbbbbbbbbbcc c'c0c@cBcWclccccdcdgdidjddde eDeIeLefejeqeuevewexeeeeeeeeeeeeeeeeemmmmmmnnHoLoNoOooooop p"pKpppppppJqNqPqeqqqyyyyyyzz z2zzz&{'{{{=|?|C|G|J|Z|||}}}}ބABFZ +,/>̆JKPy~ʇ67=ANTWY[imopv{ג!#˓ϓѓғ]acfim[_abnrtz`eIJUjnƟǟʟן.7<>?@BCDGHacgh+/;<?DI[jn "7ƪȪ˪̪ͪΪ$UZ=> !(*HزڲDELX]_#$Ƽмܼ߼SWYZnvwz57Yc"#(*=HIeiV56;<dei5Kmv{}9: txz{!}fyNRTe{ +/125B,03478;E Saf 79?BIK`gpyKLghiklosGJL_`bc !$26RVfi 4;ADQTVY]`qtux $: !"#$%)Ydeuvz} .5<?OSVadiq79LOPUZ\]c}'LO/KO\hnDalsuz"(*/01589:;?ABH )-1U`ej7;=AEPTa    A F I P            []ajmnqwPTV[}AGNSVZ[}&*/3>FNq#268<[mpt %'*,[~  $&3FPVZ[  -16}!4=@BRSYZ[\## #0#5#6###########$$$$ $$$($+$/$1$$$$$j+k+++++',(,.,J,Q,X,\,_,`,d,|,},,,,,,,,,,,,,111222 222"2B3E3F3H3666666667 7777777#767F7J7Y7]7j777777777777778 8!8+8/8284858I8M8e8z88888899$9%9)9+929B9F9G9O9Q9X9e9k9m9q9x9999999999999999999999999: :::::::F:`:d:i:m:::D;H;J;R;W;X;^;_;r;t;u;;;;;;<<[<\<]<_<d<e<i<n<x<y<<<<<<<<<<<<.=2=4=5=P=R=e=f=k=p=r=t=|=}=========>>>>/?3?5?R????????????@@@@@!@&@@@@@@@@@@@@@@@@@@@@@AAAAAABBBBDCECkClCmCrCsCCCCCqDrD{D|DDDDDEE EEBMCMMMMMNNNNbOdOmOvOPPUPYP^P`PePoPPP$S)SlS{SSSSSSSSSSSSSSSSSSSSSSSSSSSSSETRTeThTkTnTqTuTxT{T~TTTTTTTTTTTTTTTTTTTTTTUU(U=U@UAUGUJUMUPUSUVUXU\U`UbUjUmUpUsUuUxUzU}UUUUUUUUUUUUUUUVVV V VVVVVV V#V%V)V,V0V3V6V9V=V@VAVFVIVKVNVPVTVWVZV\V^V`VeVVVVVVVVVVVVVVVVVVVWWWWWWWWW W'W2WaWeWA^B^^^^^^^^_>_A_________c!c#c$c)c-c_c`cdcecmcxcUdVde eeeef f(f/fAfHfOfQffffggggg.g/g7g9gUg\gcglgpggggggg hhhhhiiii+j/j1j2j6j:jTjxjjjjjjjjkkk kkkkkkkkk!k&k(k-k/k4k6k;k=kBkJkLkPk_kbkvkkkkkkkkkkkkklll'l-l=l@l[lblfljllllllllllll mm%m.m@mImYm\momrmymmmmmmmmmmmmmmmmnn nn@nHnRnYn[n]nlnnnnnnnnnnnnno,o?oww%w;w%6<JN^bvxzċʋЋ֋ڋ>CVZ^̌͌Ռߌ  >W`df  +.>@CHX^oێ܎  !#̏ӏԏՏ֏ݏߏ  #*-/146<=?HKQWZ\efgikluz}(*,/]bۑ !%)+,’ĒŒȒʒ˒ڒےƚ˚͚КњԚךݚޚ xyFIKOY\]afk{ !"#%().012389<IQߝ4?BHKLPQTWZ[_aʟ˟ӟݟ ̠záΡϡԡաޡߡ  '*12:;V`efnqz{}~$%=?U[ijopz|  !&>}~֧ڧ`c}ĨΨѨ(,CHLceuyͩϩҩթ۩ީ   9;>?HLQUeg27GILVWZis~«߫  #'79Ĭ!(,06:=ACGJORX_dhlnsv̭Эԭۭ֭ޭ  !&).167;<@CHKOPUX]`ehmptuz}®ǮɮϮѮծ֮ڮݮGmImJmLmMmOmPmRmSm\m^mnmqm"#$% CI++g-j-./4"4)4,4G4J4555588?9F99999:: C#C)C*C2C6CFCGCQCUCaCeC}DDDD;I>IIILLPPWTZTTTbbbbbbcc;c>??AAAABBCCTNWNROZO2P;PSSTSSST T T TTT&T'T_T`TTTTTTTTTTT%U&UUUUUUUiVjVVVVVVVNWQWE^F^J^K^%_&_G_H_m_n_y_}_```!`ddddeeeef!fKgLgUgYgggggYj\jkkkk5o8o~~~=>@D~TWkpńɄЄӄ_bnrцՆYZ͇·҇և-.$%;<OPcd8;!"Ώя7:ӑ֑&)MQٟݟUYkl&*27DGQUɨөԩ۩  >BILW_«>@DFSUln׭ڭ"%*->?@CIJLM]`ҮӮڮݮVWEF۷ܷL`cd%&qr !:;  67QRopop_`$%$%wx  tuIJ0dvw23hi@A"#YZ()NODE\]efuvklOP>?-.+,~+,qrAB  &'RS  $%abCD I J           l m vwLM78WXCD*+efUV/0-. ef& ' 0!1!!!""~##4$5$%%%%&&&&)(?(|(}(])^)****h+i+@,A, - ---..a/b/C0D0001122b3c3f4g46575)6*666D7E7778899::::;;'<(<<<==_>`>;?B?B%C&CDDDDEEFFGG H HHHSITIII K KLLGL[LLLLLMM^MsMMMMMCNDNNNNN,O-OOPPP%Q&QQQRR'S(SSSwTxT0U1UUUVVWWiXjXUYVYXZYZ[[[[\\]]W^X^____2`3```rasabbbbccDdEdVjë(<ŬmFmGmImJmLmMmOmPmRmSm[m^mkmlmnmqm556677A7A77777 8 8M8M8z8z8hh =>~ɶʶ|}ӷԷ;<DEYZFmqmZY~3#3#H&H&p*p*fhj@fhj@xABxABNDND$qM0\"N\"N&8'W&8'W]]^L.nq0^`0QJo(  \^`\hH) \^`\hH. 4\^4`\hH.  \^ `\hH) | \^| `\hH.  \^ `\hH. \^`\hH) h\^h`\hH.t0^t`0o(sH   \^`\hH) \^`\hH. 4\^4`\hH.  \^ `\hH) | \^| `\hH.  \^ `\hH. \^`\hH) h\^h`\hH.h^h`o(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.h^h`QJo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\. h^h`5QJo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\. h^h`5CJo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.h^h`5o(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.h^h`OJQJ^Jo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.t0^t`0o(  \^`\hH) \^`\hH. 4\^4`\hH.  \^ `\hH) | \^| `\hH.  \^ `\hH. \^`\hH) h\^h`\hH. h^h`5QJo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.h^h`5o(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.h^h`5OJQJ^Jo(.H\^H`\)\^`\.\^`\.4\^4`\) \^ `\.| \^| `\. \^ `\)\^`\.t0^t`0o(  \^`\hH) \^`\hH. 4\^4`\hH.  \^ `\hH) | \^| `\hH.  \^ `\hH. \^`\hH) h\^h`\hH.t0^t`0o(  \^`\hH) \^`\hH. 4\^4`\hH.  \^ `\hH) | \^| `\hH.  \^ `\hH. \^`\hH) h\^h`\hH.H&3#&8'WxAB\"Np*]NDfhj@~^nq$qMЕH        |f        \`RW        |F        ~~        ;rtyEfJ3:@HmI1v*TXSY7%(x-:<NO]~"~%LvOu^dfks)fe:, y  #B Q T \  % eb h q u ^z ^ ? Z x" Y 5"k3N`cVm -40sBCOPRe&ikuB`**/A>RN|\#_4QAL6T@tcJ1E~W04(g{vx*O!nT'\j~&U? [(v+/168S3e %9F4]=T9<j#:]oo|+}$ 4 P7 !< _!+n!b"""%"v;"X"KY"Y"b"H9#nT#m#3v#$"$N$Z$:%%T0%>%tK%P%Y%"&l'&$M&T& o&7*'MH'M'r'u' ((A(e(`l(:J)FL)X),\)^)h)*m)t)+{)*/*j<*b*Ig* +\*+;/+D+H+wg+%,},i+,.,M>,A,H,b,#m-E...kT.]./ /S///'6/8/B:/=/K/0B01[H12Y2+z23<3D3I3]3O~34p455&555T5c5m6S6at6q 7QL7NX7Jo7 885878X8j8z8^9:'9 :::O:|t:y:~:;{";GZ;o;<<!(<B/<7<3[<]\<i<eE= > >d>?>@>_>p>?]?9?Ts?Et? @ak@_AvACB) BBh)B,BvBVCrCC|NCVpC)DZ^DcD"#E3E\5E5ErEUFTFJFmFG#G,G;>G?GlG"H)5H\HnHJDJ&J.JLJ LJ KKKfSK_KLL8L9LVLmLuLTL2M7FMnRMcMNN=NNG"N4N9N\tNO8Oh?O*FO`OKnO.PPC-P8PGPOPXPZP%sP]Q7Q Qh#QIQuWQ lQprQOvQ}wQyQRRvRQ)R.R3RiR3SBSCSWS\WS dSs;T@T$bTU-UdBU4WU`U(V.V?VFV-\V1WWW%9WXW5ZW_WoWXbrXY"ZKZNZUZukZnZ}Z[6[;[ n[n[_o[_\l\{\][]]]Ig]^^F^^^jG_J_SR_R```w`Saca'a4aCahasaabNb b+bMb7cWcm d^dhde=!eAe f%ff^df^ggh/h5hGhi:iEiMji{{i j ajujkdk&k-kjDk^klkqkwkll5lw|l0mB@m~N~=>N&W)!/AM]Tz>{ })h9ciE_m&+2pDEB\eikkta2?&d'*X^ whOfjQ .BXQoVsT*Ih/e?KlLsx$T`+"7t<MFF%:n=$ETYvk &1HfEhid=yX$8eHceuv|k +pV!%;YN~:'V"P45Oj p7:JX5 .R<t~0*L W&^DAOh jj"jl!&OvxH bJd9 b)<,B,BD 9? " -JDc;PZ`dgJvw68=Jjpi16<;(DLz*<F L8>2vY [H N*A $G0T@P@ZBj^%3JW/5P]Y.^4yI_!y(@V?\kyKetx C'! o- %crFt" 'S$U 3 bErN^A~dE@Td;#Rd DOUg>Af=pqw{,Zs"(45j9/A2yu=6SnY 1Oa-"\8<XfO{` ~7gIePh+rtzKB=R*deaD>Y08vBrw0BO0OD+T1<jle?7 ?s FR8Ob"LVyX|tDW'$hS $$'7=Y 0AC #{HJ*OKyS#$/MT_ *n7X :(=CfZos D[TYa{!(f9jq:Sgu9|4P^\1B&t:l=^cjo??OT0^h)IH&Sd+GS2~ 40HV:2t^6bz6 !3bD;?]tE1%<cWj?s ?@i}_Ga^eBn|m >|Y7s{tO u=St~!oe//2;A3x 94VL9+'R9>+Xm>&@W]A&C >I](@I AI/MX=OuV_X[UZz\,zf }oazpwsv#sS!t}GmImEN.InstantFormat EN.Layout EN.Libraries<ENInstantFormat><Enabled>0</Enabled><ScanUnformatted>1</ScanUnformatted><ScanChanges>1</ScanChanges><Suspended>0</Suspended></ENInstantFormat><ENLayout><Style>china</Style><LeftDelim>{</LeftDelim><RightDelim>}</RightDelim><FontName>Times New Roman</FontName><FontSize>10</FontSize><ReflistTitle></ReflistTitle><StartingRefnum>1</StartingRefnum><FirstLineIndent>0</FirstLineIndent><HangingIndent>720</HangingIndent><LineSpacing>0</LineSpacing><SpaceAfter>0</SpaceAfter><HyperlinksEnabled>1</HyperlinksEnabled><HyperlinksVisible>0</HyperlinksVisible><EnableBibliographyCategories>0</EnableBibliographyCategories></ENLayout><Libraries><item db-id="v2pvar95g9vsarepwfv59twdtpavs9v2zs9v">My EndNote Library-Converted<record-ids><item>16</item><item>1121</item><item>1347</item><item>2147</item><item>2148</item><item>2149</item><item>2150</item><item>2151</item><item>2152</item><item>2153</item><item>2154</item><item>2157</item><item>2158</item><item>2159</item><item>2160</item><item>2169</item><item>2170</item><item>2171</item><item>2172</item><item>2174</item><item>2176</item><item>2177</item><item>2178</item><item>2179</item><item>2180</item><item>2181</item><item>2183</item><item>2184</item><item>2185</item><item>2188</item><item>2189</item><item>2190</item><item>2191</item><item>2192</item><item>2194</item><item>2195</item><item>2197</item><item>2198</item><item>2199</item><item>2200</item><item>2201</item><item>2202</item><item>2203</item><item>2204</item><item>2205</item><item>2206</item><item>2207</item><item>2208</item><item>2214</item><item>2215</item><item>2216</item><item>2217</item><item>2219</item><item>2220</item><item>2222</item><item>2226</item><item>2227</item><item>2228</item><item>2280</item><item>2281</item><item>2282</item><item>2285</item><item>2286</item><item>2287</item><item>2288</item><item>2289</item><item>2290</item><item>2291</item><item>2292</item><item>2295</item><item>2296</item><item>2297</item><item>2298</item><item>2299</item><item>2300</item></record-ids></item></Libraries>@@ #%&),024567:BCEFGHJPUVW8_8`8a8b8d8fmrxyz{|}̃̅̈ŪūŬŭůŰų555555***  [[[[!"#$%j+j-l.l0l1l2l3l4l5l6l;l>l@lAlBlClEBMBNBOBZB[BdBiBpBvB{B|A}pm ,@ "$*248x@BF@LR@\`bdf@tvz|~<@h@@@@@@4@@@"P@02l@<FHLN@X\@fjntv@@ @@@T@@@@@  (@ l@8JT@hrtUnknown G.[x Times New Roman5Symbol3. .[x Arial;([SOSimSun7..{$ Calibri] .AppleSystemUIFontCambriaC.,.{$ Calibri Light5. .[`)Tahoma1. P<*_oŖў9,|8I{~ Light?|8I{~DengXianA$BCambria Math q h܋|G#2'|'B!\K=g\K=g!?!%),.:;>?]}    & 0 2 3 : !6"000 0 0 0000006:>@DZ\^ =@\]^$([{  0 0 000000Y[];[i2 l l ?QHX $PGZ;2! xx ZhoukqXuhui LiReqm&6FVfv i Z'`IZ'D         Oh+'0l   ( 4 @LT\dZhoukqNormal Xuhui Li66Microsoft Office Word@r_(@Ң:@@@R )K\ ՜.+,D՜.+, X`lt| g= l DJ([c'J _PID_HLINKSKSOProductBuildVerAI.X!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_linkX!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_linkX!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link>q _ENREF_252>r _ENREF_251X!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_linkX!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link2r _ENREF_192>hhttps://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_linkX!ihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link>hhttps://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link2q _ENREF_191>hhttps://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link?t _ENREF_247?{ _ENREF_248>s _ENREF_250?z _ENREF_249?{ _ENREF_248?t _ENREF_247?u _ENREF_246?v _ENREF_245?w _ENREF_244?s _ENREF_2408z{ _ENREF_2398{u _ENREF_2388tm _ENREF_2378ug _ENREF_2368v_ _ENREF_2358wW _ENREF_2348pO _ENREF_2338qG _ENREF_2328r? _ENREF_2318s< _ENREF_2309z4 _ENREF_2299{1 _ENREF_2289t) _ENREF_2279u! _ENREF_2269v _ENREF_2259w _ENREF_2249p _ENREF_223 E _ENREF_429q _ENREF_222:z _ENREF_2199r _ENREF_2219s _ENREF_220:z _ENREF_219:v _ENREF_215:w _ENREF_214:p _ENREF_213:q _ENREF_212;r _ENREF_201;s _ENREF_200^&ihttps://www.uptodate.com/contents/zh-Hans/100927?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link2y _ENREF_199=hhttps://www.uptodate.com/contents/zh-Hans/92811?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link2x _ENREF_1982w _ENREF_197;y~ _ENREF_1092sv _ENREF_1932rn _ENREF_1922qk _ENREF_191>dhhttps://www.uptodate.com/contents/zh-Hans/92821?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_linkX!aihttps://www.uptodate.com/contents/zh-Hans/100940?search=%E8%82%9D%E7%99%8C&topicRef=2486&source=see_link2p] _ENREF_1903xM _ENREF_1883wE _ENREF_1873vB _ENREF_1863u: _ENREF_1853t2 _ENREF_1843s* _ENREF_1833r' _ENREF_182<u _ENREF_175<t _ENREF_174 B _ENREF_36>y _ENREF_1593p _ENREF_180=r _ENREF_162 F _ENREF_77<x _ENREF_178=r _ENREF_162<w _ENREF_177<v _ENREF_176<w _ENREF_177<v _ENREF_176=v _ENREF_166>y _ENREF_159>x _ENREF_158>w _ENREF_157>t _ENREF_154>t _ENREF_154>t _ENREF_154?w _ENREF_147>vz _ENREF_156>tl _ENREF_154?wd _ENREF_147?wX _ENREF_147?vP _ENREF_1468sH _ENREF_1338qE _ENREF_131 FB _ENREF_71?s: _ENREF_143?u4 _ENREF_145?t, _ENREF_144?s$ _ENREF_143?p _ENREF_1408y _ENREF_1398x _ENREF_1388q  _ENREF_131 F _ENREF_72 G _ENREF_69:s _ENREF_1138u _ENREF_135 F _ENREF_788q _ENREF_131 F _ENREF_72 G _ENREF_698p _ENREF_1309y _ENREF_1299u _ENREF_1259t _ENREF_1249s _ENREF_1239r _ENREF_1229q _ENREF_1219p _ENREF_120:x _ENREF_118:w _ENREF_117:v _ENREF_116:u _ENREF_115:t| _ENREF_114:sv _ENREF_113:rn _ENREF_112:qf _ENREF_111;x^ _ENREF_108;wV _ENREF_107;vN _ENREF_106;rK _ENREF_102;qH _ENREF_101;u@ _ENREF_105;t8 _ENREF_104;s5 _ENREF_103;r- _ENREF_102;q* _ENREF_101;p" _ENREF_100 H _ENREF_99 H _ENREF_91 H _ENREF_98 H _ENREF_96 H _ENREF_95 H _ENREF_94 H _ENREF_93 H _ENREF_92 H _ENREF_91 H _ENREF_90 I _ENREF_89 I _ENREF_88 I _ENREF_87 I _ENREF_86 I _ENREF_85 I _ENREF_84 I _ENREF_83 I _ENREF_82 I _ENREF_81 I _ENREF_80 F _ENREF_79 F _ENREF_78 F~ _ENREF_77 Fv _ENREF_76 Fn _ENREF_75 Fk _ENREF_74 Fc _ENREF_71 F[ _ENREF_70 GS _ENREF_69 GK _ENREF_60 GE _ENREF_68 GB _ENREF_67 G: _ENREF_66 G7 _ENREF_65 D/ _ENREF_59 D' _ENREF_58 D$ _ENREF_57 D _ENREF_56 D _ENREF_55 D _ENREF_54 D _ENREF_51 E _ENREF_49 E _ENREF_46 E _ENREF_44 E _ENREF_43 E _ENREF_42 E _ENREF_41 E _ENREF_40 B _ENREF_39 B _ENREF_38 B _ENREF_37 B _ENREF_36 B _ENREF_35 B _ENREF_31 C _ENREF_28 C _ENREF_27 B _ENREF_30 C _ENREF_29 C _ENREF_28 C~ _ENREF_27 Cv _ENREF_26 Cs _ENREF_25 Ck _ENREF_22 Cc _ENREF_21 C[ _ENREF_20 @S _ENREF_19 @K _ENREF_16 @C _ENREF_11 @; _ENREF_10 H8 _ENREF_9 I0 _ENREF_8 F( _ENREF_7 G% _ENREF_6 D _ENREF_5 E _ENREF_4 B _ENREF_3 C _ENREF_2 @ _ENREF_12052-11.1.0.9208  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./013456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~        !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./012346789:;<>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abRoot Entry FyC)Data 21Table?WordDocument;bSummaryInformation(5DocumentSummaryInformation8=4KCompObjn  FMicrosoft Word 97-2003 ĵ MSWordDocWord.Document.89q